PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	KRISHNA, TSR; KONG, XP; GARY, S; BURGERS, PM; KURIYAN, J				KRISHNA, TSR; KONG, XP; GARY, S; BURGERS, PM; KURIYAN, J			CRYSTAL-STRUCTURE OF THE EUKARYOTIC DNA-POLYMERASE PROCESSIVITY FACTOR PCNA	CELL			English	Article							CELL NUCLEAR ANTIGEN; REPLICATION FACTOR-C; SACCHAROMYCES-CEREVISIAE; ACCESSORY PROTEINS; AUXILIARY PROTEIN; ESCHERICHIA-COLI; III HOLOENZYME; DELTA; BACTERIOPHAGE-T4; REFINEMENT	The crystal structure of the processivity factor required by eukaryotic DNA polymerase delta, proliferating cell nuclear antigen (PCNA) from S. cerevisiae, has been determined at 2.3 Angstrom resolution. Three PCNA molecules, each containing two topologically identical domains, are tightly associated to form a closed ring. The dimensions and electrostatic properties of the ring suggest that PCNA encircles duplex DNA, providing a DNA-bound platform for the attachment of the polymerase. The trimeric PCNA ring is strikingly similar to the dimeric ring formed by the beta subunit (processivity factor) of E. coli DNA polymerase III holoenzyme, with which it shares no significant sequence identity. This structural correspondence further substantiates the mechanistic connection between eukaryotic and prokaryotic DNA replication that has been suggested on biochemical grounds.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA	Howard Hughes Medical Institute; Rockefeller University; Washington University (WUSTL)	KRISHNA, TSR (corresponding author), ROCKEFELLER UNIV, MOLEC BIOPHYS LABS, NEW YORK, NY 10021 USA.		Burgers, Peter M/AAW-6621-2021		NIGMS NIH HHS [R01 GM032431, GM45547, GM32431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BRAND SR, 1994, J IMMUNOL, V152, P4120; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1992, XPLOR VERSION 3 1 MA; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CHA TA, 1988, EUKARYOTIC DNA REPLI, P1; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1991, DNA REPLICATION; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNA TSR, 1994, J MOL BIOL, V241, P265, DOI 10.1006/jmbi.1994.1495; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1991, J BIOL CHEM, V266, P594; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; MIYACHI K, 1978, J IMMUNOL, V121, P2228; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MULLER F, 1994, J BIOL CHEM, V269, P17086; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOSSAL NG, 1984, BACTERIOPHAGE T4, P71; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; PAHLER A, 1990, ACTA CRYSTALLOGR A, V46, P537, DOI 10.1107/S0108767390002379; PODUST VN, 1993, J BIOL CHEM, V25, P841; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROOS G, 1993, LAB INVEST, V68, P204; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SHARP KA, 1990, ANNU REV BIOPHYS BIO, V19, P301, DOI 10.1146/annurev.bb.19.060190.001505; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TAN CK, 1986, J BIOL CHEM, V261, P2310; TINKER RL, 1994, IN PRESS EMBO J; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wells A.F., 1984, STRUCTURAL INORGANIC; WOLD MS, 1988, CANCER CELL, V6, P133; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YODER BL, 1991, J BIOL CHEM, V266, P22689; ZENG XR, 1994, J BIOL CHEM, V269, P13748; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	56	766	785	27	183	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 30	1994	79	7					1233	1243		10.1016/0092-8674(94)90014-0	http://dx.doi.org/10.1016/0092-8674(94)90014-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001157				2022-12-24	WOS:A1994PZ86000014
J	WATANABE, S; TAKAHASHI, H				WATANABE, S; TAKAHASHI, H			TREATMENT OF NEVUS OF OTA WITH THE Q-SWITCHED RUBY-LASER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GUINEA-PIG SKIN; SELECTIVE PHOTOTHERMOLYSIS; IRRADIATION; PULSES; INJURY	Background. Nevus of Ota is a benign bluish gray-brown lesion of the eye and the surrounding skin that has been reported to occur in about 1 in 200 people in Japan. Prior treatments have either been ineffective or caused scarring. The Q-switched ruby laser can produce very short high-energy pulses and can selectively target cells that contain pigment, such as dermal melanocytes. Methods. We treated the skin lesions of 114 patients (25 male and 89 female) with nevi of Ota with a Q-switched ruby laser set to deliver pulses of 6 J per square centimeter of body-surface area at a wavelength of 694.3 nm, with a pulse duration of 30 nanoseconds. The interval between treatments ranged from three to four months. Five dermatologists who were not familiar with the patients independently compared a full set of pretreatment and post-treatment photographs of each patient and determined the percentage of pigment lightening of the affected areas using standard criteria. Results. Of the 35 patients who received four or five treatments, 33 had an excellent response (lightening of 70 percent or more), and 2 had a good response (lightening of 40 to 69 percent). Of the 31 patients who received three treatments, 4 had an excellent response, 26 a good response, and 1 a fair response (lightening of 10 to 39 percent). Of the 25 patients who received two treatments, 2 had an excellent response, 16 a good response, and 7 a fair response. Of the 23 patients who received one treatment, 3 had a good response, 13 a fair response, and 7 no response (lightening of 9 percent or less). No patient had hypertrophic or atrophic scarring; eight patients had postinflammatory hyperpigmentation for up to two months after the first treatment. Conclusions. Selective photothermolysis with the Q-switched ruby laser is a safe and effective method for lightening nevi of Ota. Multiple treatments increase the response rate.			WATANABE, S (corresponding author), TEIKYO UNIV,SCH MED,DEPT DERMATOL,ITABASHI KU,11-1 KAGA,2 CHOME,TOKYO 173,JAPAN.							Anderson R R, 1981, Lasers Surg Med, V1, P263; ANDERSON RR, 1989, J INVEST DERMATOL, V93, P28, DOI 10.1111/1523-1747.ep12277339; ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297; ANDERSON RR, 1981, J INVEST DERMATOL, V77, P13, DOI 10.1111/1523-1747.ep12479191; APFELBERG DB, 1981, JAMA-J AM MED ASSOC, V245, P2073, DOI 10.1001/jama.245.20.2073; DOVER JS, 1989, ARCH DERMATOL, V125, P43, DOI 10.1001/archderm.125.1.43; GERONEMUS RG, 1992, ARCH DERMATOL, V128, P1618, DOI 10.1001/archderm.128.12.1618; GOLDBERG DJ, 1992, J DERMATOL SURG ONC, V18, P817, DOI 10.1111/j.1524-4725.1992.tb03040.x; HIDANO A, 1967, ARCH DERMATOL, V95, P187, DOI 10.1001/archderm.95.2.187; HRUZA GJ, 1991, ARCH DERMATOL, V127, P1799, DOI 10.1001/archderm.127.12.1799; LOWE NJ, 1993, J AM ACAD DERMATOL, V29, P997, DOI 10.1016/0190-9622(93)70280-7; MARGOLIS RJ, 1989, LASER SURG MED, V9, P389, DOI 10.1002/lsm.1900090412; MOSHER DB, 1987, DERMATOLOGY GENERAL, V1, P854; MURPHY GF, 1983, LAB INVEST, V49, P680; POLLA LL, 1987, J INVEST DERMATOL, V89, P281, DOI 10.1111/1523-1747.ep12471397; TAYLOR CR, 1990, ARCH DERMATOL, V126, P893, DOI 10.1001/archderm.126.7.893; TAYLOR CR, 1994, J AM ACAD DERMATOL, V30, P743, DOI 10.1016/S0190-9622(08)81505-8; WATANABE S, 1991, PHOTOCHEM PHOTOBIOL, V53, P757, DOI 10.1111/j.1751-1097.1991.tb09889.x	18	108	112	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	1994	331	26					1745	1750		10.1056/NEJM199412293312604	http://dx.doi.org/10.1056/NEJM199412293312604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ266	7984195				2022-12-24	WOS:A1994PZ26600004
J	KASTELER, JS; CALLEN, JP				KASTELER, JS; CALLEN, JP			SCALP INVOLVEMENT IN DERMATOMYOSITIS - OFTEN OVERLOOKED OR MISDIAGNOSED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							IDIOPATHIC INFLAMMATORY MYOPATHIES; SINE MYOSITIS; POLYMYOSITIS	Objective.-To characterize scalp involvement in patients with dermatomyositis. Design.-Case series. Patients.-All patients with dermatomyositis seen in our office between 1988 and mid 1993. Patient inclusion in this study required fulfillment of three or more of Bohan and Peter's criteria for dermatomyositis. Results.-Of 17 patients with the diagnosis of dermatomyositis, scalp involvement was present in 14. Five of the 14 patients with scalp involvement were diagnosed as having scalp psoriasis or seborrheic dermatitis before progression of their disease or tissue examination revealed the diagnosis of dermatomyositis. In all patients, the scalp involvement was manifested as atrophic, erythematous, scaly plaques. In addition, alopecia was noted in six of the 14 patients. Treatment of cutaneous involvement included sun avoidance, topical corticosteroids and/or antimalarials, and/or methotrexate. Conclusions.-Recognition of this process is important because scalp involvement is often overlooked, may be misdiagnosed initially, and can be the presenting complaint in some patients with dermatomyositis.	UNIV LOUISVILLE,SCH MED,DIV DERMATOL,LOUISVILLE,KY 40292	University of Louisville								BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BOHAN A, 1977, MEDICINE, V56, P255, DOI 10.1097/00005792-197707000-00001; CALLEN JP, 1993, J AM ACAD DERMATOL, V28, P477, DOI 10.1016/S0190-9622(08)81757-4; CALLEN JP, 1987, DM-DIS MON, V33, P242; EUWER RL, 1991, J AM ACAD DERMATOL, V24, P959, DOI 10.1016/0190-9622(91)70153-S; FAFALAK RG, 1994, J RHEUMATOL, V21, P643; JANIS JF, 1968, ARCH DERMATOL, V97, P640, DOI 10.1001/archderm.97.6.640; JOFFE MM, 1993, AM J MED, V94, P379, DOI 10.1016/0002-9343(93)90148-I; PLOTZ PH, 1989, ANN INTERN MED, V111, P143, DOI 10.7326/0003-4819-111-2-143; SCHWIETERMAN WD, 1993, ARTHRITIS RHEUM, V36, pS118; SINOWAY PA, 1994, J RHEUMATOL, V21, P353; STONECIPHER MR, 1993, J AM ACAD DERMATOL, V28, P951, DOI 10.1016/0190-9622(93)70136-H; URBANOMARQUEZ A, 1991, ANN RHEUM DIS, V50, P191, DOI 10.1136/ard.50.3.191	13	50	50	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	1994	272	24					1939	1941		10.1001/jama.272.24.1939	http://dx.doi.org/10.1001/jama.272.24.1939			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX927	7990247				2022-12-24	WOS:A1994PX92700040
J	ELDERS, JM				ELDERS, JM			REDUCING THE RISK OF SUDDEN-INFANT-DEATH-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ELDERS, JM (corresponding author), US PHS,WASHINGTON,DC 20201, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1646	1646		10.1001/jama.272.21.1646	http://dx.doi.org/10.1001/jama.272.21.1646			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU759	7966879				2022-12-24	WOS:A1994PU75900006
J	SLOANLANCASTER, J; SHAW, AS; ROTHBARD, JB; ALLEN, PM				SLOANLANCASTER, J; SHAW, AS; ROTHBARD, JB; ALLEN, PM			PARTIAL T-CELL SIGNALING - ALTERED PHOSPHO-ZETA AND LACK OF ZAP70 RECRUITMENT IN APL-INDUCED T-CELL ANERGY	CELL			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTOR-ZETA; LYMPHOKINE PRODUCTION; CYTOPLASMIC TAIL; CROSS-LINKING; ACTIVATION; KINASE; CHAIN; TRANSDUCTION; ASSOCIATION	Studies of T cell responses to altered peptide ligands (APLs) have provided functional evidence that a T cell receptor (TCR) can interpret subtle changes in its ligand, resulting in different phenotypic outcomes. One dramatic effect of APL stimulation with live antigen-presenting cells (APCs) is the induction of energy as opposed to proliferation. We investigated the intracellular signaling events involved in generating this unresponsiveness by comparing protein-tyrosine phosphorylation patterns after stimulation with anergy-inducing APL or the immunogenic peptide. In resting T cell clones, presentation with APL/live APC stimulated a unique pattern of TCR phospho-zeta species and a subsequent lack of association with zap70. This demonstrates that the TCR-CD3 complex can engage selective intracellular biochemical signaling pathways as a direct consequence of the nature of the ligand recognized and the initial phosphotyrosine pattern of the TCR-CD3 proteins, leading to different phenotypes.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; IMMULOG, PALO ALTO, CA 94304 USA	Washington University (WUSTL)								ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BHANDOOLA A, 1993, J IMMUNOL, V151, P2355; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHO EA, 1993, J IMMUNOL, V151, P20; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIS LS, 1989, J IMMUNOL, V142, P1084; DIANZANI U, 1992, J IMMUNOL, V148, P678; EVAVOLD BD, 1992, J IMMUNOL, V148, P347; EVAVOLD BD, 1993, J IMMUNOL, V150, P3131; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; FRANK SJ, 1992, J BIOL CHEM, V267, P13656; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HERMANS MHA, 1993, EUR J IMMUNOL, V23, P2257, DOI 10.1002/eji.1830230931; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JANEWAY CA, 1989, COLD SH Q B, V54, P657; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JUNE CH, 1990, J IMMUNOL, V144, P1591; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LORENZ RG, 1989, NATURE, V340, P557, DOI 10.1038/340557a0; LOVE PE, 1994, J EXP MED, V179, P1485, DOI 10.1084/jem.179.5.1485; NORTON SD, 1991, J IMMUNOL, V146, P1125; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; QUILL H, 1987, J IMMUNOL, V138, P3704; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RONCHESE F, 1987, NATURE, V329, P254, DOI 10.1038/329254a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SLOANLANCASTER J, 1994, J EXP MED, V180, P1195, DOI 10.1084/jem.180.4.1195; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	47	587	593	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					913	922		10.1016/0092-8674(94)90080-9	http://dx.doi.org/10.1016/0092-8674(94)90080-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001128				2022-12-24	WOS:A1994PW05400018
J	ELMORE, JG; WELLS, CK; LEE, CH; HOWARD, DH; FEINSTEIN, AR				ELMORE, JG; WELLS, CK; LEE, CH; HOWARD, DH; FEINSTEIN, AR			VARIABILITY IN RADIOLOGISTS INTERPRETATIONS OF MAMMOGRAMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-CANCER MORTALITY; OBSERVER VARIATION; AGREEMENT; REDUCTION; EFFICACY; PROGRAM; PROJECT; AUDIT	Background. Despite the proved value of mammography in screening for breast cancer, its efficacy depends on radiologists' interpretations. The variability in such interpretations is not well understood. Methods. Using a technique of stratified random sampling, we selected 150 mammograms obtained in 1987: 27 from women with histopathologically confirmed breast cancer and 123 from women with no evidence of breast cancer after three years of follow-up examinations. Ten radiologists, who were unaware of the diagnoses and research hypothesis, each interpreted the 150 mammograms. Disagreement was analyzed within pairs of the 10 radiologists, as well as for the group of 150 women as a whole. Results. The diagnostic consistency between pairs of radiologists was moderate, with a median weighted percentage of agreement of 78 percent (weighted kappa, 0.47). The frequency of the radiologists' recommendations for an immediate workup ranged from 74 to 96 percent for mammograms from the women with cancer and from 11 to 65 percent for films from the women without cancer. A substantial disagreement in management recommendations - in which one radiologist recommended routine follow-up and another recommended a biopsy for the same patient - occurred in 3 percent of the pairwise comparisons but in 25 percent of the comparisons for the group of women as a whole. When two or more radiologists recommended a biopsy for the same patient, a disagreement in the stated location (right or left breast) occurred in 2 percent of the pairwise comparisons among the radiologists but in 9 percent of comparisons for the group of women as a whole. Because some disagreement was likely, given that 10 radiologists read each film, the pairwise comparison is a more conservative estimate of disagreement. Conclusions. Although mammography is of value in screening women for breast cancer, radiologists can differ, sometimes substantially, in their interpretations of mammograms and in their recommendations for management. Efforts to improve accuracy and reduce variability in interpretation may increase the effectiveness of mammography in detecting early breast cancers.	YALE UNIV,DEPT DIAGNOST RADIOL,NEW HAVEN,CT; YALE UNIV,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT	Yale University; Yale University	ELMORE, JG (corresponding author), YALE UNIV,SCH MED,CTR PRIMARY CARE,DEPT INTERNAL MED,20 YORK ST,NEW HAVEN,CT 06504, USA.		SALAZAR, ANTONIO/A-5806-2013	SALAZAR, ANTONIO/0000-0003-2639-2340				ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; [Anonymous], 1993, BREAST IMAGING REPOR; BAINES CJ, 1990, INVEST RADIOL, V25, P971, DOI 10.1097/00004424-199009000-00002; BIRD RE, 1989, RADIOLOGY, V171, P87, DOI 10.1148/radiology.171.1.2494683; BOYD NF, 1986, J CHRON DIS, V39, P465, DOI 10.1016/0021-9681(86)90113-X; BOYD NF, 1982, J NATL CANCER I, V68, P357; CICCONE G, 1992, EUR J CANCER, V28A, P1054, DOI 10.1016/0959-8049(92)90455-B; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; COLLETTE HJA, 1984, LANCET, V1, P1224; DERSHAW DD, 1992, RADIOLOGY, V184, P415, DOI 10.1148/radiology.184.2.1620839; DORSI CJ, 1993, SEMIN ROENTGENOL, V28, P204, DOI 10.1016/S0037-198X(05)80080-X; FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L; Fleiss JL, 1981, STAT METHODS RATES P; KOPANS DB, 1992, RADIOL CLIN N AM, V30, P257; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MCLELLAND R, 1991, AM J ROENTGENOL, V157, P473, DOI 10.2214/ajr.157.3.1872231; PALLI D, 1986, INT J CANCER, V38, P501, DOI 10.1002/ijc.2910380408; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SICKLES EA, 1992, RADIOL CLIN N AM, V30, P265; SICKLES EA, 1990, RADIOLOGY, V175, P323, DOI 10.1148/radiology.175.2.2326455; SWETS JA, 1991, MED DECIS MAKING, V11, P9, DOI 10.1177/0272989X9101100102; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; VERBEEK ALM, 1984, LANCET, V1, P1222; VINEIS P, 1988, TUMORI, V74, P275, DOI 10.1177/030089168807400306; 1988, LANCET, V2, P411	27	455	457	1	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1493	1499		10.1056/NEJM199412013312206	http://dx.doi.org/10.1056/NEJM199412013312206			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969300				2022-12-24	WOS:A1994PU86600006
J	KELLER, LF; ARCESE, P; SMITH, JNM; HOCHACHKA, WM; STEARNS, SC				KELLER, LF; ARCESE, P; SMITH, JNM; HOCHACHKA, WM; STEARNS, SC			SELECTION AGAINST INBRED SONG SPARROWS DURING A NATURAL-POPULATION BOTTLENECK	NATURE			English	Article							INBREEDING DEPRESSION; GREAT TIT; CONSEQUENCES; MORTALITY	THE genetic and demographic consequences of population subdivision have received considerable attention from conservation biologists. In particular, losses of genetic variability and reduced viability and fecundity due to inbreeding (inbreeding depression) are of concern(1-3). Studies of domestic, laboratory(4,5) and zoo populations(2,6,7) have shown inbreeding depression in a variety of traits related to fitness. Consequently, inbreeding depression is widely accepted as a fact. Recently, however, the relative impact of inbreeding on the viability of natural populations has been questioned(8-10). Work on the cheetah (Acinonyx jubatus), for example, has emphasized the overwhelming importance of environmental factors on mortality in the wild(9,10). Here we report that song sparrows (Melospiza melodia) that survived a severe population bottleneck were a non-random subset of the pre-crash population with respect to inbreeding, and that natural selection favoured outbred individuals. Thus, inbreeding depression was expressed in the face of an environmental challenge. Such challenges are also likely to be faced by inbred populations of endangered species. We suggest that environmental and genetic effects on survival may interact and, as a consequence, that their effects on individuals and populations should not be considered independently.	UNIV BRITISH COLUMBIA,DEPT ZOOL,VANCOUVER V6T 1Z4,BC,CANADA; UNIV BASEL,INST ZOOL,CH-4051 BASEL,SWITZERLAND	University of British Columbia; University of Basel	KELLER, LF (corresponding author), UNIV WISCONSIN,DEPT WILDLIFE ECOL,1630 LINDEN DR,MADISON,WI 53706, USA.		Hochachka, Wesley M./J-9768-2012	Hochachka, Wesley M./0000-0002-0595-7827; Lukas, Keller/0000-0002-0149-0174; Stearns, Stephen/0000-0002-6621-4373				ARCESE P, 1992, ECOLOGY, V73, P805, DOI 10.2307/1940159; BARRETT SCH, 1991, NATURE, V352, P522, DOI 10.1038/352522a0; BOYCE AJ, 1983, J HERED, V74, P400, DOI 10.1093/oxfordjournals.jhered.a109825; BULGER J, 1986, ANIM BEHAV, V36, P574; CARO TM, 1994, SCIENCE, V263, P485, DOI 10.1126/science.8290956; CAUGHLEY G, 1994, J ANIM ECOL, V63, P215, DOI 10.2307/5542; CHARLESWORTH D, 1987, ANNU REV ECOL SYST, V18, P237, DOI 10.1146/annurev.ecolsys.18.1.237; Falconer D. S., 1989, Introduction to quantitative genetics.; GIBBS HL, 1989, EVOLUTION, V43, P1273, DOI 10.1111/j.1558-5646.1989.tb02574.x; GREENWOOD PJ, 1978, NATURE, V271, P52, DOI 10.1038/271052a0; HARCOURT S, 1991, NATURE, V354, P10, DOI 10.1038/354010a0; Hoffmann A.A., 1991, EVOLUTIONARY GENETIC; HOOGLAND JL, 1992, AM NAT, V139, P591, DOI 10.1086/285345; Lacy Robert C., 1993, P352; LANDE R, 1988, SCIENCE, V241, P1455, DOI 10.1126/science.3420403; LANDE R, 1985, EVOLUTION, V39, P24, DOI 10.1111/j.1558-5646.1985.tb04077.x; MACCLUER JW, 1983, J HERED, V74, P394, DOI 10.1093/oxfordjournals.jhered.a109824; OBRIEN SJ, 1985, SCIENCE, V227, P1428, DOI 10.1126/science.2983425; Ralls K., 1986, P35; RALLS K, 1979, SCIENCE, V206, P1101, DOI 10.1126/science.493997; ROGERS CM, 1991, ORNIS SCAND, V22, P387, DOI 10.2307/3676513; SMITH JNM, 1989, AM NAT, V133, P830, DOI 10.1086/284955; SMITH JNM, 1991, 20 ACT C INT ORN, P1514; Templeton A.R., 1987, P257; Thornhill N.W., 1993, NATURAL HIST INBREED; TOMPA FS, 1971, AUK, V88, P753, DOI 10.2307/4083835; VANNOORDWIJK AJ, 1981, EVOLUTION, V35, P674, DOI 10.1111/j.1558-5646.1981.tb04929.x; Wright S., 1977, EVOLUTION GENETICS P, V3; 1986, P WKSHOP GENETIC MAN, V5, P81	29	305	310	2	109	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					356	357		10.1038/372356a0	http://dx.doi.org/10.1038/372356a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969492				2022-12-24	WOS:A1994PU28700053
J	HECK, SD; SIOK, CJ; KRAPCHO, KJ; KELBAUGH, PR; THADEIO, PF; WELCH, MJ; WILLIAMS, RD; GANONG, AH; KELLY, ME; LANZETTI, AJ; GRAY, WR; PHILLIPS, D; PARKS, TN; JACKSON, H; AHLIJANIAN, MK; SACCOMANO, NA; VOLKMANN, RA				HECK, SD; SIOK, CJ; KRAPCHO, KJ; KELBAUGH, PR; THADEIO, PF; WELCH, MJ; WILLIAMS, RD; GANONG, AH; KELLY, ME; LANZETTI, AJ; GRAY, WR; PHILLIPS, D; PARKS, TN; JACKSON, H; AHLIJANIAN, MK; SACCOMANO, NA; VOLKMANN, RA			FUNCTIONAL CONSEQUENCES OF POSTTRANSLATIONAL ISOMERIZATION OF SER(46) IN A CALCIUM-CHANNEL TOXIN	SCIENCE			English	Article							GLUTAMATE RACEMASE; OMEGA-CONOTOXIN; CA2+ CHANNELS; PERIPHERAL NEURONS; EXPRESSION; PEPTIDE; NEUROPEPTIDES; DIVERSITY; MECHANISM; CLONING	The venom of the funnel-web spider Agelenopsis aperta contains several peptides that paralyze prey by blocking voltage-sensitive calcium channels. Two peptides, omega-Aga-IVB (IVB) and omega-Aga-IVC (IVC), have identical amino acid sequences, yet have opposite absolute configurations at serine 46. These toxins had similar selectivities for blocking voltage-sensitive calcium channel subtypes but different potencies for blocking P-type voltage-sensitive calcium channels in rat cerebellar Purkinje cells as well as calcium-45 influx into rat brain synaptosomes. An enzyme purified from venom converts IVC to IVB by isomerizing serine 46, which is present in the carboxyl-terminal tail, from the L to the D configuration. Unlike the carboxyl terminus of IVC, that of IVB was resistant to the major venom protease. These results show enzymatic activities in A. aperta venom being used in an unprecedented strategy for coproduction of necessary neurotoxins that possess enhanced stability and potency.	NPS PHARMACEUT INC,SALT LAKE CITY,UT 84108; UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT ANAT,SALT LAKE CITY,UT 84112; PFIZER RES INC,GROTON,CT 06340	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Pfizer								ADAMS ME, 1993, MOL PHARMACOL, V44, P681; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BRANTON WD, 1993, NATURE, V365, P496, DOI 10.1038/365496a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; FORD R, 1986, COMP BIOCHEM PHYS C, V85, P61, DOI 10.1016/0742-8413(86)90052-6; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3991, DOI 10.1021/bi00066a020; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3981, DOI 10.1021/bi00066a019; GANONG AH, 1993, SOC NEUR ABSTR, V19, P7212; GRABNER M, 1994, FEBS LETT, V339, P189, DOI 10.1016/0014-5793(94)80413-3; HECK SD, IN PRESS J AM CHEM S; HORNBERG U, 1991, J COMP NEUROL, V303, P35; KREIL G, 1994, J BIOL CHEM, V269, P10967; LAMANGO NS, 1993, INSECT BIOCHEM MOLEC, V23, P801, DOI 10.1016/0965-1748(93)90068-4; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PHILLIPS D, 1992, Patent No. 5122596; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; RUDNICK G, 1975, BIOCHEMISTRY-US, V14, P4515, DOI 10.1021/bi00691a028; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SCHOOFS L, 1988, GEN COMP ENDOCR, V69, P1, DOI 10.1016/0016-6480(88)90046-9; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; SPEDDING M, 1992, PHARMACOL REV, V44, P363; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TANNER ME, 1993, BIOCHEMISTRY-US, V32, P3998, DOI 10.1021/bi00066a021; TERAMOTO T, 1993, BIOCHEM BIOPH RES CO, V196, P134, DOI 10.1006/bbrc.1993.2225; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; WALSH C, 1979, ENZYMATIC REACTION M, P828; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; YAMAUCHI T, 1992, J BIOL CHEM, V267, P18361; YU HT, 1993, BIOCHEMISTRY-US, V32, P13123, DOI 10.1021/bi00211a022; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	39	131	134	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1065	1068		10.1126/science.7973665	http://dx.doi.org/10.1126/science.7973665			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973665				2022-12-24	WOS:A1994PQ92400052
J	LOWE, SW; BODIS, S; MCCLATCHEY, A; REMINGTON, L; RULEY, HE; FISHER, DE; HOUSMAN, DE; JACKS, T				LOWE, SW; BODIS, S; MCCLATCHEY, A; REMINGTON, L; RULEY, HE; FISHER, DE; HOUSMAN, DE; JACKS, T			P53 STATUS AND THE EFFICACY OF CANCER-THERAPY IN-VIVO	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; C-MYC; GENE; MUTATIONS; INDUCTION; APOPTOSIS; MOUSE; TUMOR	The therapeutic responsiveness of genetically defined tumors expressing or devoid of the p53 tumor suppressor gene was compared in immunocompromised mice. Tumors expressing the p53 gene contained a high proportion of apoptotic cells and typically regressed after treatment with gamma radiation or adriamycin. In contrast, p53-deficient tumors treated with the same regimens continued to enlarge and contained few apoptotic cells. Acquired mutations in p53 were associated with both treatment resistance and relapse in p53-expressing tumors. These results establish that defects in apoptosis, here caused by the inactivation of p53, can produce treatment-resistant tumors and suggest that p53 status may be an important determinant of tumor response to therapy.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; VANDERBILT UNIV,SCH MED,DEPT IMMUNOL & MICROBIOL,NASHVILLE,TN 37232; HARVARD UNIV,CHILDRENS HOSP,SCH MED,BOSTON,MA 02115; MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Vanderbilt University; Harvard University; Boston Children's Hospital; Harvard Medical School; Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R01CA017575, R01CA040602, R37CA017575, P30CA014051] Funding Source: NIH RePORTER; NCI NIH HHS [CA14051, 5R27CA17575, R01CA40602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; ELROUBY S, 1993, BLOOD, V82, P3452; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FUJIWARA T, 1994, CANCER RES, V54, P2287; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIO Y, 1993, CANCER RES, V53, P11; HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P954; LOWE SW, UNPUB; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; PELLETIER J, COMMUNICATION; SCHEULEN ME, 1989, STRAHLENTHER ONKOL, V165, P529; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THORLACIUS S, 1993, CANCER RES, V53, P1637; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	25	1488	1539	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					807	810		10.1126/science.7973635	http://dx.doi.org/10.1126/science.7973635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973635				2022-12-24	WOS:A1994PP75300041
J	MINSHULL, J; SUN, H; TONKS, NK; MURRAY, AW				MINSHULL, J; SUN, H; TONKS, NK; MURRAY, AW			A MAP KINASE-DEPENDENT SPINDLE ASSEMBLY CHECKPOINT IN XENOPUS EGG EXTRACTS	CELL			English	Article							ACTIVATED PROTEIN-KINASE; CELL-CYCLE ARREST; WILD-TYPE P53; MATURATION-PROMOTING FACTOR; IMMEDIATE-EARLY GENE; M-PHASE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; MICROTUBULE DYNAMICS; CHROMOSOME MOVEMENT	Like early Xenopus embryos, extracts made from Xenopus eggs lack the cell cycle checkpoint that keeps anaphase from occurring before spindle assembly is complete. At very high densities of sperm nuclei, however, microtubule depolymerization arrests the extracts in mitosis. The arrested extracts have high levels of maturation-promoting factor activity, fail to degrade cyclin B, and contain activated ERK2/mitogen-activated protein (MAP) kinase. The addition of the purified MAP kinase-specific phosphatase MKP-1 demonstrates that MAP kinase activity is required for both the establishment and maintenance of the mitotic arrest induced by spindle depolymerization. Increased calcium concentrations, which release unfertilized frog eggs from their natural arrest in metaphase of meiosis II, have no effect on the mitotic arrest.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of California System; University of California San Francisco; Cold Spring Harbor Laboratory	MINSHULL, J (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, BOX 0444, SAN FRANCISCO, CA 94143 USA.				NCI NIH HHS [CA53840] Funding Source: Medline; NIGMS NIH HHS [GM43987] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043987, R01GM043987] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BAGATA N, 1988, NATURE, V335, P519; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; CALLAN H. G., 1957, JOUR GENETICS, V55, P200, DOI 10.1007/BF02981625; CHARLES CH, 1992, ONCOGENE, V7, P187; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER JA, 1989, MOL CELL BIOL, V9, P3143, DOI 10.1128/MCB.9.7.3143; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; JORDAN MA, 1992, J CELL SCI, V102, P401; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; KLINE D, 1988, DEV BIOL, V126, P346, DOI 10.1016/0012-1606(88)90145-5; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; KUBIAK JZ, 1993, EMBO J, V12, P3773, DOI 10.1002/j.1460-2075.1993.tb06055.x; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; NICKLAS RB, 1993, J CELL SCI, V104, P961; NICKLAS RB, 1992, J CELL SCI, V102, P681; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RIEDER CL, 1992, J CELL SCI, V102, P387; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SLUDER G, 1994, J CELL BIOL, V126, P189, DOI 10.1083/jcb.126.1.189; SLUDER G, 1983, J CELL BIOL, V97, P877, DOI 10.1083/jcb.97.3.877; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; TOMKIEL J, 1994, J CELL BIOL, V125, P531, DOI 10.1083/jcb.125.3.531; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	83	358	361	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	1994	79	3					475	486		10.1016/0092-8674(94)90256-9	http://dx.doi.org/10.1016/0092-8674(94)90256-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954813				2022-12-24	WOS:A1994PQ48800010
J	STONE, JM; COLLINGE, MA; SMITH, RD; HORN, MA; WALKER, JC				STONE, JM; COLLINGE, MA; SMITH, RD; HORN, MA; WALKER, JC			INTERACTION OF A PROTEIN PHOSPHATASE WITH AN ARABIDOPSIS SERINE-THREONINE RECEPTOR KINASE	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE-PHOSPHATASE; NUCLEOTIDE EXCHANGE; EXPRESSION CLONING; BRASSICA-OLERACEA; ADAPTER PROTEIN; THALIANA; DOMAINS; LOCUS; GENE	A protein phosphatase was cloned that interacts with a serine-threonine receptor-like kinase, RLK5, from Arabidopsis thaliana. The phosphatase, designated KAPP (kinase-associated protein phosphatase), is composed of three domains: an amino-terminal signal anchor, a kinase interaction (KI) domain, and a type 2C protein phosphatase catalytic region. Association of RLK5 with the KI domain is dependent on phosphorylation of RLK5 and can be abolished by dephosphorylation. KAPP may function as a signaling component in a pathway involving RLK5.	UNIV MISSOURI, DIV BIOL SCI, COLUMBIA, MO 65211 USA; UNIV MISSOURI, DEPT BIOCHEM, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia				Walker, John/0000-0002-2050-1641				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRAUN D, UNPUB; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; DECHERT U, 1994, J BIOL CHEM, V269, P5602; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; HARLOW E, 1988, ANTIBODIES LABORATOR; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; HORN MA, 1994, BIOCHIM BIOPHYS ACTA, V208, P65; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; MACKINTOSH C, 1991, BIOCHEM J, V273, P733, DOI 10.1042/bj2730733; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH RD, 1993, PLANT MOL BIOL, V21, P307, DOI 10.1007/BF00019946; SMITH RD, 1991, PLANT PHYSIOL, V97, P677, DOI 10.1104/pp.97.2.677; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; STONE JD, UNPUB; TOBIAS CM, 1992, PLANT PHYSIOL, V99, P284, DOI 10.1104/pp.99.1.284; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; WALKER JC, 1993, PLANT J, V3, P451, DOI 10.1046/j.1365-313X.1993.t01-23-00999.x; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	227	240	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	1994	266	5186					793	795		10.1126/science.7973632	http://dx.doi.org/10.1126/science.7973632			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973632				2022-12-24	WOS:A1994PP75300036
J	BARNETT, SW; MURTHY, KK; HERNDIER, BG; LEVY, JA				BARNETT, SW; MURTHY, KK; HERNDIER, BG; LEVY, JA			AN AIDS-LIKE CONDITION INDUCED IN BABOONS BY HIV-2	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; RHESUS-MONKEYS; EXPERIMENTAL-INFECTION; CELLULAR-LOCALIZATION; PERSISTENT INFECTION; CYNOMOLGUS MONKEYS; MACACA-NEMESTRINA; LYMPHOID-TISSUES; D RETROVIRUS; MACAQUES	Six baboons (Papio cynocephalus) were intravenously inoculated with the human immunodeficiency virus-type 2 (HIV-2) strain HIV-2(UC2). All seroconverted within 6 week's after inoculation; five animals became persistently infected. Four developed lymphadenopathy, and three of the animals had CD4(+) T cell loss within 18 to 24 months after inoculation. One of these baboons, showing severe clinical symptoms, showed at necropsy widespread dissemination of virus with follicular depletion in the lymph nodes, extensive fibromatosis involving lymphoid and nonlymphoid tissues, and lymphocytic interstitial pneumonitis. Another animal is cachectic and exhibited lymphoid follicular lysis and fibrous skin lesions. Other baboons inoculated with a second strain, HIV-2(UC14), have shown evidence of persistent infection. HIV-2 infection of baboons provides a valuable animal model for studying HIV persistence and pathogenesis and for evaluating approaches to antiviral therapies.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,CANC RES INST,SAN FRANCISCO,CA 94143; SW FDN BIOMED RES,SAN ANTONIO,TX 78228; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,SCH MED,DEPT PATHOL,SAN FRANCISCO,CA 94110	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Texas Biomedical Research Institute; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco					NIAID NIH HHS [U01-AI26471] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI026471] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGY MB, 1992, SCIENCE, V257, P103, DOI 10.1126/science.1621083; ALBINI A, 1988, J CELL BIOCHEM, V36, P369, DOI 10.1002/jcb.240360406; ALTER HJ, 1984, SCIENCE, V226, P549, DOI 10.1126/science.6093251; BABU PG, 1993, INDIAN J MED RES-A, V97, P49; BARNETT SW, 1993, J VIROL, V67, P1006, DOI 10.1128/JVI.67.2.1006-1014.1993; BARNETT SW, UNPUB; BLACKBOURN D, UNPUB; CASTRO BA, 1991, VIROLOGY, V184, P219, DOI 10.1016/0042-6822(91)90838-3; CHALIFOUX LV, 1987, AM J PATHOL, V128, P104; CORTES E, 1989, NEW ENGL J MED, V320, P953, DOI 10.1056/NEJM198904133201501; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; DONALDSON YK, 1994, LANCET, V343, P382, DOI 10.1016/S0140-6736(94)91222-X; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EVANS LA, 1988, LANCET, V2, P1389; FRUMKIN LR, 1993, VIROLOGY, V195, P422, DOI 10.1006/viro.1993.1392; FULTZ PN, 1986, J VIROL, V58, P116, DOI 10.1128/JVI.58.1.116-124.1986; GARDNER MB, 1989, FASEB J, V3, P2593, DOI 10.1096/fasebj.3.14.2556312; GREZ M, 1994, J VIROL, V68, P2161, DOI 10.1128/JVI.68.4.2161-2168.1994; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; HIRSCH VM, 1991, J INFECT DIS, V163, P976, DOI 10.1093/infdis/163.5.976; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; HSIA K, 1991, J INFECT DIS, V164, P470, DOI 10.1093/infdis/164.3.470; LETVIN NL, 1987, J INFECT DIS, V156, P406, DOI 10.1093/infdis/156.2.406; LI J, 1992, J ACQ IMMUN DEF SYND, V5, P639; LIVARTOWSKI J, 1992, CANCER DETECT PREV, V16, P341; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; MARX PA, 1985, J VIROL, V56, P571, DOI 10.1128/JVI.56.2.571-578.1985; MCCLURE J, 1992, 10TH ANN S NONH PRIM; MORROW WJW, 1989, AIDS RES HUM RETROV, V5, P233, DOI 10.1089/aid.1989.5.233; NICOL I, 1989, INTERVIROLOGY, V30, P258, DOI 10.1159/000150101; OBRIEN TR, 1992, JAMA-J AM MED ASSOC, V267, P2775; PAN LZ, 1993, J CLIN MICROBIOL, V31, P283, DOI 10.1128/JCM.31.2.283-288.1993; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PEETERS M, 1991, AIDS, V5, pS29; PUTKONEN P, 1989, J ACQ IMMUN DEF SYND, V2, P366; RACZ P, 1986, PROG ALLERGY, V37, P81; RINGLER DJ, 1989, AM J PATHOL, V134, P373; ROSENBERG YJ, 1993, AIDS RES HUM RETROV, V9, P639, DOI 10.1089/aid.1993.9.639; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SCHROEDER SA, 1992, CHEST, V101, P1065, DOI 10.1378/chest.101.4.1065; SHIBATA R, 1992, AIDS RES HUM RETROV, V8, P403, DOI 10.1089/aid.1992.8.403; STAHLHENNIG C, 1990, AIDS, V4, P611, DOI 10.1097/00002030-199007000-00001; STROMBERG K, 1984, SCIENCE, V224, P289, DOI 10.1126/science.6200929; TEIRSTEIN AS, 1988, CLIN CHEST MED, V9, P467; WYAND MS, 1989, AM J PATHOL, V134, P385	46	83	84	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					642	646		10.1126/science.7939718	http://dx.doi.org/10.1126/science.7939718			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939718				2022-12-24	WOS:A1994PN80700046
J	HO, MF; CHELLY, J; CARTER, N; DANEK, A; CROCKER, P; MONACO, AP				HO, MF; CHELLY, J; CARTER, N; DANEK, A; CROCKER, P; MONACO, AP			ISOLATION OF THE GENE FOR MCLEOD SYNDROME THAT ENCODES A NOVEL MEMBRANE-TRANSPORT PROTEIN	CELL			English	Article							BLOOD-GROUP SYSTEM; AMINO-ACID TRANSPORTER; X-LINKED MYOPATHY; GLUTAMATE TRANSPORTER; MUSCULAR-DYSTROPHY; RAT-BRAIN; EXPRESSION; CLONING; DNA; PHENOTYPE	Mcleod syndrome is an X-linked multisystem disorder characterized by abnormalities in the neuromuscular and hematopoietic systems. We have assembled a cosmid contig of 360 kb that encompasses the McLeod gene locus. A 50 kb deletion was detected by screening DNA from patients with radiolabeled whole cosmids, and two transcription units were identified within this deletion. The mRNA expression pattern of one of them, designated as XK, correlates closely to the McLeod phenotype. XK encodes a novel protein with structural characteristics of prokaryotic and eukaryotic membrane transport proteins. Nucleotide sequence analysis of XK from two unrelated McLeod patients has identified point mutations at conserved splice donor and acceptor sites. These findings provide direct evidence that XK is responsible for McLeod syndrome.	UNIV LONDON ST GEORGES HOSP, SCH MED, MED GENET UNIT, LONDON SW17 0RE, ENGLAND; UNIV MUNICH, NEUROL KLIN, D-81366 MUNICH 70, GERMANY	St Georges University London; University of Munich	HO, MF (corresponding author), JOHN RADCLIFFE HOSP, INST MOLEC MED, IMPERIAL CANC RES FUND, OXFORD OX3 9DU, ENGLAND.		Chelly, Jamel/J-7528-2015; Monaco, Anthony P/A-4495-2010; Danek, Adrian/G-7339-2011	Chelly, Jamel/0000-0002-0939-8719; Monaco, Anthony P/0000-0001-7480-3197; Danek, Adrian/0000-0001-8857-5383; Crocker, Paul/0000-0001-6230-0293				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BAXENDALE S, 1991, NUCLEIC ACIDS RES, V19, P6651, DOI 10.1093/nar/19.23.6651; BERTELSON CJ, 1986, AM J HUM GENET, V423, P703; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BRADLEY WG, 1978, NEUROLOGY, V28, P670, DOI 10.1212/WNL.28.7.670; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CALLENDER R, 1977, ANNU REV BIOPHYS BIO, V6, P33, DOI 10.1146/annurev.bb.06.060177.000341; CARPENTER S, 1979, BRAIN, V102, P147, DOI 10.1093/brain/102.1.147; CARTER ND, 1990, J MED GENET, V27, P345, DOI 10.1136/jmg.27.6.345; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE WG, 1990, J BIOL CHEM, V265, P17070; COULSON AFW, 1987, COMPUT J, V30, P420, DOI 10.1093/comjnl/30.5.420; DANEK A, 1994, NEUROLOGY, V44, P117, DOI 10.1212/WNL.44.1.117; DANEK A, 1990, ANN NEUROL, V28, P720, DOI 10.1002/ana.410280521; DIFIGLIA M, 1990, TRENDS NEUROSCI, V13, P286, DOI 10.1016/0166-2236(90)90111-M; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; GALEY WR, 1978, VOX SANG, V34, P152, DOI 10.1111/j.1423-0410.1978.tb02458.x; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HARDIE RJ, 1989, Q J MED, V71, P291; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HATA A, 1988, J BIOCHEM-TOKYO, V103, P302, DOI 10.1093/oxfordjournals.jbchem.a122265; HO MF, 1991, J HUM GENET, V50, P317; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KABACK HR, 1987, BIOCHEMISTRY-US, V26, P2071, DOI 10.1021/bi00382a001; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIRK K, 1994, J BIOL CHEM, V269, P3339; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUYPERS FA, 1985, FEBS LETT, V184, P20, DOI 10.1016/0014-5793(85)80644-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LEE S, 1993, BLOOD, V81, P2804; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; LEMOINE C, 1990, P NATL ACAD SCI USA, V87, P230, DOI 10.1073/pnas.87.1.230; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; Marsh W L, 1987, Transfus Med Rev, V1, P4; MARSH WL, 1981, VOX SANG, V40, P403, DOI 10.1111/j.1423-0410.1981.tb00728.x; MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; ORKIN SH, 1984, ANNU REV GENET, V18, P131; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIINES G, 1992, NATURE, V360, P464; REDMAN CM, 1986, J BIOL CHEM, V261, P9521; REDMAN CM, 1988, BRIT J HAEMATOL, V68, P131, DOI 10.1111/j.1365-2141.1988.tb04191.x; REDMAN CM, 1993, SEMIN HEMATOL, V30, P209; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; STECK TL, 1989, CELL SHAPE DETERMINA; SUCHYNA TM, 1993, NATURE, V365, P847, DOI 10.1038/365847a0; SWASH M, 1983, BRAIN, V106, P717, DOI 10.1093/brain/106.3.717; SYMMANS WA, 1979, BRIT J HAEMATOL, V42, P575, DOI 10.1111/j.1365-2141.1979.tb01170.x; TREISMAN R, 1982, CELL, V29, P90; UHL GR, 1992, TRENDS PHARMACOL SCI, V13, P421, DOI 10.1016/0165-6147(92)90133-Q; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; UNKLES SE, 1991, P NATL ACAD SCI USA, V88, P204, DOI 10.1073/pnas.88.1.204; VANHEIJNE G, 1986, EMBO J, V6, P3021; WEIL D, 1988, J BIOL CHEM, V263, P8561; WEXLER NS, 1991, ANNU REV NEUROSCI, V14, P503, DOI 10.1146/annurev.neuro.14.1.503; WIMER BM, 1977, BRIT J HAEMATOL, V36, P219, DOI 10.1111/j.1365-2141.1977.tb00642.x; WITT TN, 1992, J NEUROL, V239, P302, DOI 10.1007/BF00867584; YOU GF, 1993, NATURE, V365, P844, DOI 10.1038/365844a0	76	197	208	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					869	880		10.1016/0092-8674(94)90136-8	http://dx.doi.org/10.1016/0092-8674(94)90136-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004674				2022-12-24	WOS:A1994NT33100012
J	HOSODA, K; HAMMER, RE; RICHARDSON, JA; BAYNASH, AG; CHEUNG, JC; GIAID, A; YANAGISAWA, M				HOSODA, K; HAMMER, RE; RICHARDSON, JA; BAYNASH, AG; CHEUNG, JC; GIAID, A; YANAGISAWA, M			TARGETED AND NATURAL (PIEBALD-LETHAL) MUTATIONS OF ENDOTHELIN-B RECEPTOR GENE PRODUCE MEGACOLON ASSOCIATED WITH SPOTTED COAT COLOR IN MICE	CELL			English	Article							HIRSCHSPRUNGS-DISEASE; AGANGLIONIC MEGACOLON; NERVOUS-SYSTEM; BINDING-SITES; NEURAL CREST; DELETION; CLONING; PROTEIN; LIGAND; IRIDES	Endothelins act on two subtypes of G protein-coupled receptors, termed endothelin-A and endothelin-B receptors. We report a targeted disruption of the mouse endothelin-B receptor (EDNRB) gene that results in aganglionic megacolon associated with coat color spotting, resembling a hereditary syndrome of mice, humans, and other mammalian species. Piebald-lethal (s') mice exhibit a recessive phenotype identical to that of the EDNRB knockout mice. In crossbreeding studies, the two mutations show no complementation. Southern blotting revealed a deletion encompassing the entire EDNRB gene in the s(1) chromosome. A milder allele, piebald (s), which produces coat color spotting only, expresses low levels of structurally intact EDNRB mRNA and protein. These findings indicate an essential role for EDNRB in the development of two neural crest-derived cell lineages, myenteric ganglion neurons and epidermal melanocytes. We postulate that defects in the human EDNRB gene cause a hereditary form of Hirschsprung's disease that has recently been mapped to human chromosome 13, in which EDNRB is located.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX 75235; MONTREAL GEN HOSP,DEPT PATHOL,MONTREAL,PQ H3G 1A4,CANADA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; McGill University	HOSODA, K (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.			Hammer, Robert E./0000-0001-5487-7551				ANDERSON DJ, 1994, FASEB J, V8, P707, DOI 10.1096/fasebj.8.10.8050669; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAI H, 1993, J BIOL CHEM, V268, P3463; BAYNASH AG, 1994, CELL, V79; BOLGER GT, 1990, J CARDIOVASC PHARM, V16, P367, DOI 10.1097/00005344-199009000-00004; BRONNERFRASER M, 1994, FASEB J, V8, P699, DOI 10.1096/fasebj.8.10.8050668; CHALEPAKIS G, 1993, J NEUROBIOL, V24, P1367, DOI 10.1002/neu.480241009; DEOL MS, 1967, J EMBRYOL EXP MORPH, V17, P535; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FISHER E, 1994, NAT GENET, V7, P5, DOI 10.1038/ng0594-5; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; IKADAI H, 1979, Congenital Anomalies, V19, P31; INAGAKI H, 1991, GASTROENTEROLOGY, V101, P47, DOI 10.1016/0016-5085(91)90458-W; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JACKSON IJ, 1991, BIOESSAYS, V13, P439, DOI 10.1002/bies.950130903; KAPUR RP, 1992, DEVELOPMENT, V116, P167; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LAMONT MA, 1989, J MED GENET, V26, P100, DOI 10.1136/jmg.26.2.100; LANE PW, 1966, J HERED, V57, P29, DOI 10.1093/oxfordjournals.jhered.a107457; LEDOUARIN NM, 1994, CURR OPIN GENET DEV, V4, P685, DOI 10.1016/0959-437X(94)90135-P; LIANG JC, 1983, ARCH OPHTHALMOL-CHIC, V101, P69, DOI 10.1001/archopht.1983.01040010071011; LYON MF, 1988, GENETIC VARIANTS STR; MAYER TC, 1977, DEV BIOL, V56, P255, DOI 10.1016/0012-1606(77)90268-8; MCCABE L, 1990, AM J MED GENET, V36, P336, DOI 10.1002/ajmg.1320360319; METALLINOS DL, 1994, GENETICS, V136, P217; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PAVAN WJ, 1994, P NATL ACAD SCI USA, V91, P7159, DOI 10.1073/pnas.91.15.7159; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; PUFFENBERGER EG, 1994, CELL, V79; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHAH KN, 1981, J PEDIATR-US, V99, P432, DOI 10.1016/S0022-3476(81)80339-3; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; STEEL KP, 1992, DEVELOPMENT, V115, P1111; WEBSTER W, 1973, J EMBRYOL EXP MORPH, V30, P573; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YADA Y, 1991, J BIOL CHEM, V266, P18352; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320; YOHN JJ, 1994, BIOCHEM BIOPH RES CO, V201, P449, DOI 10.1006/bbrc.1994.1722; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	48	805	836	0	27	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1267	1276		10.1016/0092-8674(94)90017-5	http://dx.doi.org/10.1016/0092-8674(94)90017-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001159				2022-12-24	WOS:A1994PZ86000017
J	JENNEY, MEM				JENNEY, MEM			LANGERHANS CELL HISTIOCYTOSIS - WHERE DO WE GO FROM HERE	LANCET			English	Editorial Material							EPIPODOPHYLLOTOXINS; LEUKEMIA; CHILDREN				JENNEY, MEM (corresponding author), ROYAL MANCHESTER CHILDRENS HOSP,MANCHESTER,LANCS,ENGLAND.							BROADBENT V, 1989, MED PEDIATR ONCOL, V17, P97, DOI 10.1002/mpo.2950170205; CARSTENSEN H, 1923, MED PEDIATR ONCOL, V21, P387; CHU T, 1987, LANCET, V1, P208; EGELER RM, 1994, MED PEDIATR ONCOL, V23, P81, DOI 10.1002/mpo.2950230204; EGELER RM, 1993, CANCER, V71, P565; GADNER H, 1994, MED PEDIATR ONCOL, V23, P72, DOI 10.1002/mpo.2950230203; HAWKINS MM, 1992, BRIT MED J, V304, P951, DOI 10.1136/bmj.304.6832.951; KANNOURAKIS G, 1994, BRIT J CANCER, V70, pS37; KOMP DM, 1987, NEW ENGL J MED, V316, P747, DOI 10.1056/NEJM198703193161211; KOMP DM, 1980, MED PEDIATR ONCOL, V8, P35, DOI 10.1002/mpo.2950080106; Langerhans P, 1868, VIRCHOWS ARCH PATHOL, V44, P325, DOI [DOI 10.1007/BF01959006, 10.1007/BF01959006]; MATUSRIDLEY M, 1983, MED PEDIATR ONCOL, V11, P99, DOI 10.1002/mpo.2950110206; PRITCHARD J, 1994, BR J CANCER S23, V70; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RANEY RB, 1989, MED PEDIATR ONCOL, V17, P20, DOI 10.1002/mpo.2950170106; SIMS DG, 1977, ARCH DIS CHILD, V52, P433, DOI 10.1136/adc.52.6.433; WILLMAN CL, 1994, BRIT J CANCER, V70, pS29	17	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1717	1718		10.1016/S0140-6736(94)92882-7	http://dx.doi.org/10.1016/S0140-6736(94)92882-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7996998				2022-12-24	WOS:A1994PY28100005
J	FOSTER, JW; DOMINGUEZSTEGLICH, MA; GUIOLI, S; KWOK, C; WELLER, PA; STEVANOVIC, M; WEISSENBACH, J; MANSOUR, S; YOUNG, ID; GOODFELLOW, PN; BROOK, JD; SCHAFER, AJ				FOSTER, JW; DOMINGUEZSTEGLICH, MA; GUIOLI, S; KWOK, C; WELLER, PA; STEVANOVIC, M; WEISSENBACH, J; MANSOUR, S; YOUNG, ID; GOODFELLOW, PN; BROOK, JD; SCHAFER, AJ			CAMPOMELIC DYSPLASIA AND AUTOSOMAL SEX REVERSAL CAUSED BY MUTATIONS IN AN SRY-RELATED GENE	NATURE			English	Article							CAMPTOMELIC DWARFISM; DETERMINING REGION; Y-CHROMOSOME; DELETION; PROTEIN; INHERITANCE; SEQUENCES; ENCODES; SOX-4; MOUSE	Induction of testis development in mammals requires the presence of the Y-chromosome gene SRY. This gene must exert its effect by interacting with other genes in the sex-determination pathway. Cloning of a translocation chromosome breakpoint from a sex-reversed patient with campomelic dysplasia, followed by mutation analysis of an adjacent gene, indicates that SOX9, an SRY-related gene, is involved in both bone formation and control of testis development.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND; CITY HOSP,CTR MED GENET,NOTTINGHAM,ENGLAND; UNIV NOTTINGHAM,QUEENS MED CTR,DEPT GENET,NOTTINGHAM NG7 2UH,ENGLAND; LAB GENETHON,F-91002 EVRY,FRANCE; INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND	University of Cambridge; University of Nottingham; University of Nottingham; University of London; University College London				Brook, John David/0000-0002-5946-6740; Stevanovic, Milena/0000-0003-4286-7334; Guioli, Silvana/0000-0002-4920-7745	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; BENNETT CP, 1993, J MED GENET, V30, P518, DOI 10.1136/jmg.30.6.518; BERNSTEIN R, 1980, J MED GENET, V17, P291, DOI 10.1136/jmg.17.4.291; BIANCHINE JW, 1971, LANCET, V1, P1017; BLACK DM, 1993, AM J HUM GENET, V52, P702; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; BRIDGE J, 1985, AM J MED GENET, V21, P225, DOI 10.1002/ajmg.1320210204; BUEHR M, 1993, DEVELOPMENT, V117, P273; CAPEL B, 1993, NAT GENET, V5, P301, DOI 10.1038/ng1193-301; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; CREMIN BJ, 1973, LANCET, V1, P488; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; DILLON N, 1994, CURR OPIN GENET DEV, V5, P260; FARR CJ, 1993, MAMM GENOME, V4, P577, DOI 10.1007/BF00361388; FOSTER JW, 1994, P NATL ACAD SCI USA, V91, P1927, DOI 10.1073/pnas.91.5.1927; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HOEFNAGEL D, 1978, CLIN GENET, V13, P489; HOUSTON CS, 1983, AM J MED GENET, V15, P3, DOI 10.1002/ajmg.1320150103; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; LEHRACH H., 1990, GENOME ANAL, P39; LENZINI E, 1988, ANN GENET-PARIS, V31, P175; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LYNCH SA, 1993, J MED GENET, V30, P683, DOI 10.1136/jmg.30.8.683; MANSOUR S, 1994, THESIS U LONDON; MARAIA R, 1991, CLIN GENET, V39, P401; McKusick V.A., 1992, MENDELIAN INHERITANC; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PARKHURST SM, 1994, SCIENCE, V264, P924, DOI 10.1126/science.8178152; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SCHILHAM MW, 1993, NUCLEIC ACIDS RES, V21, P2009, DOI 10.1093/nar/21.8.2009; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STEVANOVIC M, 1993, HUM MOL GENET, V2, P2013, DOI 10.1093/hmg/2.12.2013; THURMON TF, 1973, J PEDIATR-US, V83, P841, DOI 10.1016/S0022-3476(73)80384-1; TOMMERUP N, 1993, NAT GENET, V4, P170, DOI 10.1038/ng0693-170; TOMMERUP N, 1993, J MED GENET, V30, P713, DOI 10.1136/jmg.30.9.713; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; WALTER MA, 1993, TRENDS GENET, V9, P352, DOI 10.1016/0168-9525(93)90040-O; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; Wheater P. R., 1979, FUNCTIONAL HISTOLOGY; WILKIE AOM, 1993, AM J MED GENET, V46, P597, DOI 10.1002/ajmg.1320460527; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744; YOUNG ID, 1992, J MED GENET, V29, P251, DOI 10.1136/jmg.29.4.251	44	1251	1313	2	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					525	530		10.1038/372525a0	http://dx.doi.org/10.1038/372525a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990924				2022-12-24	WOS:A1994PW08200044
J	FORGACS, I				FORGACS, I			ESCAPING GAS - IMMORTALITY, DEFLATION, AND TOXIC DILATION	LANCET			English	Editorial Material							MEGACOLON				FORGACS, I (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT GASTROENTEROL,LONDON,ENGLAND.							GARRETT JM, 1967, GASTROENTEROLOGY, V53, P93; GREENSTEIN AJ, 1985, J CLIN GASTROENTEROL, V7, P137, DOI 10.1097/00004836-198504000-00007; JALAN KN, 1969, GASTROENTEROLOGY, V57, P68, DOI 10.1016/s0016-5085(19)33962-9; KRAMER P, 1981, GASTROENTEROLOGY, V80, P433; MCINERNEY GT, 1962, GASTROENTEROLOGY, V42, P244; PANOS MZ, 1993, GUT, V34, P1726, DOI 10.1136/gut.34.12.1726; PRESENT DH, 1988, J CLIN GASTROENTEROL, V10, P485, DOI 10.1097/00004836-198810000-00004	7	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1521	1521		10.1016/S0140-6736(94)90344-1	http://dx.doi.org/10.1016/S0140-6736(94)90344-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983949				2022-12-24	WOS:A1994PV01700004
J	KELNER, GS; KENNEDY, J; BACON, KB; KLEYENSTEUBER, S; LARGAESPADA, DA; JENKINS, NA; COPELAND, NG; BAZAN, JF; MOORE, KW; SCHALL, TJ; ZLOTNIK, A				KELNER, GS; KENNEDY, J; BACON, KB; KLEYENSTEUBER, S; LARGAESPADA, DA; JENKINS, NA; COPELAND, NG; BAZAN, JF; MOORE, KW; SCHALL, TJ; ZLOTNIK, A			LYMPHOTACTIN - A CYTOKINE THAT REPRESENTS A NEW CLASS OF CHEMOKINE	SCIENCE			English	Article							EXPRESSION; FAMILY; RECEPTOR; CLONING; CELLS	In this study, the cytokine-producing profile of progenitor T cells (pro-T cells) was determined. During screening of a complementary DNA library generated from activated mouse pro-T cells, a cytokine designated lymphotactin was discovered. Lymphotactin is similar to members of both the Cys-Cys and Cys-X-Cys chemokine families but lacks two of the four cysteine residues that are characteristic of the chemokines. Lymphotactin is also expressed in activated CD8(+) T cells and CD4(-)CD8(-) T cell receptor alpha beta(+) thymocytes. It has chemotactic activity for lymphocytes but not for monocytes or neutrophils. The gene encoding lymphotactin maps to chromosome one. Taken together, these observations suggest that lymphotactin represents a novel addition to the chemokine superfamily.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304; NCI,FREDERICK CANC RES & DEV CTR,ADV BIOSCI LABS BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Largaespada, David/C-9832-2014; Zlotnik, Albert/C-3791-2011; Bazan, J. Fernando/B-4562-2010					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; BACON KB, 1988, BRIT J PHARMACOL, V95, P966, DOI 10.1111/j.1476-5381.1988.tb11727.x; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3097, DOI 10.1093/nar/21.13.3097; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DAVATELIS G, 1988, J EXP MED, V167, P1939, DOI 10.1084/jem.167.6.1939; ELLIOTT JF, 1990, P NATL ACAD SCI USA, V87, P6363, DOI 10.1073/pnas.87.16.6363; GODFREY DI, 1994, J IMMUNOL, V152, P4783; GODFREY DI, 1993, J IMMUNOL, V150, P4244; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KENNEDY JD, UNPUB; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387; ZLOTNIK A, 1992, J IMMUNOL, V149, P1211	18	590	631	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1395	1399		10.1126/science.7973732	http://dx.doi.org/10.1126/science.7973732			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973732				2022-12-24	WOS:A1994PT63200047
J	ZORIO, DAR; CHENG, NSN; BLUMENTHAL, T; SPIETH, J				ZORIO, DAR; CHENG, NSN; BLUMENTHAL, T; SPIETH, J			OPERONS AS A COMMON FORM OF CHROMOSOMAL ORGANIZATION IN C-ELEGANS	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; LEADER SEQUENCE; MESSENGER-RNA; GENE; PROTEIN	ALTHOUGH eukaryotic genes are usually transcribed individually, at least a few Caenorhabditis elegans genes appear to be transcribed polycistronically in clusters resembling bacterial operons(1). The spliced leader SL2 (ref. 2) is specific for trans-splicing to downstream genes in these operons(1). In addition, many C. elegans pre-mRNAs are trans-spliced to SL1 (ref. 3) near the 5' ends of pre-mRNAs(4,5). Because operons have not previously been found in higher eukaryotes, we have investigated how widespread they are in the C. elegans genome. We identified gene clusters using the extensive data generated by the genome project(6,7) and tested seven for trans-splicing specificity. All were found to fit expectations for polycistronic transcription. In addition, we surveyed reported C. elegans genes for irans-splicing specificity. Both methods indicate that the pre-mRNAs of about 70% of C. elegans genes are trans-spliced and as many as a quarter are transcribed in operons.			ZORIO, DAR (corresponding author), INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA.							CAPOWSKI EE, 1991, GENETICS, V129, P1061; CLARK SG, 1994, GENETICS, V137, P987; CONRAD R, 1993, EMBO J, V12, P1249, DOI 10.1002/j.1460-2075.1993.tb05766.x; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; HU E, 1991, J BIOL CHEM, V266, P19796; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; HUANG XY, 1989, J MOL BIOL, V206, P411, DOI 10.1016/0022-2836(89)90490-7; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KUWABARA PE, 1992, MOL BIOL CELL, V3, P461, DOI 10.1091/mbc.3.4.461; LAND M, 1994, J BIOL CHEM, V269, P14820; LEE YH, 1992, GENE, V121, P227, DOI 10.1016/0378-1119(92)90126-A; MORGAN WR, 1993, MOL CELL BIOL, V13, P7133, DOI 10.1128/MCB.13.11.7133; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	17	226	228	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	1994	372	6503					270	272		10.1038/372270a0	http://dx.doi.org/10.1038/372270a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969472				2022-12-24	WOS:A1994PR88900052
J	GESSLER, K; KRAUSS, N; STEINER, T; BETZEL, C; SANDMANN, C; SAENGER, W				GESSLER, K; KRAUSS, N; STEINER, T; BETZEL, C; SANDMANN, C; SAENGER, W			CRYSTAL-STRUCTURE OF BETA-D-CELLOTETRAOSE HEMIHYDRATE WITH IMPLICATIONS FOR THE STRUCTURE OF CELLULOSE-II	SCIENCE			English	Article							PACKING ANALYSIS; POLYSACCHARIDES	The crystal structure of beta-D-cellotetraose shows the same molecular packing as cellulose II, with two antiparallel molecules in the unit cell. For cellulose II, the orientation of the C6-O6 bonds has been described as gauche-trans and trans-gauche, respectively, for the two antiparallel molecules, which otherwise have identical conformations. In contrast, in beta-D-cellotetraose all C6-O6 bonds are gauche-trans, but the conformations of the two antiparallel molecules are different. Energy minimization and molecular dynamics studies suggest that the structure of cellulose II should be reinvestigated in light of these findings.	FREE UNIV BERLIN,INST KRISTALLOG,D-14195 BERLIN,GERMANY; DESY,EUROPEAN MOLEC BIOL LAB OUTSTN,D-22603 HAMBURG,GERMANY	Free University of Berlin; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)			Betzel, Christian/G-8105-2018	Betzel, Christian/0000-0002-3879-5019; Krauss, Norbert/0000-0002-7128-4632				ALTOMARE A, 1994, J APPL CRYSTALLOGR, V27, P435, DOI 10.1107/S002188989400021X; BLACKWELL J, 1980, FIBER DIFFRACTION ME, P315; CREMER D, 1975, J AM CHEM SOC, V97, P1354, DOI 10.1021/ja00839a011; DUDLEY RL, 1983, J AM CHEM SOC, V105, P2469, DOI 10.1021/ja00346a059; ISOGAI A, 1989, MACROMOLECULES, V22, P3168, DOI 10.1021/ma00197a045; KOLPAK FJ, 1976, MACROMOLECULES, V9, P273, DOI 10.1021/ma60050a019; PERTSIN AJ, 1987, ATOM ATOM POTENTIAL, P204; POLANYI M, 1921, NATURWISSENSCHAFTEN, V18, P337; SARKO A, 1974, MACROMOLECULES, V7, P486, DOI 10.1021/ma60040a016; SHELDRICK GM, 1976, SHELX PROGRAM CRYSTA; STEINER T, 1994, CARBOHYD RES, V259, P1, DOI 10.1016/0008-6215(94)84192-6; STEINER T, IN PRESS CARBOHYD RE; STIPANOVIC AJ, 1976, MACROMOLECULES, V9, P851, DOI 10.1021/ma60053a027; 1993, DISCOVER VERSION 310; [No title captured]	15	59	59	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1027	1029		10.1126/science.7973653	http://dx.doi.org/10.1126/science.7973653			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973653				2022-12-24	WOS:A1994PQ92400039
J	UMAR, A; BOYER, JC; KUNKEL, TA				UMAR, A; BOYER, JC; KUNKEL, TA			DNA LOOP REPAIR BY HUMAN CELL-EXTRACTS	SCIENCE			English	Article							COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; ADENOCARCINOMA CELLS; GENETIC INSTABILITY; ESCHERICHIA-COLI; CARCINOMA; LINES; ESTABLISHMENT; MUTATIONS; SEQUENCES	An activity in human cell extracts is described tt lat repairs DNA with loops of five or more unpaired bases. Repair is strand-specific and is directed by a nick located 5' or 3' to the loop. This repair is observed in a colorectal cancer cell line that is devoid of a wild-type hMLH1 gene and is deficient in repair of mismatches. However, a cell line with deletions in both hMSH2 alleles is deficient in repair of both loops and mismatches. Defects in loop repair may be relevant to the repetitive-sequence instability observed in cancers and other hereditary diseases.	NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Kunkel, Thomas A./D-5088-2019; Umar, Asad/AAI-4560-2020	Kunkel, Thomas A./0000-0002-9900-1788; Umar, Asad/0000-0002-6239-8494				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALLTONEN LA, 1994, CANCER RES, V54, P1645; BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CARRAWAY M, 1993, J BACTERIOL, V175, P3972, DOI 10.1128/JB.175.13.3972-3980.1993; DAWE CJ, 1964, JNCI-J NATL CANCER I, V33, P441; DEXTER DL, 1979, CANCER RES, V39, P1020; ENGEL LW, 1978, CANCER RES, V38, P3352; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1993, CELL, V75, P1075; FISHEL R, IN PRESS SCIENCE; FREAKE HC, 1981, BIOCHEM BIOPH RES CO, V101, P1131, DOI 10.1016/0006-291X(81)91565-5; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; HAN HJ, 1993, CANCER RES, V53, P5087; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOTHE RA, 1993, CANCER RES, V53, P5849; MERLO A, 1994, CANCER RES, V54, P2098; METZGAR RS, 1982, CANCER RES, V42, P601; MIRET JJ, 1994, ENV MOL MUTAGEN S23, V23, P45; MIRONOV NM, 1994, CANCER RES, V54, P41; Morisawa T, 1987, J JPN SOC CLIN CYTOL, V26, P433; PAPDOPOULOS N, 1994, SCIENCE, V263, P1625; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PELTOMAKI P, 1993, CANCER RES, V53, P5853; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SHIBATA D, 1994, NAT GENET, V6, P278; SHRIDHAR V, 1994, CANCER RES, V54, P2084; STRAND M, 1993, NATURE, V365, P273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TOM BH, 1976, IN VITRO CELL DEV B, V12, P180; UMAR A, 1994, J BIOL CHEM, V269, P14367; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; WU C, 1994, ONCOGENE, V9, P991; YEE CJ, 1994, CANCER RES, V54, P1641; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104	44	131	133	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					814	816		10.1126/science.7973637	http://dx.doi.org/10.1126/science.7973637			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973637				2022-12-24	WOS:A1994PP75300043
J	BLACKWELL, TK; BOWERMAN, B; PRIESS, JR; WEINTRAUB, H				BLACKWELL, TK; BOWERMAN, B; PRIESS, JR; WEINTRAUB, H			FORMATION OF A MONOMERIC DNA-BINDING DOMAIN BY SKN-1 BZIP AND HOMEODOMAIN ELEMENTS	SCIENCE			English	Article							GCN4 ACTIVATOR PROTEIN; LEUCINE ZIPPER MOTIF; C-ELEGANS EMBRYOS; CRYSTAL-STRUCTURE; TRANSCRIPTION FACTOR; BASIC REGION; ANTENNAPEDIA HOMEODOMAIN; NMR-SPECTROSCOPY; HIGH-RESOLUTION; COILED COIL	Maternally expressed Skn-1 protein is required for the correct specification of certain blastomere fates in early Caenorhabditis elegans embryos. Skn-1 contains a basic region similar to those of basic leucine zipper (bZIP) proteins but, paradoxically, it lacks a leucine zipper dimerization segment. Random sequence selection methods were used to show that Skn-1 binds to specific DNA sequences as a monomer. The Skn-1 basic region lies at the carboxyl terminus of an 85-amino acid domain that binds preferentially to a bZIP half-site and also recognizes adjacent 5' AT-rich sequences in the minor groove, apparently with an amino (NH2)-terminal ''arm'' related to those of homeodomain proteins. The intervening residues appear to stabilize interactions of these two subdomains with DNA. The Skn-1 DNA binding domain thus represents an alternative strategy for promoting binding of a basic region segment recognition helix to its cognate half-site. The results point to an underlying modularity in subdomains within established DNA binding domains.	FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center								AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, UNPUB; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BOWERMAN B, UNPUB; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHEN L, 1992, SCIENCE, V256, P240, DOI 10.1126/science.1314423; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GOUTTE C, 1994, EMBO J, V13, P1434, DOI 10.1002/j.1460-2075.1994.tb06397.x; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRAUSE M, IN PRESS DEV BIOL; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; MOHLER J, 1990, MECH DEVELOP, V34, P3; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; PU WT, 1992, NUCLEIC ACIDS RES, V20, P771, DOI 10.1093/nar/20.4.771; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RUBERTI I, 1991, EMBO J, V10, P1787, DOI 10.1002/j.1460-2075.1991.tb07703.x; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHUBERT C, UNPUB; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; SESSA G, 1993, EMBO J, V12, P3507, DOI 10.1002/j.1460-2075.1993.tb06025.x; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	69	135	139	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					621	628		10.1126/science.7939715	http://dx.doi.org/10.1126/science.7939715			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939715				2022-12-24	WOS:A1994PN80700040
J	RIDDIHOUGH, G				RIDDIHOUGH, G			ONE IN THE EYE	NATURE			English	Article							CRYSTALLINS	A double insight into visual accommodation by the eye lens in birds and into the activity of a superfamily of metabolic enzymes is provided by the structure of turkey lens delta-crystallin.										DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; PIATIGORSKY J, 1991, SCIENCE, V252, P1078, DOI 10.1126/science.252.5009.1078; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; SIMPSON A, 1994, NAT STRUCT BIOL, V1, P724, DOI 10.1038/nsb1094-724	4	2	2	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					538	538		10.1038/371538a0	http://dx.doi.org/10.1038/371538a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935769	Bronze			2022-12-24	WOS:A1994PK58900063
J	ALMOHANNA, FA; CADDY, KWT; BOLSOVER, SR				ALMOHANNA, FA; CADDY, KWT; BOLSOVER, SR			THE NUCLEUS IS INSULATED FROM LARGE CYTOSOLIC CALCIUM-ION CHANGES	NATURE			English	Article							SMOOTH-MUSCLE CELLS; C-FOS EXPRESSION; INTRACELLULAR CALCIUM; CONFOCAL MICROSCOPY; PORE COMPLEX; NEURONS; TRANSCRIPTION; TRANSIENTS; GRADIENTS; DYNAMICS	EXTRACELLULAR events regulate functions in the cell nucleus by means of calcium ions acting through effector enzymes1-5. Recently, the traditional view of the nuclear pore as freely permeable to small ions6,7 has been questioned as a result of reports that nuclear calcium can be regulated independently of cytosolic calcium8-12. We have used confocal microscopy of fluorescent Ca2+ indicators to investigate the Ca2+ dynamics between cytosol and nucleus in neurons. We find that a previously reported amplification of Ca2+ changes in the nucleus13-16 is a measurement artefact. Small changes of cytosolic Ca2+ cause equally rapid changes in nuclear Ca2+, consistent with the free diffusion of Ca2+ through nuclear pores. In contrast, large cytosolic Ca2+ increases (above 300 nM) are attempted in the nucleus. Our results show the nuclear envelope shapes but does not block the passage of Ca2+ signals from cytosol to nucleus.	UNIV LONDON UNIV COLL,DEPT PHYSIOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALMOHANNA FA, 1992, DEV BRAIN RES, V70, P287, DOI 10.1016/0165-3806(92)90209-F; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BIRCH BD, 1992, P NATL ACAD SCI USA, V89, P7978, DOI 10.1073/pnas.89.17.7978; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CONNOR JA, 1993, CELL CALCIUM, V14, P185, DOI 10.1016/0143-4160(93)90066-F; DIVIRGILIO F, 1990, CELL CALCIUM, V11, P57, DOI 10.1016/0143-4160(90)90059-4; DRAGUNOW M, 1989, NEUROSCI LETT, V101, P274, DOI 10.1016/0304-3940(89)90545-4; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HIMPENS B, 1992, AM J PHYSIOL, V263, pC95, DOI 10.1152/ajpcell.1992.263.1.C95; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOLLIDAY J, 1991, NEURON, V7, P787, DOI 10.1016/0896-6273(91)90281-4; MEHMET H, 1991, BRIT MED BULL, V47, P76, DOI 10.1093/oxfordjournals.bmb.a072463; MINTA A, 1989, J BIOL CHEM, V264, P8171; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MURDOCH GH, 1985, J BIOL CHEM, V260, P1852; NEYLON CB, 1990, AM J PHYSIOL, V259, pC675, DOI 10.1152/ajpcell.1990.259.4.C675; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SILVER RA, 1990, NATURE, V343, P751, DOI 10.1038/343751a0; STRICKER SA, 1992, DEV BIOL, V149, P370, DOI 10.1016/0012-1606(92)90292-O; WAHL M, 1992, J CELL PHYSIOL, V150, P593, DOI 10.1002/jcp.1041500321; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0	25	228	232	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					745	750		10.1038/367745a0	http://dx.doi.org/10.1038/367745a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	7993399				2022-12-24	WOS:A1994MX63100061
J	MALONEY, SA; PEARSON, ML; GORDON, MT; DELCASTILLO, R; BOYLE, JF; JARVIS, WR				MALONEY, SA; PEARSON, ML; GORDON, MT; DELCASTILLO, R; BOYLE, JF; JARVIS, WR			EFFICACY OF CONTROL MEASURES IN PREVENTING NOSOCOMIAL TRANSMISSION OF MULTIDRUG-RESISTANT TUBERCULOSIS TO PATIENTS AND HEALTH-CARE WORKERS	ANNALS OF INTERNAL MEDICINE			English	Article						RESISTANCE; MULTIPLE; CROSS INFECTION; DISEASE TRANSMISSION; TUBERCULOSIS; INFECTION CONTROL	MYCOBACTERIUM-TUBERCULOSIS; IMMUNODEFICIENCY-SYNDROME; INFECTION; OUTBREAK	Objective: To assess the efficacy of control measures in decreasing nosocomial transmission of multidrug-resistant tuberculosis. Design: Retrospective cohort study. Setting: A teaching hospital in New York City. Population: 40 patients hospitalized with multidrug-resistant tuberculosis (case-patients) and health care workers receiving tuberculin skin testing. Interventions: Centers for Disease Control and Prevention (CDC) 1990 guidelines for preventing transmission of tuberculosis, including 1) prompt isolation and treatment of patients with tuberculosis; 2) rapid diagnostic techniques for processing Mycobacterium tuberculosis specimens; 3) negative-pressure isolation rooms; and 4) molded surgical masks for health care workers. Measurements: Proportion of case-patients with nosocomially acquired tuberculosis and rate of tuberculin skin test conversion among health care workers before and after implementation of control measures. Results: The proportion of patients with multidrug-resistant strains of M. tuberculosis decreased after the interventions (10 of 70 [14%] compared with 30 of 95 [32%] patients before the intervention; relative risk [RR], 0.5; 95% CI, 0.2 to 0.9). Before onset of multidrug-resistant tuberculosis, case-patients in the intervention period were as likely to be hospitalized on high-risk wards containing patients with tuberculosis (4 of 10 compared with 17 of 30 patients; RR, 0.7; P = 0.5) but were less likely to be exposed to another case-patient with tuberculosis (1 of 10 compared with 20 of 30 patients; RR, 0.2; P = 0.003). Tuberculin skin test conversion rates for health care workers assigned to wards housing patients with tuberculosis were lower in the intervention period than in the preintervention period (4 of 78 [5%] compared with 15 of 90 [17%] conversions; P = 0.02), decreasing to levels observed for workers assigned to other wards (4 of 78 [5%] compared with 9 of 228 [4%] conversions; P = 0.7). Conclusions: Implementing control measures reduced nosocomial transmission of multidrug-resistant strains to patients and health care workers.	CTR DIS CONTROL, HOSP INFECT PROGRAM, ATLANTA, GA 30333 USA; CABRINI MED CTR, NEW YORK, NY 10003 USA	Centers for Disease Control & Prevention - USA								BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P718; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; CHEN SK, 1994, AM J INFECT CONTROL, V22, P65, DOI 10.1016/0196-6553(94)90116-3; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; DEAN AG, 1991, EPI INFO VERSION 5 0; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; HUTTON MD, 1992, AM J INFECT CONTROL, V20, P24, DOI 10.1016/S0196-6553(05)80121-X; ISEMAN MD, 1992, ANN INTERN MED, V117, P251, DOI 10.7326/0003-4819-117-3-251; NOLAN CM, 1992, AM J INFECT CONTROL, V20, P30, DOI 10.1016/S0196-6553(05)80123-3; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; PITCHENIK AE, 1990, LANCET, V336, P440, DOI 10.1016/0140-6736(90)91987-L; PUGLIESE G, 1992, AM J INFECT CONTROL, V20, P37, DOI 10.1016/S0196-6553(05)80125-7; RAMIREZ JA, 1992, INFECT CONT HOSP EP, V13, P579, DOI 10.2307/30148459; SNIDER DE, 1985, JAMA-J AM MED ASSOC, V253, P3438, DOI 10.1001/jama.253.23.3438; VALWAY S, 1993, 33 INT C ANT AG CHEM, P231	20	143	144	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					90	95		10.7326/0003-4819-122-2-199501150-00002	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7993001				2022-12-24	WOS:A1995QC05900002
J	MOSS, G; COHEN, S				MOSS, G; COHEN, S			PATENTS IN THE PUBLIC-INTEREST	NATURE			English	Article								The UH High Court has granted an injunction allowing Chiron Corporation a monopoly in selling hepatitis C virus test kits. The decision will be welcomed by the pharmaceutical and biotechnology industries.			MOSS, G (corresponding author), TAYLOR JOYNSON GARRETT,50 VICTORIA EMBANKMENT,LONDON EC4Y 0DX,ENGLAND.								0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					814	814						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997274				2022-12-24	WOS:A1994PY21200063
J	CHOO, Y; SANCHEZGARCIA, I; KLUG, A				CHOO, Y; SANCHEZGARCIA, I; KLUG, A			IN-VIVO REPRESSION BY A SITE-SPECIFIC DNA-BINDING PROTEIN DESIGNED AGAINST AN ONCOGENIC SEQUENCE	NATURE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTION FACTOR-IIIA; C-ABL PROTEIN; MAMMALIAN-CELLS; PHILADELPHIA-CHROMOSOME; DOMAINS; EXPRESSION; GENES; BCR	A DNA-binding peptide comprising three zinc-fingers has been engineered to bind specifically to a unique nine-base-pair region of a BCR-ABL fusion oncogene in preference to the parent genomic sequences. Binding to the target oncogene in chromosomal DNA is possible In transformed cells in culture, and results in blockage of transcription. Consequently, murine cells rendered independent of growth factors by the action of the oncogene revert to factor dependence upon transient transfection with a vector expressing the peptide.			CHOO, Y (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		SANCHEZ-GARCIA, ISIDRO/A-5631-2019	Choo, Yen/0000-0002-3348-9602; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905				BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; CHOO Y, 1993, NUCLEIC ACIDS RES, V21, P3341, DOI 10.1093/nar/21.15.3341; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COONEY M, 1988, SCIENCE, V245, P725; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HERSCHBACH BM, 1994, NATURE, V370, P309, DOI 10.1038/370309a0; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NOWELL PC, 1960, SCIENCE, V132, P1197; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515	37	235	300	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					642	645		10.1038/372642a0	http://dx.doi.org/10.1038/372642a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990954	Green Submitted			2022-12-24	WOS:A1994PX30700076
J	DIMARZO, V; FONTANA, A; CADAS, H; SCHINELLI, S; CIMINO, G; SCHWARTZ, JC; PIOMELLI, D				DIMARZO, V; FONTANA, A; CADAS, H; SCHINELLI, S; CIMINO, G; SCHWARTZ, JC; PIOMELLI, D			FORMATION AND INACTIVATION OF ENDOGENOUS CANNABINOID ANANDAMIDE IN CENTRAL NEURONS	NATURE			English	Article							N-ACYLETHANOLAMINE PHOSPHOLIPIDS; RECEPTOR; BRAIN; GLYCEROPHOSPHOLIPIDS; AGONIST; BINDS; CELLS	ANANDAMIDE (N-arachidonoyl-ethanolamine) was recently identified as a brain arachidonate derivative that binds to and activates cannabinoid receptors(1-4), yet the mechanisms underlying formation, release and inactivation of this putative messenger molecule are still unclear. Were we report that anandamide is produced in and released from cultured brain neurons in a calcium ion-dependent manner when the neurons are stimulated with membrane-depolarizing agents. Anandamide formation occurs through phosphodiesterase-mediated cleavage of a novel phospholipid precursor, N-arachidonoyl-phosphatidylethanolamine. A similar mechanism also governs the formation of a family of anandamide congeners, whose possible roles in neuronal signalling remain unknown. Our results and those of others(5,6) indicate therefore that multiple biochemical pathways may participate in anandamide formation in brain tissue. The life span of extracellular anandamide is limited by a rapid and selective process of cellular uptake, which is accompanied by hydrolytic degradation to ethanolamine and arachidonate. Our results thus strongly support the proposed role of anandamide as an endogenous neuronal messenger.	INSERM,CTR PAUL BROCA,UNITE NEUROBIOL & PHARMACOL,PARIS,FRANCE; CNR,IST CHIM MOLEC INTERESSE BIOL,NAPLES,ITALY	Institut National de la Sante et de la Recherche Medicale (Inserm); Consiglio Nazionale delle Ricerche (CNR)			Fontana, Angelo/AAO-2741-2021; Di Marzo, Vincenzo/AAD-7742-2019; Fontana, Angelo/C-3354-2012	Fontana, Angelo/0000-0002-5453-461X; Di Marzo, Vincenzo/0000-0002-1490-3070; Fontana, Angelo/0000-0002-5453-461X				BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; COLODZIN M, 1963, BIOCHEM BIOPH RES CO, V10, P165, DOI 10.1016/0006-291X(63)90044-5; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; EPPS DE, 1982, CELL CALCIUM, V3, P531, DOI 10.1016/0143-4160(82)90043-4; EPPS DE, 1980, BIOCHIM BIOPHYS ACTA, V618, P420, DOI 10.1016/0005-2760(80)90260-X; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; GULAYA NM, 1993, BIOCHIM BIOPHYS ACTA, V1152, P280, DOI 10.1016/0005-2736(93)90259-3; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KRUSZKA KK, 1994, J BIOL CHEM, V269, P14345; LU B, 1991, J NEUROSCI, V11, P318; MACKIE K, 1993, MOL PHARMACOL, V44, P498; MATSUMOTO M, 1973, BIOCHIM BIOPHYS ACTA, V296, P350, DOI 10.1016/0005-2760(73)90093-3; NATARAJAN V, 1984, J NEUROCHEM, V42, P1613, DOI 10.1111/j.1471-4159.1984.tb12750.x; PERTWEE RG, 1993, BRIT J PHARMACOL, V110, P1483, DOI 10.1111/j.1476-5381.1993.tb13989.x; PIOMELLI D, 1994, CRIT REV NEUROBIOL, V8, P65; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; SCHMID PC, 1983, J BIOL CHEM, V258, P9302; SCHMID PC, 1985, J BIOL CHEM, V260, P4145; YUE TL, 1994, CRIT REV NEUROBIOL, V8, P11	22	1267	1296	1	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					686	691		10.1038/372686a0	http://dx.doi.org/10.1038/372686a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990962	Green Submitted			2022-12-24	WOS:A1994PX30700089
J	GORDIS, E				GORDIS, E			UNRAVELING THE BRAIN CHEMISTRY BEHIND ALCOHOL-ABUSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GORDIS, E (corresponding author), NIAAA,BETHESDA,MD, USA.							VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P881; IN PRESS NIDA RES MO	3	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	1994	272	22					1733	1733						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PV815	7966919				2022-12-24	WOS:A1994PV81500020
J	GRUNDEMANN, D; GORBOULEV, V; GAMBARYAN, S; VEYHL, M; KOEPSELL, H				GRUNDEMANN, D; GORBOULEV, V; GAMBARYAN, S; VEYHL, M; KOEPSELL, H			DRUG EXCRETION MEDIATED BY A NEW PROTOTYPE OF POLYSPECIFIC TRANSPORTER	NATURE			English	Article							BASOLATERAL MEMBRANE-VESICLES; RENAL BRUSH-BORDER; ORGANIC CATIONS; TETRAETHYLAMMONIUM; PROTEIN; CLONING; MECHANISM; UPTAKE2; RNA	CATIONIC drugs of different types and structures (antihistaminics, antiarrhythmics, sedatives, opiates, cytostatics and antibiotics, for example) are excreted in mammals by epithelial cells of the renal proximal tubules and by hepatocytes in the liver(1-4). In the proximal tubules, two functionally disparate transport systems are involved which are localized in the basolateral and luminal plasma membrane and are different from the previously identified neuronal monoamine transporters and ATP-dependent multidrug exporting proteins(1-3,5-12). Here we report the isolation of a complementary DNA from rat kidney that encodes a 556-amino-acid membrane protein, OCT1, which has the functional characteristics of organic cation uptake over the basolateral membrane of renal proximal tubules and of organic cation uptake into hepatocytes. OCT1 is not homologous to any other known protein and is found in kidney, liver and intestine. As OCT1 translocates hydrophobic and hydrophilic organic cations of different structures, it is considered to be a new prototype of polyspecific transporters that are important for drug elimination.	UNIV WURZBURG,INST ANAT,D-97070 WURZBURG,GERMANY	University of Wurzburg			Gambaryan, Stepan/I-3940-2016; Gründemann, Dirk/AAD-2217-2022	Gambaryan, Stepan/0000-0002-1470-0791; 				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVID D, 1994, K GESELLSCHAFT NEPHR, P472; GINGRICH JA, 1992, FEBS LETT, V312, P115, DOI 10.1016/0014-5793(92)80917-6; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HOHAGE H, 1994, J PHARMACOL EXP THER, V268, P897; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; MEIJER DKF, 1990, J PHARMACOKINET BIOP, V18, P35, DOI 10.1007/BF01063621; MONTROSERAFIZADEH C, 1989, AM J PHYSIOL, V257, pF243, DOI 10.1152/ajprenal.1989.257.2.F243; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Pritchard J.B., 1992, KIDNEY PHYSL PATHOPH, P2921; Roch-Ramel F., 1992, HDB PHYSL 8, P2189; RUSS H, 1992, N-S ARCH PHARMACOL, V346, P158, DOI 10.1007/BF00165297; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLOSS P, 1992, FEBS LETT, V307, P76, DOI 10.1016/0014-5793(92)80905-V; SCHOMIG E, 1993, N-S ARCH PHARMACOL, V347, P379, DOI 10.1007/BF00165387; SCHOMIG E, 1990, N-S ARCH PHARMACOL, V341, P404; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; SOKOL PP, 1990, AM J PHYSIOL, V258, pF1599; TAKANO M, 1984, BIOCHIM BIOPHYS ACTA, V773, P113, DOI 10.1016/0005-2736(84)90556-X; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; Trendelenburg U, 1988, HDB EXP PHARM, P279; ULLRICH KJ, 1991, PFLUG ARCH EUR J PHY, V419, P84, DOI 10.1007/BF00373751; ULLRICH KJ, 1994, BBA-REV BIOMEMBRANES, V1197, P45, DOI 10.1016/0304-4157(94)90018-3; VEYHL M, 1993, J BIOL CHEM, V268, P25041; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF1040, DOI 10.1152/ajprenal.1987.253.5.F1040	27	559	575	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					549	552		10.1038/372549a0	http://dx.doi.org/10.1038/372549a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990927	Green Submitted			2022-12-24	WOS:A1994PW08200052
J	HUMPHREYS, GW; ROMANI, C; OLSON, A; RIDDOCH, MJ; DUNCAN, J				HUMPHREYS, GW; ROMANI, C; OLSON, A; RIDDOCH, MJ; DUNCAN, J			NON SPATIAL EXTINCTION FOLLOWING LESIONS OF THE PARIETAL LOBE IN HUMANS	NATURE			English	Article							ATTENTION; PICTURES; OBJECT; WORDS	EFFICIENT behaviour in the visual environment requires selection between stimuli competing for control of action. Many current models of selection are spatial: relevant objects are chosen by attending to their locations(1-3). The unilateral stimulus extinction observed following lesions of the parietal lobe provides evidence for spatial selection(4). Such patients may identify a single stimulus presented in their contralesional field, but can fail to detect the same stimulus when a competing stimulus is shown simultaneously on the ipsilesional side(5). Here we demonstrate that extinction need not be spatial in nature, but may be determined by characteristics of the objects to be selected. In two patients with parietal lobe lesions and poor spatial localization, pictures extinguished words and closed shapes extinguished open shapes. This object-based extinction indicates the existence of biases within non-spatial selection mechanisms which are independent of biases produced by spatial selection mechanisms. We suggest that selection of objects for action requires that the 'winners' produced by the independent competitive biases for selection are bound together within distinct neural areas concerned with object properties and space.	MRC,APPL PSYCHOL UNIT,CAMBRIDGE CB2 2EF,ENGLAND	University of Cambridge	HUMPHREYS, GW (corresponding author), UNIV BIRMINGHAM,SCH PSYCHOL,COGNIT SCI RES CTR,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Riddoch, Jane/F-7968-2010	Romani, Cristina/0000-0002-5693-4131; Duncan, John S/0000-0002-1373-0681; Duncan, John/0000-0002-9695-2764				Balint R, 1909, MON PSYCHIATR NEUROL, V25, P51; BIEDERMAN I, 1987, PSYCHOL REV, V94, P115, DOI 10.1037/0033-295X.94.2.115; COSLETT HB, 1991, BRAIN, V114, P1523, DOI 10.1093/brain/114.4.1523; Critchley M., 1953, PARIETAL LOBES; DRIVER J, 1991, COGNITIVE NEUROPSYCH, V8, P475, DOI 10.1080/02643299108253384; DUNCAN J, 1993, PERCEPTION, V2, P1261; EGLY R, 1994, J EXP PSYCHOL GEN, V123, P161, DOI 10.1037/0096-3445.123.2.161; HUMPHREYS GW, 1981, Q J EXP PSYCHOL-A, V33, P17, DOI 10.1080/14640748108400765; HUMPHREYS GW, 1993, ATTENTION PERFORMANC, V14; KROLL JF, 1984, J VERB LEARN VERB BE, V23, P39, DOI 10.1016/S0022-5371(84)90499-7; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; Mozer M C, 1990, J Cogn Neurosci, V2, P96, DOI 10.1162/jocn.1990.2.2.96; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POTTER MC, 1975, NATURE, V253, P437, DOI 10.1038/253437a0; UNGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOR	16	99	99	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					357	359		10.1038/372357a0	http://dx.doi.org/10.1038/372357a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PU287	7969493				2022-12-24	WOS:A1994PU28700054
J	XU, M; MORATALLA, R; GOLD, LH; HIROI, N; KOOB, GF; GRAYBIEL, AM; TONEGAWA, S				XU, M; MORATALLA, R; GOLD, LH; HIROI, N; KOOB, GF; GRAYBIEL, AM; TONEGAWA, S			DOPAMINE D1 RECEPTOR MUTANT MICE ARE DEFICIENT IN STRIATAL EXPRESSION OF DYNORPHIN AND IN DOPAMINE-MEDIATED BEHAVIORAL-RESPONSES	CELL			English	Article							C-FOS; RAT STRIATUM; SUBSTANCE-P; MOLECULAR-CLONING; BASAL GANGLIA; AUTORADIOGRAPHIC LOCALIZATION; PHENOTYPICAL CHARACTERIZATION; STRIATONIGRAL DYNORPHIN; MATRIX COMPARTMENTS; PROJECTION NEURONS	The brain dopaminergic system is a critical modulator of basal ganglia function and plasticity. To investigate the contribution of the dopamine D1 receptor to this modulation, we have used gene targeting technology to generate D1 receptor mutant mice. Histological analyses suggested that there are no major changes in general anatomy of the mutant mouse brains, but indicated that the expression of dynorphin is greatly reduced in the striatum and related regions of the basal ganglia. The mutant mice do not respond to the stimulant and suppressive effects of D1 receptor agonists and antagonists, respectively, and they exhibit locomotor hyperactivity. These results suggest that the D1 receptor regulates the neurochemical architecture of the striatum and is critical for the normal expression of motor activity.	MIT, CTR LEARNING & MEMORY, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Scripps Research Institute	XU, M (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		Moratalla, Rosario V/H-9280-2015; Hiroi, Noboru/E-2215-2013	Moratalla, Rosario V/0000-0002-7623-8010; Hiroi, Noboru/0000-0002-6846-5969; Graybiel, Ann/0000-0002-4326-7720	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD028341] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028341] Funding Source: NIH RePORTER; NICHD NIH HHS [HD28341] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; AMALRIC M, 1993, NEUROPSYCHOPHARMACOL, V8, P195, DOI 10.1038/npp.1993.21; ANDERSON KD, 1990, J COMP NEUROL, V295, P339, DOI 10.1002/cne.902950302; ANDERSON KD, 1991, BRAIN RES, V568, P235, DOI 10.1016/0006-8993(91)91403-N; ARIANO MA, 1989, P NATL ACAD SCI USA, V86, P8570, DOI 10.1073/pnas.86.21.8570; Bergman J., 1990, Behav Pharmacol, V1, P355; BERNARD V, 1992, J NEUROSCI, V12, P3591; BESSON MJ, 1990, NEUROSCIENCE, V39, P33, DOI 10.1016/0306-4522(90)90220-X; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRONSTEIN DM, 1994, MOL BRAIN RES, V23, P191, DOI 10.1016/0169-328X(94)90226-7; CABIB S, 1991, PSYCHOPHARMACOLOGY, V105, P335, DOI 10.1007/BF02244427; CAINE SB, 1994, J PHARMACOL EXP THER, V270, P209; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; DAUNAIS JB, 1993, NEUROREPORT, V4, P543, DOI 10.1097/00001756-199305000-00020; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DILTS RP, 1993, SYNAPSE, V13, P251, DOI 10.1002/syn.890130308; DREHER JK, 1989, BRAIN RES, V487, P267, DOI 10.1016/0006-8993(89)90831-7; FALLON JH, 1978, J COMP NEUROL, V180, P533, DOI 10.1002/cne.901800309; FENTRESS JC, 1981, ANAT EMBRYOL, V163, P275, DOI 10.1007/BF00315705; FISHELL G, 1991, J COMP NEUROL, V312, P33, DOI 10.1002/cne.903120104; FOSTER GA, 1987, J NEUROSCI, V7, P1994; FUXE K, 1969, NEUROENDOCRINOLOGY, V5, P257, DOI 10.1159/000121887; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GERFEN CR, 1985, P NATL ACAD SCI USA, V82, P8780, DOI 10.1073/pnas.82.24.8780; GERFEN CR, 1991, J NEUROSCI, V11, P1016; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GRAYBIEL AM, 1984, NEUROSCIENCE, V13, P1157, DOI 10.1016/0306-4522(84)90293-8; GRAYBIEL AM, 1982, P NATL ACAD SCI-BIOL, V79, P198, DOI 10.1073/pnas.79.1.198; GRAYBIEL AM, 1989, P NATL ACAD SCI USA, V86, P9020, DOI 10.1073/pnas.86.22.9020; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; GRAYBIEL AM, 1990, J NEUROSCI, V10, P720; Graybiel AM, 1984, CORTICAL INTEGRATION, P223; GRAYBIEL AM, 1983, CHEM NEUROANATOMY, P427; HANSON GR, 1987, EUR J PHARMACOL, V144, P245, DOI 10.1016/0014-2999(87)90527-9; HORNYKIEWICZ O, 1966, PHARMACOL REV, V18, P925; HURD YL, 1993, SYNAPSE, V13, P357, DOI 10.1002/syn.890130408; HURD YL, 1992, MOL BRAIN RES, V13, P165, DOI 10.1016/0169-328X(92)90058-J; JIANG HK, 1990, BRAIN RES, V507, P57, DOI 10.1016/0006-8993(90)90522-D; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; KOOB GF, 1978, J COMP PHYSIOL PSYCH, V92, P917, DOI 10.1037/h0077542; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; KOOB GF, 1987, NEUROSCI LETT, V79, P315, DOI 10.1016/0304-3940(87)90451-4; KOOB GF, 1992, SEMIN NEUROSCI, V4, P139; KUBOTA Y, 1993, NEUROREPORT, V5, P205, DOI 10.1097/00001756-199312000-00004; LEMOAL M, 1991, PHYSIOL REV, V71, P155, DOI 10.1152/physrev.1991.71.1.155; LEMOINE C, 1991, P NATL ACAD SCI USA, V88, P4205, DOI 10.1073/pnas.88.10.4205; LI S, 1986, BRAIN RES, V398, P390, DOI 10.1016/0006-8993(86)91502-7; LI SJ, 1988, J PHARMACOL EXP THER, V246, P403; LINDVALL O, 1983, CHEM NEUROANATOMY, P229; LIU FC, 1994, IN PRESS J NEUROSCI; MAILMAN RB, 1984, EUR J PHARMACOL, V101, P159, DOI 10.1016/0014-2999(84)90044-X; MEADORWOODRUFF JH, 1991, NEUROPSYCHOPHARMACOL, V5, P231; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; MOORCROFT WH, 1971, J COMP PHYSIOL PSYCH, V75, P59, DOI 10.1037/h0030670; MORATALLA R, 1993, J NEUROSCI, V13, P423; MORATALLA R, 1992, J NEUROSCI, V12, P2609; MURRIN LC, 1989, BRAIN RES, V480, P170; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; PAUL ML, 1992, J NEUROSCI, V12, P3729, DOI 10.1523/jneurosci.12-10-03729.1992; PENNYPACKER KR, 1992, MOL BRAIN RES, V15, P151, DOI 10.1016/0169-328X(92)90163-6; PERT CB, 1976, P NATL ACAD SCI USA, V73, P3729, DOI 10.1073/pnas.73.10.3729; PERTWEE RG, 1972, BRIT J PHARMACOL, V46, P753, DOI 10.1111/j.1476-5381.1972.tb06900.x; PIOMELLI D, 1991, NATURE, V353, P164, DOI 10.1038/353164a0; SAVASTA M, 1986, BRAIN RES, V375, P291, DOI 10.1016/0006-8993(86)90749-3; SCHAMBRA B, 1994, NEUROSCIENCE, V62, P65, DOI 10.1016/0306-4522(94)90315-8; SHARP T, 1987, BRAIN RES, V401, P322, DOI 10.1016/0006-8993(87)91416-8; SIBLEY DR, 1993, INT REV NEUROBIOL, V35, P391, DOI 10.1016/S0074-7742(08)60573-5; SIVAM SP, 1989, J PHARMACOL EXP THER, V250, P818; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STEINER H, 1993, J NEUROSCI, V13, P5066, DOI 10.1523/JNEUROSCI.13-12-05066.1993; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SURMEIER DJ, 1992, P NATL ACAD SCI USA, V89, P10178, DOI 10.1073/pnas.89.21.10178; SURMEIER DJ, 1993, TRENDS NEUROSCI, V16, P299, DOI 10.1016/0166-2236(93)90103-S; VANDERKOOY D, 1987, BRAIN RES, V401, P155, DOI 10.1016/0006-8993(87)91176-0; vanderKooy D, 1987, BASAL GANGLIA, P81; VINCENT SR, 1983, J COMP NEUROL, V217, P252, DOI 10.1002/cne.902170303; VOORN P, 1988, NEUROSCIENCE, V25, P857, DOI 10.1016/0306-4522(88)90041-3; WALAAS SI, 1984, J NEUROSCI, V4, P84; WEINER DM, 1990, P NATL ACAD SCI USA, V87, P7050, DOI 10.1073/pnas.87.18.7050; WEISS B, 1993, NEUROSCIENCE, V55, P607, DOI 10.1016/0306-4522(93)90426-G; WOOLVERTON WL, 1986, PHARMACOL BIOCHEM BE, V24, P531, DOI 10.1016/0091-3057(86)90553-8; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291; ZHANG M, 1993, NEUROSCI LETT, V161, P223, DOI 10.1016/0304-3940(93)90299-Z; ZHANG WQ, 1992, BRAIN RES, V577, P312, DOI 10.1016/0006-8993(92)90289-L; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	91	415	422	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 18	1994	79	4					729	742		10.1016/0092-8674(94)90557-6	http://dx.doi.org/10.1016/0092-8674(94)90557-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954836				2022-12-24	WOS:A1994PT48100019
J	MCGILL, JI; WHITE, JE				MCGILL, JI; WHITE, JE			ACYCLOVIR AND POSTHERPETIC NEURALGIA AND OCULAR INVOLVEMENT	BRITISH MEDICAL JOURNAL			English	Article							ZOSTER				MCGILL, JI (corresponding author), UNIV SOUTHAMPTON,GEN HOSP,EYE UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.							MCGILL J, 1987, BRIT J OPHTHALMOL, V71, P118, DOI 10.1136/bjo.71.2.118; MCGILL J, 1983, J INFECTION, V6, P157, DOI 10.1016/S0163-4453(83)92787-1; MCKENDRICK MW, 1986, BRIT MED J, V293, P1529, DOI 10.1136/bmj.293.6561.1529; PETERSLUND NA, 1981, LANCET, V2, P827; RAGOZZINO MW, 1982, MEDICINE, V61, P310, DOI 10.1097/00005792-198209000-00003	5	15	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1124	1124		10.1136/bmj.309.6962.1124	http://dx.doi.org/10.1136/bmj.309.6962.1124			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987104	Green Published			2022-12-24	WOS:A1994PP69100021
J	NAISH, J; BROWN, J; DENTON, B				NAISH, J; BROWN, J; DENTON, B			INTERCULTURAL CONSULTATIONS - INVESTIGATION OF FACTORS THAT DETER NON-ENGLISH SPEAKING WOMEN FROM ATTENDING THEIR GENERAL-PRACTITIONERS FOR CERVICAL SCREENING	BRITISH MEDICAL JOURNAL			English	Article							CYTOLOGY; RECALL	Objectives-To determine the factors that deter ethnic minority women living in east London from attending their general practitioner for cervical cytology screening. Design-Qualitative study by means of focus group discussions between October 1993 and March 1994. Setting-East London. Subjects-Non-health specific established community groups and specially convened groups of Bengali, Kurdish, Turkish, Urdu and Punjabi, and Chinese speaking women. Main outcome measures-The spontaneous views of non-English speaking women resident in east London on cervical screening, focusing on attitudes to screening, their experiences of the cervical cytology screening services as currently provided, and their knowledge and beliefs about cervical screening. Results-Some reported attitudinal barriers to cervical cytology screening such as fear of cancer were not deterrents. Administrative and language barriers were more important, as were inadequate surgery premises and concerns about sterility. Conclusion-Contrary to popular belief. among general practitioners in east London, women from ethnic minorities are enthusiastic about cervical cytology screening once they understand the purpose of the test and the call and recall procedures. It is possible to consult with community groups in their own language through focus group discussions, working with bilingual health advocates who have had a short practical training in facilitating small group discussions. This form of user consultation could be carried out focusing on other aspects of health promotion.	ROYAL LONDON HOSP,QUEEN MARY WESTFIELD COLL,LONDON E1 4NS,ENGLAND	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	NAISH, J (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,JOINT ACAD DEPT GEN PRACTICE & PRIMARY CARE,LONDON E1 4NS,ENGLAND.							ALLMAN ST, 1974, HLTH TRENDS, V6, P39; BAILIE R, 1990, NZ MED J, V103, P292; BEARDOW R, 1989, BMJ-BRIT MED J, V299, P98, DOI 10.1136/bmj.299.6691.98; BOWLING A, 1989, BRIT MED J, V298, P545, DOI 10.1136/bmj.298.6673.545; CULLUM DE, 1983, BRIT MED J, V287, P329, DOI 10.1136/bmj.287.6388.329; DAVISON RL, 1971, MED OFFICER, V1, P329; ELKIND AK, 1988, SOC SCI MED, V27, P651, DOI 10.1016/0277-9536(88)90014-7; Gregory S, 1991, Nurs Stand, V5, P32; KITZINGER J, 1994, SOCIOL HEALTH ILL, V16, P103, DOI 10.1111/1467-9566.ep11347023; MCKIE L, 1990, PATTERNS TAKE UP ATT; NAISH J, 1992, GENERAL PRACTITIONER; NATHOO V, 1988, BRIT MED J, V296, P1041, DOI 10.1136/bmj.296.6628.1041; PIERCE M, 1989, BMJ-BRIT MED J, V299, P160, DOI 10.1136/bmj.299.6692.160; Posner T, 1988, PREVENTION CERVICAL; ROSS SK, 1989, BRIT MED J, V299, P101, DOI 10.1136/bmj.299.6691.101; SANSOM CD, 1975, BRIT J PREV SOC MED, V29, P40; SCHWARTZ M, 1989, COMMUNITY MED, V11, P279; SHROFF KJ, 1988, BRIT MED J, V297, P1317, DOI 10.1136/bmj.297.6659.1317	18	86	87	2	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1126	1128						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987106				2022-12-24	WOS:A1994PP69100024
J	LIN, TA; KONG, XM; HAYSTEAD, TAJ; PAUSE, A; BELSHAM, G; SONENBERG, N; LAWRENCE, JC				LIN, TA; KONG, XM; HAYSTEAD, TAJ; PAUSE, A; BELSHAM, G; SONENBERG, N; LAWRENCE, JC			PHAS-1 AS A LINK BETWEEN MITOGEN-ACTIVATED PROTEIN-KINASE AND TRANSLATION INITIATION	SCIENCE			English	Article							3T3-L1 ADIPOCYTES; INSULIN ACTION; PHOSPHORYLATION; STIMULATION; MECHANISM; INVITRO	PHAS-I is a heat-stable protein (relative molecular mass approximate to 12,400) found in many tissues. It is rapidly phosphorylated in rat adipocytes incubated with insulin or growth factors. Nonphosphorylated PHAS-I bound to initiation factor 4E (eIF-4E) and inhibited protein synthesis. Serine-64 in PHAS-I was rapidly phosphorylated by mitogen-activated (MAP) kinase, the major insulin-stimulated PHAS-I kinase in adipocyte extracts. Results obtained with antibodies, immobilized PHAS-I, and a messenger RNA cap affinity resin indicated that PHAS-I did not bind eIF-4E when serine-64 was phosphorylated. Thus, PHAS-I may be a key mediator of the stimulation of protein synthesis by the diverse group of agents and stimuli that activate MAP kinase.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22903; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL H3G 1Y6,PQ,CANADA	Washington University (WUSTL); University of Virginia; McGill University; McGill University			Belsham, Graham/J-3132-2019; Belsham, Graham J./H-8589-2019	Belsham, Graham/0000-0003-1187-4873; Belsham, Graham J./0000-0003-1187-4873	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1990, J BIOL CHEM, V265, P11495; AVRUCH J, 1982, FED PROC, V41, P2629; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P1; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DENTON RM, 1981, DIABETOLOGIA, V21, P347; GALLIE DR, 1994, J BIOL CHEM, V269, P7174; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HU C, 1994, P NATL ACAD SCI USA, V91, P373; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin T.-T., UNPUB; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; PAUSE A, IN PRESS NATURE; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sonenberg Nahum, 1993, Gene Expression, V3, P317	23	595	608	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					653	656		10.1126/science.7939721	http://dx.doi.org/10.1126/science.7939721			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939721				2022-12-24	WOS:A1994PN80700049
J	WHITE, RH; MCKITTRICK, T; HUTCHINSON, R; TWITCHELL, J				WHITE, RH; MCKITTRICK, T; HUTCHINSON, R; TWITCHELL, J			TEMPORARY DISCONTINUATION OF WARFARIN THERAPY - CHANGES IN THE INTERNATIONAL NORMALIZED RATION	ANNALS OF INTERNAL MEDICINE			English	Note							ANTICOAGULANT-THERAPY; SURGERY; OPERATIONS	Objective: To measure the rate of decrease of the international normalized ratio (INR) after temporary discontinuation of warfarin therapy. Design: Prospective evaluation of an outpatient cohort. Setting: University medical center anticoagulation clinic. Patients: 22 patients receiving a fixed evening dose of warfarin for whom temporary discontinuation of therapy was deemed safe. Measurements: Serial plasma samples were drawn for INR measurements approximately 20, 65, 115, and 185 hours after patients received the last dose of warfarin. in five patients, INR was measured twice daily for 5 days. Results: For patients with a mean steady-state INR of 2.6, the mean INR 65 hours (2.7 days) after discontinuation of warfarin therapy was 1.6 (range, 1.11 to 2.16); 20 of 22 patients (98%) had an INR greater than 1.2. The mean INR 115 hours (4.7 days) after discontinuation of warfarin therapy was 1.1; 5 of 22 patients (23%) had an INR of 1.2 or greater. in 5 patients studied in detail, the INR decreased exponentially and had a half-life that ranged from 0.52 to 1.2 days; the onset of maximal decrease began 24 to 36 hours after discontinuation of warfarin therapy. In the total cohort, age was a significant (P < 0.005) independent predictor of smaller decreases in the INR between day 1 and day 3 (regression coefficient = -6.8% +/- 2%/2 days per decade of age; R(2) = 0.34). Conclusions: By simulating preoperative discontinuation of warfarin therapy, we found that the INR decreases exponentially, with wide interpatient variation in the rate of decrease. Age is associated with a slower rate of decrease. To be certain that the INR at the time of the surgery is less than 6.2, warfarin should be withheld for 96 to 115 hours (4 doses) in patients with a steady-state INR between 2.0 and 3.0. For patients with a higher steady-state INR, a longer wait is necessary.	UNIV CALIF DAVIS, DAVIS, CA 95616 USA	University of California System; University of California Davis								CADE JF, 1979, MED J AUSTRALIA, V2, P292, DOI 10.5694/j.1326-5377.1979.tb125717.x; GAINEY SP, 1989, AM J OPHTHALMOL, V108, P142, DOI 10.1016/0002-9394(89)90008-1; KATHOLI RE, 1978, AM HEART J, V96, P163, DOI 10.1016/0002-8703(78)90080-7; MCINTYRE H, 1966, LANCET, V2, P99; MOLL AC, 1989, DOC OPHTHALMOL, V72, P367, DOI 10.1007/BF00153505; MUNGALL DR, 1985, J PHARMACOKINET BIOP, V13, P213, DOI 10.1007/BF01065653; OREILLY RA, 1963, J CLIN INVEST, V42, P1542, DOI 10.1172/JCI104839; OREILLY RA, 1987, PRINCIPLES PHARM THE, P1344; RAMSTROM G, 1993, J ORAL MAXIL SURG, V51, P1211, DOI 10.1016/S0278-2391(10)80291-5; ROSE SD, 1987, MED EVALUATION SURGI, P253; SELVIN S, 1991, STATISTICAL ANAL EPI; TINKER JH, 1978, JAMA-J AM MED ASSOC, V239, P738, DOI 10.1001/jama.239.8.738; TRAVIS S, 1989, BRIT J SURG, V76, P1107, DOI 10.1002/bjs.1800761102	13	190	194	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1995	122	1					40	42		10.7326/0003-4819-122-1-199501010-00006	http://dx.doi.org/10.7326/0003-4819-122-1-199501010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY502	7985894				2022-12-24	WOS:A1995PY50200006
J	JIN, YS; HOSKINS, R; HORVITZ, HR				JIN, YS; HOSKINS, R; HORVITZ, HR			CONTROL OF TYPE-D GABAERGIC NEURON DIFFERENTIATION BY C-ELEGANS UNC-30 HOMEODOMAIN PROTEIN	NATURE			English	Article							CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; GENE ENCODES	THE Caenorhabditis elegans gene unc-30 is required for the develop ment and functioning of the 19 inhibitory GABAergic (gamma-aminobutyric-acid-secreting) type D motor neurons, which control locomotion(1-4). In unc-30 mutants the D neurons lack GABA(2) and have defects in axonal pathfinding and synaptic connections (J. White, personal communication). We report here that unc-30 encodes a homeodomain protein that is present in the nuclei of the D neurons at high levels in young larvae, in which the motor circuitry is formed, and at low levels in older animals. The UNC-30 protein is also present in six non-GABAergic neurons and is absent from the seven non-D-type GABAergic neurons. Ectopic expression of unc-30 induced GABA expression in cells that are normally not GABAergic. We propose that unc-30 functions as a transcriptional regulator within the type D neurons to control their terminal differentiation and that unc-30 is sufficient in some but not all cell types to induce GABA expression.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); MRC Laboratory Molecular Biology				Jin, Yishi/0000-0002-9371-9860				BABU P, 1981, MUTAT RES, V82, P269, DOI 10.1016/0027-5107(81)90156-1; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1993, GUIDEBOOK HOMEOBOX G, P25; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HODGKIN J, 1983, GENETICS, V103, P43; HOSKINS R, 1990, THESIS U CAMBRIDGE; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3957; MILLER DM, 1992, NATURE, V355, P841, DOI 10.1038/355841a0; RUVKUN G, 1989, GENETICS, V121, P501; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Sulston J, 1988, NEMATODE CAENORHABDI, P587; TREISMAN J, 1989, CELL, V59, P553; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; [No title captured]	30	179	183	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					780	783		10.1038/372780a0	http://dx.doi.org/10.1038/372780a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997265				2022-12-24	WOS:A1994PY21200053
J	LEE, JC; LAYDON, JT; MCDONNELL, PC; GALLAGHER, TF; KUMAR, S; GREEN, D; MCNULTY, D; BLUMENTHAL, MJ; HEYS, JR; LANDVATTER, SW; STRICKLER, JE; MCLAUGHLIN, MM; SIEMENS, IR; FISHER, SM; LIVI, GP; WHITE, JR; ADAMS, JL; YOUNG, PR				LEE, JC; LAYDON, JT; MCDONNELL, PC; GALLAGHER, TF; KUMAR, S; GREEN, D; MCNULTY, D; BLUMENTHAL, MJ; HEYS, JR; LANDVATTER, SW; STRICKLER, JE; MCLAUGHLIN, MM; SIEMENS, IR; FISHER, SM; LIVI, GP; WHITE, JR; ADAMS, JL; YOUNG, PR			A PROTEIN-KINASE INVOLVED IN THE REGULATION OF INFLAMMATORY CYTOKINE BIOSYNTHESIS	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; RNA-BINDING PROTEIN; TYROSINE PHOSPHORYLATION; MURINE MACROPHAGES; ENDOTOXIN; IL-1; LIPOPOLYSACCHARIDE; INTERLEUKIN-1; PURIFICATION; EXPRESSION	Production of interleukin-1 and tumour necrosis factor from stimulated human monocytes is inhibited by a new series of pyridinyl-imidazole compounds. Using radiolabelled and radio-photoaffinity-labelled chemical probes, the target of these compounds was identified as a pair of closely related mitogen-activated protein kinase homologues, termed CSBPs. Binding of the pyridinyl-imidazole compounds inhibited CSBP kinase activity and could be directly correlated with their ability to inhibit cytokine production, suggesting that the CSBPs are critical for cytokine production.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC IMMUNOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT RADIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	LEE, JC (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406, USA.			White, John R/0000-0003-2998-1626				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DINARELLO CA, 1991, CURR OPIN IMMUNOL, V3, P941, DOI 10.1016/S0952-7915(05)80018-4; DONG ZY, 1993, J EXP MED, V177, P1071, DOI 10.1084/jem.177.4.1071; ERICKSON RL, 1991, J BIOL CHEM, V266, P6007; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GRANTHAM R, 1981, NUCLEIC ACIDS RES, V9, pR43; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HAN JH, 1993, J BIOL CHEM, V268, P25009; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HUANG LY, 1993, J BIOL CHEM, V268, P25769; KASPAR RL, 1994, J IMMUNOL, V153, P277; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KRUYS V, 1992, P NATL ACAD SCI USA, V89, P673, DOI 10.1073/pnas.89.2.673; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDER HM, 1992, CELL IMMUNOL, V144, P155, DOI 10.1016/0008-8749(92)90233-F; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1990, INT J IMMUNOTHER, V6, P1; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAHKOV AN, 1990, J EXP MED, V171, P35; SCHINDLER R, 1990, BLOOD, V76, P1631; SETH A, 1991, J BIOL CHEM, V266, P23521; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUNG SSJ, 1992, J EXP MED, V176, P897, DOI 10.1084/jem.176.3.897; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; YOUNG P, 1993, AGENTS ACTIONS, V39, pC67, DOI 10.1007/BF01972723; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	44	3055	3188	2	122	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					739	746		10.1038/372739a0	http://dx.doi.org/10.1038/372739a0			8	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997261				2022-12-24	WOS:A1994PY21200042
J	ISNER, JM; FELDMAN, LJ				ISNER, JM; FELDMAN, LJ			GENE-THERAPY FOR ARTERIAL-DISEASE	LANCET			English	Editorial Material							INTIMAL HYPERPLASIA; EXPRESSION INVIVO; CELLS; WALL		TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT BIOMED RES,BOSTON,MA 02111	St. Elizabeth's Medical Center; Tufts University	ISNER, JM (corresponding author), TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT MED CARDIOL,BOSTON,MA 02111, USA.		Feldman, Laurent/AGM-4472-2022					FELDMAN LJ, 1994, CIRCULATION, V90, P1; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; LECLERC G, 1992, J CLIN INVEST, V90, P936, DOI 10.1172/JCI115970; LOSORDO DW, 1994, CIRCULATION, V89, P785, DOI 10.1161/01.CIR.89.2.785; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; RIESSEN R, 1993, HUM GENE THER, V4, P749, DOI 10.1089/hum.1993.4.6-749; STEG PG, 1994, CIRCULATION, V90, P1648, DOI 10.1161/01.CIR.90.4.1648; TAKESHITA S, 1994, J CLIN INVEST, V93, P652, DOI 10.1172/JCI117017; TAKESHITA S, IN PRESS P NATL ACAD; 1994, MINUTES RECOMBINANT	16	34	38	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1653	1654		10.1016/S0140-6736(94)90454-5	http://dx.doi.org/10.1016/S0140-6736(94)90454-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996957				2022-12-24	WOS:A1994PX30200005
J	LIAN, JP; STONE, S; JIANG, Y; LYONS, P; FERRONOVICK, S				LIAN, JP; STONE, S; JIANG, Y; LYONS, P; FERRONOVICK, S			YPT1P IMPLICATED IN V-SNARE ACTIVATION	NATURE			English	Article							INTEGRAL MEMBRANE-PROTEIN; ENDOPLASMIC-RETICULUM; GOLGI-COMPLEX; VESICULAR TRANSPORT; SECRETORY PATHWAY; YEAST; FUSION; ER; ENCODES; IDENTIFICATION	SYNAPTOBREVIN-LIKE membrane proteins that reside on transport vesicles, called the vesicle SNARE (v-SNARE), play a key role in ensuring that a vesicle targets and fuses with its correct acceptor compartment(1-3). Here we show that Bos1p, the v-SNARE of yeast endoplasmic reticulum-to-Golgi transport vesicles, pairs with another integral membrane protein of similar topology (Sec22p) on vesicles. This pairing, which appears to require functional Ypt1p (Rab in mammalian cells), may aid the activity of Bos1p on this compartment. These findings suggest that Rabs regulate the specificity of membrane fusion by selectively activating the v-SNARE on carrier vesicles. Because the v-SNARE resides on more than one membrane, such a regulated activation step may be necessary to prevent the premature fusion of donor and acceptor compartments(4).	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University								DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GROESCH ME, 1992, METHOD ENZYMOL, V219, P137; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; WARREN G, 1993, NATURE, V362, P297, DOI 10.1038/362297a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	21	175	177	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					698	701		10.1038/372698a0	http://dx.doi.org/10.1038/372698a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990964				2022-12-24	WOS:A1994PX30700092
J	LIUZZI, M; DEZIEL, R; MOSS, N; BEAULIEU, P; BONNEAU, AM; BOUSQUET, C; CHAFOULEAS, JG; GARNEAU, M; JARAMILLO, J; KROGSRUD, RL; LAGACE, L; MCCOLLUM, RS; NAWOOT, S; GUINDON, Y				LIUZZI, M; DEZIEL, R; MOSS, N; BEAULIEU, P; BONNEAU, AM; BOUSQUET, C; CHAFOULEAS, JG; GARNEAU, M; JARAMILLO, J; KROGSRUD, RL; LAGACE, L; MCCOLLUM, RS; NAWOOT, S; GUINDON, Y			A POTENT PEPTIDOMIMETIC INHIBITOR OF HSV RIBONUCLEOTIDE REDUCTASE WITH ANTIVIRAL ACTIVITY IN-VIVO	NATURE			English	Article							HERPES-SIMPLEX VIRUS; COLORIMETRIC ASSAY; CARBOXYL TERMINUS; DNA-POLYMERASE; MUTANTS; SUBUNIT; TYPE-1; ACYCLOVIR; ASSOCIATION; SENSITIVITY	HERPES simplex viruses (HSV) types 1 and 2 encode their own ribonucleotide reductases (RNRs) (EC 1.17.4.1) to convert ribonucleoside diphosphates into the corresponding deoxyribonucleotides(1). Like other iron-dependent RNRs, the viral enzyme is formed by the reversible association of two distinct homodimeric subunits(2). The carboxy terminus of the RNR small subunit (R2) is critical for subunit association(3,4) and synthetic peptides containing these amino-acid sequences selectively inhibit the viral enzyme by preventing subunit association(4-9). Increasing evidence indicates that the HSV RNR is important for virulence and reactivation from latency(10-14). Previously, we reported on the design of HSV RNR inhibitors with enhanced inhibitory potency in vitro(4,15,16). We now report on BILD 1263, which to our knowledge is the first HSV RNR subunit-association inhibitor with antiviral activity in vivo. This compound suppresses the replication of HSV-1, HSV-2 and acyclovir-resistant HSV strains in cell culture, and also strongly potentiates the antiviral activity of acyclovir. Most importantly, its anti-herpetic activity is shown in a murine ocular model of HSV-1-induced keratitis, providing an example of potent nonsubstrate-based antiviral agents that prevent protein-protein inter actions. The unique antiviral properties of BILD 1263 may lead to the design of new strategies to treat herpesvirus infections in humans.			LIUZZI, M (corresponding author), BIO MEGA BOEHRINGER INGELHEIM RES INC,2100 CUNARD ST,LAVAL H7S 2G5,PQ,CANADA.		Deziel, Robert/ABA-9629-2020					BRANDT CR, 1992, J VIROL METHODS, V36, P209, DOI 10.1016/0166-0934(92)90052-F; BRANDT CR, 1991, J GEN VIROL, V72, P2043, DOI 10.1099/0022-1317-72-9-2043; BRAZEAU P, 1982, P NATL ACAD SCI-BIOL, V79, P7909, DOI 10.1073/pnas.79.24.7909; CAMERON JM, 1988, J GEN VIROL, V69, P2607, DOI 10.1099/0022-1317-69-10-2607; CHATIS PA, 1992, ANTIMICROB AGENTS CH, V36, P1589, DOI 10.1128/AAC.36.8.1589; COEN DM, 1991, ANTIVIR RES, V15, P287, DOI 10.1016/0166-3542(91)90010-O; COEN DM, 1989, ANTIMICROB AGENTS CH, V33, P1395, DOI 10.1128/AAC.33.8.1395; COEN DM, 1989, P NATL ACAD SCI USA, V86, P4736, DOI 10.1073/pnas.86.12.4736; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; COSENTINO G, 1991, BIOCHEM CELL BIOL, V69, P79, DOI 10.1139/o91-011; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FILATOV D, 1992, J BIOL CHEM, V267, P15816; FURMAN PA, 1981, J VIROL, V40, P936, DOI 10.1128/JVI.40.3.936-941.1981; GARRETT C, 1979, ANAL BIOCHEM, V99, P268, DOI 10.1016/S0003-2697(79)80005-6; IDOWU AD, 1992, ANTIVIR RES, V17, P145, DOI 10.1016/0166-3542(92)90048-A; JACOBSON JG, 1989, VIROLOGY, V173, P276, DOI 10.1016/0042-6822(89)90244-4; KNIPE DM, 1982, J VIROL, V43, P314, DOI 10.1128/JVI.43.1.314-324.1982; KROGSRUD RL, 1993, ANAL BIOCHEM, V213, P386, DOI 10.1006/abio.1993.1436; LANGLOIS M, 1986, J BIOL STAND, V14, P201, DOI 10.1016/0092-1157(86)90004-1; Liuzzi Michel, 1993, P225; MCCLEMENTS W, 1988, VIROLOGY, V162, P270, DOI 10.1016/0042-6822(88)90421-7; MOSS N, 1993, J MED CHEM, V36, P3005, DOI 10.1021/jm00072a021; PARADIS H, 1988, J BIOL CHEM, V263, P16045; Reardon J E, 1991, Adv Pharmacol, V22, P1, DOI 10.1016/S1054-3589(08)60031-9; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SACKS SL, 1989, ANN INTERN MED, V111, P893, DOI 10.7326/0003-4819-111-11-893; SUHNEL J, 1990, ANTIVIR RES, V13, P23, DOI 10.1016/0166-3542(90)90042-6; YAMADA Y, 1991, J INFECT DIS, V164, P1091, DOI 10.1093/infdis/164.6.1091	30	122	134	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					695	698		10.1038/372695a0	http://dx.doi.org/10.1038/372695a0			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990963				2022-12-24	WOS:A1994PX30700091
J	TOTH, EL				TOTH, EL			NEVER AGAIN, LISA - CHILDHOOD DIABETES IN A DYSFUNCTIONAL FAMILY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											TOTH, EL (corresponding author), UNIV ALBERTA, WALTER C MACKENZIE HLTH SCI CTR 2F129, DEPT MED, EDMONTON T6G 2R7, AB, CANADA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					979	980		10.7326/0003-4819-121-12-199412150-00014	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978726				2022-12-24	WOS:A1994PW08300014
J	DRENNAN, CL; HUANG, S; DRUMMOND, JT; MATTHEWS, RG; LUDWIG, ML				DRENNAN, CL; HUANG, S; DRUMMOND, JT; MATTHEWS, RG; LUDWIG, ML			HOW A PROTEIN BINDS B-12 - A 3.0-ANGSTROM X-RAY STRUCTURE OF B-12-BINDING DOMAINS OF METHIONINE SYNTHASE	SCIENCE			English	Article							METHYLMALONYL-COA MUTASE; CYTOCHROME-C PEROXIDASE; ESCHERICHIA-COLI; METH GENE; CLONING; ACTIVATION; FLAVODOXIN; SEQUENCE; MODELS; ENZYME	The crystal structure of a 27-kilodalton methylcobalamin-containing fragment of methi onine synthase from Escherichia coli was determined at 3.0 Angstrom resolution. This structure depicts cobalamin-protein interactions and reveals that the corrin macrocycle lies between a helical amino-terminal domain and an alpha/beta carboxyl-terminal domain that is a variant of the Rossmann fold. Methylcobalamin undergoes a conformational change on binding the protein; the dimethylbenzimidazole group, which is coordinated to the cobalt in the free cofactor, moves away from the corrin and is replaced by a histidine contributed by the protein. The sequence Asp-X-His-X-X-Gly, which contains this histidine ligand, is conserved in the adenosylcobalamin-dependent enzymes methylmalonyl-coenzyme A mutase and glutamate mutase, suggesting that displacement of the dimethylbenzimidazole will be a feature common to many cobalamin-binding proteins. Thus the cobalt ligand, His(759), and the neighboring residues Asp(757) and Ser(810), may form a catalytic quartet, Co-His-Asp-Ser, that modulates the reactivity of the B-12 prosthetic group in methionine synthase.	UNIV MICHIGAN, DIV BIOPHYS RES, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Duke University					NIGMS NIH HHS [GM08570, GM16429, GM24908] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024908, R01GM024908, T32GM008570] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babior B. M., 1982, B12, V2, P263; Baker J. J., 1982, B12, V2, P203; BANERJEE RV, 1989, J BIOL CHEM, V264, P13888; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; Blakley R.L., 1982, B12, V2, P381; BRINKSHOEMAKER C, 1964, PROC R SOC LON SER-A, V278, P1, DOI 10.1098/rspa.1964.0042; BRUNGER A, 1993, X PLOR VERSION 3 1 M; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; COX JM, 1967, J MOL BIOL, V28, P151, DOI 10.1016/S0022-2836(67)80083-4; DRUMMOND JT, 1993, BIOCHEMISTRY-US, V32, P9290, DOI 10.1021/bi00087a005; DRUMMOND JT, 1994, BIOCHEMISTRY-US, V33, P3732, DOI 10.1021/bi00178a033; DRUMMOND JT, 1993, BIOCHEMISTRY-US, V32, P9282, DOI 10.1021/bi00087a004; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; FUJII K, 1977, ARCH BIOCHEM BIOPHYS, V178, P662, DOI 10.1016/0003-9861(77)90238-7; FUJII K, 1974, J BIOL CHEM, V249, P6745; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; HALPERN J, 1982, B12, V1, P501; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; HODGKIN DC, 1956, NATURE, V178, P64, DOI 10.1038/178064a0; HODGKIN DC, 1959, PROC R SOC LON SER-A, V251, P306, DOI 10.1098/rspa.1959.0111; HODGKIN DC, 1957, PROC R SOC LON SER-A, V242, P228, DOI 10.1098/rspa.1957.0174; HODGKIN DC, 1962, PROC R SOC LON SER-A, V266, P494, DOI 10.1098/rspa.1962.0074; JANSEN R, 1989, GENOMICS, V4, P198, DOI 10.1016/0888-7543(89)90300-5; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIMURA N, 1994, J AM CHEM SOC, V116, P4087, DOI 10.1021/ja00088a058; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUTLER B, 1987, HELV CHIM ACTA, V70, P1268, DOI 10.1002/hlca.19870700506; LENHERT PG, 1968, PROC R SOC LON SER-A, V303, P45, DOI 10.1098/rspa.1968.0039; LENHERT PG, 1961, NATURE, V192, P937, DOI 10.1038/192937a0; LEXA D, 1988, J AM CHEM SOC, V110, P7617, DOI 10.1021/ja00231a006; LEXA D, 1983, ACCOUNTS CHEM RES, V16, P235, DOI 10.1021/ar00091a001; LUDWIG ML, 1992, CHEM BIOCH FLAVOENZY, V3, P427; LUSCHINSKY CL, 1992, J MOL BIOL, V225, P557, DOI 10.1016/0022-2836(92)90940-L; MARSH ENG, 1992, FEBS LETT, V310, P167, DOI 10.1016/0014-5793(92)81321-C; MARSH N, 1988, J MOL BIOL, V200, P421, DOI 10.1016/0022-2836(88)90252-5; MATTHEWS RG, 1984, FOLATES PTERINS, V1, P497; MCKIE N, 1990, BIOCHEM J, V269, P293, DOI 10.1042/bj2690293; OLD IG, 1990, GENE, V87, P15, DOI 10.1016/0378-1119(90)90490-I; OSBORNE C, 1991, J BACTERIOL, V173, P1729, DOI 10.1128/jb.173.5.1729-1737.1991; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; POULOS TL, 1980, J BIOL CHEM, V255, P575; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Retey J., 1982, B12, VII, P357; ROSSI M, 1985, J AM CHEM SOC, V107, P1729, DOI 10.1021/ja00292a046; ROUSSEAU DG, 1992, J STRUCT BIOL, V109, P13; SCHRAUZER GN, 1969, J AM CHEM SOC, V91, P3341, DOI 10.1021/ja01040a041; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SMITH DR, 1994, U00017 GENBA; STEIGEMANN W, 1974, THESIS TU MUNICH; SUMMERS MF, 1983, J AM CHEM SOC, V105, P6259, DOI 10.1021/ja00358a012; SUMMERS MF, 1984, J AM CHEM SOC, V106, P4478, DOI 10.1021/ja00328a030; SWITZER RL, 1982, B12, V2, P289; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TAYLOR RT, 1982, B12, V2, P307; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; Toraya T., 1982, B12, P233; WATT W, 1991, J MOL BIOL, V218, P195, DOI 10.1016/0022-2836(91)90884-9; WHITE JG, 1962, PROC R SOC LON SER-A, V266, P440, DOI 10.1098/rspa.1962.0072; WIRT MD, 1992, BIOPHYS J, V63, P412, DOI 10.1016/S0006-3495(92)81605-3	62	523	533	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	1994	266	5191					1669	1674		10.1126/science.7992050	http://dx.doi.org/10.1126/science.7992050			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992050				2022-12-24	WOS:A1994PW30800029
J	SPECHLER, SJ; ZEROOGIAN, JM; ANTONIOLI, DA; WANG, HH; GOYAL, RK				SPECHLER, SJ; ZEROOGIAN, JM; ANTONIOLI, DA; WANG, HH; GOYAL, RK			PREVALENCE OF METAPLASIA AT THE GASTROESOPHAGEAL JUNCTION	LANCET			English	Article							BARRETTS-ESOPHAGUS; INCREASING INCIDENCE; ADENOCARCINOMA; CARDIA	Specialised columnar epithelium (SCE), a form of intestinal metaplasia usually found in Barrett's oesophagus, cannot be distinguished endoscopically from normal gastric epithelium. Endoscopists seldom obtain biopsy specimens from a normal-appearing gastro-oesophageal junction, and therefore short segments of SCE in this region may go unrecognised. We studied patients who had short segments of SCE at the gastro-oesophageal junction. All patients scheduled for elective endoscopic examinations in our general endoscopy unit, irrespective of indication, were questioned for symptoms of gastro-oesophageal reflux disease. At endoscopy, severity of oesophagitis was graded, and biopsy specimens obtained from the squamocolumnar junction, irrespective of its appearance or location in the oesophagus. Among 142 patients without endoscopically apparent Barrett's oesophagus, 26 (18%) were found to have SCE. All patients with SCE were white, and the male/female ratio was 1.9. In contrast, non-whites accounted for 14% of the 114 patients without SCE and the male/female ratio was 0.8. The groups did not differ significantly in the frequency of symptoms and endoscopic signs of gastrooesophageal reflux. We conclude that adults frequently have unrecognised segments of SCE at the gastro-oesophageal junction; this may underlie the rising frequency of cancer of the gastrooesophageal junction in the USA and Europe.	BETH ISRAEL HOSP, DEPT PATHOL, CTR SWALLOWING DISORDERS, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	SPECHLER, SJ (corresponding author), BETH ISRAEL HOSP, DEPT MED, CTR SWALLOWING DISORDERS, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031092, R01DK031092] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31092] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRETT NR, 1950, BRIT J SURG, V38, P175, DOI 10.1002/bjs.18003815005; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BLOT WJ, 1993, JAMA-J AM MED ASSOC, V270, P1320, DOI 10.1001/jama.270.11.1320; BONELLI L, 1991, INT J CANCER, V48, P364; CAMERON AJ, 1992, GASTROENTEROLOGY, V103, P1241, DOI 10.1016/0016-5085(92)91510-B; DAS KM, 1994, ANN INTERN MED, V120, P753, DOI 10.7326/0003-4819-120-9-199405010-00006; DELAPAVA S, 1964, NEW YORK STATE J MED, V64, P1831; GOYAL RK, 1970, NEW ENGL J MED, V282, P1298, DOI 10.1056/NEJM197006042822305; Goyal RK, 1985, BARRETTS ESOPHAGUS P, P1; HAGGITT RC, 1992, HUM PATHOL, V23, P475, DOI 10.1016/0046-8177(92)90121-I; Haggitt RC, 1985, BARRETTS ESOPHAGUS P, P153; HAMILTON SR, 1988, HUM PATHOL, V19, P942, DOI 10.1016/S0046-8177(88)80010-8; HANSSON LE, 1993, INT J CANCER, V54, P402, DOI 10.1002/ijc.2910540309; HASSALL E, 1993, J PEDIATR GASTR NUTR, V16, P345, DOI 10.1097/00005176-199305000-00001; KIM SL, 1994, GASTROENTEROLOGY, V107, P945, DOI 10.1016/0016-5085(94)90217-8; MCCLAVE SA, 1987, GASTROINTEST ENDOSC, V33, P413, DOI 10.1016/S0016-5107(87)71676-9; Moller H, 1992, Eur J Cancer Prev, V1, P159; MORSON BC, 1955, BRIT J CANCER, V9, P365, DOI 10.1038/bjc.1955.35; OVASKA J, 1989, DIGEST DIS SCI, V34, P1336, DOI 10.1007/BF01538065; PAULL A, 1976, NEW ENGL J MED, V295, P476, DOI 10.1056/NEJM197608262950904; POWELL J, 1990, BRIT J CANCER, V62, P440, DOI 10.1038/bjc.1990.314; RAPHAEL HA, 1966, ANN SURG; REID BJ, 1987, ANNU REV MED, V38, P477, DOI 10.1146/annurev.med.38.1.477; ROTHERY GA, 1986, GUT, V27, P1062, DOI 10.1136/gut.27.9.1062; SCHMIDT HG, 1985, J CANCER RES CLIN, V110, P145, DOI 10.1007/BF00402729; SCHNELL TG, 1992, DIGEST DIS SCI, V37, P137, DOI 10.1007/BF01308357; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; TRIER JS, 1985, BARRETTS ESOPHAGUS P, P19; Tuyns A J, 1992, Eur J Cancer Prev, V1, P275, DOI 10.1097/00008469-199204000-00010; Winters C, 1987, GASTROENTEROLOGY, V92, P118, DOI 10.1016/0016-5085(87)90847-X	30	492	500	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 3	1994	344	8936					1533	1536		10.1016/S0140-6736(94)90349-2	http://dx.doi.org/10.1016/S0140-6736(94)90349-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983953				2022-12-24	WOS:A1994PV01700009
J	JAFFE, HW; MCCURDY, JM; KALISH, ML; LIBERTI, T; METELLUS, G; BOWMAN, BH; RICHARDS, SB; NEASMAN, AR; WITTE, JJ				JAFFE, HW; MCCURDY, JM; KALISH, ML; LIBERTI, T; METELLUS, G; BOWMAN, BH; RICHARDS, SB; NEASMAN, AR; WITTE, JJ			LACK OF HIV TRANSMISSION IN THE PRACTICE OF A DENTIST WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; DENTISTS; DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT	HUMAN-IMMUNODEFICIENCY-VIRUS; TO-PATIENT TRANSMISSION; DENTAL PRACTICE; INFECTED DENTIST; SEQUENCES	Objectives: To determine whether dentist-to-patient or patient-to-patient transmission of human immunodeficiency virus (HIV) occurred in the practice of a dentist who had the acquired immunodeficiency syndrome (AIDS). Design: Retrospective epidemiologic investigation supported by molecular virology studies. Setting: The practice of a dentist with AIDS in an area with a high AIDS prevalence. Participants: A dentist with AIDS, his former employees, and his former patients, including 28 patients with HIV infection. Measurements: Identification of potential risks for acquisition of HIV infection-control practices. Results: A dentist with known behavioral risks for HIV infection, who was practicing in an area of Miami, Florida, that had a high rate of reported AIDS cases, disclosed that he frequently did invasive procedures and did not always follow recommended infection-control procedures. Of 6474 patients who had records of receiving care from the dentist during the last 5 years of practice, 1279 (19.8%) were known to have been tested for HIV infection and 24 of those (1.9%) were seropositive. Four other patients with HIV infection were identified through additional case-finding activities. Of these 28 patients with HIV infection, all but 4 had potential behavioral risk factors for infection. Phylogenetic tree analysis of HIV genetic sequences from the dentist and 24 of the patients with HIV infection showed an absence of strong bootstrap support for any grouping and therefore did not indicate that the virus strains were linked. Conclusions: Despite identifying numerous patients with HIV infection, we found no evidence of dentist-to-patient or patient-to-patient transmission of HIV during dental care. Our findings are consistent with those of all previous studies in this area, with the exception of one that did identify such transmission.	FLORIDA DEPT HLTH & REHABIL SERV, TALLAHASSEE, FL 32399 USA; ROCHE MOLEC SYST INC, ALAMEDA, CA 94501 USA	Florida Department of Health	JAFFE, HW (corresponding author), CTR DIS CONTROL & PREVENT, DIV HIV AIDS G29, ATLANTA, GA 30333 USA.							[Anonymous], 1993, MMWR Recomm Rep, V42, P1; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; ARNOW PM, 1993, PUBLIC HEALTH REP, V108, P273; BELL DM, 1993, J PUBLIC HEALTH DENT, V53, P170, DOI 10.1111/j.1752-7325.1993.tb02697.x; CABOT EL, 1989, COMPUT APPL BIOSCI, V5, P233; CHANT K, 1993, LANCET, V342, P1548, DOI 10.1016/S0140-6736(05)80112-6; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; Comer R W, 1991, J Dent Educ, V55, P187; Cottone J A, 1992, J Dent Educ, V56, P536; DICKINSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1802, DOI 10.1001/jama.269.14.1802; Favero M., 1991, DISINFECTION STERILI, P617; Felsenstein J, 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; GOOCH B, 1993, J AM DENT ASSOC, V124, P38, DOI 10.14219/jada.archive.1993.0006; Heuer M A, 1992, J Dent Educ, V56, P528; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; LEWIS DL, 1992, J CLIN MICROBIOL, V30, P401, DOI 10.1128/JCM.30.2.401-406.1992; LONGFIELD JN, 1994, J INFECT DIS, V169, P1, DOI 10.1093/infdis/169.1.1; OU CY, 1993, LANCET, V341, P1171, DOI 10.1016/0140-6736(93)91001-3; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; Taylor M, 1992, J Dent Educ, V56, P540; YORK AK, 1993, J AM DENT ASSOC, V124, P74, DOI 10.14219/jada.archive.1993.0141; 1991, MMWR-MORBID MORTAL W, V40, P377; 1991, MMWR-MORBID MORTAL W, V40, P221; 1991, MMWR-MORBID MORTAL W, V40, P233; 1993, MMOWR MORB MORTAL WK, V42, P337; 1990, MMWR MROB MORTAL WKL, V39, P489; 1993, MMWR-MORBID MORTAL W, V42, P329	28	54	55	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					855	+		10.7326/0003-4819-121-11-199412010-00005	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978698				2022-12-24	WOS:A1994PT62800005
J	NARAGHI, R; GEIGER, H; CRNAC, J; HUK, W; FAHLBUSCH, R; ENGELS, G; LUFT, FC				NARAGHI, R; GEIGER, H; CRNAC, J; HUK, W; FAHLBUSCH, R; ENGELS, G; LUFT, FC			POSTERIOR-FOSSA NEUROVASCULAR ANOMALIES IN ESSENTIAL-HYPERTENSION	LANCET			English	Article							ROSTRAL VENTROLATERAL MEDULLA; BRAIN-STEM LESIONS; NEUROGENIC HYPERTENSION; HEMIFACIAL SPASM; COMPRESSION; NEURONS; RAT; VASOPRESSIN; ETIOLOGY; RABBIT	Intraoperative observations, necropsy, and angiographic studies support the presumption that neurovascular compression of the left ventrolateral medulla may cause neurogenic hypertension. Pulsatile irritation of the ventrolateral medulla at the root-entry zone of cranial nerves IX and X increases blood pressure in animals. To identify and assess the distribution of neurovascular compression at the ventrolateral medulla in human beings, we did a prospective single-blind study in 24 patients with essential hypertension, in 14 patients with renal hypertension, and in 14 normal subjects. To detect neurovascular compression, we used axial and coronal and magnetic-resonance angiography Blood pressure control and duration of hypertension were not different in the two groups of patients. 20 patients with essential hypertension had magnetic tomographic evidence of left-sided neurovascular compression at the ventrolateral medulla; 2 patients with renal hypertension and 1 of the normal subjects had a positive finding on the left. On the right side, we found signs of neurovascular compression in 4 patients with essential hypertension, in 4 with renal hypertension, and in 2 of the normal subjects. With magnetic resonance tomography, it is possible to evaluate the neurovascular relations in the posterior fossa and detect neurovascular compression at the ventrolateral medulla. These data in living subjects give further evidence of an association between neurovascular compression at the left ventrolateral medulla acid essential hypertension.	UNIV ERLANGEN NURNBERG,DEPT MED NEPHROL,D-91054 ERLANGEN,GERMANY; UNIV ERLANGEN NURNBERG,DEPT MED CARDIOL,D-91054 ERLANGEN,GERMANY	University of Erlangen Nuremberg; University of Erlangen Nuremberg	NARAGHI, R (corresponding author), UNIV ERLANGEN NURNBERG,DEPT NEUROL SURG,D-91054 ERLANGEN,GERMANY.			Naraghi, Ramin/0000-0003-3643-791X; Luft, Friedrich/0000-0002-8635-1199				ADAMS CBT, 1989, J NEUROSURG, V70, P1, DOI 10.3171/jns.1989.70.1.0001; AMENDT K, 1979, J AUTONOM NERV SYST, V1, P103, DOI 10.1016/0165-1838(79)90009-2; [Anonymous], 1873, BERICHT VERHANDL SAC; ARMSTRONG DM, 1982, J COMP NEUROL, V212, P173, DOI 10.1002/cne.902120207; BLESSING WW, 1981, CIRC RES, V49, P949, DOI 10.1161/01.RES.49.4.949; CIRIELLO J, 1986, BRAIN RES, V367, P273, DOI 10.1016/0006-8993(86)91602-1; CIRIELLO J, 1986, BRAIN RES REV, V11, P359, DOI 10.1016/0165-0173(86)90005-6; Cushing H, 1901, B JOHNS HOPKINS HOSP, V12, P290; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; DAMPNEY RAL, 1985, J AUTONOM NERV SYST, V14, P239, DOI 10.1016/0165-1838(85)90113-4; DOBA N, 1973, CIRC RES, V32, P584, DOI 10.1161/01.RES.32.5.584; FEIN JM, 1980, NEUROSURGERY, V6, P615, DOI 10.1227/00006123-198006000-00001; GARDNER WJ, 1962, J NEUROSURG, V19, P947, DOI 10.3171/jns.1962.19.11.0947; IMAIZUMI T, 1985, J HYPERTENS, V3, P491; JANNETTA PJ, 1977, J NEUROSURG, V47, P321, DOI 10.3171/jns.1977.47.3.0321; JANNETTA PJ, 1985, ANN SURG, V201, P391, DOI 10.1097/00000658-198503000-00023; JANNETTA PJ, 1985, ANN SURG, V201, P253; JULIUS S, 1985, J HYPERTENS       S4, V3, P11; KLEINEBERG B, 1992, NEUROSURGERY, V30, P834, DOI 10.1227/00006123-199206000-00003; MARK AL, 1987, J CARDIOVASC PHARM, V10, P56; NAGASEKI Y, 1992, J NEUROSURG, V77, P379, DOI 10.3171/jns.1992.77.3.0379; NARAGHI R, 1992, J NEUROSURG, V77, P103, DOI 10.3171/jns.1992.77.1.0103; ROSS CA, 1984, J COMP NEUROL, V228, P168, DOI 10.1002/cne.902280204; ROSS CA, 1984, J NEUROSCI, V4, P474; TASH R, 1991, AM J NEURORADIOL, V12, P839; VANOUWERKERK WJR, 1989, ADV NEUROSURG, V17, P188	26	108	111	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1466	1470		10.1016/S0140-6736(94)90289-5	http://dx.doi.org/10.1016/S0140-6736(94)90289-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968120				2022-12-24	WOS:A1994PT99500008
J	HICKSON, GB; CLAYTON, EW; ENTMAN, SS; MILLER, CS; GITHENS, PB; WHETTENGOLDSTEIN, K; SLOAN, FA				HICKSON, GB; CLAYTON, EW; ENTMAN, SS; MILLER, CS; GITHENS, PB; WHETTENGOLDSTEIN, K; SLOAN, FA			OBSTETRICIANS PRIOR MALPRACTICE EXPERIENCE AND PATIENTS SATISFACTION WITH CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To examine the relationship between prior physician malpractice experience and patients' satisfaction with care. Design.-Women were interviewed using a questionnaire that contained structured and open-ended questions. Participants.-Mothers of all stillborn infants, infant deaths, and a random sampling of viable infants drawn from 1987 Florida Vital Statistics were sorted into four groups based on the malpractice claims experience of their obstetricians between 1983 and 1986. Interviews were completed with 963 of 1536 women, most by telephone, 53 by in-person interview. Main Outcome Measures.-Mothers' responses to closed-ended and open-ended questions about their perceptions of the care they received during their pregnancy, labor, and delivery. Results.-Even though none of the women actually filed a claim, a consistent pattern of differences emerged when comparing women's perceptions of care received. Patients seeing physicians with the most frequent numbers of claims but without high payments were significantly more likely to complain that they felt rushed, never received explanations for tests, and were ignored. In response to the open-ended question, ''What part of your care were you least satisfied with?'' women seeing physicians in the High Frequency malpractice risk group offered twice as many complaints as those seeing physicians who had never been sued. Problems with physician-patient communication were the most commonly offered complaints. Conclusion.-Physicians who have been sued frequently are more often the objects of complaints about the interpersonal care they provide even by their patients who do not sue.	VANDERBILT UNIV,SCH MED,DEPT PEDIAT,DIV GEN PEDIAT,NASHVILLE,TN 37212; VANDERBILT UNIV,SCH MED,DEPT OBSTET & GYNECOL,NASHVILLE,TN; VANDERBILT UNIV,SCH LAW,NASHVILLE,TN; VANDERBILT UNIV,INST PUBL POLICY STUDIES,NASHVILLE,TN; DUKE UNIV,CTR HLTH POLICY RES & EDUC,DURHAM,NC	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Duke University			Whetten, Kathryn/C-8572-2009	Whetten, Kathryn/0000-0002-4841-7695; Clayton, Ellen/0000-0002-0308-4110	AHRQ HHS [HSO6499] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1986, COSTS COMPENSATION P; CLAYTON EW, 1993, SUING MED MALPRACTIC, P50; ENTMAN SS, 1994, JAMA-J AM MED ASSOC, V272, P1588, DOI 10.1001/jama.272.20.1588; HICKSON G, 1993, SUING MED MALPRACTIC, P92; HICKSON GB, 1992, JAMA-J AM MED ASSOC, V267, P1359, DOI 10.1001/jama.267.10.1359; KORSCH BM, 1968, PEDIATRICS, V42, P855; MAY ML, 1990, LAW SOC REV, V24, P105, DOI 10.2307/3053788; NYE DJ, 1988, GEORGETOWN LAW J, V76, P1495; Pascoe G C, 1983, Eval Program Plann, V6, P185, DOI 10.1016/0149-7189(83)90002-2; SLOAN FA, 1989, JAMA-J AM MED ASSOC, V262, P3291, DOI 10.1001/jama.262.23.3291; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; WARE JE, 1976, PB288330, V1; 1989, MED PROFESSIONAL LIA, P35; 1990, PATIENTS DOCTORS LAW	14	299	301	2	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1583	1587		10.1001/jama.272.20.1583	http://dx.doi.org/10.1001/jama.272.20.1583			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PR405	7966867				2022-12-24	WOS:A1994PR40500023
J	MCDONALD, DB; POTTS, WK				MCDONALD, DB; POTTS, WK			COOPERATIVE DISPLAY AND RELATEDNESS AMONG MALES IN A LEK-MATING BIRD	SCIENCE			English	Article							LONG-TAILED MANAKIN; SEXUAL SELECTION; LEKKING BIRD; RECIPROCITY; EVOLUTION; MAMMALS; KINSHIP	Long-tailed manakins mate in leks and cooperate in multiyear male-male partnerships. An alpha male is responsible for virtually all mating, whereas a beta male assists in the courtship displays. Such altruism by the beta male poses a problem for evolutionary theory because most theoretical treatments and empirical examples of cooperative behavior involve kin selection or reciprocity. Here it is shown that alpha and beta partners are not relatives and that reciprocity is not involved. Instead, direct, though long-delayed benefits to beta males are demonstrated, which include rare copulations, ascension to alpha status, and female lek fidelity. These benefits maintain this unusual form of male-male cooperation.	ARCHBOLD BIOL STN, LAKE PLACID, FL 33852 USA; SMITHSONIAN INST, MOLEC SYSTEMAT LAB, WASHINGTON, DC 20025 USA; UNIV FLORIDA, DEPT PATHOL, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, CTR MAMMALIAN GENET, GAINESVILLE, FL 32610 USA	Smithsonian Institution; State University System of Florida; University of Florida; State University System of Florida; University of Florida			McDonald, David Bartelle/C-3195-2008	McDonald, David Bartelle/0000-0001-8582-3775; Potts, Wayne/0000-0003-4137-0326				[Anonymous], 1991, BIOL NAKED MOLE RAT; Boucher Douglas H., 1985, BIOL MUTUALISM ECOLO; Brown J.L., 1987, HELPING COMMUNAL BRE; ELGAR MA, 1989, BIOL REV, V64, P13, DOI 10.1111/j.1469-185X.1989.tb00636.x; EMLEN ST, 1988, BEHAV ECOL SOCIOBIOL, V23, P305, DOI 10.1007/BF00300577; FOSTER MS, 1985, NEOTROPICAL ORNITHOL, V36, P817; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Kruuk H., 1989, SOCIAL BADGER; LIGON JD, 1983, AM NAT, V121, P366, DOI 10.1086/284066; MCDONALD DB, 1993, BEHAV ECOL, V4, P297, DOI 10.1093/beheco/4.4.297; MCDONALD DB, 1989, ANIM BEHAV, V37, P1007, DOI 10.1016/0003-3472(89)90145-0; MCDONALD DB, 1993, ETHOLOGY, V94, P31; MCDONALD DB, 1989, AM NAT, V134, P709, DOI 10.1086/285007; MESTERTONGIBBONS M, 1992, Q REV BIOL, V67, P267, DOI 10.1086/417658; PACKER C, 1991, NATURE, V351, P562, DOI 10.1038/351562a0; QUELLER DC, 1989, EVOLUTION, V43, P258, DOI 10.1111/j.1558-5646.1989.tb04226.x; QUELLER DC, 1989, P NATL ACAD SCI USA, V86, P3224, DOI 10.1073/pnas.86.9.3224; REYER HU, 1980, BEHAV ECOL SOCIOBIOL, V6, P219, DOI 10.1007/BF00569203; Sambrook J., 1989, MOL CLONING LAB MANU; Sokal RR, 1981, BIOMETRY PRINCIPLES; SULLIVAN KA, 1984, BEHAVIOUR, V91, P294, DOI 10.1163/156853984X00128; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; TRAINER JM, 1993, CONDOR, V95, P769, DOI 10.2307/1369416; WEBER JL, 1989, AM J HUM GENET, V44, P388; WILEY RH, 1984, EVOLUTION, V38, P609, DOI 10.1111/j.1558-5646.1984.tb00326.x; Wiley RH, 1991, ADV STUD BEHAV, V20, P201	26	175	178	0	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1030	1032		10.1126/science.7973654	http://dx.doi.org/10.1126/science.7973654			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973654				2022-12-24	WOS:A1994PQ92400040
J	DIAZBENJUMEA, FJ; COHEN, B; COHEN, SM				DIAZBENJUMEA, FJ; COHEN, B; COHEN, SM			CELL-INTERACTION BETWEEN COMPARTMENTS ESTABLISHES THE PROXIMAL-DISTAL AXIS OF DROSOPHILA LEGS	NATURE			English	Article							SEGMENT-POLARITY GENE; LIMB DEVELOPMENT; PATTERN-FORMATION; IMAGINAL DISKS; DECAPENTAPLEGIC GENE; ENGRAILED GENE; WINGLESS; MELANOGASTER; EXPRESSION; LESS	THE appendage primordia of Drosophila are subdivided into compartments(1-4) by the localized expression of transcription factors(5-7). Interaction between cells in adjacent compartments establishes organizing centres responsible for generating spatial pattern and promoting cell proliferation in the developing appendages(7-9). Localized expression of hedgehog (hh) in the posterior compartment of the leg: imaginal disc directs expression of wingless (wg) in ventral-anterior cells and decapentaplegic (dpp) in dorsal-anterior cells near the anterior-posterior compartment boundary(8); wg then acts to specify ventral cell fate(10-12) and to organize the dorsal-ventral axis of the leg(13,14). Interaction between wg-expressing ventral cells and dorsal cells near the anterior-posterior compartment boundary promotes axis formation in the leg(14,15). Here we show that the combined action of log-expressing cells in the ventral-anterior compartment and dpp-expressing cells in the dorsal-anterior compartment activates expression of Distal-less, a gene required for proximal-distal axis formation in the limbs. These results demonstrate that sequential interaction between anterior-posterior and dorsal-ventral compartments establishes the proximal-distal axis of the limbs.			DIAZBENJUMEA, FJ (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,POSTFACH 102209,D-69012 HEIDELBERG,GERMANY.		Diaz-Benjumea, Fernando/K-7667-2014; Cohen, Stephen M/G-9930-2011	Diaz-Benjumea, Fernando/0000-0003-3007-2489; Cohen, Stephen M/0000-0003-2858-9163				BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; COHEN SM, 1989, ROUX ARCH DEV BIOL, V198, P157, DOI 10.1007/BF02438941; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; PEIFER M, 1991, DEVELOPMENT, V111, P1029; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; Schubiger G., 1968, Wilhelm Roux Archiv fur Entwicklungsmechanik der Organismen, V160, P9, DOI 10.1007/BF00573645; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; SUNKEL CE, 1987, ROUX ARCH DEV BIOL, V196, P124, DOI 10.1007/BF00402034; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0	29	299	299	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					175	179		10.1038/372175a0	http://dx.doi.org/10.1038/372175a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969450				2022-12-24	WOS:A1994PQ68800055
J	BISSETT, D; DAVIS, JA; GEORGE, WD				BISSETT, D; DAVIS, JA; GEORGE, WD			GYNECOLOGICAL MONITORING DURING TAMOXIFEN THERAPY	LANCET			English	Editorial Material							BREAST-CANCER		STOBHILL GEN HOSP,GLASGOW G21 3UW,LANARK,SCOTLAND		BISSETT, D (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,BEATSON ONCOL CTR,GLASGOW G11 6NT,LANARK,SCOTLAND.							CRAWFORD DJ, 1992, BREAST, V1, P35; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; FORNANDER T, 1989, LANCET, V1, P117; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; POWLES TJ, 1992, LANCET, V340, P1145, DOI 10.1016/0140-6736(92)93162-G	5	41	42	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1244	1244		10.1016/S0140-6736(94)90747-1	http://dx.doi.org/10.1016/S0140-6736(94)90747-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967983				2022-12-24	WOS:A1994PP70100005
J	LANG, WH; MORROW, BE; JU, QD; WARNER, JR; REEDER, RH				LANG, WH; MORROW, BE; JU, QD; WARNER, JR; REEDER, RH			A MODEL FOR TRANSCRIPTION TERMINATION BY RNA-POLYMERASE-I	CELL			English	Article							RIBOSOMAL GENE TERMINATOR; SACCHAROMYCES-CEREVISIAE; PROTEIN-BINDING; YEAST; SEQUENCE; ENHANCER; REB1; ELEMENT; EXPRESSION; NUCLEOSOME	The transcription termination site for yeast RNA polymerase I requires not only an 11 bp binding site for Reb1p, but also about 46 bp of 5' flanking sequence. We propose that Reb1p bound to its site is part of a pause element, while the 5' flanking sequence contains a release element. Pausing requires little other than the DNA-binding domain of Reb1p and is not specific for polymerase I. The release element, however, can be polymerase specific. We propose a general model for eukaryotic transcription terminators in which termination occurs when a relatively nonspecific signal induces polymerase to pause in the context of a release element.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	LANG, WH (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Morrow, Bernice/0000-0002-8076-4726	NIGMS NIH HHS [GM41792, GM25532] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025532, R01GM041792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BRANDL CJ, 1990, MOL CELL BIOL, V10, P4256, DOI 10.1128/MCB.10.8.4256; CAMPBELL FE, 1992, MOL CELL BIOL, V12, P2260, DOI 10.1128/MCB.12.5.2260; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CONNELLY S, 1989, MOL CELL BIOL, V9, P5254, DOI 10.1128/MCB.9.11.5254; COZZARELLI NR, 1983, CELL, V34, P829, DOI 10.1016/0092-8674(83)90540-8; ELION EA, 1986, MOL CELL BIOL, V6, P2089, DOI 10.1128/MCB.6.6.2089; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; JOHNSON SP, 1989, MOL CELL BIOL, V9, P4986, DOI 10.1128/MCB.9.11.4986; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; KEMPERSVEENSTRA AE, 1986, EMBO J, V5, P2703, DOI 10.1002/j.1460-2075.1986.tb04554.x; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KUHN A, 1988, EMBO J, V7, P1497, DOI 10.1002/j.1460-2075.1988.tb02968.x; KULKENS T, 1992, EMBO J, V11, P4665, DOI 10.1002/j.1460-2075.1992.tb05568.x; LABHART P, 1987, MOL CELL BIOL, V7, P1900, DOI 10.1128/MCB.7.5.1900; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; MORROW BE, 1993, MOL CELL BIOL, V13, P1173, DOI 10.1128/MCB.13.2.1173; MORROW BE, 1990, J BIOL CHEM, V265, P20778; MORROW BE, 1993, MOL CELL BIOL, V13, P1283, DOI 10.1128/MCB.13.2.1283; REEDER RH, 1994, MOL MICROBIOL, V12, P11, DOI 10.1111/j.1365-2958.1994.tb00989.x; REMACLE JE, 1992, MOL CELL BIOL, V12, P5516, DOI 10.1128/MCB.12.12.5516; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SCOTT EW, 1993, MOL CELL BIOL, V13, P543, DOI 10.1128/MCB.13.1.543; WANG HM, 1990, MOL CELL BIOL, V10, P1743, DOI 10.1128/MCB.10.4.1743	28	90	91	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 4	1994	79	3					527	534		10.1016/0092-8674(94)90261-5	http://dx.doi.org/10.1016/0092-8674(94)90261-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954818				2022-12-24	WOS:A1994PQ48800015
J	ZHANG, JF; ELLINOR, PT; ALDRICH, RW; TSIEN, RW				ZHANG, JF; ELLINOR, PT; ALDRICH, RW; TSIEN, RW			MOLECULAR DETERMINANTS OF VOLTAGE-DEPENDENT INACTIVATION IN CALCIUM CHANNELS	NATURE			English	Article							FUNCTIONAL EXPRESSION; SODIUM-CHANNEL; K+ CHANNELS; PERIODIC PARALYSIS; ION CHANNELS; CELLS; MECHANISMS; KINETICS; BLOCKADE; ANTIBODY	VOLTAGE-DEPENDENT Ca2+ channels respond to membrane depolarization by conformational changes that control channel opening and eventual closing by inactivation(1-3). The kinetics of inactivation differ considerably between types of Ca2+ channels(1-8) and are important in determining the amount of Ca2+ entry during electrical activity and its resulting impact on diverse cellular events(3). The most intensively characterized forms of inactivation in potassium(9,10) and sodium channels(11-13) involve pore block by a tethered plug(14). In contrast, little is known about the molecular basis of Ca2+-channel inactivation. We studied the molecular mechanism of inactivation of voltage-gated calcium channels by making chimaeras from channels with different inactivation rates. We report here that the amino acids responsible for the kinetic differences are localized to membrane-spanning segment S6 of the first repeat of the alpha(1) subunit (IS6), and to putative extracellular and cytoplasmic domains flanking IS6. Involvement of this region in Ca2+-channel inactivation was unexpected and raises interesting comparisons with Na+ channels, where the III-IV loop is a critical structural determinant. Ca2+-channel inactivation has some features that resemble C-type inactivation of potassium channels.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University				Ellinor, Patrick/0000-0002-2067-0533				ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ARMSTRONG CM, 1985, SCIENCE, V227, P65, DOI 10.1126/science.2578071; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; CANNON SC, 1993, NEURON, V10, P317, DOI 10.1016/0896-6273(93)90321-H; CARBONE E, 1989, PROG BIOPHYS MOL BIO, V54, P31, DOI 10.1016/0079-6107(89)90008-4; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; Hille B., 1992, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; KIRSCH GE, 1992, BIOPHYS J, V62, P136, DOI 10.1016/S0006-3495(92)81800-3; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; REUTER H, 1984, ANNU REV PHYSIOL, V46, P473; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; WILLIAMS ME, 1992, SCIENCE, V257, P390; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4	31	178	181	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					97	100		10.1038/372097a0	http://dx.doi.org/10.1038/372097a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969428				2022-12-24	WOS:A1994PQ34800081
J	CASS, RM				CASS, RM			A PILL FOR OLD-PEOPLE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											CASS, RM (corresponding author), UNIV ROCHESTER, ROCHESTER, NY 14620 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					717	717		10.7326/0003-4819-121-9-199411010-00015	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00015			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944084				2022-12-24	WOS:A1994PN45000015
J	AIBA, A; KANO, M; CHEN, C; STANTON, ME; FOX, GD; HERRUP, K; ZWINGMAN, TA; TONEGAWA, S				AIBA, A; KANO, M; CHEN, C; STANTON, ME; FOX, GD; HERRUP, K; ZWINGMAN, TA; TONEGAWA, S			DEFICIENT CEREBELLAR LONG-TERM DEPRESSION AND IMPAIRED MOTOR LEARNING IN MGLUR1 MUTANT MICE	CELL			English	Article							METABOTROPIC GLUTAMATE RECEPTOR; NICTITATING-MEMBRANE RESPONSE; CONDITIONED EYELID RESPONSES; PURKINJE-CELL TRANSMISSION; CENTRAL-NERVOUS-SYSTEM; MEMORY TRACE; INTERPOSITUS NUCLEUS; SYNAPTIC DEPRESSION; CLIMBING FIBER; DEVELOPING RAT	mGluR1 mutant mice are viable but show characteristic cerebellar symptoms such as ataxic gait and intention tremor. The anatomy of the cerebellum is not overtly disturbed. Excitatory synaptic transmission from parallel fibers (PFs) to Purkinje cells and that from climbing fibers (CFs) to Purkinje cells appear to be functional, and voltage-gated Ca2+ channels of Purkinje cells are normal. Both PF and CF synapses display normal short-term synaptic plasticity to paired stimuli. By marked contrast, long-term depression (LTD) is clearly deficient and conditioned eyeblink response is impaired. We conclude that mGluR1 is required for the induction of LTD and that the ataxic behavior and impaired eyeblink conditioning of the mGluR1 mutant mice are primarily due to deficient LTD.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; JICHI MED SCH, DEPT PHYSIOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; US EPA, DIV NEUROTOXICOL, RES TRIANGLE PK, NC 27711 USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; CASE WESTERN RESERVE UNIV, SCH MED, ALZHEIMERS RES LABS, CLEVELAND, OH 44106 USA	Massachusetts Institute of Technology (MIT); Jichi Medical University; United States Environmental Protection Agency; University of North Carolina; University of North Carolina Chapel Hill; Case Western Reserve University	AIBA, A (corresponding author), MIT, HOWARD HUGHES MED INST, CTR LEARNING & MEMORY, CAMBRIDGE, MA 02139 USA.		Herrup, Karl/C-5313-2014	Herrup, Karl/0000-0001-7786-5844; Aiba, Atsu/0000-0002-8192-0778; Kano, Masanobu/0000-0002-0725-3292	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925, R01NS020591] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS32925, NS20591] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; ALTMAN J, 1973, J COMP NEUROL, V149, P181, DOI 10.1002/cne.901490204; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BLOEDEL JR, 1992, BEHAV BRAIN SCI, V15, P666; BRUNNER RL, 1973, BEHAV BIOL, V9, P169, DOI 10.1016/S0091-6773(73)80154-3; CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; CLARK RE, 1992, BEHAV NEUROSCI, V106, P879, DOI 10.1037/0735-7044.106.6.879; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; CREPEL F, 1980, NEUROSCIENCE, V5, P333, DOI 10.1016/0306-4522(80)90109-8; DANIEL H, 1992, EXP BRAIN RES, V90, P327; DISTERHOFT JF, 1977, BRAIN RES, V137, P127, DOI 10.1016/0006-8993(77)91016-2; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EKEROT CF, 1985, BRAIN RES, V342, P357, DOI 10.1016/0006-8993(85)91136-9; FOTUHI M, 1993, J NEUROSCI, V13, P2001; GORMEZANO I, 1962, SCIENCE, V138, P33, DOI 10.1126/science.138.3536.33; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HALL RD, 1973, BEHAV RES METH INSTR, V5, P321, DOI 10.3758/BF03200199; HARTELL NA, 1994, NEUROREPORT, V5, P913, DOI 10.1097/00001756-199404000-00015; HARTKOP TH, 1977, J NEUROPATH EXP NEUR, V36, P519, DOI 10.1097/00005072-197705000-00009; HIRANO T, 1990, NEUROSCI LETT, V119, P145, DOI 10.1016/0304-3940(90)90819-U; ITO M, 1982, J PHYSIOL-LONDON, V324, P113, DOI 10.1113/jphysiol.1982.sp014103; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; Ito M, 1984, CEREBELLUM NEURAL CO; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; KANO M, 1992, NATURE, V356, P601, DOI 10.1038/356601a0; Kano M., 1992, P54; KANO M, 1988, NEUROSCI RES, V5, P544, DOI 10.1016/0168-0102(88)90041-7; KANO M, 1988, NEUROSCI RES, V5, P325, DOI 10.1016/0168-0102(88)90034-X; KONNERTH A, 1992, P NATL ACAD SCI USA, V89, P7051, DOI 10.1073/pnas.89.15.7051; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; KRUPA DJ, 1993, SCIENCE, V260, P989, DOI 10.1126/science.8493536; LAVOND DG, 1989, BEHAV BRAIN RES, V33, P113, DOI 10.1016/S0166-4328(89)80047-6; LAVOND DG, 1987, EXP BRAIN RES, V67, P569; LIANO I, 1991, NEURON, V7, P577; LIANO I, 1991, J PHYSL, V434, P183; LINCOLN JS, 1982, BRAIN RES, V242, P190, DOI 10.1016/0006-8993(82)90510-8; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; LINDEN DJ, 1991, SCIENCE, V254, P1656, DOI 10.1126/science.1721243; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCCORMICK DA, 1982, P NATL ACAD SCI-BIOL, V79, P2731, DOI 10.1073/pnas.79.8.2731; PELLEGRINO LJ, 1979, J COMP PHYSIOL PSYCH, V93, P1, DOI 10.1037/h0077589; PERRETT SP, 1993, J NEUROSCI, V13, P1708; RACINE RJ, 1986, EXP BRAIN RES, V63, P158; RAKIC P, 1975, ADV NEUROL, V12, P117; RAKIC P, 1973, P NATL ACAD SCI USA, V70, P240, DOI 10.1073/pnas.70.1.240; SAKURAI M, 1987, J PHYSIOL-LONDON, V394, P463, DOI 10.1113/jphysiol.1987.sp016881; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SCHMAJUK NA, 1990, PHYSIOL BEHAV, V48, P755, DOI 10.1016/0031-9384(90)90221-O; SCHNEIDERMAN N, 1962, SCIENCE, V136, P650, DOI 10.1126/science.136.3516.650; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SKELTON RW, 1988, BEHAV NEUROSCI, V102, P586, DOI 10.1037/0735-7044.102.4.586; SOTELO C, 1990, J EXP BIOL, V153, P225; STANTON ME, 1992, BEHAV NEUROSCI, V106, P657, DOI 10.1037/0735-7044.106.4.657; STANTON ME, 1994, ENVIRON HEALTH PERSP, V102, P131, DOI 10.2307/3431830; STEINMETZ JE, 1992, J NEUROSCI, V12, P4403; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; THOMPSON RF, 1994, ANNU REV NEUROSCI, V17, P519, DOI 10.1146/annurev.neuro.17.1.519; WELSH JP, 1989, J NEUROSCI, V9, P299; WELSH JP, 1991, J PHYSIOL-LONDON, V444, P459, DOI 10.1113/jphysiol.1991.sp018888; WOODWARD DJ, 1975, BRAIN RES, V97, P195, DOI 10.1016/0006-8993(75)90445-X; YEO CH, 1992, EXP BRAIN RES, V88, P623; YEO CH, 1985, EXP BRAIN RES, V60, P87, DOI 10.1007/BF00237022; YEO CH, 1985, EXP BRAIN RES, V60, P99, DOI 10.1007/BF00237023; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	75	729	752	1	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					377	388						12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954803				2022-12-24	WOS:A1994PN63000020
J	CAMPBELL, D; COX, D; CRUM, J; FOSTER, K; RILEY, A				CAMPBELL, D; COX, D; CRUM, J; FOSTER, K; RILEY, A			LATER EFFECTS OF GROUNDING OF TANKER BRAER ON HEALTH IN SHETLAND	BRITISH MEDICAL JOURNAL			English	Article									SHETLAND HLTH BOARD,LERWICK ZE1 0RB,ZETLAND,SCOTLAND; GRAMPIAN AREA HLTH BOARD,ABERDEEN AB9 1RE,SCOTLAND; LOTHIAN HLTH BOARD,EDINBURGH EH8 9RS,MIDLOTHIAN,SCOTLAND		CAMPBELL, D (corresponding author), RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,GLASGOW G20 9NB,LANARK,SCOTLAND.							CAMPBELL D, 1993, BRIT MED J, V307, P1251, DOI 10.1136/bmj.307.6914.1251; CAMPBELL DM, 1993, BRIT MED J, V306, P519, DOI 10.1136/bmj.306.6876.519-a; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; LOGUE JN, 1981, EPIDEMIOL REV, V3, P140, DOI 10.1093/oxfordjournals.epirev.a036231	4	31	31	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					773	774		10.1136/bmj.309.6957.773	http://dx.doi.org/10.1136/bmj.309.6957.773			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950562	Green Published			2022-12-24	WOS:A1994PJ28200019
J	HABETS, GGM; SCHOLTES, EHM; ZUYDGEEST, D; VANDERKAMMEN, RA; STAM, JC; BERNS, A; COLLARD, JG				HABETS, GGM; SCHOLTES, EHM; ZUYDGEEST, D; VANDERKAMMEN, RA; STAM, JC; BERNS, A; COLLARD, JG			IDENTIFICATION OF AN INVASION-INDUCING GENE, TIAM-1, THAT ENCODES A PROTEIN WITH HOMOLOGY TO GDP-GTP EXCHANGERS FOR RHO-LIKE PROTEINS	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; MURINE LEUKEMIA-VIRUS; T-LYMPHOMA CELLS; BINDING-PROTEIN; HEMATOPOIETIC-CELLS; ACTIVATING PROTEIN; SIGNALING PROTEINS; CDC42HS PROTEIN; HUMAN ONCOGENE; BCR	Using proviral tagging in combination with in vitro selection for invasiveness, we have identified a gene, designated Tiam-1, that affects invasion. In the selected invasive T lymphoma variants, proviral insertions were found within coding exons of the Tiam-1 gene, resulting in both truncated 5'-end and 3'-end transcripts that give rise to N- and C-terminal Tiam-1 protein fragments. In one invasive variant, amplification of the Tiam-1 locus was observed with concomitant increase in the amount of normal Tiam-1 protein. Cell clones that were invasive in vitro produced experimental metastases in nude mice, and transfection of truncated Tiam-1 cDNAs into noninvasive cells made these cells invasive. The predicted Tiam-1 protein harbors a Dbl- and Pleckstrin-homologous domain, which it shares with GDP-GTP exchangers for Rho-like proteins that have been implicated in cytoskeletal organization.	ANTONI VAN LEEUWENHOEK HUIS,NETHERLANDS CANC INST,DIV MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute	HABETS, GGM (corresponding author), ANTONI VAN LEEUWENHOEK HUIS,NETHERLANDS CANC INST,DIV CELL BIOL,121 PLESMANLAAN,1066 CX AMSTERDAM,NETHERLANDS.							ADAMS JM, 1992, ONCOGENE, V7, P611; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; COLLARD JG, 1987, CANCER RES, V47, P754; COLLARD JG, 1987, CANCER RES, V47, P6666; COLLARD JG, 1988, CANCER SURV, V7, P692; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CUYPERS HT, 1984, CELL, V37, P141; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DORSSERS LCJ, 1993, MOL ENDOCRINOL, V7, P870, DOI 10.1210/me.7.7.870; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HABETS GGM, 1990, CLIN EXP METASTAS, V8, P567, DOI 10.1007/BF00135878; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1991, J BIOL CHEM, V266, P20840; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KATZAV S, 1993, MOL CELL BIOL, V11, P9106; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROGERS S, 1984, SCIENCE, V37, P1043; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1076; ROOS E, 1985, CANCER RES, V45, P6238; ROOSSIEN FF, 1989, J CELL BIOL, V108, P1979, DOI 10.1083/jcb.108.5.1979; SCHWARTZBERG P, 1984, CELL, V37, P1043, DOI 10.1016/0092-8674(84)90439-2; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WIELENGA VJM, 1993, CANCER RES, V53, P4754	48	467	502	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					537	549		10.1016/0092-8674(94)90216-X	http://dx.doi.org/10.1016/0092-8674(94)90216-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	7999144				2022-12-24	WOS:A1994NM83200009
J	LAFONT, F; BURKHARDT, JK; SIMONS, K				LAFONT, F; BURKHARDT, JK; SIMONS, K			INVOLVEMENT OF MICROTUBULE MOTORS IN BASOLATERAL AND APICAL TRANSPORT IN KIDNEY-CELLS	NATURE			English	Article							DARBY CANINE KIDNEY; INTESTINAL EPITHELIAL-CELLS; PLASMA-MEMBRANE PROTEINS; MDCK CELLS; CYTOPLASMIC DYNEIN; SURFACE POLARITY; ACTIN-FILAMENTS; CACO-2; IDENTIFICATION; GLYCOPROTEIN	THE maintenance of a polarized cell surface requires vectorial transport of vesicles to the apical and the basolateral membrane domains(1). Transport of newly synthesized apical proteins and trans-cytosis from the basolateral to the apical surface have Motors been demonstrated to depend on microtubules(2-9). In contrast, movement of membrane proteins to the basolateral surface has been claimed to occur by diffusion and to be microtubule- and actin-independent(2,4,5,7,10-12). We have re-examined the role of microtubules using a recently developed polarized transport assay in permeabilized Madin-Darby canine kidney cells(13,14). Here we report that both apical and basolateral transport is inhibited by nocodazole treatment. Transport to the basolateral surface was inhibited by immunodepletion of cytosolic kinesin. In contrast, apical transport involved both dynein and kinesin. Our data demonstrate that in epithelial cells, microtubule motors are involved in the movement of apical and basolateral vesicles. Moreover, we propose that the differential requirement for microtubule-based motors is related to the microtubule organization.	EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAMME, D-69112 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)				Burkhardt, Janis/0000-0002-8176-1375; Simons, Kai/0000-0002-9231-9996; Lafont, frank/0000-0001-8668-2580				ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BACALLAO R, 1989, METHOD CELL BIOL, V31, P437; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; EILERS U, 1989, J CELL BIOL, V108, P13, DOI 10.1083/jcb.108.1.13; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; GIBBONS IR, 1978, J BIOL CHEM, V25, P2780; GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275; HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; MASSON D, 1993, J CELL BIOL, V123, P357, DOI 10.1083/jcb.123.2.357; MATTER K, 1990, EMBO J, V9, P3163, DOI 10.1002/j.1460-2075.1990.tb07514.x; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; OJAKIAN GK, 1992, J CELL SCI, V103, P677; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; REINSCH S, 1994, J CELL BIOL, V126, P1509, DOI 10.1083/jcb.126.6.1509; RINDLER MJ, 1987, J CELL BIOL, V104, P231, DOI 10.1083/jcb.104.2.231; SALAS PJI, 1986, J CELL BIOL, V102, P1853, DOI 10.1083/jcb.102.5.1853; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VANDERSLUIJS P, 1990, J CELL SCI, V95, P545; VANZEIJL MJAH, 1990, CELL REGUL, V1, P921, DOI 10.1091/mbc.1.12.921	30	168	169	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					801	803						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997271				2022-12-24	WOS:A1994PY21200059
J	ZIEGLER, A; JONASON, AS; LEFFELL, DJ; SIMON, JA; SHARMA, HW; KIMMELMAN, J; REMINGTON, L; JACKS, T; BRASH, DE				ZIEGLER, A; JONASON, AS; LEFFELL, DJ; SIMON, JA; SHARMA, HW; KIMMELMAN, J; REMINGTON, L; JACKS, T; BRASH, DE			SUNBURN AND P53 IN THE ONSET OF SKIN-CANCER	NATURE			English	Article							ULTRAVIOLET RADIATION; SOLAR KERATOSES; CELL; SUNLIGHT; MUTATION; APOPTOSIS; PROMOTION; EXPOSURE; GENE; DNA	SQUAMOUS cell carcinoma of the skin (SCC) can progress by stages: sun-damaged epidermis, with individual disordered keratinocytes; actinic keratosis (AK), spontaneously regressing keratinized patches having aberrant cell differentiation and proliferation; carcinoma in situ; SCC and metastasis(1-3). To understand how sunlight acts as a carcinogen, we determined the stage at which sunlight mutates the p53 tumour-suppressor gene and identified a function for p53 in skin. The p53 mutations induced by ultraviolet radiation and found in >90% of human SCCs4,5 were present in AKs. Inactivating p53 in mouse skin reduced the appearance of sunburn cells(6), apoptotic keratinocytes generated by overexposure to ultraviolet. Skin thus appears to possess a p53-dependent 'guardian-of-the-tissue' response to DNA damage which aborts precancerous cells. If this response is reduced in a single cell by a prior p53 mutation, sunburn can select for clonal expansion of the p53-mutated cell into the AK. Sunlight can act twice: as tumour initiator and tumour promoter.	YALE UNIV,SCH MED,DEPT DERMATOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; MIT,HOWARD HUGHES MED INST,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139	Yale University; Yale University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	ZIEGLER, A (corresponding author), YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,NEW HAVEN,CT 06510, USA.			Ziegler, Annemarie/0000-0003-0018-7031				BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BURNS FJ, 1976, CANCER RES, V36, P1422; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CAMPBELL C, 1993, CANCER RES, V53, P2697; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DANNO K, 1987, PHOTOCHEM PHOTOBIOL, V45, P683, DOI 10.1111/j.1751-1097.1987.tb07401.x; EPSTEIN JH, 1970, PHOTOCHEM PHOTOBIOL, V12, P57, DOI 10.1111/j.1751-1097.1970.tb06038.x; EPSTEIN JH, 1962, J INVEST DERMATOL, V39, P455, DOI 10.1038/jid.1962.142; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gilchrest BA., 1984, SKIN AGING PROCESSES; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HUTCHINSON F, 1994, MUTAT RES-FUND MOL M, V309, P11, DOI 10.1016/0027-5107(94)90037-X; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KRICKER A, 1991, INT J CANCER, V48, P650, DOI 10.1002/ijc.2910480504; LEY RD, 1985, J INVEST DERMATOL, V85, P365, DOI 10.1111/1523-1747.ep12276992; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARKS R, 1990, MED J AUSTRALIA, V152, P62, DOI 10.5694/j.1326-5377.1990.tb124456.x; MARKS R, 1986, BRIT J DERMATOL, V115, P649, DOI 10.1111/j.1365-2133.1986.tb06644.x; MOOLGAVKAR SH, 1981, J NATL CANCER I, V66, P1037, DOI 10.1093/jnci/66.6.1037; POTTER VR, 1984, CANCER RES, V44, P2733; ROSARIO R, 1979, BRIT J DERMATOL, V101, P299; SCHWARTZ RA, 1993, DERMATOLOGY GEN MED, P804; Singer-Sam J, 1992, PCR Methods Appl, V1, P160; URBACH F, 1972, ENV CANCER, P355; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	30	1238	1270	3	98	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					773	776		10.1038/372773a0	http://dx.doi.org/10.1038/372773a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997263				2022-12-24	WOS:A1994PY21200051
J	LURIE, P; AVINS, AL; PHILLIPS, KA; KAHN, JG; LOWE, RA; CICCARONE, D				LURIE, P; AVINS, AL; PHILLIPS, KA; KAHN, JG; LOWE, RA; CICCARONE, D			THE COST-EFFECTIVENESS OF VOLUNTARY COUNSELING AND TESTING OF HOSPITAL INPATIENTS FOR HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE WORKERS; NEEDLESTICK INJURIES; UNITED-STATES; UNIVERSAL PRECAUTIONS; SURGICAL-PROCEDURES; RISK; POPULATION; ANTIBODY; BLOOD	Objective.-To evaluate the cost-effectiveness of voluntary counseling and testing of US hospital inpatients for the human immunodeficiency virus (HIV). Data Sources.-Data for entry into the model were derived from a review of the literature, consultation with experts, and consensus of the authors. Data Extraction.-We rated our confidence in these probabilities and costs by grading the data inputs using methods adapted from those of the US Preventive Services Task Force. Data Synthesis.-Decision analysis models were developed to evaluate two outcomes: (1) cost per health care worker (HCW) HIV infection averted if measures are taken by the HCW to reduce his or her risk of acquiring HIV; and (2) cost per inpatient HIV infection detected, Sensitivity analyses were also conducted, Using baseline input values, testing to avert HCW infection may prevent 3.6 HIV infections per year at a total program cost of $2.7 billion, or a cost of $753 million per infection averted. At baseline assumptions (seroprevalence=1%), testing to detect inpatient HIV infection would cost $16104 per year per infection detected. Cost-effectiveness at baseline drops to $8353 per HIV infection detected if the seroprevalence is 10%. If testing is limited to hospitals with inpatient seroprevalences of at least 1%, approximately 5400 persons per year will be falsely labeled HIV-positive. Conclusions.-This analysis provides no justification for testing inpatients to prevent HIV infection of HCWs. Screening inpatients to detect HIV infection may be justified at seroprevalences exceeding 1%, but issues of medical or social discrimination, false-positive results, informed consent, and logistics must be resolved first.	UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94110; UNIV CALIF BERKELEY,CTR STUDENT HLTH,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California Berkeley	LURIE, P (corresponding author), UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA, USA.		Lowe, Robert A/A-4926-2008; Ciccarone, Daniel/I-5404-2013	Lowe, Robert A/0000-0002-4732-9634; Ciccarone, Daniel/0000-0002-2355-5477	AHRQ HHS [HS07373-01] Funding Source: Medline; NIMH NIH HHS [P50 MH42459, MH19105-02] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U01HS007373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019105, P50MH042459] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDRUS JK, 1989, AM J PUBLIC HEALTH, V79, P840, DOI 10.2105/AJPH.79.7.840; [Anonymous], 1989, GUIDE CLIN PREVENTIV; ARNO PS, 1991, SEP IMP REG GUID LEG; ARNOW PM, 1989, PUBLIC HEALTH REP, V104, P121; BARTON JJ, 1989, AM J OBSTET GYNECOL, V160, P1316, DOI 10.1016/0002-9378(89)90850-8; BLOOM DE, 1991, SCIENCE, V252, P1798, DOI 10.1126/science.1829547; BLOWER SM, 1994, SCIENCE, V265, P1451, DOI 10.1126/science.8073289; CLEARY PD, 1987, JAMA-J AM MED ASSOC, V258, P1757, DOI 10.1001/jama.258.13.1757; COLOMBOTOS J, 1991, PHYSICIANS NURSES AI; FREEMAN HE, 1991, MED CARE, V29, P87, DOI 10.1097/00005650-199102000-00001; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GERBERDING JL, 1991, INFECT CONT HOSP EP, V12, P443, DOI 10.1086/646376; GERBERT B, 1993, ARCH INTERN MED, V153, P313, DOI 10.1001/archinte.153.3.313; HAGEN MD, 1988, JAMA-J AM MED ASSOC, V259, P1357, DOI 10.1001/jama.259.9.1357; Hamory B H, 1984, Am J Infect Control, V12, P68, DOI 10.1016/0196-6553(84)90080-4; HAMORY BH, 1983, AM J INFECT CONTROL, V11, P174, DOI 10.1016/0196-6553(83)90077-9; HARDY LM, 1991, HIV SCREENING PREGNA, P91; HARRIS RL, 1990, INFECT CONT HOSP EP, V11, P628; HEDLUND K, 1990, 6TH INT C AIDS SAN F; HELLINGER FJ, 1992, INQUIRY-J HEALTH CAR, V29, P356; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HENDERSON DK, 1986, ANN INTERN MED, V104, P644, DOI 10.7326/0003-4819-104-5-644; HENDERSON DK, 1990, PRINCIPLES PRACTICE, P2221; HENRY K, 1992, PUBLIC HEALTH REP, V107, P138; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; HOLTGRAVE DR, 1993, ARCH INTERN MED, V153, P1225, DOI 10.1001/archinte.153.10.1225; HORVITZ DG, 1990, P SECTION SURV S218, V150; HOXIE NJ, 1990, AM J PUBLIC HEALTH, V80, P1129, DOI 10.2105/AJPH.80.9.1129; HULL HF, 1988, JAMA-J AM MED ASSOC, V260, P935, DOI 10.1001/jama.260.7.935; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; JANSSEN RS, 1992, NEW ENGL J MED, V327, P445, DOI 10.1056/NEJM199208133270701; KRAHN M, 1993, MED CARE, V31, P403, DOI 10.1097/00005650-199305000-00003; KRASINSKI K, 1988, NEW ENGL J MED, V318, P185; LAWRENCE VA, 1993, J CLIN EPIDEMIOL, V46, P1219, DOI 10.1016/0895-4356(93)90084-E; LINDAN CP, 1994, AIDS, V8, P1149, DOI 10.1097/00002030-199408000-00018; LINDSAY MK, 1989, OBSTET GYNECOL, V74, P289; LINNEMANN CC, 1991, INFECT CONT HOSP EP, V12, P214, DOI 10.2307/30146994; LURIE P, 1992, NEW ENGL J MED, V327, P1815, DOI 10.1056/NEJM199212173272512; MANGIONE CM, 1991, AM J MED, V90, P85, DOI 10.1016/0002-9343(91)90510-5; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MCCRAY E, 1986, NEW ENGL J MED, V314, P1127, DOI 10.1056/NEJM198604243141729; MCGEER A, 1990, J INFECT DIS, V162, P961, DOI 10.1093/infdis/162.4.961; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; PETERSEN LR, 1990, AM J PUBLIC HEALTH, V80, P1087, DOI 10.2105/AJPH.80.9.1087; PHILLIPS KA, 1994, JAMA-J AM MED ASSOC, V271, P851, DOI 10.1001/jama.271.11.851; PHILLIPS KA, IN PRESS PUBLIC HLTH; RIBNER BS, 1987, INFECT CONT HOSP EP, V8, P63, DOI 10.1017/S0195941700067096; SCHOCHETMAN G, 1989, ANNU REV MICROBIOL, V43, P629; SCHOCHETMAN G, 1992, AIDS TESTING METHODS; SCHWARCZ SK, 1993, AM J EPIDEMIOL, V137, P600, DOI 10.1093/oxfordjournals.aje.a116717; SCHWARTZ JS, 1988, JAMA-J AM MED ASSOC, V259, P2574, DOI 10.1001/jama.259.17.2574; SCHWARTZ JS, 1990, JAMA-J AM MED ASSOC, V264, P1704, DOI 10.1001/jama.264.13.1704; SLOAND EM, 1991, JAMA-J AM MED ASSOC, V266, P2861, DOI 10.1001/jama.266.20.2861; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; TANDBERG D, 1991, ANN EMERG MED, V20, P66, DOI 10.1016/S0196-0644(05)81122-9; TOKARS J, 1990, 6TH INT C AIDS SAN F; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; TURNOCK BJ, 1989, JAMA-J AM MED ASSOC, V261, P3415, DOI 10.1001/jama.261.23.3415; WEISS R, 1988, NEW ENGL J MED, V319, P1010, DOI 10.1056/NEJM198810133191509; Yawn B P, 1992, Fam Med, V24, P355; 1993, AIDS ALERT, V8, P49; 1991, ESTIMATES RISK ENDEM; 1994, ANN INTERN MED, V120, P310; 1990, NATIONAL HIV SEROPRE; 1989, GUIDELINES PREVENTIO; 1990, MMWR-MORBID MORTAL W, V39, P380; 1991, NATIONAL HOSPITAL DI; 1991, HIV SCREENING PREGNA; 1993, MMWR-MORBID MORTAL W, V42, P5; 1992, STATISTICAL ABSTRACT; 1991, MMWR-MORBID MORTAL W, V40, P1	73	26	26	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1832	1838		10.1001/jama.272.23.1832	http://dx.doi.org/10.1001/jama.272.23.1832			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW980	7990217				2022-12-24	WOS:A1994PW98000031
J	FEAVER, WJ; SVEJSTRUP, JQ; HENRY, NL; KORNBERG, RD				FEAVER, WJ; SVEJSTRUP, JQ; HENRY, NL; KORNBERG, RD			RELATIONSHIP OF CDK-ACTIVATING KINASE AND RNA-POLYMERASE-II CTD KINASE TFIIH/TFIIK	CELL			English	Article							CARBOXYL-TERMINAL-DOMAIN; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; INITIATION-FACTORS; CATALYTIC SUBUNIT; SEQUENCE; DNA; PHOSPHORYLATION; YEAST	KIN28, a member of the p34(cdc2/CDC28) family of protein kinases, is identified as a subunit of yeast RNA polymerase transcription factor IIH (TFIIH) on the basis of sequence determination, immunological reactivity, and copurification. KIN28 is, moreover, one of three subunits of TFIIK, a subassembly of TFIIH with protein kinase activity directed toward the C-terminal repeat domain (CTD) of the largest subunit of RNA polymerase II. Itself a phosphoprotein, KIN28 interacts specifically with the two largest subunits of RNA polymerase II. Previous work of others points to two further associations: KIN28 interacts in vivo with the cyclin CCL1, and KIN28 and CCL1 are homologous to human MO15 and cyclin H, which form the cyclin-dependent kinase-activating kinase (CAK). We show that human CAK possesses the CTD kinase activity characteristic of TFIIH.			FEAVER, WJ (corresponding author), STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,STANFORD,CA 94305, USA.			Svejstrup, Jesper/0000-0003-4964-6147	NIGMS NIH HHS [GM36659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HENRY NL, 1994, IN PRESS GENES DEV; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; NAUMOVSKI L, 1985, MOL CELL BIOL, V5, P17, DOI 10.1128/MCB.5.1.17; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROY R, 1994, CELL, V79; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TSUJI JN, 1991, P NATL ACAD SCI USA, V88, P9006; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WU LT, 1994, ONCOGENE, V9, P2089; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	48	376	381	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1103	1109		10.1016/0092-8674(94)90040-X	http://dx.doi.org/10.1016/0092-8674(94)90040-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001136				2022-12-24	WOS:A1994PY08600019
J	TAIRA, M; OTANI, H; SAINTJEANNET, JP; DAWID, IB				TAIRA, M; OTANI, H; SAINTJEANNET, JP; DAWID, IB			ROLE OF THE LIM CLASS HOMEODOMAIN PROTEIN XLIM-1 IN NEURAL AND MUSCLE INDUCTION BY THE SPEMANN ORGANIZER IN XENOPUS	NATURE			English	Article							MESSENGER-RNAS; DNA-BINDING; GENE; EXPRESSION; MESODERM; DOMAIN; LAEVIS; EMBRYOS; NOGGIN; PLATE	LIKE all known LIM class homeobox genes, Xlim-1 encodes a protein with two tandemly repeated cysteine-rich LIM domains upstream of the homeodomain(1). In Xenopus laevis, Xlim-1 is specifically expressed in the Spemann organizer, whose major functions include neural induction and dorsalization of ventral mesoderm(2-4). From RNA injection experiments we conclude here that: (1) the LIM domains behave as negative regulatory domains; (2) LIM domain mutants of Xlim-1 elicited neural differentiation in animal explants; (3) mutant, and to a lesser extent wild-type, Xlim-1 enhanced muscle formation after coinjection with Xbra; (4) both of these activities are mediated by extracellular signals as seen in combined explant experiments;. (5) Xlim-1 mutants activated goosecoid (gsc) expression in animal explants, but not expression of noggin or follistatin; (6) mutant Xlim-1 elicited formation of partial secondary axes, and cooperated with gsc in notochord formation. Thus Xlim-1 has latent activities, implicating it in organizer functions.	UNIV TOULOUSE 3,CNRS,UNITE MIXTE RECH 9925,CTR DEV BIOL,F-31062 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	TAIRA, M (corresponding author), NICHHD,MOLEC GENET LAB,BETHESDA,MD 20892, USA.							BOICE ME, 1992, DEVELOPMENT, V115, P681; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DAWID IB, 1994, J BIOL CHEM, V269, P6259; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GILBERT SF, 1993, MECH DEVELOP, V41, P73, DOI 10.1016/0925-4773(93)90039-Z; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; JAMRICH M, 1989, DEVELOPMENT, V105, P779; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; SAINTJEANNET JP, 1994, P NATL ACAD SCI USA, V91, P3049, DOI 10.1073/pnas.91.8.3049; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; STEINBEISSER H, 1993, CR ACAD SCI III-VIE, V316, P966; TAIRA M, 1994, DEVELOPMENT, V120, P1525; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; WATANABE M, 1986, J CELL BIOL, V103, P1721, DOI 10.1083/jcb.103.5.1721; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	28	181	183	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					677	679		10.1038/372677a0	http://dx.doi.org/10.1038/372677a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990959				2022-12-24	WOS:A1994PX30700086
J	BONITA, R; BEAGLEHOLE, R				BONITA, R; BEAGLEHOLE, R			CARDIOVASCULAR-DISEASE EPIDEMIOLOGY IN DEVELOPING-COUNTRIES - ETHICS AND ETIQUETTE	LANCET			English	Editorial Material									UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND	University of Auckland	BONITA, R (corresponding author), UNIV AUCKLAND,DEPT MED,GERIATR UNIT,AUCKLAND,NEW ZEALAND.							[Anonymous], 1994, MED GLOBAL SURVIVAL; [Anonymous], 1993, WORLD DEV REPORT INV; LI N, 1994, J CLIN EPIDEMIOL, V47, P599, DOI 10.1016/0895-4356(94)90208-9; LINDEBERG S, 1993, J INTERN MED, V233, P269, DOI 10.1111/j.1365-2796.1993.tb00986.x; LINDEBERG S, 1994, J INTERN MED, V236, P331, DOI 10.1111/j.1365-2796.1994.tb00804.x; PETO R, 1994, MORTALITY SMOKING; Snow J., 1855, MODE COMMUNICATION C; Wessen A., 1992, MIGRATION HLTH SMALL; 1994, CIRCULATION, V90, P583; 1992, J CLIN EPIDEMIOL, V45, P841	10	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1586	1587		10.1016/S0140-6736(94)90401-4	http://dx.doi.org/10.1016/S0140-6736(94)90401-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983989				2022-12-24	WOS:A1994PW05100004
J	DIERMAYER, M; HEDBERG, K; FLEMING, D				DIERMAYER, M; HEDBERG, K; FLEMING, D			BACKING OFF UNIVERSAL CHILDHOOD LEAD SCREENING IN THE USA - OPPORTUNITY OR PITFALL	LANCET			English	Editorial Material											DIERMAYER, M (corresponding author), OREGON HLTH DIV,PORTLAND,OR 97207, USA.							[Anonymous], 1991, PREVENTING LEAD POIS; BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; DIERMAYER M, 1994, 43RD ANN EP INT SERV, P72; PIRKLE JL, 1994, JAMA-J AM MED ASSOC, V272, P284, DOI 10.1001/jama.272.4.284	4	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1587	1588		10.1016/S0140-6736(94)90402-2	http://dx.doi.org/10.1016/S0140-6736(94)90402-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW051	7983990				2022-12-24	WOS:A1994PW05100005
J	LIU, HP; KOHLER, J; FINK, GR				LIU, HP; KOHLER, J; FINK, GR			SUPPRESSION OF HYPHAL FORMATION IN CANDIDA-ALBICANS BY MUTATION OF A STE12 HOMOLOG	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; FILAMENTOUS GROWTH; YEAST; PROTEIN	A Candida albicans gene (CPH1) was cloned that encodes a protein homologous to Saccharomyces cerevisiae Ste12p, a transcription factor that is the target of the pheromone response mitogen-activated protein kinase cascade. CPH1 complements both the mating defect of ste12 haploids and the filamentous growth defect of ste12/ste12 diploids. Candida albicans strains without a functional CPH1 gene (cph1/cph1) show suppressed hyphal formation on solid medium. However, cph1/cph1 strains can still form hyphae in liquid culture and in response to serum. Thus, filamentous growth may be activated in C. albicans by the same signaling kinase cascade that activates Ste12p in S. cerevisiae; however, alternative pathways may exist in C. albicans.	CHILDRENS HOSP, BOSTON, MA 02115 USA; MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA	Harvard University; Boston Children's Hospital; Massachusetts Institute of Technology (MIT); Whitehead Institute					NIGMS NIH HHS [GM402661] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANUETT F, 1994, GENE DEV, V8, P1367, DOI 10.1101/gad.8.12.1367; BARLOW AJE, 1974, J GEN MICROBIOL, V82, P261, DOI 10.1099/00221287-82-2-261; BUFFO J, 1984, MYCOPATHOLOGIA, V85, P21, DOI 10.1007/BF00436698; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FONZI WA, 1993, DIMORPHIC FUNGI IN BIOLOGY AND MEDICINE, P37; FONZI WA, 1993, GENETICS, V134, P717; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIMENO CJ, 1992, SCIENCE, V257, P626, DOI 10.1126/science.1496375; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GOSHORN AK, 1989, GENETICS, V123, P667; GOW NAR, 1994, P NATL ACAD SCI USA, V91, P6216, DOI 10.1073/pnas.91.13.6216; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KIRKMANCORREIA C, 1993, MOL CELL BIOL, V13, P3765, DOI 10.1128/MCB.13.6.3765; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MALATHI K, 1994, J BIOL CHEM, V269, P22945; SCHERER S, 1990, MICROBIOL REV, V54, P226, DOI 10.1128/MMBR.54.3.226-241.1990; SONG OK, 1991, GENE DEV, V5, P741, DOI 10.1101/gad.5.5.741; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; YUAN YLO, 1993, GENE DEV, V7, P1584, DOI 10.1101/gad.7.8.1584; YUAN YLO, 1991, MOL CELL BIOL, V11, P5910, DOI 10.1128/MCB.11.12.5910	24	674	707	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	1994	266	5191					1723	1726		10.1126/science.7992058	http://dx.doi.org/10.1126/science.7992058			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992058				2022-12-24	WOS:A1994PW30800045
J	MINVIELLESEBASTIA, L; PREKER, PJ; KELLER, W				MINVIELLESEBASTIA, L; PREKER, PJ; KELLER, W			RNA14 AND RNA15 PROTEINS AS COMPONENTS OF A YEAST PRE-MESSENGER-RNA 3'-END PROCESSING FACTOR	SCIENCE			English	Article							CYC1 MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; POLY(A) POLYMERASE; 3' END; GENE; SEQUENCE; POLYADENYLATION; MUTATIONS; INVITRO; BINDING	Most eukaryotic pre-messenger RNAs are processed at their 3' ends by endonucleolytic cleavage and polyadenylation. In yeast, this processing requires polyadenylate [poly(A)] polymerase (PAP) and other proteins that have not yet been characterized. Here, mutations in the PAP1 gene were shown to be synergistically lethal with previously identified mutations in the RNA14 and RNA15 genes, which suggests that their encoded proteins participate in 3'-end processing. Indeed, extracts from ma14 and ma15 mutants were shown to be deficient in both steps of processing. Biochemical complementation experiments and reconstitution of both activities with partially purified cleavage factor I (CF I) validated the genetic prediction.			MINVIELLESEBASTIA, L (corresponding author), UNIV BASEL,BIOCTR,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND.		Minvielle-Sebastia, Lionel/M-7154-2014					BLOCH JC, 1978, MOL GEN GENET, V165, P123, DOI 10.1007/BF00269900; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BONNEAUD N, 1994, J CELL SCI, V107, P913; BUTLER JS, 1988, SCIENCE, V242, P1270, DOI 10.1126/science.2848317; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; GUARENTE L, 1993, TRENDS GENET, V9, P362, DOI 10.1016/0168-9525(93)90042-G; HOU W, 1994, EMBO J, V13, P446, DOI 10.1002/j.1460-2075.1994.tb06279.x; HUFFAKER TC, 1987, ANNU REV GENET, V21, P259; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; LIAO XLC, 1993, GENE DEV, V7, P419, DOI 10.1101/gad.7.3.419; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; LINGNER J, UNPUB; MINVIELLESEBAST.L, 1992, THESIS PARIS U; MINVIELLESEBAST.L, UNPUB; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MOORE CL, 1984, CELL, V36, P581, DOI 10.1016/0092-8674(84)90337-4; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; RUBY SW, 1993, GENE DEV, V7, P1909, DOI 10.1101/gad.7.10.1909; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; Sambrook J., 1989, MOL CLONING LAB MANU; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	26	137	139	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1702	1705		10.1126/science.7992054	http://dx.doi.org/10.1126/science.7992054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992054				2022-12-24	WOS:A1994PW30800039
J	NOURSE, J; FIRPO, E; FLANAGAN, WM; COATS, S; POLYAK, K; LEE, MH; MASSAGUE, J; CRABTREE, GR; ROBERTS, JM				NOURSE, J; FIRPO, E; FLANAGAN, WM; COATS, S; POLYAK, K; LEE, MH; MASSAGUE, J; CRABTREE, GR; ROBERTS, JM			INTERLEUKIN-2-MEDIATED ELIMINATION OF THE P27(KIP1) CYCLIN-DEPENDENT KINASE INHIBITOR PREVENTED BY RAPAMYCIN	NATURE			English	Article							CATALYTIC SUBUNIT; PROTEIN-KINASE; CDK2 ACTIVITY; PHOSPHORYLATION; FIBROBLASTS; LYMPHOCYTES; ACTIVATION; P40(MO15); P34(CDC2); FK506	THE cyclin-dependent kinase (Cdk) enzymes, when associated with the G1 cycIins D and E, are rate-limiting for entry into the S phase of the cell cycle(1,2). During T-cell mitogenesis, antigen-receptor signalling promotes synthesis of cyclin E and its catalytic partner, Cdk2, and interleukin-2 (IL-2) signalling activates cyclin E/Cdk2 complexes(3). Rapamycin is a potent immunosuppressant which specifically inhibits G1-to-S-phase progression, leading to cell-cycle arrest in yeast and mammals(4-7) Here we report that IL-2 allows Cdk activation by causing the elimination of the Cdk inhibitor protein p27(Kip1), and that this is prevented by rapamycin. By contrast, the Cdk inhibitor p21 is induced by IL-2 and this induction is blocked by rapamycin. Our results show that p27(Kip1) governs Cdk activity during the transition from quiescence to S phase in T lymphocytes and that p21 function may be restricted to cycling cells.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104; MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021	Howard Hughes Medical Institute; Stanford University; Fred Hutchinson Cancer Center; Memorial Sloan Kettering Cancer Center	NOURSE, J (corresponding author), STANFORD UNIV,SCH MED,PROGRAM CANC BIOL,STANFORD,CA 94305, USA.			Lee, Mong-Hong/0000-0001-8675-8215; Massague, Joan/0000-0001-9324-8408				BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; KATO JY, IN PRESS CELL; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; MORICE WG, 1993, J BIOL CHEM, V268, P22737; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	24	903	933	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					570	573		10.1038/372570a0	http://dx.doi.org/10.1038/372570a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990932				2022-12-24	WOS:A1994PW08200058
J	GUCKENBERGER, R; HEIM, M; CEVC, G; KNAPP, HF; WIEGRABE, W; HILLEBRAND, A				GUCKENBERGER, R; HEIM, M; CEVC, G; KNAPP, HF; WIEGRABE, W; HILLEBRAND, A			SCANNING-TUNNELING-MICROSCOPY OF INSULATORS AND BIOLOGICAL SPECIMENS BASED ON LATERAL CONDUCTIVITY OF ULTRATHIN WATER FILMS	SCIENCE			English	Article							MEMBRANE; PROTEIN	Scanning tunneling microscopy is based on the flow of an electrical current and thus cannot be used to directly image insulating material. It has been found, however, that a very thin film of water (about one monolayer) adsorbed to a surface exhibits a surprisingly high conductivity that is sufficient to allow scanning tunneling microscope imaging at currents below 1 picoampere. Hydrophilic insulators, such as glass and mica, can thus be imaged in humid air. The same is true for biological specimens deposited on such surfaces, as demonstrated by the scanning tunneling microscope imaging of plasmid DNA on mica.	TECH UNIV MUNICH,KLINIKUM RECHTS ISAR,D-81675 MUNICH,GERMANY	Technical University of Munich	GUCKENBERGER, R (corresponding author), MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY.							BEAGLEHOLE D, 1991, PHYS REV LETT, V66, P2084, DOI 10.1103/PhysRevLett.66.2084; CEVC G, 1990, BIOCHIM BIOPHYS ACTA, V1031, P311, DOI 10.1016/0304-4157(90)90015-5; CEVC G, 1992, J ELECTROANAL CHEM, V330, P407, DOI 10.1016/0022-0728(92)80321-T; CEVC G, 1993, HYDRATION BIOL MACRO, P338; GATHERCOLE LJ, 1993, J CHEM SOC FARADAY T, V89, P2589, DOI 10.1039/ft9938902589; GUCKENBERGER R, 1988, ULTRAMICROSCOPY, V25, P111, DOI 10.1016/0304-3991(88)90218-5; GUCKENBERGER R, 1989, ULTRAMICROSCOPY, V31, P327, DOI 10.1016/0304-3991(89)90055-7; GUCKENBERGER R, 1991, J VAC SCI TECHNOL B, V9, P1227, DOI 10.1116/1.585210; GUCKENBERGER R, 1994, J VAC SCI TECHNOL B, V12, P1508, DOI 10.1116/1.587274; GUCKENBERGER R, UNPUB; GUCKENBERGER R, 1992, SCANNING TUNNELING M, V2, P52; HACKER B, 1992, ULTRAMICROSCOPY, V42, P1514, DOI 10.1016/0304-3991(92)90475-Y; HELM ML, UNPUB; KELL DB, 1992, BIOELECTROCH BIOENER, V27, P235, DOI 10.1016/0302-4598(92)87047-X; LEGGETT GJ, 1993, J PHYS CHEM-US, V97, P8852, DOI 10.1021/j100137a006; SCHAPER A, 1993, NUCLEIC ACIDS RES, V21, P6004, DOI 10.1093/nar/21.25.6004; WANG ZH, 1990, P NATL ACAD SCI USA, V87, P9343, DOI 10.1073/pnas.87.23.9343; YUAN JY, 1991, PHYS REV LETT, V67, P863, DOI 10.1103/PhysRevLett.67.863; [No title captured]	19	214	217	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1538	1540		10.1126/science.7985024	http://dx.doi.org/10.1126/science.7985024			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985024				2022-12-24	WOS:A1994PV01500036
J	VANDENBROUCKE, JP; KOSTER, T; BRIET, E; REITSMA, PH; BERTINA, RM; ROSENDAAL, FR				VANDENBROUCKE, JP; KOSTER, T; BRIET, E; REITSMA, PH; BERTINA, RM; ROSENDAAL, FR			INCREASED RISK OF VENOUS THROMBOSIS IN ORAL-CONTRACEPTIVE USERS WHO ARE CARRIERS OF FACTOR-V LEIDEN MUTATION	LANCET			English	Article							POOR ANTICOAGULANT RESPONSE; NONFATAL VASCULAR-DISEASE; ACTIVATED PROTEIN-C; THROMBOEMBOLISM; THROMBOPHILIA; WOMEN	We investigated whether the occurrence of venous thrombosis in young women who use oral contraceptives might be explained by the factor V Leiden mutation, which leads to resistance to activated protein C and enhances susceptibility to thrombosis. We compared 155 consecutive premenopausal women, aged 15 to 49, who had developed deep venous thrombosis in the absence of other underlying diseases, with 169 population controls. The risk of thrombosis among users of oral contraceptives was increased 4-fold (relative risk 3.8 [95% CI 2.4-6.0]). The risk of thrombosis among carriers of the mutation compared with non-carriers was increased 8-fold (7.9 [3.2-19.4]). Compared with women who did not use oral contraceptives and were not, carriers of the mutation, the risk of thrombosis among those with both risk factors was increased more than 30-fold (34.7 [7.8-154]). Recalculation of population incidences from these relative risks shows that the absolute risk of venous thrombosis in young women who use oral contraceptives is much larger when they carry the factor V Leiden mutation. When a young woman develops thrombosis, her factor V Leiden status should be considered in counselling about her future method of contraception.	LEIDEN UNIV HOSP, HAEMOSTASIS & THROMBOSIS RES CTR, 2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	VANDENBROUCKE, JP (corresponding author), LEIDEN UNIV HOSP, DEPT CLIN EPIDEMIOL, BLDG 1-CO-P, POB 9600, 2300 RC LEIDEN, NETHERLANDS.		Rosendaal, Frits/Q-3842-2017; Bertina, Rogier/AGQ-5246-2022; Vandenbroucke, Jan/AAM-3928-2020	Rosendaal, Frits/0000-0003-2558-7496; Vandenbroucke, Jan/0000-0001-5668-6716				[Anonymous], 1985, THEORETICAL EPIDEMIO; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BRIET E, 1994, BRIT J HAEMATOL, V87, P348, DOI 10.1111/j.1365-2141.1994.tb04920.x; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; GIROLAMI A, 1993, BLOOD COAGUL FIBRIN, V4, P841, DOI 10.1097/00001721-199304050-00029; HELMRICH SP, 1987, OBSTET GYNECOL, V69, P91; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; JORDAN WM, 1961, LANCET, V2, P1146, DOI DOI 10.1016/S0140-6736(61)91061-3; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOELMAN JH, 1992, J NEUROL, V230, P105; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; PABINGER I, 1994, THROMB HAEMOSTASIS, V5, P548; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; PORTER JB, 1982, OBSTET GYNECOL, V59, P299; ROSENDAAL FR, 1994, LANCET, V343, P1289; ROSENDAAL FR, IN PRESS BLOOD; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P311; SARTWELL PE, 1982, EPIDEMIOL REV, V4, P95, DOI 10.1093/oxfordjournals.epirev.a036253; SCHLESSELMAN JJ, 1987, CASE CONTROL STUDIES; STADEL BV, 1981, NEW ENGL J MED, V305, P612, DOI 10.1056/NEJM198109103051104; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; THOROGOOD M, 1992, INT J EPIDEMIOL, V21, P48, DOI 10.1093/ije/21.1.48; TRAUCHSTVANHORN JJ, 1992, AM J OBSTET GYNECOL, V167, P9968; TUDDENHAM EGD, 1994, LANCET, V343, P1515, DOI 10.1016/S0140-6736(94)92932-7; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526; 1993, STATISTISCH JB 1993	29	939	963	2	27	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1453	1457		10.1016/S0140-6736(94)90286-0	http://dx.doi.org/10.1016/S0140-6736(94)90286-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968118				2022-12-24	WOS:A1994PT99500005
J	KASAHARA, N; DOZY, AM; KAN, YW				KASAHARA, N; DOZY, AM; KAN, YW			TISSUE-SPECIFIC TARGETING OF RETROVIRAL VECTORS THROUGH LIGAND-RECEPTOR INTERACTIONS	SCIENCE			English	Article							MURINE LEUKEMIA-VIRUS; HUMAN ERYTHROPOIETIN; EXPRESSION; CLONING; CELLS; GENE; INFECTION; MUTANT; MOUSE	The development of retroviral vectors that target specific cell types could have important implications for the design of gene therapy strategies. A chimeric protein containing the polypeptide hormone erythropoietin and part of the env protein of ecotropic Moloney murine leukemia virus was engineered into the virus. This murine virus became several times more infectious for murine cells bearing the erythropoietin receptor, and it also became infectious for human cells bearing the erythropoietin receptor. This type of tissue-specific targeting by means of ligand-receptor interactions may have broad applications to a variety of gene delivery systems.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GRAD PROGRAM ENDOCRINOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Kasahara, Noriyuki/0000-0002-6069-9082	NHLBI NIH HHS [HL 20985] Funding Source: Medline; NIADDK NIH HHS [AM16666] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM016666] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL020985] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; ETIENNEJULAN M, 1992, J GEN VIROL, V73, P3251, DOI 10.1099/0022-1317-73-12-3251; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; KASAHARA N, 1994, THESIS U CALIFORNIA; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILLER DG, 1994, P NATL ACAD SCI USA, V91, P78, DOI 10.1073/pnas.91.1.78; NEDA H, 1991, J BIOL CHEM, V266, P14143; ROUX P, 1989, P NATL ACAD SCI USA, V86, P9079, DOI 10.1073/pnas.86.23.9079; RUSSELL SJ, 1993, NUCLEIC ACIDS RES, V21, P1081, DOI 10.1093/nar/21.5.1081; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SIMONSEN CC, 1988, NUCLEIC ACIDS RES, V16, P2235, DOI 10.1093/nar/16.5.2235; VALSESIAWITTMANN S, 1994, J VIROL, V68, P4609, DOI 10.1128/JVI.68.7.4609-4619.1994; VANZEIJL M, 1994, P NATL ACAD SCI USA, V91, P1168, DOI 10.1073/pnas.91.3.1168; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; WEISS R, 1984, RNA TUMOR VIRUSES MO; WILSON C, 1989, J VIROL, V63, P2374, DOI 10.1128/JVI.63.5.2374-2378.1989; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	23	385	424	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1373	1376		10.1126/science.7973726	http://dx.doi.org/10.1126/science.7973726			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973726				2022-12-24	WOS:A1994PT63200041
J	MOSS, G; COHEN, S				MOSS, G; COHEN, S			TIME TO ABANDON BRUSSELS BID ON PATENTS .2.	NATURE			English	Article								After six years of debate, the European Commission's attempts to harmonize biotechnology legislation still face opposition over the patenting of genes. Recent legal experience suggests that its efforts are unnecessary.			MOSS, G (corresponding author), TAYLOR JOYNSON GARRETT,LONDON EC4Y 0DX,ENGLAND.								0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					384	384		10.1038/372384a0	http://dx.doi.org/10.1038/372384a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969499				2022-12-24	WOS:A1994PU28700061
J	KAUSHAL, S; SCHNEIDER, JW; NADALGINARD, B; MAHDAVI, V				KAUSHAL, S; SCHNEIDER, JW; NADALGINARD, B; MAHDAVI, V			ACTIVATION OF THE MYOGENIC LINEAGE BY MEF2A, A FACTOR THAT INDUCES AND COOPERATES WITH MYOD	SCIENCE			English	Article							ENHANCER-BINDING-FACTOR; MUSCLE-SPECIFIC EXPRESSION; CREATINE-KINASE GENE; TRANSCRIPTION FACTORS; CYCLIC AMPLIFICATION; MYOCARDIAL-CELLS; FACTOR MEF-2; FACTOR-II; PROTEINS; SKELETAL	Muscle enhancer factor-2A (MEF2A), a member of the MADS family, induced myogenic development when ectopically expressed in clones of nonmuscle cells of human clones, a function previously limited to the muscle basic helix-loop-helix (bHLH) proteins. During myogenesis, MEF2A and bHLH proteins cooperatively activate skeletal muscle genes and physically interact through the MADS domain of MEF2A and the three myogenic amino acids of the muscle bHLH proteins. Thus, skeletal myogenesis is mediated by two distinct families of mutually inducible and interactive muscle transcription factors, either of which can initiate the developmental cascade.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT CARDIOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School								ANDRES V, UNPUB; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; BUCHBERGER A, 1994, J BIOL CHEM, V269, P17289; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GARFINKEL LI, 1982, J BIOL CHEM, V257, P1078; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE KJ, 1992, J BIOL CHEM, V267, P15875; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Martin J., UNPUB; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NAKATSUJI Y, 1992, MOL CELL BIOL, V12, P4384, DOI 10.1128/MCB.12.10.4384; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; TRASK RV, 1992, NUCLEIC ACIDS RES, V20, P2313, DOI 10.1093/nar/20.9.2313; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WOLD JH, 1990, P NATL ACAD SCI USA, V87, P1089; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	52	206	211	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1236	1240		10.1126/science.7973707	http://dx.doi.org/10.1126/science.7973707			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973707				2022-12-24	WOS:A1994PT13200053
J	KONDO, T; TSINOREMAS, NF; GOLDEN, SS; JOHNSON, CH; KUTSUNA, S; ISHIURA, M				KONDO, T; TSINOREMAS, NF; GOLDEN, SS; JOHNSON, CH; KUTSUNA, S; ISHIURA, M			CIRCADIAN CLOCK MUTANTS OF CYANOBACTERIA	SCIENCE			English	Article							CHLAMYDOMONAS; EXPRESSION; RHYTHMS; STRAIN; GENE	A diverse set of circadian clock mutants was isolated in a cyanobacterial strain that carries a bacterial luciferase reporter gene attached to a clock-controlled promoter. Among 150,000 clones of chemically mutagenized bioluminescent cells, 12 mutants were isolated that exhibit a broad spectrum of periods (between 16 and 60 hours), and 5 mutants were found that show a variety of unusual patterns, including arrhythmia. These mutations appear to be clock-specific. Moreover, it was demonstrated that in this cyanobacterium it is possible to clone mutant genes by complementation, which provides a means to genetically dissect the circadian mechanism.	TEXAS A&M UNIV,DEPT BIOL,COLLEGE STN,TX 77843; VANDERBILT UNIV,DEPT BIOL,NASHVILLE,TN 37235; NAGOYA UNIV,GRAD SCH HUMAN INFORMAT,NAGOYA,AICHI 465,JAPAN	Texas A&M University System; Texas A&M University College Station; Vanderbilt University; Nagoya University	KONDO, T (corresponding author), NATL INST BASIC BIOL,OKAZAKI,AICHI 444,JAPAN.		Johnson, Carl H/I-4655-2014		NIGMS NIH HHS [GM37040] Funding Source: Medline; NIMH NIH HHS [MH43836] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH043836, R01MH043836] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BINDER BJ, 1990, J BACTERIOL, V172, P2313, DOI 10.1128/jb.172.5.2313-2319.1990; BRUCE VG, 1972, GENETICS, V70, P537; Bunning E, 1973, PHYSL CLOCK; BUSTOS SA, 1991, J BACTERIOL, V173, P7525, DOI 10.1128/jb.173.23.7525-7533.1991; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; FELDMAN JF, 1982, ANNU REV PLANT PHYS, V33, P583, DOI 10.1146/annurev.pp.33.060182.003055; HALL JC, 1990, ANNU REV GENET, V24, P659; HUANG TC, 1993, CURR MICROBIOL, V27, P249, DOI 10.1007/BF01575987; KONDO T, 1994, J BACTERIOL, V176, P1881, DOI 10.1128/jb.176.7.1881-1885.1994; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; KONDO T, 1991, PLANT PHYSIOL, V95, P197, DOI 10.1104/pp.95.1.197; KONDO T, UNPUB; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; MERGENHAGEN D, 1986, EUR J CELL BIOL, V33, P13; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; SUGIURA M, COMMUNICATION; TSINOREMAS NF, 1994, J BACTERIOL, V176, P6764, DOI 10.1128/JB.176.21.6764-6768.1994; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325	18	240	252	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1233	1236		10.1126/science.7973706	http://dx.doi.org/10.1126/science.7973706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973706				2022-12-24	WOS:A1994PT13200052
J	HU, H; WATANABE, H; PAYTON, M; KORRICK, S; ROTNITZKY, A				HU, H; WATANABE, H; PAYTON, M; KORRICK, S; ROTNITZKY, A			THE RELATIONSHIP BETWEEN BONE LEAD AND HEMOGLOBIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-RAY-FLUORESCENCE; OCCUPATIONAL EXPOSURE; BLOOD LEAD; INVIVO; BURDEN	Objective.-To determine whether the concentration of lead in bone constitutes a biological marker that is more sensitive for chronic toxicity than blood lead levels. Design.-Survey. Setting.-A construction trade union with members who engage in carpentry, demolition, and other construction activities. Participants.-Members of the construction trade union. Main Outcome Measures.-We measured blood pressure, serum creatinine, hematocrit, and hemoglobin. We measured blood lead by anodic stripping voltametry and used a cadmium 109 K x-ray fluorescence instrument to make in vivo measurements of lead in the tibia (a heavily cortical bone) and the patella (a heavily trabecular bone). Information was also collected on medical history, smoking, and alcohol ingestion. Results.-Bone lead levels in the patella were found to be significantly correlated with a decrease in hemoglobin and hematocrit, even after adjusting for age, blood lead, body mass index, cigarette smoking, and alcohol ingestion and removing outliers. Blood lead levels were low (mean=0.40 mu mol/L [8.3 mu g/dl]) and were not correlated with either hemoglobin or hematocrit. In the final multivariate regression model that corrected for measurement error, an increase in patella bone lead level from the lowest to highest quintile in this study population (37 mu g/g) was associated with a decrease in hemoglobin and hematocrit of 11 g/L (95% confidence interval [Cl], 2.7 to 19.3 g/L) and 0.03 (95% Cl, 0.01 to 0.05), respectively. Conclusion.-We conclude that patella bone lead levels are associated with decreased hematocrit and hemoglobin levels despite the presence of low blood lead levels. This conclusion may reflect a subclinical effect of bone lead stores on hematopoiesis and is the first epidemiological evidence that bone lead may be an important biological marker of ongoing chronic toxicity.	HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,OCCUPAT HLTH PROGRAM,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; OSAKA MED COLL,OSAKA,JAPAN	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Osaka Medical College	HU, H (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,180 LONGWOOD AVE,BOSTON,MA 02115, USA.				NIEHS NIH HHS [P42-ES05947, 2 P30 ES 00002, ES 05257-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005257, P42ES005947, P30ES000002] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMSTRONG R, 1992, BRIT J IND MED, V49, P14; ARO ACA, IN PRESS PHYS MED BI; BARRY PSI, 1970, BRIT J IND MED, V27, P339; Burger D E, 1990, Basic Life Sci, V55, P287; CHRISTOFFERSSON JO, 1986, ARCH ENVIRON HEALTH, V41, P312, DOI 10.1080/00039896.1986.9936703; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Fuller W. A., 1987, MEASUREMENT ERROR MO; GERHARDSSON L, 1992, BRIT J IND MED, V49, P186; GOLDMAN RH, 1994, AM J IND MED, V25, P417, DOI 10.1002/ajim.4700250309; GORDON CL, 1993, BRIT J IND MED, V50, P637; GOYER RA, 1993, ENVIRON HEALTH PERSP, V100, P177, DOI 10.2307/3431524; GRAZIANO JH, 1991, ARCH ENVIRON HEALTH, V46, P347, DOI 10.1080/00039896.1991.9934401; HAJEM S, 1990, ENVIRON RES, V53, P105, DOI 10.1016/S0013-9351(05)80113-6; HERNBERG S, 1967, ARCH ENVIRON HEALTH, V14, P319, DOI 10.1080/00039896.1967.10664739; HU H, 1989, ENVIRON RES, V49, P295, DOI 10.1016/S0013-9351(89)80074-X; Hu H, 1990, Basic Life Sci, V55, P267; HU H, 1990, ARCH ENVIRON HEALTH, V45, P335, DOI 10.1080/00039896.1990.10118752; HU H, 1991, AM J IND MED, V20, P723, DOI 10.1002/ajim.4700200603; HU H, IN PRESS ENV HLTH PE; JONES KW, 1987, IN VIVO BODY COMPOSI, P363; KOSNETT MJ, 1994, JAMA-J AM MED ASSOC, V271, P197, DOI 10.1001/jama.271.3.197; LANDRIGAN PJ, 1994, JAMA-J AM MED ASSOC, V271, P239, DOI 10.1001/jama.271.3.239; LIPPMANN M, 1990, ENVIRON RES, V51, P1, DOI 10.1016/S0013-9351(05)80179-3; MANTON WI, 1985, BRIT J IND MED, V42, P168; MARCUS AH, 1985, ENVIRON RES, V36, P473, DOI 10.1016/0013-9351(85)90039-8; MORGAN WD, 1990, BIOL TRACE ELEM RES, V26-7, P407, DOI 10.1007/BF02992695; NILSSON U, 1991, PHARMACOL TOXICOL, V69, P477; OFLAHERTY EJ, 1991, TOXICOL APPL PHARM, V111, P313, DOI 10.1016/0041-008X(91)90033-B; RABINOWITZ MB, 1991, ENVIRON HEALTH PERSP, V91, P33, DOI 10.2307/3430979; RABINOWITZ MB, 1976, J CLIN INVEST, V58, P260, DOI 10.1172/JCI108467; ROSNER B, 1983, TECHNOMETRICS, V25, P165, DOI 10.2307/1268549; SALTZMAN BE, 1990, ENVIRON RES, V52, P126, DOI 10.1016/S0013-9351(05)80248-8; SCHILTZ A, 1987, ARCH ENVIRON HEALTH, V42, P340; SCHROEDER HA, 1968, ARCH ENVIRON HEALTH, V17, P965, DOI 10.1080/00039896.1968.10665354; SCHWARTZ J, 1990, AM J PUBLIC HEALTH, V80, P165, DOI 10.2105/AJPH.80.2.165; SILBERGELD EK, 1991, ENVIRON HEALTH PERSP, V91, P63, DOI 10.2307/3430984; SOKAS RK, 1990, ARCH ENVIRON HEALTH, V45, P268, DOI 10.1080/00039896.1990.10118744; SOMERVAILLE LJ, 1985, PHYS MED BIOL, V30, P929, DOI 10.1088/0031-9155/30/9/005; SOMERVAILLE LJ, 1988, BRIT J IND MED, V45, P174; WATANABE H, 1994, AM J IND MED, V26, P255, DOI 10.1002/ajim.4700260211; Wedeen R P, 1988, Contrib Nephrol, V64, P102; WIELOPOLSKI L, 1986, AM J IND MED, V9, P221; WITTMERS LE, 1988, ARCH ENVIRON HEALTH, V43, P381, DOI 10.1080/00039896.1988.9935855	43	72	74	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1512	1517		10.1001/jama.272.19.1512	http://dx.doi.org/10.1001/jama.272.19.1512			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966843				2022-12-24	WOS:A1994PQ90000030
J	SILVER, MT; ROSE, GA; PAUL, SD; ODONNELL, CJ; OGARA, PT; EAGLE, KA				SILVER, MT; ROSE, GA; PAUL, SD; ODONNELL, CJ; OGARA, PT; EAGLE, KA			A CLINICAL RULE TO PREDICT PRESERVED LEFT-VENTRICULAR EJECTION FRACTION IN PATIENTS AFTER MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; VENTRICULAR FUNCTION, LEFT; STROKE VOLUME; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; PREDICTION RULES		Objective: To derive and validate a clinical prediction rule that identifies patients after myocardial infarction who have preserved left ventricular systolic function. Design: Retrospective analysis of a prospective cohort study, with a derivation set to generate a clinical prediction rule and a validation set to test the prediction rule. Setting: Urban tertiary care hospital. Patients: 314 consecutive patients admitted with myocardial infarction who had one or more of the following tests to determine left ventricular ejection fraction: transthoracic echocardiography, contrast left ventriculography, or radionuclide ventriculography. Measurements: Left ventricular ejection fractions were determined by transthoracic echocardiography, contrast left ventriculography, and gated blood pool scan. Results: Multivariate analysis of patients in the derivation set yielded the following rule: The left ventricular ejection fraction is predicted to be 40% or more in patients who have 1) an interpretable electrocardiogram, 2) no previous Q-wave myocardial infraction, 3) no history of congestive heart failure, and 4) an index myocardial infarction that is not a Q-wave anterior infarction. In the derivation and the validation sets, the positive predictive value of the prediction rule was more than 0.98. Conclusions: A simple clinical prediction rule using easily obtained historical and electrocardiographic data reliably identifies a substantial percentage of patients after myocardial infarction (40% in our hospital) who are likely to have preserved left ventricular systolic function. If validated in other patient populations, application of this prediction rule in clinical practice could result in a substantial decrease in the cost of treating uncomplicated myocardial infarction.	MASSACHUSETTS GEN HOSP, CTR AMBULATORY CARE 475, CARDIAC UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Karavite, Dean/0000-0003-0554-5715				DEPACE NL, 1982, AM J CARDIOL, V50, P1262, DOI 10.1016/0002-9149(82)90460-X; EAGLE KA, 1988, ARCH INTERN MED, V148, P882, DOI 10.1001/archinte.148.4.882; ESTES EH, 1974, HEART, P297; FEIGENBAUM H, 1986, ECHOCARDIOGR-J CARD, P153; FIFER MA, 1991, CARDIAC CATHETERIZAT, P303; Gunnar R M, 1990, Circulation, V82, P664; HAMBY RI, 1985, AM HEART J, V109, P338, DOI 10.1016/0002-8703(85)90604-0; MADSEN EB, 1983, AM J CARDIOL, V51, P1579, DOI 10.1016/0002-9149(83)90190-X; MATTLEMAN SJ, 1983, J AM COLL CARDIOL, V1, P417, DOI 10.1016/S0735-1097(83)80068-0; MCNAMARA RF, 1988, AM J CARDIOL, V62, P192, DOI 10.1016/0002-9149(88)90210-X; MONSOUR MJ, 1991, STAT MED, V10, P443, DOI 10.1002/sim.4780100316; PALMERI ST, 1982, NEW ENGL J MED, V306, P4, DOI 10.1056/NEJM198201073060102; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PICARD MH, 1992, AM HEART J, V124, P24, DOI 10.1016/0002-8703(92)90916-J; TAYLOR GJ, 1980, CIRCULATION, V62, P960, DOI 10.1161/01.CIR.62.5.960; 1990, HLTH FACTS	16	35	35	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					750	756		10.7326/0003-4819-121-10-199411150-00004	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944052				2022-12-24	WOS:A1994PQ92800004
J	DISCHER, DE; MOHANDAS, N; EVANS, EA				DISCHER, DE; MOHANDAS, N; EVANS, EA			MOLECULAR MAPS OF RED-CELL DEFORMATION - HIDDEN ELASTICITY AND IN-SITU CONNECTIVITY	SCIENCE			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; BLOOD-CELLS; PROTEIN 4.1; SPECTRIN; SKELETON; BAND-3	Fluorescence-imaged micropipette aspiration was used to map redistribution of the proteins and lipids in highly extended human red blood cell membranes. Whereas the fluid bilayer distributed uniformly (+/-10 percent), the underlying, solidlike cytoskeleton of spectrin, actin, and protein 4.1 exhibited a steep gradient in density along the aspirated projection, which was reversible on release from deformation. Quantitation of the cytoskeletal protein density gradients showed that skeletal elasticity is well represented by a grafted polymer network with a ratio of surface dilation modulus to shear modulus of approximately 2:1. Fractionally mobile integral proteins, such as band 3, and highly mobile receptors, such as CD59 as well as glycophorin C in protein 4.1-deficient cells, appeared to be squeezed out of areas dense in the underlying network and enriched in areas of network dilation. This complementary segregation demonstrates patterning of cell surface components by cytoskeletal dilation.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV LIFE SCI, BERKELEY, CA 94720 USA; UNIV BRITISH COLUMBIA, DEPT PATHOL, VANCOUVER V6T 1W5, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT PHYS, VANCOUVER V6T 1W5, BC, CANADA	University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of British Columbia; University of British Columbia	DISCHER, DE (corresponding author), UNIV CALIF BERKELEY, JOINT GRAD GRP BIOENGN, BERKELEY, CA 94720 USA.			discher, dennis/0000-0001-6163-2229	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094, R01DK026263] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL31579-13] Funding Source: Medline; NIDDK NIH HHS [R01 DK26263-15, P01 DK32094-09] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOOM JA, 1983, BIOPHYS J, V42, P295, DOI 10.1016/S0006-3495(83)84397-5; BOAL DH, 1994, BIOPHYS J, V67, P521, DOI 10.1016/S0006-3495(94)80511-9; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; de Gennes P.G., 1988, SCALING CONCEPTS POL; DISCHER D, 1993, J BIOL CHEM, V268, P7186; DISCHER DE, 1993, THESIS U CALIFORNIA; DUBREUIL R, 1987, J CELL BIOL, V105, P2095, DOI 10.1083/jcb.105.5.2095; EVANS E, 1987, J PHYS CHEM-US, V91, P4219, DOI 10.1021/j100300a003; EVANS EA, 1989, METHOD ENZYMOL, V173, P3; EVANS EA, 1980, MECHANICS THERMODYNA; GILLIGAN DM, 1993, SEMIN HEMATOL, V30, P74; GOLAN DE, 1986, J CELL BIOL, V103, P819, DOI 10.1083/jcb.103.3.819; GOLAN DE, 1980, P NATL ACAD SCI-BIOL, V77, P2537, DOI 10.1073/pnas.77.5.2537; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; HAGELBERG C, 1990, BIOCHEM J, V271, P831, DOI 10.1042/bj2710831; HAMASAKI N, 1980, ANION TRANSPORT PROT; HIRAOKA Y, 1987, SCIENCE, V238, P36, DOI 10.1126/science.3116667; HOFFMAN JF, 1992, USE RESEALED ERYTHRO, P1; MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035; NAKASHIMA K, 1978, P NATL ACAD SCI USA, V75, P3823, DOI 10.1073/pnas.75.8.3823; PINDER JC, 1993, BLOOD, V82, P3482; PODGORSKI A, 1985, BIOCHEMISTRY-US, V24, P7871, DOI 10.1021/bi00348a004; REID ME, 1990, BLOOD, V75, P2229; SCOTT MD, 1990, J LAB CLIN MED, V115, P470; SPENCER M, 1990, DEV BIOL, V139, P279, DOI 10.1016/0012-1606(90)90297-V; STOKKE BT, 1986, J THEOR BIOL, V123, P205, DOI 10.1016/S0022-5193(86)80154-0; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; TSUJI A, 1986, BIOCHEMISTRY-US, V25, P6133, DOI 10.1021/bi00368a045; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; VIITALA J, 1985, TRENDS BIOCHEM SCI, V10, P392, DOI 10.1016/0968-0004(85)90067-2; WANG DN, 1994, EMBO J, V13, P3230, DOI 10.1002/j.1460-2075.1994.tb06624.x; WAYS P, 1964, J LIPID RES, V5, P318; WELCH MD, 1994, CURR OPIN CELL BIOL, V6, P110, DOI 10.1016/0955-0674(94)90124-4	33	279	287	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1032	1035		10.1126/science.7973655	http://dx.doi.org/10.1126/science.7973655			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973655				2022-12-24	WOS:A1994PQ92400041
J	DAWSON, PE; MUIR, TW; CLARKLEWIS, I; KENT, SBH				DAWSON, PE; MUIR, TW; CLARKLEWIS, I; KENT, SBH			SYNTHESIS OF PROTEINS BY NATIVE CHEMICAL LIGATION	SCIENCE			English	Article							SITE-SPECIFIC INCORPORATION; HIV-1 PROTEASE; CRYSTAL-STRUCTURE; INTERLEUKIN-8; PEPTIDES; BONDS	A simple technique has been devised that allows the direct synthesis of native backbone proteins of moderate size. Chemoselective reaction of two unprotected peptide segments gives an initial thioester-linked species. Spontaneous rearrangement of this transient intermediate yields a full-length product with a native peptide bond at the ligation site. The utility of native chemical ligation was demonstrated by the one-step preparation of a cytokine containing multiple disulfides. The polypeptide ligation product was folded and oxidized to form the native disulfide-containing protein molecule. Native chemical ligation is an important step toward the general application of chemistry to proteins.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, DEPT BIOCHEM, VANCOUVER V6T 1Z3, BC, CANADA	Scripps Research Institute; University of British Columbia			Ueno, Hiroshi/C-3301-2009; Muir, Tom/AHD-0860-2022; Wood, David W/B-2992-2012	Muir, Tom/0000-0001-9635-0344; 	NIGMS NIH HHS [GM48897-01, GM48870-03, GM 50969-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050969, P01GM048870, R01GM048897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHMSEN L, 1991, BIOCHEMISTRY-US, V30, P4151, DOI 10.1021/bi00231a007; AKAJI K, 1985, CHEM PHARM BULL, V33, P184; BACA M, 1993, P NATL ACAD SCI USA, V90, P11638, DOI 10.1073/pnas.90.24.11638; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BERMAN AL, 1994, P NATL ACAD SCI USA, V91, P4044, DOI 10.1073/pnas.91.9.4044; BLAKE J, 1981, INT J PEPT PROT RES, V17, P273; BRENNER M., 1967, P1; CANNE LE, UNPUB; CANNE LE, 1994, JUL ANN M PROT SOC S; CHANG TK, IN PRESS P NATL ACAD; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CORNISH VW, 1994, P NATL ACAD SCI USA, V91, P2910, DOI 10.1073/pnas.91.8.2910; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; DAWSON PE, 1993, J AM CHEM SOC, V115, P7263, DOI 10.1021/ja00069a027; EIGENBROT C, 1992, Current Opinion in Biotechnology, V3, P333, DOI 10.1016/0958-1669(92)90160-K; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; HUANG LH, 1991, BIOCHEMISTRY-US, V30, P7402, DOI 10.1021/bi00244a006; KEMP DS, 1993, J ORG CHEM, V58, P2216, DOI 10.1021/jo00060a043; LIU CF, 1994, J AM CHEM SOC, V116, P4149, DOI 10.1021/ja00089a001; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MILTON RCD, 1992, TECHNIQUES PROTEIN C, V4, P257; Muir Tom W., 1993, Current Opinion in Biotechnology, V4, P420, DOI 10.1016/0958-1669(93)90007-J; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; OFFORD RE, 1990, N HORIZ TH, P253; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; RAJARATHNAM K, 1994, BIOCHEMISTRY-US, V29, P1689; RAO C, 1994, J AM CHEM SOC, V116, P6975, DOI 10.1021/ja00094a078; ROSE K, 1994, J AM CHEM SOC, V116, P30, DOI 10.1021/ja00080a004; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SMITH M, 1994, ANGEW CHEM INT EDIT, V33, P1214, DOI 10.1002/anie.199412141; WALLACE CJA, 1992, J BIOL CHEM, V267, P3852; WILLIAMS M, IN PRESS J AM CHEM S; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; YAMASHIRO D, 1988, INT J PEPT PROT RES, V31, P322	38	3154	3598	23	788	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					776	779		10.1126/science.7973629	http://dx.doi.org/10.1126/science.7973629			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973629				2022-12-24	WOS:A1994PP75300031
J	MA, JY; YEE, A; BREWER, HB; DAS, S; POTTER, H				MA, JY; YEE, A; BREWER, HB; DAS, S; POTTER, H			AMYLOID-ASSOCIATED PROTEINS ALPHA(1)-ANTICHYMOTRYPSIN AND APOLIPOPROTEIN-E PROMOTE ASSEMBLY OF ALZHEIMER BETA-PROTEIN INTO FILAMENTS	NATURE			English	Article							INHIBITOR ALPHA-1-ANTICHYMOTRYPSIN; TYPE-4 ALLELE; DISEASE; PEPTIDE; DEPOSITS; BINDING; INVITRO; METABOLISM; FIBRILS; PLAQUE	THE protease inhibitor alpha(1)-antichymotrypsin and the lipid transport protein apolipoprotein E (apoE) are intimately associated with the 42-amino-acid beta-peptide (A beta) in the filamentous amyloid deposits of Alzheimer's disease(1-3). We report here that these two amyloid-associated proteins serve a strong stimulatory role in the polymerization of A beta into amyloid filaments. Addition of either alpha(1)-antichymotrypsin or apoE to the A beta peptide promoted a 10- to 20-fold increase in filament formation, with apoE-4, the isoform recently linked to the development of late-onset Alzheimer's disease, showing the highest catalytic activity. These and other experiments suggest that Alzheimer amyloid deposits arise when A beta is induced to form filaments by amyloid-promoting factors (pathological chaperones) expressed in certain brain regions.	NHLBI,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Harvard Medical School			Das, Saumya/R-7644-2019	Potter, Huntington/0000-0002-4051-2516; Das, Saumya/0000-0002-4521-4606				ABRAHAM CR, 1990, NEUROBIOL AGING, V11, P123, DOI 10.1016/0197-4580(90)90045-2; ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; CASTANO EM, 1986, BIOCHEM BIOPH RES CO, V141, P782, DOI 10.1016/S0006-291X(86)80241-8; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAS S, IN PRESS NEURON; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; FRASER PE, 1993, J NEUROCHEM, V61, P298, DOI 10.1111/j.1471-4159.1993.tb03568.x; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KOO EH, 1991, NEUROBIOL AGING, V12, P495, DOI 10.1016/0197-4580(91)90079-Y; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; PASTERNACK JM, 1989, AM J PATHOL, V135, P827; PICKEN MM, 1990, J NEUROPATH EXP NEUR, V49, P41, DOI 10.1097/00005072-199001000-00005; POTTER H, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P275; POTTER H, 1992, ANN NY ACAD SCI, V674, P161, DOI 10.1111/j.1749-6632.1992.tb27485.x; PROBST A, 1987, ACTA NEUROPATHOL, V74, P133, DOI 10.1007/BF00692843; REBECK GW, 1993, NEURON, V11, P575; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROZEMULLER JM, 1991, ACTA NEUROPATHOL, V82, P200, DOI 10.1007/BF00294446; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; WISNIEWSKI T, IN PRESS AM J PATH	31	846	864	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					92	94		10.1038/372092a0	http://dx.doi.org/10.1038/372092a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969426				2022-12-24	WOS:A1994PQ34800079
J	KROLL, KL; GERHART, JC				KROLL, KL; GERHART, JC			TRANSGENIC X-LAEVIS EMBRYOS FROM EGGS TRANSPLANTED WITH NUCLEI OF TRANSFECTED CULTURED-CELLS	SCIENCE			English	Article							XENOPUS-LAEVIS; OOCYTES; GENE; RANA	Transgenic Xenopus laevis embryos were produced by transplantation of transfected cultured cell nuclei into unfertilized eggs. A Xenopus cell line, X-C, was stably transfected with plasmids containing a hygromycin-resistance gene and genes for either beta-galactosidase with a heat shock promoter or chloramphenicol acetyltransferase (CAT) with a muscle-specific actin promoter. Nuclei transplanted from these cells into unfertilized eggs directed development of embryos containing stably integrated copies of the plasmids in each cell. Transgenic embryos showed somite-specific expression of CAT and uniform expression of beta-galactosidase. Transgenic embryos produced by nuclear transplantation should be useful for testing the function of cloned genes in amphibian development.			KROLL, KL (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, 229 STANLEY HALL, BERKELEY, CA 94720 USA.			Kroll, Kristen/0000-0002-5450-6694	NIGMS NIH HHS [GM19363, GM07232] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019363, T32GM007232, R37GM019363] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIENZ M, 1984, EMBO J, V3, P2477, DOI 10.1002/j.1460-2075.1984.tb02159.x; BRIGGS R, 1952, P NATL ACAD SCI USA, V38, P455, DOI 10.1073/pnas.38.5.455; BRUN RB, 1978, DEV BIOL, V65, P271, DOI 10.1016/0012-1606(78)90027-1; DENT JA, 1989, DEVELOPMENT, V105, P61; DIBERARDINO MA, 1992, DIFFERENTIATION, V50, P1, DOI 10.1111/j.1432-0436.1992.tb00480.x; DIBERARDINO MA, 1983, SCIENCE, V219, P862, DOI 10.1126/science.6600520; DIBERARDINO MA, 1970, DEV BIOL, V23, P185, DOI 10.1016/0012-1606(70)90094-1; DIBERARDINO MA, 1987, AM ZOOL, V27, P623; ETKIN LD, 1987, DEVELOPMENT, V99, P15; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; Gurdon J.B., 1979, International Review of Cytology Supplement, P161; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; GURDON JB, 1986, J CELL SCI, P287; GURDON JB, 1960, Q J MICROSC SCI, V101, P299; GURDON JB, 1970, J EMBRYOL EXP MORPH, V24, P227; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; LASKEY RA, 1970, NATURE, V228, P1332, DOI 10.1038/2281332a0; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SUBTELNY S, 1965, J EXP ZOOL, V159, P59, DOI 10.1002/jez.1401590107; TOMPKINS R, 1978, J EXP ZOOL, V203, P251, DOI 10.1002/jez.1402030207; TYMOWSKA J, 1972, CYTOGENETICS, V11, P270, DOI 10.1159/000130197; VIZE PD, 1991, METHOD CELL BIOL, V36, P367	25	33	35	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	1994	266	5185					650	653		10.1126/science.7939720	http://dx.doi.org/10.1126/science.7939720			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939720				2022-12-24	WOS:A1994PN80700048
J	SCHNEIDER, HC; BERTHOLD, J; BAUER, MF; DIETMEIER, K; GUIARD, B; BRUNNER, M; NEUPERT, W				SCHNEIDER, HC; BERTHOLD, J; BAUER, MF; DIETMEIER, K; GUIARD, B; BRUNNER, M; NEUPERT, W			MITOCHONDRIAL HSP70/MIM44 COMPLEX FACILITATES PROTEIN IMPORT	NATURE			English	Article							TRANSLOCATION CONTACT SITES; YEAST MITOCHONDRIA; INNER MEMBRANE; PRECURSOR PROTEINS; INTERMEMBRANE SPACE; MOLECULAR CHAPERONES; MATRIX; HSP70; PATHWAY; BINDING	Protein translocation into mitochondria requires the mitochondrial protein Hsp70. This molecular chaperone of the mitochondrial matrix is recruited to the protein import machinery by MIM44, a component associated with the inner membrane of the mitochondria. Formation of the mt-Hsp70/MIM44 complex is regulated by ATP. MIM44 and mt-Hsp70 interact in a sequential manner with incoming segments of unfolded preproteins and thereby facilitate stepwise vectorial translocation of proteins across the mitochondrial membranes. The complex appears to act as a molecular ratchet which is energetically driven by the hydrolysis of ATP.	UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY	University of Munich				Brunner, Michael/0000-0001-9798-3047				ARRETZ M, 1993, J BIOL CHEM, V269, P4959; BLOM J, 1993, MOL CELL BIOL, V13, P7364, DOI 10.1128/MCB.13.12.7364; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; BROACH JR, 1983, EXPT MANIPULATION GE, P85; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1994, BIOL HEAT SHOCK PROT, P85; CYR DM, 1993, J BIOL CHEM, V268, P23751; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HORST M, 1993, EMBO J, V12, P3035, DOI 10.1002/j.1460-2075.1993.tb05972.x; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; JUNGNICKEL B, 1994, FEBS LETT, V346, P73, DOI 10.1016/0014-5793(94)00367-X; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; NEUPERT W, 1993, PHILOS T ROY SOC B, V339, P355, DOI 10.1098/rstb.1993.0034; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OHBA M, 1987, EMBO J, V6, P2109, DOI 10.1002/j.1460-2075.1987.tb02477.x; OSTERMANN J, 1990, FEBS LETT, V277, P281, DOI 10.1016/0014-5793(90)80865-G; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; RYAN KR, 1993, J BIOL CHEM, V268, P23743; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; UNGERMANN C, IN PRESS SCIENCE; [No title captured]	51	332	335	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					768	774		10.1038/371768a0	http://dx.doi.org/10.1038/371768a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935837				2022-12-24	WOS:A1994PP01800050
J	TOPILKO, P; SCHNEIDERMAUNOURY, S; LEVI, G; BARONVANEVERCOOREN, A; CHENNOUFI, AB; SEITANIDOU, T; BABINET, C; CHARNAY, P				TOPILKO, P; SCHNEIDERMAUNOURY, S; LEVI, G; BARONVANEVERCOOREN, A; CHENNOUFI, AB; SEITANIDOU, T; BABINET, C; CHARNAY, P			KROX-20 CONTROLS MYELINATION IN THE PERIPHERAL NERVOUS-SYSTEM	NATURE			English	Article							SCHWANN-CELLS; BASIC-PROTEIN; PO PROTEIN; GLYCOPROTEIN; MOUSE; GENE; EXPRESSION; MICE; MOLECULES; ABSENCE	THE molecular mechanisms controlling the process of myelination by Schwann cells remain elusive, despite recent progress in the identification and characterization of genes encoding myelin components (reviewed in ref. 1). We have created a null allele in the mouse Krox-20 gene, which encodes a zinc-finger transcription factor(2,3), by in-frame insertion of the Escherichia coli lacZ gene, and have shown that hindbrain segmentation is affected in Krox-20(-/-) embryos(4). We demonstrate here that Krox-20 is also activated in Schwann cells before the onset of myelination and that its disruption blocks Schwann cells at an early stage in their differentiation, thus preventing myelination in the peripheral nervous system. In Krox-20(-/-) mice, Schwann cells wrap their cytoplasmic processes only one and a half turns around the axon, and although they express the early myelin marker, myelin-associated glycoprotein(5), late myelin gene products are absent, including those for protein zero(6) and myelin basic protein(7). Therefore Krox-20 is likely to control a set of genes required for completion of myelination in the peripheral nervous system.	ADV BIOTECHNOL CTR,I-16132 GENOA,ITALY; HOP LA PITIE SALPETRIERE,INSERM,U134,F-75651 PARIS 13,FRANCE; INST PASTEUR,CNRS,URA 361,F-75724 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	TOPILKO, P (corresponding author), ECOLE NORMALE SUPER,INSERM,U368,46 RUE ULM,F-75230 PARIS 05,FRANCE.		Evercooren, Anne S Baron-Van/G-3632-2013; Schneider-Maunoury, Sylvie/K-6795-2017; Levi, Giovanni/B-4416-2013	Schneider-Maunoury, Sylvie/0000-0002-0797-4735; Levi, Giovanni/0000-0002-7041-6787; Charnay, Patrick/0000-0002-3847-6042	Telethon [94] Funding Source: Medline	Telethon(Fondazione Telethon)		BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; BUNGE MB, 1989, DEV NEUROSCI-BASEL, V11, P348, DOI 10.1159/000111911; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FILBIN MT, 1990, NATURE, V344, P871, DOI 10.1038/344871a0; Gabe M., 1968, TECHNIQUES HISTOLOGI, P468; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; GREENFIELD S, 1973, J NEUROCHEM, V20, P1207, DOI 10.1111/j.1471-4159.1973.tb00089.x; HENRY EW, 1988, SCIENCE, V241, P344, DOI 10.1126/science.3388045; JESSEN KR, 1994, NEURON, V12, P509, DOI 10.1016/0896-6273(94)90209-7; KIES MW, 1961, CHEMICAL PATHOLOGY N, P197; KIMURA M, 1989, P NATL ACAD SCI USA, V86, P5661, DOI 10.1073/pnas.86.14.5661; KIRSCHNER DA, 1980, NATURE, V283, P207, DOI 10.1038/283207a0; LEMKE G, 1993, GLIA, V7, P263, DOI 10.1002/glia.440070402; LEVI G, 1987, J CELL BIOL, V105, P2359, DOI 10.1083/jcb.105.5.2359; LI CM, 1994, NATURE, V369, P747, DOI 10.1038/369747a0; OWENS GC, 1990, GLIA, V3, P118, DOI 10.1002/glia.440030205; SCHNEIDERMAUNOU.S, 1993, CELL, V75, P199; TRAPP BD, 1988, J CELL BIOL, V107, P675, DOI 10.1083/jcb.107.2.675; TRAPP BD, 1982, J CELL BIOL, V92, P877, DOI 10.1083/jcb.92.3.877; TRAPP BD, 1984, J CELL BIOL, V99, P594, DOI 10.1083/jcb.99.2.594; UYEMURA K, 1970, BIOCHIM BIOPHYS ACTA, V214, P190, DOI 10.1016/0005-2795(70)90083-8; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0	24	627	631	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					796	799		10.1038/371796a0	http://dx.doi.org/10.1038/371796a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935840				2022-12-24	WOS:A1994PP01800059
J	HACKETT, M; GUO, L; SHABANOWITZ, J; HUNT, DF; HEWLETT, EL				HACKETT, M; GUO, L; SHABANOWITZ, J; HUNT, DF; HEWLETT, EL			INTERNAL LYSINE PALMITOYLATION IN ADENYLATE-CYCLASE TOXIN FROM BORDETELLA-PERTUSSIS	SCIENCE			English	Article							ESCHERICHIA-COLI PROHAEMOLYSIN; DEPENDENT FATTY ACYLATION; MEMBRANE-TARGETED TOXIN; GRAM-NEGATIVE BACTERIA; ACTIVATION; PROTEINS; RECEPTOR; CYAC; POLYPEPTIDE; HEMOLYSIN	A number of bacterial protein toxins, including adenylate cyclase (AC) toxin from Bordetella pertussis, require the product of an accessory gene in order to express their biological activities. In this study, mass spectrometry was used to demonstrate that activated, wild-type AC toxin was modified by amide-linked palmitoylation on the epsilon-amino group of lysine 983. This modification was absent from a mutant in which the accessory gene had been disrupted. A synthetic palmitoylated peptide corresponding to the tryptic fragment (glutamine 972 to arginine 984) that contained the acylation blocked AC toxin-induced accumulation of adenosine 3',5'-monophosphate, whereas the nonacylated peptide had no effect.	UNIV VIRGINIA,SCH MED,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901; UNIV VIRGINIA,DEPT PATHOL,CHARLOTTESVILLE,VA 22901	University of Virginia; University of Virginia; University of Virginia; University of Virginia			Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NIAID NIH HHS [R0-1 AI18000] Funding Source: Medline; NIDDK NIH HHS [DK38942] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT D, 1993, CLIN CHEM, V39, P2005; BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BEAVIS RC, 1992, ORG MASS SPECTROM, V27, P156, DOI 10.1002/oms.1210270217; BELLALOU J, 1990, INFECT IMMUN, V58, P1195, DOI 10.1128/IAI.58.5.1195-1200.1990; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; COOTE JG, 1992, FEMS MICROBIOL LETT, V88, P137, DOI 10.1016/0378-1097(92)90688-K; EHRMANN IE, 1991, FEBS LETT, V278, P79, DOI 10.1016/0014-5793(91)80088-K; Galazka Artur, 1992, World Health Statistics Quarterly, V45, P238; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; Guo L., UNPUB; HARDIE KR, 1991, MOL MICROBIOL, V5, P1669, DOI 10.1111/j.1365-2958.1991.tb01914.x; HEDO JA, 1987, J BIOL CHEM, V262, P954; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; HEWLETT EL, 1993, J BIOL CHEM, V268, P7842; HUGHES C, 1992, FEMS MICROBIOL IMMUN, V105, P37, DOI 10.1111/j.1574-6968.1992.tb05884.x; HUNT DF, 1991, TECHNIQUES PROTEIN C, pCH43; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; LOWRY OH, 1951, J BIOL CHEM, V193, P265; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OLSON EN, 1984, J BIOL CHEM, V259, P5364; PEARSON RD, 1987, J IMMUNOL, V139, P2749; PELLETT S, 1990, INFECT IMMUN, V58, P822, DOI 10.1128/IAI.58.3.822-827.1990; PILLAI S, 1987, P NATL ACAD SCI USA, V84, P7654, DOI 10.1073/pnas.84.21.7654; ROGEL A, 1991, J BIOL CHEM, V266, P3154; SCHLESINGER MJ, 1993, LIPID MODIFICATION P, P1; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; STEVENSON FT, 1993, P NATL ACAD SCI USA, V90, P7245, DOI 10.1073/pnas.90.15.7245; STEVENSON FT, 1992, J EXP MED, V176, P1053, DOI 10.1084/jem.176.4.1053; SZABO G, IN PRESS J BIOL CHEM; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEISS AA, 1983, INFECT IMMUN, V42, P33, DOI 10.1128/IAI.42.1.33-41.1983; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; 1992, 40TH P AM SOC MASS S	39	199	205	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					433	435		10.1126/science.7939682	http://dx.doi.org/10.1126/science.7939682			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939682				2022-12-24	WOS:A1994PN27200034
J	ENSOLI, B; GENDELMAN, R; MARKHAM, P; FIORELLI, V; COLOMBINI, S; RAFFELD, M; CAFARO, A; CHANG, HK; BRADY, JN; GALLO, RC				ENSOLI, B; GENDELMAN, R; MARKHAM, P; FIORELLI, V; COLOMBINI, S; RAFFELD, M; CAFARO, A; CHANG, HK; BRADY, JN; GALLO, RC			SYNERGY BETWEEN BASIC FIBROBLAST GROWTH-FACTOR AND HIV-I TAT PROTEIN IN INDUCTION OF KAPOSIS-SARCOMA	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MELANOMA CELL INVASION; LONG-TERM CULTURE; GENE-EXPRESSION; ENDOTHELIAL-CELLS; BASEMENT-MEMBRANE; HTLV-III; AIDS; ANGIOGENESIS; COLLAGENASE	Basic fibroblast growth factor (bFGF) and human immunodeficiency virus type 1 (HIV-1) Tat protein synergize in inducing angiogenic Kaposi's sarcoma-like lesions in mice. Synergy is due to Tat, which enhances endothelial cell growth and type-IV collagenase expression in response to bFGF mimicking extracellular matrix proteins. The bFGF, extracellular Tat and Tat receptors are present in HIV-1-associated KS, which may explain the higher frequency and aggressiveness of this form compared to classical Kaposi's sarcoma where only bFGF is present.	NCI,MOLEC VIROL LAB,BETHESDA,MD 20892; ADV BIOSCI LABS INC,KENSINGTON,MD 20895; HENRY M JACKSON FDN,ROCKVILLE,MD 20850	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc	ENSOLI, B (corresponding author), NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892, USA.		Ensoli, Barbara/J-9169-2016; Cafaro, Aurelio/K-5314-2016	Ensoli, Barbara/0000-0002-0545-8737; Cafaro, Aurelio/0000-0001-9675-6344				ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; ALBINI A, IN PRESS P NATN ACAD; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CORDONCARDO C, 1990, LAB INVEST, V63, P832; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ENSOLI B, 1991, HEMATOL ONCOL CLIN N, V5, P281, DOI 10.1016/S0889-8588(18)30441-6; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; ENSOLI B, IN PRESS J CLIN INVE; FAN J, 1993, J IMMUNOL, V151, P5031; FAWELL S, 1994, P NATL ACAD SCI USA, V31, P664; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FUCHS D, 1992, J ACQ IMMUN DEF SYND, V5, P424; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GAY CG, 1991, P NATL ACAD SCI USA, V88, P296, DOI 10.1073/pnas.88.1.296; HOBER D, 1989, CLIN EXP IMMUNOL, V78, P329; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER D, 1991, J CELL BIOCHEM, V47, P236, DOI 10.1002/jcb.240470309; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAHONEY SE, 1991, J CLIN INVEST, V88, P174, DOI 10.1172/JCI115275; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; OKAMURA K, 1991, J BIOL CHEM, V266, P19162; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; REGEZI JA, 1993, AM J PATHOL, V143, P240; RUSZCZAK Z, 1987, AM J DERMATOPATH, V9, P388, DOI 10.1097/00000372-198710000-00004; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SEFTOR REB, 1993, CANCER RES, V53, P3411; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; XERRI L, 1991, AM J PATHOL, V138, P9; YANG J, 1994, J IMMUNOL, V152, P223; ZHANG YM, 1994, AM J PATHOL, V144, P51; 1982, NEW ENGL J MED, V306, P248	43	514	523	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					674	680		10.1038/371674a0	http://dx.doi.org/10.1038/371674a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935812				2022-12-24	WOS:A1994PM77300047
J	MILLSTONE, E; BRUNNER, E; WHITE, I				MILLSTONE, E; BRUNNER, E; WHITE, I			PLAGIARISM OR PROTECTING PUBLIC-HEALTH	NATURE			English	Editorial Material									UCL, DEPT EPIDEMIOL, LONDON WC1E 6EA, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, MED STAT UNIT, LONDON WC1E 7HT, ENGLAND	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine	MILLSTONE, E (corresponding author), UNIV SUSSEX, SCI POLICY RES UNIT, BRIGHTON BN1 9RF, E SUSSEX, ENGLAND.		Brunner, Eric/H-2114-2011	Brunner, Eric/0000-0002-0595-4474; White, Ian/0000-0002-6718-7661				AHMAD SR, 1993, LANCET, V341, P1018, DOI 10.1016/0140-6736(93)91098-7; GERBARG ZB, 1988, J CLIN EPIDEMIOL, V41, P503, DOI 10.1016/0895-4356(88)90053-4; Millstone E. P., 1989, BST MASTITIS PRELIMI; MORSE L, 1994, FINANC TIMES, P22; PEEL CJ, 1989, BIOTECHNOLOGY GROWTH, P110; Phipps R. H., 1989, Use of somatotropin in livestock production., P88; WHITE TC, 1994, J DAIRY SCI, V77, P2249, DOI 10.3168/jds.S0022-0302(94)77168-X; 1993, MILK MARKETING BOARD; 1986, BOVINE SOMATOTROPIN	9	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					647	648		10.1038/371647a0	http://dx.doi.org/10.1038/371647a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935806				2022-12-24	WOS:A1994PM77300022
J	BRAIG, K; OTWINOWSKI, Z; HEGDE, R; BOISVERT, DC; JOACHIMIAK, A; HORWICH, AL; SIGLER, PB				BRAIG, K; OTWINOWSKI, Z; HEGDE, R; BOISVERT, DC; JOACHIMIAK, A; HORWICH, AL; SIGLER, PB			THE CRYSTAL-STRUCTURE OF THE BACTERIAL CHAPERONIN GROEL AT 2.8-ANGSTROM	NATURE			English	Article							ESCHERICHIA-COLI GROEL; MOLECULAR CHAPERONE; HEAT-SHOCK; PROTEIN MODELS; CENTRAL CAVITY; HYDROLYSIS; INTERFACES; SURFACE; ERRORS; CYCLE	The crystal structure of Escherichia coli GroEL shows a porous cylinder of 14 subunits made of two nearly 7-fold rotationally symmetrical rings stacked back-to-back with dyad symmetry. The subunits consist of three domains: a targe equatorial domain that forms the foundation of the assembly at its waist and holds the rings together; a large loosely structured apical domain that forms the ends of the cylinder; and a small slender intermediate domain that connects the two, creating side windows. The three-dimensional structure places most of the mutationally defined functional sites on the channel walls and its outward invaginations, and at the ends of the cylinder.	YALE UNIV,SCH MED,BOYER CTR,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University; Yale University			Bremner, James D/B-1632-2013; Otwinowski, Zbyszek/F-3665-2011	Otwinowski, Zbyszek/0000-0003-3640-8545				AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BURNETT B, IN PRESS J BACT; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; ELLIS RJ, 1993, NATURE, V366, P213, DOI 10.1038/366213a0; ELLIS RJ, 1991, REV BIOCH, V60, P321; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; IKAZAKI A, 1994, NATURE STRUCT BIOL, V1, P439; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JANIN J, 1990, J BIOL CHEM, V265, P16027; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, P CCP4 STUD WEEK MOL, P91; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MCLENNAN NF, 1993, MOL MICROBIOL, V7, P49, DOI 10.1111/j.1365-2958.1993.tb01096.x; MCMULLIN TW, 1987, MOL CELL BIOL, V7, P4414, DOI 10.1128/MCB.7.12.4414; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MILLER S, 1989, PROTEIN ENG, V3, P77, DOI 10.1093/protein/3.2.77; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SVENSSON LA, 1994, J MOL BIOL, V235, P47; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0	52	1189	1201	2	71	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					578	586		10.1038/371578a0	http://dx.doi.org/10.1038/371578a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935790				2022-12-24	WOS:A1994PL55900043
J	FU, H; XIA, K; PALLAS, DC; CUI, C; CONROY, K; NARSIMHAN, RP; MAMON, H; COLLIER, RJ; ROBERTS, TM				FU, H; XIA, K; PALLAS, DC; CUI, C; CONROY, K; NARSIMHAN, RP; MAMON, H; COLLIER, RJ; ROBERTS, TM			INTERACTION OF THE PROTEIN-KINASE RAF-1 WITH 14-3-3-PROTEINS	SCIENCE			English	Article							P21(RAS); REGION; FAMILY; MIDDLE; RAS	Members of a family of highly conserved proteins, termed 14-3-3 proteins, were found by several experimental approaches to associate with Raf-1, a central component of a key signal transduction pathway. Optimal complex formation required the amino-terminal regulatory domain of Raf-1. The association of 14-3-3 proteins and Raf-1 was not substantially affected by the activation state of Raf.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,SHIPLEY INST MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Mamon, Harvey J/B-2335-2009	Mamon, Harvey J/0000-0002-6060-9059; Collier, R John/0000-0002-2427-4239	NCI NIH HHS [R01 CA057327, CA57327] Funding Source: Medline; NIAID NIH HHS [AI22021] Funding Source: Medline; NICHD NIH HHS [HD24926] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022021, R01AI022021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, UNPUB; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; PALLAS D, UNPUB; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Summers MD, 1987, MANUAL METHODS BACUL; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; XIA K, UNPUB; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	26	258	261	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					126	129		10.1126/science.7939632	http://dx.doi.org/10.1126/science.7939632			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939632				2022-12-24	WOS:A1994PK58200040
J	FUTREAL, PA; LIU, QY; SHATTUCKEIDENS, D; COCHRAN, C; HARSHMAN, K; TAVTIGIAN, S; BENNETT, LM; HAUGENSTRANO, A; SWENSEN, J; MIKI, Y; EDDINGTON, K; MCCLURE, M; FRYE, C; WEAVERFELDHAUS, J; DING, W; GHOLAMI, Z; SODERKVIST, P; TERRY, L; JHANWAR, S; BERCHUCK, A; IGLEHART, JD; MARKS, J; BALLINGER, DG; BARRETT, JC; SKOLNICK, MH; KAMB, A; WISEMAN, R				FUTREAL, PA; LIU, QY; SHATTUCKEIDENS, D; COCHRAN, C; HARSHMAN, K; TAVTIGIAN, S; BENNETT, LM; HAUGENSTRANO, A; SWENSEN, J; MIKI, Y; EDDINGTON, K; MCCLURE, M; FRYE, C; WEAVERFELDHAUS, J; DING, W; GHOLAMI, Z; SODERKVIST, P; TERRY, L; JHANWAR, S; BERCHUCK, A; IGLEHART, JD; MARKS, J; BALLINGER, DG; BARRETT, JC; SKOLNICK, MH; KAMB, A; WISEMAN, R			BRCA1 MUTATIONS IN PRIMARY BREAST AND OVARIAN CARCINOMAS	SCIENCE			English	Article							FAMILIAL BREAST; ALLELE LOSSES; CANCER; REGION; CHROMOSOME-17Q; TUMORS; PROGRESSION; LINKAGE	Loss of heterozygosity data from familial tumors suggest that BRCA1, a gene that confers susceptibility to ovarian and early-onset breast cancer, encodes a tumor suppressor. The BRCA1 region is also subject to allelic loss in sporadic breast and ovarian cancers, an indication that BRCA1 mutations may occur somatically in these tumors. The BRCA1 coding region was examined for mutations in primary breast and ovarian tumors that show allele loss at the BRCA1 locus. Mutations were detected in 3 of 32 breast and 1 of 12 ovarian carcinomas; all four mutations were germline alterations and occurred in early-onset cancers. These results suggest that mutation of BRCA1 may not be critical in the development of the majority of breast and ovarian cancers that arise in the absence of a mutant germline allele.	MYRIAD GENET,SALT LAKE CITY,UT 84108; UNIV UTAH,MED CTR,DEPT MED INFORMAT,SALT LAKE CITY,UT 84123; FAC HLTH SCI LINKOPING,DEPT OCCUPAT MED,S-58185 LINKOPING,SWEDEN; MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,NEW YORK,NY 10021; DUKE UNIV,MED CTR,DEPT GYNECOL ONCOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710	Myriad Genetics, Inc; Utah System of Higher Education; University of Utah; Linkoping University; Memorial Sloan Kettering Cancer Center; Duke University; Duke University	FUTREAL, PA (corresponding author), NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709, USA.				NCI NIH HHS [CA56749, CA48711, CA55914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055914, P01CA048711, R01CA056749] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CROPP CS, 1993, CANCER RES, V53, P5617; CROPP CS, 1994, CANCER RES, V54, P2548; EASTON DF, 1993, AM J HUM GENET, V52, P678; ECCLES DM, 1990, ONCOGENE, V5, P1599; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FUTREAL PA, 1994, HUM MOL GENET, V3, P1359, DOI 10.1093/hmg/3.8.1359; FUTREAL PA, 1992, CANCER RES, V52, P2624; FUTREAL PA, UNPUB; GLEBOV OK, 1994, CANCER RES, V54, P3703; GOLDGAR DE, UNPUB; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; JACOBS IJ, 1993, CANCER RES, V53, P1218; KELSELL DP, 1993, HUM MOL GENET, V2, P1823; KNUDSON AG, 1978, SEMIN ONCOL, V5, P57; LYNCH HT, 1990, GYNECOL ONCOL, V36, P48, DOI 10.1016/0090-8258(90)90107-V; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NEUHAUSEN SL, UNPUB; PARKIN DM, 1992, CANCER INCIDENCE 5 C, V6; SAITO H, 1993, CANCER RES, V53, P3382; SATO T, 1991, CANCER RES, V51, P5794; SATO T, 1990, CANCER RES, V50, P7184; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128	23	1093	1141	2	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					120	122		10.1126/science.7939630	http://dx.doi.org/10.1126/science.7939630			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939630				2022-12-24	WOS:A1994PK58200038
J	WANG, MH; RONSIN, C; GESNEL, MC; COUPEY, L; SKEEL, A; LEONARD, EJ; BREATHNACH, R				WANG, MH; RONSIN, C; GESNEL, MC; COUPEY, L; SKEEL, A; LEONARD, EJ; BREATHNACH, R			IDENTIFICATION OF THE RON GENE-PRODUCT AS THE RECEPTOR FOR THE HUMAN MACROPHAGE STIMULATING PROTEIN	SCIENCE			English	Article							HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE; SCATTER FACTOR; MET PROTOONCOGENE; CELL CARCINOMA; SHORT ARM; C-MET; CHROMOSOME-3; EXPRESSION; HOMOLOGY	Macrophage-stimulating protein (MSP) is a member of the hepatocyte growth factor-scatter factor (HGF-SF) family. Labeled MSP bound to Madin-Darby canine kidney (MDCK) cells transfected with complementary DNA encoding Ron, a cell membrane protein tyrosine kinase. Cross-lin king of I-125-labeled MSP to transfected cells (MDCK-RE7 cells) and immunoprecipitation by antibodies to Ron revealed a 220-kilodalton complex, a size consistent with that of MSP (80 kilodaltons) cross-linked to the beta chain of Ron (150 kilodaltons). The binding of I-125-labeled MSP to MDCK-RE7 cells was inhibited by unlabeled MSP, but not by HGF-SF. MSP caused phosphorylation of the beta chain of Ron and induced migration of MDCK-RE7 cells. These results establish the ron gene product as a specific cell-surface receptor tor MSP.	CHR NANTES,INST BIOL,INSERM,U211,F-44035 NANTES 01,FRANCE; FAC MED LIMOGES,HEMATOL EXPTL LAB,F-87025 LIMOGES,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes	WANG, MH (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,IMMUNOPATHOL SECT,FREDERICK,MD 21702, USA.		Breathnach, Richard/K-7599-2015					BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; LANE K, UNPUB; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONSIN C, 1993, ONCOGENE, V8, P1195; RONSIN C, UNPUB; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SKEEL A, 1994, J IMMUNOL, V152, P4618; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1994, J BIOL CHEM, V269, P13806; WANG MH, 1994, J BIOL CHEM, V269, P3436; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	25	245	256	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					117	119		10.1126/science.7939629	http://dx.doi.org/10.1126/science.7939629			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939629				2022-12-24	WOS:A1994PK58200037
J	BROWN, DJ				BROWN, DJ			OPINIONS OF GENERAL-PRACTITIONERS IN NOTTINGHAMSHIRE ABOUT PROVISION OF INTRAPARTUM CARE	BRITISH MEDICAL JOURNAL			English	Article							OBSTETRICS	Objective-To examine the beliefs of general practitioners concerning intrapartum care. Design-Postal questionnaire survey. Subjects-Ah general practitioners with patients in Nottinghamshire Family Health Services Authority in September 1993. Main outcome measures-General practitioners' current involvement in maternity care, and beliefs on intrapartum care. Results-Of 694 general practitioners sent questionnaires, 550 (79.2%) replied. 529 of these were on the obstetric list; 437 had not attended a delivery in the past 12 months; 36 had attended two or more; 358 general practitioners did not wish to provide more intrapartum care; 349 did not feel competent to do so. Reasons for not wanting to provide intrapartum care included current workload (453), disruption to personal life (407), and the fear of litigation (377). General practitioners who already booked women for home delivery were more Likely to wish to do more deliveries (62/42 v 61/316, chi(2) = 85.3; P < 0.0001) and to have more positive attitudes towards increasing women's choice in maternity care (90/22 v 195/151, chi(2) = 227; P < 0.0001). Conclusions-The involvement of general practitioners in intrapartum care in Nottinghamshire is low, and most general practitioners are unwilling to increase their role. However, general practitioners who already book for home delivery are keen to do more.	UNIV NOTTINGHAM,SCH MED,DEPT PUBL HLTH MED,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham				Hamblin-Brown, DJ/0000-0002-7353-8691				Bull M J, 1981, J R Coll Gen Pract, V31, P357; CAMPBELL R, 1987, WHERE BE BORN DEBATE; Campbell R., 1990, POLITICS MATERNITY C; CHAMBERS R, 1993, BRIT J GEN PRACT, V43, P410; KADRI AZ, 1992, BRIT MED J, V304, P112; KIETLY P, 1992, PREGNANCY CARE 1990S; KLEIN M, 1989, EFFECTIVE CARE PREGN, V1; LOUDON I, 1990, BRIT MED J, V301, P703, DOI 10.1136/bmj.301.6754.703; MACKENZIE GM, 1993, BRIT MED J, V307, P452; MARSH GN, 1985, BRIT MED J, V290, P901, DOI 10.1136/bmj.290.6472.901; MARTINBATES C, 1993, BRIT J GEN PRACT, V43, P413; NESBITT TS, 1992, WESTERN J MED, V157, P44; PHAFF J, 1986, PERINATAL HLTH SERVI; SMITH LFP, 1991, BRIT MED J, V303, P1443, DOI 10.1136/bmj.303.6815.1443; SMITH LFP, 1991, BRIT MED J, V303, P1447, DOI 10.1136/bmj.303.6815.1447; Tew M., 1990, SAFER CHILDBIRTH CRI; WALL EM, 1991, J AM BOARD FAM PRACT, V4, P440; YOUNG G, 1987, BRIT MED J, V294, P744, DOI 10.1136/bmj.294.6574.744; YOUNG G, 1993, PRACTITIONER, V237, P736; 1993, CHANGING CHILDBIRTH; 1992, 2ND HOUS COMM SEL CO, V1; 1959, REPORT MATERNITY SER; 1980, PERINATAL NEONATAL M; 1970, DOMICILIARY MIDWIFER; 1981, BRIT MED J, V282, P1171; 1992, YOUR CHOICES FUTURE	26	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					777	779		10.1136/bmj.309.6957.777	http://dx.doi.org/10.1136/bmj.309.6957.777			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950566	Green Published			2022-12-24	WOS:A1994PJ28200023
J	BIKKINA, M; LEVY, D; EVANS, JC; LARSON, MG; BENJAMIN, EJ; WOLF, PA; CASTELLI, WP				BIKKINA, M; LEVY, D; EVANS, JC; LARSON, MG; BENJAMIN, EJ; WOLF, PA; CASTELLI, WP			LEFT-VENTRICULAR MASS AND RISK OF STROKE IN AN ELDERLY COHORT - THE FRAMINGHAM HEART-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPERTROPHY; ECHOCARDIOGRAPHY; CRITERIA; DISEASE; EVENTS	Objective.-To evaluate the association of echocardiographically determined left ventricular mass (LVM) with incidence of stroke or transient ischemic attack in an elderly cohort. Design.-Cohort study with a follow-up period of 8 years. Setting.-Population-based sample. Subjects.-Elderly original cohort subjects of the Framingham Heart Study who were free of cerebrovascular disease and atrial fibrillation at the 16th biennial examination and who had adequate echocardiograms. This group consisted of 447 men (mean age, 67.8 years; range, 60 to 90 years) and 783 women (mean age, 69.2 years; range 59 to 90 years). Main Outcome Measures.-Age-adjusted 8 year incidence of stroke was examined as a function of baseline quartiles of LVM-to-height ratio. Proportional hazards regression was used in multivariate analyses to assess risk of stroke as a function of LVM-to-height ratio quartile, adjusting for age, sex, systolic blood pressure, hypertension treatment, diabetes, cigarette smoking, and blood lipid levels. Results.-Among the 1230 subjects eligible, 89 cerebrovascular disease events (62 strokes and 27 transient ischemic attacks) occurred during follow-up. In men, 8-year age-adjusted incidence of cerebrovascular events was 18.4% in the highest quartile of LVM-to-height ratio and 5.2% in the lowest quartile. Corresponding values in women were 12.2% and 2.9%. The hazard ratio for cerebrovascular events comparing highest to lowest quartile of LVM-to-height ratio was 2.72 (95% confidence interval [CI], 1.39 to 5.36) after adjusting for age, sex, systolic blood pressure, hypertension treatment, diabetes, cigarette smoking, and the ratio of total cholesterol to high-density lipoprotein cholesterol. After adjusting for age, sex, and cardiovascular disease risk factors, the hazard ratio for cerebrovascular events was 1.45 (95% CI, 1.17 to 1.80) for each quartile increment of LVM-to-height ratio. Conclusions.-Echocardiographically determined LVM-to-height ratio offers prognostic information beyond that provided by traditional cerebrovascular disease risk factors. Echocardiography provides information that facilitates identification of individuals at high risk for stroke and transient ischemic attack.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY,FRAMINGHAM,MA 01701; NHLBI,BETHESDA,MD; BOSTON UNIV,SCH MED,DIV EPIDEMIOL & PREVENT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DIV CARDIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DIV NEUROL,BOSTON,MA 02118; BETH ISRAEL HOSP,DIV CARDIOL,BOSTON,MA; BETH ISRAEL HOSP,DIV CLIN EPIDEMIOL,BOSTON,MA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center			Benjamin, Emelia/E-7103-2011; Levy, Daniel/ABB-2752-2021	Benjamin, Emelia/0000-0003-4076-2336; Levy, Daniel/0000-0003-1843-8724; Wolf, Philip/0000-0002-3628-301X; Larson, Martin/0000-0002-9631-1254	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-RO1-NS-17950-12] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARONOW WS, 1988, AM J CARDIOL, V61, P1130, DOI 10.1016/0002-9149(88)90145-2; BAHEMUKA M, 1987, STROKE, V18, P531, DOI 10.1161/01.STR.18.2.531; BAHEMUKA M, 1988, Q J MED, V67, P467; BENJAMIN EJ, 1992, NEW ENGL J MED, V327, P374, DOI 10.1056/NEJM199208063270602; BHALI JK, 1992, ANN INTERN MED, V117, P831; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; CUPPLES LA, 1988, NIH882969 US DEP HLT; Dawber, 1959, J CHRON DIS, V10, P186, DOI 10.1016/0021-9681(59)90002-5; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; FROHLICH ED, 1971, CIRCULATION, V44, P446, DOI 10.1161/01.CIR.44.3.446; KANNEL WB, 1987, AM J CARDIOL, V60, P851; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; MILLER JT, 1988, AM HEART J, V116, P1048, DOI 10.1016/0002-8703(88)90158-5; NISHIDE M, 1983, STROKE, V14, P541, DOI 10.1161/01.STR.14.4.541; SALONEN JT, 1982, STROKE, V13, P327, DOI 10.1161/01.STR.13.3.327; SAVAGE DD, 1987, HYPERTENSION, V9, P40; TROY BL, 1972, CIRCULATION, V45, P602, DOI 10.1161/01.CIR.45.3.602; VAZIRI SM, 1994, CIRCULATION, V89, P724, DOI 10.1161/01.CIR.89.2.724; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1975, CEREBRAL VASCULAR DI, P105; WOYTHALER JN, 1983, J AM COLL CARDIOL, V2, P305, DOI 10.1016/S0735-1097(83)80167-3; 1993, MONTHLY VITAL STAT R, V42, P1; 1992, ANN INTERN MED, V116, P6	30	254	259	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	1994	272	1					33	36		10.1001/jama.272.1.33	http://dx.doi.org/10.1001/jama.272.1.33			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU485	8007076				2022-12-24	WOS:A1994NU48500026
J	WEETMAN, AP				WEETMAN, AP			ENZYMES AS CATALYSTS OF AUTOIMMUNITY	LANCET			English	Editorial Material							HYDRALAZINE; PROPYLTHIOURACIL; LUPUS				WEETMAN, AP (corresponding author), NO GEN HOSP,DEPT MED,SHEFFIELD,S YORKSHIRE,ENGLAND.							BATCHELOR JR, 1980, LANCET, V1, P1107; CORNACCHIA E, 1988, J IMMUNOL, V140, P2197; DOLMAN KM, 1993, LANCET, V342, P651, DOI 10.1016/0140-6736(93)91761-A; FIBBE WE, 1986, BRIT J HAEMATOL, V64, P363, DOI 10.1111/j.1365-2141.1986.tb04130.x; HOFSTRA AH, 1992, DRUG METAB DISPOS, V20, P205; JIANG XX, 1994, SCIENCE, V266, P810, DOI 10.1126/science.7973636; UCHIGATA Y, 1993, J CLIN ENDOCR METAB, V77, P249, DOI 10.1210/jc.77.1.249; WEETMAN AP, 1984, CLIN ENDOCRINOL, V21, P1636; YAMAMOTO K, 1991, BIOCHEM PHARMACOL, V41, P905; YUNG RL, 1994, RHEUM DIS CLIN N AM, V20, P61; 1992, LANCET, V339, P779	11	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1716	1717		10.1016/S0140-6736(94)92881-9	http://dx.doi.org/10.1016/S0140-6736(94)92881-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7996997				2022-12-24	WOS:A1994PY28100004
J	THIBODEAU, J; CLOUTIER, I; LAVOIE, PM; LABRECQUE, N; MOURAD, W; JARDETZKY, T; SEKALY, RP				THIBODEAU, J; CLOUTIER, I; LAVOIE, PM; LABRECQUE, N; MOURAD, W; JARDETZKY, T; SEKALY, RP			SUBSETS OF HLA-DR1 MOLECULES DEFINED BY SEB AND TSST-1 BINDING	SCIENCE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-B; SHOCK SYNDROME TOXIN-1; CLASS-II MOLECULES; HLA-DR; T-CELLS; ANTIGEN; COMPLEX; SUPERANTIGEN; CHAIN; EXPRESSION	Superantigens bind to major histocompatibility complex class II molecules on antigen-presenting cells and stimulate T cells. Staphylococcus aureus enterotoxin B (SEB) and toxic shock syndrome toxin-1 (TSST-1) bind to the same region of human lymphocyte antigen (HL4)-DR1 but do not compete with each other, which indicates that they bind to different subsets of DR1 molecules. Here, a mutation in the peptide-binding groove disrupted the SEB and TSST-1 binding sites, which suggests that peptides can influence the interaction with bacterial toxins. in support of this, the expression of the DR1 molecule in various cell types differentially affected the binding of these toxins.	CLIN RES INST MONTREAL,IMMUNOL LAB,MONTREAL H2W 1R7,PQ,CANADA; UNIV MONTREAL,FAC MED,DEPT IMMUNOL & MICROBIOL,MONTREAL,PQ,CANADA; MCGILL UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,MONTREAL H3A 2B4,PQ,CANADA; CHU LAVAL,DEPT IMMUNOL & RHUMATOL,ST FOY G1V 4G2,PQ,CANADA; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University; Laval University; Harvard University				Mourad, Walid/0000-0002-1859-9387; Lavoie, Pascal/0000-0002-2205-0362				ACHARYA KR, 1994, NATURE, V367, P94, DOI 10.1038/367094a0; BLUESTONE JA, 1992, J EXP MED, V176, P1757, DOI 10.1084/jem.176.6.1757; BRAUNSTEIN NS, 1992, J EXP MED, V175, P1301, DOI 10.1084/jem.175.5.1301; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CHINTAGUMPALA MM, 1991, J IMMUNOL, V147, P3876; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HERMAN A, 1991, P NATL ACAD SCI USA, V88, P9954, DOI 10.1073/pnas.88.22.9954; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; LABRECQUE N, 1993, RES IMMUNOL, V144, P175, DOI 10.1016/0923-2494(93)80113-D; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LONG EO, 1991, HUM IMMUNOL, V31, P229, DOI 10.1016/0198-8859(91)90092-N; MARRACK P, 1993, J EXP MED, V178, P2173, DOI 10.1084/jem.178.6.2173; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MOLLICK JA, 1991, J IMMUNOL, V146, P463; NORCROSS MA, 1984, J EXP MED, V160, P1316, DOI 10.1084/jem.160.5.1316; PANINABORDIGNON P, 1992, J EXP MED, V176, P1779, DOI 10.1084/jem.176.6.1779; SCHOLL PR, 1990, EUR J IMMUNOL, V20, P1911, DOI 10.1002/eji.1830200907; SCHOLL PR, 1990, J IMMUNOL, V144, P226; SCHOLL PR, 1989, J IMMUNOL, V143, P2583; SEKALY RP, 1986, J EXP MED, V164, P1490, DOI 10.1084/jem.164.5.1490; SHERMAN MA, 1994, J EXP MED, V179, P229, DOI 10.1084/jem.179.1.229; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; THIBODEAU J, 1994, J EXP MED, V179, P1029, DOI 10.1084/jem.179.3.1029; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; VIGNALI DAA, 1994, J EXP MED, V179, P1945, DOI 10.1084/jem.179.6.1945; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YAGI JJ, 1991, J IMMUNOL, V147, P1398	38	89	90	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1874	1878		10.1126/science.7997881	http://dx.doi.org/10.1126/science.7997881			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997881				2022-12-24	WOS:A1994PX38300038
J	MINDEN, A; LIN, A; MCMAHON, M; LANGECARTER, C; DERIJARD, B; DAVIS, RJ; JOHNSON, GL; KARIN, M				MINDEN, A; LIN, A; MCMAHON, M; LANGECARTER, C; DERIJARD, B; DAVIS, RJ; JOHNSON, GL; KARIN, M			DIFFERENTIAL ACTIVATION OF ERK AND JNK MITOGEN-ACTIVATED PROTEIN-KINASES BY RAF-1 AND MEKK	SCIENCE			English	Article							C-JUN ACTIVITY; MAP KINASE; PHOSPHORYLATION; CELLS; GROWTH; EXPRESSION; TYROSINE; CASCADE; DOMAIN; SERINE-63	Growth factors activate mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinases (ERKs) and Jun kinases (JNKs). Although the signaling cascade from growth factor receptors to ERKs is relatively well understood, the pathway leading to JNK activation is more obscure. Activation of JNK by epidermal growth factor (EGF) or nerve growth factor (NGF) was dependent on H-Ras activation, whereas JNK activation by tumor necrosis factor alpha (TNF-alpha) was Ras-independent. Ras activates two protein kinases, Raf-1 and MEK (MAPK, or ERK, kinase) kinase (MEKK). Raf-1 contributes directly to ERK activation but not to JNK activation, whereas MEKK participated in JNK activation but caused ERK activation only after overexpression. These results demonstrate the existence of two distinct Ras-dependent MAPK cascades-one initiated by Raf-1 leading to ERK activation, and the other initiated by MEKK leading to JNK activation.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605	University of California System; University of California San Diego; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; National Jewish Health; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester			McMahon, Martin/L-3303-2013	McMahon, Martin/0000-0003-2812-1042; Lange, Carol/0000-0003-2751-3976				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AMERER G, 1994, CURR OPIN GENES DEV, V4, P90; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOULTON TG, 1991, CELL, V65, P664; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENG T, COMMUNICATION; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1028; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gupta SK, UNPUB; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAND H, 1986, MOL CELL BIOL, V6, P1979; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AL, UNPUB; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MINDEN A, UNPUB; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEGER R, 1992, J BIOL CHEM, V267, P25628; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WESTWICK JK, IN PRESS J BIOL CHEM; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	48	1049	1075	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1719	1723		10.1126/science.7992057	http://dx.doi.org/10.1126/science.7992057			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992057				2022-12-24	WOS:A1994PW30800044
J	ROLDAN, ERS; MURASE, T; SHI, QX				ROLDAN, ERS; MURASE, T; SHI, QX			EXOCYTOSIS IN SPERMATOZOA IN RESPONSE TO PROGESTERONE AND ZONA-PELLUCIDA	SCIENCE			English	Article							RAM SPERM ACROSOME; PHOSPHOLIPASE-D; SUBSEQUENT EXOCYTOSIS; TYROSINE KINASE; BINDING-SITES; MOUSE SPERM; ACTIVATION; PROTEIN; CA-2+; DIACYLGLYCEROL	Exocytosis in mammalian spermatozoa (the acrosome reaction) is a process essential for fertilization. Both progesterone and zona pellucida induce exocytosis in spermatozoa, which may encounter both during penetration of the oocyte's vestments. When mouse spermatozoa were exposed first to progesterone and then to zona pellucida, exocytosis was enhanced to a greater degree than that seen when the agonists were presented together or in the inverse order, which suggests that the steroid exerts a priming effect. Progesterone similarly primed the generation of intracellular messengers evoked by zona pellucida. The effects triggered by progesterone were mimicked by gamma-aminobutyric acid (GABA) and were blocked by bicuculline, which indicates that the steroid acts on a GABA(A) receptor.			ROLDAN, ERS (corresponding author), BIOTECHNOL & BIOL SCI RES COUNCIL,BABRAHAM INST,DEPT DEV & SIGNALLING,CAMBRIDGE CB2 4AT,ENGLAND.		Roldan, Eduardo R.S./M-7947-2014	Roldan, Eduardo R.S./0000-0002-7545-4248				BAULIEU EE, 1988, ANTIPROGESTIN STEROI; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376; Bleil J.D., 1991, ELEMENTS MAMMALIAN F, V1, P133; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; DOMINO SE, 1989, J BIOL CHEM, V264, P9412; ERDO SL, 1990, LIFE SCI, V47, P1147, DOI 10.1016/0024-3205(90)90175-Q; EXTON JH, 1990, J BIOL CHEM, V265, P1; FLORMAN HM, 1989, DEV BIOL, V135, P133, DOI 10.1016/0012-1606(89)90164-4; FRASER LR, 1989, J REPROD FERTIL, V86, P223, DOI 10.1530/jrf.0.0860223; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LEYTON L, 1992, P NATL ACAD SCI USA, V89, P11692, DOI 10.1073/pnas.89.24.11692; MEIZEL S, 1991, MOL CELL ENDOCRINOL, V11, pR1; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; NILSSON M, 1993, NEUROSCIENCE, V54, P605, DOI 10.1016/0306-4522(93)90232-5; OSMAN RA, 1989, BIOCHEM BIOPH RES CO, V160, P828, DOI 10.1016/0006-291X(89)92508-4; PAI JK, 1988, J BIOL CHEM, V263, P12472; PARINAUD J, 1992, FERTIL STERIL, V58, P599; ROBEL P, 1994, TRENDS ENDOCRIN MET, V5, P1, DOI 10.1016/1043-2760(94)90114-7; ROLDAN E, UNPUB; ROLDAN ERS, 1993, BIOCHIM BIOPHYS ACTA, V1168, P108, DOI 10.1016/0005-2760(93)90273-C; ROLDAN ERS, 1989, BIOCHEM J, V259, P397, DOI 10.1042/bj2590397; ROLDAN ERS, 1992, BIOCHEM J, V281, P767, DOI 10.1042/bj2810767; ROLDAN ERS, 1993, BIOCHEM SOC T, V21, P284, DOI 10.1042/bst0210284; ROLDAN ERS, 1993, BIOCHIM BIOPHYS ACTA, V1210, P48, DOI 10.1016/0005-2760(93)90048-E; ROLDAN ERS, 1993, J BIOL CHEM, V268, P13962; ROLDAN ERS, 1990, SERONO S, P179; SIEGHART W, 1992, TRENDS PHARMACOL SCI, V13, P446, DOI 10.1016/0165-6147(92)90142-S; TESARIK J, 1993, ENDOCRINOLOGY, V133, P328, DOI 10.1210/en.133.1.328; TESARIK J, 1993, MOL REPROD DEV, V34, P183, DOI 10.1002/mrd.1080340210; THOMAS P, 1989, BIOCHEM J, V264, P539, DOI 10.1042/bj2640539; TURNER KO, 1994, MOL CELL ENDOCRINOL, V101, P221, DOI 10.1016/0303-7207(94)90238-0; WARD CR, 1992, J BIOL CHEM, V267, P14061; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165; WISTROM CA, 1993, DEV BIOL, V159, P679; Yanagimachi R., 1994, P189; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893	37	284	299	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1578	1581		10.1126/science.7985030	http://dx.doi.org/10.1126/science.7985030			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985030				2022-12-24	WOS:A1994PV01500049
J	SASAI, Y; LU, B; STEINBEISSER, H; GEISSERT, D; GONT, LK; DEROBERTIS, EM				SASAI, Y; LU, B; STEINBEISSER, H; GEISSERT, D; GONT, LK; DEROBERTIS, EM			XENOPUS CHORDIN - A NOVEL DORSALIZING FACTOR-ACTIVATED BY ORGANIZER-SPECIFIC HOMEOBOX GENES	CELL			English	Article							SPEMANN ORGANIZER; LAEVIS EMBRYOS; MESODERM INDUCTION; INJECTED XWNT-8; BOX GENE; EXPRESSION; AXIS; DOMAIN; HYBRIDIZATION; ECTODERM	A Xenopus gene whose expression can be activated by the organizer-specific homeobox genes goosecoid and Xnot2 was isolated by differential screening. The chordin gene encodes a novel protein of 941 amino acids that has a signal sequence and four Cys-rich domains. The expression of chordin starts in Spemann's organizer subsequent to that of goosecoid, and its induction by activin requires de novo protein synthesis. Microinjection of chordin mRNA induces twinned axes and can completely rescue axial development in ventralized embryos. This molecule is a potent dorsalizing factor that is expressed at the right time and in the right place to regulate cell-cell interactions in the organizing centers of head, trunk, and tail development.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				De Robertis, Edward/0000-0002-7843-1869	NICHD NIH HHS [R37 HD021502-13, R01 HD021502, R37 HD021502, HD21502-09] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502, R01HD021502] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTABA ARI, 1992, DEVELOPMENT, V116, P81; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CUNLIFFE V, 1994, EMBO J, V13, P349, DOI 10.1002/j.1460-2075.1994.tb06268.x; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; GERHART J, 1991, BOD MAR LAB, P57; GILBERT SF, 1994, DEV BIOL, P597; GONT LK, 1993, DEVELOPMENT, V119, P991; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HUNT LT, 1987, BIOCHEM BIOPH RES CO, V144, P876, DOI 10.1016/S0006-291X(87)80046-3; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KELLER RE, 1991, METHOD CELL BIOL, V36, P62; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MOON RT, 1992, CELL, V71, P709, DOI 10.1016/0092-8674(92)90545-N; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SLACK JMW, 1988, DEVELOPMENT, V103, P581; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; SMITH JC, 1985, DIFFERENTIATION, V29, P109, DOI 10.1111/j.1432-0436.1985.tb00302.x; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPEMANN H, 1931, ROUX ARCH ENTW MECH, V123, P389; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; STEWART RM, 1990, DEVELOPMENT, V109, P363; TADANO T, 1993, DEV GENET, V14, P204, DOI 10.1002/dvg.1020140307; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4	47	933	977	0	37	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	DEC 2	1994	79	5					779	790		10.1016/0092-8674(94)90068-X	http://dx.doi.org/10.1016/0092-8674(94)90068-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001117	Green Accepted			2022-12-24	WOS:A1994PW05400006
J	FRANKE, EK; YUAN, HEH; LUBAN, J				FRANKE, EK; YUAN, HEH; LUBAN, J			SPECIFIC INCORPORATION OF CYCLOPHILIN-A INTO HIV-1 VIRIONS	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYCLOSPORINE-A; GAG; CALCINEURIN; INHIBITION; EXPRESSION; SEQUENCE; BINDING; CELLS; RNA	LITTLE is known about host factors necessary for retroviral virion assembly or uncoating. We have previously shown that the principal structural protein of the human immunodeficiency virus HIV-1, the Gag polyprotein, binds the cyclophilin peptidyl-prolyl isomerases(1); cyclophilins catalyse a rate-limiting step in protein folding(2) and protect cells from heat shock(3). Here we demonstrate that cyclophilin A is specifically incorporated into HIV-1 virions but not into virions of other primate immunodeficiency viruses. A proline-rich region conserved in all HIV-1 Gag polyproteins is required for cyclophilin A binding and incorporation. Disruption of a single proline blocks the Gag-cyclophilin interaction in vitro, prevents cyclophilin A incorporation into virions, and inhibits HIV-1 replication. Our results indicate that the interaction of Gag with cyclophilin A is necessary for the formation of infectious HIV-1 virions.			FRANKE, EK (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,701 W 168TH ST,NEW YORK,NY 10032, USA.			Luban, Jeremy/0000-0001-5650-4054				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEWHURST S, 1990, NATURE, V345, P636, DOI 10.1038/345636a0; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FRANKE EK, 1994, J VIROL, V68, P5300, DOI 10.1128/JVI.68.8.5300-5305.1994; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; JIN MJ, 1994, EMBO J, V13, P2935, DOI 10.1002/j.1460-2075.1994.tb06588.x; KARPAS A, 1992, P NATL ACAD SCI USA, V89, P8351, DOI 10.1073/pnas.89.17.8351; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; KORNFELD H, 1987, NATURE, V326, P610, DOI 10.1038/326610a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LUBAN J, 1994, J VIROL, V68, P3784, DOI 10.1128/JVI.68.6.3784-3793.1994; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; LUBAN J, 1991, J VIROL, V65, P3203, DOI 10.1128/JVI.65.6.3203-3212.1991; MAMMANO F, 1994, J VIROL, V68, P4927, DOI 10.1128/JVI.68.8.4927-4936.1994; MYERS G, 1993, HUMAN RETROVIRUSES A; PANET A, 1975, J VIROL, V16, P146, DOI 10.1128/JVI.16.1.146-152.1975; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; SCHWARTZ S, 1992, J VIROL, V66, P7176, DOI 10.1128/JVI.66.12.7176-7182.1992; SYKES K, 1993, P NATL ACAD SCI USA, V90, P5853, DOI 10.1073/pnas.90.12.5853	26	614	635	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					359	362		10.1038/372359a0	http://dx.doi.org/10.1038/372359a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969494				2022-12-24	WOS:A1994PU28700055
J	DAVIS, AA; TEMPLE, S				DAVIS, AA; TEMPLE, S			A SELF-RENEWING MULTIPOTENTIAL STEM-CELL IN EMBRYONIC RAT CEREBRAL-CORTEX	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; NEURAL CREST; NEURONS; LINEAGE; DIFFERENTIATION; GENERATION; ASTROCYTES; PROGENITOR; RETINA; OLIGODENDROCYTES	NEUROECTODERM cells in the cortical ventricular zone generate many diverse cell types, maintain the ventricular zone during embryonic life and create another germinal layer, the subventricular zone, which persists into adulthood(1,2). In other vertebrate tissues, including skin, intestine, blood and neural crest, stem cells are important in maintaining a germinal population and generating differentiated progeny(3-6). By following the fates of single ventricular zone cells in culture, we show here that self-renewing, multipotential stem cells are present in the embryonic rat cerebral cortex. Forty per cent of these stem cells produced all three principal cell types of the central nervous system: neurons, astrocytes and oligodendrocytes. Stem cells constituted about 7% of cortical clones; in contrast, over 80% consisted of small numbers of neurons or glia. We suggest that multipotential stem cells may be the ancestors of other cortical progenitor cells that exhibit more limited proliferation and more restricted repertoires of progeny fates.	ALBANY MED COLL,DIV NEUROSURG,ALBANY,NY 12208	Albany Medical College	DAVIS, AA (corresponding author), ALBANY MED COLL,DEPT PHARMACOL,ALBANY,NY 12208, USA.							ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; AUSTIN CP, 1990, DEVELOPMENT, V110, P713; Bayer S.A., 1991, NEOCORTICAL DEV; CEPKO CL, 1990, COLD SH Q B, V55, P265; DAVIS AA, 1993, SOC NEUR ABSTR, V19; DEXTER TM, 1987, ANNU REV CELL BIOL, V3, P423; HALL PA, 1989, DEVELOPMENT, V106, P619; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; Jacobson M., 1991, DEV NEUROBIOLOGY; KAWAMOTO JC, 1986, BRAIN RES, V384, P84, DOI 10.1016/0006-8993(86)91222-9; LAJTHA LG, 1979, DIFFERENTIATION, V14, P23, DOI 10.1111/j.1432-0436.1979.tb01007.x; LEBER SM, 1990, J NEUROSCI, V10, P2451; LUMSDEN A, 1994, DEVELOPMENT, V120, P1581; LUSKIN MB, 1993, J NEUROSCI, V13, P1730; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; OGAWA M, 1983, BLOOD, V61, P823; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE J, 1991, DEVELOPMENT S, V2, P23; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; TEMPLE S, 1994, DEVELOPMENT, V120, P999; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; WILLIAMS BP, 1991, NEURON, V7, P685, DOI 10.1016/0896-6273(91)90381-9	29	483	548	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					263	266		10.1038/372263a0	http://dx.doi.org/10.1038/372263a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969470				2022-12-24	WOS:A1994PR88900050
J	ELLINOR, PT; ZHANG, JF; HORNE, WA; TSIEN, RW				ELLINOR, PT; ZHANG, JF; HORNE, WA; TSIEN, RW			STRUCTURAL DETERMINANTS OF THE BLOCKADE OF N-TYPE CALCIUM CHANNELS BY A PEPTIDE NEUROTOXIN	NATURE			English	Article							OMEGA-CONOTOXIN GVIA; CA2+ CHANNELS; FUNCTIONAL EXPRESSION; PERIPHERAL NEURONS; BRAIN; SUBUNIT; SENSITIVITY; SELECTIVITY; SYNAPSES	NEUROTOXINS that selectively block Na+, K+ or Ca2+ channels have provided valuable information about the functional diversity of the voltage-gated channel superfamily(1). For Ca2+ channels, a variety of toxins have been found to block individual channel types(2,3). The best-known example is omega-conotoxin-GVIA, a member of a large family of peptide toxins derived from venomous cone snails(2,3), which potently and selectively blocks N-type Ca2+ channels(4-9), allowing their purification(10,11), cellular localization(12,13), and the elucidation of their roles in Ca2+ entry(14), neurotransmitter release(15,16) and neuronal migration(17). In contrast to Na+ and K+ channels, little is known about the molecular features that underlie Ca2+-channel susceptibility to toxin block; it is also unknown whether block occurs by direct physical occlusion(3) or an action on channel gating(18). Here we describe structural determinants of the N-type Ca2+ channel's interaction with omega-conotoxin-GVIA. When chimaeras combining individual motifs from the N-type channel and from a channel insensitive to omega-conotoxin-GVIA were expressed in Xenopus oocytes, each of the four motifs appeared to contribute to interaction with the toxin. The most dramatic effects on toxin interactions were seen at a single cluster of residues in the large putative extracellular loop between IIIS5 and IIIH5, consistent with a direct pore-blocking mechanism. These results provide a starting point for delineating the architecture of the outer vestibule of the Ca2+ channel.	STANFORD UNIV,MED CTR,DEPT CELLULAR & MOLEC PHYSIOL,STANFORD,CA 94305; NEUREX CORP,MENLO PK,CA 94025	Stanford University				Ellinor, Patrick/0000-0002-2067-0533				AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; BOLAND LM, IN PRESS J NEUROSCI; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; Hille B., 1992, IONIC CHANNELS EXCIT; HIMING LD, 1988, SCIENCE, V239, P57; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; KOMORU H, 1992, SCIENCE, V257, P806; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MILLER C, 1994, BIOPHYS J, V66, pA23; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; OLIVERA BM, 1984, BIOCHEMISTRY-US, V23, P5087, DOI 10.1021/bi00317a001; OLIVERA BM, IN PRESS A REV BIOCH; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; STANLEY EF, 1991, J NEUROSCI, V11, P985; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; WITCHER DR, 1993, NEUROPHARMACOLOGY, V32, P1127, DOI 10.1016/0028-3908(93)90007-P; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; YOSHIKAMI D, 1989, ANN NY ACAD SCI, V560, P230, DOI 10.1111/j.1749-6632.1989.tb24100.x; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	29	165	169	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					272	275		10.1038/372272a0	http://dx.doi.org/10.1038/372272a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969473				2022-12-24	WOS:A1994PR88900053
J	TANIFUJI, M; SUGIYAMA, T; MURASE, K				TANIFUJI, M; SUGIYAMA, T; MURASE, K			HORIZONTAL PROPAGATION OF EXCITATION IN RAT VISUAL CORTICAL SLICES REVEALED BY OPTICAL IMAGING	SCIENCE			English	Article							INTRINSIC CONNECTIONS; ELECTRICAL-ACTIVITY; CORTEX; CAT; PROJECTIONS	Optical imaging with high spatial and temporal resolution of neural activity in rat cortical slices was used to investigate the dynamics of signal transmission through neural connections in the visual cortex. When inhibition due to gamma-aminobutyric acid was slightly suppressed, horizontal propagation of excitation in both the supra- and infragranular layers became prominent. This propagation was not affected by vertical cuts in either the supra- or infragranular layer, which suggests that excitation is at least partially conveyed horizontally by reciprocal vertical connections between neurons in these layers.			TANIFUJI, M (corresponding author), FUKUI UNIV,DEPT INFORMAT SCI,BUNKYO KU,FUKUI 910,JAPAN.		Murase, Kazuyuki/O-4881-2014; Tanifuji, Manabu/H-1744-2019	Murase, Kazuyuki/0000-0002-2358-995X; Tanifuji, Manabu/0000-0001-7754-7774				ALBOWITZ B, 1993, EXP BRAIN RES, V93, P213; BURKHALTER A, 1989, J COMP NEUROL, V279, P171, DOI 10.1002/cne.902790202; FERSTER D, 1983, J PHYSIOL-LONDON, V342, P181, DOI 10.1113/jphysiol.1983.sp014846; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1992, NEURON, V9, P1, DOI 10.1016/0896-6273(92)90215-Y; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRINVALD A, 1982, J PHYSIOL-LONDON, V333, P269, DOI 10.1113/jphysiol.1982.sp014453; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; ICHIKAWA M, 1993, BRAIN MECHANISMS OF PERCEPTION AND MEMORY: FROM NEURON TO BEHAVIOR, P638; KOMATSU Y, 1988, BRAIN RES, V442, P359, DOI 10.1016/0006-8993(88)91526-0; KONNERTH A, 1987, J PHYSIOL-LONDON, V393, P681, DOI 10.1113/jphysiol.1987.sp016848; KUROTANI T, 1993, DEV BRAIN RES, V71, P151, DOI 10.1016/0165-3806(93)90168-A; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MITZDORF U, 1978, EXP BRAIN RES, V33, P371; ROCKLAND KS, 1983, J COMP NEUROL, V216, P303, DOI 10.1002/cne.902160307; SUGITANI M, 1994, NEUROSCI LETT, V171, P175, DOI 10.1016/0304-3940(94)90633-5; SUGITANI M, 1994, NEUROSCI LETT, V165, P215, DOI 10.1016/0304-3940(94)90748-X; TANIFUJI M, 1991, Society for Neuroscience Abstracts, V17, P114; TANIFUJI M, UNPUB; TOYAMA K, 1991, BIOMED RES-TOKYO, V12, P145; NK3630 NIPP KANK SHI	21	135	135	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1057	1059		10.1126/science.7973662	http://dx.doi.org/10.1126/science.7973662			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973662				2022-12-24	WOS:A1994PQ92400049
J	FANJUL, A; DAWSON, MI; HOBBS, PD; JONG, L; CAMERON, JF; HARLEV, E; GRAUPNER, G; LU, XP; PFAHL, M				FANJUL, A; DAWSON, MI; HOBBS, PD; JONG, L; CAMERON, JF; HARLEV, E; GRAUPNER, G; LU, XP; PFAHL, M			A NEW CLASS OF RETINOIDS WITH SELECTIVE-INHIBITION OF AP-1 INHIBITS PROLIFERATION	NATURE			English	Article							ACID RECEPTOR-ALPHA; ISOTRETINOIN; PREVENTION; PATHWAYS; ANALOGS; LIGANDS; CANCER	RETINOIDS regulate many biological processes, including differentiation, morphogenesis and cell proliferation(1-3). They are also important therapeutic agents, but their clinical usefulness is limited because of side effects(4-8). Retinoid activities are mediated by specific nuclear receptors, the RARs and RXRs, which can induce transcriptional activation through specific DNA sites(3,9-11) or by inhibiting the transcription factor AP-1 (refs 12-15), which usually mediates cell proliferation signals(16). Because the two types of receptor actions are mechanistically distinct(12,15) we investigated whether conformationally restricted retinoids, selective for each type of receptor action, could be identified, Here we describe a new class of retinoids that selectively inhibits AP-1 activity but does not activate transcription. These retinoids do not induce differentiation in F9 cells but inhibit effectively the proliferation of several tumour cell lines, and could thus serve as candidates for new retinoid therapeutic agents with reduced side effects.	SRI INT,DIV LIFE SCI,MENLO PK,CA 94025; LA JOLLA CANC RES FDN,CTR CANC,LA JOLLA,CA 92037	SRI International; Sanford Burnham Prebys Medical Discovery Institute								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BOLLAG W, 1992, ANN ONCOL, V3, P513, DOI 10.1093/oxfordjournals.annonc.a058252; Dawson M. I., 1990, CHEM BIOL SYNTHETIC; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUSSMAN M, 1991, MOL CELL BIOL, V11, P4097; KRAEMER KH, 1988, NEW ENGL J MED, V318, P1633, DOI 10.1056/NEJM198806233182501; LEE MO, 1994, P NATL ACAD SCI USA, V91, P5632, DOI 10.1073/pnas.91.12.5632; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; Morris-Kay G., 1992, RETINOIDS NORMAL DEV; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; ROBERTS AB, 1984, RETINOIDS, V2, P209; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; YANGYEN HF, 1991, NEW BIOL, V3, P1206; [No title captured]	28	315	327	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					107	111		10.1038/372107a0	http://dx.doi.org/10.1038/372107a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969403				2022-12-24	WOS:A1994PQ34800084
J	CARNON, AG; SSEMWOGERERE, A; LAMONT, DW; HOLE, DJ; MALLON, EA; GEORGE, WD; GILLIS, CR				CARNON, AG; SSEMWOGERERE, A; LAMONT, DW; HOLE, DJ; MALLON, EA; GEORGE, WD; GILLIS, CR			RELATION BETWEEN SOCIOECONOMIC DEPRIVATION AND PATHOLOGICAL PROGNOSTIC FACTORS IN WOMEN WITH BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article							LATE-STAGE DIAGNOSIS; SOCIAL-CLASS; SURVIVAL; RACE; DELAY; AGE	Objective-To investigate the relation between socioeconomic deprivation and pathological prognostic factors in women with breast cancer as a possible explanation for socioeconomic differences in survival. Design-Retrospective analysis of data from cancer registry and from pathology and biochemistry records. Setting-Catchment areas of two large teaching hospitals in Glasgow. Subjects-1361 women aged under 75 who had breast cancer diagnosed between 1980 and 1987. Main outcome measures-Tumour size, axillary lymph node status, histological grade, and oestrogen receptor concentration in relation to deprivation category of area of residence. Results-There was no significant relation between socioeconomic deprivation and four pathological prognostic factors: 93 (32%) women in the most affluent group presented with tumours less than 20 mm in size compared with 91 (31%) women in the most deprived group; 152 (48%) of the most affluent group presented with negative nodes compared with 129 (46%) of the most deprived group; 23 (22%) of the most affluent group presented with grade I tumours compared with 12 (17%) of the most deprived group; and 142 (51%) of the most affluent group had a low oestrogen receptor concentration at presentation compared with 148 (52%) of the most deprived group. None of these differences was statistically significant. Conclusions-Differences in survival from breast cancer by socioeconomic deprivation category could not be accounted for by differences in tumour stage or biology. Other possible explanations, such as differences in treatment or in host response, should be investigated.	RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT PATHOL,GLASGOW G11 6NT,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT SURG,GLASGOW G11 6NT,LANARK,SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow								AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Carstairs V., 1991, DEPRIVATION HLTH SCO; COATES RJ, 1992, JNCI-J NATL CANCER I, V84, P938, DOI 10.1093/jnci/84.12.938; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FARLEY TA, 1989, AM J PUBLIC HEALTH, V79, P1508, DOI 10.2105/AJPH.79.11.1508; GORDON NH, 1992, AM J EPIDEMIOL, V135, P609, DOI 10.1093/oxfordjournals.aje.a116340; KARJALAINEN S, 1990, CANCER-AM CANCER SOC, V66, P819, DOI 10.1002/1097-0142(19900815)66:4<819::AID-CNCR2820660437>3.0.CO;2-E; KEIRN W, 1985, CANCER, V55, P1552, DOI 10.1002/1097-0142(19850401)55:7<1552::AID-CNCR2820550723>3.0.CO;2-E; KOGEVINAS M, 1991, J EPIDEMIOL COMMUN H, V45, P216, DOI 10.1136/jech.45.3.216; MANDELBLATT J, 1991, AM J PUBLIC HEALTH, V81, P646, DOI 10.2105/AJPH.81.5.646; MITTRA I, 1991, EUR J CANCER, V27, P1583; MOHLA S, 1982, CANCER-AM CANCER SOC, V50, P552, DOI 10.1002/1097-0142(19820801)50:3<552::AID-CNCR2820500328>3.0.CO;2-G; NATARAJAN N, 1985, CANCER-AM CANCER SOC, V56, P1704, DOI 10.1002/1097-0142(19851001)56:7<1704::AID-CNCR2820560740>3.0.CO;2-L; OWNBY HE, 1985, J NATL CANCER I, V75, P55; RICHARDSON JL, 1992, BRIT J CANCER, V65, P922, DOI 10.1038/bjc.1992.193; TOMATIS L, 1990, CANCER CAUSES OCCURR; VAGERO D, 1987, J EPIDEMIOL COMMUN H, V41, P204, DOI 10.1136/jech.41.3.204; VERNON SW, 1985, CANCER-AM CANCER SOC, V55, P1563, DOI 10.1002/1097-0142(19850401)55:7<1563::AID-CNCR2820550726>3.0.CO;2-1; WELLS BL, 1992, AM J PUBLIC HEALTH, V82, P1383, DOI 10.2105/AJPH.82.10.1383; 1987, TNM CLASSIFICATION M; 1991, BREAST CANCER SCREEN	22	60	61	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1054	1057		10.1136/bmj.309.6961.1054	http://dx.doi.org/10.1136/bmj.309.6961.1054			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN733	7950739	Green Published			2022-12-24	WOS:A1994PN73300022
J	CHEN, C; RAINNIE, DG; GREENE, RW; TONEGAWA, S				CHEN, C; RAINNIE, DG; GREENE, RW; TONEGAWA, S			ABNORMAL FEAR RESPONSE AND AGGRESSIVE-BEHAVIOR IN MUTANT MICE DEFICIENT FOR ALPHA-CALCIUM-CALMODULIN KINASE-II	SCIENCE			English	Article							DORSAL RAPHE NEURONS; RAT-BRAIN; TRYPTOPHAN-HYDROXYLASE; CONDITIONED FEAR; PROTEIN-KINASE; SEROTONIN; PHOSPHORYLATION; DISORDERS; MONOAMINE; SLICES	Mice deficient for the gene encoding alpha-calcium-calmodulin-dependent kinase II (alpha-CaMKII knockout mice) provide a promising tool to link behavioral and cellular abnormalities with a specific molecular lesion. The heterozygous mouse exhibited a well-circumscribed syndrome of behavioral abnormalities, consisting primarily of a decreased fear response and an increase in defensive aggression, in the absence of any measured cognitive deficits. Unlike the heterozygote, the homozygote displayed abnormal behavior in all paradigms tested. At the cellular level, both extracellular and whole-cell patch clamp recordings indicated that serotonin release in putative serotonergic neurons of the dorsal raphe was reduced. Thus, alpha-CaMKII knockout mice, in particular the heterozygote, may provide a model for studying the molecular and cellular basis underlying emotional disorders involving fear and aggression.	MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, SCH MED, DEPT PSYCHIAT, BROCKTON, MA 02401 USA; VET ADM MED CTR, BROCKTON, MA 02401 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	CHEN, C (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		Rainnie, Donald/L-3853-2016	Rainnie, Donald/0000-0003-0758-0530; Greene, Robert/0000-0003-1355-9797				ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; AGHAJANIAN GK, 1984, BRAIN RES, V305, P181, DOI 10.1016/0006-8993(84)91137-5; BARNETT SA, 1975, RAT STUDY BEHAVIOR; BENTON D, 1985, PHARM BIOCH BEHAV, V23, P979; BOLLES RC, 1970, PSYCHOL REV, V77, P32, DOI 10.1037/h0028589; BRAIN PF, 1989, E M I LIF S, V6, P1; BROWN GL, 1990, J CLIN PSYCHIAT, V51, P31; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CHARNEY DS, 1990, ANN NY ACAD SCI, V600, P558, DOI 10.1111/j.1749-6632.1990.tb16910.x; EHRET M, 1989, J NEUROCHEM, V52, P1886, DOI 10.1111/j.1471-4159.1989.tb07272.x; FANSELOW MS, 1992, BEHAV NEUROSCI, V106, P336, DOI 10.1037/0735-7044.106.2.336; FANSELOW MS, 1986, ANN NY ACAD SCI, V467, P40, DOI 10.1111/j.1749-6632.1986.tb14617.x; FANSELOW MS, 1984, TRENDS NEUROSCI, V7, P460; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; GRANT L D, 1973, Pharmacology Biochemistry and Behavior, V1, P77, DOI 10.1016/0091-3057(73)90059-2; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hen R., 1993, Society for Neuroscience Abstracts, V19, P632; HIGLEY JD, 1992, ARCH GEN PSYCHIAT, V49, P436; INOUE T, 1993, PHARMACOL BIOCHEM BE, V44, P371, DOI 10.1016/0091-3057(93)90476-A; ISOBE T, 1991, J MOL BIOL, V217, P125, DOI 10.1016/0022-2836(91)90616-E; KIM JJ, 1991, BEHAV NEUROSCI, V105, P126, DOI 10.1037/0735-7044.105.1.126; KOOLHAAS M, 1991, NEUROMETHODS, V19, P249; KOSTOWSKI W, 1980, PHYSIOL BEHAV, V25, P161, DOI 10.1016/0031-9384(80)90201-2; KSHAMA D, 1990, BEHAV NEURAL BIOL, V54, P234, DOI 10.1016/0163-1047(90)90617-F; MICZEK KA, 1994, NEUROSCI BIOBEHAV R, V18, P97, DOI 10.1016/0149-7634(94)90040-X; NEVINS ME, 1994, J PHARMACOL EXP THER, V268, P248; NORMAN TR, 1989, INT J CLIN PHARM RES, V9, P151; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; TREIT D, 1993, BEHAV BRAIN RES, V54, P23, DOI 10.1016/0166-4328(93)90045-R; VANDERMAELEN CP, 1983, BRAIN RES, V289, P109, DOI 10.1016/0006-8993(83)90011-2; VANPRAAG HM, 1990, BRIT J PSYCHIAT, V157, P723, DOI 10.1192/bjp.157.5.723; WALLETSCHEK H, 1982, PHYSIOL BEHAV, V28, P697, DOI 10.1016/0031-9384(82)90054-3; WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037/0033-2909.83.3.482; WESTENBERG HGM, 1989, PSYCHOPATHOLOGY, V22, P68, DOI 10.1159/000284628; WILLIAMS JT, 1988, J NEUROSCI, V8, P3499	36	224	233	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	1994	266	5183					291	294		10.1126/science.7939668	http://dx.doi.org/10.1126/science.7939668			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939668				2022-12-24	WOS:A1994PM13400039
J	KUROKAWA, R; DIRENZO, J; BOEHM, M; SUGARMAN, J; GLOSS, B; ROSENFELD, MG; HEYMAN, RA; GLASS, CK				KUROKAWA, R; DIRENZO, J; BOEHM, M; SUGARMAN, J; GLOSS, B; ROSENFELD, MG; HEYMAN, RA; GLASS, CK			REGULATION OF RETINOID SIGNALING BY RECEPTOR POLARITY AND ALLOSTERIC CONTROL OF LIGAND-BINDING	NATURE			English	Article							THYROID-HORMONE; X-RECEPTOR; RESPONSE ELEMENTS; NUCLEAR RECEPTOR; DNA-BINDING; DIRECT REPEAT; AMINO-ACIDS; BETA-GENE; RXR-BETA; RAR	RETINOIC acid receptors (RARs) and retinoid X receptors (RXRs) regulate transcription by binding to response elements in target genes that generally consist of two direct repeat half-sites of consensus sequence AGGTCA (ref. 1). RAR/RXR heterodimers activate transcription in response to all-irans or 9-cis retinoic acid by binding to direct repeats spaced by five base pairs (DR5 elements)(2-8), such that RAR occupies the downstream half-site(9-12). RXR homodimers activate transcription in response to 9-cis retinoic acid by binding to direct repeats spaced by one base pair (DR1 elements)(8,13,14). Although RXR/RAR heterodimers bind to DR1 elements with higher affinity than RXR homodimers, in most contexts they are unable to activate transcription in response to either all-trans or 9-cis retinoic acid(3-5). AS a result, RARs inhibit RXR-dependent transcription from these sites(13,15). We report that the switching of the RAR from an activator to an inhibitor of retinoid-dependent transcription requires that it be bound to the upstream half-site of DR1 elements and that it allosterically block the binding of ligand to the RXR.	UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; LIGAND PHARMACEUT,DEPT CELL BIOL,SAN DIEGO,CA 92121	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Ligand Pharmaceuticals			Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592				DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; GLASS C. K., 1994, ENDOCR REV, V15, P1503; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; KLLEWER SA, 1992, NATURE, V355, P446; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	26	391	403	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					528	531		10.1038/371528a0	http://dx.doi.org/10.1038/371528a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935766				2022-12-24	WOS:A1994PK58900059
J	GREEN, JM				GREEN, JM			SERUM SCREENING FOR DOWNS-SYNDROME - EXPERIENCES OF OBSTETRICIANS IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To assess the experiences of obstetricians in England and Wales of serum screening for Down's syndrome. Design-Postal questionnaire survey. Subjects-Questionnaires were sent to all practising obstetricians in England and Wales with nonacademic appointments who had not participated in an earlier (randomly sampled) survey of obstetricians' attitudes (n = 555). Responses were received from 393 (71%), of which 351 were analysed. The data represent about one third of obstetric consultants in England and Wales. Main outcome measures-The extent of use of serum screening for Down's syndrome, and the problems encountered. Results-Serum screening for Down's syndrome was being offered on some basis by virtually all obstetricians in the survey. Nearly half the sample said that they did not have adequate resources for counselling all the women to whom screening was offered. Many problems were reported, which in all cases were more common than equivalent problems encountered with serum screening for neural tube defects. Over 80% (289) said that women not understanding the test was a problem. Conclusions-There is considerable confusion associated with serum screening for Down's syndrome. The precedent of serum screening for neural tube defects does not seem to have lessened the problems experienced, rather the contrary. Many obstetricians report inadequate resources for counselling, which is consistent with the high prevalence of problems associated with women not understanding the test. There is an urgent need to consider what counselling should consist of and who should undertake it and to ensure that necessary resources are available.			GREEN, JM (corresponding author), UNIV CAMBRIDGE,CTR FAMILY RES,CAMBRIDGE CB2 3RF,ENGLAND.							GREEN JM, 1993, LANCET, V342, P1179, DOI 10.1016/0140-6736(93)92164-O; GREEN JM, 1990, OCCASIONAL PAPERS, V2; GREEN JM, 1994, PRENATAL DIAGNOSIS H, P37; MARTEAU TM, 1992, PUBLIC HEALTH, V106, P131, DOI 10.1016/S0033-3506(05)80390-7; STATHAM H, 1993, BRIT MED J, V307, P174, DOI 10.1136/bmj.307.6897.174; WALD N, 1992, LANCET, V340, P494, DOI 10.1016/0140-6736(92)91822-P; 1994, GENETIC SCREENING ET	7	67	67	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					769	772		10.1136/bmj.309.6957.769	http://dx.doi.org/10.1136/bmj.309.6957.769			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950560	Green Published			2022-12-24	WOS:A1994PJ28200017
J	STRAUSS, JK; MAHER, LJ				STRAUSS, JK; MAHER, LJ			DNA BENDING BY ASYMMETRIC PHOSPHATE NEUTRALIZATION	SCIENCE			English	Article							INTRINSICALLY BENT DNA; CRYSTAL-STRUCTURE; OLIGODEOXYRIBONUCLEOSIDE METHYLPHOSPHONATES; GENE-EXPRESSION; PROTEIN; OLIGONUCLEOTIDES; CURVATURE; COMPLEX; FLEXIBILITY; ADENINE	DNA is often bent when complexed with proteins. Understanding the forces responsible for DNA bending would be of fundamental Value in exploring the interplay of these macromolecules. A series of experiments was devised to test the hypothesis that proteins with cationic surfaces can induce substantial DNA bending by neutralizing phosphates on one DNA face. Repulsions between phosphates in the remaining anionic helix are predicted to result in an unbalanced compression force acting to deform the DNA toward the protein. This hypothesis is supported by the results of electrophoretic experiments in which DNA spontaneously bends when one helical face is partially modified by incorporation of neutral phosphate analogs. Phasing with respect to a site of intrinsic DNA curvature (hexadeoxyadenylate tract) permits estimation of the electrostatic bend angle, and demonstrates that such modified DNAs are deformed toward the neutralized surface, as predicted. Similar model systems may be useful in exploring the extent to which phosphate neutralization can account for DNA bending by particular proteins.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOLEC BIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NCI NIH HHS [P30 CA36727-08] Funding Source: Medline; NIGMS NIH HHS [GM47814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; BOTFIELD MC, 1994, BIOCHEMISTRY-US, V33, P2349, DOI 10.1021/bi00175a001; BOWER M, 1987, NUCLEIC ACIDS RES, V15, P4915, DOI 10.1093/nar/15.12.4915; CALLAHAN L, 1986, P NATL ACAD SCI USA, V83, P1617, DOI 10.1073/pnas.83.6.1617; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P46; CROTHERS DM, 1993, CURR BIOL, V3, P675, DOI 10.1016/0960-9822(93)90065-V; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DRIPPS D, 1987, J BIOMOL STRUCT DYN, V5, P1; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HAMY F, 1993, J MOL BIOL, V230, P111, DOI 10.1006/jmbi.1993.1129; HAN F, 1990, NUCLEIC ACIDS RES, V18, P2759, DOI 10.1093/nar/18.9.2759; HODGESGARCIA Y, 1992, BIOCHEMISTRY-US, V31, P7595, DOI 10.1021/bi00148a022; HOGREFE RI, 1993, NUCLEIC ACIDS RES, V21, P2031, DOI 10.1093/nar/21.9.2031; IKEDA K, 1993, GENE, V136, P341; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KAN LS, 1980, BIOCHEMISTRY-US, V19, P2122, DOI 10.1021/bi00551a020; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; MAHER LJ, 1988, NUCLEIC ACIDS RES, V16, P3341, DOI 10.1093/nar/16.8.3341; MANNING GS, 1989, J BIOMOL STRUCT DYN, V6, P877, DOI 10.1080/07391102.1989.10506519; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MCGHEE JD, 1980, NUCLEIC ACIDS RES, V8, P2751, DOI 10.1093/nar/8.12.2751; MILLER PS, 1988, ANNU REP MED CHEM, V23, P295; MILLER PS, 1987, ANTI-CANCER DRUG DES, V2, P117; MILLER PS, 1990, HERPESVIRUSES IMMUNE, P343; NOBLE SA, 1984, NUCLEIC ACIDS RES, V12, P3387, DOI 10.1093/nar/12.7.3387; OLSON WK, 1993, J MOL BIOL, V232, P530, DOI 10.1006/jmbi.1993.1409; PIELES U, 1993, NUCLEIC ACIDS RES, V21, P3191, DOI 10.1093/nar/21.14.3191; RICE JA, 1989, BIOCHEMISTRY-US, V28, P4512, DOI 10.1021/bi00436a058; ROJO F, 1991, EMBO J, V10, P3429, DOI 10.1002/j.1460-2075.1991.tb04907.x; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; UHLMANN E, 1990, CHEM REV, V90, P544; WARWICKER J, 1987, PROTEINS, V2, P283, DOI 10.1002/prot.340020404; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	50	268	274	2	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1829	1834		10.1126/science.7997878	http://dx.doi.org/10.1126/science.7997878			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997878				2022-12-24	WOS:A1994PX38300027
J	BLAU, JN				BLAU, JN			MIGRAINE IN DOCTORS - WORK LOSS AND CONSUMPTION OF MEDICATION	LANCET			English	Editorial Material							HEADACHE				BLAU, JN (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							BOSANQUET N, 1992, BR J MED EC, V2, P82; HONKASALO ML, 1993, HEADACHE, V33, P403, DOI 10.1111/j.1526-4610.1993.hed3308403.x; Jarcho S, 1967, B N Y ACAD MED, V43, P1224; JONES A, 1980, J INT MED RES, V8, P321, DOI 10.1177/030006058000800503; LIPTON RB, 1993, NEUROLOGY, V43, P6; RASMUSSEN BK, 1991, HEADACHE, V31, P290, DOI 10.1111/j.1526-4610.1991.hed3105290.x	6	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1623	1624		10.1016/S0140-6736(94)90413-8	http://dx.doi.org/10.1016/S0140-6736(94)90413-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983999				2022-12-24	WOS:A1994PW05100016
J	CHANFREAU, G; JACQUIER, A				CHANFREAU, G; JACQUIER, A			CATALYTIC SITE COMPONENTS COMMON TO BOTH SPLICING STEPS OF A GROUP-II INTRON	SCIENCE			English	Article							RNA; SPLICEOSOME; MECHANISM; LARIAT	The splicing of group II introns occurs in two steps involving substrates with different chemical configurations. The question of whether these two steps are catalyzed by a single or two separate active sites is a matter of debate. Here, certain bases and phosphate oxygen atoms at conserved positions in domain V of a group II self-splicing intron are shown to be required for catalysis of both splicing steps. These results show that the active sites catalyzing the two steps must, at least, share common components, ruling out the existence of two completely distinct active sites in group II introns.	INST PASTEUR, DEPT BIOL MOLEC,UNITE GENET MOLEC LEVURES,CNRS, URA 1149, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				JACQUIER, ALAIN/0000-0001-5707-9184				BACHL J, 1990, J MOL BIOL, V212, P113, DOI 10.1016/0022-2836(90)90308-9; CHANFREAU G, UNPUB; CHRISTIAN EL, 1993, BIOCHEMISTRY-US, V32, P4475, DOI 10.1021/bi00068a001; CONWAY L, 1989, METHOD ENZYMOL, V180, P369; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KOCH JL, 1992, MOL CELL BIOL, V12, P1950, DOI 10.1128/MCB.12.5.1950; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; NILSEN T, COMMUNICATION; PEEBLES C, COMMUNICATION; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P2716, DOI 10.1021/bi00175a047; PYLE AM, COMMUNICATION; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SUH E, 1992, NUCLEIC ACIDS RES, V20, P6303, DOI 10.1093/nar/20.23.6303	18	114	118	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	1994	266	5189					1383	1387		10.1126/science.7973729	http://dx.doi.org/10.1126/science.7973729			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973729				2022-12-24	WOS:A1994PT63200044
J	GUTTMAN, DS; DYKHUIZEN, DE				GUTTMAN, DS; DYKHUIZEN, DE			CLONAL DIVERGENCE IN ESCHERICHIA-COLI AS A RESULT OF RECOMBINATION, NOT MUTATION	SCIENCE			English	Article							MOLECULAR EVOLUTION; NATURAL-POPULATIONS; BACTERIA; CHROMOSOME; SEQUENCES; BOOTSTRAP; DNA	Nucleotide sequence analysis was performed on 12 natural isolates of Escherichia coli in four loci located in close proximity on the chromosome. A comparison of gene genealogies indicated that three recombination events have occurred in a subset of the strains (ECOR group A) in the time since their divergence from a common ancestor, while during the same time, no mutational divergence has occurred. The common ancestor of this subset existed no more than 2400 years ago, and recombination was shown to occur at a rate of 5.0 x 10(-9) changes per nucleotide per generation-50-fold higher than the mutation rate. Thus, recombination has been the dominant force driving the clonal divergence of the ECOR group A strains and must be considered a significant factor in structuring E. coli populations.			GUTTMAN, DS (corresponding author), SUNY STONY BROOK,DEPT ECOL & EVOLUT,DIV BIOL SCI,STONY BROOK,NY 11794, USA.		Guttman, David S/A-7839-2011	Guttman, David S/0000-0001-8479-3869	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032454] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32454] Funding Source: Medline; NIGMS NIH HHS [GM3020] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Drake J. W, 1970, MOL BASIS MUTATION; DYKHUIZEN DE, 1991, J BACTERIOL, V173, P7257, DOI 10.1128/jb.173.22.7257-7268.1991; DYKHUIZEN DE, UNPUB; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; GUTTMAN DS, IN PRESS GENETICS; HERZER PJ, 1990, J BACTERIOL, V172, P6175, DOI 10.1128/jb.172.11.6175-6181.1990; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUDSON RR, 1987, GENET RES, V50, P245, DOI 10.1017/S0016672300023776; HUDSON RR, 1985, GENETICS, V111, P147; LAWRENCE JG, 1992, GENETICS, V131, P753; LAWRENCE JG, 1992, GENETICS, V131, P9; MARGOLIN P, 1987, ESCHERICHIA COLI SAL, V2, P1154; MILKMAN R, 1988, GENETICS, V120, P359; MILKMAN R, 1990, GENETICS, V126, P505; MILKMAN R, 1993, GENETICS, V133, P455; OCHMAN H, 1984, J BACTERIOL, V157, P690, DOI 10.1128/JB.157.2.690-693.1984; RUDD KE, 1992, SHORT COURSE BACTERI; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SELANDER RK, 1987, ESCHERICHIA COLI SAL, V2, P1625; SMITH JM, 1993, P NATL ACAD SCI USA, V90, P4384, DOI 10.1073/pnas.90.10.4384; Swofford D. L., 1993, ILLINOIS NATURAL HIS; VALDES AM, 1992, EVOLUTION, V46, P641, DOI 10.1111/j.1558-5646.1992.tb02072.x; WHITTAM TS, 1983, P NATL ACAD SCI-BIOL, V80, P1751, DOI 10.1073/pnas.80.6.1751; WHITTAM TS, 1993, MECHANISMS OF MOLECULAR EVOLUTION, P223; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; WOESE CR, 1980, NATURE, V283, P212, DOI 10.1038/283212a0	26	322	329	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1380	1383		10.1126/science.7973728	http://dx.doi.org/10.1126/science.7973728			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973728				2022-12-24	WOS:A1994PT63200043
J	FLETCHER, RH; FLETCHER, SW				FLETCHER, RH; FLETCHER, SW			GLUTATHIONE AND AGING - IDEAS AND EVIDENCE	LANCET			English	Editorial Material									HARVARD UNIV,COMMUNITY HLTH PLAN,BOSTON,MA	Harvard University	FLETCHER, RH (corresponding author), HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA, USA.							BUCK C, 1975, INT J EPIDEMIOL, V4, P159, DOI 10.1093/ije/4.3.159; DATTA M, 1993, LANCET, V342, P345, DOI 10.1016/0140-6736(93)91478-5; JULIUS M, 1994, J CLIN EPIDEMIOL, V47, P1021, DOI 10.1016/0895-4356(94)90117-1; LANG CA, 1992, J LAB CLIN MED, V120, P720; LOCK S, 1994, ANN INTERN MED, V121, P60, DOI 10.7326/0003-4819-121-1-199407010-00012; MACLURE M, 1985, AM J EPIDEMIOL, V121, P35; TUKEY JW, 1977, SCIENCE, V198, P679, DOI 10.1126/science.333584	7	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1379	1380		10.1016/S0140-6736(94)90562-2	http://dx.doi.org/10.1016/S0140-6736(94)90562-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968069				2022-12-24	WOS:A1994PR78600003
J	IRVINE, KD; WIESCHAUS, E				IRVINE, KD; WIESCHAUS, E			FRINGE, A BOUNDARY-SPECIFIC SIGNALING MOLECULE, MEDIATES INTERACTIONS BETWEEN DORSAL AND VENTRAL CELLS DURING DROSOPHILA WING DEVELOPMENT	CELL			English	Article							PATTERN-FORMATION; IMAGINAL DISKS; HEDGEHOG GENE; MELANOGASTER; REGENERATION; TRANSCRIPTION; EXPRESSION; PROTEIN; FIELDS	Wing formation in Drosophila requires interactions between dorsal and ventral cells. We describe a new gene, fringe, which is expressed in dorsal cells and encodes for a novel protein that is predicted to be secreted. Wing margin formation and distal wing outgrowth can be induced by the juxtaposition of cells with and without fringe expression, whether at the normal wing margin, at the boundaries of fringe mutant clones in the dorsal wing, or at sites of fringe misexpression in the ventral wing. By contrast, both loss of fringe expression and uniform fringe expression cause wing loss. These observations suggest that fringe encodes a boundary-specific cell-signaling molecule that is responsible for dorsal-ventral cell interactions during wing development.			IRVINE, KD (corresponding author), PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022780] Funding Source: NIH RePORTER; NICHD NIH HHS [5R01HD22780] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAKER NE, 1988, DEVELOPMENT, V102, P489; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; BRYANT PJ, 1975, J EXP ZOOL, V193, P49, DOI 10.1002/jez.1401930106; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; BUTTERWORTH FM, 1965, GENETICS, V52, P1153; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COHEN SM, 1993, DEV DROSOPHILA MELAN, P474; COUSO JP, 1994, DEVELOPMENT, V120, P621; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GELBART WM, 1989, DEVELOPMENT, V107, P65; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; HAYNIE JL, 1976, NATURE, V259, P659, DOI 10.1038/259659b0; IRVINE KD, 1991, DEVELOPMENT, V111, P407; KARLSSON J, 1980, J EMBRYOL EXP MORPH, V59, P315; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEHMANN R, 1985, THESIS U TUBINGEN TU; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MEINHARDT H, 1982, DEV ORDER ITS ORIGIN, P439; MOHLER J, 1992, DEVELOPMENT, V115, P957; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; ROBERTSON HM, 1988, GENETICS, V118, P461; STEVENS ME, 1986, DEV BIOL, V117, P326, DOI 10.1016/0012-1606(86)90375-1; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILCOX M, 1980, ROUX ARCH DEV BIOL, V188, P157, DOI 10.1007/BF00848808; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; WILLIAMS JA, 1993, BIOESSAYS, V15, P567, DOI 10.1002/bies.950150902; XU T, 1993, DEVELOPMENT, V117, P1223	41	296	303	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 18	1994	79	4					595	606		10.1016/0092-8674(94)90545-2	http://dx.doi.org/10.1016/0092-8674(94)90545-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954826				2022-12-24	WOS:A1994PT48100007
J	MOSBACHER, J; SCHOEPFER, R; MONYER, H; BURNASHEV, N; SEEBURG, PH; RUPPERSBERG, JP				MOSBACHER, J; SCHOEPFER, R; MONYER, H; BURNASHEV, N; SEEBURG, PH; RUPPERSBERG, JP			A MOLECULAR DETERMINANT FOR SUBMILLISECOND DESENSITIZATION IN GLUTAMATE RECEPTORS	SCIENCE			English	Article							AMPA-KAINATE RECEPTORS; RAT HIPPOCAMPAL SLICES; SYNAPTIC TRANSMISSION; OPERATED CHANNELS; ION FLOW; PERMEABILITY; SUBUNITS; NEURONS; CELLS; CURRENTS	The decay of excitatory postsynaptic currents in central neurons mediated by alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors is likely to be shaped either by receptor desensitization or by offset after removal of glutamate from the synaptic cleft. Native AMPA receptors show desensitization time constants of 1 to about 10 milliseconds, but the underlying molecular determinants of these large differences are unknown. Cloned AMPA receptors carrying the ''flop'' splice variants of glutamate receptor subtype C (GluR-C) and GluR-D are shown to have desensitization time constants of around 1 millisecond, whereas those with the ''flip'' variants are about four ti mes slower. Cerebellar granule cells switch their expression of GluR-D splice variants from mostly flip forms in early stages to predominantly flop forms in the adult rat brain. These findings suggest that rapid desensitization of AM PA receptors can be regulated by the expression and alternative splicing of GluR-D gene transcripts.	UNIV TUBINGEN,EAR NOSE & THROAT HOSP,DEPT SENSORY BIOPHYS,D-72076 TUBINGEN,GERMANY; MAX PLANCK INST MED RES,D-69028 HEIDELBERG,GERMANY; UNIV LONDON UNIV COLL,DEPT PHARMACOL,WELLCOME LAB MOLEC PHARMACOL,LONDON WC1E 6BT,ENGLAND; UNIV HEIDELBERG,CTR BIOL MOLEC,D-69120 HEIDELBERG,GERMANY	Eberhard Karls University of Tubingen; Max Planck Society; University of London; University College London; Ruprecht Karls University Heidelberg			Burnashev, Nail/G-4056-2013	Monyer, Hannah/0000-0002-9332-5749	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; BOCHET P, 1994, NEURON, V12, P383, DOI 10.1016/0896-6273(94)90279-8; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; BURNASHEV N, 1993, CELL PHYSIOL BIOCHEM, V3, P318, DOI 10.1159/000154696; BURNASHEV N, 1992, SCIENCE, V256, P1566, DOI 10.1126/science.1317970; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; DUDEL J, 1987, NEUROSCI LETT, V77, P199; Edmonds B., 1993, Society for Neuroscience Abstracts, V19, P1515; GALLO V, 1992, J NEUROSCI, V12, P1010; HACKETT JT, 1982, NEUROSCIENCE, V7, P1455, DOI 10.1016/0306-4522(82)90257-3; HERLITZE S, 1993, NEURON, V10, P1131, DOI 10.1016/0896-6273(93)90061-U; HESTRIN S, 1993, NEURON, V11, P1083, DOI 10.1016/0896-6273(93)90221-C; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JONAS P, 1992, J PHYSIOL-LONDON, V455, P143, DOI 10.1113/jphysiol.1992.sp019294; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; RAMAN IM, 1992, NEURON, V9, P173, DOI 10.1016/0896-6273(92)90232-3; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VYKLICKY L, 1991, NEURON, V7, P971, DOI 10.1016/0896-6273(91)90342-W	27	485	491	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1059	1062		10.1126/science.7973663	http://dx.doi.org/10.1126/science.7973663			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973663				2022-12-24	WOS:A1994PQ92400050
J	ENQUIST, M; ARAK, A				ENQUIST, M; ARAK, A			SYMMETRY, BEAUTY AND EVOLUTION	NATURE			English	Article								HUMANS and certain other species find symmetrical patterns more attractive than asymmetrical ones. These preferences may appear in response to biological signals(1-3), or in situations where there is no obvious signalling context, such as exploratory behaviour(4,5) and human aesthetic response to pattern(6-8). It has been proposed(9,10) that preferences for symmetry have evolved in animals because the degree of symmetry in signals indicates the signaller's quality. By contrast, we show here that symmetry preferences may arise as a by-product of the need to recognize objects irrespective of their position and orientation in the visual field. The existence of sensory biases for symmetry may have been exploited independently by natural selection acting on biological signals and by human artistic innovation. This may account for the observed convergence on symmetrical forms in nature and decorative art(11).	ARCHWAY ENGN UK LTD,ELLAND HX5 9JP,W YORKSHIRE,ENGLAND		ENQUIST, M (corresponding author), UNIV STOCKHOLM,DEPT ZOOL,S-10691 STOCKHOLM,SWEDEN.							ARAK A, 1993, PHILOS T R SOC B, V340, P207, DOI 10.1098/rstb.1993.0059; Berlyne D. E., 1971, AESTHETICS PSYCHOBIO; BROOKES M, 1994, TRENDS ECOL EVOL, V9, P201, DOI 10.1016/0169-5347(94)90241-0; Cronly-Dillon J., 1991, EVOLUTION EYE VISUAL; Darwin C., 1872, EXPRESS EMOT MAN, DOI [10.1037/h0076058, DOI 10.1037/10001-000]; DEREFELDT G, 1991, PERCEPTION COLOUR, P218; DOLL TJ, 1967, J EXP PSYCHOL, V75, P508, DOI 10.1037/h0025116; ENQUIST M, 1993, NATURE, V361, P446, DOI 10.1038/361446a0; GOMBRICH EH, 1984, SENSE ORDER; HUBBELL MB, 1940, AM J PSYCHOL, V53, P46; LEIMAR O, 1986, AM NAT, V128, P469, DOI 10.1086/284581; Mackintosh N. J., 1974, PSYCHOL ANIMAL LEARN; MOLLER AP, 1992, NATURE, V357, P238, DOI 10.1038/357238a0; MUSINGER H, 1964, PSYCHOL MONOGR, V9, P1; RADESATER T, 1993, ANIM BEHAV, V45, P626, DOI 10.1006/anbe.1993.1075; Rensch B., 1957, Zeitschrift fuer Tierpsychologie, V14, P71; Rensch B., 1958, Zeitschrift fuer Tierpsychologie, V15, P447; RYAN MJ, 1991, OXFORD SURVEYS EVOLU, V7, P156; STADDON JER, 1975, AM NAT, V109, P541, DOI 10.1086/283025; Stewart I., 1993, FEARFUL SYMMETRY IS; SWADDLE JP, 1994, NATURE, V367, P165, DOI 10.1038/367165a0; Tinbergen, 1951, STUDY INSTINCT; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; Wallace AR, 1889, DARWINISM EXPOSITION; WATSON PJ, 1994, TRENDS ECOL EVOL, V9, P21, DOI 10.1016/0169-5347(94)90227-5	25	297	301	4	94	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					169	172		10.1038/372169a0	http://dx.doi.org/10.1038/372169a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969448				2022-12-24	WOS:A1994PQ68800053
J	CHEN, ZW; KOH, M; VANDRIESSCHE, G; VANBEEUMEN, JJ; BARTSCH, RG; MEYER, TE; CUSANOVICH, MA; MATHEWS, FS				CHEN, ZW; KOH, M; VANDRIESSCHE, G; VANBEEUMEN, JJ; BARTSCH, RG; MEYER, TE; CUSANOVICH, MA; MATHEWS, FS			THE STRUCTURE OF FLAVOCYTOCHROME-C SULFIDE DEHYDROGENASE FROM A PURPLE PHOTOTROPHIC BACTERIUM	SCIENCE			English	Article							CHROMATIUM-VINOSUM; SEQUENCE; FLAVIN; FLAVOPROTEIN; KINETICS; SUBUNIT	The structure of the heterodimeric flavocytochrome c sulfide dehydrogenase from Chromatium vinosum was determined at a resolution of 2.53 angstroms. It contains a glutathione reductase-like flavin-binding subunit and a diheme cytochrome subunit. The diheme cytochrome folds as two domains, each resembling mitochondrial cytochrome c, and has an unusual interpropionic acid linkage joining the two heme groups in the interior of the subunit. The active site of the flavoprotein subunit contains a catalytically important disulfide bridge located above the pyrimidine portion of the flavin ring. A tryptophan, threonine, or tyrosine side chain may provide a partial conduit for electron transfer to one of the heme groups located 10 angstroms from the flavin.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; STATE UNIV GHENT,DEPT BIOCHEM PHYSIOL & MICROBIOL,B-9000 GHENT,BELGIUM; UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721	Washington University (WUSTL); Ghent University; University of Arizona					NIGMS NIH HHS [GM-21277, GM-20530] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021277] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cusanovich M, 1991, CHEM BIOCH FLAVOENZY, V2, P377; CUSANOVICH MA, 1985, BIOCHEMISTRY-US, V24, P1281, DOI 10.1021/bi00327a002; DOLATA MM, 1993, J BIOL CHEM, V268, P14426; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; KENNEY WC, 1974, EUR J BIOCHEM, V48, P449, DOI 10.1111/j.1432-1033.1974.tb03785.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MATHEWS FS, 1990, BIOCHEMISTRY-US, V31, P238; MEYER TE, 1991, BIOCHEMISTRY-US, V30, P8840, DOI 10.1021/bi00100a016; MEYER TE, 1991, ARCH BIOCHEM BIOPHYS, V287, P128, DOI 10.1016/0003-9861(91)90397-2; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; REGAN J, 1993, PATHWAYS, V2; Roussel A, 1991, SILICON GRAPHICS GEO, P86; SALEMME FR, 1982, J MOL BIOL, V159, P551, DOI 10.1016/0022-2836(82)90302-3; SCHULZ GE, 1978, NATURE, V273, P120, DOI 10.1038/273120a0; VANBEEUMAN JJ, UNPUB; VANBEEUMEN JJ, 1991, J BIOL CHEM, V266, P12921; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	19	126	133	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					430	432		10.1126/science.7939681	http://dx.doi.org/10.1126/science.7939681			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939681				2022-12-24	WOS:A1994PN27200033
J	HABRAKEN, Y; SUNG, P; PRAKASH, L; PRAKASH, S				HABRAKEN, Y; SUNG, P; PRAKASH, L; PRAKASH, S			HOLIDAY JUNCTION CLEAVAGE BY YEAST RAD1 PROTEIN	NATURE			English	Article							DNA-REPAIR; ESCHERICHIA-COLI; HOLLIDAY JUNCTIONS; ENDONUCLEASE; RESOLUTION	IN Saccharomyces cerevisiae, of the many genes required for excision repair of ultraviolet-damaged DNA, only RAD1 and RAD10 also function in genetic recombination(1). Complex formation between the RAD1 and RAD10 gene products(1) activates an endonucleolytic function that nicks single-stranded DNA(2,3) and negatively supercoiled double-stranded DNA(2). To characterize the recombination role of the proteins Rad1 and Rad10, we have investigated their interaction with the Holliday junction, a four-stranded structure that results from single-stranded crossover between two duplex DNA molecules and whose resolution is obligatory for the generation of mature recombinants. We show that Rad1 binds specifically to a Holliday junction and, in the presence of magnesium, catalyses the endonucleolytic cleavage of the junction. Junction cleavage by Rad1 proceeds sufficiently without Rad10, thus identifying Rad1 as the catalytic subunit of Rad1/Rad10 endonuclease.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444				BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; Egel R., 1989, MOL BIOL FISSION YEA, P31; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; RODEL C, 1992, NUCLEIC ACIDS RES, V20, P6347, DOI 10.1093/nar/20.23.6347; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1992, NATURE, V355, P743, DOI 10.1038/355743a0; TAYLOR AF, 1992, CELL, V69, P1063, DOI 10.1016/0092-8674(92)90626-N; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757	13	41	42	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					531	534		10.1038/371531a0	http://dx.doi.org/10.1038/371531a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935767				2022-12-24	WOS:A1994PK58900060
J	JONES, G; NGUYEN, T; SAMBROOK, P; KELLY, PJ; EISMAN, JA				JONES, G; NGUYEN, T; SAMBROOK, P; KELLY, PJ; EISMAN, JA			PROGRESSIVE LOSS OF BONE IN THE FEMORAL-NECK IN ELDERLY PEOPLE - LONGITUDINAL FINDINGS FROM THE DUBBO OSTEOPOROSIS EPIDEMIOLOGY STUDY	BRITISH MEDICAL JOURNAL			English	Article							MINERAL DENSITY; POSTMENOPAUSAL WOMEN; CIGARETTE-SMOKING; DIETARY-INTAKE; AGE; MEN; CALCIUM; SPINE; MASS; FRACTURES	Objectives-To determine prospectively the rates of change in bone mineral density in elderly people and to examine the relation between lifestyle and demographic factors and these rates of change. Design-Longitudinal population based study. Setting-Dubbo, New South Wales, Australia. Subjects-Representative sample (n = 769) of residents aged greater than or equal to 60 on 1 January 1989. Main outcome measure-Rates of change in bone mineral density measured prospectively (mean scan interval 2.5 years) at the femoral neck and lumbar spine by dual energy x ray absorptiometry. Results-Summary rates of loss in the femoral neck were 0.96% per year (95% confidence interval 0.64% to 1.28%) in women and 0.82% per year (0.52% to 1.12%) in men. Importantly, rates of loss at the femoral neck (both percentage and absolute) increased in both sexes with advancing age. No significant loss was evident in either sex at the lumbar spine, probably because of coexistent osteoarthritis. Lifestyle factors had only modest effects on rates of loss at either site. Conclusions-These data show that bone density of the femoral neck declines at an increasing rate in elderly people, and as this site is predictive of fracture suggest that treatment to minimise bone loss may be important even in very elderly people.	ST VINCENTS HOSP,GARVAN INST MED RES,DIV BONE & MINERAL,DARLINGHURST,NSW 2010,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney			Nguyen, Tuan V/B-6147-2008; Nguyen, Tuan V./AAD-9503-2020; Eisman, John A/C-2886-2014	Nguyen, Tuan V/0000-0002-3246-6281; Nguyen, Tuan V./0000-0002-3246-6281; 				ALOIA JF, 1985, AM J MED, V78, P95, DOI 10.1016/0002-9343(85)90468-1; ANGUS RM, 1988, BONE MINER, V4, P265; BROWNER WS, 1991, LANCET, V338, P355, DOI 10.1016/0140-6736(91)90489-C; CHRISTIANSEN C, 1987, Lancet, V1, P1105; CUMMING RG, 1990, CALCIFIED TISSUE INT, V47, P194; DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298; DAVIS JW, 1989, J BONE MINER RES, V4, P351; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; GOTFREDSEN A, 1987, J LAB CLIN MED, V110, P362; HANNAN MT, 1992, J BONE MINER RES, V7, P547; HEANEY RP, 1986, BONE MINER, V1, P99; Hui S L, 1990, Osteoporos Int, V1, P30, DOI 10.1007/BF01880413; HUI SL, 1982, J CHRON DIS, V35, P715, DOI 10.1016/0021-9681(82)90095-9; JONES G, 1994, OSTEOPOROSIS INT, V4, P273; KELLY PJ, 1993, J BONE MINER RES, V8, P11; KRALL EA, 1991, J BONE MINER RES, V6, P331; KROLNER B, 1982, CLIN SCI, V62, P329, DOI 10.1042/cs0620329; LORD SR, 1991, J GERONTOL, V46, pM57; MASAUD T, 1993, BRIT MED J, V307, P172; MAZESS RB, 1987, BONE MINER, V2, P211; MAZESS RB, 1990, J BONE MINER RES, V5, P645; MAZESS RB, 1991, AM J CLIN NUTR, V53, P132, DOI 10.1093/ajcn/53.1.132; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; Myers R., 1990, CLASSICAL MODERN REG; NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111; NGUYEN T, 1994, IN PRESS J BONE MINE; ORWOLL ES, 1990, J CLIN ENDOCR METAB, V70, P1202, DOI 10.1210/jcem-70-4-1202; POCOCK NA, 1989, BONE, V10, P329, DOI 10.1016/8756-3282(89)90128-2; RIGGS BL, 1981, J CLIN INVEST, V67, P328, DOI 10.1172/JCI110039; RIGGS BL, 1986, J CLIN INVEST, V77, P1487, DOI 10.1172/JCI112462; SAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404; SAMBROOK PN, 1987, J BONE MINER RES, V2, P109; SIMONS LA, 1990, AUST NZ J MED, V20, P783, DOI 10.1111/j.1445-5994.1990.tb00423.x; SLEMENDA CW, 1992, ANN INTERN MED, V117, P286, DOI 10.7326/0003-4819-117-4-286; SLEMENDA CW, 1989, J BONE MINER RES, V4, P737, DOI 10.1002/jbmr.5650040513; STEIGER P, 1992, J BONE MINER RES, V7, P625; VANHEMERT AM, 1990, J CLIN EPIDEMIOL, V43, P579, DOI 10.1016/0895-4356(90)90162-I; 1990, SAS USERS GUIDES STA	39	358	366	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					691	695		10.1136/bmj.309.6956.691	http://dx.doi.org/10.1136/bmj.309.6956.691			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7950520	Green Published			2022-12-24	WOS:A1994PH40700013
J	ALLAND, D; KALKUT, GE; MOSS, AR; MCADAM, RA; HAHN, JA; BOSWORTH, W; DRUCKER, E; BLOOM, BR				ALLAND, D; KALKUT, GE; MOSS, AR; MCADAM, RA; HAHN, JA; BOSWORTH, W; DRUCKER, E; BLOOM, BR			TRANSMISSION OF TUBERCULOSIS IN NEW-YORK-CITY - AN ANALYSIS BY DNA-FINGERPRINTING AND CONVENTIONAL EPIDEMIOLOGIC METHODS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MYCOBACTERIUM-TUBERCULOSIS; COMPLEX STRAINS; INFECTION; OUTBREAK; HOMELESS; SHELTER; RISK; TOOL	Background. The incidence of tuberculosis and drug resistance is increasing in the United States, but it is not clear how much of the increase is due to reactivation of latent infection and how much to recent transmission. Methods. We performed DNA fingerprinting using restriction-fragment-length polymorphism (RFLP) analysis of at least one isolate from every patient with confirmed tuberculosis at a major hospital in the Bronx, New York, from December 1, 1989, through December 31, 1992. Medical records and census-tract data were reviewed for relevant clinical, social, and demographic data. Results. Of 130 patients with tuberculosis, 104 adults (80 percent) had complete medical records and isolates whose DNA fingerprints could be evaluated. Isolates from 65 patients (62.5 percent) had unique RFLP patterns, whereas isolates from 39 patients (37.5 percent) had RFLP patterns that were identical to those of an isolate from at least 1 other study patient; the isolates in the latter group were classified into 12 clusters. Patients whose isolates were included in one of the clusters were inferred to have recently transmitted disease. Independent risk factors for having a clustered isolate included seropositivity for the human immunodeficiency virus (HIV) (odds ratio for Hispanic patients, 4.31; P = 0.02; for non-Hispanic patients, 3.12; P = 0.07), Hispanic ethnicity combined with HIV seronegativity (odds ratio, 5.13; P = 0.05), infection with drug-resistant tuberculosis (odds ratio, 4.52; P = 0.005), and younger age (odds ratio, 1.59; P = 0.02). Residence in sections of the Bronx with a median household income below $20,000 was also associated with having a clustered isolate (odds ratio, 3.22; P = 0.04). Conclusions. In the inner-city community we studied, recently transmitted tuberculosis accounts for approximately 40 percent of the incident cases and almost two thirds of drug-resistant cases. Recent transmission of tuberculosis, and not only reactivation of latent disease, contributes substantially to the increase in tuberculosis.	MONTEFIORE MED CTR,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10467; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,DIV EPIDEMIOL & MED,SAN FRANCISCO,CA 94110; CUNY HERBERT H LEHMAN COLL,DEPT POLIT SCI,BRONX,NY 10468	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; City University of New York (CUNY) System; Lehman College (CUNY)	ALLAND, D (corresponding author), MONTEFIORE MED CTR,N CENT BRONX HOSP,DEPT MED,DIV INFECT DIS,111 E 210 ST,BRONX,NY 10467, USA.		Hahn, Judith/J-5813-2014	Hahn, Judith/0000-0002-2697-8264; Kalkut, Gary/0000-0002-6160-2262	NCI NIH HHS [2T32CA09173-16] Funding Source: Medline; NIAID NIH HHS [T32AI07183-13, T32AI07183-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007183] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DOBKIN J, 1993, 9 INT C AIDS JUN 6 1, P324; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1993, NEW ENGL J MED, V329, P148; HERMANS PWM, 1991, INFECT IMMUN, V59, P2695, DOI 10.1128/IAI.59.8.2695-2705.1991; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; Hewlett D. Jr., 1993, Morbidity and Mortality Weekly Report, V42, P427; Kent PT, 1985, GUIDE LEVEL 3 LAB; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NARDELL EA, 1993, AM REV RESPIR DIS, V148, P2, DOI 10.1164/ajrccm/148.1.2; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; STYBLO K, 1984, EPIDEMIOLOGY TUBERCU; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; 1990, MMWR-MORBID MORTAL W, V39, P1; 1992, AM REV RESPIR DIS, V146, P1623; 1993, TUBERCULOSIS NEW YOR; 1990, MMWR-MORBID MORTAL W, V39, P9; 1991, MMWR-MORBID MORTAL W, V40, P585; 1992, TUBERCULOSIS NEW YOR; 1993, MMWR-MORBID MORTAL W, V42, P696; 1993, MMWR-MORBID MORTAL W, V42, P703	28	760	779	1	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	1994	330	24					1710	1716		10.1056/NEJM199406163302403	http://dx.doi.org/10.1056/NEJM199406163302403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR109	7993412	Bronze			2022-12-24	WOS:A1994NR10900003
J	CAO, XY; JIANG, XM; DOU, ZH; RAKEMAN, MA; ZHANG, ML; ODONNELL, K; MA, T; AMETTE, K; DELONG, N; DELONG, GR				CAO, XY; JIANG, XM; DOU, ZH; RAKEMAN, MA; ZHANG, ML; ODONNELL, K; MA, T; AMETTE, K; DELONG, N; DELONG, GR			TIMING OF VULNERABILITY OF THE BRAIN TO IODINE DEFICIENCY IN ENDEMIC CRETINISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IODIZED OIL; PREGNANCY; SUPPLEMENTATION; DISORDER	Background. Endemic cretinism, caused by severe iodine deficiency during pregnancy, is the world's most common preventable cause of mental retardation. It can be prevented by iodine treatment before conception, but whether it can be prevented or ameliorated by treatment during pregnancy or after delivery is not known. Methods. In a severely iodine-deficient area of the Xinjiang region of China, we systematically administered iodine to groups of children from birth to three years of age (n = 689) and women at each trimester of pregnancy (n = 295); we then followed the treated children and the babies born to the treated women for two years. We used three independent measures of neural development: the results of the neurologic examination, the head circumference (which correlates with brain weight in the first postnatal year), and indexes of cognitive and motor development. Untreated children one to three years of age, who were studied when first seen, served as control subjects. Results. The prevalence of moderate or severe neurologic abnormalities among the 120 infants whose mothers received iodine in the first or second trimester was 2 percent, as compared with 9 percent among the 752 infants who received iodine during the third trimester (through the treatment of their mothers) or after birth (P = 0.008). The prevalence of microcephaly (defined as a head circumference more than 3 SD below U.S. norms) decreased from 27 percent in the untreated children to 11 percent in the treated children (P = 0.006), and the mean (+/-SD) developmental quotient at two years of age increased (90 +/- 14, vs. 75 +/- 18 in the untreated children; P < 0.001). Treatment in the third trimester of pregnancy or after delivery did not improve neurologic status, but head growth and developmental quotients improved slightly. Treatment during the first trimester, which was technically problematic, improved the neurologic outcome. Conclusions. Up to the end of the second trimester, iodine treatment protects the fetal brain from the effects of iodine deficiency. Treatment later in pregnancy or after delivery may improve brain growth and developmental achievement slightly, but it does not improve neurologic status.	DUKE UNIV,MED CTR,DIV PEDIAT NEUROL,DURHAM,NC 27710; TIANJIN MED COLL,TIANJIN,PEOPLES R CHINA; XINJIANG ANTIEPIDEM & HLTH STN,URUMQI,PEOPLES R CHINA; INST ENDEM DIS RES,URUMQI,PEOPLES R CHINA	Duke University; Tianjin Medical University								Bayley N., 1969, BAYLEY SCALES INFANT; Bleichrodt N., 1989, IODINE BRAIN, P269; BOYAGES SC, 1989, MED J AUSTRALIA, V150, P676, DOI 10.5694/j.1326-5377.1989.tb136760.x; CAO XY, 1994, LANCET, V344, P107, DOI 10.1016/S0140-6736(94)91286-6; CHOUFOER JC, 1965, J CLIN ENDOCR METAB, V25, P385, DOI 10.1210/jcem-25-3-385; DEESCOBAR GM, 1993, AM J CLIN NUTR, V57, pS280; DELONG GR, 1985, DEV MED CHILD NEUROL, V27, P317; DOBBING J, 1974, SCI F PAEDIATRICS, P565; DUNN JT, 1993, ANN NY ACAD SCI, V678, P158; EAYRS JT, 1960, BRIT MED BULL, V16, P122, DOI 10.1093/oxfordjournals.bmb.a069810; GILLES FH, 1983, DEV HUMAN BRAIN GROW, P58; GLINOER D, 1990, J CLIN ENDOCR METAB, V71, P276, DOI 10.1210/jcem-71-2-276; HALPERN JP, 1991, BRAIN, V114, P825, DOI 10.1093/brain/114.2.825; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HETZEL BS, 1989, J NUTR, V119, P145, DOI 10.1093/jn/119.2.145; KOCHUPILLAI N, 1986, IODINE NUTR THYROXIN, P87; Legrand J, 1984, NEUROBEHAVIORAL TERA, P331; LIU JL, 1989, IODINE BRAIN, P249; MA T, 1993, ANN NEUROL, V34, P91, DOI 10.1002/ana.410340116; Ma T., 1989, IODINE BRAIN, P259, DOI 10.1007/978-1-4613-0765-5_24; MANO MT, 1989, ACTA ENDOCRINOL-COP, V121, P7, DOI 10.1530/acta.0.1210007; McCarrison R, 1908, LANCET, V2, P1275; Pharoah P O, 1972, Adv Exp Med Biol, V30, P201; PHAROAH POD, 1991, ARCH DIS CHILD, V66, P145, DOI 10.1136/adc.66.1.145; PHAROAH POD, 1971, LANCET, V1, P308; TONGLET R, 1992, NEW ENGL J MED, V326, P236, DOI 10.1056/NEJM199201233260405; WEINBERG WA, 1974, J PEDIATR-US, V85, P482, DOI 10.1016/S0022-3476(74)80449-X; 1981, LANCET, V2, P1095; [No title captured]	29	274	293	1	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	1994	331	26					1739	1744		10.1056/NEJM199412293312603	http://dx.doi.org/10.1056/NEJM199412293312603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ266	7984194	Bronze			2022-12-24	WOS:A1994PZ26600003
J	PANKRATZ, L; JACKSON, J				PANKRATZ, L; JACKSON, J			HABITUALLY WANDERING PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POPULATION; SERVICES; CARE	Background. Physicians are sometimes confronted with patients who gain admission to one hospital after another, sometimes referred to as ''wandering patients.'' Little is known about the presenting symptoms of these patients, their use of hospital resources, or the costs of their medical care, We analyzed the demographic and clinical characteristics of wandering patients served by Department of Veterans Affairs medical centers (VAMCs), Methods. For each patient they admit, all 159 hospitals in the Veterans Affairs medical system submit demographic and diagnostic information to a central data base at the Data Processing Center in Austin, Texas, We searched these records to identify patients who were admitted to four or more VAMCs within each year from fiscal year 1988 through 1992. Patients so identified in any one year were called ''wanderers''; those identified in all five years were designated ''habitual wanderers, Results. We identified 1013 wanderers in 1988. The number gradually declined each year to 729 in 1992, In 1991 there were 810 wandering patients, who averaged about eight admissions per year and more than 100 days of inpatient care; they accounted for about $26.5 million in costs for inpatient and outpatient care in that year. Only 35 patients wandered in all five years from 1988 through 1992. The most common discharge diagnoses of these 35 men were related to substance abuse (mostly alcoholism) and mental disorders. Their 2268 admissions and 7832 outpatient visits cost an estimated $6.5 million over the five-year period. Conclusions. Patients who are repeatedly admitted to different hospitals - wandering patients - accumulate high numbers of admissions, cause diagnostic confusion, and receive uncoordinated care. Because of the complexity of their disorders, such patients require case management on a regional or national basis.	OREGON HLTH SCI UNIV,DEPT PSYCHIAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PSYCHOL MED,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University	PANKRATZ, L (corresponding author), VET AFFAIRS MED CTR,PSYCHOL SERV 116B,POB 1034,PORTLAND,OR 97207, USA.							ANDERSON GF, 1984, NEW ENGL J MED, V311, P1349, DOI 10.1056/NEJM198411223112105; BUCKLEY R, 1992, COMMUNITY MENT HLT J, V28, P43, DOI 10.1007/BF00756701; CATON CLM, 1981, HOSP COMMUNITY PSYCH, V32, P475; DRAKE RE, 1992, COMMUNITY MENT HLT J, V28, P5, DOI 10.1007/BF00756697; Durance P W, 1992, J Ment Health Adm, V19, P178, DOI 10.1007/BF02521318; FINK P, 1993, GEN HOSP PSYCHIAT, V15, P211, DOI 10.1016/0163-8343(93)90035-M; GELLER JL, 1992, AM J PSYCHIAT, V149, P1526; GELLER JL, 1992, HOSP COMMUNITY PSYCH, V43, P904; Gordon R E, 1975, J Fla Med Assoc, V62, P21; Gordon R E, 1973, JFMA, V60, P27; Hadley T R, 1990, Psychiatr Q, V61, P41, DOI 10.1007/BF01065163; McLean E K, 1990, Int J Soc Psychiatry, V36, P172, DOI 10.1177/002076409003600302; MECHANIC D, 1987, NEW ENGL J MED, V317, P1634, DOI 10.1056/NEJM198712243172605; PANKRATZ L, 1989, DRUG ALCOHOL DEPEN, V24, P115, DOI 10.1016/0376-8716(89)90073-2; PANKRATZ L, 1978, J OPER PSYCHIATR, V9, P42; PANKRATZ L, 1989, PERSPECT HEALTHCARE, V9, P5; PEPPER B, 1981, HOSP COMMUNITY PSYCH, V32, P463; ROSENHECK R, 1993, SCHIZOPHRENIA BULL, V19, P843, DOI 10.1093/schbul/19.4.843; SCHWARTZ SR, 1981, HOSP COMMUNITY PSYCH, V32, P470; SPARR L, 1983, AM J PSYCHIAT, V140, P1016; SURLES RC, 1987, HOSP COMMUNITY PSYCH, V38, P401; VICTOR CR, 1989, BRIT MED J, V299, P725, DOI 10.1136/bmj.299.6701.725	22	25	26	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	1994	331	26					1752	1755		10.1056/NEJM199412293312606	http://dx.doi.org/10.1056/NEJM199412293312606			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PZ266	7984197				2022-12-24	WOS:A1994PZ26600006
J	HUBBARD, SR; WEI, L; ELIS, L; HENDRICKSON, WA				HUBBARD, SR; WEI, L; ELIS, L; HENDRICKSON, WA			CRYSTAL-STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN-RECEPTOR	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; AUTOPHOSPHORYLATION; PHOSPHOTRANSFERASE; PHOSPHORYLATION; IDENTIFICATION; INHIBITOR; FEATURES; FAMILY; CELLS	The X-ray crystal structure of the tyrosine kinase domain of the human insulin receptor has been determined by multiwavelength anomalous diffraction phasing and refined to 2.1 Angstrom resolution. The structure reveals the determinants of substrate preference for tyrosine rather than serine or threonine and a novel autoinhibition mechanism whereby one of the tyrosines that is autophosphorylated in response to insulin, Tyr 1,162, is bound in the active site.	COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032; TEXAS A&M UNIV,INST BIOSCI & TECHNOL,WM KECK CTR GENOME INFORMAT,HOUSTON,TX 77030	Columbia University; Howard Hughes Medical Institute; Texas A&M University System	HUBBARD, SR (corresponding author), COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.							ACCILI D, 1992, J ENDOCRINOL INVEST, V15, P857, DOI 10.1007/BF03348820; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COBB MH, 1989, J BIOL CHEM, V264, P18701; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5773, DOI 10.1021/bi00073a008; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHOELSON SE, 1991, BIOCHEMISTRY-US, V30, P7740, DOI 10.1021/bi00245a010; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VERNON M, 1993, P NATL ACAD SCI USA, V90, P10618; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848; WEI L, 1994, CURR OPIN STRUC BIOL, V4, P450, DOI 10.1016/S0959-440X(94)90115-5; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, J BIOL CHEM, V263, P2969; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; 1979, SERC4 DAR LAB COLL C	47	930	973	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					746	754		10.1038/372746a0	http://dx.doi.org/10.1038/372746a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997262				2022-12-24	WOS:A1994PY21200043
J	PERNEGER, TV; WHELTON, PK; KLAG, MJ				PERNEGER, TV; WHELTON, PK; KLAG, MJ			RISK OF KIDNEY FAILURE ASSOCIATED WITH THE USE OF ACETAMINOPHEN, ASPIRIN, AND NONSTEROIDAL ANTIINFLAMMATORY DRUGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC RENAL-DISEASE; ANALGESIC USE; IBUPROFEN; SULINDAC	Background. People who take analgesic drugs frequently may be at increased risk of end-stage renal disease (ESRD), but the extent of this risk remains unclear. Methods. We studied 716 patients treated for ESRD and 361 control subjects of similar age from Maryland, Virginia, West Virginia, and Washington, D.C. The study participants were interviewed by telephone about their past use of medications containing acetaminophen, aspirin, and other nonsteroidal antiinflammatory drugs (NSAIDs). For each analgesic drug, the average use (in pills per year) and the cumulative intake (in pills) were examined for any association with ESRD. Results. Heavier acetaminophen use was associated with an increased risk of ESRD in a dose-dependent fashion. When persons who took an average of 0 to 104 pills per year were used for reference, the odds ratio of ESRD was 1.4 (95 percent confidence interval, 0.8 to 2.4) for those who took 105 to 365 pills per year and 2.1 (95 percent confidence interval, 1.1 to 3.7) for those who took 366 or more pills per year, after adjustment for race, sex, age, and intake of other analgesic drugs. When persons who had taken fewer than 1000 pills containing acetaminophen in their lifetime were used for reference, the odds ratio was 2.0 (95 percent confidence interval, 1.3 to 3.2) for those who had taken 1000 to 4999 pills and 2.4 (95 percent confidence interval, 1.2 to 4.8) for those who had taken 5000 or more pills. Approximately 8 to 10 percent of the overall incidence of ESRD was attributable to acetaminophen use. A cumulative dose of 5000 or more pills containing NSAIDs was also associated with an increased odds of ESRD (odds ratio, 8.8), but the use of aspirin was not. Conclusions. People who often take acetaminophen or NSAIDs have an increased risk of ESRD, but not those who often take aspirin.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MED,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,WELCH CTR PREVENT EPIDEMIOL & CLIN RES,BALTIMORE,MD	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	PERNEGER, TV (corresponding author), UNIV GENEVA,CTR MED,INST SOCIAL & PREVENT MED,UNIV CASE POSTALE,CH-1211 GENEVA 4,SWITZERLAND.				AHRQ HHS [R03 HS 06978-01] Funding Source: Medline; NCRR NIH HHS [RR00035, 5MOIRR00722] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS006978] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CIABATTONI G, 1984, NEW ENGL J MED, V310, P279, DOI 10.1056/NEJM198402023100502; DUBACH UC, 1991, NEW ENGL J MED, V324, P155, DOI 10.1056/NEJM199101173240304; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; MORLANS M, 1990, BRIT J CLIN PHARMACO, V30, P717, DOI 10.1111/j.1365-2125.1990.tb03841.x; MURRAY TG, 1983, ARCH INTERN MED, V143, P1687, DOI 10.1001/archinte.143.9.1687; NATH KA, 1992, AM J KIDNEY DIS, V20, P1; PERNEGER TV, 1993, AM J EPIDEMIOL, V138, P574, DOI 10.1093/oxfordjournals.aje.a116898; POMMER W, 1989, AM J NEPHROL, V9, P403, DOI 10.1159/000168002; SANDLER DP, 1989, NEW ENGL J MED, V320, P1238, DOI 10.1056/NEJM198905113201903; SANDLER DP, 1991, ANN INTERN MED, V115, P165, DOI 10.7326/0003-4819-115-3-165; SCHWARZ A, 1984, LANCET, V2, P1163; SPUHLER O, 1953, Z KLIN MED, V151, P1; STEWART J, 1993, ANALGESIC NSAID INDU; WHELTON A, 1990, ANN INTERN MED, V112, P568, DOI 10.7326/0003-4819-112-8-568; WILKINSON L, 1990, SYSTAT SYSTEM STATIS; 1993, USRDS1993 NAT I DIAB	17	353	367	1	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	1994	331	25					1675	1679		10.1056/NEJM199412223312502	http://dx.doi.org/10.1056/NEJM199412223312502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX382	7969358				2022-12-24	WOS:A1994PX38200002
J	BALICEGORDON, RJ; LICHTMAN, JW				BALICEGORDON, RJ; LICHTMAN, JW			LONG-TERM SYNAPSE LESS INDUCED BY FOCAL BLOCKADE OF POSTSYNAPTIC RECEPTORS	NATURE			English	Article							DEVELOPING NEUROMUSCULAR-JUNCTIONS; ACETYLCHOLINE-RECEPTOR; INVIVO VISUALIZATION; NERVE-TERMINALS; SKELETAL-MUSCLE; RAT MUSCLE; ELIMINATION; MOUSE; INNERVATION; PROTEIN	Focal application in vivo of alpha-bungarotoxin to block neurotransmission in a small region of a neuromuscular junction causes long-lasting synapse elimination at that site. In contrast, blockade of neurotransmission throughout a junction does not cause synapse elimination. These and related experiments indicate that active synaptic sites can destabilize inactive synapses in their vicinity.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Balice-Gordon, Rita/0000-0002-9950-7965				BALICEGORDON RJ, 1990, J NEUROSCI, V10, P894; BALICEGORDON RJ, 1990, J NEUROSCI, V10, P2660; BALICEGORDON RJ, 1993, NEURON, V11, P801, DOI 10.1016/0896-6273(93)90110-D; BALICEGORDON RJ, 1993, J NEUROSCI, V13, P834; BENOIT P, 1978, BRAIN RES, V149, P89, DOI 10.1016/0006-8993(78)90589-9; BROWN MC, 1976, J PHYSIOL-LONDON, V261, P387, DOI 10.1113/jphysiol.1976.sp011565; Burke RE, 1994, MYOLOGY, P464; CALLAWAY EM, 1987, NATURE, V328, P422, DOI 10.1038/328422a0; CHEN LL, 1991, J NEUROSCI, V11, P2920; COLMAN H, 1993, DEV BIOL, V156, P1, DOI 10.1006/dbio.1993.1054; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; Culican S. M., 1993, Society for Neuroscience Abstracts, V19, P1294; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FRASER SE, 1982, CURR TOP DEV BIOL, V17, P77; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; HATA Y, 1994, SCIENCE, V265, P1732, DOI 10.1126/science.8085163; HENNEMAN E, 1957, SCIENCE, V126, P1345, DOI 10.1126/science.126.3287.1345; HERRERA AA, 1990, J NEUROCYTOL, V19, P85, DOI 10.1007/BF01188441; HILL RR, 1991, J NEUROCYTOL, V20, P165, DOI 10.1007/BF01186990; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041, DOI 10.1152/jn.1965.28.6.1041; LANGENFELDOSTER B, 1993, J NEUROCYTOL, V22, P517, DOI 10.1007/BF01189040; LEVITT TA, 1980, SCIENCE, V210, P550, DOI 10.1126/science.7423205; LICHTMAN JW, 1985, NATURE, V314, P357, DOI 10.1038/314357a0; LICHTMAN JW, 1987, J NEUROSCI, V7, P1215; LINGLE CJ, 1988, INT ANESTHESIOL CLIN, V26, P288, DOI 10.1097/00004311-198802640-00007; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LUTHER PW, 1985, J CELL BIOL, V100, P235, DOI 10.1083/jcb.100.1.235; MA J, 1993, J BIOL CHEM, V288, P25108; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; OBRIEN RAD, 1984, NEUROSCIENCE, V12, P637, DOI 10.1016/0306-4522(84)90079-4; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; POO MM, 1985, ANNU REV NEUROSCI, V8, P369; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; RIBCHESTER RR, 1988, J PHYSL, V40, P53; RICH M, 1989, NEURON, V3, P677, DOI 10.1016/0896-6273(89)90236-5; RICH MM, 1994, NEUROLOGY, V44, P2138, DOI 10.1212/WNL.44.11.2138; RICH MM, 1989, J NEUROSCI, V9, P1781, DOI 10.1523/jneurosci.09-05-01781.1989; RIDGE RMAP, 1984, J NEUROSCI, V4, P2614; SCOTT LJC, 1990, J NEUROSCI, V10, P346; SRIHARI T, 1978, J NEUROCYTOL, V7, P529, DOI 10.1007/BF01260887; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; THOMPSON W, 1983, NATURE, V302, P614, DOI 10.1038/302614a0; VANMIER P, 1994, J NEUROSCI, V14, P5672; WERNIG A, 1980, J NEUROCYTOL, V9, P277, DOI 10.1007/BF01181538; WIESEL TN, 1965, J NEUROPHYSIOL, V28, P1029, DOI 10.1152/jn.1965.28.6.1029; WIGSTON DJ, 1990, J NEUROSCI, V10, P1753; WIGSTON DJ, 1989, J NEUROSCI, V9, P639	49	223	224	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					519	524		10.1038/372519a0	http://dx.doi.org/10.1038/372519a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990923				2022-12-24	WOS:A1994PW08200043
J	YUN, MS; HO, PTP; LO, KY				YUN, MS; HO, PTP; LO, KY			A HIGH-RESOLUTION IMAGE OF ATOMIC-HYDROGEN IN THE M81 GROUP OF GALAXIES	NATURE			English	Article							NEUTRAL-HYDROGEN; KINEMATICS; NGC-3077	It has long been recognized that interactions between galaxies are important in determining their evolution. The distribution of gas-out of which new stars are formed-is strongly affected; in particular, gas may be concentrated near the nucleus, leading to a burst of star formation(1-4). Here we present a map of atomic hydrogen (H I) in the nearest interacting group of galaxies (that dominated by M81), obtained by combining 12 separate fields observed with the Very Large Array. The Hr that surrounds M81, M82 and NGC3077 (the most prominent galaxies in the group) is dominated by filamentary structures, clearly demonstrating the violent disruption of this system by tidal interactions. These observations should have detected all H I complexes more massive than 10(6) solar masses, meaning that our map contains all structures that might evolve into new dwarf galaxies.	CALTECH,PASADENA,CA 91125; UNIV ILLINOIS,DEPT ASTRON,URBANA,IL 61801	California Institute of Technology; University of Illinois System; University of Illinois Urbana-Champaign	YUN, MS (corresponding author), HARVARD SMITHSONIAN CTR ASTROPHYS,60 GARDEN ST,CAMBRIDGE,MA 02138, USA.		Ho, Paul/AAZ-5108-2020	Ho, Paul/0000-0002-3412-4306				APPLETON PN, 1988, MON NOT R ASTRON SOC, V234, P957, DOI 10.1093/mnras/234.4.957; APPLETON PN, 1981, MON NOT R ASTRON SOC, V195, P327, DOI 10.1093/mnras/195.2.327; ARP H, 1965, SCIENCE, V148, P363, DOI 10.1126/science.148.3668.363; BARBIERI C, 1974, ASTRON ASTROPHYS, V35, P463; Barnes J. E, 1988, APJ, V331, P669; BARNES JE, 1991, ASTROPHYS J, V370, pL65, DOI 10.1086/185978; BROUILLET N, 1992, ASTRON ASTROPHYS, V262, pL5; COTTRELL GA, 1977, MON NOT R ASTRON SOC, V178, P577, DOI 10.1093/mnras/178.4.577; COTTRELL GA, 1976, MON NOT R ASTRON SOC, V174, P455, DOI 10.1093/mnras/174.2.455; DEMOULIN M, 1960, ASTROPHYS J, V157, P81; FREEDMAN WL, 1994, ASTROPHYS J, V427, P628, DOI 10.1086/174172; GOTTESMAN ST, 1977, ASTROPHYS J, V211, P47, DOI 10.1086/154902; GOTTESMAN ST, 1975, ASTROPHYS J, V195, P23, DOI 10.1086/153301; HIBBARD JE, 1994, ASTRON J, V107, P67, DOI 10.1086/116835; KENT SM, 1987, ASTRON J, V93, P816, DOI 10.1086/114366; LIN CC, 1969, ASTROPHYS J, V155, P721, DOI 10.1086/149907; PEIMBERT M, 1981, ASTROPHYS J, V245, P845, DOI 10.1086/158860; PRICE JS, 1989, ASTROPHYS J, V337, P658, DOI 10.1086/167137; RIEKE GH, 1980, ASTROPHYS J, V238, P24, DOI 10.1086/157954; ROBERTS MS, 1972, EXTERNAL GALAXIES QU, P12; Rots A. H., 1980, Astronomy & Astrophysics Supplement Series, V41, P189; ROTS AH, 1975, ASTRON ASTROPHYS, V45, P25; ROTS AH, 1975, ASTRON ASTROPHYS, V45, P43; SANDERS DB, 1988, ASTROPHYS J, V325, P74, DOI 10.1086/165983; SCOVILLE N, 1991, P C MASSIVE STARS ST, P233; TOOMRE A, 1972, ASTROPHYS J, V178, P623, DOI 10.1086/151823; VANDERHULST JM, 1979, ASTRON ASTROPHYS, V75, P97; VISSER HCD, 1978, STRUCTURE PROPERTIES, P105; WISNIEWSKI WZ, 1968, ASTRON J, V73, P866, DOI 10.1086/110721; YUN MS, 1993, ASTROPHYS J, V411, pL17, DOI 10.1086/186901	30	404	406	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					530	532		10.1038/372530a0	http://dx.doi.org/10.1038/372530a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990925				2022-12-24	WOS:A1994PW08200045
J	PAROUSH, Z; FINLEY, RL; KIDD, T; WAINWRIGHT, SM; INGHAM, PW; BRENT, R; ISHHOROWICZ, D				PAROUSH, Z; FINLEY, RL; KIDD, T; WAINWRIGHT, SM; INGHAM, PW; BRENT, R; ISHHOROWICZ, D			GROUCHO IS REQUIRED FOR DROSOPHILA NEUROGENESIS, SEGMENTATION, AND SEX DETERMINATION AND INTERACTS DIRECTLY WITH HAIRY-RELATED BHLH PROTEINS	CELL			English	Article							HELIX-LOOP-HELIX; RULE GENE-EXPRESSION; OF-SPLIT COMPLEX; PAN-NEURAL GENE; FUSHI-TARAZU; DETERMINATION SIGNAL; ACHAETE-SCUTE; DNA-BINDING; ZYGOTIC CONTROL; SHOWS HOMOLOGY	We have used the interaction trap, a yeast two-hybrid system, to identify proteins interacting with hairy, a basic-helix-loop-helix (bHLH) protein that represses transcription during Drosophila embryonic segmentation. We find that the groucho (gro) protein binds specifically to hairy and also to hairy-related bHLH proteins encoded by deadpan and the Enhancer of split complex. The C-terminal WRPW motif present in all these bHLH proteins is essential for this interaction. We demonstrate that these associations reflect in vivo maternal requirements for gro during neurogenesis, segmentation, and sex determination, three processes regulated by the above bHLH proteins, and we propose that gro is a transcriptional corepressor recruited to specific target promoters by hairy-related bHLH proteins.	UNIV OXFORD,DEPT ZOOL,IMPERIAL CANC RES FUND,DEV BIOL UNIT,DEV GENET LAB,OXFORD OX1 3PS,ENGLAND; UNIV OXFORD,DEPT ZOOL,IMPERIAL CANC RES FUND,DEV BIOL UNIT,MOLEC EMBRYOL LAB,OXFORD OX1 3PS,ENGLAND; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114	University of Oxford; University of Oxford; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Ingham, Philip William/AAH-5884-2020; Kidd, Thomas/AAT-9993-2020; Ingham, Philip W/E-6710-2010; Ingham, Philip W/G-9903-2011	Ingham, Philip William/0000-0001-8224-9958; Ingham, Philip W/0000-0001-8224-9958; Finley, Russ/0000-0003-1144-6887; Ish-Horowicz, David/0000-0001-5684-7129; Kidd, Thomas/0000-0001-7190-4208				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIER E, 1992, GENE DEV, V6, P2137, DOI 10.1101/gad.6.11.2137; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; Campos-Ortega Jose A., 1993, P1091; CARROLL SB, 1986, CELL, V45, P113, DOI 10.1016/0092-8674(86)90543-X; CARROLL SB, 1989, DEVELOPMENT, V107, P673; CLINE TW, 1988, GENETICS, V119, P829; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DELIDAKIS C, 1992, P NATL ACAD SCI USA, V89, P8731, DOI 10.1073/pnas.89.18.8731; DELIDAKIS C, 1991, GENETICS, V129, P803; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY RL, 1994, IN PRESS GENE PROBES; FORBES Z, 1993, ESSENTIAL DEV BIOL P, P3; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; Howard K, 1990, Semin Cell Biol, V1, P161; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1986, EMBO J, V5, P1659, DOI 10.1002/j.1460-2075.1986.tb04409.x; INGHAM PW, 1985, GENETICS, V111, P643; ISHHOROWICZ D, 1987, CELL, V51, P405, DOI 10.1016/0092-8674(87)90636-2; ISHHOROWICZ D, 1989, CELL, V57, P223, DOI 10.1016/0092-8674(89)90960-4; JACKLE H, 1992, J CELL SCI S, V16, pS39; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KNUST E, 1992, GENETICS, V132, P505; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; LAWRENCE PA, 1989, DEVELOPMENT, V107, P847; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; MANOUKIAN AS, 1992, GENE DEV, V6, P1740, DOI 10.1101/gad.6.9.1740; MARTINEZ C, 1993, MOL CELL BIOL, V13, P3514, DOI 10.1128/MCB.13.6.3514; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PARKHURST SM, 1994, SCIENCE, V264, P924, DOI 10.1126/science.8178152; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PARKHURST SM, 1993, DEVELOPMENT, V117, P737; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; Sambrook J., 1989, MOL CLONING LAB MANU; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCHRONS H, 1992, GENETICS, V132, P481; SMITH DB, 1988, GENE AMST, V76, P31; SOMMER RJ, 1993, NATURE, V361, P448, DOI 10.1038/361448a0; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; TIETZE K, 1992, P NATL ACAD SCI USA, V89, P6152, DOI 10.1073/pnas.89.13.6152; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VAVRA SH, 1989, DEVELOPMENT, V107, P663; WAINWRIGHT SM, 1992, MOL CELL BIOL, V12, P2475, DOI 10.1128/MCB.12.6.2475; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Wieschaus E., 1986, P199; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YOUNGERSHEPHERD S, 1992, CELL, V70, P911, DOI 10.1016/0092-8674(92)90242-5	72	503	518	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 2	1994	79	5					805	815		10.1016/0092-8674(94)90070-1	http://dx.doi.org/10.1016/0092-8674(94)90070-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001118				2022-12-24	WOS:A1994PW05400008
J	RUETER, P; RABUS, R; WILKES, H; AECKERSBERG, F; RAINEY, FA; JANNASCH, HW; WIDDEL, F				RUETER, P; RABUS, R; WILKES, H; AECKERSBERG, F; RAINEY, FA; JANNASCH, HW; WIDDEL, F			ANAEROBIC OXIDATION OF HYDROCARBONS IN CRUDE-OIL BY NEW TYPES OF SULFATE-REDUCING BACTERIA	NATURE			English	Article							HYDROTHERMAL VENT SITE; 16S RDNA ANALYSIS; MICROBIAL-DEGRADATION; GUAYMAS BASIN; NORTH-SEA; SULFATE; PETROLEUM; TOLUENE; SEDIMENTS	MANY crude oil constituents are biodegradable in the presence of oxygen; however, a substantial anaerobic degradation has never been demonstrated(1,2). An unusually low content of n-alkanes in oils of certain deposits is commonly attributed to selective utilization of these hydrocarbons by aerobic microorganisms(3,4). On the other hand, oil wells and production fluids were shown to harbour anaerobic sulphate-reducing bacteria(5-8), but their actual electron donors and carbon sources were unknown. On the basis of nutritional properties of various bacterial isolates it was assumed that fatty acids and H-2 are potential electron donors for sulphate reduction in situ(5-8). Here we demonstrate that hydrocarbons in crude oil are used directly by sulphate-reducing bacteria growing under strictly anoxic conditions. A moderately thermophilic pure culture selectively utilizes n-alkanes in oil for sulphate reduction to sulphide. In addition, a mesophilic sulphate-reducing enrichment culture is shown to oxidize alkylbenzenes in oil. Thus, sulphate-reducing bacteria utilizing aliphatic and aromatic hydrocarbons as electron donors may present a significant source of sulphide in oil deposits and oil production plants.	MAX PLANCK INST MARINE MIKROBIOL, D-28359 BREMEN, GERMANY; FORSCHUNGSZENTRUM JULICH, FORSCHUNGSZENTRUM, INST ERDOL & ORGAN GEOCHEM ICG4, D-52428 JULICH, GERMANY; DEUTSCH SAMMLUNG MIKROORGANISMEN & ZELLKULTUREN, D-38124 BRAUNSCHWEIG, GERMANY; WOODS HOLE OCEANOG INST, WOODS HOLE, MA 02543 USA	Max Planck Society; Helmholtz Association; Research Center Julich; Leibniz Institut fur Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); Woods Hole Oceanographic Institution			Abu Laban, Nidal/E-5809-2011; Rainey, Fred A/C-8767-2013; Rainey, Fred/AAG-7996-2019	Rainey, Fred A/0000-0001-9129-6844; 				AECKERSBERG F, 1991, ARCH MICROBIOL, V156, P5, DOI 10.1007/BF00418180; ATLAS RM, 1981, MICROBIOL REV, V45, P180, DOI 10.1128/MMBR.45.1.180-209.1981; Balows A., 1992, PROKARYOTES, P3352, DOI [10.1007/978-1-4757-2191-1_21, DOI 10.1007/978-1-4757-2191-1_]; BAZYLINSKI DA, 1989, APPL ENVIRON MICROB, V55, P2832, DOI 10.1128/AEM.55.11.2832-2836.1989; BAZYLINSKI DA, 1988, ORG GEOCHEM, V12, P547, DOI 10.1016/0146-6380(88)90146-5; BELLER HR, 1992, APPL ENVIRON MICROB, V58, P786, DOI 10.1128/AEM.58.3.786-793.1992; Blanc Ph., 1993, APPL PETROLEUM GEOCH, P151; CORDRUWISCH R, 1987, J PETROL TECHNOL, V39, P97, DOI 10.2118/13554-PA; DESOETE G, 1983, PSYCHOMETRIKA, V48, P621, DOI 10.1007/BF02293884; EDWARDS EA, 1992, APPL ENVIRON MICROB, V58, P794, DOI 10.1128/AEM.58.3.794-800.1992; JORGENSEN BB, 1992, SCIENCE, V258, P1756, DOI 10.1126/science.258.5089.1756; Jukes T. H., 1969, MAMMALIAN PROTEIN ME; LEAHY JG, 1990, MICROBIOL REV, V54, P305, DOI 10.1128/MMBR.54.3.305-315.1990; NAZINA TN, 1985, GEOMICROBIOL J, V4, P103, DOI 10.1080/01490458509385927; NIELSEN H, 1991, SCOPE, V43, P65; ORR WL, 1974, AAPG BULL, V58, P2295; Postgate JR, 1984, SULPHATE REDUCING BA, V2nd; RABUS R, 1993, APPL ENVIRON MICROB, V59, P1444, DOI 10.1128/AEM.59.5.1444-1451.1993; RADKE M, 1980, ANAL CHEM, V52, P406, DOI 10.1021/ac50053a009; RAINEY FA, 1993, FEMS MICROBIOL LETT, V113, P125, DOI 10.1111/j.1574-6968.1993.tb06501.x; RAINEY FA, 1992, SYST APPL MICROBIOL, V15, P197, DOI 10.1016/S0723-2020(11)80092-5; ROSNES JT, 1991, APPL ENVIRON MICROB, V57, P2302, DOI 10.1128/AEM.57.8.2302-2307.1991; Schidlowski M., 1983, P149; SIMONEIT BRT, 1982, NATURE, V295, P198, DOI 10.1038/295198a0; STETTER KO, 1993, NATURE, V365, P743, DOI 10.1038/365743a0; Tissot B.P., 1984, PETROLEUM FORMATION, DOI 10.1007/978-3-642-96446-6	26	342	368	1	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					455	458		10.1038/372455a0	http://dx.doi.org/10.1038/372455a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984238				2022-12-24	WOS:A1994PV01200054
J	SMITH, ML; CHEN, IT; ZHAN, QM; BAE, IS; CHEN, CY; GILMER, TM; KASTAN, MB; OCONNOR, PM; FORNACE, AJ				SMITH, ML; CHEN, IT; ZHAN, QM; BAE, IS; CHEN, CY; GILMER, TM; KASTAN, MB; OCONNOR, PM; FORNACE, AJ			INTERACTION OF THE P53-REGULATED PROTEIN GADD45 WITH PROLIFERATING CELL NUCLEAR ANTIGEN	SCIENCE			English	Article							CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; EXCISION REPAIR; P53; PCNA	GADD45 is a ubiquitously expressed mammalian gene that is induced by DNA damage and certain other stresses. Like another p53-regulated gene, p21(WAF1/CIP1), whose product binds to cyclin-dependent kinases (Cdk's) and proliferating cell nuclear antigen (PCNA), GADD45 has been associated with growth suppression. Gadd45 was found to bind to PCNA, a normal component of Cdk complexes and a protein involved in DNA replication and repair. Gadd45 stimulated DNA excision repair in vitro and inhibited entry of cells into S phase. These results establish GADD45 as a link between the p53-dependent cell cycle checkpoint and DNA repair.	NCI, DEV THERAPEUT PROGRAM, MOLEC PHARMACOL LAB, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, CTR ONCOL, BALTIMORE, MD 21287 USA; GLAXO INC, RES INST, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Johns Hopkins Medicine; GlaxoSmithKline			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005777, R37ES005777] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05777] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KILPATRICK KE, IN PRESS J BIOL CHEM; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; MICHIELI P, 1994, CANCER RES, V54, P3391; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WASEEM NH, 1990, J CELL SCI, V96, P121; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YOON K, 1988, GENE, V66, P11, DOI 10.1016/0378-1119(88)90220-X; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	26	911	942	2	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	1994	266	5189					1376	1380		10.1126/science.7973727	http://dx.doi.org/10.1126/science.7973727			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973727	Green Submitted			2022-12-24	WOS:A1994PT63200042
J	PHAROAH, POD				PHAROAH, POD			FAMILY SPACING, BREAST-FEEDING, AND CONTRACEPTION	LANCET			English	Editorial Material							HEALTH				PHAROAH, POD (corresponding author), UNIV LIVERPOOL,DEPT PUBL HLTH,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							KING M, 1990, LANCET, V336, P664, DOI 10.1016/0140-6736(90)92156-C; SCHUFTAN C, 1990, FAM PRACT, V7, P329, DOI 10.1093/fampra/7.4.329; WISNER B, 1988, SOC SCI MED, V26, P963, DOI 10.1016/0277-9536(88)90417-0; 1994, CONTRACEPTION, V50, P55; 1994, CONTRACEPTION, V50, P35	5	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1382	1382		10.1016/S0140-6736(94)90565-7	http://dx.doi.org/10.1016/S0140-6736(94)90565-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PR786	7968072				2022-12-24	WOS:A1994PR78600006
J	FICKER, E; TAGLIALATELA, M; WIBLE, BA; HENLEY, CM; BROWN, AM				FICKER, E; TAGLIALATELA, M; WIBLE, BA; HENLEY, CM; BROWN, AM			SPERMINE AND SPERMIDINE AS GATING MOLECULES FOR INWARD RECTIFIER K+ CHANNELS	SCIENCE			English	Article							RECTIFYING POTASSIUM CURRENT; INTERNAL MG-2+; CELLS; RECTIFICATION; EXPRESSION; POLYAMINES; MYOCYTES; HEART; BLOCK	Inward rectifier K+ channels pass prominent inward currents, while outward currents are largely blocked. The inward rectification is due to block by intracellular Mg2+ and a Mg2+-independent process described as intrinsic gating. The rapid loss of gating upon patch excision suggests that cytoplasmic factors participate in gating. ''intrinsic'' gating can be restored in excised patches by nanomolar concentrations of two naturally occurring polyamines, spermine and spermidine. Spermine and spermidine may function as physiological blockers of inward rectifier K+ channels and ''intrinsic'' gating may largely reflect voltage-dependent block by these cations.	CASE WESTERN RESERVE UNIV,METRO HLTH SYST,RAMMELKAMP CTR,CLEVELAND,OH 44109; CASE WESTERN RESERVE UNIV,DEPT PHYSIOL,CLEVELAND,OH 44109; BAYLOR COLL MED,DEPT PHYSIOL & MOLEC BIOPHYS,HOUSTON,TX 77030; UNIV NAPLES FEDERICO II,SCH MED 2,DEPT NEUROSCI,PHARMACOL SECT,I-80121 NAPLES,ITALY; BAYLOR COLL MED,DEPT OTORHINOLARYNGOL,HOUSTON,TX 77030	Case Western Reserve University; MetroHealth System; Case Western Reserve University; Baylor College of Medicine; University of Naples Federico II; Baylor College of Medicine			Taglialatela, Maurizio/A-2062-2019; Taglialatela, Maurizio/ABH-4262-2020; Taglialatela, Maurizio/K-1840-2013; Taglialatela, Maurizio/AAB-8621-2022	Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037044, R01HL036930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37044, HL36930] Funding Source: Medline; NINDS NIH HHS [NS23877] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDRICH R, 1993, NATURE, V362, P107, DOI 10.1038/362107a0; ANUMONWO JMB, 1991, CARDIOVASC DRUG REV, V9, P299, DOI 10.1111/j.1527-3466.1991.tb00418.x; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BROCK M, 1994, HEARING RES, V72, P37, DOI 10.1016/0378-5955(94)90203-8; BROWN ND, 1982, J CHROMATOGR, V245, P101, DOI 10.1016/S0021-9673(00)82479-6; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HARVEY RD, 1988, J GEN PHYSIOL, V91, P593, DOI 10.1085/jgp.91.4.593; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LOPATIN AN, 1994, J PHYSIOL-LONDON, V477P, pP86; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; PEGG AE, 1988, CANCER RES, V48, P759; SCOTT RH, 1993, TRENDS NEUROSCI, V16, P153, DOI 10.1016/0166-2236(93)90124-5; SHIMONI Y, 1992, J PHYSIOL-LONDON, V448, P709, DOI 10.1113/jphysiol.1992.sp019066; SILVER MR, 1990, J GEN PHYSIOL, V96, P109, DOI 10.1085/jgp.96.1.109; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; USHERWOOD PNR, 1991, PHARMACOL THERAPEUT, V52, P245, DOI 10.1016/0163-7258(91)90012-B; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WEIGER T, 1994, J MEMBRANE BIOL, V140, P133; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; WILLIAMS K, 1991, LIFE SCI, V48, P469, DOI 10.1016/0024-3205(91)90463-L	30	463	467	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1068	1072		10.1126/science.7973666	http://dx.doi.org/10.1126/science.7973666			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973666				2022-12-24	WOS:A1994PQ92400053
J	PUVACIC, Z; WEINBERG, J				PUVACIC, Z; WEINBERG, J			IMPACT OF WAR ON INFECTIOUS-DISEASE IN BOSNIA-HERZEGOVINA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH		REPUBL INST PUBL HLTH, DEPT EPIDEMIOL, SARAJEVO, BOSNIA & HERCEG; WHO, HLTH MONITORING UNIT, ZAGREB AREA OFF, ZAGREB, CROATIA	World Health Organization								ARMENIAN HK, 1986, AM J EPIDEMIOL, V124, P28, DOI 10.1093/oxfordjournals.aje.a114367; SHEARS P, 1987, BMJ-BRIT MED J, V295, P314, DOI 10.1136/bmj.295.6593.314; TOOLE MJ, 1993, LANCET, V341, P1193, DOI 10.1016/0140-6736(93)91013-C; 1990, LANCET, V336, P845; 1993, MMWR-MORBID MORTAL W, V42, P973	5	4	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	1994	309	6963					1207	1208		10.1136/bmj.309.6963.1207	http://dx.doi.org/10.1136/bmj.309.6963.1207			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7987152	Green Published			2022-12-24	WOS:A1994PQ66200022
J	GONZALEZREYES, A; STJOHNSTON, D				GONZALEZREYES, A; STJOHNSTON, D			ROLE OF OOCYTE POSITION IN ESTABLISHMENT OF ANTERIOR-POSTERIOR POLARITY IN DROSOPHILA	SCIENCE			English	Article							BICOID RNA; LOCALIZATION; OOGENESIS; FOLLICLE; ENCODES; OSKAR; EGG; TRANSPORT; PROTEIN; EMBRYO	The polarized microtubule cytoskeleton of the Drosophila oocyte directs the localization of the maternal determinants which establish the anterior-posterior (AP) axis of the embryo. Because the formation of this microtubule array is dependent on signals from the follicle cells that surround the oocyte, it has been proposed that AP polarity originates in the follicle cells. Here it is shown that the movement of the oocyte to the posterior of the egg chamber early in oogenesis determines AP polarity in the follicle cell layer, and also in the oocyte. Moreover, the generation of AP asymmetry requires signaling from the germ line to the soma and back again.	UNIV CAMBRIDGE,WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge; University of Cambridge			St Johnston, Daniel/C-9568-2009; Gonzalez-Reyes, Acaimo/L-1993-2014	Gonzalez-Reyes, Acaimo/0000-0003-3048-0968; St Johnston, Daniel/0000-0001-5582-3301	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CHASAN R, 1993, GENETICA BIOL DROSOP, V1, P387; CHEUNG HK, 1992, DEVELOPMENT, V114, P653; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; GINIGER E, 1993, ROUX ARCH DEV BIOL, V202, P112, DOI 10.1007/BF00636536; GONZALEZREYES A, UNPUB; GOODE S, 1992, DEVELOPMENT, V116, P177; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JOHNSTON DS, 1992, CELL, V68, P201; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; LOHSSCHARDIN M, 1982, ROUX ARCH DEV BIOL, V191, P28, DOI 10.1007/BF00848543; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; PEIFER M, 1993, DEVELOPMENT, V118, P1191; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; RUOHOLABAKER H, 1994, TRENDS GENET, V10, P89, DOI 10.1016/0168-9525(94)90231-3; Spradling A.C., 1993, DEV DROSOPHILA MELAN, VI, P1; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	27	98	99	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					639	642		10.1126/science.7939717	http://dx.doi.org/10.1126/science.7939717			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939717				2022-12-24	WOS:A1994PN80700045
J	WOLPERT, L				WOLPERT, L			DO WE UNDERSTAND DEVELOPMENT	SCIENCE			English	Editorial Material											WOLPERT, L (corresponding author), UCL, DEPT ANAT & DEV BIOL, LONDON, ENGLAND.							BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; GRUNWALD T, 1992, CELL, V68, P271; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; KELLER R, 1992, DEVELOPMENT, P81; KENYON C, 1994, CELL, V78, P175, DOI 10.1016/0092-8674(94)90288-7; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lawrence P., 1992, MAKING FLY GENETICS; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; NIESWANDER L, IN PRESS NATURE; OLSEN EN, 1991, GENE DEV, V4, P1454; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WOLPERT L, 1990, BIOL J LINN SOC, V39, P109, DOI 10.1111/j.1095-8312.1990.tb00506.x; WOLPERT L, IN PRESS DEVELOPME S; WOLPERT L, 1989, DEVELOPMENT S, P3	18	70	72	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					571	572		10.1126/science.7939707	http://dx.doi.org/10.1126/science.7939707			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939707				2022-12-24	WOS:A1994PN80700031
J	AMOR, JC; HARRISON, DH; KAHN, RA; RINGE, D				AMOR, JC; HARRISON, DH; KAHN, RA; RINGE, D			STRUCTURE OF THE HUMAN ADP-RIBOSYLATION FACTOR-1 COMPLEXED WITH GDP	NATURE			English	Article							PHOSPHOLIPASE-D; PROTEIN; BINDING; RESOLUTION; COFACTOR; ARF	ADP-ribosylation factors (ARFs) are essential and ubiquitous in eukaryotes, being involved in vesicular transport and functioning as an activator of phospholipase D (refs 1, 2) and cholera toxin(3,4). The functions of ARF proteins in membrane traffic and organelle integrity(5,6) are intimately tied to its reversible association with membranes and specific interactions with membrane phospholipids. One common feature of these functions is their regulation by the binding and hydrolysis of GTP. Here we report the three-dimensional structure of full-length human ARF1 (M(r) 21,000) in its GDP-bound non-myristoylated form. The presence of a unique amino-terminal alpha-helix and loop, together with differences in Mg2+ ligation and the existence of a non-crystallographic dimer, set this structure apart from other GTP-binding proteins. These features provide a structural basis for the GTP-dependent modulation of membrane affinity, the lack of intrinsic GTPase activity, and the nature of effector binding surfaces.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOCHEM,PROGRAM BIOORGAN CHEM,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT CHEM & BIOCHEM,WALTHAM,MA 02254; NCI,DEV THERAPEUT PROGRAM,BIOL CHEM LAB,BETHESDA,MD 20892	Brandeis University; Brandeis University; Brandeis University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				Barbacid M., 1987, REV BIOCH, V56, P779; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DICKERSO.RE, 1968, ACTA CRYSTALL B-STRU, VB 24, P997, DOI 10.1107/S0567740868003626; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; HALKIDES CJ, 1994, BIOCHEMISTRY-US, V33, P4019, DOI 10.1021/bi00179a031; JOHN J, 1989, J BIOL CHEM, V264, P13086; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, IN PRESS J BIOL CHEM; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; ROSENWALD AG, 1994, GTPASE CONTROLLED MO; SEUELL JL, 1988, P NATL ACAD SCI USA, V85, P4620; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISS O, 1989, J BIOL CHEM, V264, P21066; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; PROGRAM MANUAL GCG P	29	242	247	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					704	708						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990966				2022-12-24	WOS:A1994PX30700094
J	GEERTS, WH; CODE, KI; JAY, RM; CHEN, EL; SZALAI, JP				GEERTS, WH; CODE, KI; JAY, RM; CHEN, EL; SZALAI, JP			A PROSPECTIVE-STUDY OF VENOUS THROMBOEMBOLISM AFTER MAJOR TRAUMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; SPINAL-CORD INJURY; IMPEDANCE PLETHYSMOGRAPHY; PULMONARY-EMBOLISM; HIP-SURGERY; MULTIPLE TRAUMA; LEG; DIAGNOSIS; ULTRASONOGRAPHY; PHLEBOGRAPHY	Background, Although deep-vein thrombosis and pulmonary embolism are considered common complications after major trauma, their frequency and the associated risk factors have not been carefully quantified. Methods. We performed serial impedance plethysmography and lower-extremity contrast venography to detect deep-vein thrombosis in a cohort of 716 patients admitted to a regional trauma unit. Prophylaxis against thromboembolism was not used. Results. Deep-vein thrombosis in the lower extremities was found in 201 of the 349 patients (58 percent) with adequate venographic studies, and proximal-vein thrombosis was found in 63 (18 percent). Three patients died of massive pulmonary embolism before venography could be performed. Before venography, only three of the patients with deep-vein thrombosis had clinical features suggestive of the condition. Deep-vein thrombosis was found in 65 of the 129 patients with major injuries involving the face, chest, or abdomen (50 percent); in 49 of the 91 patients with major head injuries (54 percent); in 41 of the 66 with spinal injuries (62 percent); and in 126 of the 182 with lower-extremity orthopedic injuries (69 percent). Thrombi were detected in 61 of the 100 patients with pelvic fractures (61 percent), in 59 of the 74 with femoral fractures (80 percent), and in 66 of the 86 with tibial fractures (77 percent). A multivariate analysis identified five independent risk factors for deep-vein thrombosis: older age (odds ratio, 1.05 per year of age; 95 percent confidence interval, 1.03 to 1.06), blood transfusion (odds ratio, 1.74; 95 percent confidence interval, 1.03 to 2.93), surgery (odds ratio, 2.30; 95 percent confidence interval, 1.08 to 4.89), fracture of the femur or tibia (odds ratio, 4.82; 95 percent confidence interval, 2.79 to 8.33), and spinal cord injury (odds ratio, 8.59; 95 percent confidence interval, 2.92 to 25.28). Conclusions. Venous thromboembolism is a common complication in patients with major trauma, and effective, safe prophylactic regimens are needed.	UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT RES DESIGN & BIOSTAT, TORONTO M4N 3M5, ON, CANADA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, CLIN EPIDEMIOL UNIT, TORONTO M4N 3M5, ON, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	GEERTS, WH (corresponding author), UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT MED, RM D674, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ON, CANADA.							AGNELLI G, 1991, ARCH INTERN MED, V151, P2167, DOI 10.1001/archinte.151.11.2167; ANDERSON FA, 1992, ARCH INTERN MED, V152, P1660, DOI 10.1001/archinte.152.8.1660; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bauer G, 1944, ACTA CHIR SCAND, V90, P229; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; BORRIS LC, 1989, THROMB HAEMOSTASIS, V61, P363; BOULANGER BR, 1993, J TRAUMA, V35, P261, DOI 10.1097/00005373-199308000-00015; BURNS GA, 1993, J TRAUMA, V35, P405, DOI 10.1097/00005373-199309000-00012; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; CLAGETT GP, 1992, CHEST, V102, pS391, DOI 10.1378/chest.102.4_Supplement.391S; COLDITZ GA, 1986, LANCET, V2, P143; CRUICKSHANK MK, 1989, THROMB HAEMOSTASIS, V62, P830; DAVIDSON BL, 1992, ANN INTERN MED, V117, P735, DOI 10.7326/0003-4819-117-9-735; ELLIOTT CG, 1993, ANGIOLOGY, V44, P26, DOI 10.1177/000331979304400105; FREEARK RJ, 1967, ARCH SURG-CHICAGO, V95, P567; GILLUM RF, 1987, AM HEART J, V114, P1262, DOI 10.1016/0002-8703(87)90212-2; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; HAAKE DA, 1989, CLIN ORTHOP RELAT R, P212; HARLAN LC, 1990, AM J PUBLIC HEALTH, V80, P453, DOI 10.2105/AJPH.80.4.453; HJELMSTEDT A, 1968, ACTA CHIR SCAND, V134, P209; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1992, CHEST, V102, pS658; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; HULL RD, 1984, CLIN CHEST MED, V5, P439; KAKKAR VV, 1970, AM J SURG, V120, P527, DOI 10.1016/S0002-9610(70)80023-X; KNUDSON MM, 1992, J TRAUMA, V32, P2, DOI 10.1097/00005373-199201000-00002; KUDSK KA, 1989, AM J SURG, V158, P515, DOI 10.1016/0002-9610(89)90182-7; McCartney JS, 1927, ARCH PATHOL LAB MED, V3, P921; MCMURTRY RY, 1989, CAN MED ASSOC J, V141, P555; MONTREY JS, 1985, J TRAUMA, V25, P534, DOI 10.1097/00005373-198506000-00011; Moser, 1988, J INTENSIVE CARE MED, V3, P87, DOI DOI 10.1177/088506668800300205; MYLLYNEN P, 1985, J TRAUMA, V25, P541, DOI 10.1097/00005373-198506000-00013; PAIEMENT G, 1988, AM J SURG, V155, P400, DOI 10.1016/S0002-9610(88)80099-0; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; SEVITT S, 1968, BRIT J SURG, V55, P481, DOI 10.1002/bjs.1800550702; SHACKFORD SR, 1990, AM J SURG, V159, P365, DOI 10.1016/S0002-9610(05)81272-3; VANCE BM, 1934, AM J SURG, V26, P19; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WEBB P, 1981, BRIT J SURG, V68, P807; WOOLSON ST, 1991, CLIN ORTHOP RELAT R, V273, P131; YELNIK A, 1991, PARAPLEGIA, V29, P253, DOI 10.1038/sc.1991.36; 1988, J TRAUMA, V28, P87; 1985, INJURY AM CONTINUING; 1992, J TRAUMA, V32, P130	46	994	1053	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1601	1606		10.1056/NEJM199412153312401	http://dx.doi.org/10.1056/NEJM199412153312401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7969340				2022-12-24	WOS:A1994PW44600001
J	ZHENG, B; XUE, W; KELSOE, G				ZHENG, B; XUE, W; KELSOE, G			LOCUS-SPECIFIC SOMATIC HYPERMUTATION IN GERMINAL CENTER T-CELLS	NATURE			English	Article							IMMUNOGLOBULIN GENES; ANTIGEN RECEPTOR; IMMUNE-RESPONSE; CHAIN GENES; MUTATION; GENERATION; SEQUENCES; CENTERS; MEMORY; DNA	SOMATIC hypermutation and affinity-driven selection of active immunoglobulin genes occur in germinal centres (GCs), resulting in the generation of high-affinity memory B cells(1-3). In contrast, T lymphocytes do not require the germinal centre microenvironment to establish memory and the T-cell antigen receptor (TCR) genes, though homologous to immunoglobulin genes, are believed to be incapable of hypermutation(5-7). Here we present direct evidence that the small population of antigen-specific T cells that are recruited into splenic GCs acquire mutations in the variable region of genes encoding TCR alpha-chains (V alpha) but not those of beta-chains. These locus-specific mutations reach frequencies comparable to mutated inmunoglobulin V-H exons recovered from the same site and exhibit similar substitution biases and DNA strand polarity. T cells bearing identical mutations appear in multiple GCs, raising the possibility that some cells bearing mutant TCRs may re-enter the peripheral lymphocyte pool.			ZHENG, B (corresponding author), UNIV MARYLAND,SCH MED,DEPT MICROBIOL & IMMUNOL,655 W BALTIMORE ST,BALTIMORE,MD 21201, USA.			Kelsoe, Garnett/0000-0002-8770-040X				ALLEN D, 1988, EMBO J, V7, P1995, DOI 10.1002/j.1460-2075.1988.tb03038.x; BECKER DM, 1985, NATURE, V317, P430, DOI 10.1038/317430a0; BERNARD O, 1978, CELL, V15, P1133, DOI 10.1016/0092-8674(78)90041-7; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; BLOMBERG B, 1982, P NATL ACAD SCI-BIOL, V79, P530, DOI 10.1073/pnas.79.2.530; CHIEN YH, 1984, NATURE, V309, P322, DOI 10.1038/309322a0; CUMANO A, 1986, EMBO J, V5, P2459, DOI 10.1002/j.1460-2075.1986.tb04522.x; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; FULLER K, 1993, J IMMUNOL, V9, P4505; HACKETT J, 1992, J EXP MED, V176, P225, DOI 10.1084/jem.176.1.225; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; JACOB J, 1993, J EXP MED, V178, P1293, DOI 10.1084/jem.178.4.1293; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1992, J EXP MED, V176, P678; KELSOE G, 1993, CURR OPIN IMMUNOL, V5, P418, DOI 10.1016/0952-7915(93)90062-W; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LANE P, 1994, J EXP MED, V179, P819, DOI 10.1084/jem.179.3.819; LEBECQUE SG, 1990, J EXP MED, V172, P1717, DOI 10.1084/jem.172.6.1717; LUNDBERG KS, 1991, GENE, V106, P1; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MALISSEN M, 1988, CELL, V55, P49, DOI 10.1016/0092-8674(88)90008-6; OKADA A, 1994, J EXP MED, V180, P261, DOI 10.1084/jem.180.1.261; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; TAO W, 1990, J IMMUNOL, V145, P3216; VITETTA ES, 1991, ANNU REV IMMUNOL, V9, P193, DOI 10.1146/annurev.iy.09.040191.001205; WEISS U, 1990, J EXP MED, V172, P1680; WINOTO A, 1986, NATURE, V324, P679, DOI 10.1038/324679a0; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	30	115	117	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					556	559		10.1038/372556a0	http://dx.doi.org/10.1038/372556a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990929				2022-12-24	WOS:A1994PW08200054
J	SANDERSON, F; KLEIJMEER, MJ; KELLY, A; VERWOERD, D; TULP, A; NEEFJES, JJ; GEUZE, HJ; TROWSDALE, J				SANDERSON, F; KLEIJMEER, MJ; KELLY, A; VERWOERD, D; TULP, A; NEEFJES, JJ; GEUZE, HJ; TROWSDALE, J			ACCUMULATION OF HLA-DM, A REGULATOR OF ANTIGEN PRESENTATION, IN MHC CLASS-II COMPARTMENTS	SCIENCE			English	Article							INVARIANT CHAIN PEPTIDES; PROCESSING MUTANT; RNA-POLYMERASE; DR MOLECULES; CLONED GENES; EXPRESSION; LOCUS	The HLA-DM genes encode an unconventional HLA (human leukocyte antigen) class II molecule that is required for appropriate binding of peptide to classical HLA class II products. In the absence of DM, other class II molecules are unstable upon electrophoresis in sodium dodecyl sulfate and are largely associated with a nested set of peptides derived from the invariant chain called CLIP, for class Ii-associated invariant chain peptides. DMA and DMB associated and accumulated in multilaminar, intracellular compartments with classical class II molecules, but were found infrequently, if at all, at the cell surface. Thus, DM may facilitate peptide binding to class II molecules within these intracellular compartments.	IMPERIAL CANC RES FUND,HUMAN IMMUNOGENET LAB,LONDON WC2A 3PX,ENGLAND; UNIV UTRECHT,SCH MED,DEPT CELL BIOL,3584 CX UTRECHT,NETHERLANDS; NETHERLANDS CANC INST,DEPT CELLULAR BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS	Cancer Research UK; Utrecht University; Netherlands Cancer Institute			Neefjes, Jacques J.C./H-8780-2017	Neefjes, Jacques J.C./0000-0001-6763-2211				AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GEUZE HJ, 1981, J CELL BIOL, V89, P653, DOI 10.1083/jcb.89.3.653; HARDING CV, 1993, J IMMUNOL, V151, P3988; HARLOW E, 1988, ANTIBODIES LABORATOR; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; LIOU W, 1994, P INT C ELECTRON MIC, V13; LUZIO JP, 1993, TRENDS BIOCHEM SCI, V18, P395, DOI 10.1016/0968-0004(93)90097-7; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; RIBERDY JM, 1994, J CELL BIOL, V125, P1225, DOI 10.1083/jcb.125.6.1225; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; STAM NJ, 1986, J IMMUNOL, V137, P2299; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THORPE C, COMMUNICATION; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TULP A, 1993, ELECTROPHORESIS, V14, P1295, DOI 10.1002/elps.11501401198; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	29	232	235	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1566	1569		10.1126/science.7985027	http://dx.doi.org/10.1126/science.7985027			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985027				2022-12-24	WOS:A1994PV01500045
J	SOMERS, W; ULTSCH, M; DEVOS, AM; KOSSIAKOFF, AA				SOMERS, W; ULTSCH, M; DEVOS, AM; KOSSIAKOFF, AA			THE X-RAY STRUCTURE OF A GROWTH-HORMONE PROLACTIN RECEPTOR COMPLEX	NATURE			English	Article							EXTRACELLULAR DOMAIN; BINDING DETERMINANTS; RATIONAL DESIGN; DIMERIZATION; SUPERFAMILY; ANTAGONISTS; REFINEMENT; VARIANTS; CRYSTALS; DETECTOR	THE human pituitary hormones, growth hormone (hGH) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation(1). These activities are initiated by hormone-receptor binding. The hGH and hPRL receptors (hGH(R) and hPRL(R), respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily(2,3). This classification is based on sequence similarity in their extracellular domains, notably a highly conserved pentapeptide, the so-called 'WSXWS box', the function of which is controversial. All ligands in class 1 activate their respective receptors by clustering mechanisms(4). In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex(5-8). hPRL does not bind to the hGH receptor, but hGH binds to both the hGH(R) and hPRL(R), and mutagenesis studies have shown that the receptor-binding sites on hGH overlap(9). We present here the crystal structure of the 1:1 complex of hGH bound to the extracellular domain of the hPRL(R). Comparisons with the hGH-hGH(R) complex(10) reveal how hGH can bind to the two distinctly different receptor binding surfaces.	GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRUNER AT, 1992, X PLOR REFERENCE MAN; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CHAWLA RK, 1983, ANNU REV MED, V34, P519, DOI 10.1146/annurev.me.34.020183.002511; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; ROZAKISADCOCK M, 1992, J BIOL CHEM, V267, P7428; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; ULTSCH M, 1991, J MOL BIOL, V222, P865, DOI 10.1016/0022-2836(91)90578-T; ULTSCH M, 1993, J MOL BIOL, V231, P1133, DOI 10.1006/jmbi.1993.1359; ULTSCH MH, 1994, J MOL BIOL, V236, P286, DOI 10.1006/jmbi.1994.1135	24	339	350	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					478	481		10.1038/372478a0	http://dx.doi.org/10.1038/372478a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984244				2022-12-24	WOS:A1994PV01200061
J	BURTON, DR; PYATI, J; KODURI, R; SHARP, SJ; THORNTON, GB; PARREN, PWHI; SAWYER, LSW; HENDRY, RM; DUNLOP, N; NARA, PL; LAMACCHIA, M; GARRATTY, E; STIEHM, ER; BRYSON, YJ; CAO, YZ; MOORE, JP; HO, DD; BARBAS, CF				BURTON, DR; PYATI, J; KODURI, R; SHARP, SJ; THORNTON, GB; PARREN, PWHI; SAWYER, LSW; HENDRY, RM; DUNLOP, N; NARA, PL; LAMACCHIA, M; GARRATTY, E; STIEHM, ER; BRYSON, YJ; CAO, YZ; MOORE, JP; HO, DD; BARBAS, CF			EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SOLUBLE CD4; COMBINATORIAL LIBRARIES; TYPE-1; GP120; ASSAY; VACCINE; BINDING; GP160; GENES	The ability of antibodies to neutralize diverse primary isolates of human immunodeficiency virus-type 1 in vitro has been questioned, with implications for the likely efficacy of vaccines. A recombinant human antibody to envelope glycoprotein gp120 was generated and used to show that primary isolates are not refractory to antibody neutralization. The recombinant antibody neutralized more than 75 percent of the primary isolates tested at concentrations that could be achieved by passive immunization, for example, to interrupt maternal-fetal transmission of virus. The broad specificity and efficacy of the antibody implies the conservation of a structural feature on gp120, which could be important in vaccine design.	SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA; RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; CALIF DEPT HLTH SERV, VIRAL & RICKETTSIAL DIS LAB, BERKELEY, CA 94704 USA; NCI, FREDERICK CANC RES & DEV CTR, TUMOR CELL BIOL LAB, VIRUS BIOL SECT, FREDERICK, MD 21702 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, LOS ANGELES, CA 90024 USA; NYU, SCH MED, AARON DIAMOND AIDS RES CTR, NEW YORK, NY 10016 USA	Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA; California Department of Health Care Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; New York University	BURTON, DR (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Dr. Peter L. Nara, M.Sc./I-7432-2019	Parren, Paul/0000-0002-4365-3859; Thornton, George/0000-0002-8744-4987	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027742, R01AI033292, R37AI033292] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33292, AI27742, AI35168] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBAS CF, 1994, P NATL ACAD SCI USA, V91, P3809, DOI 10.1073/pnas.91.9.3809; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARBAS CF, 1993, J MOL BIOL, V230, P812, DOI 10.1006/jmbi.1993.1203; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P9939; Bender Eckhard, 1993, Human Antibodies and Hybridomas, V4, P74; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BRYSON Y, 1993, J CELL BIOCH SE, V17, P95; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; COHEN J, 1994, SCIENCE, V264, P1072, DOI 10.1126/science.8178162; COHEN J, 1993, SCIENCE, V262, P980, DOI 10.1126/science.8235635; CONLEY AJ, 1994, P NATL ACAD SCI USA, V91, P3348, DOI 10.1073/pnas.91.8.3348; CUMMINS LM, 1991, BLOOD, V77, P1111; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; DSOUZA MP, 1994, AIDS, V8, P169; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HANSON CV, 1990, J CLIN MICROBIOL, V28, P2030, DOI 10.1128/JCM.28.9.2030-2034.1990; HANSON CV, 1994, AIDS RES HUM RETROV, V10, P633; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; LETVIN NL, 1993, NEW ENGL J MED, V329, P1400, DOI 10.1056/NEJM199311043291908; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MOORE JP, 1990, AIDS, V4, P307, DOI 10.1097/00002030-199004000-00004; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; MOORE JP, 1989, AIDS, V3, P155, DOI 10.1097/00002030-198903000-00006; MOORE JS, UNPUB; NARA PL, 1987, AIDS RES HUM RETROV, V3, P283, DOI 10.1089/aid.1987.3.283; OBRIEN WA, 1992, J VIROL, V66, P3125, DOI 10.1128/JVI.66.5.3125-3130.1992; OBRIEN WA, 1994, J VIROL, V68, P5264, DOI 10.1128/JVI.68.8.5264-5269.1994; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; ROBERTGUROFF M, 1985, NATURE, V316, P72, DOI 10.1038/316072a0; SAWYER LSW, 1994, J VIROL, V68, P1342, DOI 10.1128/JVI.68.3.1342-1349.1994; SCARLATTI G, 1993, J INFECT DIS, V168, P207, DOI 10.1093/infdis/168.1.207; SCHWARTZ DH, 1993, LANCET, V342, P69, DOI 10.1016/0140-6736(93)91283-R; WRIN T, 1994, J ACQ IMMUN DEF SYND, V7, P211; 1993, AIDS CLIN TRIALS GRO	38	956	1041	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1024	1027		10.1126/science.7973652	http://dx.doi.org/10.1126/science.7973652			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973652				2022-12-24	WOS:A1994PQ92400038
J	WERNER, S; SMOLA, H; LIAO, X; LONGAKER, MT; KRIEG, T; HOFSCHNEIDER, PH; WILLIAMS, LT				WERNER, S; SMOLA, H; LIAO, X; LONGAKER, MT; KRIEG, T; HOFSCHNEIDER, PH; WILLIAMS, LT			THE FUNCTION OF KGF IN MORPHOGENESIS OF EPITHELIUM AND REEPITHELIALIZATION OF WOUNDS	SCIENCE			English	Article							KERATINOCYTE GROWTH-FACTOR; TRANSGENIC MICE; EXPRESSION; DIFFERENTIATION; RECEPTOR; INHIBITION; INSIGHTS; ALPHA; GENE; SKIN	The function of keratinocyte growth factor (KGF) in normal and wounded skin was assessed by expression of a dominant-negative KGF receptor transgene in basal keratinocytes. The skin of transgenic mice was characterized by epidermal atrophy, abnormalities in the hair follicles, and dermal hyperthickening. Upon skin injury, inhibition of KGF receptor signaling reduced the proliferation rate of epidermal keratinocytes at the wound edge, resulting in substantially delayed reepithelialization of the wound.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV COLOGNE,DERMATOL & VENEROL KLIN,D-50931 COLOGNE,GERMANY; NYU,MED CTR,INST RECONSTRUCT PLAST SURG,NEW YORK,NY 10016	University of California System; University of California San Francisco; University of Cologne; New York University	WERNER, S (corresponding author), MAX PLANCK INST BIOCHEM,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.			Werner, Sabine/0000-0001-7397-8710	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821, R01HL032898] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL32898, HL-43821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Clark RAF, 1991, PHYSL BIOCH MOL BIOL, P576; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; MARTIN P, 1992, Progress in Growth Factor Research, V4, P25, DOI 10.1016/0955-2235(92)90003-Z; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; PETERS KG, 1992, DEVELOPMENT, V114, P233; PIERCE GF, 1994, J EXP MED, V179, P831, DOI 10.1084/jem.179.3.831; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; TSUBOI R, 1993, J INVEST DERMATOL, V101, P49, DOI 10.1111/1523-1747.ep12358892; TURKSEN K, 1992, P NATL ACAD SCI USA, V89, P5068, DOI 10.1073/pnas.89.11.5068; UENO H, 1993, J BIOL CHEM, V268, P22814; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1397; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WERNER S, UNPUB	19	512	529	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					819	822		10.1126/science.7973639	http://dx.doi.org/10.1126/science.7973639			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973639				2022-12-24	WOS:A1994PP75300045
J	CALDER, SJ; ANDERSON, GH; HARPER, WM; GREGG, PJ				CALDER, SJ; ANDERSON, GH; HARPER, WM; GREGG, PJ			ETHNIC VARIATION IN EPIDEMIOLOGY AND REHABILITATION OF HIP FRACTURE	BRITISH MEDICAL JOURNAL			English	Article							OSTEOMALACIA				CALDER, SJ (corresponding author), UNIV LEICESTER,GLENFIELD GEN HOSP,DEPT ORTHOPAED SURG,LEICESTER LE3 9QP,LEICS,ENGLAND.							ANDERSON GH, 1993, J BONE JOINT SURG BR, V75, P441, DOI 10.1302/0301-620X.75B3.8496217; ROBINSON CM, 1992, INJURY, V23, P300, DOI 10.1016/0020-1383(92)90172-O; STAMP TCB, 1980, CLIN ENDOCRINOL META, V9, P81, DOI 10.1016/S0300-595X(80)80022-3; STEPHENS WP, 1982, Q J MED, V202, P171; WILTON TJ, 1987, J BONE JOINT SURG BR, V69, P388, DOI 10.1302/0301-620X.69B3.3584190	5	11	12	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1124	1125		10.1136/bmj.309.6962.1124a	http://dx.doi.org/10.1136/bmj.309.6962.1124a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987105	Green Published			2022-12-24	WOS:A1994PP69100022
J	PATEL, P; MENDALL, MA; KHULUSI, S; NORTHFIELD, TC; STRACHAN, DP				PATEL, P; MENDALL, MA; KHULUSI, S; NORTHFIELD, TC; STRACHAN, DP			HELICOBACTER-PYLORI INFECTION IN CHILDHOOD - RISK-FACTORS AND EFFECT ON GROWTH	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNIDENTIFIED CURVED BACILLI; CAMPYLOBACTER-PYLORI; GASTRITIS; SEROEPIDEMIOLOGY; SYMPTOMS; HEIGHT	Objective-To investigate the current prevalence of Helicobacter pylori infection in childhood, the risk factors for infection, and the effect of infection on growth in preadolescent schoolchildren. Design-Population based sample of 7 year old schoolchildren followed up at age 11; data on risk factors for infection collected at age 7; presence of infection at age 11 determined by measurement of salivary IgG against H pylori by a newly developed: enzyme linked immunosorbent assay (ELISA). Height was measured at 7 and 11 years of age. Subjects-554 schoolchildren from Edinburgh. Results-62 (11%) children had H pylori infection. Independent risk factors for infection were single parent families (adjusted odds ratio=2.5; 95% confidence interval 1.1 to 5.7), the 10% most crowded homes (3.1; 1.3 to 7.2), and schools serving predominantly rented housing estates (2.5; 1.0 to 6.5). School catchment area was more important than parental social class or housing tenure. Growth in height between 7 and 11 was diminished in infected children by a mean of 1.1 cm (0.3 to 2.0 cm) over four years. This growth reduction was largely confined to girls (1.6 cm over four years), among whom it correlated with salivary IgG (P=0.015). Conclusion-Data from salivary assay to investigate the epidemiology of H pylori suggest that factors relating to the type of community in which the child lives may now be as important for acquisition of this infection as features of the family home. The greater reduction of growth among infected girls raises the possibility that H pylori infection may delay or diminish the pubertal growth spurt.	ST GEORGE HOSP, SCH MED, DEPT PUBL HLTH SCI, LONDON SW17 0RE, ENGLAND	St Georges University London	PATEL, P (corresponding author), ST GEORGE HOSP, SCH MED, DIV BIOCHEM MED, LONDON SW17 0RE, ENGLAND.							BAKER RJ, 1978, GLIM SYSTEM; BIRKHOLZ S, 1993, FEMS IMMUNOL MED MIC, V6, P317, DOI 10.1016/0928-8244(93)90008-R; CAMPBELL AGM, 1992, FORFAR ARNEILS TXB P, P423; CRABTREE JE, 1993, SCAND J IMMUNOL, V37, P65, DOI 10.1111/j.1365-3083.1993.tb01666.x; CROWNE EC, 1991, EUR J PEDIATR, V150, P708, DOI 10.1007/BF01958760; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; FORMAN D, 1993, LANCET, V341, P1359; GRAHAM DY, 1991, DIGEST DIS SCI, V36, P1084, DOI 10.1007/BF01297451; HILL ID, 1987, ARCH DIS CHILD, V62, P1215, DOI 10.1136/adc.62.12.1215; JIVANI SKM, 1973, ARCH DIS CHILD, V48, P109, DOI 10.1136/adc.48.2.109; JONES DM, 1987, BRIT MED J, V294, P615, DOI 10.1136/bmj.294.6572.615-a; KLEIN PD, 1991, LANCET, V337, P1503, DOI 10.1016/0140-6736(91)93196-G; KUH DL, 1991, INT J EPIDEMIOL, V20, P1001, DOI 10.1093/ije/20.4.1001; MARSHALL BJ, 1984, LANCET, V1, P1311; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; MENDALL M, 1994, GUT               S1, V35, pS4; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MENDALL MA, 1993, GUT, V34, pS3; MURCH SH, 1991, GUT, V32, P913, DOI 10.1136/gut.32.8.913; PARSONNET J, 1992, GASTROENTEROLOGY, V102, P41, DOI 10.1016/0016-5085(92)91782-Y; PATEL D, 1994, GUT, V35, pS64; PATEL P, IN PRESS LANCET; RAYMOND J, 1994, J CLIN MICROBIOL, V32, P461, DOI 10.1128/JCM.32.2.461-463.1994; ROTHWELL NJ, 1991, J ENDOCRINOL, V128, P171, DOI 10.1677/joe.0.1280171; STRACHAN DP, 1988, BMJ-BRIT MED J, V297, P1223, DOI 10.1136/bmj.297.6658.1223; TANNER JM, 1973, NATURE, V243, P95, DOI 10.1038/243095a0; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; THOMAS J, 1988, GUT, V29, pA707; WARREN JR, 1983, LANCET, V1, P1273; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; 1991, ITALIAN J GASTROE S2, V23, P19	31	210	215	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 29	1994	309	6962					1119	1123		10.1136/bmj.309.6962.1119	http://dx.doi.org/10.1136/bmj.309.6962.1119			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987103	Green Published			2022-12-24	WOS:A1994PP69100020
J	FARKAS, G; GAUSZ, J; GALLONI, M; REUTER, G; GYURKOVICS, H; KARCH, F				FARKAS, G; GAUSZ, J; GALLONI, M; REUTER, G; GYURKOVICS, H; KARCH, F			THE TRITHORAX-LIKE GENE ENCODES THE DROSOPHILA GAGA FACTOR	NATURE			English	Article							POSITION-EFFECT VARIEGATION; BITHORAX COMPLEX; TRANSCRIPTION; MELANOGASTER; CHROMATIN; PROTEINS; ANTIREPRESSION; SEGMENTATION; TRANSPOSON; EXPRESSION	LITTLE is known about the way higher-order chromatin structure influences gene expression and chromosome topology in general. Genetic analysis in Drosophila has led to the discovery of two classes of genes, the regulators of homeotic genes and the modifiers of position-effect variegation, which seem to be good candidates for encoding some of the factors regulating chromatin functions(1,2). The Trithorax-like gene we describe here is required for the normal expression of the homeotic genes and is a modifier of position-effect variegation. We found that Trithorax-like encodes the GAGA factor which is involved in the formation of an accessible chromatin structure at promoter sequences(3). Our genetic analysis suggests that the chromatin modelling function of the GAGA factor is not restricted to promoter regions.	HUNGARIAN ACAD SCI,BIOL RES CTR,INST GENET,H-6701 SZEGED,HUNGARY; UNIV GENEVA,DEPT ZOOL & ANIM BIOL,CH-1224 GENEVA,SWITZERLAND; UNIV HALLE WITTENBERG,INST GENET,D-06108 HALLE,GERMANY	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; University of Geneva; Martin Luther University Halle Wittenberg			Galloni, Mireille/F-2665-2019	Galloni, Mireille/0000-0002-5099-1709				BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; CHI HC, 1991, DNA CELL BIOL, V10, P451, DOI 10.1089/dna.1991.10.451; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DIBELLO PR, 1991, GENETICS, V129, P385; DORN R, 1993, GENETICS, V133, P279; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; DUNCAN IM, 1982, GENETICS, V102, P49; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GODT D, 1993, DEVELOPMENT, V119, P799; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; INGHAM PW, 1981, ROUX ARCH DEV BIOL, V190, P365, DOI 10.1007/BF00863275; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; READ D, 1990, MOL CELL BIOL, V10, P4334, DOI 10.1128/MCB.10.8.4334; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; SHEARN A, 1989, GENETICS, V121, P517; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; THUMMEL C, 1989, GENE DEV, V6, P2635; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	27	343	353	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					806	808		10.1038/371806a0	http://dx.doi.org/10.1038/371806a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935842				2022-12-24	WOS:A1994PP01800062
J	WANG, Q; SCHOENLEIN, RW; PETEANU, LA; MATHIES, RA; SHANK, CV				WANG, Q; SCHOENLEIN, RW; PETEANU, LA; MATHIES, RA; SHANK, CV			VIBRATIONALLY COHERENT PHOTOCHEMISTRY IN THE FEMTOSECOND PRIMARY EVENT OF VISION	SCIENCE			English	Article							CIS-TRANS ISOMERIZATION; 1ST STEP; IMPULSIVE EXCITATION; DYNAMICS; BACTERIORHODOPSIN; RHODOPSIN; PHOTOISOMERIZATION; FEMTOCHEMISTRY; ISORHODOPSIN; SPECTROSCOPY	Femtosecond pump-probe experiments reveal the impulsive production of photoproduct in the primary event in vision. The retinal chromophore of rhodopsin was excited with a 35-femtosecond pulse at 500 nanometers, and transient changes in absorption were measured with 10-femtosecond probe pulses. At probe wavelengths within the photoproduct absorption band, oscillatory features with a period of 550 femtoseconds (60 wavenumbers) were observed whose phase and amplitude demonstrate that they are the result of nonstationary vibrational motion in the ground state of the photoproduct. The observation of coherent vibrational motion of the photoproduct supports the idea that the primary step in vision is a vibrationally coherent process and that the high quantum yield of the cis-->trans isomerization in rhodopsin is a consequence of the extreme speed of the excited-state torsional motion.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley	WANG, Q (corresponding author), UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV MAT SCI,BERKELEY,CA 94720, USA.		Schoenlein, Robert W/D-1301-2014; Peteanu, Linda/O-5581-2017	Schoenlein, Robert W/0000-0002-6066-7566; Peteanu, Linda/0000-0003-0075-6521	NATIONAL EYE INSTITUTE [R01EY002051, R37EY002051] Funding Source: NIH RePORTER; NEI NIH HHS [EY-02051] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAGCHI B, 1990, J PHYS CHEM-US, V94, P9, DOI 10.1021/j100364a004; BANIN U, 1993, J CHEM PHYS, V98, P4391, DOI 10.1063/1.465066; DEXHEIMER SL, 1992, CHEM PHYS LETT, V188, P61, DOI 10.1016/0009-2614(92)85089-S; DOUGHERTY TP, 1992, SCIENCE, V258, P770, DOI 10.1126/science.258.5083.770; FRAGNITO HL, 1989, CHEM PHYS LETT, V160, P101, DOI 10.1016/0009-2614(89)87564-5; KOCHENDOERFER G, 1994, 208TH NAT AM CHEM SO; Landau LD, 1932, PHYS Z SOWJETUNION, V2, P46, DOI DOI 10.1098/RSPA.1932.0165; LOPPNOW GR, 1988, BIOPHYS J, V54, P35, DOI 10.1016/S0006-3495(88)82928-X; MATHIES RA, 1988, SCIENCE, V240, P777, DOI 10.1126/science.3363359; PALINGS I, 1987, BIOCHEMISTRY-US, V26, P2544, DOI 10.1021/bi00383a021; PETEANU LA, 1993, P NATL ACAD SCI USA, V90, P11762, DOI 10.1073/pnas.90.24.11762; POLLARD WT, 1992, J PHYS CHEM-US, V96, P6147, DOI 10.1021/j100194a013; ROSENFELD T, 1977, PURE APPL CHEM, V49, P341, DOI 10.1351/pac197749030341; SCHOENLEIN RW, 1991, APPL PHYS LETT, V58, P801, DOI 10.1063/1.104494; SCHOENLEIN RW, 1993, J PHYS CHEM-US, V97, P12087, DOI 10.1021/j100148a040; SCHOENLEIN RW, 1991, SCIENCE, V254, P412, DOI 10.1126/science.1925597; SENSION RJ, 1993, J CHEM PHYS, V98, P6291, DOI 10.1063/1.464824; VOS MH, 1993, NATURE, V363, P320, DOI 10.1038/363320a0; WARSHEL A, 1982, J AM CHEM SOC, V104, P1469, DOI 10.1021/ja00370a003; WARSHEL A, 1976, NATURE, V260, P679, DOI 10.1038/260679a0; WEISS RM, 1979, J AM CHEM SOC, V101, P6131, DOI 10.1021/ja00514a051; Zener C, 1932, P R SOC LOND A-CONTA, V137, P696, DOI 10.1098/rspa.1932.0165; ZEWAIL AH, 1988, SCIENCE, V242, P1645, DOI 10.1126/science.242.4886.1645; ZEWAIL AH, 1993, J PHYS CHEM-US, V97, P12427, DOI 10.1021/j100150a001	24	553	563	5	167	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					422	424		10.1126/science.7939680	http://dx.doi.org/10.1126/science.7939680			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939680				2022-12-24	WOS:A1994PN27200030
J	STEVENS, CF; WANG, YY				STEVENS, CF; WANG, YY			CHANGES IN RELIABILITY OF SYNAPTIC FUNCTION AS A MECHANISM FOR PLASTICITY	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL SLICES; AREA CA1; PROBABILITY; DEPRESSION; RECORDINGS; INDUCTION; CURRENTS; RELEASE; NEURONS	SYNAPTIC transmission in the hippocampus is rather unreliable, with many presynaptic action potentials failing to release neurotransmitter(1-4). How is this unreliability affected by the alterations in synaptic strength seen in long-term potentiation (LTP)(5) and long-term depression(6,7) (LTD)? We find that LTP increases synaptic reliability, and LTD decreases it, both without a change in the size of those postsynaptic currents that do occur. Thus LTD is a functional inverse of LTP.			STEVENS, CF (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,MOLEC NEUROBIOL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92110, USA.							ALLEN C, IN PRESS P NATN ACAD; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; Korn S.J., 1991, METHODS NEUROSCIENCE, VVolume 4, P364; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x	18	317	318	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					704	707		10.1038/371704a0	http://dx.doi.org/10.1038/371704a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935816				2022-12-24	WOS:A1994PM77300057
J	BURGER, H; VANDAELE, PLA; ALGRA, D; HOFMAN, A; GROBBEE, DE; SCHUTTE, HE; BIRKENHAGER, JC; POLS, HAP				BURGER, H; VANDAELE, PLA; ALGRA, D; HOFMAN, A; GROBBEE, DE; SCHUTTE, HE; BIRKENHAGER, JC; POLS, HAP			VERTEBRAL DEFORMITIES AS PREDICTORS OF NON-VERTEBRAL FRACTURES	BRITISH MEDICAL JOURNAL			English	Article									ERASMUS UNIV ROTTERDAM,DEPT EPIDEMIOL & BIOSTAT RADIOL & INTERNAL MED,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam			Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; 1991, AM J MED, V90, P107	5	79	82	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					991	992		10.1136/bmj.309.6960.991	http://dx.doi.org/10.1136/bmj.309.6960.991			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950721	Green Published			2022-12-24	WOS:A1994PM41700023
J	WHITE, RR; RIDGWAY, EJ				WHITE, RR; RIDGWAY, EJ			MANAGING INJURIES FROM SHARP INSTRUMENTS IN HEALTH-CARE WORKERS IN MERSEY	BRITISH MEDICAL JOURNAL			English	Article											WHITE, RR (corresponding author), ROYAL LIVERPOOL UNIV HOSP,DEPT MICROBIOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; MANIAN FA, 1992, ANN INTERN MED, V116, P345; Newman C P, 1992, Commun Dis Rep CDR Rev, V2, pR30; 1990, GUIDANCE CLIN HLTH C; 1992, COMMUNICABLE DISEASE, V2, pR97	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					989	990		10.1136/bmj.309.6960.989	http://dx.doi.org/10.1136/bmj.309.6960.989			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950719	Green Published			2022-12-24	WOS:A1994PM41700021
J	GATTI, DL; PALFEY, BA; LAH, MS; ENTSCH, B; MASSEY, V; BALLOU, DP; LUDWIG, ML				GATTI, DL; PALFEY, BA; LAH, MS; ENTSCH, B; MASSEY, V; BALLOU, DP; LUDWIG, ML			THE MOBILE FLAVIN OF 4-OH BENZOATE HYDROXYLASE	SCIENCE			English	Article							PARA-HYDROXYBENZOATE HYDROXYLASE; CRYSTAL-STRUCTURE; PSEUDOMONAS-FLUORESCENS; CONFORMATIONAL CHANGE; ACTIVE-SITE; RESOLUTION; CHEMISTRY; MECHANISM	Para-hydroxybenzoate hydroxylase inserts oxygen into substrates by means of the labile intermediate, flavin C(4a)-hydroperoxide. This reaction requires transient isolation of the flavin and substrate from the bulk solvent. Previous crystal structures have revealed the position of the substrate para-hydroxybenzoate during oxygenation but not how it enters the active site. In this study, enzyme structures with the flavin ring displaced relative to the protein were determined, and it was established that these or similar flavin conformations also occur in solution. Movement of the flavin appears to be essential for the translocation of substrates and products into the solvent-shielded active site during catalysis.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOPHYS RES,ANN ARBOR,MI 48109; UNIV NEW ENGLAND,DEPT BIOCHEM & MICROBIOL,ARMIDALE,NSW 2351,AUSTRALIA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of New England			dballou@umich.edu, David P/A-1298-2007; Lah, Myoung Soo/E-5885-2010	Lah, Myoung Soo/0000-0001-9517-7519; Palfey, Bruce/0000-0001-5098-259X	NIGMS NIH HHS [GM 20877, GM 11106, GM 16429] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020877, R37GM011106, R01GM011106, R01GM020877] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballou D. P., 1984, FLAVINS FLAVOPROTEIN, P605; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BRUICE TC, 1984, ISRAEL J CHEM, V24, P54; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR VERSION 3 1; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; ENTSCH B, IN PRESS FLAVINS FLA; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; GHISLA S, 1986, BIOCHEMISTRY-US, V25, P3282, DOI 10.1021/bi00359a030; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; LAH MS, 1994, BIOCHEMISTRY-US, V33, P1555, DOI 10.1021/bi00172a036; LAH MS, IN PRESS FLAVINS FLA; MERENYI G, 1991, J AM CHEM SOC, V113, P3146, DOI 10.1021/ja00008a051; Mitchell P, 1966, CHEMIOSMOTIC COUPLIN; Ornston L N, 1977, Curr Top Cell Regul, V12, P209; READ RJ, 1990, ACTA CRYSTALLOGR A, V46, P900, DOI 10.1107/S0108767390005529; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; SCHREUDER HA, 1988, J MOL BIOL, V199, P637, DOI 10.1016/0022-2836(88)90307-5; SCHREUDER HA, 1992, PROTEINS, V14, P178, DOI 10.1002/prot.340140205; SCHREUDER HA, 1990, BIOCHEMISTRY-US, V29, P3101, DOI 10.1021/bi00464a029; SCHREUDER HA, 1988, J BIOL CHEM, V263, P3131; Schulz GE, 1991, CURR OPIN STRUC BIOL, V1, P883, DOI 10.1016/0959-440X(91)90082-5; SHARP KA, 1990, ANNU REV BIOPHYS BIO, V19, P301, DOI 10.1146/annurev.bb.19.060190.001505; SHOUN H, 1983, J BIOCHEM-TOKYO, V93, P169, DOI 10.1093/oxfordjournals.jbchem.a134151; STEENNIS PJ, 1973, FEBS LETT, V36, P177, DOI 10.1016/0014-5793(73)80363-1; VERVOORT J, 1991, EUR J BIOCHEM, V200, P731, DOI 10.1111/j.1432-1033.1991.tb16238.x; VINOGRADOV AD, 1994, BIOPHYS J, V66, pA12; WIERENGA RK, 1979, J MOL BIOL, V131, P55, DOI 10.1016/0022-2836(79)90301-2; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	34	175	176	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					110	114		10.1126/science.7939628	http://dx.doi.org/10.1126/science.7939628			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939628				2022-12-24	WOS:A1994PK58200035
J	MACKEWICZ, CE; YANG, LC; LIFSON, JD; LEVY, JA				MACKEWICZ, CE; YANG, LC; LIFSON, JD; LEVY, JA			NONCYTOLYTIC CD8 T-CELL ANTI-HIV RESPONSES IN PRIMARY HIV-1 INFECTION	LANCET			English	Note							PLASMA; VIRUS	Acute HIV infection is accompanied by a sharp rise in virus titres that soon fall, but the role of humoral and cellular immunity is not clear in the control of initial virus replication. We have found seven HIV-1 infected subjects who had CD8 T-cell non-cytolytic anti-HIV activity in plasma many months before neutralising antibodies can be detected. We observed an inverse relation between the extent of this CD8 cell response and the level of plasma viraemia in some subjects. These results suggest that a cellular immune response controls viral replication soon after HIV infection.	UNIV CALIF SAN FRANCISCO,SCH MED,CANC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143; GENELABS TECHNOL INC,REDWOOD CITY,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAID NIH HHS [AI35467, R01-AI30350] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030350, R01AI035467, R37AI035467] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CHENGMAYER C, 1988, P NATL ACAD SCI USA, V85, P2815, DOI 10.1073/pnas.85.8.2815; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LANDAY AL, 1993, CLIN IMMUNOL IMMUNOP, V69, P106, DOI 10.1006/clin.1993.1157; MACKEWICZ C, 1992, AIDS RES HUM RETROV, V8, P629; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SHEPPARD HW, 1993, J ACQ IMMUN DEF SYND, V6, P1339; TINDALL B, 1991, AIDS, V5, P1, DOI 10.1097/00002030-199101000-00001; WALKER BD, 1990, AIDS, V4, P177, DOI 10.1097/00002030-199003000-00001	10	102	107	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1671	1673						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996961				2022-12-24	WOS:A1994PX30200010
J	ORENGO, CA; JONES, DT; THORNTON, JM				ORENGO, CA; JONES, DT; THORNTON, JM			PROTEIN SUPERFAMILIES AND DOMAIN SUPERFOLDS	NATURE			English	Article							STRUCTURE ALIGNMENT; GLOBULAR-PROTEINS; SEQUENCES; FOLD; SIMILARITIES; FAMILIES	As the protein sequence and structure databases expand rapidly a better understanding of the relationships between proteins is required. A classification is considered that extends the sequence-based superfamilies to include proteins with similar function and three-dimensional structures but no sequence similarity. So far there are only nine protein folds known to recur in proteins having neither sequence nor functional similarity. These folds dominate the structure database, representing more than 30 per cent of all determined structures. This observation has implications for protein-fold recognition.	NATL INST MED RES,MATH BIOL LAB,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	ORENGO, CA (corresponding author), UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,BIOMOLEC STRUCT & MODELLING UNIT,GOWER ST,LONDON WC1E 6BT,ENGLAND.			Thornton, Janet/0000-0003-0824-4096	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEXANDROV NN, 1994, PROTEIN SCI, V3, P866; BORK P, 1994, CURR OPIN STRUC BIOL, V4, P393, DOI 10.1016/S0959-440X(94)90109-0; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; Dayhoff MO, 1978, ATLAS PROTEIN SEQUEN, V5; FINKELSTEIN AV, 1987, PROG BIOPHYS MOL BIO, V50, P171, DOI 10.1016/0079-6107(87)90013-7; FINKELSTEIN AV, 1994, CURR OPIN STRUC BIOL, V4, P422, DOI 10.1016/S0959-440X(94)90112-0; FLORES TP, 1993, PROTEIN SCI, V2, P1811, DOI 10.1002/pro.5560021104; GOTOH O, 1982, J MOL BIOL, V162, P705, DOI 10.1016/0022-2836(82)90398-9; HILBERT M, 1993, PROTEINS, V17, P138, DOI 10.1002/prot.340170204; HOLM L, 1992, PROTEIN SCI, V1, P1691, DOI 10.1002/pro.5560011217; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; ORENGO CA, 1992, PROTEINS, V14, P139, DOI 10.1002/prot.340140203; ORENGO CA, 1993, PROTEIN ENG, V6, P485, DOI 10.1093/protein/6.5.485; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; PASCARELLA S, 1992, PROTEIN ENG, V5, P121, DOI 10.1093/protein/5.2.121; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PTITSYN OB, 1980, Q REV BIOPHYS, V13, P339, DOI 10.1017/S0033583500001724; RACKOVSKY S, 1990, PROTEINS, V7, P378, DOI 10.1002/prot.340070409; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; TAYLOR WR, 1989, J MOL BIOL, V208, P1, DOI 10.1016/0022-2836(89)90084-3; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; YEE DP, 1993, PROTEIN SCI, V2, P884, DOI 10.1002/pro.5560020603	27	652	677	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					631	634		10.1038/372631a0	http://dx.doi.org/10.1038/372631a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990952				2022-12-24	WOS:A1994PX30700074
J	ROMANEK, CS; GRADY, MM; WRIGHT, IP; MITTLEFEHLDT, DW; SOCKI, RA; PILLINGER, CT; GIBSON, EK				ROMANEK, CS; GRADY, MM; WRIGHT, IP; MITTLEFEHLDT, DW; SOCKI, RA; PILLINGER, CT; GIBSON, EK			RECORD OF FLUID-ROCK INTERACTIONS ON MARS FROM THE METEORITE ALH84001	NATURE			English	Article							ISOTOPE FRACTIONATIONS; STABLE ISOTOPES; SNC METEORITES; CARBON-DIOXIDE; OXYGEN; CALCITE; EVOLUTION	ALLAN HILLS (ALH) 84001 is the most recently recognized(1) member of a suite of meteorites-the SNCs-that almost certainly originated on Mars(2). Several factors distinguish ALH84001 from the other SNC meteorites. Preliminary studies(3,4) suggest that it may be older than other martian meteorites. Moreover, it contains abundant, zoned domains of calcium-iron-magnesium carbonate that are indigenous to the sample(1) and thus may hold important clues regarding near-surface processes on Mars and the evolution of the martian atmosphere. We report here analyses of the carbon and oxygen stable-isotope Compositions of the carbonates that place constraints on their formation conditions. Our results imply the presence of at least two chemically distinct carbonates-one Ca,Fe-rich, the other Mg-rich-that are enriched in C-13 relative to terrestrial carbonates (delta(13)C approximate to + 41%parts per thousand), consistent with martian atmospheric CO2 as the carbon source. The oxygen isotope compositions of the carbonates indicate that they precipitated from a low-temperature fluid in the martian crust. Combined with textural and bulk geochemical considerations, the isotope data suggest that carbonate deposition took place in an open-system environment in which the ambient temperature fluctuated.	BRITISH MUSEUM NAT HIST,DEPT MINERAL,LONDON SW7 5BD,ENGLAND; OPEN UNIV,DEPT EARTH SCI,PLANETARY SCI UNIT,MILTON KEYNES MK7 6AA,BUCKS,ENGLAND; LOCKHEED ENGN & SCI CO,HOUSTON,TX 77058	British Museum of Natural History; Open University - UK; Lockheed Martin	ROMANEK, CS (corresponding author), NASA,LYNDON B JOHNSON SPACE CTR,PLANETARY SCI BRANCH SN4,HOUSTON,TX 77058, USA.			Grady, Monica/0000-0002-4055-533X				ALASAM IS, 1990, CHEM GEOL, V80, P119; BOGARD DD, 1983, SCIENCE, V221, P651, DOI 10.1126/science.221.4611.651; CARR RH, 1985, NATURE, V314, P248, DOI 10.1038/314248a0; CHACKO T, 1991, GEOCHIM COSMOCHIM AC, V55, P2867, DOI 10.1016/0016-7037(91)90452-B; CHIBA H, 1989, GEOCHIM COSMOCHIM AC, V53, P2985, DOI 10.1016/0016-7037(89)90174-9; Clayton R., 1993, ANTARCT METEORITE NE, V16, P4; CLAYTON RN, 1988, GEOCHIM COSMOCHIM AC, V52, P925, DOI 10.1016/0016-7037(88)90363-8; CLIFFORD SM, 1993, J GEOPHYS RES-PLANET, V98, P10973, DOI 10.1029/93JE00225; GRADY MM, 1994, METEORITICS, V29, P469; JAGOUTZ E, 1994, METEORITICS, V29, P478; JAKOSKY BM, 1991, ICARUS, V94, P14, DOI 10.1016/0019-1035(91)90138-J; JULL AJT, 1994, METEORITICS, V29, P479; MCCREA JM, 1950, J CHEM PHYS, V18, P849, DOI 10.1063/1.1747785; MCSWEEN HY, 1985, REV GEOPHYS, V23, P391, DOI 10.1029/RG023i004p00391; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; MOZLEY PS, 1993, J SEDIMENT PETROL, V63, P73; Owen T., 1977, J GEOPHYS RES, V82, P4635, DOI DOI 10.1029/JS082I028P04635; ROSENBAUM J, 1986, GEOCHIM COSMOCHIM AC, V50, P1147, DOI 10.1016/0016-7037(86)90396-0; SQUYRES SW, 1994, SCIENCE, V265, P744, DOI 10.1126/science.265.5173.744; SWART PK, 1991, CHEM GEOL, V86, P89, DOI 10.1016/0168-9622(91)90055-2; TREIMAN AH, 1994, METEORITICS, V29, P542; Veizer J., 1983, REV MINERAL GEOCHEM, V11, P265; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; WRIGHT IP, 1992, GEOCHIM COSMOCHIM AC, V56, P817, DOI 10.1016/0016-7037(92)90100-W; [No title captured]	25	198	201	0	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					655	657		10.1038/372655a0	http://dx.doi.org/10.1038/372655a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990956				2022-12-24	WOS:A1994PX30700079
J	DANON, A; MAYFIELD, SP				DANON, A; MAYFIELD, SP			LIGHT-REGULATED TRANSLATION OF CHLOROPLAST MESSENGER-RNAS THROUGH REDOX POTENTIAL	SCIENCE			English	Article							CHLAMYDOMONAS-REINHARDTII; GENE-EXPRESSION; PHOTOSYSTEM-II; CO2 ASSIMILATION; HIGHER-PLANTS; MUTATIONS; NUCLEAR; PSBA; BIOGENESIS; PROTEINS	Translation of key proteins in the chloroplast is regulated by light. Genetic and biochemical studies in the unicellular alga Chlamydomonas reinhardtii suggest that light may regulate translation by modulating the binding of activator proteins to the 5' untranslated region of chloroplast messenger RNAs. in vitro binding of the activator proteins to psbA messenger RNA and in vivo translation of psbA messenger RNA is regulated by the redox state of these proteins, suggesting that the light stimulus is transduced by the photosynthesis-generated redox potential.	Scripps Res Inst, DEPT CELL BIOL, DIV PLANT BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute								BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DANON AD, UNPUB; DENG XW, 1988, EMBO J, V7, P3301, DOI 10.1002/j.1460-2075.1988.tb03200.x; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FROMM H, 1985, EMBO J, V4, P291, DOI 10.1002/j.1460-2075.1985.tb03628.x; GIRARDBASCOU J, 1987, CURR GENET, V12, P483, DOI 10.1007/BF00419556; GIRARDBASCOU J, 1992, CURR GENET, V22, P47, DOI 10.1007/BF00351741; GRANT DM, 1980, P NATL ACAD SCI-BIOL, V77, P6067, DOI 10.1073/pnas.77.10.6067; JENSEN KH, 1986, J CELL BIOL, V103, P1315, DOI 10.1083/jcb.103.4.1315; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KLEIN RR, 1988, J CELL BIOL, V106, P289, DOI 10.1083/jcb.106.2.289; KRUPINSKA K, 1989, MOL GEN GENET, V219, P467, DOI 10.1007/BF00259621; KUCHKA MR, 1988, EMBO J, V7, P319, DOI 10.1002/j.1460-2075.1988.tb02815.x; MALNOE P, 1988, J CELL BIOL, V106, P609, DOI 10.1083/jcb.106.3.609; MATTOO AK, 1981, P NATL ACAD SCI-BIOL, V78, P1572, DOI 10.1073/pnas.78.3.1572; MAYFIELD SP, 1994, J CELL BIOL, V127, P6; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; ROCHAIX JD, 1989, EMBO J, V8, P1013, DOI 10.1002/j.1460-2075.1989.tb03468.x; TOBIN EM, 1985, ANNU REV PLANT PHYS, V36, P569, DOI 10.1146/annurev.pp.36.060185.003033; WETTERN M, 1984, ISRAEL J BOT, V33, P253; WOLOSIUK RA, 1993, FASEB J, V7, P622, DOI 10.1096/fasebj.7.8.8500687	23	279	284	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1717	1719		10.1126/science.7992056	http://dx.doi.org/10.1126/science.7992056			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992056				2022-12-24	WOS:A1994PW30800043
J	SILVERSTEIN, MD; REED, CE; OCONNELL, EJ; MELTON, LJ; OFALLON, WM; YUNGINGER, JW				SILVERSTEIN, MD; REED, CE; OCONNELL, EJ; MELTON, LJ; OFALLON, WM; YUNGINGER, JW			LONG-TERM SURVIVAL OF A COHORT OF COMMUNITY RESIDENTS WITH ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDHOOD ASTHMA; RECENT INCREASE; MORTALITY; DEATHS; EPIDEMIOLOGY; PROGNOSIS; RATES; POPULATION; ACCURACY; RECORD	Background. Reports of an increase in asthma-related mortality have been based on studies of death certificates from the general U.S. population on which asthma was listed as an underlying cause of death. We addressed the issue in a different way by analyzing longterm survival in a defined, population-based cohort of patients with asthma. Methods. We identified all residents of Rochester, Minnesota, in whom asthma was diagnosed from January 1, 1964, through December 31, 1983, by reviewing the medical records of ail patients with asthma and associated diagnoses, using explicit predefined criteria. The patients' vital status at last follow-up was ascertained. Medical records, death certificates, and autopsy reports were reviewed to classify deaths as due either to asthma or to other conditions. Results. We identified 2499 patients with definite or probable asthma. The mean duration of follow-up was 14 years (range, 0 to 29). There were 140 deaths during 32,605 person-years of follow-up. Overall survival was not significantly different from the survival that was expected for residents of Rochester, Survival was less than expected in patients who were 35 years of age or older when their asthma was diagnosed and who also had another lung disease (predominantly chronic obstructive pulmonary disease). Four percent of all deaths in the study cohort were due to asthma, and all were among adults. Survival was not related to the year of onset of asthma. Conclusions. Survival among patients with asthma but no other lung disease was not significantly different from expected survival, However, patients 35 or older who had asthma associated with chronic obstructive pulmonary disease did have worse than expected survival. Asthma was classified as the cause of death in only 4 percent of the patients, and there was no evidence of an increased risk of death among patients with a more recent diagnosis of asthma. These results provide assurance that community-based patients with asthma usually have a good prognosis.	MAYO CLIN & MAYO FDN,DIV ALLERG DIS & INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PEDIAT & ADOLESCENT MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic	SILVERSTEIN, MD (corresponding author), MAYO CLIN & MAYO FDN,DIV AREA GEN INTERNAL MED,200 1ST ST SW,ROCHESTER,MN 55905, USA.		Silverstein, Marc D/D-8592-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 25187] Funding Source: Medline; NIAMS NIH HHS [AR 30582] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALMIND M, 1992, DAN MED BULL, V39, P561; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; [Anonymous], 1984, Thorax, V39, P505; BARGER LW, 1988, ANN ALLERGY, V60, P31; BEARD CM, 1992, J CLIN EPIDEMIOL, V45, P1013; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P389, DOI 10.1016/0091-6749(87)90056-X; BURNEY P, 1988, J EPIDEMIOL COMMUN H, V42, P316, DOI 10.1136/jech.42.4.316; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; HANNAWAY PJ, 1988, PEDIATR ASTHMA ALLER, V2, P99; HUNT LW, 1993, JAMA-J AM MED ASSOC, V269, P1947, DOI 10.1001/jama.269.15.1947; JONSSON JA, 1987, ACTA PAEDIATR SCAND, V76, P950, DOI 10.1111/j.1651-2227.1987.tb17270.x; KAPLAN KM, 1993, PUBLIC HEALTH REP, V108, P66; KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; Kurland LT, 1970, COMMUNITY EPIDEMIOLO, P47; MALVEAUX FJ, 1988, J ALLERGY CLIN IMMUN, V81, P306; MAO Y, 1987, CAN MED ASSOC J, V137, P620; MARKOWE HLJ, 1987, BRIT MED J, V295, P949, DOI 10.1136/bmj.295.6604.949; MUSK AW, 1987, MED J AUSTRALIA, V147, P423, DOI 10.5694/j.1326-5377.1987.tb133582.x; PAULOZZI LJ, 1986, ANN ALLERGY, V56, P392; RACHELEFKSY GS, 1987, J ALLERGY CLIN IMMUN, V79, P183; RYSSING E, 1959, Acta Paediatr, V48, P255; SCHACHTER EN, 1984, CHEST, V85, P623, DOI 10.1378/chest.85.5.623; SEARS MR, 1986, AM J EPIDEMIOL, V124, P1004, DOI 10.1093/oxfordjournals.aje.a114470; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P383, DOI 10.1016/0091-6749(87)90055-8; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	27	108	109	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1537	1541		10.1056/NEJM199412083312301	http://dx.doi.org/10.1056/NEJM199412083312301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV292	7969322				2022-12-24	WOS:A1994PV29200001
J	NABER, SP				NABER, SP			MOLECULAR PATHOLOGY - DETECTION OF NEOPLASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											NABER, SP (corresponding author), BAYSTATE MED CTR,DEPT PATHOL,SPRINGFIELD,MA 01199, USA.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ROSENTHAL N, 1994, NEW ENGL J MED, V331, P315, DOI 10.1056/NEJM199408043310508; SKLAR J, 1992, CANCER, V70, P1710, DOI 10.1002/1097-0142(19920915)70:4+<1710::AID-CNCR2820701610>3.0.CO;2-J; WAINSCOAT JS, 1990, CANCER RES, V50, P1355	4	34	50	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1508	1510		10.1056/NEJM199412013312208	http://dx.doi.org/10.1056/NEJM199412013312208			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969302				2022-12-24	WOS:A1994PU86600008
J	SAINTRUF, C; UNGEWISS, K; GROETTRUP, M; BRUNO, L; FEHLING, HJ; VONBOEHMER, H				SAINTRUF, C; UNGEWISS, K; GROETTRUP, M; BRUNO, L; FEHLING, HJ; VONBOEHMER, H			ANALYSIS AND EXPRESSION OF A CLONED PRE-T CELL-RECEPTOR GENE	SCIENCE			English	Article							BETA-CHAIN GENE; THYMOCYTE DEVELOPMENT; TRANSGENIC MICE; IMMATURE THYMOCYTES; REARRANGEMENT; TCR; RESTORATION; CD3-EPSILON; PROTEINS; SURFACE	The T cell antigen receptor (TCR) beta chain regulates early T cell development in the absence of the TCR alpha chain. The developmentally controlled gene described here encodes the pre-TCR alpha (pT alpha) chain, which covalently associates with TCR beta and with the CD3 proteins forms a pre-TCR complex that transduces signals in immature thymocytes. Unlike the lambda 5 pre-B cell receptor protein, the pT alpha chain is a type I transmembrane protein whose cytoplasmic tail contains two potential phosphorylation sites and a Src homology 3 (SH3)-domain binding sequence. Pre-TCR alpha transfection experiments indicated that surface expression of the pre-TCR is controlled by additional developmentally regulated proteins. Identification of the pT alpha gene represents an essential step in the structure-function analysis of the pre-TCR complex.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND		SAINTRUF, C (corresponding author), INST NECKER,INSERM,U373,F-75730 PARIS 15,FRANCE.							ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CHANG HC, 1990, J EXP MED, V172, P351, DOI 10.1084/jem.172.1.351; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DUDLEY EC, 1994, IMMUNITY, V1, P83, DOI 10.1016/1074-7613(94)90102-3; FENG DF, 1987, J MOL EVOL, V35, P359; FENTON RG, 1988, SCIENCE, V241, P1089, DOI 10.1126/science.2970670; GROETTRUP M, 1993, EUR J IMMUNOL, V23, P1393, DOI 10.1002/eji.1830230633; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; GROETTRUP M, 1993, THESIS U BASEL; GROETTRUP M, 1993, IMMUNOL TODAY, V14, P6101; JACOBS H, 1994, EUR J IMMUNOL, V24, P934, DOI 10.1002/eji.1830240423; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; LEVELT CN, 1993, J EXP MED, V177, P707, DOI 10.1084/jem.177.3.707; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LYNCH F, 1993, INT IMMUNOL, V5, P991, DOI 10.1093/intimm/5.8.991; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; RODEWALD HR, UNPUB; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SHORES EW, 1991, EUR J IMMUNOL, V21, P973, DOI 10.1002/eji.1830210417; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VONBOEHMER H, 1988, P NATL ACAD SCI USA, V85, P9729, DOI 10.1073/pnas.85.24.9729; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; YU H, 1994, STRUCTURAL BIOL, V1, P417	38	362	365	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1208	1212		10.1126/science.7973703	http://dx.doi.org/10.1126/science.7973703			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973703	Green Submitted			2022-12-24	WOS:A1994PT13200045
J	NOBRE, AC; ALLISON, T; MCCARTHY, G				NOBRE, AC; ALLISON, T; MCCARTHY, G			WORD RECOGNITION IN THE HUMAN INFERIOR TEMPORAL-LOBE	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; CORTEX; CELLS; FACE	STUDIES of primates(1) and of patients with brain lesions(2) have shown that the visual system represents the external world in regions and pathways specialized to compute visual features and attributes. For example, object recognition is performed by a ventral pathway located in the inferior portion of the temporal lobe(3). We studied visual processing of words and word-like stimuli (letter-strings) by recording held potentials directly from the human inferior temporal lobe. Our results showed that two discrete portions of the fusiform gyrus responded preferentially to letter-strings. A region of the posterior fusiform gyrus responded equally to words and nonwords, and was unaffected by the semantic context in which words were presented. In contrast, a region of the anterior fusiform gyrus was sensitive to these stimulus dimensions. These regions were distinct from areas that responded to other types of complex visual stimuli, including faces and coloured patterns, and thus form a functionally specialized stream within the ventral visual pathway.	VET ADM MED CTR,NEUROPSYCHOL LAB,W HAVEN,CT 06516; YALE UNIV,SCH MED,DEPT NEUROL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,NEUROSURG SECT,NEW HAVEN,CT 06510	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Yale University				Nobre, Anna Christina/0000-0001-5762-2802				ALLISON T, 1994, J NEUROPHYSIOL, V71, P5; Allison T., 1994, CEREB CORTEX, V5, P544; ALLISON T, 1986, PSYCHOPHYSIOLOGY, P385; Black S., 1994, LOCALIZATION NEUROIM, P331; CORBETTA M, 1991, J NEUROSCI, V11, P2382; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; DERENZI E, 1987, BRAIN, V110, P1099, DOI 10.1093/brain/110.5.1099; DESIMONE R, 1991, J COGNITIVE NEUROSCI, V3, P1, DOI 10.1162/jocn.1991.3.1.1; FARA MJ, 1990, VISUAL AGNOSIA; GROSS CG, 1993, 3RD P ANN NEC RES S, P44; HAXBY JV, 1993, FUNCTIONAL ORG HUMAN, P329; HOWARD D, 1992, BRAIN, V115, P1769, DOI 10.1093/brain/115.6.1769; KUTAS M, 1980, SCIENCE, V207, P203, DOI 10.1126/science.7350657; LUDERS H, 1991, BRAIN, V114, P743, DOI 10.1093/brain/114.2.743; MCCARTHY G, IN PRESS J NEUROSCI; MESULAM MM, 1994, PRINCIPLES PRACTICE, P2640; NOBRE AC, IN PRESS J NEUROSCI; PERRETT DI, 1992, PHILOS T ROY SOC B, V335, P23, DOI 10.1098/rstb.1992.0003; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; ROLLS ET, 1985, VISION RES, V25, P1021, DOI 10.1016/0042-6989(85)90091-4; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SPENCER SS, 1982, ANN NEUROL, V12, P248, DOI 10.1002/ana.410120306; Talairach J., 1988, COPLANAR STEREOTAXIC; UNGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOR; VANESSEN DC, 1992, SCIENCE, V255, P419, DOI 10.1126/science.1734518; WARRINGTON EK, 1980, BRAIN, V103, P99, DOI 10.1093/brain/103.1.99; ZEKL SM, 1990, BRAIN, V113, P1721	29	617	623	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					260	263		10.1038/372260a0	http://dx.doi.org/10.1038/372260a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969469				2022-12-24	WOS:A1994PR88900049
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA PROPOSES SPECIAL LABELING AND PACKAGING TO PREVENT CHILDHOOD IRON POISONING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1488	1488						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966836				2022-12-24	WOS:A1994PQ90000021
J	GRAZIANO, MSA; YAP, GS; GROSS, CG				GRAZIANO, MSA; YAP, GS; GROSS, CG			CODING OF VISUAL SPACE BY PREMOTOR NEURONS	SCIENCE			English	Article							PARIETAL NEURONS; CORTEX; MOVEMENTS; REPRESENTATION; ORGANIZATION; MONKEY	In primates, the premotor cortex is involved in the sensory guidance of movement. Many neurons in ventral premotor cortex respond to visual stimuli in the space adjacent to the hand or arm. These visual receptive fields were found to move when the arm moved but not when the eye moved; that is, they are in arm-centered, not retinocentric, coordinates. Thus, they provide a representation of space near the body that may be useful for the visual control of reaching.			GRAZIANO, MSA (corresponding author), PRINCETON UNIV, DEPT PSYCHOL, PRINCETON, NJ 08544 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH019420] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 19420] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Andersen R A, 1993, Curr Opin Neurobiol, V3, P171, DOI 10.1016/0959-4388(93)90206-E; ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; BRUCE CJ, 1990, NEUROSCI IN, P261; CAMINITI R, 1990, J NEUROSCI, V10, P2039; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; FOGASSI L, 1992, EXP BRAIN RES, V89, P686, DOI 10.1007/BF00229894; GALLETTI C, 1989, J NEUROSCI, V9, P1112; GALLETTI C, 1993, EXP BRAIN RES, V96, P221; GENTILUCCI M, 1988, EXP BRAIN RES, V71, P475, DOI 10.1007/BF00248741; GOLDMANRAKIC PS, 1990, COLD SPRING HARB SYM, V55, P1025; GRAZIANO MS, 1992, BEHAV BRAIN SCI, V15, P750; GRAZIANO MS, ATTENTION PERFORMANC, V16; GRAZIANO MSA, 1993, EXP BRAIN RES, V97, P96; GRAZIANO MSA, 1994, CURR DIR PSYCHOL SCI, V3, P164, DOI 10.1111/1467-8721.ep10770670; GRAZIANO MSA, 1994, COGNITIVE NEUROSCIEN, P1021; GROSS CG, IN PRESS NEUROSCIENT; HE SQ, 1993, J NEUROSCI, V13, P952; MILLER EK, 1993, BRAIN RES, V616, P25, DOI 10.1016/0006-8993(93)90187-R; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; RIZZOLATTI G, 1981, BEHAV BRAIN RES, V2, P147, DOI 10.1016/0166-4328(81)90053-X; Rosenthal Robert., 1985, CONTRAST ANAL FOCUSE; SPARKS DL, 1991, BRAIN SPACE, P3; WISE SP, 1985, ANNU REV NEUROSCI, V8, P1, DOI 10.1146/annurev.ne.08.030185.000245	23	553	560	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1054	1057		10.1126/science.7973661	http://dx.doi.org/10.1126/science.7973661			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973661	Green Published			2022-12-24	WOS:A1994PQ92400048
J	CEPEK, KL; SHAW, SK; PARKER, CM; RUSSELL, GJ; MORROW, JS; RIMM, DL; BRENNER, MB				CEPEK, KL; SHAW, SK; PARKER, CM; RUSSELL, GJ; MORROW, JS; RIMM, DL; BRENNER, MB			ADHESION BETWEEN EPITHELIAL-CELLS AND T-LYMPHOCYTES MEDIATED BY E-CADHERIN AND THE ALPHA(E)BETA(7) INTEGRIN	NATURE			English	Article							MONOCLONAL-ANTIBODY; VLA-4; EXPRESSION; MOLECULES; RECEPTOR; PROTEINS; HOMOLOGY; ANTIGEN; SUBUNIT; FAMILY	IN contrast to sessile cell types, lymphocytes migrate through the vasculature to become diffusely distributed in tissues or organized in lymphoid structures. A complex array of adhesion molecules including selectins, integrins and their counter-receptors mediate lymphocyte homing and migration into tissues and may be constitutively expressed or induced(1,2). However, the molecules that mediate the tissue-specific retention of lymphocytes within the parenchyma have not been identified. Along the epithelium at the basolateral surface of enterocytes, intestinal intraepithelial lymphocytes are found. These T cells of the mucosal immune system serve as a model for the tissue-specific compartmentalization of lymphocytes. We investigated whether the localization of these intestinal intraepithelial lymphocytes could be mediated by specific interactions between adhesion molecules expressed selectively on this subpopulation of T cells and tissue-restricted adhesion molecules on epithelial cells. Here we show that heterotypic adhesive interactions between epithelial cells and intraepithelial lymphocytes in vitro are mediated by E-cadherin and the alpha(E) beta(7) integrin.	HARVARD UNIV,DIV MED SCI,BOSTON,MA 02115; YALE UNIV,DEPT PATHOL,NEW HAVEN,CT 06510	Harvard University; Yale University	CEPEK, KL (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT RHEUMATOL & IMMUNOL,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115, USA.			Shaw, Sunil/0000-0001-9701-6065; Rimm, David/0000-0001-5820-4397				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRENNER MB, 1987, J IMMUNOL, V138, P1502; CEPEK KL, 1993, J IMMUNOL, V150, P3459; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CERFBENSUSSAN N, 1983, J IMMUNOL, V130, P2615; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVID V, 1993, J BIOL CHEM, V268, P9585; DAVIES MDJ, 1981, GUT, V22, P481, DOI 10.1136/gut.22.6.481; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KRUSCHWITZ M, 1991, J CLIN PATHOL, V44, P636, DOI 10.1136/jcp.44.8.636; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mackay C R, 1992, Semin Immunol, V4, P51; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; RIMM DL, 1994, BIOCHEM BIOPH RES CO, V200, P1754, DOI 10.1006/bbrc.1994.1656; ROBERTS AI, 1993, CANCER RES, V53, P1608; RUSSELL GJ, IN PRESS EUR J IMMUN; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TANG AM, 1993, NATURE, V361, P82, DOI 10.1038/361082a0; YUAN Q, 1990, INT IMMUNOL, V2, P1097, DOI 10.1093/intimm/2.11.1097	27	943	961	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					190	193		10.1038/372190a0	http://dx.doi.org/10.1038/372190a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969453				2022-12-24	WOS:A1994PQ68800059
J	VAJANAPHANICH, M; SCHULTZ, C; RUDOLF, MT; WASSERMAN, M; ENYEDI, P; CRAXTON, A; SHEARS, SB; TSIEN, RY; BARRETT, KE; TRAYNORKAPLAN, A				VAJANAPHANICH, M; SCHULTZ, C; RUDOLF, MT; WASSERMAN, M; ENYEDI, P; CRAXTON, A; SHEARS, SB; TSIEN, RY; BARRETT, KE; TRAYNORKAPLAN, A			LONG-TERM UNCOUPLING OF CHLORIDE SECRETION FROM INTRACELLULAR CALCIUM LEVELS BY INS(3,4,5,6)P-4	NATURE			English	Article							EPITHELIAL-CELL LINE; INOSITOL TETRAKISPHOSPHATE; RAT-LIVER; PURIFICATION; PHOSPHATES; TRANSPORT	OSMOREGULATION, inhibitory neurotransmission and pH balance depend on chloride ion (Cl-) flux. In intestinal epithelial cells, apical Cl- channels control salt and fluid secretion and are, in turn, regulated by agonists acting through cyclic nucleotides and internal calcium ion concentration ([Ca2+](i))(1-3). Recently, we found that muscarinic pretreatment prevents [Ca2+](i) increases from eliciting Cl- secretion in T-84 colonic epithelial cells(4). By studying concomitant inositol phosphate metabolism, ae have now identified D-myo-inositol 3,4,5,6-tetrakisphosphate (Ins(3,4,5,6)P-4), as the inositol phosphate most likely to mediate this uncoupling. A novel, membrane-permeant ester prepared by total synthesis delivers Ins(3,4,5,6)P-4 intracellularly and confirms that this emerging messenger(5) does inhibit Cl- flux resulting from thapsigargin- or histamine-induced [Ca2+](i) elevations.	UNIV CALIF SAN DIEGO,SCH MED,DEPT MED 8414,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV BREMEN,INST ORGAN CHEM,W-2800 BREMEN,GERMANY; NIEHS,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of Bremen; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Barrett, Kim Elaine/AAE-7762-2019; Shears, Stephen B/C-6335-2019; Barrett, Kim/AAE-2794-2022	Barrett, Kim Elaine/0000-0002-6704-998X; Shears, Stephen B/0000-0001-7309-8916; Schultz, Carsten/0000-0002-5824-2171				ABDULLAH M, 1992, J BIOL CHEM, V267, P22340; ANGYAL SJ, 1965, J CHEM SOC, P6949, DOI 10.1039/jr9650006949; CRAXTON A, 1994, J BIOL CHEM, V269, P4337; DHARMASATHAPHOR.K, 1984, AM J PHYSIOL, V9, pG204; DHARMSATHAPHORN K, 1989, AM J PHYSIOL, V256, pC1224, DOI 10.1152/ajpcell.1989.256.6.C1224; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; DHARMSATHAPHORN K, 1991, TXB INTERNAL MED, P398; FRIZZELL RA, 1986, ION TRANSPORT EPITHE, V36, P137; KACHINTORN U, 1993, BRIT J PHARMACOL, V109, P510, DOI 10.1111/j.1476-5381.1993.tb13599.x; KACHINTORN U, 1993, AM J PHYSIOL, V264, pC671, DOI 10.1152/ajpcell.1993.264.3.C671; MANDEL KG, 1986, J BIOL CHEM, V261, P704; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; PITTET D, 1989, J BIOL CHEM, V264, P18489; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; SCHULTZ C, 1993, J BIOL CHEM, V268, P6316; TRAYNORKAPLAN AE, IN PRESS AM J PHYSL; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; WONG NS, 1988, BIOCHEM J, V252, P1	20	171	174	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					711	714		10.1038/371711a0	http://dx.doi.org/10.1038/371711a0			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935818				2022-12-24	WOS:A1994PM77300059
J	KAISER, J				KAISER, J			BREAST-CANCER - ARMY DOLES OUT ITS FIRST 210-MILLION-DOLLARS	SCIENCE			English	Editorial Material																		1994, SCIENCE, V264, P1068	1	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					212	212		10.1126/science.7939652	http://dx.doi.org/10.1126/science.7939652			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939652				2022-12-24	WOS:A1994PM13400011
J	BAYNASH, AG; HOSODA, K; GIAID, A; RICHARDSON, JA; EMOTO, N; HAMMER, RE; YANAGISAWA, M				BAYNASH, AG; HOSODA, K; GIAID, A; RICHARDSON, JA; EMOTO, N; HAMMER, RE; YANAGISAWA, M			INTERACTION OF ENDOTHELIN-3 WITH ENDOTHELIN-B RECEPTOR IS ESSENTIAL FOR DEVELOPMENT OF EPIDERMAL MELANOCYTES AND ENTERIC NEURONS	CELL			English	Article							PROTEIN-KINASE-C; PROCESSING ENDOPROTEASES; SUBTILISIN FAMILY; NEURAL CREST; CLONING; CDNA; GENE; MICE; EXPRESSION; CELLS	Defects in the gene encoding the endothelin-B receptor produce aganglionic megacolon and pigmentary disorders in mice and humans. We report that a targeted disruption of the mouse endothelin-3 ligand (EDN3) gene produces a similar recessive phenotype of megacolon and coat color spotting. A natural recessive mutation that results in the same developmental defects in mice, lethal spotting (Is), failed to complement the targeted EDN3 allele. The Is mice carry a point mutation of the EDN3 gene, which replaces the Arg residue at the C-terminus of the inactive intermediate big EDN3 with a Trp residue. This mutation prevents the proteolytic activation of big EDN3 by ECE-1. These findings indicate that interaction of EDN3 with the endothelin-B receptor is essential in the development of neural crest-derived cell lineages. We postulate that defects in the human EDN3 gene may cause Hirschsprung's disease.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; MONTREAL GEN HOSP,DEPT PATHOL,MONTREAL,PQ H3G 1A4,CANADA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; McGill University	BAYNASH, AG (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.			Hammer, Robert E./0000-0001-5487-7551; Emoto, Noriaki/0000-0001-6673-2616				ANDERSON DJ, 1994, FASEB J, V8, P707, DOI 10.1096/fasebj.8.10.8050669; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARINAMI T, 1991, AM J HUM GENET, V48, P990; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BLOCH KD, 1989, J BIOL CHEM, V264, P18156; BRONNERFRASER M, 1994, FASEB J, V8, P699, DOI 10.1096/fasebj.8.10.8050668; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; DOUGLAS SA, 1994, TRENDS PHARMACOL SCI, V15, P313, DOI 10.1016/0165-6147(94)90019-1; EIPPER BA, 1993, PROTEIN SCI, V2, P489; FABBRINI MS, 1993, P NATL ACAD SCI USA, V90, P3923, DOI 10.1073/pnas.90.9.3923; Hosoda K, 1994, CELL, V79; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KAPUR RP, 1993, DEVELOPMENT, V117, P993; KOSAKA T, 1994, J BIOCHEM-TOKYO, V116, P443, DOI 10.1093/oxfordjournals.jbchem.a124544; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LANE PW, 1966, J HERED, V57, P29, DOI 10.1093/oxfordjournals.jhered.a107457; LEDOUARIN NM, 1994, CURR OPIN GENET DEV, V4, P685, DOI 10.1016/0959-437X(94)90135-P; Lyon M., 1989, GENETIC VARIANTS STR; MALEK AM, 1993, P NATL ACAD SCI USA, V90, P5999, DOI 10.1073/pnas.90.13.5999; MATSUMOTO H, 1989, BIOCHEM BIOPH RES CO, V164, P74, DOI 10.1016/0006-291X(89)91684-7; MAYER TC, 1977, DEV BIOL, V56, P255, DOI 10.1016/0012-1606(77)90268-8; OHLSTEIN EH, 1994, P NATL ACAD SCI USA, V91, P8052, DOI 10.1073/pnas.91.17.8052; OKADA K, 1993, EUR J BIOCHEM, V218, P493, DOI 10.1111/j.1432-1033.1993.tb18401.x; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; PUFFENBERGER EG, 1994, CELL, V79; RANDALL MD, 1994, LANCET, V344, P832, DOI 10.1016/S0140-6736(94)92819-3; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; ROTHMAN TP, 1993, DEV BIOL, V159, P559, DOI 10.1006/dbio.1993.1264; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SHIBA R, 1992, BIOCHEM BIOPH RES CO, V186, P588, DOI 10.1016/S0006-291X(05)80849-6; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; STEINER DF, 1992, J BIOL CHEM, V267, P23435; SUZUKI N, 1990, BIOCHEM BIOPH RES CO, V169, P809, DOI 10.1016/0006-291X(90)90403-A; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	43	724	745	0	26	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1277	1285		10.1016/0092-8674(94)90018-3	http://dx.doi.org/10.1016/0092-8674(94)90018-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001160				2022-12-24	WOS:A1994PZ86000018
J	FAN, CM; TESSIERLAVIGNE, M				FAN, CM; TESSIERLAVIGNE, M			PATTERNING OF MAMMALIAN SOMITES BY SURFACE ECTODERM AND NOTOCHORD - EVIDENCE FOR SCLEROTOME INDUCTION BY A HEDGEHOG HOMOLOG	CELL			English	Article							FLOOR PLATE; CELL-DIFFERENTIATION; NEURAL-TUBE; GENE; MOUSE; SEGMENTATION; MORPHOGENESIS; SPECIFICATION; NEUROGENESIS; EXPRESSION	An early step in the development of vertebrae, ribs, muscle, and dermis is the differentiation of the semitic mesoderm into dermomyotome dorsally and sclerotome ventrally. To analyze this process, we have developed an in vitro assay for semitic mesoderm differentiation. We show that sclerotomal markers can be induced by a diffusible factor secreted by notochord and floor plate and that heterologous cells expressing Sonic hedgehog (shh/vhh-1) mimic this effect. In contrast, expression of dermomyotomal markers can be caused by a contact-dependent signal from surface ectoderm and a diffusible signal from dorsal neural tube. Our results extend previous studies by suggesting that dorsoventral patterning of somites involves the coordinate action of multiple dorsalizing and ventralizing signals and that a diffusible form of Shh/Vhh-1 mediates sclerotome induction.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	FAN, CM (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143, USA.							AOYAMA H, 1988, DEVELOPMENT, V104, P15; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; BUFFINGER N, 1994, DEVELOPMENT, V120, P1443; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRIST B, 1974, Verhandlungen der Anatomischen Gesellschaft, V68, P573; CHRIST B, 1992, ANAT EMBRYOL, V186, P505; CREWS S, 1992, J EXP ZOOL, V261, P234, DOI 10.1002/jez.1402610303; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; Dickinson ME, 1992, CURR OPIN GENET DEV, V2, P562, DOI 10.1016/S0959-437X(05)80172-8; DIETRICH S, 1993, MECH DEVELOP, V44, P189, DOI 10.1016/0925-4773(93)90067-8; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; Gallera J., 1966, Revue Suisse de Zoologie, V73, P492; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; JESSELL TM, 1992, HARVEY LECT, V86, P87; JOHNSON RL, 1994, CELL, V79; JONES CM, 1991, DEVELOPMENT, V111, P531; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KENNYMOBBS T, 1987, DEVELOPMENT, V100, P449; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOSEKI H, 1993, DEVELOPMENT, V119, P649; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; KURATANI S, 1994, DEV BIOL, V161, P357, DOI 10.1006/dbio.1994.1037; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MOURY JD, 1989, DEV BIOL, V141, P243; OFARRELL F, 1994, NATURE, V368, P188; ORDAHL CP, 1993, MOL BASIS MORPHOGENE, P165; PARR BA, 1993, DEVELOPMENT, V119, P247; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RIDDLE RD, 1993, CELL, V75, P1501; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RONG PM, 1992, DEVELOPMENT, V115, P657; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH JC, 1994, CELL, V76, P193, DOI 10.1016/0092-8674(94)90325-5; STERN CD, 1988, DEVELOPMENT, V104, P231; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAM PPL, 1986, J EMBRYOL EXP MORPH, V92, P269; TESSIERLAVIGNE M, 1987, NATURE, V336, P775; THEILER K, 1988, ADV ANAT EMBRYOL CEL, V112, P1; WATTERSON RL, 1954, AM J ANAT, V95, P337, DOI 10.1002/aja.1000950302; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I	49	507	542	1	20	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1175	1186		10.1016/0092-8674(94)90009-4	http://dx.doi.org/10.1016/0092-8674(94)90009-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001153				2022-12-24	WOS:A1994PZ86000009
J	RUSTGI, AK				RUSTGI, AK			MEDICAL PROGRESS - HEREDITARY GASTROINTESTINAL POLYPOSIS AND NONPOLYPOSIS SYNDROMES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FAMILIAL ADENOMATOUS POLYPOSIS; PEUTZ-JEGHERS SYNDROME; COLI GARDNERS-SYNDROME; OCULAR FUNDUS LESIONS; MUIR-TORRE SYNDROME; (LYNCH SYNDROME-I; APC GENE-PRODUCT; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; JUVENILE POLYPOSIS		HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	RUSTGI, AK (corresponding author), MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,JACKSON 7,50 BLOSSOM ST,BOSTON,MA 02114, USA.				PHS HHS [R01 43351] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAUGHMAN FA, 1969, NEW ENGL J MED, V281, P1345, DOI 10.1056/NEJM196912112812407; BECKER JM, 1991, SURGERY, V110, P718; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOMAN BM, 1988, CANCER GENET CYTOGEN, V34, P153, DOI 10.1016/0165-4608(88)90182-3; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUFILL JA, 1990, ANN INTERN MED, V113, P779, DOI 10.7326/0003-4819-113-10-779; BULOW S, 1984, DIS COLON RECTUM, V27, P105, DOI 10.1007/BF02553986; BURDICK D, 1982, CANCER, V50, P2139, DOI 10.1002/1097-0142(19821115)50:10<2139::AID-CNCR2820501028>3.0.CO;2-K; BURT RW, 1984, GASTROENTEROLOGY, V86, P295; BURT RW, 1988, GASTROENTEROL CLIN N, V17, P657; Bussey H.J.R., 1975, FAMILIAL POLYPOSIS C; BUSSEY HJR, 1978, GASTROENTEROLOGY, V74, P1325; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CARLSON HE, 1986, AM J HUM GENET, V38, P908; COHEN PR, 1991, AM J MED, V90, P606; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FISHEL R, 1994, CELL, V77, P167; FOLEY TR, 1988, GASTROENTEROLOGY, V95, P1535, DOI 10.1016/S0016-5085(88)80074-X; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; GOODMAN ZD, 1979, CANCER, V43, P1906, DOI 10.1002/1097-0142(197905)43:5<1906::AID-CNCR2820430548>3.0.CO;2-O; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GURBUZ AK, 1994, GUT, V35, P377, DOI 10.1136/gut.35.3.377; HAGGITT RC, 1986, AM J SURG PATHOL, V10, P871, DOI 10.1097/00000478-198612000-00006; HAKALA T, 1991, CANCER, V68, P1656, DOI 10.1002/1097-0142(19911001)68:7<1656::AID-CNCR2820680732>3.0.CO;2-7; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; HIXSON LJ, 1993, AM J GASTROENTEROL, V88, P1652; HOWELL J, 1981, J PEDIATR SURG, V16, P82, DOI 10.1016/S0022-3468(81)80124-8; IIDA M, 1985, GASTROENTEROLOGY, V89, P1021, DOI 10.1016/0016-5085(85)90203-3; IIDA M, 1989, GASTROENTEROLOGY, V96, P1301, DOI 10.1016/S0016-5085(89)80017-4; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JARVINEN H, 1983, GUT, V24, P333, DOI 10.1136/gut.24.4.333; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KLEIN WA, 1987, CANCER, V60, P2863, DOI 10.1002/1097-0142(19871215)60:12<2863::AID-CNCR2820601202>3.0.CO;2-I; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KONISHI F, 1987, DIS COLON RECTUM, V30, P790, DOI 10.1007/BF02554629; KURTZ RC, 1987, DIGEST DIS SCI, V32, P459, DOI 10.1007/BF01296027; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LAW IP, 1977, CANCER-AM CANCER SOC, V39, P1229, DOI 10.1002/1097-0142(197703)39:3<1229::AID-CNCR2820390331>3.0.CO;2-J; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LIU B, 1994, CANCER RES, V54, P4590; LUK GD, 1984, NEW ENGL J MED, V311, P80, DOI 10.1056/NEJM198407123110202; LYNCH HT, 1990, J UROLOGY, V143, P24, DOI 10.1016/S0022-5347(17)39853-1; LYNCH HT, 1992, DIS COLON RECTUM, V35, P411, DOI 10.1007/BF02049396; LYNCH HT, 1985, CANCER, V56, P934, DOI 10.1002/1097-0142(19850815)56:4<934::AID-CNCR2820560439>3.0.CO;2-I; LYNCH HT, 1985, BRIT J CANCER, V52, P271, DOI 10.1038/bjc.1985.187; LYNCH HT, 1985, BRIT J DERMATOL, V113, P295, DOI 10.1111/j.1365-2133.1985.tb02081.x; LYNCH HT, 1993, CANCER, V71, P2709, DOI 10.1002/1097-0142(19930501)71:9<2709::AID-CNCR2820710904>3.0.CO;2-T; LYNCH HT, 1985, CANCER, V56, P939, DOI 10.1002/1097-0142(19850815)56:4<939::AID-CNCR2820560440>3.0.CO;2-T; LYNCH HT, 1991, SEMIN ONCOL, V18, P337; MARRA G, 1994, J CLIN GASTROENTEROL, V18, P42, DOI 10.1097/00004836-199401000-00011; MECKLIN JP, 1992, CANCER, V69, P1112; MECKLIN JP, 1987, GASTROENTEROLOGY, V93, P101; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; NICHOLLS RJ, 1988, BRIT MED J, V296, P1707, DOI 10.1136/bmj.296.6638.1707-a; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1980, DOI 10.1016/0016-5085(92)90322-P; OLSCHWANG S, 1993, CELL, V75, P959, DOI 10.1016/0092-8674(93)90539-3; ORIORDAIN DS, 1991, CANCER, V68, P889, DOI 10.1002/1097-0142(19910815)68:4<889::AID-CNCR2820680435>3.0.CO;2-0; PAINTER TA, 1985, CANCER, V55, P2001, DOI 10.1002/1097-0142(19850501)55:9<2001::AID-CNCR2820550929>3.0.CO;2-7; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1991, CANCER RES, V51, P4135; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PERZIN KH, 1982, CANCER-AM CANCER SOC, V49, P971, DOI 10.1002/1097-0142(19820301)49:5<971::AID-CNCR2820490522>3.0.CO;2-1; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RICHARDS RC, 1981, CANCER, V47, P597, DOI 10.1002/1097-0142(19810201)47:3<597::AID-CNCR2820470329>3.0.CO;2-Z; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUTGEERTS P, 1981, GASTROINTEST ENDOSC, V27, P22, DOI 10.1016/S0016-5107(81)73137-7; SALEM OS, 1983, J AM ACAD DERMATOL, V8, P686, DOI 10.1016/S0190-9622(83)70081-2; SARRE RG, 1987, SURGERY, V101, P50; SCULLY RE, 1970, CANCER, V25, P1107, DOI 10.1002/1097-0142(197005)25:5<1107::AID-CNCR2820250516>3.0.CO;2-7; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SOGOL PB, 1983, WESTERN J MED, V139, P324; SPIRIO L, 1992, AM J HUM GENET, V51, P92; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; STARINK TM, 1986, CLIN GENET, V29, P222; STERN HS, 1990, SURGERY, V108, P528; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TONELLI F, 1985, DIS COLON RECTUM, V28, P664, DOI 10.1007/BF02553447; TOPS CMJ, 1993, AM J MED GENET, V47, P563, DOI 10.1002/ajmg.1320470425; TRABOULSI EI, 1990, ARCH OPHTHALMOL-CHIC, V108, P525, DOI 10.1001/archopht.1990.01070060073052; TRABOULSI EI, 1987, NEW ENGL J MED, V316, P661, DOI 10.1056/NEJM198703123161104; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; VOGEL VG, 1989, HEMATOL ONCOL CLIN N, V3, P35, DOI 10.1016/S0889-8588(18)30566-5; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WATANABE H, 1978, HUM PATHOL, V9, P269, DOI 10.1016/S0046-8177(78)80085-9; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WINAWER SJ, 1991, JNCI-J NATL CANCER I, V83, P243, DOI 10.1093/jnci/83.4.243	105	179	188	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	1994	331	25					1694	1702		10.1056/NEJM199412223312507	http://dx.doi.org/10.1056/NEJM199412223312507			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX382	7969362				2022-12-24	WOS:A1994PX38200007
J	MUSCATELLI, F; STROM, TM; WALKER, AP; ZANARIA, E; RECAN, D; MEINDL, A; BARDONI, B; GUIOLI, S; ZEHETNER, G; RABL, W; SCHWARZ, HP; KAPLAN, JC; CAMERINO, G; MEITINGER, T; MONACO, AP				MUSCATELLI, F; STROM, TM; WALKER, AP; ZANARIA, E; RECAN, D; MEINDL, A; BARDONI, B; GUIOLI, S; ZEHETNER, G; RABL, W; SCHWARZ, HP; KAPLAN, JC; CAMERINO, G; MEITINGER, T; MONACO, AP			MUTATIONS IN THE DAX-1 GENE GIVE RISE TO BOTH X-LINKED ADRENAL HYPOPLASIA CONGENITA AND HYPOGONADOTROPIC HYPOGONADISM	NATURE			English	Article							GLYCEROL KINASE-DEFICIENCY; RESTRICTION MAP; INDUCE PUBERTY; HEMOPHILIA-A; XP21; DELETION; FAILURE; CLONING; DISTAL; CONTIG	ADRENAL hypoplasia congenita (AHC) is an X-linked disorder characterized by primary adrenal insufficiency(1,2). Hypogonadotropic hypogonadism (HHG) is frequently associated with this disorder but is thought not to be caused by the low adrenal androgen levels due to adrenal hypoplasia(3,4). It is uncertain whether there are two distinct yet physically linked genes responsible for AHC and HHG or a single gene responsible for both diseases. AHC can occur as a part of a contiguous deletion syndrome together with Duchenne muscular dystrophy (DMD) and/or glycerol kinase deficiency (GKD). From the analysis of deletions, the following gene order has been deduced: Xpter-AHC-GKD-DMD-cen(5,6). An AHC critical region of 200-500 kilobases has been defined by physical mapping(7,8) and partially overlaps with a 160-kilobase dosage-sensitive sex (DSS) reversal critical region(9). The DAX-1 (DSS-AHC critical region on the X, gene 1) gene was isolated and found to encode a new member of the nuclear hormone receptor family(10). Here we report that DAX-1 is deleted in 14 patients and point mutations were found in the coding region in DNA from 12 unrelated individuals. All AHC patients over 14 years old and with only point mutations in DAX-1 mere also diagnosed with HHG, confirming that the DAX-1 gene is responsible for both X-linked AHC and HHG. But in four sporadic cases and a single familial case, no point mutations were found, suggesting genetic heterogeneity or differential expression of DAX-1.	UNIV MUNICH,KINDERPOLIKLIN,PADIAT GENET ABT,D-80336 MUNICH,GERMANY; UNIV PAVIA,I-27100 PAVIA,ITALY; HOP COCHIN,F-75014 PARIS,FRANCE; ICRF LABS,LONDON WC2A 3PX,ENGLAND; TECH UNIV MUNICH,KINDERKLIN,D-80804 MUNICH,GERMANY; UNIV MUNICH,DR VON HAUNERSCHES KINDERSPITAL,D-80337 MUNICH,GERMANY	University of Munich; University of Pavia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Technical University of Munich; University of Munich	MUSCATELLI, F (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND.		Bardoni, Barbara/F-9918-2013; Monaco, Anthony P/A-4495-2010; Muscatelli, Françoise/P-4650-2016; Walker, Ann P/C-1628-2008	Monaco, Anthony P/0000-0001-7480-3197; Muscatelli, Françoise/0000-0003-4001-6528; Guioli, Silvana/0000-0002-4920-7745; Meitinger, Thomas/0000-0002-8838-8403; Bardoni, Barbara/0000-0001-6411-1517	Telethon [B.05] Funding Source: Medline	Telethon(Fondazione Telethon)		BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; BASERGA SJ, 1988, P NATL ACAD SCI USA, V85, P2056, DOI 10.1073/pnas.85.7.2056; BAXENDALE S, 1993, NAT GENET, V4, P181, DOI 10.1038/ng0693-181; CHELLY J, 1988, HUM GENET, V78, P222, DOI 10.1007/BF00291665; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; COHEN HN, 1982, LANCET, V2, P1471; FAIRWEATHER N, 1994, HUM MOL GENET, V3, P29, DOI 10.1093/hmg/3.1.29; FRANCKE U, 1987, AM J HUM GENET, V40, P212; GOONEWARDENA P, 1989, CLIN GENET, V35, P5; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; Kelch RP, 1984, PEDIATR ADOLESC ENDO, V13, P156; KIKUCHI K, 1987, ACTA ENDOCRINOL-COP, V114, P153, DOI 10.1530/acta.0.1140153; KLECZKOWSKA A, 1991, GENET COUNSELING, V1, P241; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MARHLENS F, 1987, HUM GENET, V77, P379; MATFIN G, 1994, CLIN ENDOCRINOL, V40, P807, DOI 10.1111/j.1365-2265.1994.tb02517.x; NAYLOR JA, 1993, HUM MOL GENET, V2, P11, DOI 10.1093/hmg/2.1.11; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; RACKWITZ HR, 1985, GENE, V40, P259, DOI 10.1016/0378-1119(85)90048-4; RECAN D, 1992, J CLIN INVEST, V89, P712, DOI 10.1172/JCI115640; Sambrook J., 1989, MOL CLONING LAB MANU; SIZONENKO PC, 1978, AM J DIS CHILD, V132, P704, DOI 10.1001/archpedi.1978.02120320064015; WALKER AP, 1992, HUM MOL GENET, V1, P579, DOI 10.1093/hmg/1.8.579; WALKER AP, 1993, HUM MOL GENET, V2, P107, DOI 10.1093/hmg/2.2.107; WORLEY KC, 1993, GENOMICS, V16, P407, DOI 10.1006/geno.1993.1204; YATES JRW, 1987, CYTOGENET CELL GENET, V46, P723; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; ZEHETNER G, 1986, NUCLEIC ACIDS RES, V14, P335, DOI 10.1093/nar/14.1.335	29	586	609	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					672	676		10.1038/372672a0	http://dx.doi.org/10.1038/372672a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990958				2022-12-24	WOS:A1994PX30700085
J	STARK, K; VAINIO, S; VASSILEVA, G; MCMAHON, AP				STARK, K; VAINIO, S; VASSILEVA, G; MCMAHON, AP			EPITHELIAL TRANSFORMATION OF METANEPHRIC MESENCHYME IN THE DEVELOPING KIDNEY REGULATED BY WNT-4	NATURE			English	Article							DEVELOPING EXCRETORY SYSTEM; WILMS-TUMOR GENE; MOUSE DEVELOPMENT; EXPRESSION; PROTOONCOGENE; EMBRYO; DISRUPTION; HOMOLOG	THE kidney has been widely exploited as a model system for the study of tissue inductions regulating vertebrate organogenesis(1,2). Kidney development is initiated by the ingrowth of the Wolfian duct-derived ureteric bud into the presumptive kidney mesenchyme. In response to a signal from the ureter, mesenchymal cells condense, aggregate into pretubular clusters and undergo an epithelial conversion generating a simple tubule. This then undergoes morphogenesis and is transformed into the excretory system of the kidney, the nephron. We report here that the expression of Wnt-4, which encodes a secreted glycoprotein, correlates with, and is required for, kidney tubulogenesis. Mice lacking Wnt-1 activity fail to form pretubular cell aggregates; however, other aspects of mesenchymal and ureteric development are unaffected. Thus, Wnt-4 appears to act as an autoinducer of the mesenchyme to epithelial transition that underlies nephron development.	HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, BIOLABS, CAMBRIDGE, MA 02138 USA	Harvard University			McMahon, Andrew P/ABE-7520-2020; Vassileva, Galya/A-6807-2009	Vainio, Seppo/0000-0001-9319-3566				ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; GUMBINER BM, 1993, J CELL SCI, P155; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOON RT, 1993, DEVELOPMENT, V119, P97; MUGRAUER G, 1991, J CELL BIOL, V112, P13, DOI 10.1083/jcb.112.1.13; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PARR BA, 1993, DEVELOPMENT, V119, P247; PLACHOV D, 1990, DEVELOPMENT, V110, P643; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; SAXEN L, 1971, EXP CELL RES, V66, P369, DOI 10.1016/0014-4827(71)90690-2; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHIMAMURA K, 1994, DEVELOPMENT, V120, P2225; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SONNENBERG E, 1991, EMBO J, V10, P3693, DOI 10.1002/j.1460-2075.1991.tb04937.x; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; VESTWEBER D, 1985, DEV BIOL, V112, P213, DOI 10.1016/0012-1606(85)90135-6; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	30	845	872	0	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 15	1994	372	6507					679	683		10.1038/372679a0	http://dx.doi.org/10.1038/372679a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990960				2022-12-24	WOS:A1994PX30700087
J	LAI, CG; LYMAN, RF; LONG, AD; LANGLEY, CH; MACKAY, TFC				LAI, CG; LYMAN, RF; LONG, AD; LANGLEY, CH; MACKAY, TFC			NATURALLY-OCCURRING VARIATION IN BRISTLE NUMBER AND DNA POLYMORPHISMS AT THE SCABROUS LOCUS OF DROSOPHILA-MELANOGASTER	SCIENCE			English	Article							PERIPHERAL NERVOUS-SYSTEM; STABILIZING SELECTION; MUTATION; GENETICS; BALANCE	The association between quantitative genetic variation in bristle number and molecular Variation at a candidate neurogenic locus, scabrous, was examined in Drosophila melanogaster. Approximately 32 percent of the genetic Variation in abdominal bristle number (21 percent for sternopleural bristle number) among 47 second chromosomes from a natural population was correlated with DNA sequence polymorphisms at this locus. Several polymorphic sites associated with large phenotypic effects occurred at intermediate frequency. Quantitative genetic variation in natural populations caused by alleles that have large effects at a few loci and that segregate at intermediate frequencies conflicts with the classical infinitesimal model of the genetic basis of quantitative variation.	N CAROLINA STATE UNIV, DEPT GENET, RALEIGH, NC 27695 USA; MCMASTER UNIV, DEPT BIOL, HAMILTON L8S 4K1, ON, CANADA	University of North Carolina; North Carolina State University; McMaster University	LAI, CG (corresponding author), UNIV CALIF DAVIS, CTR POPULAT BIOL, DAVIS, CA 95616 USA.			Lai, Chao-Qiang/0000-0003-1107-8375; Long, Tony/0000-0002-5007-8514	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM045344, R01GM045146] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45146, GM45344] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUADE M, 1994, P NATL ACAD SCI USA, V91, P4658, DOI 10.1073/pnas.91.11.4658; AGUADE M, 1989, GENETICS, V122, P607; AQUADRO CF, 1992, TRENDS GENET, V8, P355, DOI 10.1016/0168-9525(92)90281-8; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BARTON NH, 1989, ANNU REV GENET, V23, P337, DOI 10.1146/annurev.ge.23.120189.002005; CLAYTON G. A., 1957, JOUR GENETICS, V55, P131, DOI 10.1007/BF02981620; Falconer D. S., 1989, Introduction to quantitative genetics.; Frankham R., 1980, Selection experiments in laboratory and domestic animals., P56; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GRABA Y, 1992, EMBO J, V11, P3375, DOI 10.1002/j.1460-2075.1992.tb05416.x; HELD LI, 1991, BIOESSAYS, V13, P633, DOI 10.1002/bies.950131203; HILL WG, 1990, 4TH WORLD C GEN APPL, P219; HOLM S, 1979, SCAND J STAT, V6, P65; KEARSEY MJ, 1970, HEREDITY, V25, P11, DOI 10.1038/hdy.1970.2; KEIGHTLEY PD, 1990, P ROY SOC B-BIOL SCI, V242, P95, DOI 10.1098/rspb.1990.0110; KEIGHTLEY PD, 1988, GENET RES, V52, P33, DOI 10.1017/S0016672300027282; KONDRASHOV AS, 1992, GENETICS, V132, P603; LANDE R, 1975, GENET RES, V26, P221, DOI 10.1017/S0016672300016037; LANGLEY CH, 1990, POPULATION BIOL GENE, P75; Long A., UNPUB; LYNCH M, 1986, EVOLUTION, V40, P915, DOI 10.1111/j.1558-5646.1986.tb00561.x; MACKAY TFC, 1990, NATURE, V348, P64, DOI 10.1038/348064a0; MACKAY TFC, 1990, 4TH P WORLD C GEN AP; MARTIN R, 1990, BIOTECHNIQUES, V9, P762; MCBRIDE G, 1963, GENET RES, V4, P356, DOI 10.1017/S001667230000375X; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; NUZHDIN SV, INPRESS GENETICS; ORR HA, 1992, AM NAT, V140, P725, DOI 10.1086/285437; POSAKONY JW, 1994, CELL, V76, P415, DOI 10.1016/0092-8674(94)90105-8; SHERIDAN A K, 1968, Theoretical and Applied Genetics, V38, P179, DOI 10.1007/BF00935264; SIMPSON P, 1990, DEVELOPMENT, V109, P509; TURELLI M, 1984, THEOR POPUL BIOL, V25, P138, DOI 10.1016/0040-5809(84)90017-0	33	135	136	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	1994	266	5191					1697	1702		10.1126/science.7992053	http://dx.doi.org/10.1126/science.7992053			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992053				2022-12-24	WOS:A1994PW30800038
J	GREENGARD, JS; EICHINGER, S; GRIFFIN, JH; BAUER, KA				GREENGARD, JS; EICHINGER, S; GRIFFIN, JH; BAUER, KA			VARIABILITY OF THROMBOSIS AMONG HOMOZYGOUS SIBLINGS WITH RESISTANCE TO ACTIVATED PROTEIN-C DUE TO AN ARG-]GLN MUTATION IN THE GENE FOR FACTOR-V	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							POOR ANTICOAGULANT RESPONSE; VENOUS THROMBOSIS; PURPURA FULMINANS; DEFICIENCY; THROMBOPHILIA; FRAGMENT; MARKERS; NEWBORN; INFANT		SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, DEPT MED, BOSTON, MA USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, BOSTON, MA USA	Scripps Research Institute; Scripps Research Institute; Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School				Griffin, John/0000-0002-4302-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014, R01HL021544] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 21544, HL 33014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUER KA, 1984, J CLIN INVEST, V74, P2033, DOI 10.1172/JCI111626; BAUER KA, 1988, BLOOD, V71, P1418; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BRANSON HE, 1983, LANCET, V2, P1165; CONARD J, 1993, BLOOD, V82, P1159; CRIPE LD, 1992, BIOCHEMISTRY-US, V31, P3777, DOI 10.1021/bi00130a007; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; FAIONI EM, 1993, THROMB HAEMOSTASIS, V70, P1067; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; GRIFFIN JH, 1993, BLOOD, V82, P1989; HALBMAYER WM, 1994, BLOOD COAGUL FIBRIN, V5, P51, DOI 10.1097/00001721-199402000-00008; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LINDBLOM B, 1988, GENE ANAL TECH, V5, P97, DOI 10.1016/0735-0651(88)90003-9; MAHASANDANA C, 1990, J PEDIATR-US, V117, P750, DOI 10.1016/S0022-3476(05)83335-9; MANNUCCI PM, 1992, THROMB HAEMOSTASIS, V67, P200; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; SUN X, 1994, BLOOD, V83, P3120; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TEITEL JM, 1982, BLOOD, V59, P1086; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8	24	138	140	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1559	1562		10.1056/NEJM199412083312305	http://dx.doi.org/10.1056/NEJM199412083312305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV292	7969326				2022-12-24	WOS:A1994PV29200005
J	STEVENSON, JC; GODSLAND, IF; WYNN, V				STEVENSON, JC; GODSLAND, IF; WYNN, V			CARDIOLOGISTS REBUKED	LANCET			English	Editorial Material											STEVENSON, JC (corresponding author), WYNN INST METAB RES, LONDON NW8 9SQ, ENGLAND.							BERG G, 1994, MODERN MANAGEMENT ME; CLARKE KW, 1994, BMJ-BRIT MED J, V309, P563, DOI 10.1136/bmj.309.6954.563; COLLINS P, 1993, LANCET, V341, P1264, DOI 10.1016/0140-6736(93)91158-I; JACKSON G, 1994, BRIT MED J, V309, P555, DOI 10.1136/bmj.309.6954.555; LACROIX AZ, 1989, AM J EPIDEMIOL, V129, P669, DOI 10.1093/oxfordjournals.aje.a115183; LEY CJ, 1994, J AM COLL CARDIOL, V23, P377, DOI 10.1016/0735-1097(94)90423-5; OLIVER MF, 1994, LANCET, V344, P633; PEDERSEN TR, 1994, LANCET, V344, P1383; PYORALA K, 1994, EUR HEART J, V15, P1300; ROBERTS WC, 1993, AM J CARDIOL, V72, P745, DOI 10.1016/0002-9149(93)90898-M; STEVENSON JC, 1994, HORIZONS MED, V5, P92; WILKINSON P, 1994, BRIT MED J, V309, P566, DOI 10.1136/bmj.309.6954.566; 1994, EUR HEART J S, V15	13	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 3	1994	344	8936					1557	1557		10.1016/S0140-6736(94)90356-5	http://dx.doi.org/10.1016/S0140-6736(94)90356-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983960				2022-12-24	WOS:A1994PV01700016
J	THALI, M; BUKOVSKY, A; KONDO, E; ROSENWIRTH, B; WALSH, CT; SODROSKI, J; GOTTLINGER, HG				THALI, M; BUKOVSKY, A; KONDO, E; ROSENWIRTH, B; WALSH, CT; SODROSKI, J; GOTTLINGER, HG			FUNCTIONAL ASSOCIATION OF CYCLOPHILIN-A WITH HIV-1 VIRIONS	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CIS-TRANS ISOMERASE; BINDING-PROTEIN; CYCLOSPORINE-A; HISTOCOMPATIBILITY; REPLICATION; CELLS; GENE	CYCLOPHILINS are a family of proteins that bind the immunosuppressant cyclosporin A, possess peptidyl-prolyl cis-trans isomerase activity, and assist in the folding of proteins(1-6). Human cyclophilins A and B are host cell proteins that bind specifically to the HIV-1 Gag polyprotein p55(gag) in vitro(7). Here we report that viral particles formed by p55(gag), in contrast to particles formed by the Gag polyproteins of other retroviruses, contain significant amounts of cyclophilin A. Sequences in the capsid domain of p55(gag) are both required and sufficient for the virion-association of cyclophilin A. The association of cyclophilin A with HIV-1 virions was inhibited in a dose-dependent manner by cyclosporin A as well as by SDZ NIM811 ([Melle-4] cyclosporin), a non-immunosuppressive analogue of cyclosporin A(8). Drug-induced reductions in virion-associated cyclophilin A levels were accompanied by reductions in virion infectivity, indicating that the association is functionally relevant. Moreover, SDZ NIM811 inhibited the replication of HIV-1 but was inactive against SIVIMAC, a primate immunodeficiency virus closely related to HIV-1, which does not incorporate cyclophilin A.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HUMAN RETROVIROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; SANDOZ GMBH,FORSCHUNGSINST,A-1235 VIENNA,AUSTRIA; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Novartis; Sandoz; Harvard University; Harvard Medical School				Gottlinger, Heinrich/0000-0003-4124-5824; Thali, Markus/0000-0001-8621-2095				ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DORFMAN T, 1994, J VIROL, V68, P1689, DOI 10.1128/JVI.68.3.1689-1696.1994; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GELDERBLOM H, 1987, Z NATURFORSCH C, V42, P1328; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; GOTTLINGER HG, 1993, P NATL ACAD SCI USA, V90, P7381, DOI 10.1073/pnas.90.15.7381; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; KANNAGI M, 1987, J VIROL, V61, P1421, DOI 10.1128/JVI.61.5.1421-1426.1987; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MAMMANO F, 1994, J VIROL, V68, P4927, DOI 10.1128/JVI.68.8.4927-4936.1994; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; SCHOLS D, 1992, VIROLOGY, V189, P374, DOI 10.1016/0042-6822(92)90719-6; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; STAMNES M A, 1992, Trends in Cell Biology, V2, P272, DOI 10.1016/0962-8924(92)90200-7; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TERWILLIGER EF, 1989, P NATL ACAD SCI USA, V86, P3857, DOI 10.1073/pnas.86.10.3857; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002	23	551	570	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					363	365		10.1038/372363a0	http://dx.doi.org/10.1038/372363a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969495				2022-12-24	WOS:A1994PU28700056
J	SCHABLE, C; ZEKENG, L; PAU, CP; HU, D; KAPTUE, L; GURTLER, L; DONDERO, T; TSAGUE, JM; SCHOCHETMAN, G; JAFFE, H; GEORGE, JR				SCHABLE, C; ZEKENG, L; PAU, CP; HU, D; KAPTUE, L; GURTLER, L; DONDERO, T; TSAGUE, JM; SCHOCHETMAN, G; JAFFE, H; GEORGE, JR			SENSITIVITY OF UNITED-STATES HIV ANTIBODY TESTS FOR DETECTION OF HIV-1 GROUP-O INFECTIONS	LANCET			English	Note								Infections by highly divergent strains of HIV-1, first detected in central Africa and grouped provisionally as group O, have not been reliably detected by certain European HIV screening tests. Serum specimens from eight probable group O infections from Cameroon were tested by ten HIV assays licensed by the US Food and Drug Administration. All assays based on synthetic peptides or recombinant antigens failed to detect at least one of the infections; assays based on whole-virus lysates performed better. Divergent HIV strains may be undetected by current HIV tests. Thus active surveillance for and characterisation of HIV variants to evaluate and, when necessary, modify current tests is urgently needed.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; UNIV YAOUNDE,YAOUNDE,CAMEROON; MAX VON PETTENKOFER INST,W-8000 MUNICH,GERMANY	Centers for Disease Control & Prevention - USA; University of Yaounde I; University of Munich				Gurtler, Lutz/0000-0003-3435-9030				DELEYS R, 1990, J VIROL, V64, P1207, DOI 10.1128/JVI.64.3.1207-1216.1990; GURTLER LG, 1994, J VIROL, V68, P1581; LOUSSERTAJAKA I, 1994, LANCET, V343, P1393, DOI 10.1016/S0140-6736(94)92524-0; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; MYERS G, 1993, HUMAN RETROVIRUSES A; NKENGASONG JN, 1993, AIDS, V7, P1536, DOI 10.1097/00002030-199311000-00026; PAU CP, 1993, AIDS, V7, P337, DOI 10.1097/00002030-199303000-00005	7	110	117	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1333	1334		10.1016/S0140-6736(94)90695-5	http://dx.doi.org/10.1016/S0140-6736(94)90695-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968029				2022-12-24	WOS:A1994PQ92600011
J	WILSON, APR				WILSON, APR			THE DANGERS OF BIPP	LANCET			English	Editorial Material											WILSON, APR (corresponding author), UCL HOSP, DEPT CLIN MICROBIOL, LONDON, ENGLAND.							BLACK B, 1979, CLIN OTOLARYNGOL, V4, P207, DOI 10.1111/j.1365-2273.1979.tb01887.x; Chambers H, 1917, LANCET, V1, P333; CHEVRETTON EB, 1991, J LARYNGOL OTOL, V105, P916, DOI 10.1017/S0022215100117803; Colman G, 1962, BR DENT J, V113, P22; JONES JAH, 1990, ORAL SURG ORAL MED O, V69, P668, DOI 10.1016/0030-4220(90)90344-R; KRUGER G, 1976, LANCET, V2, P485; LEQUESNE PM, 1981, J NEUROL NEUROSUR PS, V44, P1, DOI 10.1136/jnnp.44.1.1; MCRAE RDR, 1992, J LARYNGOL OTOL, V106, P387; MILLER WA, 1974, BRIT DENT J, V137, P278, DOI 10.1038/sj.bdj.4803305; NIGAM A, 1990, CLIN OTOLARYNGOL, V15, P173, DOI 10.1111/j.1365-2273.1990.tb00452.x; OCONNOR AFF, 1977, J LARYNGOL OTOL, V91, P903, DOI 10.1017/S002221510008453X; SHARMA RR, 1994, J NEUROL NEUROSUR PS, V57, P990, DOI 10.1136/jnnp.57.8.990	12	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1313	1314		10.1016/S0140-6736(94)90689-0	http://dx.doi.org/10.1016/S0140-6736(94)90689-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968025				2022-12-24	WOS:A1994PQ92600005
J	SCHNELL, DJ; KESSLER, F; BLOBEL, G				SCHNELL, DJ; KESSLER, F; BLOBEL, G			ISOLATION OF COMPONENTS OF THE CHLOROPLAST PROTEIN IMPORT MACHINERY	SCIENCE			English	Article							SIGNAL RECOGNITION PARTICLE; ENVELOPE CONTACT SITES; TRANSIT PEPTIDE; PHOSPHATE TRANSLOCATOR; PRECURSOR PROTEINS; MEMBRANES; RECEPTOR; BINDING; IDENTIFICATION; SEQUENCE	Components of the protein import machinery of the chloroplast were isolated by a procedure in which the import machinery was engaged in vitro with a tagged import substrate under conditions that yielded largely chloroplast envelope-bound import intermediates. Subsequent detergent solubilization of envelope membranes showed that six envelope polypeptides copurified specifically and, apparently, stoichiometrically with the import intermediates. Four of these polypeptides are components of the outer membrane import machinery and are associated with early import intermediates. Two of these polypeptides have been characterized. One is a homolog of the heat shock protein hsp70; the other one is a channel-protein candidate.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University	SCHNELL, DJ (corresponding author), RUTGERS STATE UNIV,DEPT BIOL SCI,NEWARK,NJ 07102, USA.		Kessler, Felix Henrique/AAO-1722-2020	Kessler, Felix/0000-0001-6409-5043				ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BUVINGER WE, 1989, J BIOL CHEM, V264, P1195; CHUA NH, 1979, J CELL BIOL, V81, P461, DOI 10.1083/jcb.81.3.461; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; CLINE K, 1985, PROTOPLASMA, V125, P111, DOI 10.1007/BF01297356; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CORNWELL KL, 1987, PLANT PHYSIOL, V85, P780, DOI 10.1104/pp.85.3.780; COWAN SW, 1994, SCIENCE, V264, P914, DOI 10.1126/science.8178151; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; FRIEDMAN AL, 1989, PLANT PHYSIOL, V89, P993, DOI 10.1104/pp.89.3.993; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GROSSMAN A, 1980, NATURE, V285, P625, DOI 10.1038/285625a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; KADERBHAI MA, 1988, FEBS LETT, V232, P313, DOI 10.1016/0014-5793(88)80760-9; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LODDENKOTTER B, 1993, P NATL ACAD SCI USA, V90, P2155, DOI 10.1073/pnas.90.6.2155; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PAUL C, 1985, EMBO J, V4, P1593, DOI 10.1002/j.1460-2075.1985.tb03822.x; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PERRY SE, 1991, J BIOL CHEM, V266, P11882; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1991, J BIOL CHEM, V266, P3335; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1985, NUCLEIC ACIDS RES, V13, P3179, DOI 10.1093/nar/13.9.3179; THEG SM, 1989, J BIOL CHEM, V264, P6730; TIANF, UNPUB; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x	38	339	355	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1007	1012		10.1126/science.7973649	http://dx.doi.org/10.1126/science.7973649			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973649				2022-12-24	WOS:A1994PQ92400033
J	JONES, DA; THOMAS, CM; HAMMONDKOSACK, KE; BALINTKURTI, PJ; JONES, JDG				JONES, DA; THOMAS, CM; HAMMONDKOSACK, KE; BALINTKURTI, PJ; JONES, JDG			ISOLATION OF THE TOMATO CF-9 GENE FOR RESISTANCE TO CLADOSPORIUM-FULVUM BY TRANSPOSON TAGGING	SCIENCE			English	Article							PLATELET GLYCOPROTEIN-IB; LEUCINE-RICH REPEATS; PROTEIN-KINASE; TRANSMEMBRANE PROTEIN; DISEASE-RESISTANCE; ARABIDOPSIS-THALIANA; RECEPTOR; CLONING; DOMAIN; SEQUENCE	The tomato Cf-9 gene confers resistance to infection by races of the fungus Cladosporium fulvum that carry the avirulence gene Avr9. The Cf-9 gene was isolated by transposon tagging with the maize transposable element Dissociation, The DNA sequence of Cf-9 encodes a putative membrane-anchored extracytoplasmic glycoprotein. The predicted protein shows homology to the receptor domain of several receptor-like protein kinases in Arabidopsis, to antifungal polygalacturonase-inhibiting proteins in plants, and to other members of the leucine-rich repeat family of proteins. This structure is consistent with that of a receptor that could bind Avr9 peptide and activate plant defense.	JOHN INNES INST,JOHN INNES CTR PLANT SCI RES,SAINSBURY LAB,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Jones, David A/C-9507-2009; Jones, Jonathan DG/J-5129-2012; Balint-kurti, Peter/AES-0111-2022	Jones, David A/0000-0001-8809-5822; Jones, Jonathan DG/0000-0002-4953-261X; Balint-Kurti, Peter/0000-0002-3916-194X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; HAMMONDKOSACK KE, 1994, PLANT CELL, V6, P361, DOI 10.2307/3869756; HAMMONDKOSACK KE, 1994, P NATL ACAD SCI USA, V91, P10445, DOI 10.1073/pnas.91.22.10445; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; Jones D. B., UNPUB; JONES DA, 1993, MOL PLANT MICROBE IN, V6, P348, DOI 10.1094/MPMI-6-348; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; PRYOR T, 1987, TRENDS GENET, V3, P157, DOI 10.1016/0168-9525(87)90217-4; PRYOR T, 1993, ADV PLANT PATHOL, V10, P281; ROMMENS CMT, 1992, PLANT MOL BIOL, V20, P61, DOI 10.1007/BF00029149; ROTH S, 1994, CURR BIOL, V4, P755, DOI 10.1016/S0960-9822(00)00170-6; SCOFIELD SR, 1992, PLANT CELL, V4, P573, DOI 10.1105/tpc.4.5.573; STEINMAYR M, 1994, PLANT J, V5, P459, DOI 10.1046/j.1365-313X.1994.5040459.x; STOTZ HU, 1993, PLANT PHYSIOL, V102, P133, DOI 10.1104/pp.102.1.133; STOTZ HU, 1994, PLANT MOL BIOL, V25, P607, DOI 10.1007/BF00029600; SUDUPAK MA, 1993, GENETICS, V133, P119; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TOUBART P, 1992, PLANT J, V2, P367; TOURVIEILLE B, 1986, SCIENCE, V234, P610, DOI 10.1126/science.3094146; TOWNSLEY FM, 1994, EUROPEAN J CELL BIOL, V64, P221; VALON C, 1993, PLANT MOL BIOL, V23, P415, DOI 10.1007/BF00029017; VANDENACKERVEKEN GFJM, 1992, PLANT J, V2, P359, DOI 10.1111/j.1365-313X.1992.00359.x; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALKER JC, 1993, PLANT J, V3, P451, DOI 10.1046/j.1365-313X.1993.t01-23-00999.x; WARE J, 1993, J CLIN INVEST, V92, P1213, DOI 10.1172/JCI116692; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6	38	715	896	6	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					789	793		10.1126/science.7973631	http://dx.doi.org/10.1126/science.7973631			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973631				2022-12-24	WOS:A1994PP75300035
J	LEE, GU; CHRISEY, LA; COLTON, RJ				LEE, GU; CHRISEY, LA; COLTON, RJ			DIRECT MEASUREMENT OF THE FORCES BETWEEN COMPLEMENTARY STRANDS OF DNA	SCIENCE			English	Article							MICROSCOPY; OLIGONUCLEOTIDES; MOLECULES	Interaction forces between single strands of DNA were measured with the atomic force microscope by a procedure in which DNA oligonucleotides were covalently attached to a spherical probe and surface. Adhesive forces measured between complementary 20-base strands fell into three distinct distributions centered at 1.52, 1.11, and 0.83 nano-newtons, which are associated with the rupture of the interchain interaction between a single pair of molecules involving 20, 16, and 12 base pairs, respectively. When a third long DNA molecule was coupled between complementary surfaces, both intra- and interchain forces were observed. The intrachain interaction resulting from the molecule's elasticity manifested itself as a long-range cohesive force.z	USN, RES LAB, CTR BIOMOLEC SCI & ENGN, WASHINGTON, DC 20375 USA	United States Department of Defense; United States Navy; Naval Research Laboratory	LEE, GU (corresponding author), USN, RES LAB, DIV CHEM, CODE 6177, WASHINGTON, DC 20375 USA.		Lee, Gil U/P-8696-2016	Lee, Gil U/0000-0002-7949-5848				ALBRECHT TR, 1988, J VAC SCI TECHNOL A, V6, P271, DOI 10.1116/1.575441; ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BHATIA SK, 1989, ANAL BIOCHEM, V178, P408, DOI 10.1016/0003-2697(89)90662-3; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; CHRISEY LA, 1994, MATER RES SOC SYMP P, V330, P179; CONNOLLY BA, 1985, NUCLEIC ACIDS RES, V13, P4485, DOI 10.1093/nar/13.12.4485; DENG GR, 1983, METHOD ENZYMOL, V100, P96; DURIG U, 1992, J APPL PHYS, V72, P1778, DOI 10.1063/1.352348; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; Flory P. J, 1953, PRINCIPLES POLYM CHE; FLORY PJ, 1989, STATISTICAL MECHANIC; INMAN RB, 1964, J MOL BIOL, V8, P452, DOI 10.1016/S0022-2836(64)80003-6; INMAN RB, 1964, J MOL BIOL, V9, P624, DOI 10.1016/S0022-2836(64)80171-6; ISRAELACHVILI JN, 1992, INTERMOLECULAR SURFA, pCH10; James HM, 1943, J CHEM PHYS, V11, P455, DOI 10.1063/1.1723785; KLUMP HH, 1988, BIOCH THERMODYNAMICS, P105; KUMAR A, 1991, NUCLEIC ACIDS RES, V19, P4561, DOI 10.1093/nar/19.16.4561; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; MEYER G, 1988, APPL PHYS LETT, V53, P1045, DOI 10.1063/1.100061; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; PUTMAN CAJ, 1992, J APPL PHYS, V72, P6, DOI 10.1063/1.352149; RAU DC, 1984, P NATL ACAD SCI-BIOL, V81, P2621, DOI 10.1073/pnas.81.9.2621; SAENGER W, 1983, PRINCIPLES NUCLEIC A, pCH6; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0	28	745	793	4	148	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					771	773		10.1126/science.7973628	http://dx.doi.org/10.1126/science.7973628			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973628				2022-12-24	WOS:A1994PP75300029
J	SURH, CD; SPRENT, J				SURH, CD; SPRENT, J			T-CELL APOPTOSIS DETECTED IN-SITU DURING POSITIVE AND NEGATIVE SELECTION IN THE THYMUS	NATURE			English	Article							MONOCLONAL-ANTIBODIES; COMPLEX; DEATH; IDENTIFICATION; THYMOCYTES; MEDULLA; INVIVO	BECAUSE of positive and negative selection to molecules of the major histocompatibility complex (MHC)(1), only a small proportion of the massive numbers of T cells generated is the thymus are selected for expert(2,3). Immature thymocytes have a rapid turnover(2), and it has long been assumed that most thymocytes die in situ(4,5), presumably from apoptosis(6). This has yet to be proved, however, and conventional staining techniques have shown only minimal evidence of cell death in the normal thymus(7,8). Using a method for detecting cells with DNA strand breaks, we now present direct evidence for apoptosis in the normal thymus. In sections of thymus from adult mice, apoptotic cells are scattered throughout the cortex and are engulfed locally by F4/80(+) macrophages. Apoptosis in the thymic cortex is not reduced in MHC-deficient mice, which suggests that T-cell death is primarily a reflection of lack of positive selection rather than negative selection. Direct evidence for apoptosis due to negative selection was obtained by crossing a V beta 5 transgenic line(9) to I-E(+) and I-E(-) mice: I-E(+) mice are known to eliminate V beta 5(+) T cells in the thymus whereas I-E(-) mice do not(10). In marked contrast to I-E(-) mice, the medulla of I-E(+) V beta 5 transgenic mice contains dense aggregates of apoptotic cells; these cells are engulfed by a distinct population of F4/80(-) MAC-3(+) macrophages. Negative selection of V beta 5(+) cells is thus restricted to the medulla.			SURH, CD (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL IMM4, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							Anderson R E, 1976, Adv Immunol, V24, P215, DOI 10.1016/S0065-2776(08)60331-4; CARDELL S, 1994, ADV IMMUNOL, V55, P423; DUIJVESTIJN AM, 1981, CELL TISSUE RES, V218, P279; FINK PJ, 1992, J EXP MED, V176, P1733, DOI 10.1084/jem.176.6.1733; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HENGARTNER H, 1988, NATURE, V336, P388, DOI 10.1038/336388a0; KENDALL MD, 1984, IMMUNOL TODAY, V5, P286, DOI 10.1016/0167-5699(84)90148-8; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; METCALF DONALD, 1966, P242; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; PULLEN AM, 1989, IMMUNOL REV, V107, P125, DOI 10.1111/j.1600-065X.1989.tb00006.x; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; Saint-Marie G., 1970, REV CAN BIOL, V30, P51; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCOLLAY R, 1985, RECOGNITION REGULATI, P3; SHI YF, 1991, J IMMUNOL, V146, P3340; Shortman K, 1990, Semin Immunol, V2, P3; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SURH CD, 1992, J EXP MED, V176, P495, DOI 10.1084/jem.176.2.495; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	29	884	902	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					100	103		10.1038/372100a0	http://dx.doi.org/10.1038/372100a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969401				2022-12-24	WOS:A1994PQ34800082
J	SCHLICHTING, I; BERENDZEN, J; PHILLIPS, GN; SWEET, RM				SCHLICHTING, I; BERENDZEN, J; PHILLIPS, GN; SWEET, RM			CRYSTAL-STRUCTURE OF PHOTOLYZED CARBONMONOXY-MYOGLOBIN	NATURE			English	Article							LIGAND-BINDING; HEME-PROTEINS; MOLECULAR-DYNAMICS; PHOTOPRODUCTS; RESOLUTION; MONOXIDE; RAMAN; CRYSTALLOGRAPHY; DIFFRACTION; REFINEMENT	MYOGLOBIN is a globular haem protein that reversibly binds ligands such as O-2 and CO. Single photons of visible light can break the covalent bond between CO and the haem iron in carbon-monoxy-myoglobin (MbCO) and thus form an unstable intermediate, Mb*CO, with the CO inside the protein(1,2). The ensuing rebinding process has been extensively studied as a model for the interplay of dynamics, structure and function in protein reactions. We have used X-ray crystallography at liquid-helium temperatures to determine the structure of Mb*CO to a resolution of 1.5 Angstrom. The photodissociated CO lies on top of the haem pyrrole ring C. Comparison with the CO-bound and unligated myoglobin structures reveals that on photodissociation of the CO, the haem 'domes', the iron moves partially out of the haem plane, the iron-proximal histidine bond is compressed, the F helix is strained and the distal histidine swings towards the outside of the ligand-binding pocket.	MAX PLANCK INST MED RES,DEPT BIOPHYS,D-69120 HEIDELBERG,GERMANY; RICE UNIV,WM KECK CTR COMPUTAT BIOL,HOUSTON,TX 77251; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	Max Planck Society; Rice University; United States Department of Energy (DOE); Brookhaven National Laboratory			Schlichting, Ilme/I-1339-2013	Berendzen, Joel/0000-0002-9454-9074				AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; AHMED AM, 1991, CHEM PHYS, V158, P329, DOI 10.1016/0301-0104(91)87076-8; ALBEN JO, 1982, P NATL ACAD SCI-BIOL, V79, P3744, DOI 10.1073/pnas.79.12.3744; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BARTUNIK HD, 1983, NUCL INSTRUM METHODS, V208, P523, DOI 10.1016/0167-5087(83)91176-6; BRUNGER AT, 1993, XPLOR VERSION 31 MAN; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CHENG XD, 1991, J MOL BIOL, V220, P381, DOI 10.1016/0022-2836(91)90020-7; DASGUPTA S, 1986, BIOCHEMISTRY-US, V25, P5941, DOI 10.1021/bi00368a016; GIBSON QH, 1992, J BIOL CHEM, V268, P17908; HONG MK, 1989, THESIS U ILLINOIS UR; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KUCZERA K, 1993, P NATL ACAD SCI USA, V90, P5805, DOI 10.1073/pnas.90.12.5805; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; POWERS L, 1987, BIOCHEMISTRY-US, V26, P4785, DOI 10.1021/bi00389a028; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; ROTHBERG LJ, 1991, P SPIE INT SOC OPT E, V1599, P309; ROUSSEAU DL, 1986, P NATL ACAD SCI USA, V83, P1310, DOI 10.1073/pnas.83.5.1310; SASSAROLI M, 1986, J BIOL CHEM, V261, P3704; STAVROV SS, 1993, BIOPHYS J, V65, P1942, DOI 10.1016/S0006-3495(93)81265-7; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; STRAUB JE, 1991, CHEM PHYS, V158, P221, DOI 10.1016/0301-0104(91)87068-7; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TENG TY, 1987, BIOCHEMISTRY-US, V26, P8066, DOI 10.1021/bi00399a007; TLTON RF, 1982, BIOCHEMISTRY-US, V23, P2849	31	336	338	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					808	812		10.1038/371808a0	http://dx.doi.org/10.1038/371808a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935843				2022-12-24	WOS:A1994PP01800063
J	JACKSON, DY; BURNIER, J; QUAN, C; STANLEY, M; TOM, J; WELLS, JA				JACKSON, DY; BURNIER, J; QUAN, C; STANLEY, M; TOM, J; WELLS, JA			A DESIGNED PEPTIDE LIGASE FOR TOTAL SYNTHESIS OF RIBONUCLEASE-A WITH UNNATURAL CATALYTIC RESIDUES	SCIENCE			English	Article							BOVINE PANCREATIC RIBONUCLEASE; AMINO-ACIDS; PROTEINS; DEPENDENCE; ENZYMES	An engineered variant of subtilisin BPN', termed subtilligase, which efficiently ligates esterified peptides in aqueous solution, was used for the complete synthesis of ribonuclease (RNase) A that contains unnatural catalytic residues. Fully active RNase A (124 residues long) was produced in milligram quantities by stepwise ligation of six esterified peptide fragments (each 12 to 30 residues long) at yields averaging 70 percent per ligation. Variants of RNase A were produced in which the catalytic histidines at positions 12 and 119 were substituted with the unnatural amino acid 4-fluorohistidine, which has a pK(a) of 3.5 compared to 6.8 for histidine. Large changes in the profile of the pH as it affects rate occurred for the single and double mutants with surprisingly little change in the k(cat) for either the RNA cleavage or hydrolysis steps. The data indicate that these imidazoles function as general acids and bases, but that the proton transfer steps are not rate-limiting when the imidazoles are present in their correct protonation states. These studies indicate the potential of subtilligase for the blockwise synthesis of large proteins.	GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT BIOORGAN CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech			Wells, Jim A/O-9854-2016					ABRAHMSEN L, 1991, BIOCHEMISTRY-US, V30, P4151, DOI 10.1021/bi00231a007; ANSLYN E, 1989, J AM CHEM SOC, V111, P4473, DOI 10.1021/ja00194a050; BLACKBURN P, 1982, ENZYMES, V15; BODANSZKY M, 1984, PRACTICE PEPTIDE SYN, V21; BRESLOW R, 1991, TETRAHEDRON, V47, P2365, DOI 10.1016/S0040-4020(01)81774-9; BROWN TB, 1981, J CHEM SOC CHEM COMM, V408, P648; BRUICE TC, 1963, J AM CHEM SOC, V85, P1659, DOI 10.1021/ja00894a028; CAMPBELL RL, 1987, BIOCHEMISTRY-US, V26, P8579, DOI 10.1021/bi00400a013; CHANG TK, IN PRESS P NATL ACAD; DUNN BM, 1974, J BIOL CHEM, V249, P6295; FINDLAY D, 1962, BIOCHEM J, V85, P139, DOI 10.1042/bj0850139; FINK AL, 1987, BIOCHEMISTRY-US, V26, P8571, DOI 10.1021/bi00400a012; FUJII N, 1981, J CHEM SOC PERK T 1, P804, DOI 10.1039/p19810000804; FUJII N, 1981, J CHEM SOC PERK T 1, P789, DOI 10.1039/p19810000789; FUJII N, 1981, J CHEM SOC PERK T 1, P797, DOI 10.1039/p19810000797; GUTTE B, 1971, J BIOL CHEM, V246, P1922; HIRSCHMANN R, 1969, J AM CHEM SOC, V91, P502; Ipata P L., 1968, FEBS Lett, V1, P29, DOI 10.1016/0014-5793(68)80010-9; KAISER ET, 1989, ACCOUNTS CHEM RES, V22, P47, DOI 10.1021/ar00158a001; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; KIRK KL, 1973, J AM CHEM SOC, V95, P4619, DOI 10.1021/ja00795a026; KNOWLES JR, 1976, CRC CR REV BIOCH MOL, V4, P165, DOI 10.3109/10409237609105457; KULLMAN W, 1987, ENZYMATIC PEPTIDE SY; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MENDEL D, 1992, SCIENCE, V256, P1798, DOI 10.1126/science.1615324; NAKATSUKA T, 1987, J AM CHEM SOC, V109, P3808, DOI 10.1021/ja00246a064; NEET KE, 1966, P NATL ACAD SCI USA, V56, P1606, DOI 10.1073/pnas.56.5.1606; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; POLGAR L, 1966, J AM CHEM SOC, V88, P3153, DOI 10.1021/ja00965a060; RICO M, 1991, Journal of Biomolecular NMR, V1, P283, DOI 10.1007/BF01875521; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2671, DOI 10.1021/bi00061a027; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; TAYLOR HC, 1981, J MOL BIOL, V149, P313, DOI 10.1016/0022-2836(81)90305-3; THOMPSON JE, 1994, J AM CHEM SOC, V116, P5467, DOI 10.1021/ja00091a060; TRAUTWEIN K, 1991, FEBS LETT, V281, P275, DOI 10.1016/0014-5793(91)80410-5; USHER DA, 1972, P NATL ACAD SCI USA, V69, P115, DOI 10.1073/pnas.69.1.115; VEBER DF, 1977, J ORG CHEM, V42, P3286, DOI 10.1021/jo00440a018; WONG CH, 1993, J AM CHEM SOC, V115, P5893, DOI 10.1021/ja00067a001; WU Z, 1989, J AM CHEM SOC, V111, P2414	40	244	283	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					243	247		10.1126/science.7939659	http://dx.doi.org/10.1126/science.7939659			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939659				2022-12-24	WOS:A1994PM13400023
J	SETO, E; LEWIS, B; SHENK, T				SETO, E; LEWIS, B; SHENK, T			INTERACTION BETWEEN TRANSCRIPTION FACTORS SP1 AND YY1	NATURE			English	Article							SYNERGISTIC ACTIVATION; INITIATOR; ENHANCER; PROTEIN; DOMAINS; TRANSACTIVATOR; REPRESSION; EXPRESSION; ELEMENTS; INVITRO	A BASAL level of transcription is usually observed when all but a small region of DNA has been deleted from a eukaryotic gene promoter. These promoter elements, which are necessary and sufficient for specific transcription initiation, are referred to as minimal or core promoter elements. One element that is commonly present in a core promoter is the initiator. It has been demonstrated that the presence of Sp1 binding sites can greatly enhance the level of transcription initiation at initiator elements1-4. A binding site for the YY1 transcription factor, located at the initiation site of the adeno-associated virus P5 promoter, functions as an initiator element; a synergistic enhancement of its activity is observed in vitro when upstream Sp1 binding sites are present3. Here we report that this synergistic activation probably occurs through protein-protein interactions.	PRINCETON UNIV,HOWARD HUGHES MED INST,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Howard Hughes Medical Institute; Princeton University	SETO, E (corresponding author), UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,INST BIOTECHNOL,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78245, USA.							BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	20	260	264	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					462	464		10.1038/365462a0	http://dx.doi.org/10.1038/365462a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8003102				2022-12-24	WOS:A1993LZ63300063
J	MCCLAIN, KL; LEACH, CT; JENSON, HB; JOSHI, VV; POLLOCK, BH; PARMLEY, RT; DICARLO, FJ; CHADWICK, EG; MURPHY, SB				MCCLAIN, KL; LEACH, CT; JENSON, HB; JOSHI, VV; POLLOCK, BH; PARMLEY, RT; DICARLO, FJ; CHADWICK, EG; MURPHY, SB			ASSOCIATION OF EPSTEIN-BARR-VIRUS WITH LEIOMYOSARCOMAS IN YOUNG-PEOPLE WITH AIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; POLYMERASE CHAIN-REACTION; MONOCLONAL-ANTIBODIES; CELL-LINES; DNA; AMPLIFICATION; NEOPLASIA; INFECTION; CHILDREN; LYMPHOMA	Background. Children with the acquired immunodeficiency syndrome (AIDS) have an unusually high incidence of smooth-muscle tumors (leiomyomas and leiomyosarcomas) in addition to malignant lymphomas. We tested the hypothesis that the smooth-muscle tumors in these children are associated with the Epstein-Barr virus (EBV). Methods. Tissue specimens of five leiomyosarcomas and two leiomyomas from five children and one young man with AIDS were studied for evidence of the human immunodeficiency virus (HIV) and EBV by in situ hybridization and quantitative polymerase chain reaction (PCR). Comparison specimens included samples of leiomyosarcoma and leiomyoma from HIV-negative children, EBV clonality of leiomyosarcomas was determined by Southern blot analysis with oligonucleotide probes for EBV terminal-repeat fragments, Tumor specimens were tested by immunoperoxidase staining for infiltration by B lymphocytes and expression of the EBV receptor, Serologic testing for EBV was performed. Results. In situ hybridization showed EBV genomes in all muscle cells of the five leiomyosarcomas and the two leiomyomas from the six HIV-infected patients, Quantitative PCR demonstrated strikingly high levels of EBV in tumor tissue, with as many as 4.3 genome copies per cell, Two colonic leiomyosarcomas obtained from different sites at different times from one patient contained different episomal EBV clones, signifying the presence of distinct monoclonal EBV-related tumors, We found biclonal EBV infection in the leiomyosarcoma of another patient, No EBV was detected in normal muscle or tumor specimens from HIV-negative patients, Immunostaining for the EBV receptor was strongly positive in six of the seven leiomyomas and leiomyosarcomas from the patients with AIDS. Conclusions. EBV can infect smooth-muscle cells, at least in patients with AIDS, and it may contribute to the pathogenesis of leiomyomas and leiomyosarcomas in patients with AIDS, EBV seems to play no part in smooth-muscle tumors in HIV-negative patients.	BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; UNIV TEXAS, HLTH SCI CTR, DEPT PEDIAT, SAN ANTONIO, TX 78284 USA; E CAROLINA UNIV, DEPT PATHOL & LAB MED, GREENVILLE, NC 27834 USA; UNIV FLORIDA, COLL MED, DEPT PEDIAT, GAINESVILLE, FL USA; CAROLINAS MED CTR, CHARLOTTE, NC 28203 USA; CHILDRENS HOSP NEW JERSEY, DEPT PATHOL, NEWARK, NJ USA; NORTHWESTERN UNIV, SCH MED, DEPT PEDIAT, CHICAGO, IL 60611 USA; CHILDRENS MEM HOSP, CHICAGO, IL 60614 USA	Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio; University of North Carolina; East Carolina University; State University System of Florida; University of Florida; Carolinas Medical Center; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago				Jenson, Hal/0000-0002-6549-860X; McClain, Kenneth/0000-0003-0725-6263	NATIONAL CANCER INSTITUTE [R01CA056296, U10CA030969, R01CA055507] Funding Source: NIH RePORTER; NCI NIH HHS [CA55507, CA30969, CA56296] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAN GJ, 1989, VIROLOGY, V173, P489, DOI 10.1016/0042-6822(89)90561-8; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; CHADWICK EG, 1990, JAMA-J AM MED ASSOC, V263, P3182, DOI 10.1001/jama.263.23.3182; CHANG KL, 1993, BLOOD, V81, P496; CHEUNG A, 1982, J VIROL, V44, P286, DOI 10.1128/JVI.44.1.286-294.1982; CUNNINGHAM L, 1991, BRIT MED BULL, V47, P852, DOI 10.1093/oxfordjournals.bmb.a072516; DELECLUSE HJ, 1993, J VIROL, V67, P1292, DOI 10.1128/JVI.67.3.1292-1299.1993; ERICKSONVIITANEN S, 1989, AIDS RES HUM RETROV, V5, P577, DOI 10.1089/aid.1989.5.577; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; FRICKHOFEN N, 1991, J VIROL METHODS, V35, P65, DOI 10.1016/0166-0934(91)90086-F; GAFFEY MJ, 1992, PATHOL ANNU, V27, P55; KARP JE, 1991, CANCER RES, V51, P4743; KNOWLES DM, 1988, ANN INTERN MED, V108, P744, DOI 10.7326/0003-4819-108-5-744; LACK E E, 1986, Pediatric Pathology, V6, P181; LEE E, 1993, MODERN PATHOL, V6, pA127; LEVINE PH, 1992, LEUKEMIA, V6, pS54; MCLOUGHLIN LC, 1991, CANCER, V67, P2618, DOI 10.1002/1097-0142(19910515)67:10<2618::AID-CNCR2820671036>3.0.CO;2-5; MUELLER BU, 1994, PEDIATRIC AIDS CHALL, P603; NAKAMURA S, 1994, CANCER, V73, P2239, DOI 10.1002/1097-0142(19940501)73:9<2239::AID-CNCR2820730902>3.0.CO;2-#; ORLOW SJ, 1992, AM J PEDIAT HEMATOL, V14, P265; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; OU CY, 1988, SCIENCE, V240, P130; PEIPER SC, 1990, ARCH PATHOL LAB MED, V114, P711; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; ROSS JS, 1992, HUM PATHOL, V23, P69, DOI 10.1016/0046-8177(92)90014-T; ROWLANDS DC, 1993, BRIT J CANCER, V68, P1014, DOI 10.1038/bjc.1993.472; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STARASOLER L, 1991, AM J CLIN PATHOL, V95, P858, DOI 10.1093/ajcp/95.6.858; SUMAYA CV, 1992, MANUAL CLIN LABORATO, P568; TIMENS W, 1991, HISTOCHEMISTRY, V95, P605, DOI 10.1007/BF00266748; VANHOEVEN KH, 1993, AM J SURG PATHOL, V17, P1176, DOI 10.1097/00000478-199311000-00011	32	417	431	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					12	18		10.1056/NEJM199501053320103	http://dx.doi.org/10.1056/NEJM199501053320103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990860				2022-12-24	WOS:A1995PZ49700003
J	RORTH, P				RORTH, P			SPECIFICATION OF C/EBP FUNCTION DURING DROSOPHILA DEVELOPMENT BY THE BZIP BASIC REGION	SCIENCE			English	Article							NF-KAPPA-B; LEUCINE ZIPPER; DNA-BINDING; SEQUENCE RECOGNITION; TRANSCRIPTION FACTOR; NUCLEAR-PROTEIN; FAMILY MEMBERS; GENE; EXPRESSION; CELLS	The biologically relevant interactions of a transcription factor are those that are important for function in the organism. Here, a transgenic rescue assay was used to determine which molecular functions of Drosophila CCAAT/enhancer binding protein (C/EBP), a basic region-leucine zipper transcription factor, are required for it to fulfill its essential role during development. Chimeric proteins that contain the Drosophila C/EBP (DmC/EBP) basic region, a heterologous zipper, and a heterologous activation domain could functionally substitute for DmC/EBP. Mammalian C/EBPs were also functional in Drosophila. In contrast, 9 of 25 single amino acid substitutions in the basic region disrupted biological function. Thus, the conserved basic region specifies DmC/EBP activity in the organism.			RORTH, P (corresponding author), CARNEGIE INST WASHINGTON,DEPT EMBRYOL,115 W UNIV PKWY,BALTIMORE,MD 21210, USA.		Rørth, Pernille/H-3020-2011					AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; KIM J, 1993, P NATL ACAD SCI USA, V90, P4513, DOI 10.1073/pnas.90.10.4513; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RORTH P, 1992, GENE DEV, V6, P2299, DOI 10.1101/gad.6.12a.2299; RORTH P, UNPUB; SCOTT LM, 1992, BLOOD, V80, P1725; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SUCKOW M, 1993, EMBO J, V12, P1193, DOI 10.1002/j.1460-2075.1993.tb05760.x; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343	30	28	30	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1878	1881		10.1126/science.7997882	http://dx.doi.org/10.1126/science.7997882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997882				2022-12-24	WOS:A1994PX38300039
J	BECKER, L; BADA, JL; WINANS, RE; BUNCH, TE				BECKER, L; BADA, JL; WINANS, RE; BUNCH, TE			FULLERENES IN ALLENDE METEORITE	NATURE			English	Letter							CHEMISTRY		ARGONNE NATL LAB,DIV CHEM,ARGONNE,IL 60439; NASA,AMES RES CTR,DIV SPACE SCI,MOFFETT FIELD,CA 94035	United States Department of Energy (DOE); Argonne National Laboratory; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	BECKER, L (corresponding author), UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093, USA.			Winans, Randall/0000-0002-7080-7673				BECKER L, 1994, SCIENCE, V265, P642, DOI 10.1126/science.11536660; BECKER L, 1993, NATURE, V361, P595, DOI 10.1038/361595a0; BOHME DK, 1992, CHEM REV, V92, P1487, DOI 10.1021/cr00015a002; DEVRIES MS, 1993, GEOCHIM COSMOCHIM AC, V57, P933, DOI 10.1016/0016-7037(93)90179-Z; DIBROZOLO FR, 1994, NATURE, V369, P37, DOI 10.1038/369037a0; HAHN JH, 1988, SCIENCE, V239, P1523, DOI 10.1126/science.239.4847.1523; HEYMANN D, 1994, SCIENCE, V265, P645, DOI 10.1126/science.265.5172.645; PETRIE S, 1993, ASTRON ASTROPHYS, V271, P275; POPE CJ, 1993, J PHYS CHEM-US, V97, P11001, DOI 10.1021/j100144a018; TIELENS AGGM, 1990, NASA CONF P, V3061, P59	10	60	61	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					507	507		10.1038/372507a0	http://dx.doi.org/10.1038/372507a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990921				2022-12-24	WOS:A1994PW08200033
J	TAMEMOTO, H; KADOWAKI, T; TOBE, K; YAGI, T; SAKURA, H; HAYAKAWA, T; TERAUCHI, Y; UEKI, K; KABURAGI, Y; SATOH, S; SEKIHARA, H; YOSHIOKA, S; HORIKOSHI, H; FURUTA, Y; IKAWA, Y; KASUGA, M; YAZAKI, Y; AIZAWA, S				TAMEMOTO, H; KADOWAKI, T; TOBE, K; YAGI, T; SAKURA, H; HAYAKAWA, T; TERAUCHI, Y; UEKI, K; KABURAGI, Y; SATOH, S; SEKIHARA, H; YOSHIOKA, S; HORIKOSHI, H; FURUTA, Y; IKAWA, Y; KASUGA, M; YAZAKI, Y; AIZAWA, S			INSULIN-RESISTANCE AND GROWTH-RETARDATION IN MICE LACKING INSULIN-RECEPTOR SUBSTRATE-1	NATURE			English	Article							TYROSINE-PHOSPHORYLATION; RAT ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; SIGNALING PATHWAYS; FACTOR-I; PROTEIN; IRS-1; KINASE; ASSOCIATION	INSULIN receptor substrate-1 (IRS-1) is the major substrate of insulin receptor and IGF-1 receptor tyrosine kinases; it has an apparent relative molecular mass of 160-190,000 (M(r), 160-190K) on SDS polyacrylamide gel(1-3). Tyrosine-phosphorylated IRS-1 binds the 85K subunit of phosphatidylinositol 3-kinase(4,5) which may be involved in the translocation of glucose transporters(6,7) and the abundant src homology protein (ASH)/Grb2(8,9) which may be involved in activation of p21(ras) and MAP kinase cascade(10). IRS-1 also has binding sites for Syp(11) and Nck(12) and other src homology 2 (SH2) signalling molecules. To clarify the physiological roles of IRS-1 in vivo, we made mice with a targeted disruption of the IRS-1 gene locus. Mice homozygous for targeted disruption of the IRS-1 gene were born alive but were retarded in embryonal and postnatal growth. They also had resistance to the glucose-lowering effects of insulin, IGF-1 and IGF-2. These data suggest the existence of both IRS-1-dependent and IRS-1-independent pathways for signal transduction of insulin and IGFs.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,ONCOL MOLEC LAB,TSUKUBA,IBARAKI 305,JAPAN; SANKYO CO LTD,PHARMACOL & MOLEC BIOL RES LABS,SHINAGAWA KU,TOKYO 140,JAPAN; YOKOHAMA CITY UNIV,FAC MED,SCH MED,DEPT INTERNAL MED 3,YOKOHAMA,KANAGAWA 236,JAPAN; UNIV KOBE,FAC MED,DEPT INTERNAL MED 2,KOBE,HYOGO 650,JAPAN	University of Tokyo; RIKEN; Daiichi Sankyo Company Limited; Yokohama City University; Kobe University			Terauchi, Yasuo/AAO-4347-2020; Sancheti, Harsh/H-3538-2012					BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; HARA K, IN PRESS P NATN ACAD; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MOONEY RA, 1992, ENDOCRINOLOGY, V130, P1533, DOI 10.1210/en.130.3.1533; OKADA T, 1994, J BIOL CHEM, V269, P3568; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STAGSTED J, 1990, CELL, V62, P297, DOI 10.1016/0092-8674(90)90367-N; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOBE K, 1993, J BIOL CHEM, V268, P11167; URLAUB G, 1989, MOL CELL BIOL, V9, P2868; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1994, J BIOL CHEM, V268, P1; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAMAMOTOHONDA R, 1993, J BIOL CHEM, V268, P16859; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	30	844	873	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					182	186		10.1038/372182a0	http://dx.doi.org/10.1038/372182a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969452				2022-12-24	WOS:A1994PQ68800057
J	YUAN, JG; HENRY, R; MCCAFFERY, M; CLINE, K				YUAN, JG; HENRY, R; MCCAFFERY, M; CLINE, K			SECA HOMOLOG IN PROTEIN-TRANSPORT WITHIN CHLOROPLASTS - EVIDENCE FOR ENDOSYMBIONT-DERIVED SORTING	SCIENCE			English	Article							THYLAKOID PRECURSOR PROTEIN; ESCHERICHIA-COLI; CHROMOPHYTIC ALGA; RED ALGA; MEMBRANE; IMPORT; TRANSLOCATION; GENOME; INTEGRATION; MACHINERY	The SecA protein is an essential, azide-sensitive component of the bacterial protein translocation machinery. A SecA protein homolog (CPSecA) now identified in pea chloroplasts was purified to homogeneity. CPSecA supported protein transport into thylakoids, the chloroplast internal membrane network, in an azide-sensitive fashion. Only one of three pathways for protein transport into thylakoids uses the CPSecA mechanism. The use of a bacteria-homologous mechanism in intrachloroplast protein transport provides evidence for conservative sorting of proteins within chloroplasts.	UNIV FLORIDA,PLANT MOLEC & CELLULAR BIOL PROGRAM,GAINESVILLE,FL 32611; UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611	State University System of Florida; University of Florida; State University System of Florida; University of Florida			Cline, Kenneth/J-6238-2013		NIGMS NIH HHS [1 R01 GM46951] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046951] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1986, J BIOL CHEM, V261, P4804; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; FLACHMANN R, 1993, J BIOL CHEM, V268, P7514; FULSON DR, 1988, PLANT PHYSIOL, V88, P1146, DOI 10.1104/pp.88.4.1146; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HENRY R, 1994, J BIOL CHEM, V269, P10189; HULFORD A, 1994, J BIOL CHEM, V269, P3251; KLOSE M, 1993, J BIOL CHEM, V268, P4504; KNOTT TG, 1994, J BIOL CHEM, V269, P7843; MATSUYAMA S, 1992, BIOCHIM BIOPHYS ACTA, V1122, P77, DOI 10.1016/0167-4838(92)90130-6; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; REITH M, 1993, PLANT CELL, V5, P465, DOI 10.1105/tpc.5.4.465; SCARAMUZZI CD, 1992, FEBS LETT, V304, P119, DOI 10.1016/0014-5793(92)80601-C; SCARAMUZZI CD, 1992, CURR GENET, V22, P421, DOI 10.1007/BF00352444; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; SIMPSON DJ, 1989, CARLSBERG RES COMMUN, V54, P55, DOI 10.1007/BF02907585; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; Theg Steven M., 1993, Trends in Cell Biology, V3, P186, DOI 10.1016/0962-8924(93)90212-J; VALENTIN K, 1993, MOL GEN GENET, V236, P245, DOI 10.1007/BF00277119; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; YUAN J, UNPUB; YUAN JG, 1993, P NATL ACAD SCI USA, V90, P8552, DOI 10.1073/pnas.90.18.8552; YUAN JG, 1994, J BIOL CHEM, V269, P18463	35	150	152	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					796	798		10.1126/science.7973633	http://dx.doi.org/10.1126/science.7973633			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973633				2022-12-24	WOS:A1994PP75300037
J	YANG, YD; BLAKE, R				YANG, YD; BLAKE, R			BROAD TUNING FOR SPATIAL-FREQUENCY OF NEURAL MECHANISMS UNDERLYING VISUAL-PERCEPTION OF COHERENT MOTION	NATURE			English	Article								NEURAL events underlying perception of coherent motion are generally believed to be hierarchical(1,2): information about local motion is registered by spatio-temporal coincidence detectors(3-5) whose outputs are cooperatively integrated at a subsequent stage(6,7). There is disagreement, however, concerning the spatial scale of the neural filters underlying these operations. According to one class of models, motion registration is initially accomplished in parallel at multiple spatial scales(3-5), with filters tuned to lower spatial frequencies responsive to larger motion displacements than filters tuned to higher frequencies. According to another scheme, motion analysis involves a single, broadly tuned spatial filter, with optimal displacement dependent on spacing of local elements(8). Here we use a masking procedure to measure the extent to which dynamic noise depicted at one spatial scale interferes with detection of coherent motion conveyed by image features at another spatial scale. Our results indicate that a single filter, broadly tuned for spatial frequency, is mediating detection of coherent motion. This finding dovetails with known physiological properties of neurons at an intermediate stage of motion processing.			YANG, YD (corresponding author), VANDERBILT UNIV,DEPT PSYCHOL,NASHVILLE,TN 37240, USA.							ADELSON EH, 1985, J OPT SOC AM A, V2, P284, DOI 10.1364/JOSAA.2.000284; ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; ADELSON EH, 1991, OPTICS PHOTONICS NEW, V2, P24; ANDERSON SJJ, 1985, VISION RES, V13, P1147; BRADDICK O, 1993, TRENDS NEUROSCI, V16, P263, DOI 10.1016/0166-2236(93)90179-P; BRITTEN KH, 1993, VISUAL NEUROSCI, V10, P1157, DOI 10.1017/S0952523800010269; CHANG JJ, 1984, VISION RES, V24, P1781, DOI 10.1016/0042-6989(84)90009-9; CLEARY R, 1990, VISION RES, V30, P303, DOI 10.1016/0042-6989(90)90045-M; MORGAN MJ, 1992, NATURE, V355, P344, DOI 10.1038/355344a0; MOVSHON A, 1990, IMAGES UNDERSTANDING; NAWROT M, 1990, VISION RES, V30, P1439, DOI 10.1016/0042-6989(90)90025-G; SMITH AT, 1994, VISION RES, V34, P2425, DOI 10.1016/0042-6989(94)90286-0; VANDEGRIND WA, 1992, EXP BRAIN RES, V91, P135, DOI 10.1007/BF00230022; VANSANTEN JPH, 1984, J OPT SOC AM A, V1, P451, DOI 10.1364/JOSAA.1.000451; WATSON AB, 1986, J OPT SOC AM A, V3, P300, DOI 10.1364/JOSAA.3.000300; WERKHOVEN P, 1993, VISION RES, V33, P463, DOI 10.1016/0042-6989(93)90253-S; WILLIAMS DW, 1984, VISION RES, V24, P55, DOI 10.1016/0042-6989(84)90144-5; WILSON HR, 1994, VISION RES, V34, P1835, DOI 10.1016/0042-6989(94)90308-5; YANG Y, 1991, VISION RES, V31, P1177	19	35	35	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					793	796		10.1038/371793a0	http://dx.doi.org/10.1038/371793a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935839				2022-12-24	WOS:A1994PP01800058
J	HAMMOND, C; HELENIUS, A				HAMMOND, C; HELENIUS, A			FOLDING OF VSV G-PROTEIN - SEQUENTIAL INTERACTION WITH BIP AND CALNEXIN	SCIENCE			English	Article							STOMATITIS-VIRUS-G; CHAIN BINDING-PROTEIN; ER; TRANSPORT	The endoplasmic reticulum (ER) contains molecular chaperones that facilitate the folding of proteins in mammalian cells. Biosynthetic labeling was used to study the interactions of two chaperones, BiP and calnexin, with vesicular stomatitis virus (VSV) glycoprotein (G protein). Coimmunoprecipitation of G protein with the chaperones showed that BiP bound maximally to early folding Intermediates of G protein, whereas calnexin bound after a short lag to more folded molecules. Castanospermine, an inhibitor of ER glucosidases, blocked the binding of proteins to calnexin and inhibited G protein folding. Interaction with calnexin was necessary for efficient folding of G protein and for retention of partially folded forms.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Yale University					NCI NIH HHS [P01 CA46128] Funding Source: Medline; NIGMS NIH HHS [R01 GM38346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038346] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DUNIGAN DD, 1983, J VIROL, V45, P618, DOI 10.1128/JVI.45.2.618-626.1983; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; GEHTING MJ, 1992, NATURE, V355, P33; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1993, CURR BIOL, V3, P884, DOI 10.1016/0960-9822(93)90226-E; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; SARASTE J, 1991, J CELL SCI, V100, P415; SCHLESINGER S, 1984, J BIOL CHEM, V259, P7597; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8	24	285	286	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					456	458		10.1126/science.7939687	http://dx.doi.org/10.1126/science.7939687			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939687				2022-12-24	WOS:A1994PN27200040
J	STRASSER, A; HARRIS, AW; JACKS, T; CORY, S				STRASSER, A; HARRIS, AW; JACKS, T; CORY, S			DNA-DAMAGE CAN INDUCE APOPTOSIS IN PROLIFERATING LYMPHOID-CELLS VIA P53-INDEPENDENT MECHANISMS INHIBITABLE BY BCL-2	CELL			English	Article							WILD-TYPE P53; MYELOID-LEUKEMIA CELLS; DEATH GENE CED-3; CYCLE CONTROL; ERYTHROLEUKEMIA-CELLS; MICE DEFICIENT; STRAND BREAKS; MUTANT P53; PRE-B; PROTEIN	The roles of p53 as an inducer and Bcl-2 as an inhibitor of apoptotic death were explored in lymphoid cells. Lymphocytes from p53(-/-) mice were radioresistant, but unexpectedly, cycling T lymphoma cells and mitogenically activated T lymphocytes from these animals underwent apoptosis after irradiation or genotoxic drug treatment. Hence, p53 is not the only mediator of apoptosis provoked by DNA damage. Irradiated p53(-/-) lymphoblasts expressing Bcl-2 were subject to growth arrest but resisted apoptosis. Their accumulation in G1 as well as G2 is suggestive of a p53-independent DNA-damage G1 checkpoint. Since Bcl-2 increased the clonogenic survival of the irradiated cells, expression of survival genes may pose a greater impediment to genotoxic cancer therapy than loss of p53.	MIT,HOWARD HUGHES MED INST,CTR CANC RES,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	STRASSER, A (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA.		Strasser, Andreas/C-7581-2013; Cory, Suzanne/E-1642-2013	Strasser, Andreas/0000-0002-5020-4891; Cory, Suzanne/0000-0002-6818-3451	NCI NIH HHS [CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CAMPOS L, 1993, BLOOD, V81, P3091; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; DELALUNA S, 1992, METHOD ENZYMOL, V216, P376; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FISHER TC, 1993, CANCER RES, V53, P3321; FRITSCHE M, 1993, ONCOGENE, V8, P307; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; GORCZYCA W, 1993, CANCER RES, V53, P1945; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HORNING SJ, 1984, NEW ENGL J MED, V311, P1471, DOI 10.1056/NEJM198412063112303; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; IKEGAKI N, 1994, CANCER RES, V54, P6; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KAMESAKI S, 1993, CANCER RES, V53, P4251; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KORSMEYER SJ, 1992, BLOOD, V80, P879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIMPENS J, 1991, ONCOGENE, V6, P2271; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MANOME Y, 1993, ONCOL RES, V5, P139; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MERRITT AJ, 1994, CANCER RES, V54, P614; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1992, CANCER RES, V52, P5407; PETTERSSON M, 1992, BLOOD, V79, P495; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PURDIE CA, 1994, ONCOGENE, V9, P603; RAMQVIST T, 1993, ONCOGENE, V8, P1495; REED JC, 1991, CANCER RES, V51, P6529; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TAYLOR IW, 1980, J HISTOCHEM CYTOCHEM, V28, P1021, DOI 10.1177/28.9.6157714; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WANG YS, 1993, ONCOGENE, V8, P3427; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZUTTER M, 1991, BLOOD, V78, P1062	71	672	687	2	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					329	339		10.1016/0092-8674(94)90201-1	http://dx.doi.org/10.1016/0092-8674(94)90201-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954799				2022-12-24	WOS:A1994PN63000016
J	YU, YG; KING, DS; SHIN, YK				YU, YG; KING, DS; SHIN, YK			INSERTION OF A COILED-COIL PEPTIDE FROM INFLUENZA-VIRUS HEMAGGLUTININ INTO MEMBRANES	SCIENCE			English	Article							CONFORMATIONAL CHANGE; FUSION ACTIVITY; GLYCOPROTEIN; AGGREGATION; MUTANTS	The trimeric protein hemagglutinin (HA) of the influenza viral envelope is essential for cell entry. To investigate the interaction of HA with membranes, two 40-residue, cysteine-substituted peptides comprising the loop region and the first part of the coiled-coil stem were synthesized and modified with a nitroxide spin label. Electron paramagnetic resonance analysis revealed that the peptide inserts reversibly into phospholipid vesicles under endosomal pH conditions. This result suggests that some or all of the long coiled-coil trimer of HA may insert into membranes, which could bring the viral and cell membranes closer together and facilitate fusion.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV STRUCT BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley								ALTENBACH C, 1988, PROTEINS, V3, P230, DOI 10.1002/prot.340030404; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ARCHER SJ, 1991, BIOPHYS J, V60, P389, DOI 10.1016/S0006-3495(91)82064-1; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DOMS RW, 1985, J BIOL CHEM, V260, P2973; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KEMBLE GW, 1992, J VIROL, V66, P4940, DOI 10.1128/JVI.66.8.4940-4950.1992; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; WHARTON SA, 1986, VIROLOGY, V149, P27, DOI 10.1016/0042-6822(86)90083-8; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	19	107	108	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					274	276		10.1126/science.7939662	http://dx.doi.org/10.1126/science.7939662			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939662				2022-12-24	WOS:A1994PM13400033
J	BEDOS, JP; CHASTANG, C; LUCET, JC; KALO, T; GACHOT, B; WOLFF, M				BEDOS, JP; CHASTANG, C; LUCET, JC; KALO, T; GACHOT, B; WOLFF, M			EARLY PREDICTORS OF OUTCOME FOR HIV PATIENTS WITH NEUROLOGICAL FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; INTENSIVE-CARE; RESPIRATORY-FAILURE; MECHANICAL VENTILATION; CONTROLLED TRIAL; VIRUS INFECTION; AIDS; SURVIVAL; CORTICOSTEROIDS	Objective.-To carry out a descriptive study of human immunodeficiency virus (HIV)-infected patients admitted to an intensive care unit (ICU) with neurological failure and to identify parameters that are predictive of death within 3 months. Design.-Case series study. Population and Setting.-A total of 84 consecutive HIV-infected patients admitted to an infectious disease ICU in a university hospital for neurological failure. A thorough clinical, laboratory, and brain computed tomography (CT) scan workup was done within 48 hours of admission. Main Results.-The mean (+/-SD) CD4(+) lymphocyte count was 0.067 (+/-0.086) x10(9)/L. Mechanical ventilation was necessary within 48 hours of admission in 67 cases (80%). The brain CT scan revealed abscesses in 51 patients (61%). The abscesses were attributed to probable toxoplasmosis in 47 patients. A total of 57 patients died, yielding a 3-month survival rate of 32%. By the log-rank test, the following factors were predictive of death within 3 months of admission to the ICU: Glasgow Coma Scale score less than 7 (P=.01), signs of brain stem involvement (P=.001), and need for mechanical ventilation in the 48 hours after admission (P=.02). In a Cox model, only Glasgow Coma Scale score less than 7 (P=.006) and clinical signs of brain stem involvement (P=.02) were predictive of death within 3 months of admission to the ICU. Conclusions.-Despite a thorough examination, no initial HIV-specific parameters were identified as predictive of death. The prognostic factors found simply reflected the severity of neurological involvement in the various etiologies.	HOP ST LOUIS,DEPT BIOSTAT & MED COMP,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	BEDOS, JP (corresponding author), UNIV LYON 1,HOP BICHAT,REANIMAT MALAD INFECT CLIN,INFECT INTENS CARE UNIT,48 RUE HENRI HUCHARD,F-75018 PARIS,FRANCE.							BEDOS JP, 1992, SCAND J INFECT DIS, V24, P309, DOI 10.3109/00365549209061336; BISHBURG E, 1989, ARCH INTERN MED, V149, P941, DOI 10.1001/archinte.149.4.941; BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; BREW BJ, 1992, MED CLIN N AM, V76, P63, DOI 10.1016/S0025-7125(16)30371-6; CASALINO E, 1993, 9TH INT C AIDS BERL; CHUN CH, 1986, MEDICINE, V65, P415, DOI 10.1097/00005792-198611000-00006; DEPALO VA, 1993, AM REV RESPIR DIS, V147, pA1004; EFFEREN LS, 1989, AM J MED, V87, P401, DOI 10.1016/S0002-9343(89)80821-6; FISCHER PA, 1987, J NEUROL, V234, P269, DOI 10.1007/BF00314279; FRIEDMAN Y, 1989, CHEST, V96, P862, DOI 10.1378/chest.96.4.862; FRIEDMAN Y, 1991, JAMA-J AM MED ASSOC, V266, P89, DOI 10.1001/jama.266.1.89; GACHOT B, 1992, INTENS CARE MED, V18, P155, DOI 10.1007/BF01709239; GAGNON S, 1990, NEW ENGL J MED, V323, P1444, DOI 10.1056/NEJM199011223232103; GARAY SM, 1989, CHEST, V95, P769, DOI 10.1378/chest.95.4.769; KALES CP, 1987, ARCH INTERN MED, V147, P1413; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; LEVY RM, 1988, ANN NEUROL, V23, pS7, DOI 10.1002/ana.410230706; LUCE JM, 1988, AM REV RESPIR DIS, V137, P1261, DOI 10.1164/ajrccm/137.6.1261; LUFT BJ, 1988, J INFECT DIS, V157, P1, DOI 10.1093/infdis/157.1.1; MASON GR, 1987, AM REV RESPIR DIS, V139, P1336; MCARTHUR JC, 1987, MEDICINE, V66, P407, DOI 10.1097/00005792-198711000-00001; MILLER RF, 1990, THORAX, V45, P140, DOI 10.1136/thx.45.2.140; MONTANER JSG, 1989, CHEST, V95, P881, DOI 10.1378/chest.95.4.881; NIELSEN TL, 1991, SCAND J INFECT DIS, V23, P37, DOI 10.3109/00365549109023372; NIGHTINGALE SD, 1993, ARCH INTERN MED, V153, P1313, DOI 10.1001/archinte.153.11.1313; ROGERS PL, 1989, CRIT CARE MED, V17, P113, DOI 10.1097/00003246-198902000-00001; ROSEN MJ, 1986, J INTENSIVE CARE MED, V1, P55; SCHEIN RMH, 1986, CRIT CARE MED, V14, P1026, DOI 10.1097/00003246-198612000-00006; SMITH RL, 1989, CHEST, V96, P857, DOI 10.1378/chest.96.4.857; STAIKOWSKY F, 1993, CHEST, V104, P756, DOI 10.1378/chest.104.3.756; STEINBROOK R, 1985, ANN INTERN MED, V103, P787, DOI 10.7326/0003-4819-103-5-787; WACHTER RM, 1991, AM REV RESPIR DIS, V143, P251, DOI 10.1164/ajrccm/143.2.251; WACHTER RM, 1986, AM REV RESPIR DIS, V134, P891, DOI 10.1164/arrd.1986.134.5.891; WACHTER RM, 1992, JAMA-J AM MED ASSOC, V267, P541, DOI 10.1001/jama.267.4.541; ZAMAN MK, 1985, AM REV RESPIR DIS, V137, P796; 1992, LANCET, V340, P1135; 1990, NEW ENGL J MED, V323, P1500	38	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 4	1995	273	1					35	40		10.1001/jama.273.1.35	http://dx.doi.org/10.1001/jama.273.1.35			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ042	7996648				2022-12-24	WOS:A1995PZ04200025
J	DAKE, MD; MILLER, DC; SEMBA, CP; MITCHELL, RS; WALKER, PJ; LIDDELL, RP				DAKE, MD; MILLER, DC; SEMBA, CP; MITCHELL, RS; WALKER, PJ; LIDDELL, RP			TRANSLUMINAL PLACEMENT OF ENDOVASCULAR STENT-GRAFTS FOR THE TREATMENT OF DESCENDING THORACIC AORTIC-ANEURYSMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-HISTORY; GRAFT PLACEMENT; FEASIBILITY	Background. The usual treatment for thoracic aortic aneurysms is surgical replacement with a prosthetic graft, but the associated morbidity and mortality are considerable. We studied the use of transluminally placed endovascular stent-graft devices as an alternative to surgical repair. Methods. We evaluated the feasibility, safety, and effectiveness of transluminally placed stent-grafts to treat descending thoracic aortic aneurysms in 13 patients over a 24-month period. Atherosclerotic, anastomotic, and post-traumatic true or false aneurysms and aortic dissections were treated. The mean diameter of the aneurysms was 6.1 cm (range, 5 to 8). The endovascular stent-grafts were custom-designed for each patient and were constructed of self-expanding stainless-steel stents covered with woven Dacron grafts. Results. Endovascular placement of the stent-graft prosthesis was successful in all patients. There was complete thrombosis of the thoracic aortic aneurysm surrounding the stent-graft in 12 patients, and partial thrombosis in 1. Two patients initially had small, residual patent proximal tracts into the aneurysm sac, but both tracts thrombosed within two months after the procedure. in four patients, two prostheses were required to bridge the aneurysm adequately. There have been no deaths or instances of paraplegia, stroke, distal embolization, or infection during an average follow-up of 11.6 months. One patient with an extensive chronic aortic dissection required open surgical graft replacement four months later because of progressive dilatation of the arch. Conclusions. These preliminary results demonstrate that endovascular stent-graft repair is safe in highly selected patients with descending thoracic aortic aneurysms. This new method of treatment will, however, require careful long-term evaluation.	STANFORD UNIV,SCH MED,DEPT RADIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT CARDIOVASC SURG,STANFORD,CA 94305	Stanford University; Stanford University			Walker, Philip J/F-3034-2010	Miller, D. Craig/0000-0001-7619-0080				BALKO A, 1986, J SURG RES, V40, P305, DOI 10.1016/0022-4804(86)90191-5; BICKERSTAFF LK, 1982, SURGERY, V92, P1103; CHUTER TAM, 1993, J VASC SURG, V18, P185, DOI 10.1016/0741-5214(93)90598-G; CRAGG AH, 1993, RADIOLOGY, V187, P643, DOI 10.1148/radiology.187.3.8497609; DOTTER CT, 1969, INVEST RADIOL, V4, P329, DOI 10.1097/00004424-196909000-00008; ESTES JE, 1950, CIRCULATION, V2, P258, DOI 10.1161/01.CIR.2.2.258; JOYCE JW, 1964, CIRCULATION, V29, P176, DOI 10.1161/01.CIR.29.2.176; LABORDE JC, 1992, RADIOLOGY, V184, P185, DOI 10.1148/radiology.184.1.1535160; LAWRENCE DD, 1987, RADIOLOGY, V163, P357, DOI 10.1148/radiology.163.2.2951767; MARIN ML, 1993, J VASC SURG, V18, P299, DOI 10.1016/0741-5214(93)90611-O; MAY J, 1993, J VASC SURG, V18, P1056, DOI 10.1016/0741-5214(93)90562-Z; MCNAMARA JJ, 1978, ANN THORAC SURG, V26, P468, DOI 10.1016/S0003-4975(10)62927-X; MIRICH D, 1989, RADIOLOGY, V170, P1033, DOI 10.1148/radiology.170.3.2916054; MITCHELL RS, 1983, J THORAC CARDIOV SUR, V86, P400; MORENOCABRAL CE, 1984, J THORAC CARDIOV SUR, V88, P1020; Najafi H, 1980, World J Surg, V4, P553; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; PRESSLER V, 1980, J THORAC CARDIOV SUR, V79, P489; YOSHIOKA T, 1988, AM J ROENTGENOL, V151, P673, DOI 10.2214/ajr.151.4.673	19	1162	1365	2	53	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	1994	331	26					1729	1734		10.1056/NEJM199412293312601	http://dx.doi.org/10.1056/NEJM199412293312601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ266	7984192				2022-12-24	WOS:A1994PZ26600001
J	YAN, MH; DAI, TN; DEAK, JC; KYRIAKIS, JM; ZON, LI; WOODGETT, JR; TEMPLETON, DJ				YAN, MH; DAI, TN; DEAK, JC; KYRIAKIS, JM; ZON, LI; WOODGETT, JR; TEMPLETON, DJ			ACTIVATION OF STRESS-ACTIVATED PROTEIN-KINASE BY MEKK1 PHOSPHORYLATION OF ITS ACTIVATOR SEK1	NATURE			English	Article							RAF; TYROSINE	A KINASE distinct from the MEK activator Raf(1-3), termed MEK kinase-1 (MEKK), was originally identified by virtue of its homology to kinases involved in yeast mating signal cascades(4). Like Raf, MEKK is capable of activating MEK in vitro(4,5). High-level expression of MEKK in COS-7 cells(4) or using vaccinia virus vectors(5) also activates MEK and MAPK, indicating that MEKK and Raf provide alternative means of activating the MAPK signalling pathmay. We have derived NIH3T3 cell sublines that can be induced to express active MEKK. Here we show that induction of MEKK does not result in the activation of MAPK, but instead stimulates the stress-activated protein kinases (SAPKs)(6-8) which are identical to a Jun amino-terminal kinase(9,10). We find that MEKK regulates a new signalling cascade by phosphorylating an SAPK activator, SEK1 which in turn phosphorylates and activates SAPK.	CASE WESTERN RESERVE UNIV HOSP, SCH MED, CELL BIOL PROGRAM, CLEVELAND, OH 44106 USA; PRINCESS MARGARET HOSP, ONTARIO CANC INST, TORONTO M4X 1K9, ON, CANADA; MASSACHUSETTS GEN HOSP E, MED SERV, DIABET RES LAB, BOSTON, MA 02129 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP EAST, DEPT MED, BOSTON, MA 02129 USA; HARVARD UNIV, CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST, DIV HEMATOL, BOSTON, MA 02115 USA	Case Western Reserve University; Case Western Reserve University Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	YAN, MH (corresponding author), CASE WESTERN RESERVE UNIV HOSP, SCH MED, INST PATHOL, 10900 E EUCLID AVE, CLEVELAND, OH 44106 USA.		Woodgett, Jim/F-1087-2010; Templeton, Dennis J/F-7695-2011	Woodgett, Jim/0000-0003-3731-5797; 				DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; YAN MH, 1994, J BIOL CHEM, V269, P19067	20	706	723	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					798	800						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997270				2022-12-24	WOS:A1994PY21200058
J	HEINZE, HJ; MANGUN, GR; BURCHERT, W; HINRICHS, H; SCHOLZ, M; MUNTE, TF; GOS, A; SCHERG, M; JOHANNES, S; HUNDESHAGEN, H; GAZZANIGA, MS; HILLYARD, SA				HEINZE, HJ; MANGUN, GR; BURCHERT, W; HINRICHS, H; SCHOLZ, M; MUNTE, TF; GOS, A; SCHERG, M; JOHANNES, S; HUNDESHAGEN, H; GAZZANIGA, MS; HILLYARD, SA			COMBINED SPATIAL AND TEMPORAL IMAGING OF BRAIN ACTIVITY DURING VISUAL SELECTIVE ATTENTION IN HUMANS	NATURE			English	Article							PET IMAGES; CORTEX	VISUAL-SPATIAL attention is an essential brain function that enables os to select and preferentially process high priority information in the visual fields. Several brain areas have been shown to participate in the control of spatial attention in humans(3-5), but little is known about the underlying selection mechanisms. Non-invasive scalp recordings of event-related potentials (e.r.ps) in humans have shown that attended visual stimuli are preferentially selected as early as 80-90 ms after stimulus onset(6,7), but current e.r.p. methods do not permit a- precise localization of the participating cortical areas. In this study we combined neuroimaging (positron emission tomography) with e.r.p. recording in order to describe both the cortical anatomy and time course of attentional selection processes. Together these methods showed that visual inputs from attended locations receive enhanced processing in the extrastriate cortex (fusiform gyrus) at 80-130 ms after stimulus onset. These findings reinforce early selection models of attention(8-10).	UNIV CALIF DAVIS, DEPT PSYCHOL, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, CTR NEUROSCI, DAVIS, CA 95616 USA; HANNOVER MED SCH, DEPT NUCL MED, W-3000 HANNOVER, GERMANY; UNIV HEIDELBERG, DEPT NEUROL, HEIDELBERG, GERMANY; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA	University of California System; University of California Davis; University of California System; University of California Davis; Hannover Medical School; Ruprecht Karls University Heidelberg; University of California System; University of California San Diego	HEINZE, HJ (corresponding author), UNIV MAGDEBURG, DEPT CLIN NEUROPHYSIOL, D-39120 MAGDEBURG, GERMANY.		Burchert, Wolfgang/ABF-4194-2020; Münte, Thomas/C-2077-2014					Broadbent D. E., 1958, PERCEPTION COMMUNICA; CORBETTA M, 1991, J NEUROSCI, V11, P2383; CORBETTA M, 1993, J NEUROSCI, V13, P1202; DESIMONE R, 1992, COLD SPRING HARB SYM, P963; FISCHER B, 1985, BRAIN RES, V345, P111, DOI 10.1016/0006-8993(85)90841-8; FOX PT, 1989, J NUCL MED, V30, P141; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; GONZALEZ G, IN PRESS BRAIN TOPOG; HAWKINS HL, 1990, J EXP PSYCHOL HUMAN, V16, P802, DOI 10.1037/0096-1523.16.4.802; HEINZE HJ, 1994, PERCEPT PSYCHOPHYS, V56, P42, DOI 10.3758/BF03211689; HILLYARD SA, 1993, CURR OPIN NEUROBIOL, V3, P217, DOI 10.1016/0959-4388(93)90213-I; JEFFREYS DA, 1972, EXP BRAIN RES, V16, P1; Laberge D, 1990, J Cogn Neurosci, V2, P358, DOI 10.1162/jocn.1990.2.4.358; MANGUN GR, 1993, ATTENTION PERFORM, V14, P219; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; Petersen S E, 1992, Curr Opin Neurobiol, V2, P217, DOI 10.1016/0959-4388(92)90016-E; PETERSEN SE, 1993, BRAIN MECHANISMS OF PERCEPTION AND MEMORY: FROM NEURON TO BEHAVIOR, P413; Posner M I, 1992, Curr Opin Neurobiol, V2, P165, DOI 10.1016/0959-4388(92)90006-7; POSNER MI, 1980, J EXP PSYCHOL GEN, V109, P160, DOI 10.1037/0096-3445.109.2.160; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.neuro.13.1.25; SCHERG M, 1991, Brain Topography, V4, P143, DOI 10.1007/BF01132771; SPITZER H, 1988, SCIENCE, V240, P338, DOI 10.1126/science.3353728; Talairach I., 1988, COPLANAR STEREOTACTI; TANAKA K, 1993, J NEUROPHYSIOL, V69, P128, DOI 10.1152/jn.1993.69.1.128; TREISMAN A, 1988, Q J EXP PSYCHOL-A, V40, P201, DOI 10.1080/02724988843000104; Ungerleider LG., 1982, ANAL VISUAL BEHAV, P549; van der Heijden AHC., 1992, SELECTIVE ATTENTION; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; ZEKI S, 1991, J NEUROSCI, V11, P641	30	758	770	1	47	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 8	1994	372	6506					543	546		10.1038/372543a0	http://dx.doi.org/10.1038/372543a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990926				2022-12-24	WOS:A1994PW08200050
J	TAKAGAKI, Y; MANLEY, JL				TAKAGAKI, Y; MANLEY, JL			A POLYADENYLATION FACTOR SUBUNIT IS THE HUMAN HOMOLOG OF THE DROSOPHILA SUPPRESSOR OF FORKED PROTEIN	NATURE			English	Article							PRE-MESSENGER-RNAS; POLY(A) POLYMERASE; SACCHAROMYCES-CEREVISIAE; SPECIFICITY FACTOR; BINDING DOMAIN; MELANOGASTER; CLEAVAGE; EXPRESSION; SEQUENCE; GENES	POLYADENYLATION of messenger RNA precursors is a complex process that requires multiple protein factors (for reviews, see refs 1, 2). Cleavage stimulation factor (CstF) is one of these, functioning together with cleavage-polyadenylation specificity factor, two cleavage factors, and poly(A)(+) polymerase(3-7) CstF is composed of three subunits of M(r) 77, 64 and 50K(8,9). The 64K(10) and 50K(11) subunits contain, respectively, an RNP-type RNA-binding domain that contacts the pre-mRNA and transducin repeats characteristic of G-protein beta-subunits. Here we report the cloning and characterization of the 77K subunit of human CstF (referred to as 77K). We show that the 77K subunit is required for formation of active CstF and bridges the 64K and 50K subunits. Sequence analyses indicate that the 77K subunit is the homologue of the protein encoded by the Drosophila melanogaster suppressor of forked (su(f)) gene(12). Mutations in su(f) can enhance or suppress the effects of transposable element insertions(13), and our data indicate that this is due to changes in polyadenylation. Both the 77K subunit and the su(f) protein share homology with Saccharomyces cerevisiae RNA14 previously shown to be involved in mRNA metabolism(14). Our results thus also indicate that components of the complex polyadenylation machinery are conserved from yeast to man.			TAKAGAKI, Y (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Manley, James/0000-0002-8341-1459				AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; DORSETT D, 1989, GENE DEV, V3, P454, DOI 10.1101/gad.3.4.454; DRIVER A, 1989, MOL GEN GENET, V220, P49, DOI 10.1007/BF00260854; DUDICK ME, 1974, GENETICS, V76, P487; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HARLOW E, 1988, ANTIBODIES LABORATOR; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MANLEY JL, 1994, GENE DEV, V8, P259, DOI 10.1101/gad.8.3.259; MILLER DW, 1986, GENETIC ENG PRINCIPL, V8, P277; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MITCHELSON A, 1993, GENE DEV, V7, P241, DOI 10.1101/gad.7.2.241; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RUTLEDGE BJ, 1988, GENETICS, V119, P391; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WILSON TG, 1980, J EMBRYOL EXP MORPH, V55, P247; ZACHAR ZZ, 1987, EMBO J, V6, P4105, DOI 10.1002/j.1460-2075.1987.tb02756.x	30	118	119	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					471	474		10.1038/372471a0	http://dx.doi.org/10.1038/372471a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984242				2022-12-24	WOS:A1994PV01200059
J	AUGARTEN, A; YAHAV, Y; KEREM, BS; HALLE, D; LAUFER, J; SZEINBERG, A; DOR, J; MASHIACH, S; GAZIT, E; MADGAR, I				AUGARTEN, A; YAHAV, Y; KEREM, BS; HALLE, D; LAUFER, J; SZEINBERG, A; DOR, J; MASHIACH, S; GAZIT, E; MADGAR, I			CONGENITAL BILATERAL ABSENCE OF VAS-DEFERENS IN THE ABSENCE OF CYSTIC-FIBROSIS	LANCET			English	Note							MEN	The high frequency of mutations in the cystic fibrosis gene in patients with congenital bilateral absence of vas deferens (CBAVD) has raised the question whether all of them have a genital form of cystic fibrosis. We investigated 47 CBAVD patients by ultrasonography, 10 (21%) had renal malformations and 37 (79%) did not. In the former group, no cystic fibrosis mutations were found and sweat chloride concentrations were normal. In the latter group, 18 patients (49%) carried at least one cystic fibrosis mutation and sweat chloride was high in 17 of 26 tested (65%). Our findings suggest that CBAVD patients with renal malformations do not necessarily have cystic fibrosis.	CHAIM SHEBA MED CTR,DEPT GYNAECOL,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,DEPT UROL,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,TISSUE TYPING LAB,IL-52621 TEL HASHOMER,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,IL-69978 TEL AVIV,ISRAEL; HEBREW UNIV JERUSALEM,DEPT GENET,IL-91904 JERUSALEM,ISRAEL	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem	AUGARTEN, A (corresponding author), CHAIM SHEBA MED CTR,DEPT PAEDIAT,IL-52621 TEL HASHOMER,ISRAEL.							AMOS JA, 1992, PEDIAT PULMON S, V8, P142; ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; DUMUR V, 1990, LANCET, V336, P512, DOI 10.1016/0140-6736(90)92066-Q; OATES RD, 1994, J ANDROL, V15, P1; OATES RD, 1993, WORLD J UROL, V11, P82; OSBORNE LR, 1993, HUM MOL GENET, V2, P1605, DOI 10.1093/hmg/2.10.1605; RUBIN SO, 1975, SCAND J UROL NEPHROL, V9, P94, DOI 10.3109/00365597509180913; 1992, LANCET, V339, P1328	8	96	97	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1473	1474		10.1016/S0140-6736(94)90292-5	http://dx.doi.org/10.1016/S0140-6736(94)90292-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968122				2022-12-24	WOS:A1994PT99500011
J	MCANULTY, JM; FLEMING, DW; GONZALEZ, AH				MCANULTY, JM; FLEMING, DW; GONZALEZ, AH			A COMMUNITY-WIDE OUTBREAK OF CRYPTOSPORIDIOSIS ASSOCIATED WITH SWIMMING AT A WAVE POOL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DAY-CARE-CENTER; GIARDIA; IMMUNOCOMPETENT; CONTAMINATION; TRANSMISSION; DIARRHEA; GEORGIA; CALVES	Objective.-To determine the cause of a community-wide outbreak of cryptosporidiosis. Design.-A matched case-control study. Setting.-General community of Lane County, Oregon. Patients and Other Participants.-Persons with Cryptosporidium detected in their stool from June to October 1992 were identified by contacting laboratories serving the area. Exposures of the first 18 case patients identified were compared with those of 18 age- and neighborhood-matched controls selected from a reverse telephone directory. Main Outcome Measures.-Reported exposures to risk factors for cryptosporidiosis and abatement of cryptosporidiosis outbreak. Results.-Fifty-five patients with cryptosporidiosis were detected, including 37 who were the first individuals ill in their households. The case-control study involving the first 18 case patients showed no association between illness and attendance at day care or drinking municipal water or drinking untreated surface waters (river or lake water) in the 2 weeks before onset of illness. However, nine of 18 case patients reported swimming at a local wave pool, compared with none of 18 controls. We ultimately identified 17 case patients who reported swimming at the same wave pool during their incubation periods, whose exposure dates spanned a 2-month period. Inspection of the pool's filtration system did not detect any abnormalities. The outbreak subsided after the pool water was drained and replaced. Conclusions.-This prolonged outbreak of cryptosporidiosis was likely caused by exposure to fecally contaminated wave pool water. Since Cryptosporidium is highly chlorine resistant and inadequately removed by sand filters, such outbreaks may represent an unrecognized hazard of wave pools, where the likelihood of inadvertent water ingestion is high. Such outbreaks may go undetected in areas where cryptosporidiosis is not reportable or laboratory screening is infrequent.	CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30341; OREGON MED LABS,EUGENE,OR	Centers for Disease Control & Prevention - USA	MCANULTY, JM (corresponding author), OREGON HLTH DIV,CTR DIS CONTROL & PREVENT,800 NE OREGON ST,PORTLAND,OR 97232, USA.							ADDISS DG, 1991, PEDIATR INFECT DIS J, V10, P907, DOI 10.1097/00006454-199112000-00005; CASEMORE DP, 1989, J INFECTION, V19, P101, DOI 10.1016/S0163-4453(89)91764-7; CRAWFORD FG, 1988, PEDIATR INFECT DIS J, V7, P806, DOI 10.1097/00006454-198811000-00013; CURRENT WL, 1983, NEW ENGL J MED, V308, P1252, DOI 10.1056/NEJM198305263082102; DANTONIO RG, 1985, ANN INTERN MED, V103, P886, DOI 10.7326/0003-4819-103-6-886; DEAN AG, 1994, EPI INFO VERSION 6; FERSON MJ, 1992, MED J AUSTRALIA, V156, P813, DOI 10.5694/j.1326-5377.1992.tb121578.x; GARCIA LS, 1988, DIAGNOSTIC MED PARAS, P389; GREENSMITH CT, 1988, PEDIATR INFECT DIS J, V7, P91, DOI 10.1097/00006454-198802000-00005; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; JOCE RE, 1991, EPIDEMIOL INFECT, V107, P497, DOI 10.1017/S0950268800049190; KORICH DG, 1990, APPL ENVIRON MICROB, V56, P1423, DOI 10.1128/AEM.56.5.1423-1428.1990; LECHEVALLIER MW, 1991, GIARDIA CRYPTOSPORID; MEISEL JL, 1976, GASTROENTEROLOGY, V70, P1156; MILLER RA, 1990, J INFECT DIS, V161, P312, DOI 10.1093/infdis/161.2.312; MIRON D, 1991, PEDIATR INFECT DIS J, V10, P438, DOI 10.1097/00006454-199106000-00004; NAVIN TR, 1984, REV INFECT DIS, V6, P313; NIME FA, 1976, GASTROENTEROLOGY, V70, P592; PORTER JD, 1988, AM J PUBLIC HEALTH, V78, P659, DOI 10.2105/AJPH.78.6.659; REIF JS, 1989, AM J PUBLIC HEALTH, V79, P1528, DOI 10.2105/AJPH.79.11.1528; ROSE JB, 1991, ENVIRON SCI TECHNOL, V25, P1393, DOI 10.1021/es00020a005; SCHULER PF, 1990, J AM WATER WORKS ASS, V82, P67; SMITH HV, 1989, EPIDEMIOL INFECT, V103, P703, DOI 10.1017/S0950268800031101; SORVILLO FJ, 1992, AM J PUBLIC HEALTH, V82, P742, DOI 10.2105/AJPH.82.5.742; Sterling C.R., 1990, P51; TANGERMANN RH, 1991, AM J EPIDEMIOL, V133, P471, DOI 10.1093/oxfordjournals.aje.a115914; WEBER J, 1983, NEW ENGL J MED, V309, P1326; WOLFSON JS, 1985, NEW ENGL J MED, V312, P1278, DOI 10.1056/NEJM198505163122002; 1993, CD SUMMARY, V42, P1; 1994, MMWR-MORBID MORTAL W, V43, P561; 1984, MMWR-MORBID MORTAL W, V33, P599	31	64	68	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1597	1600		10.1001/jama.272.20.1597	http://dx.doi.org/10.1001/jama.272.20.1597			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR405	7966870				2022-12-24	WOS:A1994PR40500026
J	HUYSMANS, DAKC; HERMUS, ARMM; CORSTENS, FHM; BARENTSZ, JO; KLOPPENBORG, PWC				HUYSMANS, DAKC; HERMUS, ARMM; CORSTENS, FHM; BARENTSZ, JO; KLOPPENBORG, PWC			LARGE, COMPRESSIVE GOITERS TREATED WITH RADIOIODINE	ANNALS OF INTERNAL MEDICINE			English	Article						IODINE RADIOISOTOPES; GOITER, NODULAR; AGED; SURGERY, OPERATIVE; LEVOTHYROXINE	MULTINODULAR NONTOXIC GOITER; RADIOACTIVE IODINE; TOXIC GOITER; THERAPY; HYPERTHYROIDISM; THYROIDECTOMY; MANAGEMENT; THYROXINE; DISEASE	Objective: To evaluate the effectiveness of radioiodine therapy as an alternative for surgery in elderly patients with a large, compressive goiter using objective methods for measuring thyroid volume and tracheal compression. Design: Prospective study. Setting: University hospital in the Netherlands. Patients: 19 patients (mean age +/- SD, 66 +/- 14 years) with a large, compressive multinodular goiter who had a high operative risk or refused to have thyroid surgery. Intervention: A single intravenous dose of I-131 at 2.6 +/- 1.0 GBq (70 +/- 28 mCi) (3.7 MBq or 100 mu Ci/g of thyroid tissue), followed by daily administration of L-thyroxine in doses that did not suppress thyroid-stimulating hormone. Measurements: Clinical evaluation and measurements of thyroid volume, maximal tracheal deviation, and the smallest cross-sectional area of the tracheal lumen with magnetic resonance imaging before and 1 year after I-131 treatment. Results: No exacerbation of compressive symptoms after I-131 therapy was observed. Thyroid volume was 269 +/- 153 mL before treatment and 154 +/- 73 mL 1 year after treatment (P < 0.001). Thyroid volume was reduced 40% +/- 15% (range, 19% to 68%). Maximal tracheal deviation (1.9 +/- 0.8 cm before and 1.5 +/- 0.7 cm 1 year after therapy) had decreased by 20% +/- 20% (range, -4% to 73%; P < 0.001), and the smallest cross-sectional area of the tracheal lumen (0.78 +/- 0.38 cm(2) before and 1.04 +/- 0.48 cm(2) 1 year after therapy) had increased by 36% +/- 38% (range, -3% to 125%; P < 0.001). Clinical signs and symptoms improved in 8 of 12 patients with dyspnea and inspiratory strider and in both patients with compression of the superior vena cava. Conclusions:Therapy with I-131 is an effective alternative to surgery for elderly patients with a large, compressive multinodular goiter.	UNIV NIJMEGEN HOSP, DEPT ENDOCRINOL, 6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen	HUYSMANS, DAKC (corresponding author), DEWEEZENLANDEN HOSP, DEPT NUCL MED, POB 10500, 8000 GM ZWOLLE, NETHERLANDS.		Barentsz, Jelle/D-3515-2009; Hermus, A.R.M.M./H-8043-2014	Hermus, A.R.M.M./0000-0003-1075-2655				BERDING G, 1990, NUKLEARMED, V29, P158; BERGHOUT A, 1989, CLIN ENDOCRINOL, V31, P193, DOI 10.1111/j.1365-2265.1989.tb01242.x; BERGHOUT A, 1988, CLIN ENDOCRINOL, V28, P409, DOI 10.1111/j.1365-2265.1988.tb03672.x; BERGHOUT A, 1990, LANCET, V336, P193, DOI 10.1016/0140-6736(90)91730-X; BLIDDAL H, 1982, ACTA ENDOCRINOL-COP, V99, P517, DOI 10.1530/acta.0.0990517; Cooper DS, 1991, WERNER INGBARS THYRO, P887; DeGroot LJ, 1975, THYROID ITS DISEASES, P314; DOERING P, 1958, Strahlentherapie, V105, P245; FOSTER RS, 1978, SURG GYNECOL OBSTET, V146, P423; FREY KW, 1979, FORTSCHR RONTG NEUEN, V130, P172; GEERDSEN JP, 1984, CLIN ENDOCRINOL, V21, P529, DOI 10.1111/j.1365-2265.1984.tb01391.x; HAMBURGER JI, 1985, J NUCL MED, V26, P888; HEGEDUS L, 1990, DAN MED BULL, V37, P249; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; HUYSMANS DAKC, 1994, BRIT J RADIOL, V67, P519, DOI 10.1259/0007-1285-67-798-519; KAY TWH, 1987, ANN INTERN MED, V107, P857, DOI 10.7326/0003-4819-107-6-857; KAY TWH, 1988, AM J MED, V84, P19, DOI 10.1016/0002-9343(88)90003-4; KEIDERLING W, 1964, DEUT MED WOCHENSCHR, V89, P453, DOI 10.1055/s-0028-1111038; MILLER MR, 1990, Q J MED, V74, P177; NYGAARD B, 1993, BRIT MED J, V307, P828, DOI 10.1136/bmj.307.6908.828; Rohrer F, 1915, PFLUG ARCH GES PHYS, V162, P225, DOI 10.1007/BF01681259; SAILER R, 1986, CHIRURGIE SCHILDDRUS, P77; SHIMAOKA K, 1974, AM J MED, V57, P576, DOI 10.1016/0002-9343(74)90009-6; STUDLEY J, 1993, SURG ENDOCRINOLOGY, P231; TAMMELING GJ, 1979, CONTOURS BREATHING, V1, P76; VERELST J, 1990, ACTA ENDOCRINOL-COP, V122, P417, DOI 10.1530/acta.0.1220417; WEITENSFELDER W, 1989, CHIRURG, V60, P29	27	115	115	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					757	762		10.7326/0003-4819-121-10-199411150-00005	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944053				2022-12-24	WOS:A1994PQ92800005
J	ROLLS, MM; WEBSTER, P; BALBA, NH; ROSE, JK				ROLLS, MM; WEBSTER, P; BALBA, NH; ROSE, JK			NOVEL INFECTIOUS PARTICLES GENERATED BY EXPRESSION OF THE VESICULAR STOMATITIS-VIRUS GLYCOPROTEIN FROM A SELF-REPLICATING RNA	CELL			English	Article							SEMLIKI FOREST VIRUS; CELL-SURFACE; ANIMAL-CELLS; SINDBIS VIRUS; RABIES VIRUS; G-PROTEIN; TRANSPORT; MEMBRANE; MUTANTS; VECTORS	Self-propagating infectious particles were produced in animal cells transfected with an RNA replicon encoding a single viral structural protein, the vesicular stomatitis virus glycoprotein (VSV-G). The replicon is derived from an alphavirus, Semliki Forest virus (SFV), and encodes the SFV RNA replicase, but none of the SFV structural proteins. After transfection of the replicon into tissue culture cells, expression of G protein spread from small foci throughout the culture. Supernatants from the cells contained infectious, virus-like particles that could be passaged and were neutralized by anti-VSV serum. The majority of the infectious particles were smaller and less dense than either VSV or SFV. Characterization by electron microscopy showed membrane-enveloped vesicles that contained the VSV-G protein. Infectious particles were apparently generated by budding of vesicles containing VSV-G protein and the RNA replicon. These experiments reveal that an enveloped infectious agent can be much simpler than previously thought.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT BIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University; Yale University			Rolls, Melissa/G-6402-2014	Rolls, Melissa/0000-0002-5021-4360; Webster, Paul/0000-0002-1980-6931	NIAID NIH HHS [AI-24345] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024345, R37AI024345] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWN T, 1993, CURRENT PROTOCOLS MO; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FLORKIEWICZ RZ, 1984, SCIENCE, V225, P721, DOI 10.1126/science.6087454; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; GRAHAM JM, 1988, BIOCHEM J, V252, P437, DOI 10.1042/bj2520437; GRIMLEY PM, 1968, J VIROL, V2, P1326, DOI 10.1128/JVI.2.11.1326-1338.1968; HARTFORD SL, 1975, P NATL ACAD SCI USA, V72, P1202, DOI 10.1073/pnas.72.3.1202; KAARIAINEN L, 1969, ANN MED EXP BIOL FEN, V47, P235; Kelley J M, 1972, J Virol, V10, P1231; KNIPE DM, 1977, J VIROL, V21, P1149, DOI 10.1128/JVI.21.3.1149-1158.1977; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MATLIN KS, 1982, J MOL BIOL, V156, P609, DOI 10.1016/0022-2836(82)90269-8; MCCOMBS RM, 1966, J BACTERIOL, V91, P803, DOI 10.1128/JB.91.2.803-812.1966; METSIKKO K, 1986, EMBO J, V5, P1913, DOI 10.1002/j.1460-2075.1986.tb04444.x; OWENS RJ, 1993, J VIROL, V67, P360, DOI 10.1128/JVI.67.1.360-365.1993; PAUL NL, 1993, AIDS RES HUM RETROV, V9, P963, DOI 10.1089/aid.1993.9.963; RICE CM, 1987, J VIROL, V61, P3809, DOI 10.1128/JVI.61.12.3809-3819.1987; RIEDEL H, 1984, EMBO J, V3, P1477, DOI 10.1002/j.1460-2075.1984.tb01999.x; ROSE J, 1987, RHABDOVIRUSES; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; ROSE JK, 1982, J VIROL, V43, P361, DOI 10.1128/JVI.43.1.361-364.1982; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SCHLESINGER MJ, 1986, TOGAVIRIDAE FLAVIVIR; SIMONS K, 1980, J GEN VIROL, V50, P1, DOI 10.1099/0022-1317-50-1-1; Strauss EG, 1986, TOGAVIRIDAE FLAVIVIR; SUOMALAINEN M, 1992, J VIROL, V66, P4737, DOI 10.1128/JVI.66.8.4737-4747.1992; WHITT MA, 1989, J VIROL, V63, P3569, DOI 10.1128/JVI.63.9.3569-3578.1989; WHITT MA, 1991, VIROLOGY, V185, P681, DOI 10.1016/0042-6822(91)90539-N; WHITT MA, 1990, J VIROL, V64, P4907, DOI 10.1128/JVI.64.10.4907-4913.1990; XIONG C, 1989, SCIENCE, V243, P1188, DOI 10.1126/science.2922607; ZAVADA J, 1982, J GEN VIROL, V63, P15, DOI 10.1099/0022-1317-63-1-15; ZHAO HX, 1992, J VIROL, V66, P7089, DOI 10.1128/JVI.66.12.7089-7095.1992	34	109	124	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	1994	79	3					497	506		10.1016/0092-8674(94)90258-5	http://dx.doi.org/10.1016/0092-8674(94)90258-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954815				2022-12-24	WOS:A1994PQ48800012
J	ZHU, LY; SAGE, JT; CHAMPION, PM				ZHU, LY; SAGE, JT; CHAMPION, PM			OBSERVATION OF COHERENT REACTION DYNAMICS IN HEME-PROTEINS	SCIENCE			English	Article							GEMINATE RECOMBINATION; IMPULSIVE EXCITATION; OPTICAL SPECTROSCOPY; CO BINDING; RELAXATION; ABSORPTION; MYOGLOBIN; RAMAN; MOTION; MODEL	Femtosecond laser pulses, resonant with the Soret band of the nitric oxide complex of myoglobin (MbNO), were used to probe coherent, low-frequency nuclear motion of the heme group after photolysis. Distinct oscillations with periods of 430 and 150 femtoseconds were observed and are attributed to heme doming and iron-histidine motion, respectively. These results verify that the nuclear motion of the heme is strongly coupled to the ligand binding reaction and demonstrate that such motion is not determined by overdamped (diffusive) dynamics. The relative phases and frequencies of the nuclear motion of the photoproduct suggest that the coherence arises from impulsive electronic forces associated with the spin-state change of the heme iron atom and the depopulation of its d(z)2 orbital during the bond-breaking event.	NORTHEASTERN UNIV,DEPT PHYS,BOSTON,MA 02115	Northeastern University					NIADDK NIH HHS [AM-35090] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM035090] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; AGMON N, 1992, J CHEM PHYS, V97, P7270, DOI 10.1063/1.463500; AHMED AM, 1991, CHEM PHYS, V158, P329, DOI 10.1016/0301-0104(91)87076-8; BANIN U, 1993, J CHEM PHYS, V98, P4391, DOI 10.1063/1.465066; BERLIN YA, 1992, CHEM PHYS LETT, V197, P81, DOI 10.1016/0009-2614(92)86026-E; CHAMPION PM, 1992, J RAMAN SPECTROSC, V23, P557, DOI 10.1002/jrs.1250231008; CHERNOFF DA, 1980, P NATL ACAD SCI USA, V77, P5606, DOI 10.1073/pnas.77.10.5606; DEXHEIMER SL, 1992, CHEM PHYS LETT, V188, P61, DOI 10.1016/0009-2614(92)85089-S; DHAR L, 1994, CHEM REV, V94, P157, DOI 10.1021/cr00025a006; FINDSEN EW, 1985, J AM CHEM SOC, V107, P3355, DOI 10.1021/ja00297a056; FRAGNITO HL, 1989, CHEM PHYS LETT, V160, P101, DOI 10.1016/0009-2614(89)87564-5; FRANKE G, 1894, ARCH LARYNGOL RHINOL, V1, P230; GU YG, 1994, J CHEM PHYS, V100, P2547, DOI 10.1063/1.467232; LEE D, 1985, ADV INFRARED RAMAN S, V12, P179; LI XY, 1992, CHEM PHYS LETT, V188, P16, DOI 10.1016/0009-2614(92)85081-K; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; MUKAMEL S, 1990, ANNU REV PHYS CHEM, V41, P647, DOI 10.1146/annurev.pc.41.100190.003243; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; POLLARD WT, 1992, ANNU REV PHYS CHEM, V43, P497, DOI 10.1146/annurev.pc.43.100192.002433; PUGLIANO N, 1993, J CHEM PHYS, V99, P7273, DOI 10.1063/1.465422; ROSKER MJ, 1988, J CHEM PHYS, V89, P6113, DOI 10.1063/1.455427; ROSKER MJ, 1986, PHYS REV LETT, V57, P321, DOI 10.1103/PhysRevLett.57.321; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; RUHMAN S, 1987, J CHEM PHYS, V86, P6563, DOI 10.1063/1.452400; SCHEIDT WR, 1976, J AM CHEM SOC, V98, P1913, DOI 10.1021/ja00423a044; SCHERER NF, 1992, J CHEM PHYS, V96, P5544, DOI 10.1063/1.462693; SRAJER V, 1988, J AM CHEM SOC, V110, P6656, DOI 10.1021/ja00228a009; SRAJER V, 1991, BIOCHEMISTRY-US, V30, P7390, DOI 10.1021/bi00244a005; SRAJER V, 1986, PHYS REV LETT, V57, P1267, DOI 10.1103/PhysRevLett.57.1267; VOS MH, 1993, NATURE, V363, P320, DOI 10.1038/363320a0; WALTERS MA, 1982, BIOCHEMISTRY-US, V21, P6989, DOI 10.1021/bi00269a057; WISE FW, 1987, IEEE J QUANTUM ELECT, V23, P1116, DOI 10.1109/JQE.1987.1073483; ZEWAIL AH, 1988, SCIENCE, V242, P1645, DOI 10.1126/science.242.4886.1645; ZHU L, 1994, PHYS REV LETT, V72, P301, DOI 10.1103/PhysRevLett.72.301	35	178	179	3	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					629	632		10.1126/science.7939716	http://dx.doi.org/10.1126/science.7939716			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939716				2022-12-24	WOS:A1994PN80700041
J	WHITE, RJ; KHOO, BCE; INOSTROZA, JA; REINBERG, D; JACKSON, SP				WHITE, RJ; KHOO, BCE; INOSTROZA, JA; REINBERG, D; JACKSON, SP			DIFFERENTIAL REGULATION OF RNA POLYMERASE-I, POLYMERASE-II, AND POLYMERASE-III BY THE TBP-BINDING REPRESSOR DR1	SCIENCE			English	Article							TRANSCRIPTION FACTOR-TFIIIB; FUNCTIONAL DOMAINS; TATA-LESS; PROTEIN; COMPLEX; COMPONENTS; ACTIVATION; MECHANISM; PROMOTER; HOMOLOGY	RNA polymerases I, II, and III each use the TATA-binding protein (TBP). Regulators that target this shared factor may therefore provide a means to coordinate the activities of the three nuclear RNA polymerases; The repressor Dr1 binds to TBP and blocks the interaction of TBP with polymerase II- and polymerase III-specific factors. This enables Drl to coordinately regulate transcription by RNA polymerases II and III, Under the same conditions, Dr1 does not inhibit polymerase I transcription. By selectively repressing polymerases II and III, Drl may shift the physiological balance of transcriptional output in favor of polymerase I.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND; UNIV MED & DENT NEW JERSEY,DEPT BIOCHEM,PISCATAWAY,NJ 08854	University of Cambridge; Rutgers State University New Brunswick; Rutgers State University Medical Center	WHITE, RJ (corresponding author), UNIV CAMBRIDGE,WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND.		Khoo, Bernard/B-1247-2009; Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Khoo, Bernard/0000-0002-4223-9736; Jackson, Stephen Philip/0000-0001-9317-7937; Reinberg, Danny/0000-0003-4288-2016	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; DEAN N, 1987, NUCLEIC ACIDS RES, V15, P9895, DOI 10.1093/nar/15.23.9895; EBERHARD D, 1993, NUCLEIC ACIDS RES, V21, P4180, DOI 10.1093/nar/21.18.4180; Gill Grace, 1992, Current Biology, V2, P565, DOI 10.1016/0960-9822(92)90046-D; GODDARD JP, 1983, NUCLEIC ACIDS RES, V11, P2551, DOI 10.1093/nar/11.9.2551; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; INOSTROZA JA, 1992, CELL, V70, P477; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KHOO BCE, IN PRESS GENES DEV; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; STRUHL K, 1994, SCIENCE, V263, P1103, DOI 10.1126/science.8108728; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; WERNER M, 1993, J BIOL CHEM, V268, P20721; White R.C., UNPUB; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	43	56	58	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					448	450		10.1126/science.7939686	http://dx.doi.org/10.1126/science.7939686			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939686				2022-12-24	WOS:A1994PN27200038
J	SEMPOS, CT; LOOKER, AC; GILLUM, RF; MAKUC, DM				SEMPOS, CT; LOOKER, AC; GILLUM, RF; MAKUC, DM			BODY IRON STORES AND THE RISK OF CORONARY HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BINDING PROTEINS; MORTALITY; DEFICIENCY; HEMATOCRIT; PROGRAM; CANCER; MEN; INFORMATION; FRAMINGHAM; SMOKING	Background. Recent studies have suggested an association between higher body iron stores and the risk of coronary heart disease. To assess these findings, we examined the association between transferrin saturation and the risk of coronary heart disease, myocardial infarction, overall mortality, and mortality from cardiovascular causes in a large population. Methods. We studied a total of 4518 men and women from the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study, using a multivariate Cox proportional-hazards model. Base-line data were collected from 1971 to 1974, with follow-up through 1987. Transferrin saturation (serum iron concentration divided by total iron-binding capacity) was used as a measure of the amount of circulating iron available to tissues. Results. The risk of coronary heart disease was not related to transferrin-saturation levels in white men or women. Estimates of the relative risk of coronary heart disease for the fifth quintile of transferrin saturation as compared with the first quintile were 0.72 (95 percent confidence interval, 0.51 to 1.00) for men and 0.85 (95 percent confidence interval, 0.60 to 1.21) for women. The results were similar for myocardial infarction. A significant inverse association with transferrin saturation was found for overall mortality and for mortality from cardiovascular causes in white men and women. Transferrin saturation was not associated with any of the clinical outcomes in blacks, possibly owing to the small sample. Conclusions. Higher transferrin-saturation levels were not associated with an increased risk of coronary heart disease or myocardial infarction. On the contrary, the results indicate that there may be an inverse association of iron stores with overall mortality and with mortality from cardiovascular causes.			SEMPOS, CT (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, 6525 BELCREST RD, RM 1070, HYATTSVILLE, MD 20782 USA.							ABELL LL, 1952, J BIOL CHEM, V195, P357; ABRAHAM S, 1978, VITAL HLTH STAT, V11, P1; ABUZEID HAH, 1976, J CHRON DIS, V29, P395, DOI 10.1016/0021-9681(76)90060-6; BAKER IA, 1982, BRIT HEART J, V47, P490, DOI 10.1136/hrt.47.5.490; BEATON GH, 1989, AM J CLIN NUTR, V50, P575, DOI 10.1093/ajcn/50.3.575; Bothwell T.H., 1979, IRON METABOLISM MAN; BOTTIGER LE, 1980, ATHEROSCLEROSIS, V36, P389, DOI 10.1016/0021-9150(80)90219-1; BRAND RJ, 1976, CIRCULATION, V53, P348, DOI 10.1161/01.CIR.53.2.348; BURCH GE, 1962, JAMA-J AM MED ASSOC, V180, P63, DOI 10.1001/jama.1962.03050140065017b; Campbell M J, 1983, Stat Med, V2, P223, DOI 10.1002/sim.4780020217; CAMPBELL MJ, 1985, J CHRON DIS, V38, P881, DOI 10.1016/0021-9681(85)90113-4; CARTER C, 1983, AM HEART J, V105, P674, DOI 10.1016/0002-8703(83)90493-3; Clayton D., 1993, STAT MODELS EPIDEMIO, P249; Cohen B B, 1987, Vital Health Stat 1, P1; COOPER RS, 1993, CIRCULATION, V87, P686; COX CS, 1992, VITAL HLTH STAT, V1, P1; COX DR, 1972, J R STAT SOC B, V34, P187; CULLEN KJ, 1981, LANCET, V2, P1288; DEPASQUALE NP, 1963, JAMA-J AM MED ASSOC, V183, P142; DOUMAS BT, 1971, CLIN CHIM ACTA, V31, P87, DOI 10.1016/0009-8981(71)90365-2; EAVENSON E, 1966, J AM OIL CHEM SOC, V43, P652, DOI 10.1007/BF02682563; ELWOOD PC, 1974, LANCET, V1, P891; FINCH CA, 1982, NEW ENGL J MED, V306, P1520, DOI 10.1056/NEJM198206243062504; FINCH CA, 1984, AM J CLIN NUTR, V39, P471, DOI 10.1093/ajcn/39.3.471; Finucane F F, 1990, Vital Health Stat 1, P1; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; GIOVANNIELLO TJ, 1968, J LAB CLIN MED, V71, P874; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; INGRAM DD, IN PRESS VITAL HLTH, V2; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12; KNOTTNERUS JA, 1988, J CLIN EPIDEMIOL, V41, P67, DOI 10.1016/0895-4356(88)90010-8; KORN EL, 1991, AM J PUBLIC HEALTH, V81, P1166, DOI 10.2105/AJPH.81.9.1166; LAUFFER RB, 1991, MED HYPOTHESES, V35, P96, DOI 10.1016/0306-9877(91)90030-3; MACHLIN SR, 1989, STAT MED, V8, P997, DOI 10.1002/sim.4780080810; MADANS JH, 1986, PUBLIC HEALTH REP, V101, P474; MAYER GA, 1965, CAN MED ASSOC J, V93, P1151; MCLAUGHLIN JK, 1987, AM J EPIDEMIOL, V126, P144, DOI 10.1093/oxfordjournals.aje.a114647; MILLIMAN JD, 1973, BIOL GEOLOGY CORAL R, V1, P1; PAUL O, 1963, CIRCULATION, V28, P20, DOI 10.1161/01.CIR.28.1.20; RAMSAY WNM, 1957, CLIN CHIM ACTA, V2, P221, DOI 10.1016/0009-8981(57)90106-7; RIMM EB, 1993, CIRCULATION, V87, P692; ROBERTS J, 1977, VITAL HLTH STAT, V11, P1; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SCHATZKIN A, 1984, AM J EPIDEMIOL, V120, P888, DOI 10.1093/oxfordjournals.aje.a113960; SELBY JV, 1988, INT J CANCER, V41, P677, DOI 10.1002/ijc.2910410507; SHAH BV, 1991, SUDAAN USERS MANUAL; SORLIE PD, 1981, AM HEART J, V101, P456, DOI 10.1016/0002-8703(81)90136-8; STAMPFER MJ, 1993, CIRCULATION, V87, P688; STEVENS RG, 1986, J NATL CANCER I, V76, P605, DOI 10.1093/jnci/76.4.605; STEVENS RG, 1983, AM J EPIDEMIOL, V118, P550, DOI 10.1093/oxfordjournals.aje.a113660; STEVENS RG, 1988, NEW ENGL J MED, V319, P1047, DOI 10.1056/NEJM198810203191603; STUART J, 1988, J CLIN PATHOL, V41, P1203; SULLIVAN JL, 1989, AM HEART J, V117, P1177, DOI 10.1016/0002-8703(89)90887-9; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; TAKKUNEN H, 1974, LANCET, V2, P523; TRUETT J, 1967, J CHRON DIS, V20, P511, DOI 10.1016/0021-9681(67)90082-3; WILHELMSEN L, 1973, CIRCULATION, V48, P950, DOI 10.1161/01.CIR.48.5.950; Wintrobe MM, 1935, AM J MED SCI, V189, P102, DOI 10.1097/00000441-193501000-00012; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; YIP R, 1988, AM J CLIN NUTR, V48, P1295, DOI 10.1093/ajcn/48.5.1295; 1986, SGI SUPPLEMENTAL LIB; 1971, TECHNICON AUTO ANAL; 1979, HANES 1 HEMATOLOGY C	63	225	227	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 21	1994	330	16					1119	1124		10.1056/NEJM199404213301604	http://dx.doi.org/10.1056/NEJM199404213301604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF699	7993405				2022-12-24	WOS:A1994NF69900004
J	LUTHI, A; LAURENT, JP; FIGUROV, A; MULLER, D; SCHACHNER, M				LUTHI, A; LAURENT, JP; FIGUROV, A; MULLER, D; SCHACHNER, M			HIPPOCAMPAL LONG-TERM POTENTIATION AND PLEURAL CELL-ADHESION MOLECULES L1 AND NCAM	NATURE			English	Article							IMMUNOELECTRON-MICROSCOPIC LOCALIZATION; PASSIVE-AVOIDANCE RESPONSE; N-CAM; NEURITE OUTGROWTH; MOUSE CEREBELLUM; MEMORY; CONSOLIDATION; ASSOCIATION; COMPONENT; MEMBRANES	SYNAPTIC membranes express cell adhesion molecules(1). Here we investigate the role of the neural cell adhesion molecules L1 and NCAM in hippocampal long-term potentiation (LTP), a sustained-use-dependent increase in synaptic efficacy that has been implicated in learning and memory(2). L1 and NCAM mediate cell interactions during neural development(3) and are strongly expressed in the hippocampus(4,5). They cooperate to strengthen L1-dependent cell adhesion(6-9) and are coupled to second messenger pathways(10-12). We show that LTP in CA1 neurons of rat hippocampal slices was reduced by application of various L1 and NCAM antibodies, recombinant L1 fragments, and upon dissociation of the L1/NCAM complex through oligomannosidic carbohydrates and NCAM peptides. Neither the activation of NMDA (N-methyl-D-aspartate) receptors nor the maintenance of LTP was affected. These results suggest that L1 and NCAM modulate the development or the stabilization of LTP(13).	CTR MED UNIV GENEVA,DEPT PHARMACOL,CH-1211 GENEVA 4,SWITZERLAND; ETH ZURICH,DEPT NEUROBIOL,CH-8093 ZURICH,SWITZERLAND	University of Geneva; Swiss Federal Institutes of Technology Domain; ETH Zurich	LUTHI, A (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PRECLIN RES,DIV PHARMA,CH-4002 BASEL,SWITZERLAND.							APPEL F, 1993, J NEUROSCI, V13, P4764; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; DOYLE E, 1992, J NEUROSCI RES, V31, P513, DOI 10.1002/jnr.490310315; DOYLE E, 1992, J NEUROCHEM, V59, P1570, DOI 10.1111/j.1471-4159.1992.tb08477.x; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P142, DOI 10.1016/0166-2236(88)90139-7; HANSE E, 1994, NEUROSCI RES, V20, P15, DOI 10.1016/0168-0102(94)90018-3; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; MILLER PD, 1993, J COMP NEUROL, V327, P341, DOI 10.1002/cne.903270303; PERSOHN E, 1987, J CELL BIOL, V105, P569, DOI 10.1083/jcb.105.1.569; PERSOHN E, 1989, J COMP NEUROL, V288, P92, DOI 10.1002/cne.902880108; RATHJEN FG, 1984, EMBO J, V3, P1; SCHOLEY AB, 1993, NEUROSCIENCE, V55, P499, DOI 10.1016/0306-4522(93)90519-L; SIMON H, 1991, EUR J NEUROSCI, V3, P634, DOI 10.1111/j.1460-9568.1991.tb00849.x; VONBOHLEN F, 1992, EUR J NEUROSCI, V4, P896; ZHANG H, 1992, J NEUROSCI, V12, P3107, DOI 10.1523/JNEUROSCI.12-08-03107.1992	25	451	459	2	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					777	779		10.1038/372777a0	http://dx.doi.org/10.1038/372777a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997264				2022-12-24	WOS:A1994PY21200052
J	LOMELI, H; MOSBACHER, J; MELCHER, T; HOGER, T; GEIGER, JRP; KUNER, T; MONYER, H; HIGUCHI, M; BACH, A; SEEBURG, PH				LOMELI, H; MOSBACHER, J; MELCHER, T; HOGER, T; GEIGER, JRP; KUNER, T; MONYER, H; HIGUCHI, M; BACH, A; SEEBURG, PH			CONTROL OF KINETIC-PROPERTIES OF AMPA RECEPTOR CHANNELS BY NUCLEAR-RNA EDITING	SCIENCE			English	Article							GLUTAMATE-OPERATED CHANNELS; RAT HIPPOCAMPAL SLICES; CA2+ PERMEABILITY; BRAIN-SLICES; DESENSITIZATION; NEURONS; PATCHES; SUBUNIT; SWITCH; CELLS	AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor channels mediate the fast component of excitatory postsynaptic currents in the central nervous system. Site-selective nuclear RNA editing controls the calcium permeability of these channels, and RNA editing at a second site is shown here to affect the kinetic aspects of these channels in rat brain. In three of the four AMPA receptor subunits (GluR-B, -C, and -D), intronic elements determine a codon switch (AGA, arginine, to GGA, glycine) in the primary transcripts in a position termed the R/G site, which immediately precedes the alternatively spliced modules ''flip'' and ''flop.'' The extent of editing at this site progresses with brain development in a manner specific for subunit and splice form, and edited channels possess faster recovery rates from desensitization.	UNIV HEIDELBERG,CTR BIOL MOLEC,MOLEC NEUROENDOCRINOL LAB,D-69120 HEIDELBERG,GERMANY; MAX PLANCK INST MED RES,D-69120 HEIDELBERG,GERMANY; BASF AG,D-67056 LUDWIGSHAFEN,GERMANY	Ruprecht Karls University Heidelberg; Max Planck Society; BASF				Lomeli, Hilda/0000-0001-9659-0102; Monyer, Hannah/0000-0002-9332-5749				BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; BOCHET P, 1994, NEURON, V12, P383, DOI 10.1016/0896-6273(94)90279-8; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; DODT HU, 1990, BRAIN RES, V537, P333, DOI 10.1016/0006-8993(90)90380-T; FRANKE C, 1987, NEUROSCI LETT, V77, P199, DOI 10.1016/0304-3940(87)90586-6; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HIGUCHI M, UNPUB; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JONAS P, 1992, J PHYSIOL-LONDON, V455, P143, DOI 10.1113/jphysiol.1992.sp019294; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; JONAS P, 1994, CURR OPIN NEUROBIOL, V4, P365; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; KOHLER M, 1994, J BIOL CHEM, V269, P17367; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; MOSBACHER J, IN PRESS SCIENCE; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; PARTIN KM, 1994, MOL PHARMACOL, V46, P129; ROCHE KW, 1994, J BIOL CHEM, V269, P11679; SCHELL TJ, 1990, CELL, V61, P361; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STEIN E, 1992, MOL PHARMACOL, V42, P864; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; TAVERNA FA, 1994, J BIOL CHEM, V269, P14159; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; TRUSSELL LO, 1994, SEMIN NEUROSCI, V6, P71; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	623	640	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1709	1713		10.1126/science.7992055	http://dx.doi.org/10.1126/science.7992055			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992055				2022-12-24	WOS:A1994PW30800041
J	LEE, JJ; EKKER, SC; VONKESSLER, DP; PORTER, JA; SUN, BI; BEACHY, PA				LEE, JJ; EKKER, SC; VONKESSLER, DP; PORTER, JA; SUN, BI; BEACHY, PA			AUTOPROTEOLYSIS IN HEDGEHOG PROTEIN BIOGENESIS	SCIENCE			English	Article							CELL-CELL COMMUNICATION; POLARITY GENE HEDGEHOG; DROSOPHILA-EMBRYO; EXPRESSION; TRANSCRIPTION; MEMBER	Extracellular signaling proteins encoded by the hedgehog (hh) multigene family are responsible for the patterning of a variety of embryonic structures in vertebrates and invertebrates. The Drosophila hh gene has now been shown to generate two predominant protein species that are derived by an internal autoproteolytic cleavage of a larger precursor. Mutations that reduced the efficiency of autoproteolysis in vitro diminished precursor cleavage in vivo and also impaired the signaling and patterning activities of the HH protein. The two HH protein species exhibited distinctive biochemical properties and tissue distribution, and these differences suggest a mechanism that could account for the long- and short-range signaling activities of HH in vivo.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University				Ekker, Stephen/0000-0003-0726-4212				ARIAS AM, 1988, DEVELOPMENT, V103, P157; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHANG DT, IN PRESS DEVELOPMENT; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, UNPUB; Eugene O., 1979, TCA (TISSUE CULTURE ASSOCIATION) MANUAL, V5, P1055, DOI 10.1007/BF00919788; FAN CM, IN PRESS CELL; HARLOW E, 1988, ANTIBODIES LABORATOR; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JONES DH, 1992, BIOTECHNIQUES, V12, P528; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE J, 1993, DROSOPHILA RES C; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PATEL H, METHODS CELL BIOL; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1993, CELL, V75, P761; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; VONKESSLER DP, UNPUB	37	441	478	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1528	1537		10.1126/science.7985023	http://dx.doi.org/10.1126/science.7985023			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985023				2022-12-24	WOS:A1994PV01500035
J	MEASDAY, V; MOORE, L; OGAS, J; TYERS, M; ANDREWS, B				MEASDAY, V; MOORE, L; OGAS, J; TYERS, M; ANDREWS, B			THE PCL2 (ORFD)-PHO85 CYCLIN-DEPENDENT KINASE COMPLEX - A CELL-CYCLE REGULATOR IN YEAST	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; MATING PHEROMONE; G1 CYCLINS; PHO SYSTEM; GENE; SWI4; PHOSPHATASE; CDC28; CLN1	Cyclin-dependent kinase (cdk) complexes are essential activators of cell cycle progression in all eukaryotes. In contrast to mammalian cells, in which multiple cdk's contribute to cell cycle regulation, the yeast cell cycle is largely controlled by the activity of a single cdk, CDC28. Analysis of the putative G(1) cyclin PCL2 (ORFD) identified a second cyclin-cdk complex that contributes to cell cycle progression in yeast. PCL2 interacted with the cdk PHO85 in vivo and in vitro and formed a kinase complex that had G(1)-periodic activity. Under genetic conditions in which the Start transition was compromised, PHO85 and its associated cyclin subunits were essential for cell cycle commitment. Because PHO85 and another cyclin-like molecule, PHO80, also take part in inorganic phosphate metabolism, this cdk enzyme may integrate responses to nutritional conditions with the cell cycle.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ON, CANADA; UNIV TORONTO, BANTING & BEST DEPT MED RES, TORONTO M5G 1L6, ON, CANADA; STANFORD UNIV, CARNEGIE INST, STANFORD, CA 94305 USA	University of Toronto; University of Toronto; Carnegie Institution for Science; Stanford University			Tyers, Michael/ABE-3194-2021	Ogas, Joe/0000-0002-1332-7729				Andrews B., UNPUB; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1992, P NATL ACAD SCI USA, V89, P11852, DOI 10.1073/pnas.89.24.11852; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; CROSS FR, 1994, MOL CELL BIOL, V14, P4779, DOI 10.1128/MCB.14.7.4779; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ESPINOZA H, 1994, SCIENCE, V266, P1388; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARPER JW, 1993, CELL, V75, P805; Hunt T., COMMUNICATION; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, pCH5; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; MEASDAY V, UNPUB; MOORE L, UNPUB; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; OGAS J, 1992, THESIS U CALIFORNIA; PINES J, 1993, BIOCHEM SOC T, V21, P921, DOI 10.1042/bst0210921; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SIKORSKI RS, 1989, GENETICS, V122, P19; STUART D, 1994, MOL CELL BIOL, V14, P4788, DOI 10.1128/MCB.14.7.4788; TOHE A, 1988, MOL GEN GENET, V214, P162, DOI 10.1007/BF00340196; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; TYERS M, 1992, EMBO J, V11, P1173; TYERS M, UNPUB; UEDA Y, 1975, J BACTERIOL, V122, P911, DOI 10.1128/JB.122.3.911-922.1975; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	39	153	157	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	1994	266	5189					1391	1395		10.1126/science.7973731	http://dx.doi.org/10.1126/science.7973731			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973731				2022-12-24	WOS:A1994PT63200046
J	JONES, P; RODGERS, B; MURRAY, R; MARMOT, M				JONES, P; RODGERS, B; MURRAY, R; MARMOT, M			CHILD DEVELOPMENTAL RISK-FACTORS FOR ADULT SCHIZOPHRENIA IN THE BRITISH 1946 BIRTH COHORT	LANCET			English	Article							DISORDER; LIFE	Schizophrenia has been linked with childhood psychological abnormalities since it was first described, but studies of associations have not used population samples and so may be subject to bias. We have studied associations between adult-onset schizophrenia and childhood sociodemographic, neurodevelopmental, cognitive, and behavioural factors within a cohort of 5362 people born in the week March 3-9, 1946. Childhood data were gathered prospectively and case ascertainment was independent of routine follow-up of this cohort. 30 cases of schizophrenia arose between ages 16 and 43 years (cumulative risk 0.63% [95% CI 0.41-0.86%]). Milestones of motor development were reached later in cases than in controls, particularly walking (difference in means 1.2 months [0.1-2.3], p = 0.005), and up to age 15, cases had more speech problems than had controls (odds ratio 2.8 [0.9-7.8], p = 0.04). Low educational test scores at ages 8, 11, and 15 years were a risk factor, with significant linear trends across population distributions; risk was not confined to very low scores. Solitary play preference at ages 4 and 6 years predicted schizophrenia (odds ratios 2.1, 2.5, p = 0.05). At 13 years cases rated themselves as less socially confident (p for trend, 0.04). At 15 years, teachers rated cases as being more anxious in social situations (p for trend 0.003), independent of intelligence quotient. A health visitor's rating of the mother as having below average mothering skills and understanding of her child at age 4 years was a predictor of schizophrenia in that child (odds ratio 5.8 [0.8-31.8], p = 0.02). Differences between children destined to develop schizophrenia as adults and the general population were found across a range of developmental domains. As with some other adult illnesses, the origins of schizophrenia may be found in early life.	UCL, DEPT EPIDEMIOL & PUBL HLTH, MRC, NATL SURVEY HLTH & DEV, LONDON, ENGLAND	University of London; University College London	JONES, P (corresponding author), INST PSYCHIAT, DEPT PSYCHOL MED, DE CRESPIGNY PK, LONDON SE5 8AF, ENGLAND.		Marmot, M G/Y-3920-2019; Rodgers, Bryan/B-2090-2013; murray, robin/F-8658-2012	Marmot, M G/0000-0002-2431-6419; Rodgers, Bryan/0000-0002-2863-3737; Jones, Peter Brian/0000-0002-0387-880X; murray, robin/0000-0003-0829-0519	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		[Anonymous], 1970, CLASSIFICATION OCCUP; AYLWARD E, 1984, SCHIZOPHRENIA BULL, V10, P430, DOI 10.1093/schbul/10.3.430; DONE DJ, 1994, BRIT MED J, V309, P699, DOI 10.1136/bmj.309.6956.699; DONE DJ, 1991, BRIT MED J, V302, P1576, DOI 10.1136/bmj.302.6792.1576; FISH B, 1992, ARCH GEN PSYCHIAT, V49, P221; GITTELMA.R, 1969, J PSYCHIAT RES, V7, P35, DOI 10.1016/0022-3956(69)90010-7; LEWIS G, 1992, LANCET, V340, P137, DOI 10.1016/0140-6736(92)93213-7; Lewis SW, 1989, SCHIZOPHRENIA, P56; MCGUIRE PK, 1993, LANCET, V342, P703, DOI 10.1016/0140-6736(93)91707-S; MEDNICK SA, 1988, ARCH GEN PSYCHIAT, V45, P188; MURRAY RM, 1987, BRIT MED J, V295, P681, DOI 10.1136/bmj.295.6600.681; PIDGEON DA, 1968, ALL OUR FUTURES, P194; PIDGEON DA, 1964, HOME SCH, P129; ROBERTS GW, 1990, BRIT J PSYCHIAT, V157, P1; Robins L. N., 1966, DEVIANT CHILDREN GRO; RODGERS B, 1978, DEV MED CHILD NEUROL, V20, P421, DOI 10.1111/j.1469-8749.1978.tb15242.x; RODGERS B, 1990, J CHILD PSYCHOL PSYC, V31, P393, DOI 10.1111/j.1469-7610.1990.tb01577.x; RODGERS B, 1986, PSYCHOL MED, V16, P689, DOI 10.1017/S0033291700010436; RODGERS B, 1990, BRIT J PSYCHIAT, V157, P539, DOI 10.1192/bjp.157.4.539; Rose G., 1992, STRATEGY PREVENTIVE; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; SUSSER ES, 1992, ARCH GEN PSYCHIAT, V49, P983; TIENARI P, 1987, SCHIZOPHRENIA BULL, V13, P477, DOI 10.1093/schbul/13.3.477; Wadsworth M. E. J., 1991, IMPRINT TIME CHILDHO; WADSWORTH MEJ, 1992, J EPIDEMIOL COMMUN H, V46, P300, DOI 10.1136/jech.46.3.300; WALKER E, 1990, AM J PSYCHIAT, V147, P1052; WATT NF, 1978, ARCH GEN PSYCHIAT, V35, P160; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012; 1987, DIAGNOSTIC STATISTIC; 1948, MATERNITY GB	30	988	1002	0	60	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1398	1402		10.1016/S0140-6736(94)90569-X	http://dx.doi.org/10.1016/S0140-6736(94)90569-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968076				2022-12-24	WOS:A1994PR78600010
J	GO, ES; URBAN, C; BURNS, J; KREISWIRTH, B; EISNER, W; MARIANO, N; MOSINKASNIPAS, K; RAHAL, JJ				GO, ES; URBAN, C; BURNS, J; KREISWIRTH, B; EISNER, W; MARIANO, N; MOSINKASNIPAS, K; RAHAL, JJ			CLINICAL AND MOLECULAR EPIDEMIOLOGY OF ACINETOBACTER INFECTIONS SENSITIVE ONLY TO POLYMYXIN-B AND SULBACTAM	LANCET			English	Article							CALCOACETICUS BIOTYPE ANITRATUS; IMIPENEM-RESISTANT; ANTIBIOTIC-RESISTANCE; NOSOCOMIAL INFECTIONS; SUSCEPTIBILITY; BAUMANNII	A nosocomial outbreak of infections due to imipenem-resistant Acinetobacter baumannii occurred in a New York hospital after increased use of imipenem for cephalosporin-resistant klebsiella infections. We identified all A baumannii isolates over 12 months, reviewed corresponding patient records, and compared strains with different antibiotic susceptibility patterns by restriction endonuclease analysis. Environmental surveillance cultures were done before and after institution of control measures. 59 patients harboured imipenem-resistant A baumannii, and 18 were infected, isolates from patients were resistant to all routinely tested antibiotics, including imipenem. Further studies showed susceptibility to polymyxin B and sulbactam. These isolates were identical by restriction endonuclease analysis to A baumannii isolates susceptible to imipenem alone, or to imipenem and amikacin, but differed from broadly susceptible isolates. Surveillance cultures showed hand and environmental colonisation by imipenem-resistant strains. Infection and colonisation were eliminated by intensive infection control measures, and irrigation of wounds with polymyxin B. Increased use of imipenem against cephalosporin-resistant klebsiella may lead to imipenem resistance among other species, particularly acinetobacter. Such resistance appears to derive from a prior multi-resistant clone, in contrast to one which retains susceptibility to several antibiotics.	CORNELL UNIV,SCH MED,DEPT MED,NEW YORK,NY 10021; CORNELL UNIV,SCH MED,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,NEW YORK HOSP,MED CTR QUEENS,DEPT MED,INFECT DIS SECT,NEW YORK,NY; CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY; NEW YORK CITY DEPT HLTH,BUR LABS,NEW YORK,NY 10013	Cornell University; Cornell University; Cornell University; NewYork-Presbyterian Hospital; Cornell University; New York City Department of Health & Mental Hygiene								ALKHOJA MS, 1979, J CLIN PATHOL, V32, P497, DOI 10.1136/jcp.32.5.497; ALLARDETSERVENT A, 1989, J CLIN MICROBIOL, V27, P2057, DOI 10.1128/JCM.27.9.2057-2061.1989; BECKSAGUE CM, 1990, AM J EPIDEMIOL, V132, P723, DOI 10.1093/oxfordjournals.aje.a115714; BUXTON AE, 1978, AM J MED, V65, P507, DOI 10.1016/0002-9343(78)90777-5; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; DECHAMPS C, 1993, J CLIN MICROBIOL, V31, P123, DOI 10.1128/JCM.31.1.123-127.1993; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GAYNES RP, 1992, INFECT CONT HOSP EP, V13, P10, DOI 10.1086/646417; GEHRLEIN M, 1991, CHEMOTHERAPY, V37, P405, DOI 10.1159/000238887; GLEW RH, 1977, MEDICINE, V56, P79, DOI 10.1097/00005792-197703000-00001; HARSTEIN AI, 1988, AM J MED, V85, P624; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; LEVY SB, 1993, JAMA-J AM MED ASSOC, V269, P1840, DOI 10.1001/jama.269.14.1840; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Paton R, 1993, Int J Antimicrob Agents, V2, P81, DOI 10.1016/0924-8579(93)90045-7; PATTERSON JE, 1991, AM J MED, V91, P479, DOI 10.1016/0002-9343(91)90183-X; RAIMONDI A, 1991, ANTIMICROB AGENTS CH, V35, P1174, DOI 10.1128/AAC.35.6.1174; ROLSTON KVI, 1986, ANTIMICROB AGENTS CH, V30, P769, DOI 10.1128/AAC.30.5.769; SATO K, 1991, J ANTIMICROB CHEMOTH, V28, P35, DOI 10.1093/jac/28.1.35; SEIFERT H, 1993, ANTIMICROB AGENTS CH, V37, P750, DOI 10.1128/AAC.37.4.750; TAPLIN D, 1963, JAMA-J AM MED ASSOC, V186, P952; TRAUB WH, 1989, ANTIMICROB AGENTS CH, V33, P1617, DOI 10.1128/AAC.33.9.1617; URBAN C, 1993, J INFECT DIS, V167, P448, DOI 10.1093/infdis/167.2.448; WOOD CA, 1993, J INFECT DIS, V168, P1602, DOI 10.1093/infdis/168.6.1602	25	284	305	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1329	1332		10.1016/S0140-6736(94)90694-7	http://dx.doi.org/10.1016/S0140-6736(94)90694-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968028				2022-12-24	WOS:A1994PQ92600010
J	PIJNENBORG, L; VANDELDEN, JJM; KARDAUN, JWPF; GLERUM, JJ; van der Maas, PJ				PIJNENBORG, L; VANDELDEN, JJM; KARDAUN, JWPF; GLERUM, JJ; van der Maas, PJ			NATIONWIDE STUDY OF DECISIONS CONCERNING THE END OF LIFE IN GENERAL-PRACTICE IN THE NETHERLANDS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FAMILY DOCTORS; PATIENT; PHYSICIAN; EUTHANASIA	Objective-To gain insight into decisions made in general practice about the end of life. Design-Study I: interviews with 405 physicians. Study II: analysis of death certificates with data obtained on 5197 cases in which decisions about the end of life may have been made. Study III: prospective study with doctors from study I: questionnaires used to collect information about 2257 deaths. The information was representative for all deaths in the Netherlands. Results-Over two fifths of all patients in the Netherlands die at home. General practitioners took fewer decisions about the end of life than hospital doctors and doctors in nursing homes (34%, 40%, and 56% of all dying patients, respectively). Specifically, decisions to withhold or withdraw treatment to prolong life were taken less often. Euthanasia or assisted suicide, however, was performed in 3.2% of all deaths in general practice compared with 1.4% in hospital practice. In over half of the cases concerning pain relief or non-treatment general practitioners did not discuss the decision with the patient, mostly because of incapacity of the patient, but in 20% of cases for ''paternalistic'' reasons. Older general practitioners discussed such decisions less often with their patients. Colleagues were consulted more often if the general practitioner worked in group practice. Conclusion-Differences in work situation between general practitioners and hospital doctors and differences between the group of general practitioners contribute to differences in the number and type of decisions about the end of life as well as in the decision making process.	UNIV UTRECHT, CTR BIOETH & HLTH LAW, UTRECHT, NETHERLANDS; STAT NETHERLANDS, VOORBURG, NETHERLANDS	Utrecht University	PIJNENBORG, L (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.							BATTIN MP, 1994, LEAST WORST DEATH ES, P130; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; HOFFMASTER CB, 1991, SOC SCI MED, V33, P647, DOI 10.1016/0277-9536(91)90018-8; ORR RD, 1991, J FAM PRACTICE, V33, P500; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; SIEGLER M, 1985, ARCH INTERN MED, V145, P713, DOI 10.1001/archinte.145.4.713; van der Maas P. J., 1992, EUTHANASIA OTHER MED; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERWAL G, 1992, FAM PRACT, V9, P130, DOI 10.1093/fampra/9.2.130; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; 1987, BIOETHICS, V1, P163; 1992, END LIFE MED PRACTIC	13	15	15	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	1994	309	6963					1209	1212		10.1136/bmj.309.6963.1209	http://dx.doi.org/10.1136/bmj.309.6963.1209			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7987154	Green Published			2022-12-24	WOS:A1994PQ66200024
J	SCHWOB, E; BOHM, T; MENDENHALL, MD; NASMYTH, K				SCHWOB, E; BOHM, T; MENDENHALL, MD; NASMYTH, K			THE B-TYPE CYCLIN KINASE INHIBITOR P40(SIC1) CONTROLS THE G1 TO S TRANSITION IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							YEAST-CELL CYCLE; SIGNAL-TRANSDUCTION PATHWAY; MATURATION-PROMOTING FACTOR; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; CDC28; GENE; FAR1; PROTEOLYSIS; EXPRESSION	When yeast cells reach a critical size, they initiate bud formation, spindle pole body duplication, and DNA replication almost simultaneously. All three events depend on activation of Cdc28 protein kinase by the G1 cyclins Cln1, -2, and -3. We show that DNA replication also requires activation of Cdc28 by B-type (Clb) cyclins. A sextuple clb1-6 mutant arrests as multibudded G1 cells that resemble cells lacking the Cdc34 ubiquitin-conjugating enzyme. cdc34 mutants cannot enter S phase because they fail to destroy p40(SIC1), which is a potent inhibitor of Clb but not Cln forms of the Cdc28 kinase. In wild-type cells, p40(SIC1) protein appears at the end of mitosis and disappears shortly before S phase. Proteolysis of a cyclin-specific inhibitor of Cdc28 is therefore an essential aspect of the G1 to S phase transition.	UNIV KENTUCKY,LUCILLE P MARKEY CANC CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky	SCHWOB, E (corresponding author), IMP RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		Schwob, Etienne/AAC-3050-2020; Schwob, Etienne/H-4678-2015	Schwob, Etienne/0000-0002-9369-6419; Nasmyth, Kim/0000-0001-7030-4403				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; KILLANDER D, 1965, EXP CELL RES, V40, P12, DOI 10.1016/0014-4827(65)90285-5; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; YOCHEM J, 1987, J MOL BIOL, V195, P223	40	793	805	1	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					233	244		10.1016/0092-8674(94)90193-7	http://dx.doi.org/10.1016/0092-8674(94)90193-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954792				2022-12-24	WOS:A1994PN63000008
J	KLEIN, C; STRUHL, K				KLEIN, C; STRUHL, K			INCREASED RECRUITMENT OF TATA-BINDING PROTEIN TO THE PROMOTER BY TRANSCRIPTIONAL ACTIVATION DOMAINS IN-VIVO	SCIENCE			English	Article							RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; YEAST; CHROMATIN; MECHANISM; DNA; NUCLEOSOME; INVITRO; REPLICATION	The rate at which the TATA-binding protein (TBP) interacts with the TATA element and promotes transcription by RNA polymerase II was determined in yeast cells. A TBP derivative with altered TATA-element specificity was rapidly induced, and transcription from promoters with appropriately mutated TATA elements was measured. Without a functional activator protein, basal transcription was observed only after a lag of several hours. In contrast, GCN4-activated transcription occurred rapidly upon induction of the TBP derivative. These results suggest that accessibility of TBP to the chromatin template in vivo is rate limiting and that activation domains increase recruitment of TBP to the promoter.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030186, R37GM030186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; CHI TH, 1993, MOL CELL BIOL, V13, P7045, DOI 10.1128/MCB.13.11.7045; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; Croston GE, 1993, CURR OPIN CELL BIOL, V5, P417, DOI 10.1016/0955-0674(93)90006-C; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GRECO MA, 1990, J BACTERIOL, V172, P317, DOI 10.1128/JB.172.1.317-325.1990; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEIN C, UNPUB; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MORSE RH, 1993, SCIENCE, V262, P1563, DOI 10.1126/science.8248805; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PRIOLEAU MN, 1994, CELL, V77, P439, DOI 10.1016/0092-8674(94)90158-9; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; SIKORSKI RS, 1989, GENETICS, V122, P19; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STRUHL K, 1993, CURR BIOL, V3, P220, DOI 10.1016/0960-9822(93)90338-O; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; STRUHL K, 1987, MOL CELL BIOL, V7, P104, DOI 10.1128/MCB.7.1.104; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; ZAWEL L, 1993, INITIATION TRANSCRIP, V2	47	113	114	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					280	282		10.1126/science.7939664	http://dx.doi.org/10.1126/science.7939664			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939664				2022-12-24	WOS:A1994PM13400035
J	HILEY, CMH; MORLEY, CJ				HILEY, CMH; MORLEY, CJ			EVALUATION OF GOVERNMENTS CAMPAIGN TO REDUCE RISK OF COT DEATH	BRITISH MEDICAL JOURNAL			English	Article									UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT PAEDIAT,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge				Morley, Colin/0000-0001-5388-0214				FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; MCKENNA JJ, 1990, AM J PHYS ANTHROPOL, V83, P331, DOI 10.1002/ajpa.1330830307; 1991, SLEEPING POSITION IN; 1993, OPCS MONITOR	4	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					703	704		10.1136/bmj.309.6956.703	http://dx.doi.org/10.1136/bmj.309.6956.703			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PH407	7950523	Green Published			2022-12-24	WOS:A1994PH40700016
J	CAULEY, JA; SEELEY, DG; ENSRUD, K; ETTINGER, B; BLACK, D; CUMMINGS, SR				CAULEY, JA; SEELEY, DG; ENSRUD, K; ETTINGER, B; BLACK, D; CUMMINGS, SR			ESTROGEN REPLACEMENT THERAPY AND FRACTURES IN OLDER WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						ESTROGEN REPLACEMENT THERAPY; FRACTURES; OSTEOPOROSIS, POSTMENOPAUSAL; AGE FACTORS; BONE DENSITY	POST-MENOPAUSAL WOMEN; HIP FRACTURE; ELDERLY WOMEN; POSTMENOPAUSAL OSTEOPOROSIS; BONE-DENSITY; CIGARETTE-SMOKING; PHYSICAL-ACTIVITY; TRABECULAR BONE; RISK; DISEASE	Objective: To determine the relation between estrogen replacement therapy and fractures. Design: Prospective cohort study. Setting: Four clinical centers in Baltimore County, Maryland; Minneapolis, Minnesota; Portland, Oregon; and the Monongahela Valley, Pennsylvania. Participants: 9704 ambulatory, nonblack women 65 years of age or older. Measurements: Estrogen use, medical history, and anthropometric data were obtained by questionnaire, interview, and examination. Appendicular bone mass was measured by single-photon absorptiometry. Incident fractures were validated by radiographic report. Results: After adjustment for potential confounders, current estrogen use was associated with a decrease int he risk for wrist fractures (relative risk [RR], 0.39; 95% Cl, 0.24 to 0.64) and for all nonspinal fractures (RR, 0.66; Cl, 0.54 to 0.80) when compared with no estrogen use. Results were similar for women using unopposed estrogen or estrogen plus progestin, for women younger or older than 75 years of age, and for current smokers or nonsmokers. The effect of estrogen remained after adjustment was made for appendicular bone mass. The relative risk for hip fracture tended to be lower among current users (RR, 0.60; Cl, 0.36 to 1.02) than among never-users. Estrogen was most effective in preventing hip fracture among those older than 75 years. Current users who started estrogen within 5 years of menopause had a decreased risk for hip fractures (RR, 0.29; Cl, 0.09 to 0.92), wrist fractures (RR, 0.29; Cl, 0.13 to 0.68), and all nonspinal fractures (RR, 0.50; Cl, 0.36 to 0.70) when compared with women who had never used estrogen. Previous use of estrogen for more than 10 years or use begun soon after menopause had no substantial effect on the risk for fractures. Conclusions: Current use of estrogen appears to decrease the risk for fracture in older women. These results suggest that for protection against fractures, estrogen should be initiated soon after menopause and continued indefinitely.	UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94143 USA; VET AFFAIRS MED CTR, DEPT MED, MINNEAPOLIS, MN 55417 USA; KAISER PERMANENTE MED CARE PROGRAM, DIV RES, OAKLAND, CA 94611 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Kaiser Permanente; University of Minnesota System; University of Minnesota Twin Cities	CAULEY, JA (corresponding author), UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT EPIDEMIOL, A524 CRABTREE HALL, 130 DESOTO ST, PITTSBURGH, PA 15261 USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005395] Funding Source: NIH RePORTER; NIADDK NIH HHS [1-R01-AM35584] Funding Source: Medline; NIAMS NIH HHS [1-R01-AR35582] Funding Source: Medline; NIA NIH HHS [1-R01-AG05395] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BUSH TL, 1991, 31ST ANN C CARD DIS; CAULEY JA, 1989, AM J EPIDEMIOL, V129, P1120, DOI 10.1093/oxfordjournals.aje.a115234; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; CAULEY JA, 1987, J CHRON DIS, V40, P115, DOI 10.1016/0021-9681(87)90062-2; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CIVITELLI R, 1988, CALCIFIED TISSUE INT, V42, P77, DOI 10.1007/BF02556338; CUMMINGS SR, 1987, AM J EPIDEMIOL, V126, P796, DOI 10.1093/oxfordjournals.aje.a114716; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GALLAGHER JC, 1991, AM J MED, V90, P171; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HUTCHINSON TA, 1979, LANCET, V2, P705; JOHNSON RE, 1981, AM J PUBLIC HEALTH, V71, P138, DOI 10.2105/AJPH.71.2.138; KANIS JA, 1992, BRIT MED J, V305, P1124, DOI 10.1136/bmj.305.6862.1124; KIEL DP, 1992, ANN INTERN MED, V116, P716, DOI 10.7326/0003-4819-116-9-716; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; LINDENSTROM E, 1993, STROKE, V24, P1468, DOI 10.1161/01.STR.24.10.1468; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MARX CW, 1992, J BONE MINER RES, V7, P1275; MAXIM P, 1994, IN PRESS OSTEOPOROSI; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PECK WA, 1993, AM J MED, V94, P646; PHILLIPS SK, 1993, CLIN SCI, V84, P95, DOI 10.1042/cs0840095; QUIGLEY MET, 1987, AM J OBSTET GYNECOL, V156, P1516; RIIS BJ, 1987, AM J OBSTET GYNECOL, V156, P61, DOI 10.1016/0002-9378(87)90203-1; SCHLENKER RA, 1976, CALC TISS RES, V20, P41, DOI 10.1007/BF02546396; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; SEELEY DG, 1994, IN PRESS ARCH INTERN; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; VOGEL JM, 1987, OSTEOPOROSIS UPDATE, P219; WASNICH RD, 1986, OBSTET GYNECOL, V67, P457; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P695	43	680	689	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1995	122	1					9	16		10.7326/0003-4819-122-1-199501010-00002	http://dx.doi.org/10.7326/0003-4819-122-1-199501010-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY502	7985914				2022-12-24	WOS:A1995PY50200002
J	LETOURNEUR, F; GAYNOR, EC; HENNECKE, S; DEMOLLIERE, C; DUDEN, R; EMR, SD; RIEZMAN, H; COSSON, P				LETOURNEUR, F; GAYNOR, EC; HENNECKE, S; DEMOLLIERE, C; DUDEN, R; EMR, SD; RIEZMAN, H; COSSON, P			COATOMER IS ESSENTIAL FOR RETRIEVAL OF DILYSINE-TAGGED PROTEINS TO THE ENDOPLASMIC-RETICULUM	CELL			English	Article							CLATHRIN-COATED VESICLES; ALPHA-PHEROMONE RECEPTOR; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEINS; SECRETORY PATHWAY; POLYACRYLAMIDE GELS; YEAST COATOMER; GOLGI-COMPLEX; BETA-COP; SUBUNIT	Dilysine motifs in cytoplasmic domains of transmembrane proteins are signals for their continuous retrieval from the Golgi back to the endoplasmic reticulum (ER). We describe a system to assess retrieval to the ER in yeast cells making use of a dilysine-tagged Ste2 protein. Whereas retrieval was unaffected in most sec mutants tested (sec7, sec12, sec13, sec16, sec17, sec18, sec19, sec22, and sec23), a defect in retrieval was observed in previously characterized coatomer mutants (sec21-1, sec27-1), as well as in newly isolated retrieval mutants (sec21-2, ret1-1). RET1 was cloned by complementation and found to encode the alpha subunit of coatomer. While temperature-sensitive for growth, the newly isolated coatomer mutants exhibited a very modest defect in secretion at the nonpermissive temperature. Coatomer from beta'-COP (sec27-1) and alpha-COP (ret1-1) mutants, but not from gamma-COP (sec21) mutants, had lost the ability to bind dilysine motifs in vitro. Together, these results suggest that coatomer plays an essential role in retrograde Golgi-to-ER transport and retrieval of dilysine-tagged proteins back to the ER.	UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California Berkeley; University of Basel	LETOURNEUR, F (corresponding author), BASEL INST IMMUNOL, GRENZACHERSTR 487, CH-4005 BASEL, SWITZERLAND.		Duden, Rainer/GXH-3206-2022; Duden, Rainer/C-8917-2011	Riezman, Howard/0000-0003-4680-9422; Letourneur, Francois/0000-0003-2232-6127				BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, IN PRESS J BIOL CHEM, V269; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; HARTER C, 1993, FEBS LETT, V332, P71, DOI 10.1016/0014-5793(93)80487-F; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; Maniatis T., 1982, MOL CLONING; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P3777, DOI 10.1128/MCB.8.9.3777; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	43	679	688	1	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 30	1994	79	7					1199	1207		10.1016/0092-8674(94)90011-6	http://dx.doi.org/10.1016/0092-8674(94)90011-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001155				2022-12-24	WOS:A1994PZ86000011
J	PUFFENBERGER, EG; HOSODA, K; WASHINGTON, SS; NAKAO, K; DEWIT, D; YANAGISAWA, M; CHAKRAVARTI, A				PUFFENBERGER, EG; HOSODA, K; WASHINGTON, SS; NAKAO, K; DEWIT, D; YANAGISAWA, M; CHAKRAVARTI, A			A MISSENSE MUTATION OF THE ENDOTHELIN-B RECEPTOR GENE IN MULTIGENIC HIRSCHSPRUNGS-DISEASE	CELL			English	Article							CHROMOSOMAL ASSIGNMENT; AGANGLIONIC MEGACOLON; FUNCTIONAL EXPRESSION; CLONING; IDENTIFICATION; ORGANIZATION; CDNA; ASSOCIATION; ANTAGONIST; DELETION	Hirschsprung's disease (HSCR) is characterized by an absence of enteric ganglia in the distal colon and a failure of innervation in the gastrointestinal tract. We recently mapped a recessive susceptibility locus (HSCR2) to human chromosome 13q22, which we now demonstrate to be the endothelin-B receptor gene (EDNRB). We identified in HSCR patients a G-->T missense mutation in EDNRB exon 4 that substitutes the highly conserved Trp-276 residue in the fifth transmembrane helix of the G protein-coupled receptor with a Cys residue (W276C). The mutant W276C receptor exhibited a partial impairment of ligand-induced Ca2+ transient levels in transfected cells. The mutation is dosage sensitive, in that W276C homozygotes and heterozygotes have a 74% and a 21% risk, respectively, of developing HSCR. Genotype analysis of patients in a Mennonite pedigree shows HSCR to he a multigenic disorder.	CASE WESTERN RESERVE UNIV,SCH MED,CTR HUMAN GENET,CLEVELAND,OH 44106; UNIV CLEVELAND HOSP,CLEVELAND,OH 44106; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; KYOTO UNIV,SCH MED,DEPT MED,DIV 2,KYOTO 606,JAPAN	Case Western Reserve University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Kyoto University	PUFFENBERGER, EG (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT GENET,CLEVELAND,OH 44106, USA.			Puffenberger, Erik/0000-0002-6388-9148	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008056] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-28088] Funding Source: Medline; NIGMS NIH HHS [T32GM08056] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGRIST M, 1993, NAT GENET, V4, P351, DOI 10.1038/ng0893-351; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAI H, 1993, J BIOL CHEM, V268, P3463; ARINAMI T, 1991, AM J HUM GENET, V48, P990; BADNER JA, 1990, AM J HUM GENET, V46, P568; BADNER JA, 1990, AM J MED GENET, V35, P100, DOI 10.1002/ajmg.1320350119; BAYNASH AG, 1994, CELL, V79; BECKER A, 1994, EUR J BIOCHEM, V221, P951, DOI 10.1111/j.1432-1033.1994.tb18810.x; Bergey LL, 1992, PA MENNON HERIT, V15, P9; BOTTANI A, 1991, HUM GENET, V87, P748; CECCHERINI I, 1994, ONCOGENE, V9, P3025; CHAKRAVARTI A, 1992, CYTOGENET CELL GENET, V59, P99, DOI 10.1159/000133212; CLAPHAM DE, 1994, NATURE, V371, P109, DOI 10.1038/371109a0; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; EARLAM RJ, 1972, AM J DIG DIS, V17, P255, DOI 10.1007/BF02232298; EDERY P, 1994, J MED GENET, V31, P602, DOI 10.1136/jmg.31.8.602; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HEYL DL, 1993, PEPTIDE RES, V6, P238; HOSODA K, 1992, J BIOL CHEM, V267, P18797; Hosoda K, 1994, CELL, V79; IKADAI H, 1979, Congenital Anomalies, V19, P31; INAGAKI H, 1991, GASTROENTEROLOGY, V101, P47, DOI 10.1016/0016-5085(91)90458-W; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA K, 1994, P NATL ACAD SCI USA, V91, P4892, DOI 10.1073/pnas.91.11.4892; JACOBSCOHEN RJ, 1987, J COMP NEUROL, V255, P425, DOI 10.1002/cne.902550309; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KAPUR RP, 1993, DEVELOPMENT, V117, P993; KARNE S, 1993, J BIOL CHEM, V268, P19126; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KISS P, 1989, J MED GENET, V26, P793, DOI 10.1136/jmg.26.12.793; KUMAR C, 1994, J BIOL CHEM, V269, P13414; LAIRMORE TC, 1993, P NATL ACAD SCI USA, V90, P492, DOI 10.1073/pnas.90.2.492; LAMONT MA, 1989, J MED GENET, V26, P100, DOI 10.1136/jmg.26.2.100; LANE PW, 1984, J HERED, V75, P435, DOI 10.1093/oxfordjournals.jhered.a109980; LANE PW, 1966, J HERED, V57, P29, DOI 10.1093/oxfordjournals.jhered.a107457; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MCCABE L, 1990, AM J MED GENET, V36, P336, DOI 10.1002/ajmg.1320360319; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; REPASKE R, 1985, J VIROL, V54, P764, DOI 10.1128/JVI.54.3.764-772.1985; ROMEO G, 1994, NATURE, V357, P377; SAITO Y, 1991, J BIOL CHEM, V266, P23433; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; SOGABE K, 1993, J PHARMACOL EXP THER, V264, P1040; SPARKES RS, 1984, HUM GENET, V68, P258, DOI 10.1007/BF00418397; WILKIE TM, 1993, GENOMICS, V18, P175, DOI 10.1006/geno.1993.1452; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320	54	730	797	2	25	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1257	1266		10.1016/0092-8674(94)90016-7	http://dx.doi.org/10.1016/0092-8674(94)90016-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001158				2022-12-24	WOS:A1994PZ86000016
J	BAINTON, DF				BAINTON, DF			CALIFORNIA BIGFOOT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											BAINTON, DF (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143, USA.								0	0	0	1	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	1994	331	25					1693	1693						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX382	7969361				2022-12-24	WOS:A1994PX38200006
J	KEHLENBACH, RH; MATTHEY, J; HUTTNER, WB				KEHLENBACH, RH; MATTHEY, J; HUTTNER, WB			XL-ALPHA-S IS A NEW-TYPE OF G-PROTEIN	NATURE			English	Article							CONSTITUTIVE SECRETORY VESICLES; SYNAPTIC-LIKE MICROVESICLES; TRANS-GOLGI NETWORK; GTP-BINDING; RECEPTOR; MEMBRANE; MUTATIONS; ENDOSOMES; SUBUNITS; P100	THE GTP-binding proteins are well-known regulators of cellular functions(1-4), including vesicular transport(5-7). Cholera toxin, which is known to catalyse ADP-ribosylation of the as subunit of heterotrimeric G proteins, stimulates secretory vesicle formation from the trans-Golgi network(8). Here we describe a new cholera toxin target, an 'extra large' G protein (XLas; M(r) 92K) which consists of a new 51K XL-portion linked to a Gas truncated at the amino terminus. XLas is specifically associated with the trans-Golgi network and occurs selectively in cells containing both the regulated and the constitutive pathway of protein secretion. Hence, XLas may mediate the effects of cholera toxin on secretory vesicle formation.	UNIV HEIDELBERG, INST NEUROBIOL, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg			Huttner, Wieland B./P-4080-2018	Kehlenbach, Ralph/0000-0003-4920-9916				Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DESHAZER D, 1994, BIOTECHNIQUES, V17, P288; GILL DM, 1991, METHOD ENZYMOL, V195, P267; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HINSCH KD, 1988, FEBS LETT, V238, P191, DOI 10.1016/0014-5793(88)80254-0; ISHIKAWA Y, 1990, J BIOL CHEM, V265, P8458; JONES DT, 1987, J BIOL CHEM, V262, P14241; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MONTMAYEUR JP, 1994, SCIENCE, V263, P95, DOI 10.1126/science.8272874; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; Sambrook J., 1989, MOL CLONING LAB MANU; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SWAROOP A, 1991, NUCLEIC ACIDS RES, V19, P4725, DOI 10.1093/nar/19.17.4725; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TOOZE SA, 1992, METHOD ENZYMOL, V219, P81; TRAUB LM, 1991, J BIOL CHEM, V266, P24642; TRAUB LM, 1991, BIOCHEM J, V280, P171, DOI 10.1042/bj2800171; TRAUB LM, 1990, BIOCHEM J, V272, P453, DOI 10.1042/bj2720453; UDRISAR D, 1990, P NATL ACAD SCI USA, V87, P6321, DOI 10.1073/pnas.87.16.6321; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	35	186	189	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					804	809						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997272				2022-12-24	WOS:A1994PY21200060
J	ZHANG, GH; TANEJA, KL; SINGER, RH; GREEN, MR				ZHANG, GH; TANEJA, KL; SINGER, RH; GREEN, MR			LOCALIZATION OF PRE-MESSENGER-RNA SPLICING IN MAMMALIAN NUCLEI	NATURE			English	Article							INSITU HYBRIDIZATION; NASCENT TRANSCRIPTS; CELL-NUCLEUS; POLY(A) RNA; RIBONUCLEOPROTEINS; ORGANIZATION; IDENTIFICATION; DOMAINS; PROTEIN; INTERPHASE	IN mammalian nuclei, precursor messenger RNA splicing factors are distributed non-uniformly. Antibodies directed against structural polypeptides of small nuclear ribonucleoprotein particles (snRNPs)(1) and some non-snRNP splicing factors(2) have shown that these components are concentrated in about 20-50 nuclear 'speckles'. These and other non-homogeneous distributions have been proposed to indicate nuclear 'compartments' that are distinct from the sites of transcription and in which RNA processing (3-9). We have tested this idea using a new approach. Previous structural(10-13) and biochemical(14-16) data have shown that splicing can occur in association with transcription. Nascent RNA of specific genes can be detected by in situ hybridization as intense spots of nuclear stain which map to the sites of transcription(17-19). Here we identify active pre-mRNA splicing sites by localizing the nascent spliced mRNA of specific genes. We find that splicing occurs at the sites of transcription, which are not coincident with intranuclear speckles. We conclude that the nucleus is not compartmentalized with respect to transcription and pre-mRNA splicing.	UNIV MASSACHUSETTS,MED CTR,DEPT CELL BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	ZHANG, GH (corresponding author), UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605, USA.							AEBI M, 1987, TRENDS GENET, V3, P102, DOI 10.1016/0168-9525(87)90193-4; BAUREN G, 1994, CELL, V76, P183, DOI 10.1016/0092-8674(94)90182-1; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BRIDGE E, 1993, J VIROL, V67, P5792, DOI 10.1128/JVI.67.10.5792-5802.1993; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; FAKAN S, 1984, J CELL BIOL, V98, P358, DOI 10.1083/jcb.98.1.358; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEMAIRE MF, 1990, MOL CELL BIOL, V10, P6059, DOI 10.1128/MCB.10.11.6059; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; ROSBASH M, 1993, CELL, V75, P399, DOI 10.1016/0092-8674(93)90373-X; SASS H, 1984, J MOL BIOL, V180, P911, DOI 10.1016/0022-2836(84)90263-8; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cb.09.110193.001405; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; TURNER BM, 1987, J CELL SCI, V87, P269; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; VAZQUEZNIN GH, 1990, CHROMOSOMA, V99, P44, DOI 10.1007/BF01737288; VOELKERDING K, 1986, J VIROL, V60, P353, DOI 10.1128/JVI.60.2.353-362.1986; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WU ZG, 1991, J CELL BIOL, V113, P465, DOI 10.1083/jcb.113.3.465; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; Xing Yigong, 1993, Trends in Cell Biology, V3, P346, DOI 10.1016/0962-8924(93)90105-A; ZACHAR Z, 1993, J CELL BIOL, V121, P729, DOI 10.1083/jcb.121.4.729	30	229	234	1	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					809	812						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997273				2022-12-24	WOS:A1994PY21200061
J	BURMEISTER, WP; GASTINEL, LN; SIMISTER, NE; BLUM, ML; BJORKMAN, PJ				BURMEISTER, WP; GASTINEL, LN; SIMISTER, NE; BLUM, ML; BJORKMAN, PJ			CRYSTAL-STRUCTURE AT 2.2-ANGSTROM RESOLUTION OF THE MHC-RELATED NEONATAL FC RECEPTOR	NATURE			English	Article							CLASS-I H-2K(B); HISTOCOMPATIBILITY ANTIGEN; 3-DIMENSIONAL STRUCTURE; PEPTIDE ANTIGENS; SMALL-INTESTINE; BINDING; COMPLEX; RECOGNITION; HLA-A2; RAT	The three-dimensional structure of the rat neonatal Fe receptor (FcRn) is similar to the structure of molecules of the major histocompatibility complex (MHC). The counterpart of the MHC peptide-binding site is closed in FcRn, making the FcRn groove incapable of binding peptides. A dimer of FcRn heterodimers seen in the crystals may represent a receptor dimer that forms when the Fc portion of a single immunoglobulin binds. An alternative use of the MHC fold for immune recognition is indicated by the FcRn and FcRn/Fc co-crystal structures.	CALTECH,DEPT BIOL,PASADENA,CA 91125; CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Brandeis University; Brandeis University				Burmeister, Wim/0000-0003-0876-6118				AHOUSE JJ, 1993, J IMMUNOL, V151, P6076; BEAVIL AJ, 1993, BIOCHEM SOC T, V21, P968, DOI 10.1042/bst0210968; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1992, XPLOR VERSION 31 SYS; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; DAVIES DR, 1983, ANNU REV IMMUNOL, V1, P87, DOI 10.1146/annurev.iy.01.040183.000511; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FAHNESTOCK ML, 1992, SCIENCE, V258, P1658, DOI 10.1126/science.1360705; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOPE H, 1990, ANNU REV BIOPHYS BIO, V19, P107; HUBER AH, 1993, J MOL BIOL, V230, P1077, DOI 10.1006/jmbi.1993.1220; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, SET AVERAGING PROGRA; JONES TA, 1993, CRYSTALLOGRAPHIC COM; Kabat EA, 1991, SEQUENCES PROTEINS I; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANCET D, 1979, P NATL ACAD SCI USA, V76, P3844, DOI 10.1073/pnas.76.8.3844; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MARTIN LH, 1987, P NATL ACAD SCI USA, V84, P9189, DOI 10.1073/pnas.84.24.9189; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; RAGHAVAN M, 1994, IMMUNITY, V1, P303, DOI 10.1016/1074-7613(94)90082-5; RAGHAVAN M, 1993, BIOCHEMISTRY-US, V32, P8654, DOI 10.1021/bi00084a037; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; ROBERTS DM, 1990, J CELL BIOL, V111, P1867, DOI 10.1083/jcb.111.5.1867; RODEWALD R, 1976, J CELL BIOL, V71, P666, DOI 10.1083/jcb.71.2.666; RODEWALD R, 1970, J CELL BIOL, V45, P635, DOI 10.1083/jcb.45.3.635; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHALL S, 1969, J MOL BIOL, V41, P237; SIMISTER NE, 1985, EUR J IMMUNOL, V15, P733, DOI 10.1002/eji.1830150718; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403; 1979, CCP4 ERC DAR LAB COL	50	266	282	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					336	343		10.1038/372336a0	http://dx.doi.org/10.1038/372336a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969491				2022-12-24	WOS:A1994PU28700047
J	GOTZ, R; KOSTER, R; WINKLER, C; RAULF, F; LOTTSPEICH, F; SCHARTL, M; THOENEN, H				GOTZ, R; KOSTER, R; WINKLER, C; RAULF, F; LOTTSPEICH, F; SCHARTL, M; THOENEN, H			NEUROTROPHIN-6 IS A NEW MEMBER OF THE NERVE GROWTH-FACTOR FAMILY	NATURE			English	Article							EMBRYONIC-DEVELOPMENT; SENSORY NEURONS; CELL-SURFACE; IDENTIFICATION; SURVIVAL; CLEAVAGE; PROTEINS; RECEPTOR; BINDING; BIOLOGY	DURING vertebrate development, many neurons depend for survival and differentiation on their target cells(1-3). The best documented mediator of such a retrograde trophic action is the neurotrophin nerve growth factor (NGF)(1). NGF and the other known members of the neurotrophin family, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5) are conserved as distinct genes over large evolutionary distances(4-6). Here we report the cloning of neurotrophin-6 (NT-6), a new member of this family from the teleost fish Xiphophorus. NT-6 distinguishes itself from the other known neurotrophins in that it is not found as a soluble protein in the medium of producing cells. The addition of heparin (but not chondroitin) effects the release of NT-6 from cell surface and extracellular matrix molecules. Recombinant purified NT-6 has a spectrum of actions similar to NGF on chick sympathetic and sensory neurons, albeit with a lower potency. NT-6 is expressed in the embryonic valvulla cerebelli; expression persists in some adult tissues. The interaction of NT-6 with heparin-binding molecules may modulate its action in the nervous system.	MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM,D-82152 MARTINSRIED,GERMANY; UNIV WURZBURG,BIOZENTRUM,DEPT PHYSIOL CHEM 1,D-97074 WURZBURG,GERMANY; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society; University of Wurzburg; Max Planck Society			Winkler, Christoph/G-4822-2012	Schartl, Manfred/0000-0001-9882-5948; Koster, Reinhard/0000-0001-6593-8196; Winkler, Christoph/0000-0003-4688-6241				BARDE YA, 1980, P NATL ACAD SCI-BIOL, V77, P1199, DOI 10.1073/pnas.77.2.1199; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; CRAWFORD JL, 1973, P NATL ACAD SCI USA, V70, P538, DOI 10.1073/pnas.70.2.538; GOTZ R, 1994, COMP BIOCHEM PHYS C, V108, P1, DOI 10.1016/1367-8280(94)90082-5; GOTZ R, 1992, J NEUROCHEM, V59, P432, DOI 10.1111/j.1471-4159.1992.tb09389.x; GOTZ R, 1992, EUR J BIOCHEM, V204, P745, DOI 10.1111/j.1432-1033.1992.tb16689.x; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; KRIMLAUF R, 1991, GENE TRANSFER EXPRES, P307; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LEE BA, 1991, J CELL BIOL, V113, P361, DOI 10.1083/jcb.113.2.361; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MARCEY D, 1986, NATURE, V321, P380, DOI 10.1038/321380a0; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MEEK J, 1992, EUR J MORPHOL, V1, P37; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; POWERS DA, 1989, SCIENCE, V246, P352, DOI 10.1126/science.2678474; PURVES D, 1988, BODY BRAIN TROPIC TH; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROSSANT J, 1992, GENE DEV, V6, P1, DOI 10.1101/gad.6.1.1; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; TAVOLGA WILLIAM N., 1949, BULL AMER MUS NAT HIST, V94, P161; VLODAVSKY L, 1991, TRENDS BIOCHEM SCI, V168, P268; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	30	338	373	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					266	269		10.1038/372266a0	http://dx.doi.org/10.1038/372266a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969471	Green Published			2022-12-24	WOS:A1994PR88900051
J	FINE, PEM; STERNE, JAC; PONNIGHAUS, JM; REES, RJW				FINE, PEM; STERNE, JAC; PONNIGHAUS, JM; REES, RJW			DELAYED-TYPE HYPERSENSITIVITY, MYCOBACTERIAL VACCINES AND PROTECTIVE IMMUNITY	LANCET			English	Article							NORTHERN MALAWI; LEPROSY VACCINE; TUBERCULOSIS; LEPRAE	There is a longstanding debate over the implications of natural and vaccine-induced delayed type hypertensivity for protective immunity to mycobacterial infections. The identification of correlates of vaccine-induced protective immunity should help explain the inconsistent behaviour of BCG vaccines in different populations and assist in efforts to devise improved vaccines. More than 70 000 subjects in Karonga District, northern Malawi were skin tested with soluble antigens of the tubercle and leprosy bacilli, and then followed up for five years for tuberculosis and leprosy incidence. Incidence rate ratios were calculated to compare subjects with different levels of prior shin test sensitivity, after controlling for the effects of age, sex and previous BCG vaccination. BCG vaccination protected against leprosy without persistent delayed-type hypersensitivity to tuberculin or to soluble antigens of the leprosy bacillus. In subjects who had not received BCG, hypersensitivity to tuberculin or to antigens of the leprosy bacillus was associated with strong protection against leprosy. In BCG-vaccinated and unvaccinated subjects, there was a J-shaped relation between hypersensitivity to tuberculin and subsequent rates of tuberculosis, with lowest rates associated with low grade sensitivity (induration 1-10 mm). This study shows that delayed-type hypersensitivity to antigens has different implications for and leprosy: low-level hypersensitivity (probably attributable to environmental mycobacteria) is associated with protection, but persistent vaccine-associated hypersensitivity to mycobacterial antigens is not a correlate of vaccine-derived protection against mycobacterial diseases.	LEPRA,CHILUMBA,MALAWI; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	FINE, PEM (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND.		Sterne, Jonathan/Z-3106-2019	Sterne, Jonathan/0000-0001-8496-6053				[Anonymous], 1972, B WORLD HEALTH ORGAN, V46, P371; BECHELLI LM, 1973, B WORLD HEALTH ORGAN, V48, P323; COMSTOCK GW, 1988, AM REV RESPIR DIS, V138, P479, DOI 10.1164/ajrccm/138.2.479; DANNENBERG AM, 1989, REV INFECT DIS, V11, pS369; DRAPER P, 1994, J GEN MICROBIOL, V69, P313; FINE PEM, 1993, TUBERCULOSIS BACK FU, P53; GILL HK, 1986, B WORLD HEALTH ORGAN, V64, P121; GUPTE MD, 1990, LEPROSY REV, V61, P132; HART P. D'A., 1967, Tubercle, V48, P201, DOI 10.1016/S0041-3879(67)80024-2; MACKANESS GB, 1991, INT P US DHEW, V14, P69; PALMER CE, 1967, ARCH ENVIRON HEALTH, V15, P792, DOI 10.1080/00039896.1967.10664998; PALMER CE, 1957, B INT UNION TUBERC, V27, P106; PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4; PONNIGHAUS JM, 1987, INT J LEPROSY, V55, P454; PONNIGHAUS JM, 1986, INT J LEPROSY, V54, P25; PONNIGHAUS JM, 1987, LEPROSY REV, V58, P359; PONNIGHAUS JM, 1994, INT J LEPROSY, V61, P10; SHEPARD CC, 1980, BRIT J EXP PATHOL, V61, P376; STANLEY SJ, 1981, J HYG CAMB, V87, P235; Youmans G.P., 1979, TUBERCULOSIS, P302; 3RD IMMLEP SCI WORK, P20	21	147	149	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1245	1249		10.1016/S0140-6736(94)90748-X	http://dx.doi.org/10.1016/S0140-6736(94)90748-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967984				2022-12-24	WOS:A1994PP70100006
J	DAVIS, S; GALE, NW; ALDRICH, TH; MAISONPIERRE, PC; LHOTAK, V; PAWSON, T; GOLDFARB, M; YANCOPOULOS, GD				DAVIS, S; GALE, NW; ALDRICH, TH; MAISONPIERRE, PC; LHOTAK, V; PAWSON, T; GOLDFARB, M; YANCOPOULOS, GD			LIGANDS FOR EPH-RELATED RECEPTOR TYROSINE KINASES THAT REQUIRE MEMBRANE ATTACHMENT OR CLUSTERING FOR ACTIVITY	SCIENCE			English	Article							NEUROTROPHIC FACTOR; NERVOUS-SYSTEM; PROTEIN; GENE; FAMILY; EXPRESSION; IDENTIFICATION; HINDBRAIN; CLONING; CHICKEN	The EPH-related transmembrane tyrosine kinases constitute the largest known family of receptor-like tyrosine kinases, with many members displaying specific patterns of expression in the developing and adult nervous system. A family of cell surface-bound ligands exhibiting distinct, but overlapping, specificities for these EPH-related kinases was identified. These ligands were unable to act as conventional soluble factors. However, they did function when presented in membrane-bound form, suggesting that they require direct cell-to-cell contact to activate their receptors. Membrane attachment may serve to facilitate ligand dimerization or aggregation, because antibody-mediated clustering activated previously inactive soluble forms of these ligands.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	DAVIS, S (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.		Pawson, Tony J/E-4578-2013					BAPTISTA CA, 1994, NEURON, V12, P243, DOI 10.1016/0896-6273(94)90268-2; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BOYD AW, 1992, J BIOL CHEM, V267, P3262; CHAN J, 1991, ONCOGENE, V6, P1057; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Davis S.M, UNPUB; GALE NW, UNPUB; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HART AC, 1993, NATURE, V361, P732, DOI 10.1038/361732a0; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; NIETO MA, 1992, DEVELOPMENT, V116, P1137; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKINSON D, COMMUNICATION	31	627	673	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	1994	266	5186					816	819		10.1126/science.7973638	http://dx.doi.org/10.1126/science.7973638			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973638				2022-12-24	WOS:A1994PP75300044
J	POTAMITIS, T; AGGARWAL, RK; TSALOUMAS, M; RENE, C; MCLAUGHLIN, J; ONEILL, E				POTAMITIS, T; AGGARWAL, RK; TSALOUMAS, M; RENE, C; MCLAUGHLIN, J; ONEILL, E			DRIVING, GLAUCOMA, AND THE LAW	BRITISH MEDICAL JOURNAL			English	Article											POTAMITIS, T (corresponding author), BIRMINGHAM & MIDLAND EYE HOSP,BIRMINGHAM B3 2NS,W MIDLANDS,ENGLAND.							KIRN MM, 1978, AM JOPHTHALMOL, V85, P28; NORTH RV, 1985, OPHTHAL PHYSL OPT, V5, P205, DOI 10.1111/j.1475-1313.1985.tb00657.x	2	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1057	1058		10.1136/bmj.309.6961.1057	http://dx.doi.org/10.1136/bmj.309.6961.1057			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN733	7950740	Green Published			2022-12-24	WOS:A1994PN73300023
J	SMIDER, V; RATHMELL, WK; LIEBER, MR; CHU, G				SMIDER, V; RATHMELL, WK; LIEBER, MR; CHU, G			RESTORATION OF X-RAY RESISTANCE AND V(D)J RECOMBINATION IN MUTANT-CELLS BY KU CDNA	SCIENCE			English	Article							STRAND BREAK REPAIR; PROTEIN; DNA; AUTOANTIBODIES; OVERLAP; SUBUNIT; ANTIGEN	Three genetic complementation groups of rodent cells are defective for both repair of x-ray-induced double-strand breaks and V(D)J recombination. Cells from one group lack a DNA end-binding activity that is biochemically and antigenically similar to the Ku autoantigen. Transfection of complementary DNA (cDNA) that encoded the 86-kilodalton subunit of Ku rescued these mutant cells for DNA end-binding activity, x-ray resistance, and V(D)J recombination activity. These results establish a role for Ku in DNA repair and recombination. Furthermore, as a component of a DNA-dependent protein kinase, Ku may initiate a signaling pathway induced by DNA damage.	STANFORD UNIV,MED CTR,DEPT MED,STANFORD,CA 94305; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Stanford University; Washington University (WUSTL)				Lieber, Michael/0000-0001-8809-0909; Smider, Vaughn/0000-0003-3488-6383; Lieber, Michael/0000-0003-3700-6345				ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BLIER PR, 1993, J BIOL CHEM, V268, P7594; CAL QQ, 1994, CYTOGENET CELL GENET, V65, P221; CHEN DJ, 1994, GENOMICS, V21, P423, DOI 10.1006/geno.1994.1287; COLLINS AR, 1993, MUTAT RES, V293, P99, DOI 10.1016/0921-8777(93)90062-L; FALZON M, 1993, J BIOL CHEM, V268, P10546; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; HAFEZPARAST M, 1993, SOMAT CELL MOLEC GEN, V19, P413, DOI 10.1007/BF01233246; HAMILTON AA, 1987, MOL CELL BIOL, V7, P1409, DOI 10.1128/MCB.7.4.1409; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOORE PD, 1986, MUTAT RES, V160, P149, DOI 10.1016/0027-5107(86)90038-2; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; REEVES WH, 1989, J BIOL CHEM, V264, P5047; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Taccioli G E, 1992, Curr Top Microbiol Immunol, V182, P107; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TAKABE Y, 1988, MOL CELL BIOL, V8, P466; YANEVA M, 1989, J BIOL CHEM, V264, P13407	27	329	333	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					288	291		10.1126/science.7939667	http://dx.doi.org/10.1126/science.7939667			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939667				2022-12-24	WOS:A1994PM13400038
J	CHREN, MM; LANDEFELD, CS				CHREN, MM; LANDEFELD, CS			A COST-ANALYSIS OF TOPICAL DRUG REGIMENS FOR DERMATOPHYTE INFECTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERDIGITAL TINEA-PEDIS; TERBINAFINE; 1-WEEK; CREAM	Objective.-To examine the extra cost of using higher-priced drugs as initial therapy for dermatophyte infections, because the many available effective drugs vary considerably in cost. Design.-Cost analysis from the purchaser's perspective, comparing two prototypical regimens to treat tinea pedis: one in which all patients initially receive a fewer-priced drug and those with unresponsive infections receive a higher-priced drug at a follow-up office visit, and one in which all patients receive the higher-priced drug from the outset. The reference drug was miconazole, an imidazole available without a prescription, for which reported overall efficacy rates are 70% to 100%. Main Outcome Measures.-The threshold efficacy rate (the efficacy rate of miconazole below which it is always less expensive to use a specific higher-priced drug first) and the extra cost (of beginning therapy with a higher-priced drug). Results.-Assuming the Medicare-approved charge for a follow-up visit ($21.98), it is less expensive to begin therapy with a prescription drug only if the efficacy rate of miconazole is less than 55%; this threshold efficacy rate varied from 26% (for a $0 total cost of the follow-up visit) to 79% (for an $89 total cost of the follow-up visit). If the efficacy rate of miconazole is 70%, the extra cost per patient for all patients to receive the least expensive prescription antifungal drug instead of miconazole first was $15.23 and $8.64 if total visit costs were $0 and $21.98, miconazole remained the less expensive alternative as long as the total cost of the follow-up visit was less than $50.76. Conclusion.-For reported efficacy rates and standard costs of a follow-up office visit, using miconazole first and then treating only those patients with unresponsive infections with a higher-priced prescription drug is less expensive than treating ail patients with the higher-priced drug.	VET AFFAIRS MED CTR,PROGRAM HLTH CARE RES,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH; UNIV CLEVELAND HOSP,CLEVELAND,OH 44106; VET AFFAIRS MED CTR,DEPT MED,CLEVELAND,OH 44106	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	CHREN, MM (corresponding author), VET AFFAIRS MED CTR,DEPT DERMATOL,11-GW,10701 EAST BLVD,CLEVELAND,OH 44106, USA.							BERGSTRESSER PR, 1993, J AM ACAD DERMATOL, V28, P648, DOI 10.1016/S0190-9622(08)81787-2; BERMAN B, 1992, J AM ACAD DERMATOL, V26, P956, DOI 10.1016/0190-9622(92)70141-2; BLOOM BS, 1986, JAMA-J AM MED ASSOC, V256, P2523, DOI 10.1001/jama.256.18.2523; CHREN MM, 1994, J AM ACAD DERMATOL, V31, pS103, DOI 10.1016/S0190-9622(08)81278-9; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ELDAROUTI MA, 1990, INT J DERMATOL, V29, P521, DOI 10.1111/j.1365-4362.1990.tb04851.x; FULTON JE, 1975, ARCH DERMATOL, V111, P596, DOI 10.1001/archderm.111.5.596; HAY RJ, 1990, SEMIN DERMATOL, V9, P309; HAY RJ, 1992, CLIN EXP DERMATOL, V17, P2, DOI 10.1111/j.1365-2230.1992.tb00268.x; JONES HE, 1982, MED CLIN N AM, V66, P873, DOI 10.1016/S0025-7125(16)31399-2; MANDY SJ, 1974, JAMA-J AM MED ASSOC, V230, P72, DOI 10.1001/jama.230.1.72; ORTIZ LG, 1978, CLIN THER, V1, P444; SAWYER PR, 1975, DRUGS, V9, P406, DOI 10.2165/00003495-197509060-00002; Smith E B, 1976, Cutis, V17, P54; STERN RS, 1993, DERMATOLOGY GEN MED, P7; SVEJGAAR.E, 1973, ACTA DERM-VENEREOL, V53, P497; 1984, CAN MED ASSOC J, V130, P1428; 1993, MED LETT DRUGS THER, V35, P76; 1993, 1993 RED BOOK; 1984, CAN MED ASSOC J, V130, P1542	20	17	17	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	1994	272	24					1922	1925		10.1001/jama.272.24.1922	http://dx.doi.org/10.1001/jama.272.24.1922			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX927	7990244				2022-12-24	WOS:A1994PX92700037
J	ANDREASEN, NC; FLASHMAN, L; FLAUM, M; ARNDT, S; SWAYZE, V; OLEARY, DS; EHRHARDT, JC; YUH, WTC				ANDREASEN, NC; FLASHMAN, L; FLAUM, M; ARNDT, S; SWAYZE, V; OLEARY, DS; EHRHARDT, JC; YUH, WTC			REGIONAL BRAIN ABNORMALITIES IN SCHIZOPHRENIA MEASURED WITH MAGNETIC-RESONANCE-IMAGING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CEREBRAL BLOOD-FLOW; DORSOLATERAL PREFRONTAL CORTEX; TEMPORAL-LOBE; STRUCTURAL ABNORMALITIES; PHYSIOLOGIC DYSFUNCTION; COMPUTED-TOMOGRAPHY; NEGATIVE SYMPTOMS; MONOZYGOTIC TWINS; CORPUS-CALLOSUM; DISORDER	Objective.-To determine general and regional indices of structural brain abnormality in schizophrenia. Design.-Case-control comparison study. Subjects.-Fifty-two patients diagnosed as having schizophrenia according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition, were compared with 90 healthy volunteers recruited from the community. Measurements.-Structural brain images were acquired using magnetic resonance; measurements were obtained using three-dimensional visualization of volume-rendered brains and an automated atlas-based dissection of specific regions. General measures included the volume of total brain tissue, total cerebrospinal fluid (CSF), and CSF within the ventricular system. Regional measures included the volume of tissue and CSF in the frontal; temporal, parietal, and occipital lobes and the cerebellum. Results.-Compared with the controls, the patients had a smaller average volume of total brain tissue and a greater average volume of total and ventricular CSF. A specific relative decrease in brain tissue was found only in the frontal lobes, although the volume of CSF was greater in patients than in controls in all brain regions. Conclusion.-In addition to the generalized brain abnormalities observed in schizophrenia, a regional abnormality may be present in frontal regions. Since the frontal lobes integrate multimodality information and perform a variety of ''higher'' cognitive and emotional functions that are impaired in schizophrenia, the frontal abnormality noted is consistent with the clinical presentation of the illness. Impaired frontal function and a disruption in its complex circuitry (including thalamocortical projections) may explain why patients with schizophrenia often have significant deficits in formulating concepts and organizing their thinking and behavior.	UNIV IOWA HOSP & CLIN, DEPT RADIOL, IOWA CITY, IA 52242 USA	University of Iowa	ANDREASEN, NC (corresponding author), UNIV IOWA HOSP & CLIN, MENTAL HLTH CLIN RES CTR, DEPT PSYCHIAT, 200 HAWKINS DR, 2911 JPP, IOWA CITY, IA 52242 USA.		Arndt, Stephan/A-6976-2013	Arndt, Stephan/0000-0003-0783-8204; Swayze, Victor/0000-0002-6434-3606; O'Leary, Daniel/0000-0003-1959-6521	NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH043271, R37MH031593, R01MH040856, R01MH031593, P50MH043271] Funding Source: NIH RePORTER; NIMH NIH HHS [MHCRC 43271, MH40856, MH31593] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDREASEN N, 1986, ARCH GEN PSYCHIAT, V43, P136; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P615; ANDREASEN NC, 1994, P NATL ACAD SCI USA, V91, P93, DOI 10.1073/pnas.91.1.93; ANDREASEN NC, 1992, J NEUROPSYCH CLIN N, V4, P125; ANDREASEN NC, 1994, SCIENCE, V266, P294, DOI 10.1126/science.7939669; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943; ANDREASEN NC, 1993, J NEUROPSYCH CLIN N, V5, P121; ANDREASEN NC, 1990, ARCH GEN PSYCHIAT, V47, P35; ANDREASEN NC, 1988, SCIENCE, V239, P1381, DOI 10.1126/science.3279509; ANDREASEN NC, 1994, AUTOMATED ATLAS BASE; Arndt S, 1994, Neuroimage, V1, P191, DOI 10.1006/nimg.1994.1004; ARNDT S, 1991, PSYCHIAT RES-NEUROIM, V40, P79; BARTA PE, 1990, AM J PSYCHIAT, V147, P1457; Becker T, 1990, Eur Neuropsychopharmacol, V1, P83, DOI 10.1016/0924-977X(90)90018-6; BERMAN KF, 1986, ARCH GEN PSYCHIAT, V43, P126; BLEUJER E, 1950, DEMENTIA PRAECOX GRO; BOGERTS B, 1993, SCHIZOPHRENIA BULL, V19, P431, DOI 10.1093/schbul/19.2.431; BOGERTS B, 1990, PSYCHIAT RES-NEUROIM, V35, P1; BUCHSBAUM MS, 1990, SCHIZOPHRENIA BULL, V16, P379, DOI 10.1093/schbul/16.3.379; BUCHSBAUM MS, 1984, ARCH GEN PSYCHIAT, V41, P1159; BUCHSBAUM MS, 1992, ARCH GEN PSYCHIAT, V49, P935; CIZADLO T, 1994, SPIE INT SOC OPTICAL, V2168, P423; CLEGHORN JM, 1989, PSYCHIAT RES, V28, P119, DOI 10.1016/0165-1781(89)90040-1; COHEN G, 1992, PSYCHIAT RES-NEUROIM, V45, P33, DOI 10.1016/0925-4927(92)90012-S; DEGREEF G, 1992, AM J NEURORADIOL, V13, P835; DEGREEF G, 1992, ARCH GEN PSYCHIAT, V49, P531; DELISI LE, 1988, SCHIZOPHRENIA BULL, V14, P185, DOI 10.1093/schbul/14.2.185; DELISI LE, 1991, BIOL PSYCHIAT, V29, P159, DOI 10.1016/0006-3223(91)90044-M; DELISI LE, 1989, COMPR PSYCHIAT, V30, P197, DOI 10.1016/0010-440X(89)90038-2; DEMYER MK, 1988, SCHIZOPHRENIA BULL, V14, P21, DOI 10.1093/schbul/14.1.21; DEVOUS MD, 1985, J CEREB BLOOD FLO S1, V5, pS201; FEINBERG I, 1983, J PSYCHIAT RES, V17, P319, DOI 10.1016/0022-3956(82)90038-3; FLAUM M, 1990, AM J PSYCHIAT, V147, P1327; FLAUM M, IN PRESS AM J PSYCHI; FRANZEN G, 1975, J PSYCHIAT RES, V12, P199, DOI 10.1016/0022-3956(75)90027-8; Fuster J.M., 1989, PREFRONTAL CORTEX; GOLDMANRAKIC PS, 1990, PROG BRAIN RES, V85, P325; GUR RE, 1993, SCHIZOPHRENIA BULL, V19, P337, DOI 10.1093/schbul/19.2.337; GUR RE, 1994, AM J PSYCHIAT, V151, P343; GUR RE, 1991, ARCH GEN PSYCHIAT, V48, P407; HOFF AL, 1992, SCHIZOPHRENIA BULL, V18, P257, DOI 10.1093/schbul/18.2.257; JERNIGAN TL, 1991, ARCH GEN PSYCHIAT, V48, P881; KELSOE JR, 1988, ARCH GEN PSYCHIAT, V45, P533; KLEIST K, 1960, J MENT SCI, V106, P246, DOI 10.1192/bjp.106.442.246; Kraepelin E., 1919, CUTTING SHEPHERD; LIDDLE PF, 1990, BRIT J PSYCHIAT, V157, P558, DOI 10.1192/bjp.157.4.558; MCNEIL TF, 1993, BRIT J PSYCHIAT, V162, P517, DOI 10.1192/bjp.162.4.517; NASRALLAH HA, 1986, BIOL PSYCHIAT, V21, P274, DOI 10.1016/0006-3223(86)90048-X; NYBACK H, 1982, ACTA PSYCHIAT SCAND, V65, P403, DOI 10.1111/j.1600-0447.1982.tb00864.x; PEARLSON GD, 1993, AM PSYCHIATRIC PRESS, V12, P347; PETRIDES M, 1984, J COMP NEUROL, V228, P105, DOI 10.1002/cne.902280110; PFEFFERBAUM A, 1990, SCHIZOPHRENIA BULL, V16, P453, DOI 10.1093/schbul/16.3.453; PFEFFERBAUM A, 1991, SCHIZOPHR RES, V4, P193, DOI 10.1016/0920-9964(91)90033-N; REZAI K, 1993, ARCH NEUROL-CHICAGO, V50, P636, DOI 10.1001/archneur.1993.00540060066020; ROSSI A, 1990, BIOL PSYCHIAT, V27, P61, DOI 10.1016/0006-3223(90)90020-3; RUBIN P, 1991, ARCH GEN PSYCHIAT, V48, P987; SCHULZ SC, 1983, AM J PSYCHIAT, V140, P1592; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; SUDDATH RL, 1989, AM J PSYCHIAT, V146, P464; SWAYZE VW, 1990, ARCH GEN PSYCHIAT, V47, P1054; SWAYZE VW, 1990, ARCH NEUROL-CHICAGO, V47, P805, DOI 10.1001/archneur.1990.00530070103018; Talairach J., 1988, COPLANAR STEREOTAXIC; TURNER SW, 1986, PSYCHOL MED, V16, P219, DOI 10.1017/S003329170000266X; VOLKOW ND, 1986, J NEUROL NEUROSUR PS, V49, P1199, DOI 10.1136/jnnp.49.10.1199; WEINBERGER DR, 1992, AM J PSYCHIAT, V149, P890; WEINBERGER DR, 1982, ARCH GEN PSYCHIAT, V39, P778; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WILLIAMSON P, 1991, BRIT J PSYCHIAT, V159, P130, DOI 10.1192/bjp.159.1.130; WOLKIN A, 1992, ARCH GEN PSYCHIAT, V49, P959; WOOD FB, 1990, SCHIZOPHRENIA BULL, V16, P413, DOI 10.1093/schbul/16.3.413; ZIPURSKY RB, 1992, ARCH GEN PSYCHIAT, V49, P195; 1987, DIAGNOSTIC STATISTIC	73	273	280	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	1994	272	22					1763	1769		10.1001/jama.272.22.1763	http://dx.doi.org/10.1001/jama.272.22.1763			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV815	7966925				2022-12-24	WOS:A1994PV81500026
J	BATTISTUTTA, D; PALMER, J; WALTERS, M; WALKER, G; NANCARROW, D; HAYWARD, N				BATTISTUTTA, D; PALMER, J; WALTERS, M; WALKER, G; NANCARROW, D; HAYWARD, N			INCIDENCE OF FAMILIAL MELANOMA AND MLM2 GENE	LANCET			English	Note							INCREASING INCIDENCE; LINKAGE; LOCUS	The overall incidence of melanoma is increasing world wide. We investigated whether there has been an increase in familial melanoma by studying age at onset among different birth cohorts in 18 melanoma kindreds linked to a predisposition gene (MLM2) on chromosome 9. The cumulative incidence of melanoma was 21-fold higher (95% CI 5.2-84.6) among subjects born after 1959 than in those born before 1900. The expected age of onset of the group born after 1959 was 24 years earlier (21.0 vs 45.0 years). These data support the notion that phenotypic penetrance of the MLM2 gene is increasing, presumably as a result of the interaction of sunlight exposure and mutation at this locus.	QUEENSLAND INST MED RES,HERSTON,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute			hayward, nicholas k/C-1367-2015; hayward, nick/AAV-8802-2020	hayward, nicholas k/0000-0003-4760-1033; 				CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; GRUIS NA, 1993, MELANOMA RES, V3, P271; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; NAROD S, 1993, LANCET, V341, P1101, DOI 10.1016/0140-6736(93)92468-9; RING IT, 1989, T MENZIES F, V15, P157; WALKER GJ, 1994, ONCOGENE, V9, P819; WLKER GJ, 1993, MELANOMA RES, V4, P29	10	17	17	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1607	1608		10.1016/S0140-6736(94)90408-1	http://dx.doi.org/10.1016/S0140-6736(94)90408-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983995				2022-12-24	WOS:A1994PW05100011
J	LANGERMANN, S; PALASZYNSKI, S; SADZIENE, A; STOVER, CK; KOENIG, S				LANGERMANN, S; PALASZYNSKI, S; SADZIENE, A; STOVER, CK; KOENIG, S			SYSTEMIC AND MUCOSAL IMMUNITY INDUCED BY BCG VECTOR EXPRESSING OUTER-SURFACE PROTEIN-A OF BORRELIA-BURGDORFERI	NATURE			English	Article							ANTIBODY-SECRETING CELLS; ORAL IMMUNIZATION; CHOLERA-TOXIN; OSPA; MICE; ENUMERATION; VACCINE	THE bacillus Calmette-Guerin (BCG) is a live attenuated strain of Mycobacterium bovis which offers potential advantages as a vector for mucosal delivery of antigens(1-3). Recombinant BCG elicits protective humoral immune responses to a variety of antigens(4). Furthermore, BCG binds specifically to microfold cells(5) present in the epithelium overlying lymphoid follicles throughout the mucosal immune system(6-8). Here we show that a single intranasal vaccination with recombinant BCG expressing the outersurface protein A antigen from B. burgdorferi(9) results in a prolonged (more than one year) protective systemic IgG response and a highly sustained secretory IgA response which is disseminated throughout the mucosal immune system. Furthermore, intranasal immunization induces marked, organized lymphocyte accumulation in the proximal nasopharyngeal lymphoid tissue as well as at distal mucosal sites; the appearance and persistence of lymphoid aggregates correlates with the secretory immune responses. Thus intranasal immunization with recombinant BCG is a powerful method for inducing long-lasting secretory and systemic immune responses.	UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	LANGERMANN, S (corresponding author), MEDIMMUNE INC, GAITHERSBURG, MD 20878 USA.			Stover, Charles/0000-0002-7406-1696				ABRAHAM E, 1992, J IMMUNOL, V149, P3719; BERGSTROM S, 1989, MOL MICROBIOL, V3, P479, DOI 10.1111/j.1365-2958.1989.tb00194.x; CZERKINSKY C, 1987, P NATL ACAD SCI USA, V84, P2449, DOI 10.1073/pnas.84.8.2449; CZERKINSKY CC, 1983, J IMMUNOL METHODS, V65, P109, DOI 10.1016/0022-1759(83)90308-3; FIKRIG E, 1990, SCIENCE, V250, P553, DOI 10.1126/science.2237407; FUHRMAN JA, 1981, J EXP MED, V153, P534, DOI 10.1084/jem.153.3.534; FUJIMURA Y, 1986, Gastroenterologia Japonica, V21, P325; HANEBERG B, 1994, INFECT IMMUN, V62, P15, DOI 10.1128/IAI.62.1.15-23.1994; JACOBS WR, 1990, CURR TOP MICROBIOL, V155, P153; JACOBS WR, 1987, NATURE, V327, P532, DOI 10.1038/327532a0; KUPER CF, 1992, IMMUNOL TODAY, V13, P219; LANGERMANN S, 1993, CURR OPIN GASTROEN, V8, P983; MCDERMOTT MR, 1979, J IMMUNOL, V122, P1892; Neutra M R, 1992, Trends Cell Biol, V2, P134, DOI 10.1016/0962-8924(92)90099-9; OHAGAN DT, 1993, VACCINE, V11, P149, DOI 10.1016/0264-410X(93)90011-L; QULDING M, 1991, J CLIN INVEST, V88, P143; SADZIENE A, 1993, J INFECT DIS, V167, P165, DOI 10.1093/infdis/167.1.165; SCHWAN TG, 1988, J CLIN MICROBIOL, V26, P893, DOI 10.1128/JCM.26.5.893-895.1988; SEDGWICK JD, 1983, J IMMUNOL METHODS, V57, P301, DOI 10.1016/0022-1759(83)90091-1; SIMON MM, 1991, J INFECT DIS, V164, P123, DOI 10.1093/infdis/164.1.123; STOVER CK, 1993, J EXP MED, V178, P197, DOI 10.1084/jem.178.1.197; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; STOVER CK, 1994, RECOMBINANT VECTORS, P153; TRIER JS, 1991, GASTROENTEROL CLIN N, V20, P531; VAJDY M, 1992, IMMUNOLOGY, V75, P488; Young J T, 1981, Fundam Appl Toxicol, V1, P309, DOI 10.1016/S0272-0590(81)80037-1	26	143	153	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 8	1994	372	6506					552	555		10.1038/372552a0	http://dx.doi.org/10.1038/372552a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990928	Bronze			2022-12-24	WOS:A1994PW08200053
J	WEBER, BL				WEBER, BL			SUSCEPTIBILITY GENES FOR BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											WEBER, BL (corresponding author), UNIV PENN,MED CTR,PHILADELPHIA,PA 19104, USA.							EASTON DF, 1993, AM J HUM GENET, V52, P678; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	5	19	19	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1523	1524		10.1056/NEJM199412013312214	http://dx.doi.org/10.1056/NEJM199412013312214			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969307				2022-12-24	WOS:A1994PU86600014
J	ZHANG, YY; PROENCA, R; MAFFEI, M; BARONE, M; LEOPOLD, L; FRIEDMAN, JM				ZHANG, YY; PROENCA, R; MAFFEI, M; BARONE, M; LEOPOLD, L; FRIEDMAN, JM			POSITIONAL CLONING OF THE MOUSE OBESE GENE AND ITS HUMAN HOMOLOG	NATURE			English	Article							ARTIFICIAL-CHROMOSOME LIBRARIES; POLYMERASE CHAIN-REACTION; DNA FRAGMENTS; MESSENGER-RNA; OB MUTATION; YEAST; IDENTIFICATION; MICE	The mechanisms that balance food intake and energy expenditure determine who will be obese and who will be lean. One of the molecules that regulates energy balance in the mouse is the obese (ob) gene. Mutation of ob results in profound obesity and type II diabetes as part of a syndrome that resembles morbid obesity in humans. The ob gene product may function as part of a signalling pathway from adipose tissue that acts to regulate the size of the body fat depot.	HOWARD HUGHES MED INST,NEW YORK,NY 10021; ROCKEFELLER UNIV,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University								ADOLPH EF, 1947, AM J PHYSIOL, V151, P110, DOI 10.1152/ajplegacy.1947.151.1.110; BAHARY N, 1990, P NATL ACAD SCI USA, V87, P8642, DOI 10.1073/pnas.87.21.8642; BAHARY N, 1993, MAMM GENOME, V4, P511, DOI 10.1007/BF00364786; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRAY GA, 1990, INT J OBESITY, V14, P909; BRAY GA, 1991, J NUTR, V121, P1146, DOI 10.1093/jn/121.8.1146; BROBECK JR, 1948, YALE J BIOL MED, V20, P545; BRUBECK JR, 1946, PHYSIOL REV, V25, P541; BURMEISTER M, 1989, TRENDS GENET, V5, P41, DOI 10.1016/0168-9525(89)90019-X; BURROS M, 1994, NY TIMES        0717; Cannon WB, 1912, AM J PHYSIOL, V29, P441, DOI 10.1152/ajplegacy.1912.29.5.441; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; COLEMAN DL, 1979, SCIENCE, V203, P663, DOI 10.1126/science.760211; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Dickie M. M., 1957, MOUSE NEWS LETT, V17, P52; DIETRICH W, 1992, GENETICS, V131, P423; FRIEDMAN JM, 1991, GENOMICS, V11, P1054, DOI 10.1016/0888-7543(91)90032-A; FRIEDMAN JM, 1984, J MOL BIOL, V179, P37, DOI 10.1016/0022-2836(84)90305-X; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GRUNDY SM, 1990, DM-DIS MON, V36, P645; HARTI DL, 1993, BIOTECHNIQUES, V15, P201; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; HERMANSON GG, 1991, NUCLEIC ACIDS RES, V19, P4943, DOI 10.1093/nar/19.18.4943; HERVEY GR, 1959, J PHYSIOL-LONDON, V145, P336, DOI 10.1113/jphysiol.1959.sp006145; HERVEY GR, 1969, NATURE, V222, P629, DOI 10.1038/222629a0; Hetherington AW, 1942, AM J PHYSIOL, V136, P609, DOI 10.1152/ajplegacy.1942.136.4.609; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; MAYER J, 1955, ANN NY ACAD SCI, V63, P15, DOI 10.1111/j.1749-6632.1955.tb36543.x; NEEL JV, 1962, AM J HUM GENET, V14, P353; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Rubner M., 1894, Z BIOL, V30, P73; SABATINI D, 1989, METABOLIC BASIS INHE, P177; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; VENTER CJ, 1993, AUTOMATED DNA SEQUEN; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931	49	10609	11485	33	1121	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					425	432		10.1038/372425a0	http://dx.doi.org/10.1038/372425a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984236				2022-12-24	WOS:A1994PV01200046
J	HENDERSON, CE; PHILLIPS, HS; POLLOCK, RA; DAVIES, AM; LEMEULLE, C; ARMANINI, M; SIMPSON, LC; MOFFET, B; VANDLEN, RA; KOLIATSOS, VE; ROSENTHAL, A				HENDERSON, CE; PHILLIPS, HS; POLLOCK, RA; DAVIES, AM; LEMEULLE, C; ARMANINI, M; SIMPSON, LC; MOFFET, B; VANDLEN, RA; KOLIATSOS, VE; ROSENTHAL, A			GDNF - A POTENT SURVIVAL FACTOR FOR MOTONEURONS PRESENT IN PERIPHERAL-NERVE AND MUSCLE	SCIENCE			English	Article							NEUROTROPHIC FACTOR; EMBRYONIC MOTONEURONS; MOTOR NEURONS; SCHWANN-CELLS; EXPRESSION; DEATH; RAT; INVITRO; INVIVO; CHICK	For survival, embryonic motoneurons in vertebrates depend on as yet undefined neurotrophic factors present in the limb bud. Members of the neurotrophin family are currently the best candidates for such neurotrophic factors, but inactivation of their receptor genes leads to only partial loss of motoneurons, which suggests that other factors are involved. Glial cell line-derived neurotrophic factor (GDNF), originally identified as a trophic factor specific for dopaminergic neurons, was found to be 75-fold more potent than the neurotrophins in supporting the survival of purified embryonic rat motoneurons in culture. GDNF messenger RNA was found in the immediate vicinity of motoneurons during the period of cell death in development. In vivo, GDNF rescues and prevents the atrophy of facial motoneurons that have been deprived of target-derived survival factors by axotomy. GDNF may therefore be a physiological trophic factor for spinal motoneurons. Its potency and specificity in vitro and in vivo also make it a good candidate for treatment of motoneuron disease.	GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080; IBDM,INSERM,U382,F-13288 MARSEILLE 9,FRANCE; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; SCH BIOL & MED SCI ST ANDREWS,ST ANDREWS,FIFE,SCOTLAND; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL NEUROL & NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,NEUROPATHOL LAB,BALTIMORE,MD 21205	Roche Holding; Genentech; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Roche Holding; Genentech; Roche Holding; Genentech; University of St Andrews; Johns Hopkins University; Johns Hopkins University			Davies, Alun M/A-4334-2010	Davies, Alun M/0000-0001-5841-8176; Henderson, Christopher/0000-0002-9936-3279	NINDS NIH HHS [NS 10580] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CAMU W, 1993, NEUROPROTOCOLS, V2, P191; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; HALLER FR, 1971, AM J ANAT, V131, P1, DOI 10.1002/aja.1001310102; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HENDERSON CE, 1993, RESTOR NEUROL NEUROS, V5, P15, DOI 10.3233/RNN-1993-5105; JENSEN EBV, 1993, J MICROSC-OXFORD, V170, P35, DOI 10.1111/j.1365-2818.1993.tb03321.x; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; JONES GE, 1990, J CELL SCI, V97, P659; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; KOLIATSOS VE, 1994, J COMP NEUROL, V342, P35, DOI 10.1002/cne.903420105; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1989, TRENDS NEUROSCI, V12, P252, DOI 10.1016/0166-2236(89)90021-0; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; POULSEN KT, IN PRESS NEURON; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; STROMBERG I, 1993, EXP NEUROL, V124, P401, DOI 10.1006/exnr.1993.1214; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YANSURA DG, 1990, METHOD ENZYMOL, V185, P54	29	1119	1210	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1062	1064		10.1126/science.7973664	http://dx.doi.org/10.1126/science.7973664			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973664				2022-12-24	WOS:A1994PQ92400051
J	LU, DS; WILLARD, D; PATEL, IR; KADWELL, S; OVERTON, L; KOST, T; LUTHER, M; CHEN, WB; WOYCHIK, RP; WILKISON, WO; CONE, RD				LU, DS; WILLARD, D; PATEL, IR; KADWELL, S; OVERTON, L; KOST, T; LUTHER, M; CHEN, WB; WOYCHIK, RP; WILKISON, WO; CONE, RD			AGOUTI PROTEIN IS AN ANTAGONIST OF THE MELANOCYTE-STIMULATING-HORMONE RECEPTOR	NATURE			English	Article							MOLECULAR-CLONING; MELANOCORTIN RECEPTOR; EXPRESSION; LOCUS; ASSAY; CELLS; MICE	THE genetic loci agouti and extension control the relative amounts of eumelanin (brown-black) and phaeomelanin (yellow-red) pigments in mammals(1): extension encodes the receptor for melanocyte-stimulating hormone (MSH)(2) and agouti encodes a novel 131-amino-acid protein containing a signal sequence(3,4). Agouti, which is produced in the hair follicle(5), acts on follicular melanocytes(6) to inhibit alpha-MSH-induced eumelanin production, resulting in the subterminal band of phaeomelanin often visible in mammalian fur. Here we use partially purified agouti protein to demonstrate that agouti is a high-affinity antagonist of the MSH receptor and blocks alpha-MSH stimulation of adenylyl cyclase, the effector through which alpha-MSH induces eumelanin synthesis, Agouti was also found to be an antagonist of the melanocortin-4 receptor(7,8), a related MSH-binding receptor. Consequently, the obesity caused by ectopic expression of agouti in the lethal yellow (A(y)) mouse(9) may be due to the inhibition of melanocortin reteptor(s) outside the hair follicle.	GLAXO INC, RES INST, DIV MOLEC SCI, RES TRIANGLE PK, NC 27709 USA; OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA; OAK RIDGE NATL LAB, DIV BIOL, OAK RIDGE, TN 37831 USA	GlaxoSmithKline; Oregon Health & Science University; United States Department of Energy (DOE); Oak Ridge National Laboratory			Woychik, Richard P/C-8345-2019; Chen, Wenbiao/ABG-1276-2020	Woychik, Richard P/0000-0001-8196-1732; Chen, Wenbiao/0000-0002-0750-8275				BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CHHAJLANI V, 1993, BIOCHEM BIOPH RES CO, V195, P866, DOI 10.1006/bbrc.1993.2125; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; CONKLIN BR, 1993, NATURE, V364, P110, DOI 10.1038/364110b0; DESARNAUD F, 1994, BIOCHEM J, V299, P367, DOI 10.1042/bj2990367; DICKERSON GE, 1947, SCIENCE, V105, P496, DOI 10.1126/science.105.2732.496-a; FRAZIER AL, 1990, MOL ENDOCRINOL, V4, P1264, DOI 10.1210/mend-4-8-1264; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANZ I, 1993, J BIOL CHEM, V268, P8246; JACKSON IJ, 1993, NATURE, V362, P587, DOI 10.1038/362587a0; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KWON HY, IN PRESS P NATN ACAD; LAMOREUX ML, 1975, DEV BIOL, V46, P160, DOI 10.1016/0012-1606(75)90094-9; Little C., 1957, INHERITANCE COAT COL; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; Mountjoy K.G., 1992, SCIENCE, V257, P543; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; RAINEY WE, 1989, J BIOL CHEM, V264, P21474; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SIEGRIST W, 1988, J RECEPTOR RES, V8, P323, DOI 10.3109/10799898809048996; SILVERS WK, 1955, J EXP ZOOL, V130, P199, DOI 10.1002/jez.1401300203; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SUMMERS MD, 1987, TEXAS AGR EXP ST B, V1555	25	892	937	4	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	1994	371	6500					799	802		10.1038/371799a0	http://dx.doi.org/10.1038/371799a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935841				2022-12-24	WOS:A1994PP01800060
J	SCHMEICHEL, KL; BECKERLE, MC				SCHMEICHEL, KL; BECKERLE, MC			THE LIM DOMAIN IS A MODULAR PROTEIN-BINDING INTERFACE	CELL			English	Article							INSULIN GENE; MOTIF; IDENTIFICATION; DIMERIZATION; HOMEODOMAIN; REGULATORS; ZYXIN	LIM domains are zinc-binding protein sequences that are found in a growing number of proteins, including certain transcriptional regulators, proto-oncogene products, and adhesion plaque constituents. Here we define the biological activity of the LIM domain through studies of an adhesion plaque protein called zyxin that displays three C-terminal LIM domains. We have used our ability to reconstitute complexes between zyxin and its two known binding partners, alpha-actinin and the cysteine-rich protein (CRP), to examine the involvement of LIM domains in protein-protein interactions. We have determined that one of the three LIM domains of zyxin is necessary and sufficient to support the association of zyxin with CRP. Our findings demonstrate that the LIM domain functions as a specific protein-binding interface.			SCHMEICHEL, KL (corresponding author), UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112, USA.				NCI NIH HHS [CA42014, CA09602] Funding Source: Medline; NIGMS NIH HHS [R01 GM050877, GM50877] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009602, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050877] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER VEV, 1994, P NATL ACAD SCI USA, V91, P316, DOI 10.1073/pnas.91.1.316; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOEHM T, 1990, ONCOGENE, V5, P1103; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	31	427	438	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					211	219		10.1016/0092-8674(94)90191-0	http://dx.doi.org/10.1016/0092-8674(94)90191-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954790				2022-12-24	WOS:A1994PN63000006
J	KAMIYA, H; ZUCKER, RS				KAMIYA, H; ZUCKER, RS			RESIDUAL CA2+ AND SHORT-TERM SYNAPTIC PLASTICITY	NATURE			English	Article							FROG NEUROMUSCULAR-JUNCTION; SQUID GIANT SYNAPSE; TRANSMITTER RELEASE; POSTTETANIC POTENTIATION; CALCIUM CHELATORS; INTRACELLULAR CALCIUM; NERVE-TERMINALS; DM-NITROPHEN; FACILITATION; CA-2+	AT many synapses, the amount of transmitter released by action potentials increases progressively during a train of spikes. This enhancement of evoked transmitter release grows during tetanic stimulation with several time constants, each bearing a different name (facilitation: tens to hundreds of milliseconds; augmentation: several seconds; potentiation: several minutes), and the enhancement of release to test spikes after a tetanus decays with similar time constants. All these processes depend on presynaptic Ca2+ influx during the conditioning tetanus(1). It has often been proposed that these forms of synaptic plasticity are due to residual Ca2+ present in nerve terminals following conditioning activity(2). We tested this idea directly by using photolabile Ca2+ chelators to reduce residual Ca2+ following conditioning stimulation or to generate an artificial elevation in Ca2+ concentration, and observed the effects on synaptic transmission at crayfish neuromuscular junctions. We found that facilitation, augmentation and potentiation are caused by the continuing action of residual Ca2+. Augmentation and potentiation seem to arise from Ca2+ acting at a separate site from facilitation, and these sites are different from the molecular target triggering neurosecretion.	UNIV CALIF BERKELEY, DIV NEUROBIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Zucker, Robert S/J-9995-2012; Kamiya, Haruyuki/E-7199-2010	Zucker, Robert S/0000-0003-1068-2343; Kamiya, Haruyuki/0000-0002-2618-3146				ADAMS SR, 1989, J AM CHEM SOC, V111, P7957, DOI 10.1021/ja00202a042; ADLER EM, 1991, J NEUROSCI, V11, P1496; BAIN AI, 1992, J PHYSIOL-LONDON, V455, P383, DOI 10.1113/jphysiol.1992.sp019307; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BITTNER GD, 1981, BRAIN RES, V210, P431, DOI 10.1016/0006-8993(81)90922-7; DELANEY K, 1991, J NEUROSCI, V11, P2631; DELANEY KR, 1989, J NEUROSCI, V9, P3558; DELANEY KR, IN PRESS J NEUROSCI; HOCHNER B, 1991, NEUROSCI LETT, V125, P215, DOI 10.1016/0304-3940(91)90032-O; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; LANDO L, 1994, J NEUROPHYSIOL, V72, P825, DOI 10.1152/jn.1994.72.2.825; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; MAGLEBY KL, 1982, J GEN PHYSIOL, V80, P613, DOI 10.1085/jgp.80.4.613; MINTA A, 1989, J BIOL CHEM, V264, P8171; MULKEY RM, 1992, J NEUROSCI, V12, P4327; MULKEY RM, 1993, J PHYSIOL-LONDON, V462, P243, DOI 10.1113/jphysiol.1993.sp019553; REGEHR WG, 1994, J NEUROSCI, V14, P523; ROBITAILLE R, 1991, ANN NY ACAD SCI, V635, P492, DOI 10.1111/j.1749-6632.1991.tb36537.x; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; TANABE N, 1989, NEUROSCI LETT, V99, P147, DOI 10.1016/0304-3940(89)90280-2; TANABE N, 1992, J PHYSIOL-LONDON, V455, P271, DOI 10.1113/jphysiol.1992.sp019301; VANDERKLOOT W, 1993, J NEUROPHYSIOL, V69, P717, DOI 10.1152/jn.1993.69.3.717; VANDERKLOOT W, 1994, J NEUROSCI, V14, P5722; YAMADA WM, 1992, BIOPHYS J, V61, P671, DOI 10.1016/S0006-3495(92)81872-6; ZENGEL JE, 1980, J GEN PHYSIOL, V76, P175, DOI 10.1085/jgp.76.2.175; ZENGEL JE, 1981, J GEN PHYSIOL, V77, P503, DOI 10.1085/jgp.77.5.503; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; ZUCKER RS, 1992, CELL CALCIUM, V13, P29, DOI 10.1016/0143-4160(92)90027-P; ZUCKER RS, 1974, J PHYSIOL-LONDON, V241, P91, DOI 10.1113/jphysiol.1974.sp010642; ZUCKER RS, 1993, CELL CALCIUM, V14, P87, DOI 10.1016/0143-4160(93)90079-L	30	278	280	1	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 13	1994	371	6498					603	606		10.1038/371603a0	http://dx.doi.org/10.1038/371603a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935792				2022-12-24	WOS:A1994PL55900051
J	CROWTHER, RA; KISELEV, NA; BOTTCHER, B; BERRIMAN, JA; BORISOVA, GP; OSE, V; PUMPENS, P				CROWTHER, RA; KISELEV, NA; BOTTCHER, B; BERRIMAN, JA; BORISOVA, GP; OSE, V; PUMPENS, P			3-DIMENSIONAL STRUCTURE OF HEPATITIS-B VIRUS CORE PARTICLES DETERMINED BY ELECTRON CRYOMICROSCOPY	CELL			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; ANTIGENIC DETERMINANTS; CAPSID PARTICLES; MICROSCOPY; PROTEIN; SURFACE; RNA; EXPRESSION; MODEL	Human hepatitis B virus core protein expressed in E. coli assembles into two sizes of particle. We have determined their three-dimensional structures by electron cryomicroscopy and image processing. The large and small particles correspond to triangulation number T = 4 and T = 3 dimer clustered packings, containing 240 and 180 protein subunits, respectively. The local packing of subunits is very similar in the two sizes of particle and shows holes or channels through the shell. The native viral core particle packages RNA and is active in reverse transciption to DNA. The holes we observe may provide access for the necessary small molecules. Shells assembled from the intact core protein contain additional material, probably RNA, which appears as an icosahedrally ordered inner shell in the three-dimensional map.	RUSSIAN ACAD SCI,INST CRYSTALLOG,MOSCOW 117333,RUSSIA; UNIV LATVIA,CTR BIOMED RES & STUDY,RIGA 1065,LATVIA	Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; Latvian Biomedical Research & Study Centre; University of Latvia	CROWTHER, RA (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Kiselev, Nikolay/H-2534-2014; Bottcher, Bettina/E-9397-2010; Pumpens, Paul/A-2163-2008	Kiselev, Nikolay/0000-0001-8130-8629; Bottcher, Bettina/0000-0002-7962-4849; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041449] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41449] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1988, EMBO J, V7, P819, DOI 10.1002/j.1460-2075.1988.tb02880.x; BIRNBAUM F, 1990, J VIROL, V64, P3319, DOI 10.1128/JVI.64.7.3319-3330.1990; BORISOVA G, 1993, J VIROL, V67, P3696, DOI 10.1128/JVI.67.6.3696-3701.1993; BORISOVA GP, 1984, DOKL AKAD NAUK SSSR+, V279, P1245; BORISOVA GP, 1988, DOKL AKAD NAUK SSSR+, V298, P1474; BORISOVA GP, 1989, FEBS LETT, V259, P121, DOI 10.1016/0014-5793(89)81509-1; CHENG RH, 1992, VIROLOGY, V186, P655, DOI 10.1016/0042-6822(92)90032-K; COHEN BJ, 1982, NATURE, V296, P677, DOI 10.1038/296677a0; CROWTHER RA, 1971, PHILOS T ROY SOC B, V261, P2211; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EDMAN JC, 1981, NATURE, V291, P503, DOI 10.1038/291503a0; GALLINA A, 1989, J VIROL, V63, P4645, DOI 10.1128/JVI.63.11.4645-4652.1989; HATTON T, 1992, J VIROL, V66, P5232, DOI 10.1128/JVI.66.9.5232-5241.1992; HULL R, 1987, J CELL SCI S, V7, P213; JUNKERNIEPMANN M, 1990, EMBO J, V9, P3389, DOI 10.1002/j.1460-2075.1990.tb07540.x; METCALF P, 1991, EMBO J, V10, P3129, DOI 10.1002/j.1460-2075.1991.tb04874.x; NASSAL M, 1992, J MOL BIOL, V225, P1013, DOI 10.1016/0022-2836(92)90101-O; Nassal M, 1993, Trends Microbiol, V1, P221, DOI 10.1016/0966-842X(93)90136-F; NASSAL M, 1993, HEPATITS B VIRUS NUC, P41; ONODERA S, 1982, J MED VIROL, V10, P147, DOI 10.1002/jmv.1890100209; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; PRASAD BVV, 1992, J VIROL, V66, P2135, DOI 10.1128/JVI.66.4.2135-2142.1992; PRASAD BVV, 1988, J MOL BIOL, V199, P269, DOI 10.1016/0022-2836(88)90313-0; SALFELD J, 1989, J VIROL, V63, P798, DOI 10.1128/JVI.63.2.798-808.1989; ULRICH R, 1993, VACCINES93 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P323; VIGERS GPA, 1986, THESIS U CAMBRIDGE; ZHENG J, 1992, J BIOL CHEM, V267, P9422; ZHOU S, 1992, P NATL ACAD SCI USA, V89, P10046, DOI 10.1073/pnas.89.21.10046	28	416	451	4	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					943	950		10.1016/0092-8674(94)90142-2	http://dx.doi.org/10.1016/0092-8674(94)90142-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004680				2022-12-24	WOS:A1994NT33100018
J	KLEYMAN, TR; ROBERTS, C; LING, BN				KLEYMAN, TR; ROBERTS, C; LING, BN			A MECHANISM FOR PENTAMIDINE-INDUCED HYPERKALEMIA - INHIBITION OF DISTAL NEPHRON SODIUM-TRANSPORT	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERKALEMIA; PENTAMIDINE; ACQUIRED IMMUNODEFICIENCY SYNDROME; ION TRANSPORT; POTASSIUM	PNEUMOCYSTIS-CARINII PNEUMONIA; CORTICAL COLLECTING TUBULE; POTASSIUM CHANNELS; PRIMARY CULTURES; THERAPY; AIDS	Objectives: To determine whether pentamidine directly affects the transport of renal ions and thus provides a mechanism for hyperkalemia, which develops in as many as 100% of patients with the acquired immunodeficiency syndrome (AIDS) who receive pentamidine for more than 6 days. Design: Transepithelial and single-channel electrical measurements were made on two models of distal-nephron ion transport: an amphibian distal-nephron cell line (A6) and primary cultures of rabbit cortical collecting tubules. Results: Luminal bath application of pentamidine to A6 monolayers inhibited the amiloride-sensitive, short-circuit current with a 50% inhibitory concentration of 700 mu M (five experiments). In the principal cell apical membranes of cortical collecting tubule primary cultures, amiloride-sensitive, 4-picosiemen Na+ channels in cell-attached patches were also identified. When the luminal membrane was directly exposed to 1.0 mu M of pentamidine in the patch pipette solution, channel activity decreased by 40% (11 experiments). Channel inhibition rapidly reversed with washout of intrapipette pentamidine (four experiments). In contrast, replacement of either the luminal bath outside the patch pipette (four experiments) or the serosal bath (five experiments) with pentamidine did not significantly affect Na+ channel activity in the patches. Conclusions: Luminal or ''urinary'' pentamidine inhibits distal nephron reabsorption of Na+ by blocking apical Na+ channels in a manner similar to ''potassium-sparing'' diuretics (for example, amiloride and triamterene). This results in a decrease in the electrochemical gradients that drive secretion of distal nephron K+. Because pentamidine is eliminated through urinary excretion, this renal tubular effect provides a mechanism for pentamidine-induced hyperkalemia.	EMORY UNIV, SCH MED, DIV RENAL, ATLANTA, GA 30322 USA; UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA; DEPT VET AFFAIRS MED CTR, PHILADELPHIA, PA 19104 USA; VET AFFAIRS MED CTR, ATLANTA, GA 30033 USA	Emory University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002111] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08-DK02111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNS JS, 1991, J AM SOC NEPHROL, V1, P1061; BUFF DD, 1990, AM J MED, V88, P552, DOI 10.1016/0002-9343(90)90446-K; CHOI MJ, 1993, NEW ENGL J MED, V328, P703, DOI 10.1056/NEJM199303113281006; CONTE JE, 1987, J INFECT DIS, V156, P885, DOI 10.1093/infdis/156.6.885; DEVITA VT, 1969, NEW ENGL J MED, V280, P287, DOI 10.1056/NEJM196902062800602; EATON DC, 1988, ION CHANNELS, P251; EATON DC, 1994, IN PRESS KIDNEY INT; KLEYMAN TR, 1988, SEMIN NEPHROL, V8, P242; LACHAAL M, 1989, AM J MED, V87, P260, DOI 10.1016/S0002-9343(89)80147-0; LANG F, 1992, PHYSIOL REV, V72, P1, DOI 10.1152/physrev.1992.72.1.1; LING BN, 1991, AM J PHYSIOL, V261, pF933, DOI 10.1152/ajprenal.1991.261.6.F933; LING BN, 1991, KIDNEY INT, V40, P441, DOI 10.1038/ki.1991.231; MARINO PL, 1990, AM J MED, V89, P397, DOI 10.1016/0002-9343(90)90364-J; PELTZ S, 1989, AM J MED, V87, P698, DOI 10.1016/S0002-9343(89)80411-5; PONCE SP, 1985, MEDICINE, V64, P357, DOI 10.1097/00005792-198511000-00001; SANDS M, 1985, REV INFECT DIS, V7, P625; SCHLANGER LE, 1994, KIDNEY INT, V45, P1070, DOI 10.1038/ki.1994.143; Schlanger Lynn E., 1993, Journal of the American Society of Nephrology, V4, P878; SMALDONE GC, 1991, CHEST, V100, P1219, DOI 10.1378/chest.100.5.1219; WALZER PD, 1974, ANN INTERN MED, V80, P83, DOI 10.7326/0003-4819-80-1-83; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; WESTERN KA, 1970, ANN INTERN MED, V73, P695, DOI 10.7326/0003-4819-73-5-695	22	53	54	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					103	106		10.7326/0003-4819-122-2-199501150-00004	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7992983				2022-12-24	WOS:A1995QC05900004
J	FRANCOMANO, CA				FRANCOMANO, CA			THE GENETIC-BASIS OF DWARFISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; FIBROBLAST				FRANCOMANO, CA (corresponding author), NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892, USA.			Francomano, Clair/0000-0002-4032-7425				FRANCOMANO CA, 1994, HUM MOL GENET, V3, P787, DOI 10.1093/hmg/3.5.787; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; IWAMOTO M, 1991, J BIOL CHEM, V266, P461; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KOEBERL DD, 1990, AM J HUM GENET, V47, P202; LEMERRER M, 1994, NAT GENET, V6, P318; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; VELINOV M, 1994, NAT GENET, V6, P314, DOI 10.1038/ng0394-314	10	33	34	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					58	59		10.1056/NEJM199501053320113	http://dx.doi.org/10.1056/NEJM199501053320113			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990869				2022-12-24	WOS:A1995PZ49700013
J	ROBINSON, CV; GROSS, M; EYLES, SJ; EWBANK, JJ; MAYHEW, M; HARTL, FU; DOBSON, CM; RADFORD, SE				ROBINSON, CV; GROSS, M; EYLES, SJ; EWBANK, JJ; MAYHEW, M; HARTL, FU; DOBSON, CM; RADFORD, SE			CONFORMATION OF GROEL-BOUND ALPHA-LACTALBUMIN PROBED BY MASS-SPECTROMETRY	NATURE			English	Article							MOLTEN GLOBULE STATE; GROUP HYDROGEN-EXCHANGE; EGG-WHITE LYSOZYME; STRUCTURAL CHARACTERIZATION; 2-DIMENSIONAL NMR; CHAPERONIN GROEL; 1.7-A RESOLUTION; CENTRAL CAVITY; HEN LYSOZYME; PROTEIN	The conformation of a three-disulphide derivative of bovine alpha-lactalbumin bound to the molecular chaperone GroEL has been investigated by monitoring directly its hydrogen exchange kinetics using electrospray ionization mass spectrometry. The bound protein is weakly protected from exchange to an extent closely similar to that of an uncomplexed molten globule state of the three-disulphide protein. Binding to GroEL in this system appears to involve relatively disordered partly folded states resembling intermediates formed in the very early stages of kinetic folding of many proteins in vitro.	UNIV OXFORD,OXFORD CTR MOLEC SCI,NEW CHEM LAB,OXFORD OX1 3QT,ENGLAND; UNIV OXFORD,OXFORD CTR MOLEC SCI,DYSON PERRINS LAB,OXFORD OX1 3QT,ENGLAND; EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	University of Oxford; University of Oxford; European Molecular Biology Laboratory (EMBL); Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Eyles, Stephen/F-4077-2010; Hartl, F. Ulrich/Y-8206-2019; Ewbank, Jonathan J/G-4948-2010	Ewbank, Jonathan J/0000-0002-1257-6862; Radford, Sheena/0000-0002-3079-8039; Eyles, Stephen/0000-0003-0451-2903; robinson, carol/0000-0001-7829-5505				ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; ACHARYA KR, 1991, J MOL BIOL, V221, P571; ALEXANDRESCU AT, 1993, BIOCHEMISTRY-US, V32, P1707, DOI 10.1021/bi00058a003; ARAMINI JM, 1992, BIOCHEMISTRY-US, V31, P6761, DOI 10.1021/bi00144a016; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCK M, 1994, J MOL BIOL, V237, P247, DOI 10.1006/jmbi.1994.1228; Bychkova V. E., 1993, CHEMTRACTS BIOCH MOL, V4, P133; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHOWDHURY SK, 1990, J AM CHEM SOC, V112, P9012, DOI 10.1021/ja00180a074; CHYAN CL, 1993, BIOCHEMISTRY-US, V32, P5681, DOI 10.1021/bi00072a025; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; CREIGHTON TE, 1992, BIOCHEMISTRY-US, V31, P12695; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.bb.21.060192.001331; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3694, DOI 10.1021/bi00065a023; EYLES SJ, 1994, BIOCHEMISTRY-US, V333, P1534; FLYNN GC, 1993, P NATL ACAD SCI USA, V90, P10826, DOI 10.1073/pnas.90.22.10826; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IKEGUCHI M, 1992, BIOCHEMISTRY-US, V31, P12695, DOI 10.1021/bi00165a021; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; KRONMAN MJ, 1989, CRIT REV BIOCHEM MOL, V24, P565, DOI 10.3109/10409238909080054; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LIGHTWAHL KJ, 1993, J AM CHEM SOC, V115, P5869, DOI 10.1021/ja00066a083; LISSIN NM, 1993, FEBS LETT, V324, P41, DOI 10.1016/0014-5793(93)81528-8; LOO JA, 1991, RAPID COMMUN MASS SP, V5, P101, DOI 10.1002/rcm.1290050303; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MIRANKER A, 1993, SCIENCE, V262, P896, DOI 10.1126/science.8235611; OKAZAKI A, 1994, NAT STRUCT BIOL, V1, P439, DOI 10.1038/nsb0794-439; PEDERSEN TG, 1993, J MOL BIOL, V230, P651, DOI 10.1006/jmbi.1993.1176; RADFORD SE, 1992, PROTEINS, V14, P237, DOI 10.1002/prot.340140210; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RADFORD SE, 1991, BIOCHEM J, V273, P211, DOI 10.1042/bj2730211; RICHARME G, 1994, J BIOL CHEM, V269, P7095; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SHEWALE JG, 1984, J BIOL CHEM, V259, P4947; SMITH RD, 1990, ANAL CHEM, V62, P882, DOI 10.1021/ac00208a002; WANG M, 1989, J BIOL CHEM, V264, P21116; WOODWARD CK, 1994, CURR OPIN STRUC BIOL, V4, P112, DOI 10.1016/S0959-440X(94)90068-X; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0	51	202	202	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					646	651		10.1038/372646a0	http://dx.doi.org/10.1038/372646a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990955				2022-12-24	WOS:A1994PX30700077
J	LANG, DM; POLANSKY, M				LANG, DM; POLANSKY, M			PATTERNS OF ASTHMA MORTALITY IN PHILADELPHIA FROM 1969 TO 1991	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDHOOD ASTHMA; AIR-POLLUTION; CHILDREN; DEATHS; PREDICTORS; RISK; CITY; RACE	Background. The rate of mortality from asthma has increased substantially in the United States since 1978. We analyzed the patterns of the rates of death from asthma in Philadelphia between 1969 and 1991. Methods. The rates of death from asthma were analyzed and compared with trends in the concentrations of major air pollutants: ozone, carbon monoxide, nitrogen dioxide, particulate matter (particles <10 mu m in diameter), and sulfur dioxide. Univariate and multivariate analyses were used to study the rates of death from asthma from 1985 to 1991 and their association with race, poverty, sex, and other factors. Results. The rate of death from asthma decreased from 1.68 per 100,000 people in 1969 to 0.68 per 100,000 in 1977, but then increased to 0.92 per 100,000 in 1978 and 2.41 per 100,000 in 1991. Between 1965 and 1990, the concentrations of major air pollutants declined substantially. From 1985 to 1991, 258 people were identified for whom asthma was the primary cause of death. According to multivariate analysis, the rates of death from asthma from 1985 to 1991 were significantly higher in census tracts with higher percentages of blacks (P = 0.032), Hispanics (P = 0.013), female residents (P<0.001), and people with incomes in the poverty range (P<0.001). Conclusions. The rates of death from asthma have increased in Philadelphia, whereas concentrations of major air pollutants have declined. The rates are highest in census tracts with the highest percentages of poor people and minority residents, particularly blacks. Public health efforts should target urban areas where the risk of death from asthma is highest.	HAHNEMANN UNIV,DEPT MED,DIV ALLERGY & IMMUNOL,PHILADELPHIA,PA 19102; HAHNEMANN UNIV,DEPT HUMAN SOCIAL SCI & BIOMETR,PHILADELPHIA,PA 19102	Drexel University; Drexel University								Aitken M, 1989, STATISTICAL MODELLIN, P217; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; COULTAS DB, 1994, AM J RESP CRIT CARE, V149, pS93, DOI 10.1164/ajrccm/149.3_Pt_2.S93; DRECHSLERPARKS DM, 1987, RES REP HLTH EFF I, V6, P1; Gadde JN, 1993, BRONCHIAL ASTHMA MEC, P1154; GIRSH LS, 1967, J ALLERGY, V39, P347, DOI 10.1016/0021-8707(67)90047-0; GREENBERGER PA, 1993, ALLERGY PROC, V14, P321, DOI 10.2500/108854193778773994; GREENLAND S, 1980, AM J EPIDEMIOL, V112, P564, DOI 10.1093/oxfordjournals.aje.a113025; HUNT LW, 1993, JAMA-J AM MED ASSOC, V269, P1947, DOI 10.1001/jama.269.15.1947; KAPLAN KM, 1993, PUBLIC HEALTH REP, V108, P66; MALVEAUX FJ, 1989, J ALLERGY CLIN IMMUN, V83, P1029, DOI 10.1016/0091-6749(89)90443-0; MARDER D, 1992, CHEST, V101, pS426, DOI 10.1378/chest.101.6.426S; MARGOLIS PA, 1992, AM J PUBLIC HEALTH, V82, P1119, DOI 10.2105/AJPH.82.8.1119; MASSICOT JG, 1986, J ALLERGY CLIN IMMUN, V78, P954, DOI 10.1016/0091-6749(86)90284-8; MCWHORTER WP, 1989, AM REV RESPIR DIS, V139, P721, DOI 10.1164/ajrccm/139.3.721; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; PLAUT TF, 1991, JAMA-J AM MED ASSOC, V265, P725, DOI 10.1001/jama.1991.03460060054021; POMA PA, 1988, J NATL MED ASSOC, V80, P1275; SAMET JM, 1987, AM REV RESPIR DIS, V136, P1486, DOI 10.1164/ajrccm/136.6.1486; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; STRUNK RC, 1989, J ALLERGY CLIN IMMUN, V83, P477, DOI 10.1016/0091-6749(89)90137-1; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WOOLSON RF, 1987, STAT METHODS ANAL BI, P366; 1991, EPA450491023 PUBL; 1990, VITAL STATISTICS REP; 1993, CURRENT POPULATI P60, V185	34	227	228	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1542	1546		10.1056/NEJM199412083312302	http://dx.doi.org/10.1056/NEJM199412083312302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PV292	7969323	Bronze			2022-12-24	WOS:A1994PV29200002
J	TYCOWSKI, KT; SHU, MD; STEITZ, JA				TYCOWSKI, KT; SHU, MD; STEITZ, JA			REQUIREMENT FOR INTRON-ENCODED U22 SMALL NUCLEOLAR RNA IN 18S RIBOSOMAL-RNA MATURATION	SCIENCE			English	Article							EXTERNAL TRANSCRIBED SPACER; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; PRERIBOSOMAL RNA; PRE-RRNA; YEAST; U3; CLEAVAGE; DISRUPTION; PRECURSOR	The nucleoli of vertebrate cells contain a number of small RNAs that are generated by the processing of intron fragments of protein-coding gene transcripts. The host gene (UHG) for intron-encoded human U22 is unusual in that it specifies a polyadenylated but apparently noncoding RNA. Depletion of U22 from Xenopus oocytes by oligonucleotide-directed ribonuclease H targeting prevented the processing of 18S ribosomal RNA (rRNA) at both ends. The appearance of 18S rRNA was restored by injection of in vitro-synthesized U22 RNA. These results identify a cellular function for an intronencoded small RNA.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06536	Howard Hughes Medical Institute; Yale University					NIGMS NIH HHS [GM26154] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026154, R37GM026154] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; BELTRAME M, 1992, EMBO J, V11, P1531, DOI 10.1002/j.1460-2075.1992.tb05198.x; BOWMAN LH, 1983, MOL CELL BIOL, V3, P1501, DOI 10.1128/MCB.3.8.1501; CHU S, 1994, P NATL ACAD SCI USA, V91, P659, DOI 10.1073/pnas.91.2.659; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; FILIPOWICZ W, 1993, MOL BIOL REP, V18, P149, DOI 10.1007/BF00986770; FOURNIER MJ, 1993, TRENDS BIOCHEM SCI, V18, P131, DOI 10.1016/0968-0004(93)90020-N; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Hadjiolov AA, 1985, NUCLEOLUS RIBOSOME B; HADJIOLOVA KV, 1993, EUR J BIOCHEM, V212, P211, DOI 10.1111/j.1432-1033.1993.tb17652.x; HADJIOLOVA KV, 1984, BIOCHIM BIOPHYS ACTA, V782, P195, DOI 10.1016/0167-4781(84)90024-1; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; HOGAN NC, 1994, J CELL BIOL, V125, P21, DOI 10.1083/jcb.125.1.21; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; JENSEN R, 1993, EMBO J, V12, P2549; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; MASER RL, 1989, P NATL ACAD SCI USA, V86, P6523, DOI 10.1073/pnas.86.17.6523; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; MOUGEY EB, 1993, MOL CELL BIOL, V13, P5990, DOI 10.1128/MCB.13.10.5990; PARKER KA, 1987, MOL CELL BIOL, V7, P2899, DOI 10.1128/MCB.7.8.2899; PECULIS BA, 1994, GENE DEV, V8, P2241, DOI 10.1101/gad.8.18.2241; PECULIS BA, 1993, CELL, V73, P1233, DOI 10.1016/0092-8674(93)90651-6; PFEIFER K, 1994, GENE DEV, V8, P1867, DOI 10.1101/gad.8.16.1867; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PRIVES C, 1991, METHOD CELL BIOL, V36, P185; Sambrook J., 1989, MOL CLONING LAB MANU; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935; SOLLNERWEBB B, 1993, CELL, V75, P403, DOI 10.1016/0092-8674(93)90374-Y; SOLLNERWEBB B, IN PRESS RIBOSOMAL R; STROKE IL, 1989, J MOL BIOL, V210, P497, DOI 10.1016/0022-2836(89)90126-5; TOLLERVEY D, 1985, EMBO J, V4, P3873, DOI 10.1002/j.1460-2075.1985.tb04160.x; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; TYCOWSKI KT, 1993, GENE DEV, V7, P1176, DOI 10.1101/gad.7.7a.1176; TYCOWSKI KT, UNPUB; WELLAUER PK, 1974, J MOL BIOL, V89, P379, DOI 10.1016/0022-2836(74)90526-9	41	132	134	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1558	1561		10.1126/science.7985025	http://dx.doi.org/10.1126/science.7985025			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985025				2022-12-24	WOS:A1994PV01500043
J	KISELEV, A; SUBRAMANIAM, S				KISELEV, A; SUBRAMANIAM, S			ACTIVATION AND REGENERATION OF RHODOPSIN IN THE INSECT VISUAL CYCLE	SCIENCE			English	Article							INVERTEBRATE PHOTORECEPTORS; ARRESTIN; PROTEIN; PIGMENT; MEMBRANES; PHOSPHORYLATION; TRANSDUCTION	Light absorption by rhodopsin generates metarhodopsin, which activates heterotrimeric guanine nucleotide-binding proteins (G proteins) in photoreceptor cells of vertebrates and invertebrates. In contrast to vertebrate metarhodopsins, most invertebrate metarhodopsins are thermally stable and regenerate rhodopsin by absorption of a second photon. In experiments with Rh1 Drosophila rhodopsin, the thermal stability of metarhodopsin was found not to be an intrinsic property of the visual pigment but a consequence of its interaction with arrestin (49 kilodaltons). The Stabilization of metarhodopsin resulted in a large decrease in the efficiency of G protein activation. Light absorption by thermally stable metarhodopsin initially regenerated an inactive rhodopsin-like intermediate, which was subsequently converted in the dark to active rhodopsin. The accumulation of inactive rhodopsin at higher light levels may represent a mechanism for gain regulation in the insect visual cycle.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University				Subramaniam, Sriram/0000-0003-4231-4115				BENTROP J, 1993, EUR J BIOCHEM, V216, P67, DOI 10.1111/j.1432-1033.1993.tb18117.x; BENTROP J, 1986, EUR J BIOCHEM, V161, P61, DOI 10.1111/j.1432-1033.1986.tb10124.x; BLUMENFELD A, 1985, P NATL ACAD SCI USA, V82, P7116, DOI 10.1073/pnas.82.20.7116; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; HAMDORF K, 1980, NATURE, V283, P859, DOI 10.1038/283859a0; HAMDORF K, 1977, BIOPHYS STRUCT MECH, V3, P163, DOI 10.1007/BF00535813; Hamdorf K., 1979, HDB SENSORY PHYSL, V7/6A, P145; HILLMAN P, 1983, PHYSIOL REV, V63, P668, DOI 10.1152/physrev.1983.63.2.668; HOFMANN KP, 1986, PHOTOBIOCH PHOTOBIOP, V13, P309; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; KISELEV AD, UNPUB; LEVINE E, 1987, J GEN PHYSIOL, V90, P575, DOI 10.1085/jgp.90.4.575; MATSUMOTO H, 1994, NEURON, V12, P997, DOI 10.1016/0896-6273(94)90309-3; OSTROY SE, 1978, J GEN PHYSIOL, V72, P717, DOI 10.1085/jgp.72.5.717; PAK WL, 1974, J GEN PHYSIOL, V63, P740, DOI 10.1085/jgp.63.6.740; PAK WL, 1991, PHOTOCHEM PHOTOBIOL, V53, P871, DOI 10.1111/j.1751-1097.1991.tb09901.x; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PAULSEN R, 1984, J COMP PHYSIOL, V155, P47, DOI 10.1007/BF00610930; RANGANATHAN R, 1991, TRENDS NEUROSCI, V14, P486, DOI 10.1016/0166-2236(91)90060-8; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; STRYER L, 1988, COLD SPRING HARB SYM, V53, P283, DOI 10.1101/SQB.1988.053.01.035; TANIMURA T, 1986, PHOTOCHEM PHOTOBIOL, V43, P225, DOI 10.1111/j.1751-1097.1986.tb09519.x; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174	26	46	47	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1369	1373		10.1126/science.7973725	http://dx.doi.org/10.1126/science.7973725			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973725				2022-12-24	WOS:A1994PT63200040
J	ROBERTS, SB; FUSS, P; HEYMAN, MB; EVANS, WJ; TSAY, R; RASMUSSEN, H; FIATARONE, M; CORTIELLA, J; DALLAL, GE; YOUNG, VR				ROBERTS, SB; FUSS, P; HEYMAN, MB; EVANS, WJ; TSAY, R; RASMUSSEN, H; FIATARONE, M; CORTIELLA, J; DALLAL, GE; YOUNG, VR			CONTROL OF FOOD-INTAKE IN OLDER MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLY LABELED WATER; ENERGY-EXPENDITURE; NATIONAL COHORT; BODY-WEIGHT; ADULTS; NUTRITION; HUMANS	Objective.-To investigate the effects of aging on mechanisms of body energy regulation and thereby determine the causes of unexplained weight loss in older persons, a factor predisposing to premature death and disability. Design.-Dietary intervention study. Setting.-Metabolic ward and outpatient. Participants.-The subjects were 35 healthy younger and older men of normal body weight consuming a diet of typical composition and performing usual activities. Main Outcome Measures.-Subjects were either overfed by a mean (+/-SD) of 4.09 (+/-0.26) MJ/d (n=17) or underfed by 3.17 (+/-0.68) MJ/d (n=18) for 21 days. Measurements were made of changes in body weight, body composition, and energy expenditure during overfeeding or underfeeding, and of subsequent voluntary nutrient intakes and changes in body weight. Results.-There was no significant effect of aging on changes in body composition, body weight, or energy expenditure with overfeeding or underfeeding. However, following overfeeding, younger men exhibited spontaneous hypophagia, whereas the older men did not (mean [+/-SD] changes in energy intake relative to control values were -2.11 [+/-2.18] and 1.55 [+/-2.11] MJ/d, respectively; P=.006). As a result, the younger men lost the excess body weight gained during overfeeding but the older men did not. Similarly, following underfeeding, the younger men exhibited hyperphagia while the older men did not (mean [+/-SD] changes in energy intake relative to control values were 1.88 [+/-2.31] and -0.52 [+/-1.54] MJ/d, respectively; P=.02), and as a result the older men failed to regain the weight lost during underfeeding. Conclusions.-These results in 35 men suggest that aging may be associated with a significant impairment in the ability to control food intake following overeating or undereating. Since overeating and undereating occur routinely as part of the normal pattern of energy regulation, the findings reported herein may help to explain the vulnerability of older persons to unexplained weight gain and weight loss.	MIT, CLIN RES CTR, CAMBRIDGE, MA 02139 USA; UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA	Massachusetts Institute of Technology (MIT); University of California System; University of California San Francisco	ROBERTS, SB (corresponding author), TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, ENERGY METAB LAB, 711 WASHINGTON ST, BOSTON, MA 02111 USA.				NATIONAL INSTITUTE ON AGING [R37AG007388] Funding Source: NIH RePORTER; NIA NIH HHS [AG07388] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		DELMI M, 1990, LANCET, V335, P1013, DOI 10.1016/0140-6736(90)91073-J; DIPIETRO L, 1992, INT J OBESITY, V16, P745; DOTY RL, 1984, SCIENCE, V226, P1441, DOI 10.1126/science.6505700; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; EDHOLM OG, 1970, BRIT J NUTR, V24, P1091, DOI 10.1079/BJN19700112; Energy and protein requirements, 1985, TECHNICAL REPORT SER, V724; FANELLI MT, 1989, ANN NY ACAD SCI, V561, P94; FISCHER J, 1990, J AM DIET ASSOC, V90, P1697; GLICK Z, 1990, GERIATRIC NUTRITION, P27; GOSNELL BA, 1983, LIFE SCI, V32, P2793, DOI 10.1016/0024-3205(83)90401-0; LEAF A, 1984, NEW ENGL J MED, V311, P791, DOI 10.1056/NEJM198409203111209; LEIBOWITZ SF, 1988, NEUROBIOL AGING, V9, P20, DOI 10.1016/S0197-4580(88)80007-1; LIPSCHITZ DA, 1991, SEMIN DERMATOL, V10, P273; MILLER DK, 1990, J AM GERIATR SOC, V38, P645, DOI 10.1111/j.1532-5415.1990.tb01423.x; Morley J., 1990, GERIATRIC NUTRITION, P89; MORLEY JE, 1988, NEUROBIOL AGING, V9, P9, DOI 10.1016/S0197-4580(88)80004-6; MOWE M, 1994, AM J CLIN NUTR, V59, P317, DOI 10.1093/ajcn/59.2.317; NELSON RC, 1989, MED CLIN N AM, V73, P1531, DOI 10.1016/S0025-7125(16)30615-0; PACE N, 1945, J BIOL CHEM, V158, P685; PAMUK ER, 1992, AM J EPIDEMIOL, V136, P686, DOI 10.1093/oxfordjournals.aje.a116548; RABIN DL, 1987, LONG TERM CARE ELDER; ROBERTS SB, 1990, AM J PHYSIOL, V259, pR461, DOI 10.1152/ajpregu.1990.259.3.R461; ROBERTS SB, 1989, CAN J PHYSIOL PHARM, V67, P1190, DOI 10.1139/y89-189; ROBERTS SB, 1992, INT J OBESITY, V16, P969; ROBERTS SB, 1992, AM J PHYSIOL, V263, pR250; ROLLS BJ, 1992, NUTR REV, V50, P422, DOI 10.1111/j.1753-4887.1992.tb02496.x; ROSENBERG IH, 1992, NUTR REV, V50, P349; RUDMAN D, 1990, GERIATRIC NUTRITION, P325; SCHIFFMAN SS, 1989, ANN NY ACAD SCI, V561, P267, DOI 10.1111/j.1749-6632.1989.tb20988.x; SCHOELLER DA, 1988, J NUTR, V118, P1278, DOI 10.1093/jn/118.11.1278; Schutz Y., 1984, HUMAN ENERGY METABOL, P169; SHIMOKATA H, 1989, J GERONTOL, V44, pM66, DOI 10.1093/geronj/44.2.M66; SILVER AJ, 1988, PEPTIDES, V9, P221, DOI 10.1016/0196-9781(88)90254-9; STEEN B, 1988, NUTR REV, V46, P45, DOI 10.1111/j.1753-4887.1988.tb05386.x; TAYBACK M, 1990, ARCH INTERN MED, V150, P1065, DOI 10.1001/archinte.150.5.1065; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; 1990, PHS901232 US DEP HLT; 1983, PHS831681 US DEP HLT; 1991, EXTENDING LIFE ENHAN	39	290	297	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1601	1606		10.1001/jama.272.20.1601	http://dx.doi.org/10.1001/jama.272.20.1601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR405	7966871				2022-12-24	WOS:A1994PR40500027
J	STEVENS, J				STEVENS, J			JAPAN PICKS A WINNER IN THE RICE GENOME PROJECT	SCIENCE			English	Editorial Material																			0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1186	1187		10.1126/science.7973698	http://dx.doi.org/10.1126/science.7973698			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973698				2022-12-24	WOS:A1994PT13200037
J	KAPLAN, NM				KAPLAN, NM			MANAGEMENT OF HYPERTENSIVE EMERGENCIES	LANCET			English	Article							CEREBRAL BLOOD-FLOW; SODIUM-NITROPRUSSIDE; RENOVASCULAR HYPERTENSION; INTRAVENOUS LABETALOL; DANISH MULTICENTER; ORAL NIFEDIPINE; GRADE-III; PRESSURE; TRIAL; FENOLDOPAM				KAPLAN, NM (corresponding author), UNIV TEXAS,SW MED CTR,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							ANGELI P, 1991, ARCH INTERN MED, V151, P678, DOI 10.1001/archinte.151.4.678; BARNETT AJ, 1973, MED J AUSTRALIA, V2, P960, DOI 10.5694/j.1326-5377.1973.tb129861.x; BARRY DI, 1989, AM J CARDIOL, V63, pC14, DOI 10.1016/0002-9149(89)90399-8; BING RF, 1986, J HYPERTENS, V4, pS42; BURNETT CF, 1955, NEW ENGL J MED, V253, P395, DOI 10.1056/NEJM195509082531001; CALHOUN DA, 1990, NEW ENGL J MED, V323, P1177; CHITWOOD WR, 1992, ANN THORAC SURG, V54, P517, DOI 10.1016/0003-4975(92)90446-B; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COTTRELL JE, 1978, J NEUROSURG, V48, P329, DOI 10.3171/jns.1978.48.3.0329; DAVIS BA, 1979, NEW ENGL J MED, V301, P1273, DOI 10.1056/NEJM197912063012307; DUNN FG, 1983, CLIN PHARMACOL THER, V33, P139, DOI 10.1038/clpt.1983.21; DUSTAN HP, 1958, CIRCULATION, V18, P644, DOI 10.1161/01.CIR.18.4.644; FELDMAN JM, 1987, J CLIN PHARMACOL, V27, P288, DOI 10.1002/j.1552-4604.1987.tb03015.x; GIFFORD RW, 1991, JAMA-J AM MED ASSOC, V266, P829, DOI 10.1001/jama.266.6.829; HARRINGTON M, 1959, BRIT MED J, V2, P978; HOOD B, 1970, ACTA MED SCAND, V187, P291; ISLES CG, 1984, Q J MED, V51, P439; Kaplan N, 1994, CLIN HYPERTENSION, P389; Kaplan NM., 1994, CLIN HYPERTENSION, P281; Keith NM, 1939, AM J MED SCI, V197, P332, DOI 10.1097/00000441-193903000-00006; KROGSGAARD AR, 1986, ACTA MED SCAND, V220, P25; MACMAHON S, 1993, CLIN EXP HYPERTENS, V15, P967, DOI 10.3109/10641969309037085; MAHARAJ B, 1992, AM HEART J, V124, P720, DOI 10.1016/0002-8703(92)90283-2; MANN SJ, 1992, ANN INTERN MED, V117, P845, DOI 10.7326/0003-4819-117-10-845; MCDONALD AJ, 1993, AM J EMERG MED, V11, P460, DOI 10.1016/0735-6757(93)90083-N; MCNAIR A, 1986, ACTA MED SCAND, V220, P15; OMVIK P, 1980, HYPERTENSION, V2, P515, DOI 10.1161/01.HYP.2.4.515; PERRY HM, 1958, ARCH INTERN MED, V102, P418, DOI 10.1001/archinte.1958.00030010418011; PHILLIPS SJ, 1994, HYPERTENSION, V23, P131, DOI 10.1161/01.HYP.23.1.131; PILMER BL, 1993, J CLIN PHARMACOL, V33, P549, DOI 10.1002/j.1552-4604.1993.tb04702.x; SCHWARTZ M, 1990, ARCH INTERN MED, V150, P686, DOI 10.1001/archinte.150.3.686; SHEPHERD AMM, 1986, J CARDIOVASC PHARM, V8, P527, DOI 10.1097/00005344-198605000-00014; SHUSTERMAN NH, 1993, AM J MED, V95, P161, DOI 10.1016/0002-9343(93)90256-O; SIMPSON F O, 1958, Scott Med J, V3, P1; STRANDGAARD S, 1989, AM J HYPERTENS, V2, P486, DOI 10.1093/ajh/2.6.486; STRANDGAARD S, 1973, BMJ-BRIT MED J, V1, P507, DOI 10.1136/bmj.1.5852.507; THULIN T, 1993, J HYPERTENS, V11, P83, DOI 10.1097/00004872-199301000-00012; WALLIN JD, 1989, ARCH INTERN MED, V149, P2662, DOI 10.1001/archinte.149.12.2662; WEBSTER J, 1993, Q J MED, V96, P485; WILSON DJ, 1983, AM J MED, V75, P95, DOI 10.1016/0002-9343(83)90141-9	40	60	62	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1335	1338		10.1016/S0140-6736(94)90696-3	http://dx.doi.org/10.1016/S0140-6736(94)90696-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968030				2022-12-24	WOS:A1994PQ92600012
J	WATTERS, JK				WATTERS, JK			BEHAVIORAL-SCIENCE IN THE AIDS EPIDEMIC	LANCET			English	Editorial Material							SAN-FRANCISCO; MEN		UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	WATTERS, JK (corresponding author), UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143, USA.							BOOTH RE, 1994, AIDS, V8, P1515, DOI 10.1097/00002030-199411000-00001; Brown B. S., 1993, HDB RISK AIDS INJECT; FRIEDMAN SR, 1994, 10TH INT C AIDS YOK; MCKUSICK L, 1985, AM J PUBLIC HEALTH, V75, P493, DOI 10.2105/AJPH.75.5.493; MORRIS M, 1994, AM J EPIDEMIOL, V140, P217, DOI 10.1093/oxfordjournals.aje.a117241; NELSON KE, 1991, JAMA-J AM MED ASSOC, V266, P2250; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; VARMUS, 1994, LANCET          1029, P1215; WATTERS JK, 1994, JAMA-J AM MED ASSOC, V271, P115, DOI 10.1001/jama.271.2.115; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472; 1994, WORKSHOP NEEDLE EXCH; 1990, MMWR-MORBID MORTAL W, V39, P529; 1994, LANCET, V344, P535; 1994, AIDS RISK BEHAVIOR I	14	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1312	1313		10.1016/S0140-6736(94)90688-2	http://dx.doi.org/10.1016/S0140-6736(94)90688-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PQ926	7968024				2022-12-24	WOS:A1994PQ92600004
J	JOHNSTONE, RA				JOHNSTONE, RA			FEMALE PREFERENCE FOR SYMMETRICAL MALES AS A BY-PRODUCT OF SELECTION FOR MATE RECOGNITION	NATURE			English	Article							MALE SEXUAL ORNAMENTS; FLUCTUATING ASYMMETRY; EVOLUTION; PATTERNS; STRESS; BIASES	FLUCTUATING asymmetry (FA) refers to the random, stress-induced deviations from perfect symmetry that develop during the growth of bilaterally symmetrical traits(1,2). Individual differences in the level of FA may influence mate choice(3): in a number of species, females prefer to mate with males that have more symmetrical sexual ornaments(4-7). As the degree of FA has been shown to reflect the ability of individuals to cope with a wide variety of environmental stresses(2,8,9), it has been suggested that mating preferences for symmetry evolve for adaptive reasons, because the degree of FA provides honest information about male quality(10,11). Here I use simple, artificial neural networks to show that such preferences are likely to arise in the absence of any link between symmetry and quality, as a by-product of selection for mate recognition.			JOHNSTONE, RA (corresponding author), UNIV CAMBRIDGE,DEPT ZOOL,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.							ARAK A, 1993, PHILOS T R SOC B, V340, P207, DOI 10.1098/rstb.1993.0059; ENQUIST M, 1993, NATURE, V361, P446, DOI 10.1038/361446a0; HARVEY IF, 1993, ECOL ENTOMOL, V18, P198, DOI 10.1111/j.1365-2311.1993.tb01090.x; LEARY RF, 1989, TRENDS ECOL EVOL, V4, P214, DOI 10.1016/0169-5347(89)90077-3; LEIMAR O, 1986, AM NAT, V128, P469, DOI 10.1086/284581; MOLLER AP, 1993, BEHAV ECOL SOCIOBIOL, V32, P167; MOLLER AP, 1992, NATURE, V357, P238, DOI 10.1038/357238a0; MOLLER AP, 1990, ANIM BEHAV, V40, P1185, DOI 10.1016/S0003-3472(05)80187-3; MOLLER AP, 1993, BEHAV ECOL SOCIOBIOL, V32, P371, DOI 10.1007/BF00168820; PACKER C, 1993, NATURE, V362, P595, DOI 10.1038/362595a0; PALMER AR, 1986, ANNU REV ECOL SYST, V17, P391, DOI 10.1146/annurev.es.17.110186.002135; PARSONS PA, 1990, BIOL REV, V65, P131, DOI 10.1111/j.1469-185X.1990.tb01186.x; RADESATER T, 1993, ANIM BEHAV, V45, P626, DOI 10.1006/anbe.1993.1075; Ryan M.J., 1990, Oxford Surveys in Evolutionary Biology, V7, P157; RYAN MJ, 1993, PHILOS T ROY SOC B, V340, P187, DOI 10.1098/rstb.1993.0057; RYAN MJ, 1992, AM NAT, V139, pS4, DOI 10.1086/285303; STADDON JER, 1975, AM NAT, V109, P541, DOI 10.1086/283025; SWADDLE JP, 1994, NATURE, V367, P165, DOI 10.1038/367165a0; VANVALEN L, 1962, EVOLUTION, V16, P125; WATSON PJ, 1994, TRENDS ECOL EVOL, V9, P21, DOI 10.1016/0169-5347(94)90227-5; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3	21	162	162	1	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					172	175		10.1038/372172a0	http://dx.doi.org/10.1038/372172a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969449				2022-12-24	WOS:A1994PQ68800054
J	PLEY, HW; FLAHERTY, KM; MCKAY, DB				PLEY, HW; FLAHERTY, KM; MCKAY, DB			3-DIMENSIONAL STRUCTURE OF A HAMMERHEAD RIBOZYME	NATURE			English	Article							SELF-CLEAVAGE REACTION; VIRUS SATELLITE RNA; EFFICIENT CLEAVAGE; MOLECULAR-DYNAMICS; PURINE AMINO; OLIGORIBONUCLEOTIDES; PHOSPHOROTHIOATE; GUANOSINES; MECHANISM; SEQUENCE	The hammerhead ribozyme is a small catalytic RNA motif made up of three base-paired stems and a core of highly conserved, non-complementary nucleotides essential for catalysis. The X-ray crystallographic structure of a hammerhead RNA-RNA ribozyme-inhibitor complex at 2.6 Angstrom resolution reveals that the base-paired stems are A-form helices and that the core has two structural domains. The first domain is formed by the sequence 5'-CUGA following stem I and is a sharp turn identical to the uridine turn of transfer RNA, whereas the second is a non-Watson-Crick three-base-pair duplex with a divalent-ion binding site. The phosphodiester backbone of the DNA inhibitor strand is splayed out at the phosphate 5' to the cleavage site. The structure indicates that the ribozyme may destabilize a substrate strand in order to facilitate twisting of the substrate to allow cleavage of the scissile bond.	STANFORD UNIV, SCH MED, DEPT BIOL STRUCT, BECKMAN LABS STRUCT BIOL, STANFORD, CA 94305 USA	Stanford University								BRANDHUBER BJ, 1987, J BIOL CHEM, V262, P12306; BRATTY J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P345, DOI 10.1016/0167-4781(93)90001-T; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUZAYAN JM, 1986, NUCLEIC ACIDS RES, V14, P9729, DOI 10.1093/nar/14.24.9729; BUZAYAN JM, 1986, NATURE, V323, P349, DOI 10.1038/323349a0; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; DAHM SC, 1990, BIOCHIMIE, V72, P819, DOI 10.1016/0300-9084(90)90191-I; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; FU DJ, 1992, P NATL ACAD SCI USA, V89, P3985, DOI 10.1073/pnas.89.9.3985; FU DJ, 1993, BIOCHEMISTRY-US, V32, P10629, DOI 10.1021/bi00091a013; GRASBY JA, 1993, NUCLEIC ACIDS RES, V21, P4444, DOI 10.1093/nar/21.19.4444; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PLEY HW, 1993, J BIOL CHEM, V268, P19656; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; ROSSMANN MG, 1976, ACTA CRYSTALLOGR A, V32, P774, DOI 10.1107/S0567739476001587; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; SANTALUCIA J, 1993, BIOCHEMISTRY-US, V32, P12612, DOI 10.1021/bi00210a009; SHELDON CC, 1989, NUCLEIC ACIDS RES, V17, P5679, DOI 10.1093/nar/17.14.5679; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; SLIM G, 1992, BIOCHEM BIOPH RES CO, V183, P605, DOI 10.1016/0006-291X(92)90525-P; STEIGEMANN W, 1974, THESIS TU MUNCHEN; TUSCHL T, 1993, P NATL ACAD SCI USA, V90, P6991, DOI 10.1073/pnas.90.15.6991; TUSCHL T, 1993, BIOCHEMISTRY-US, V32, P11658, DOI 10.1021/bi00094a023; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VANTOL H, 1990, NUCLEIC ACIDS RES, V18, P1971, DOI 10.1093/nar/18.8.1971; WILLIAMS DM, 1992, P NATL ACAD SCI USA, V89, P918, DOI 10.1073/pnas.89.3.918	36	938	982	4	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	1994	372	6501					68	74		10.1038/372068a0	http://dx.doi.org/10.1038/372068a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969422				2022-12-24	WOS:A1994PQ34800071
J	RIDDIHOUGH, G				RIDDIHOUGH, G			FIRST-LINE DEFENSE	NATURE			English	Article							BINDING	Structural insight into the trimeric organization of the human mannose-binding protein sheds light on the workings of the non-clonal, innate immune response in vertebrates.										HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	5	3	3	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					114	114		10.1038/372114a0	http://dx.doi.org/10.1038/372114a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969405				2022-12-24	WOS:A1994PQ34800086
J	BRENNWALD, P; KEARNS, B; CHAMPION, K; KERANEN, S; BANKAITIS, V; NOVICK, P				BRENNWALD, P; KEARNS, B; CHAMPION, K; KERANEN, S; BANKAITIS, V; NOVICK, P			SEC9 IS A SNAP-25-LIKE COMPONENT OF A YEAST SNARE COMPLEX THAT MAY BE THE EFFECTOR OF SEC4 FUNCTION IN EXOCYTOSIS	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; GTP-BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; SECRETORY VESICLES; SYNAPTIC VESICLES; PLASMA-MEMBRANE; PATHWAY; FUSION; FAMILY	To identify potential Sec4 effecters, we isolated high copy suppressors of a Sec4 effector domain mutant. The most potent of these was found to be SEC9, a gene required for post-Golgi transport. The sole essential domain of Sec9 has significant sequence similarity to the neuronal protein SNAP-25, a component of the SNARE complex, that is implicated in vesicle targeting and fusion. Analogous to SNAP-25, Sec9 is bound to the yeast plasma membrane and is absent from post-Golgi vesicles. Furthermore, Sec9 is physically associated with two proteins that are homologous to components of the neuronal SNARE complex. Our results identify Sec9 as the yeast cognate of SNAP-25 and suggest that SNARE complexes acting at specific stages of vesicular transport serve as the ultimate targets of regulation by members of the Sec4/Ypt1/Rab family of GTPases.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06520 USA; UNIV ALABAMA, DEPT CELL BIOL, BIRMINGHAM, AL 35294 USA; UNIV ILLINOIS, DEPT MICROBIOL, URBANA, IL 61801 USA; VTT BIOTECHNOL & FOOD RES, SF-02044 ESPOO, FINLAND	Yale University; University of Alabama System; University of Alabama Birmingham; University of Illinois System; University of Illinois Urbana-Champaign; VTT Technical Research Center Finland					NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035370, R01GM044530, R01GM035370] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline; NIGMS NIH HHS [GM44530, GM35370] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; INOUE A, 1992, J BIOL CHEM, V267, P10613; KIBBE WA, 1993, RAS SUPERFAMILY GTPA, P367; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; RINE J, 1991, METHOD ENZYMOL, V194, P239; RISINGER C, 1993, P NATL ACAD SCI USA, V90, P10598, DOI 10.1073/pnas.90.22.10598; RISINGER C, 1993, J BIOL CHEM, V268, P24408; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; SCHLAVO G, 1993, J BIOL CHEM, V288, P23784; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WALWORTH NC, 1989, METHOD CELL BIOL, V31, P335; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	33	305	308	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					245	258		10.1016/0092-8674(94)90194-5	http://dx.doi.org/10.1016/0092-8674(94)90194-5			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954793				2022-12-24	WOS:A1994PN63000009
J	SHIINA, N; GOTOH, Y; KUBOMURA, N; IWAMATSU, A; NISHIDA, E				SHIINA, N; GOTOH, Y; KUBOMURA, N; IWAMATSU, A; NISHIDA, E			MICROTUBULE SEVERING BY ELONGATION-FACTOR 1-ALPHA	SCIENCE			English	Article							POLYPEPTIDE-CHAIN ELONGATION; SEA-URCHIN EGGS; STABLE MICROTUBULES; BINDING PROTEIN; FACTOR-1-ALPHA; IDENTIFICATION; DICTYOSTELIUM; EF-1-ALPHA; EXTRACTS; MITOSIS	An activity that severs stable microtubules is thought to be involved in microtubule reorganization during the cell cycle. Here, a 48-kilodalton microtubule-severing protein was purified from Xenopus eggs and identified as translational elongation factor 1 alpha (EF-1 alpha). Bacterially expressed human EF-1 alpha also displayed microtubule-severing activity in vitro and, when microinjected into fibroblasts, induced rapid and transient fragmentation of cytoplasmic microtubule arrays. Thus, EF-1 alpha, an essential component of the eukaryotic translational apparatus, appears to have a second role as a regulator of cytoskeletal rearrangements.	KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA 236,JAPAN	Kyoto University; Kirin Brewery Company Limited				Shiina, Nobuyuki/0000-0002-1854-4239				BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; COPPARD NJ, 1991, J CELL BIOL, V112, P237, DOI 10.1083/jcb.112.2.237; DJE MK, 1990, NUCLEIC ACIDS RES, V18, P3489, DOI 10.1093/nar/18.12.3489; HARLOW E, 1988, ANTIBODIES; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KARSENTI E, 1993, CURR BIOL, V3, P208, DOI 10.1016/0960-9822(93)90334-K; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KITANISHIYUMURA T, 1987, CELL MOTIL CYTOSKEL, V8, P106, DOI 10.1002/cm.970080203; KURIYAMA R, 1990, J CELL SCI, V95, P231; MCNALLY FJ, 1993, CELL, V75, P419, DOI 10.1016/0092-8674(93)90377-3; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; NISHIDA E, 1987, J BIOL CHEM, V262, P16200; OHTA K, 1990, J BIOL CHEM, V265, P3240; SANDERS MA, 1994, J CELL BIOL, V124, P795, DOI 10.1083/jcb.124.5.795; SHIINA N, 1992, EMBO J, V11, P4723, DOI 10.1002/j.1460-2075.1992.tb05577.x; SHIINA N, 1992, EMBO J, V11, P3977, DOI 10.1002/j.1460-2075.1992.tb05491.x; SHIINA N, UNPUB; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VALE RD, 1991, CELL, V64, P827, DOI 10.1016/0092-8674(91)90511-V; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	24	228	237	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					282	285		10.1126/science.7939665	http://dx.doi.org/10.1126/science.7939665			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939665				2022-12-24	WOS:A1994PM13400036
J	COLLINS, EJ; GARBOCZI, DN; WILEY, DC				COLLINS, EJ; GARBOCZI, DN; WILEY, DC			3-DIMENSIONAL STRUCTURE OF A PEPTIDE EXTENDING FROM ONE END OF A CLASS-I MHC BINDING-SITE	NATURE			English	Article							VIRAL PEPTIDES; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURES; ANTIGEN; COMPLEXES; MOLECULES; HLA-B27; H-2K(B); HLA-A2	CLASS I major histocompatibility complex (MHC) molecules present peptides to CD8(+) T cells for immunological surveillance (reviewed in ref. 1). The structures of complexes of class I MHC molecules with octamer, nonamer and decamer peptides determined until now(2-8) show a common binding mode, with both peptide termini bound in conserved pockets at the ends of the peptide binding site. Length variations were accommodated by the peptide bulging(5,6) or zig-zagging(4) in the middle. Here we describe the structure of a decamer peptide which binds with the carboxy-terminal residue positioned outside the peptide binding site. Several protein side chains have rearranged to allow the peptide to exit. The structure suggests that even longer peptides could bind. The energetic effect of the altered mode of binding has been assessed by measuring the stability of the complex to thermal denaturation. Peptides bound in this novel manner are stable at physiological temperature, raising questions about their role in T-cell recognition and their production by proteolytic processing.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University								BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR VERSION 3 0 M; CHEN Y, 1994, J IMMUNOL, V152, P2874; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GARBOCZI DN, 1994, J MOL BIOL, V239, P581, DOI 10.1006/jmbi.1994.1398; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; OLSEN AC, 1994, EUR J IMMUNOL, V24, P3585; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; URBAN RG, 1994, P NATL ACAD SCI USA, V91, P1534, DOI 10.1073/pnas.91.4.1534; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	25	195	199	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					626	629		10.1038/371626a0	http://dx.doi.org/10.1038/371626a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935798				2022-12-24	WOS:A1994PL55900058
J	JONSSON, J; CARLSSON, L; EDLUND, T; EDLUND, H				JONSSON, J; CARLSSON, L; EDLUND, T; EDLUND, H			INSULIN-PROMOTER-FACTOR-1 IS REQUIRED FOR PANCREAS DEVELOPMENT IN MICE	NATURE			English	Article							MAMMALIAN PANCREAS; GENE; EXPRESSION; CELLS	THE mammalian pancreas is a mixed exocrine and endocrine gland that, in most species, arises from ventral and dorsal buds which subsequently merge to form the pancreas. In both mouse and rat the first histological sign of morphogenesis of the dorsal pancreas is a dorsal evagination of the duodenum ai the level of the liver at around the 22-25-somite stage, and shortly thereafter a ventral evagination appears as a derivative of the liver diverticulum(1-3). Low levels of insulin gene transcripts are already present and restricted to the dorsal foregut endoderm at 20 somites, suggesting that pancreas- or insulin gene-specific transcriptional factors are present in this region before the onset of morphogenesis(4). Insulin-promoter-factor 1 (IPF1) is a homeodomain protein which, in the adult mouse pancreas, is selectively expressed in the beta-cells and binds to and transactivates the insulin promoter(5). In mouse embryos, IPF1 expression is restricted to the developing pancreatic anlagen and is initiated when the foregut endoderm is committed to a pancreatic fate(5). We now show that mice homozygous for a targeted mutation in the Ipf1 gene selectively lack a pancreas. The mutant pups survive fetal development but die within a few days after birth. The gastrointestinal part and all other internal organs were normal in appearance. No pancreatic tissue and no ectopic expression of insulin or pancreatic amylase could be detected in mutant embryos and neonates. These findings show that IPF1 is needed for the formation of the pancreas and suggest that it acts to determine the fate of common pancreatic precursor cells and/or to regulate their propagation.	UMEA UNIV,DEPT MICROBIOL,S-90187 UMEA,SWEDEN	Umea University				Edlund, Helena/0000-0002-3553-7348				GITHENS S, 1989, HUMAN GASTROINTESTIN, P669; GITTES GK, 1992, P NATL ACAD SCI USA, V89, P1128, DOI 10.1073/pnas.89.3.1128; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; HOGAN B, 1986, MANIPULATING MOUSE E, P194; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Pictet R., 1972, HDB PHYSL, P25; SPOONER BS, 1970, J CELL BIOL, V47, P235, DOI 10.1083/jcb.47.1.235; SPOONER BS, 1977, DEV BIOL, V61, P119, DOI 10.1016/0012-1606(77)90285-8; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WESSELLS NK, 1967, DEV BIOL, V15, P237, DOI 10.1016/0012-1606(67)90042-5; WRIGHT CVE, 1988, DEVELOPMENT, V104, P787	14	1467	1542	0	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					606	609		10.1038/371606a0	http://dx.doi.org/10.1038/371606a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935793				2022-12-24	WOS:A1994PL55900052
J	HEIDELBERGER, R; HEINEMANN, C; NEHER, E; MATTHEWS, G				HEIDELBERGER, R; HEINEMANN, C; NEHER, E; MATTHEWS, G			CALCIUM-DEPENDENCE OF THE RATE OF EXOCYTOSIS IN A SYNAPTIC TERMINAL	NATURE			English	Article							SQUID GIANT SYNAPSE; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; CHROMAFFIN CELLS; GOLDFISH RETINA; BIPOLAR CELLS; SECRETION; CHANNELS; INFLUX; CHELATORS	RAPID calcium-dependent exocytosis underlies neurotransmitter release from nerve terminals. Despite the fundamental importance of this process, neither the relationship between presynaptic intracellular calcium ion concentration ([Ca2+](i)) and rate of exocytosis, nor the maximal rate of secretion is known quantitatively. To provide this information, we have used flash photolysis of caged Ca2+ to elevate [Ca2+](i) rapidly and uniformly in synaptic terminals, while measuring membrane capacitance as ao index of exocytosis and monitoring [Ca2+](i) with a Ca2+-indicator dye. When [Ca2+](i) was abruptly increased to > 10 mu M, capacitance rose at a rate that increased steeply with [Ca2+](i). The steepness suggested that at least four calcium ions must bind to activate synaptic vesicle fusion. Half-saturation was at 194 mu M, and the maximal rate constant was 2,000-3,000 s(-1). A given synaptic vesicle can exocytose with high probability within a few hundred microseconds, if [Ca2+](i) rises above 100 mu M These properties provide for the extremely rapid signalling required for neuronal communication.	SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	HEIDELBERGER, R (corresponding author), MAX PLANCK INST BIOPHYS CHEM,MEMBRANBIOPHYS ABT,FASSBERG,W-3400 GOTTINGEN,GERMANY.		Neher, Erwin/A-2109-2013	Heidelberger, Ruth/0000-0002-8033-2050				ADLER EM, 1991, J NEUROSCI, V11, P1496; ALMERS W, 1994, NATURE, V367, P682; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; CHAD JE, 1984, BIOPHYS J, V45, P993, DOI 10.1016/S0006-3495(84)84244-7; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; DELANEY KR, 1990, J PHYSIOL-LONDON, V426, P473, DOI 10.1113/jphysiol.1990.sp018150; DOWLING JE, 1987, RETINA APPROACHABLE, P42; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIDELBERGER R, 1992, J PHYSIOL-LONDON, V447, P235, DOI 10.1113/jphysiol.1992.sp019000; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; HEINEMANN C, IN PRESS BIOPHYS J; HERRINGTON J, 1993, PULSE CONTROL V3 0 I; ISHIDA AT, 1980, J COMP NEUROL, V191, P315, DOI 10.1002/cne.901910302; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P483, DOI 10.1098/rspb.1965.0016; KONISHI M, 1991, J GEN PHYSIOL, V97, P271, DOI 10.1085/jgp.97.2.271; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MCCRAY J, 1992, BIOCHEMISTRY-US, V37, P8856; PARNAS H, 1986, PFLUG ARCH EUR J PHY, V406, P121, DOI 10.1007/BF00586672; ROBERTS WM, 1990, J NEUROSCI, V10, P3664; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; THOMAS P, 1993, EMBO J, V12, P303, DOI 10.1002/j.1460-2075.1993.tb05657.x; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; VONGERSDORFF H, 1994, NATURE, V370, P652, DOI 10.1038/370652a0; YAZULLA S, 1987, BRAIN RES, V411, P400, DOI 10.1016/0006-8993(87)91095-X; ZUCKER RS, 1993, CELL CALCIUM, V14, P87, DOI 10.1016/0143-4160(93)90079-L; ZUCKER RS, 1986, P NATL ACAD SCI USA, V83, P3032, DOI 10.1073/pnas.83.9.3032	30	620	628	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					513	515		10.1038/371513a0	http://dx.doi.org/10.1038/371513a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935764				2022-12-24	WOS:A1994PK58900055
J	ABUAREFEH, I; RUSSELL, G				ABUAREFEH, I; RUSSELL, G			PREVALENCE OF HEADACHE AND MIGRAINE IN SCHOOLCHILDREN	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; EPIDEMIOLOGY; CRITERIA	Objectives-To determine the prevalence rates of the various causes of severe headache in school-children, with special emphasis on migraine and its impact on school attendance. Design-Population based study in two stages, comprising an initial screening questionnaire followed by clinical interviews and examination of children with symptoms and a control group of asymptomatic children matched for age and sex. Setting-67 primary and secondary schools in the city of Aberdeen. Subjects-2165 children, representing a random sample of 10% of schoolchildren in Aberdeen aged 5-15 years. Main outcome measures-(a) the prevalence of migraine (International Headache Society criteria) and of other types of headache; (b) the impact of migraine on school attendance. Results-The estimated prevalence rates of migraine and tension headache were 10.6% (95% confidence interval 9.1 to 12.3) and 0.9% (0.5 to 1.5) respectively. The estimated prevalence rates for migraine without aura and migraine with aura were 7.8% (95% confidence interval 6.5 to 9.3) and 2.8% (2.0 to 3.8) respectively. In addition, 10 children (0.7%) had headaches which, though lasting less than two hours, also fulfilled the International Headache Society criteria for migraine, 14 (0.9%) had tension headaches, and 20 (1.3%) had non-specific recurrent headache. The prevalence of migraine increased with age, with male preponderance in children under 12 and female preponderance thereafter. Children with migraine lost a mean of 7.8 school days a year due to all illnesses (2.8 days (range 0-80) due to headache) as compared with a mean of 3.7 days lost by controls. Conclusions-Migraine is a common cause of headache in children and causes significantly reduced school attendance.	ROYAL ABERDEEN CHILDRENS HOSP,DEPT MED PAEDIAT,ABERDEEN AB9 2ZG,SCOTLAND	University of Aberdeen			Abu-Arafeh, Ishaq/H-7417-2019	Abu-Arafeh, Ishaq/0000-0003-1252-0153				BARLOW C, 1984, HEADACHE MIGRAINE CH, P172; BILLE B, 1962, ACTA PAED STOCK S136, V51, P1, DOI DOI 10.1111/J.1651-2227.1962.TB06591.X; CHEN TC, 1990, ARCH NEUROL-CHICAGO, V47, P1227, DOI 10.1001/archneur.1990.00530110087022; DALSGAAR.T, 1970, DAN MED BULL, V17, P138; DEUNBER DC, 1977, HEADACHE, V17, P173; GARDNER S, 1989, CONFIDENCE INTERVAL; GREEN JE, 1975, MIGRAINE NEWS    SEP, P30; Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; HENRY P, 1992, CEPHALALGIA, V12, P229, DOI 10.1046/j.1468-2982.1992.1204229.x; Hockaday J.M., 1988, MIGRAINE CHILDHOOD, P5; HOCKADAY JM, 1991, MATERN CHILD HLTH J, V16, P246; MORTIMER MJ, 1992, DEV MED CHILD NEUROL, V34, P1095; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; RASMUSSEN BK, 1992, CEPHALALGIA, V12, P221, DOI 10.1046/j.1468-2982.1992.1204221.x; ROSSI LN, 1992, DEV MED CHILD NEUROL, V34, P516; SILLANPAA M, 1983, HEADACHE, V23, P15; SPARKS JP, 1978, PRACTITIONER, V221, P407; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; VAHLQUIST B, 1949, ACTA PAEDIATR, V38, P622, DOI 10.1111/j.1651-2227.1949.tb17914.x; 1962, JAMA-J AM MED ASSOC, V179, P717; 1993, SPSS WINDOWS RELEASE; 1991, WKLY EPIDEMIOL REC, V66, P324	23	548	561	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					765	769		10.1136/bmj.309.6957.765	http://dx.doi.org/10.1136/bmj.309.6957.765			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950559	Green Published			2022-12-24	WOS:A1994PJ28200016
J	TARDIFF, K; MARZUK, PM; LEON, AC; HIRSCH, CS; STAJIC, M; PORTERA, L; HARTWELL, N				TARDIFF, K; MARZUK, PM; LEON, AC; HIRSCH, CS; STAJIC, M; PORTERA, L; HARTWELL, N			HOMICIDE IN NEW-YORK-CITY - COCAINE USE AND FIREARMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-EXCRETION; UNITED-STATES; RECENT TRENDS; VIOLENCE; HANDGUNS; COUNTY; DEATH; ABUSE; BENZOYLECGONINE; COMPLICATIONS	Objective.-To determine differences between racial/ethnic groups in overall rates of death by homicide, proportion of firearm homicides, and the use of cocaine prior to death. Design.-Descriptive epidemiologic survey of a complete 2-year sample of homicides. Setting.-New York City, NY (population 7 322 564). Subjects.-All residents (N=4298) of New York City who were victims of homicide during 1990 and 1991. Main Outcome Measures.-Using medical examiner data, age- and gender-specific rates of homicide were calculated for African Americans, Latinos, and whites. Separate logistic regression analyses were conducted to examine the association between demographic variables and both recent cocaine use and firearm-related homicides. Results.-Young African-American and Latino men were more likely to be victims of homicide than all other demographic groups. Approximately three fourths of all homicides involved firearms. In the subset of homicide victims dying within 48 hours (n=3890), 31.0% were positive for cocaine metabolites. African Americans (odds ratio [OR], 1.6; 95% confidence interval [CI], 1.2 to 2.1), Latinos (OR, 1.4; 95% CI, 1.1 to 1.9), and victims 25 through 34 years of age (OR, 2.9; 95% CI, 2.5 to 3.5) and 35 through 44 years of age (OR, 2.7; 95% CI, 2.2 to 3.4) were more likely to be positive for cocaine metabolites than other groups. Young males and females were equally likely to have used cocaine before death. Victims 15 through 24 years of age were more likely than other age groups to be killed by a firearm. African Americans (OR, 1.7; 95% CI, 1.3 to 2.3), Latinos (OR, 1.5; 95% CI, 1.2 to 2.0), and Asians (OR, 2.2; 95% CI, 1.4 to 3.6) were more likely than whites to be killed by a firearm. Men (OR, 4.8; 95% CI, 4.0 to 5.9) were more likely than women to be killed by a firearm. There was no association between having used cocaine before death and being killed by a firearm. Conclusions.-The high rates of death by homicide among young African Americans and Latinos may be due to the increased involvement with both cocaine use and firearms. New efforts must be made to decrease cocaine use and firearm availability.	CORNELL UNIV, COLL MED, DEPT PUBL HLTH, NEW YORK, NY USA; OFF CHIEF MED EXAMINER, NEW YORK, NY USA; NYU, SCH MED, DEPT FORENS MED, NEW YORK, NY USA	Cornell University; New York University	TARDIFF, K (corresponding author), CORNELL UNIV, COLL MED,DEPT PSYCHIAT,EPIDEMIOL SECT, 525 E 68TH ST, BOX 147, NEW YORK, NY 10021 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006534] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-06534] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMBRE J, 1988, J ANAL TOXICOL, V12, P301, DOI 10.1093/jat/12.6.301; AMBRE J, 1985, J ANAL TOXICOL, V9, P241, DOI 10.1093/jat/9.6.241; BAILEY DN, 1989, J FORENSIC SCI, V34, P407; BASELT RC, 1974, DISPOSITION TOXIC DR; BUDD RD, 1989, AM J DRUG ALCOHOL AB, V15, P375, DOI 10.3109/00952998908992798; CALLAHAN CM, 1992, JAMA-J AM MED ASSOC, V267, P3038, DOI 10.1001/jama.267.22.3038; CENTERWALL BS, 1991, AM J EPIDEMIOL, V134, P1245, DOI 10.1093/oxfordjournals.aje.a116027; CENTERWALL BS, 1984, AM J PUBLIC HEALTH, V74, P813, DOI 10.2105/AJPH.74.8.813; Collins JJ, 1985, CRIMINOLOGY, V23, P743, DOI 10.1111/j.1745-9125.1985.tb00372.x; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; Fagan J, 1990, NIDA Res Monogr, V103, P8; FINGERHUT LA, 1992, JAMA-J AM MED ASSOC, V267, P3048, DOI 10.1001/jama.267.22.3048; FINGERHUT LA, 1990, JAMA-J AM MED ASSOC, V263, P3292, DOI 10.1001/jama.263.24.3292; Gerstein D. R., 1993, PREVENTING DRUG ABUS; Goldstein P.J., 1989, CONTEMP DRUG PROBL, V16, P651; GOLDSTEIN PJ, 1991, J DRUG ISSUES, V21, P345, DOI 10.1177/002204269102100207; GOLDSTEIN PJ, 1985, J DRUG ISSUES, V15, P493, DOI 10.1177/002204268501500406; Goldstein PJ, 1979, PROSTITUTION DRUGS; GRIFFITH EEH, 1989, JAMA-J AM MED ASSOC, V262, P2265, DOI 10.1001/jama.262.16.2265; HAMID A, 1990, CONTEMP DRUG PROBL, V17, P31; HANZLICK R, 1991, JAMA-J AM MED ASSOC, V265, P760, DOI 10.1001/jama.265.6.760; HARRUFF RC, 1988, J FORENSIC SCI, V33, P1231; HOUSER HB, 1991, AM J EPIDEMIOL, V134, P1261, DOI 10.1093/oxfordjournals.aje.a116028; INCIARDI JA, 1990, NATIONAL I DRUG ABUS, V103; JATLOW PI, 1987, CLIN CHEM, V33, pB66; KANDEL DB, 1984, AM J PUBLIC HEALTH, V74, P660, DOI 10.2105/AJPH.74.7.660; KASSIRER JP, 1991, NEW ENGL J MED, V325, P1647, DOI 10.1056/NEJM199112053252311; LILLIEBLANTON M, 1993, JAMA-J AM MED ASSOC, V269, P993, DOI 10.1001/jama.269.8.993; LOFTIN C, 1991, NEW ENGL J MED, V325, P1615, DOI 10.1056/NEJM199112053252305; LOWENSTEIN DH, 1987, AM J MED, V83, P841, DOI 10.1016/0002-9343(87)90640-1; LOWRY PW, 1988, AM J EPIDEMIOL, V128, P1130; MARZUK PM, 1992, JAMA-J AM MED ASSOC, V267, P2635; MENDOZA R, 1992, HOSP COMMUNITY PSYCH, V43, P677; MESSNER SF, 1986, CRIMINOLOGY, V24, P297, DOI 10.1111/j.1745-9125.1986.tb01497.x; OCARROLL PW, 1991, AM J PUBLIC HEALTH, V81, P576, DOI 10.2105/AJPH.81.5.576; ROGERS JN, 1986, J FORENSIC SCI, V31, P1404; ROPP L, 1992, JAMA-J AM MED ASSOC, V267, P2905, DOI 10.1001/jama.267.21.2905; TARDIFF K, 1989, J FORENSIC SCI, V34, P53; TRENT B, 1991, CAN MED ASSOC J, V145, P1332; WALLACE JE, 1977, J ANAL TOXICOL, V1, P20, DOI 10.1093/jat/1.1.20; WEBSTER DW, 1993, AM J PUBLIC HEALTH, V83, P1604, DOI 10.2105/AJPH.83.11.1604; WETLI CV, 1985, J FORENSIC SCI, V30, P873; Wolfgang M. E., 1967, SUBCULTURE VIOLENCE; ZAHN M, 1989, HOMICIDE 20TH CENTUR, P1; 1993, SMA931980 US DEP MEN; 1993, UNDERSTANDING PREVEN; 1990, VITAL HLTH STAT, V11; 1990, MMWR-MORBID MORTAL W, V39, P869; 1990, TREATING DRUG PROBLE, V1, P220; 1991, MMWR-MORBID MORTAL W, V40, P681	50	58	59	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	1994	272	1					43	46		10.1001/jama.272.1.43	http://dx.doi.org/10.1001/jama.272.1.43			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU485	8007078				2022-12-24	WOS:A1994NU48500028
J	SIGURDSSON, E; THORGEIRSSON, G; SIGVALDASON, H; SIGFUSSON, N				SIGURDSSON, E; THORGEIRSSON, G; SIGVALDASON, H; SIGFUSSON, N			UNRECOGNIZED MYOCARDIAL-INFARCTION - EPIDEMIOLOGY, CLINICAL CHARACTERISTICS, AND THE PROGNOSTIC ROLE OF ANGINA-PECTORIS - THE REYKJAVIK STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; ANGINA PECTORIS; CORONARY DISEASE; ELECTROCARDIOGRAPHY; RISK ASSESSMENT	CORONARY-ARTERY DISEASE; AUTONOMIC NEUROPATHY; WARNING SYSTEM; HEART-DISEASE; CHEST PAIN; FOLLOW-UP; SILENT; PREVALENCE; ISCHEMIA; MEN	Objective: To evaluate the incidence, prevalence, characteristics, and prognosis associated with clinically unrecognized myocardial infarction as diagnosed by electrocardiographic changes. Design: Prospective, population-based cohort study with 4- to 20-year follow-up. Setting: Icelandic Heart Association Preventive Clinic. Participants: 9141 men residing in the Reykjavik area who were born between 1907 and 1934. Measurements: Patients were assigned to categories of coronary heart disease at first visit on the basis of hospital records, Rose chest pain questionnaire, standardized 12-lead electrocardiogram, and history and physical examination. Incidence and prevalence of unrecognized myocardial infarction were determined, survival was measured, and causes of death were determined from death certificates and autopsy records. Results: Prevalence was strongly influenced by age. Nearly undetectable in the youngest age group, it increased to more than 5% in the group aged 75 to 79 years. Incidence was almost zero up to age 40, then increased steeply to more than 300 cases per year per 100 000 persons at age 60, and decreased with age after age 65. Ten- and 15-year survival probabilities were 51% and 45%, respectively, and were similar to those for patients with recognized myocardial infarction. One third of men with unrecognized and 58% of men with recognized myocardial infarction had a history of angina pectoris (P < 0.001). Angina pectoris had a greater effect on coronary heart disease mortality in the former group than in the latter. The risk ratio for unrecognized myocardial infarction was 4.6 without angina (95% CI, 2.4 to 8.6) and 16.9 with angina (CI, 9.4 to 30.3); the risk ratio for recognized myocardial infarction was 6.3 without angina (CI, 3.7 to 10.6) and 8.5 with angina (CI, 5.8 to 12.6). Conclusion: At least one third of all myocardial infarctions were unrecognized. Prognosis and risk factor profiles for patients with recognized and unrecognized myocardial infarction were similar. Although those with unrecognized myocardial infarction were less likely than those with recognized myocardial infarction to have a history of angina pectoris, angina in these cases was usually associated with ischemic electrocardiographic changes and a poor prognosis, suggesting severe coronary heart disease.	NATL UNIV HOSP REYKJAVIK, DEPT MED, IS-121 REYKJAVIK, ICELAND; GOTHENBURG UNIV, GOTHENBURG, SWEDEN; HLTH CTR MARIESTAD, MARIESTAD, SWEDEN; ICELAND HEART ASSOC, HEART PREVENT CLIN, IS-108 REYKJAVIK, ICELAND; NATL UNIV HOSP REYKJAVIK, DEPT MED LANDSPITALINN, IS-121 REYKJAVIK, ICELAND	Landspitali National University Hospital; University of Gothenburg; Icelandic Heart Association; Landspitali National University Hospital								AIRAKSINEN KEJ, 1992, DIABETES CARE, V15, P288, DOI 10.2337/diacare.15.2.288; [Anonymous], 1988, J CLIN EPIDEMIOL, V41, P105, DOI 10.1016/0895-4356(88)90084-4; Bertolet B D, 1989, Cardiovasc Clin, V20, P173; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; COHN PF, 1980, AM J CARDIOL, V45, P697, DOI 10.1016/S0002-9149(80)80024-5; COHN PF, 1988, AM J CARDIOL, V61, pB4; DROSTE C, 1983, J AM COLL CARDIOL, V1, P940, DOI 10.1016/S0735-1097(83)80214-9; DROSTE C, 1986, PAIN, V26, P199, DOI 10.1016/0304-3959(86)90075-8; HEDBLAD B, 1989, EUR HEART J, V10, P149, DOI 10.1093/oxfordjournals.eurheartj.a059455; Herrick JB, 1912, J AMER MED ASSOC, V59, P2015; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KANNEL WB, 1987, CIRCULATION, V75, P4; KANNEL WB, 1990, ADV CARDIOL, V37, P202; KOISTINEN MJ, 1992, ACTA DIABETOL, V28, P199, DOI 10.1007/BF00778998; MARGOLIS JR, 1973, AM J CARDIOL, V32, P1, DOI 10.1016/S0002-9149(73)80079-7; MEDALIE JH, 1976, ANN INTERN MED, V84, P526, DOI 10.7326/0003-4819-84-5-526; NADELMANN J, 1990, AM J CARDIOL, V66, P533, DOI 10.1016/0002-9149(90)90477-I; NIAKAN E, 1986, ARCH INTERN MED, V146, P2229, DOI 10.1001/archinte.146.11.2229; OSULLIVAN JJ, 1991, BRIT HEART J, V66, P313; PYORALA K, 1974, ANN CLIN RES, V6, P137; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; ROSE GA, 1968, CARDIOVASCULAR SURVE, P56; ROSEMAN MD, 1954, ANN INTERN MED, V41, P1, DOI 10.7326/0003-4819-41-1-1; ROSENMAN RH, 1970, J CHRON DIS, V23, P173, DOI 10.1016/0021-9681(70)90094-9; SIGURDSSON E, 1993, EUR HEART J, V14, P584, DOI 10.1093/eurheartj/14.5.584; URETSKY BF, 1977, AM J CARDIOL, V40, P498, DOI 10.1016/0002-9149(77)90062-5; YANO K, 1989, ARCH INTERN MED, V149, P1528, DOI 10.1001/archinte.149.7.1528; 1990, EGRET REFERENCE MANU	28	187	190	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					96	102		10.7326/0003-4819-122-2-199501150-00003	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7993002				2022-12-24	WOS:A1995QC05900003
J	SCHLAEPFER, DD; HANKS, SK; HUNTER, T; VANDERGEER, P				SCHLAEPFER, DD; HANKS, SK; HUNTER, T; VANDERGEER, P			INTEGRIN-MEDIATED SIGNAL-TRANSDUCTION LINKED TO RAS PATHWAY BY GRB2 BINDING TO FOCAL ADHESION KINASE	NATURE			English	Article							PROTEIN-TYROSINE KINASE; CELL-ADHESION; SH3 DOMAIN; PHOSPHORYLATION; RECEPTOR	THE cytoplasmic focal adhesion protein-tyrosine kinase (FAK) localizes with surface integrin receptors at sites where cells attach to the extracellular matrix. Increased FAK tyrosine phosphorylation occurs upon integrin engagement with fibronectin. Here we show that adhesion of murine NIH3T3 fibroblasts to fibronectin promotes SH2-domain-mediated association of the GRB2 adaptor protein and the c-Src protein-tyrosine kinase (PTK) with FAK in vivo, and also results in activation of mitogen-activated protein kinase (MAPK). In v-Src-transformed NIH3T3, the association of v-Src, GRB2 and Sos with FAK is independent of cell adhesion to fibronectin. The GRB2 SH2 domain binds directly to tyrosine-phosphorylated FAK. Mutation of tyrosine residue 925 of FAK (YENV motif) to phenylalanine blocks GRB2 SH2-domain binding to PAK in vitro. Our results show that fibronectin binding to integrins on NIH3T3 fibroblasts promotes c-Src and FAK association and formation of an integrin-activated signalling complex. Phosphorylation of FAK at Tyr 925 upon fibronectin stimulation creates an SH2-binding site for GRB2 which may link integrin engagement to the activation of the Ras/MAPK signal transduction pathway.	VANDERBILT UNIV, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	Vanderbilt University	SCHLAEPFER, DD (corresponding author), SALK INST, MOLEC BIOL & VIROL LAB, POB 85800, SAN DIEGO, CA 92186 USA.							BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB M, IN PRESS MOL CELL BI; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	22	1443	1471	1	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					786	791						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997267				2022-12-24	WOS:A1994PY21200055
J	VASSAR, R; CHAO, SK; SITCHERAN, R; NUNEZ, JM; VOSSHALL, LB; AXEL, R				VASSAR, R; CHAO, SK; SITCHERAN, R; NUNEZ, JM; VOSSHALL, LB; AXEL, R			TOPOGRAPHIC ORGANIZATION OF SENSORY PROJECTIONS TO THE OLFACTORY-BULB	CELL			English	Article							ODORANT RECEPTOR EXPRESSION; MITRAL TUFTED CELLS; MARKER PROTEIN; GENE-EXPRESSION; MESSENGER-RNA; RAT; FAMILY; EPITHELIUM; NEURONS; MOLECULES	The detection of odorant receptor mRNAs within the axon terminals of sensory neurons has permitted us to ask whether neurons expressing a given receptor project their axons to common glomeruli within the olfactory bulb. In situ hybridization with five different receptor probes demonstrates that axons from neurons expressing a given receptor converge on one, or at most, a few glomeruli within the olfactory bulb. Moreover, the position of specific glomeruli is bilaterally symmetric and is constant in different individuals within a species. These data support a model in which exposure to a given odorant may result in the stimulation of a spatially restricted set of glomeruli, such that the individual odorants would be associated with specific topographic patterns of activity within the olfactory bulb.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	VASSAR, R (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.			Sitcheran, Raquel/0000-0001-8916-9707; Axel, Richard/0000-0002-3141-4076; Vosshall, Leslie/0000-0002-6060-8099	NIGMS NIH HHS [T32 GM07367] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTIC L, 1986, BRAIN RES BULL, V16, P445, DOI 10.1016/0361-9230(86)90172-3; ASTIC L, 1987, BRAIN RES, V424, P144, DOI 10.1016/0006-8993(87)91204-2; BAIER H, 1994, J NEUROSCI, V14, P219; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BERKLEY KJ, 1985, DEV ORG PROCESSING S, P191; BRUNET JF, 1991, SCIENCE, V252, P856, DOI 10.1126/science.1840700; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; BUONVISO N, 1991, EUR J NEUROSCI, V3, P493, DOI 10.1111/j.1460-9568.1991.tb00836.x; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CONSTANTINEPATO.M, 1990, ANN REV NEUROSCI, V13, P129; DYKES RW, 1982, J NEUROPHYSIOL, V47, P389, DOI 10.1152/jn.1982.47.3.389; EHRLICH ME, 1990, MOL BRAIN RES, V7, P115, DOI 10.1016/0169-328X(90)90088-U; FARBMAN AI, 1980, DEV BIOL, V74, P205, DOI 10.1016/0012-1606(80)90062-7; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOODMAN CS, 1993, NEURON S, V10, P77; HABERLY LB, 1977, BRAIN RES, V129, P152, DOI 10.1016/0006-8993(77)90978-7; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; IMAMURA K, 1992, J NEUROPHYSIOL, V68, P1986, DOI 10.1152/jn.1992.68.6.1986; JIRIKOWSKI GF, 1990, P NATL ACAD SCI USA, V87, P7400, DOI 10.1073/pnas.87.19.7400; JOURDAN F, 1980, BRAIN RES, V188, P139, DOI 10.1016/0006-8993(80)90563-6; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P516; KATOH K, 1993, J NEUROPHYSIOL, V70, P2161, DOI 10.1152/jn.1993.70.5.2161; KAUER JS, 1987, BRAIN RES, V418, P255, DOI 10.1016/0006-8993(87)90093-X; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LANCET D, 1982, P NATL ACAD SCI-BIOL, V79, P670, DOI 10.1073/pnas.79.2.670; LANDRY C, 1992, J NEUROBIOL, V23, P89, DOI 10.1002/neu.480230109; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416; LUSKIN MB, 1982, J COMP NEUROL, V209, P249, DOI 10.1002/cne.902090304; MARGOLIS FL, 1978, SOC NEUR ABSTR, V4, P88; MEISAMI E, 1989, DEV BRAIN RES, V46, P9, DOI 10.1016/0165-3806(89)90139-9; MEISAMI E, 1979, NEURAL GROWTH DIFFER; MELTON DA, 1984, NUCLEIC ACIDS RES, V13, P7035; MOHR E, 1991, EMBO J, V10, P2419, DOI 10.1002/j.1460-2075.1991.tb07781.x; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; NADI NS, 1981, BRAIN RES, V213, P365, DOI 10.1016/0006-8993(81)90241-9; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; OJIMA H, 1984, J COMP NEUROL, V230, P77, DOI 10.1002/cne.902300107; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; PERL ER, 1962, J NEUROPHYSIOL, V25, P337, DOI 10.1152/jn.1962.25.3.337; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; Ressler Kerry J., 1994, Current Opinion in Neurobiology, V4, P588, DOI 10.1016/0959-4388(94)90061-2; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; ROGERS KE, 1987, P NATL ACAD SCI USA, V84, P1704, DOI 10.1073/pnas.84.6.1704; ROYET JP, 1988, J COMP NEUROL, V270, P559, DOI 10.1002/cne.902700409; ROYET JP, 1987, BRAIN RES, V417, P1, DOI 10.1016/0006-8993(87)90173-9; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHOENFELD TA, 1994, BRAIN RES BULL, V34, P183, DOI 10.1016/0361-9230(94)90059-0; SCHWOB JE, 1978, BRAIN RES, V151, P369, DOI 10.1016/0006-8993(78)90891-0; SCOTT JW, 1980, J COMP NEUROL, V194, P519, DOI 10.1002/cne.901940304; Shepherd G. M., 1991, OLFACTION MODEL SYST; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; VERHAAGEN J, 1990, J NEUROSCI RES, V26, P31, DOI 10.1002/jnr.490260105; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	64	981	996	0	34	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					981	991		10.1016/0092-8674(94)90029-9	http://dx.doi.org/10.1016/0092-8674(94)90029-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001145				2022-12-24	WOS:A1994PY08600008
J	ADOLPHS, R; TRANEL, D; DAMASIO, H; DAMASIO, A				ADOLPHS, R; TRANEL, D; DAMASIO, H; DAMASIO, A			IMPAIRED RECOGNITION OF EMOTION IN FACIAL EXPRESSIONS FOLLOWING BILATERAL DAMAGE TO THE HUMAN AMYGDALA	NATURE			English	Article							CIRCUMPLEX MODEL; IDENTITY; LESIONS; MONKEY	STUDIES in animals have shown that the amygdala receives highly processed visual input(1,2), contains neurons that respond selectively to faces(3), and that it participates in emotion(4,5) and social behaviour(6). Although studies in epileptic patients support its role in emotion(7), determination of the amygdala's function in humans has been hampered by the rarity of patients with selective amygdala lesions(8). Here, with the help of one such rare patient, we report findings that suggest the human amygdala may be indispensable to: (1) recognize fear in facial expressions; (2) recognize multiple emotions in a single facial expression; but (3) is not required to recognize personal identity from faces. These results suggest that damage restricted to the amygdala causes very specific recognition impairments, and thus constrains the broad notion that the amygdala is involved in emotion.	SALK INST BIOL STUDIES,LA JOLLA,CA 92186	Salk Institute	ADOLPHS, R (corresponding author), UNIV IOWA,COLL MED,DEPT NEUROL,DIV COGNIT NEUROSCI,IOWA CITY,IA 52242, USA.		Damasio, Antonio/AAD-1342-2019; Tudusciuc, Oana/C-1339-2011	Tranel, Daniel/0000-0002-1338-1389				AGGLETON J P, 1992, P485; AMARAL D G, 1992, P1; Amaral DG, 1992, AMYGDALA NEUROBIOLOG, P465; BLANCHARD DC, 1972, J COMP PHYSIOL PSYCH, V81, P281, DOI 10.1037/h0033521; DAMASIO AR, 1990, ANNU REV NEUROSCI, V13, P89, DOI 10.1146/annurev.ne.13.030190.000513; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; Damasio H, 1989, ANAL NEUROPSYCHOLOGY; Darwin C., 1965, EXPRESSION EMOTIONS; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; Ekman P., 1976, PICTURES FACIAL AFFE; Ekman Paul, 1973, DARWIN FACIAL EXPRES; GUTTMAN L, 1968, PSYCHOMETRIKA, V33, P469, DOI 10.1007/BF02290164; HALGREN E, 1978, BRAIN, V101, P83, DOI 10.1093/brain/101.1.83; HASSELMO ME, 1989, BEHAV BRAIN RES, V32, P203, DOI 10.1016/S0166-4328(89)80054-3; HERZOG AG, 1976, BRAIN RES, V115, P57, DOI 10.1016/0006-8993(76)90822-2; HOFER PA, 1973, ACTA DERM-VENEREOL, V53, P5; HUMPHREYS GW, 1993, NEUROPSYCHOLOGIA, V31, P173, DOI 10.1016/0028-3932(93)90045-2; KLING A S, 1992, P353; KRUSKAL JB, 1964, PSYCHOMETRIKA, V29, P115, DOI 10.1007/BF02289694; LEDOUX JE, 1993, BEHAV BRAIN RES, V58, P69, DOI 10.1016/0166-4328(93)90091-4; NAHM FKD, 1993, NEUROPSYCHOLOGIA, V31, P727, DOI 10.1016/0028-3932(93)90125-J; ROLLS E T, 1992, P143; RUSSELL JA, 1989, J PERS SOC PSYCHOL, V57, P848, DOI 10.1037/0022-3514.57.5.848; RUSSELL JA, 1980, J PERS SOC PSYCHOL, V39, P1161, DOI 10.1037/h0077714; RUSSELL JA, 1991, PSYCHOL BULL, V110, P426, DOI 10.1037/0033-2909.110.3.426; RUSSELL JA, 1985, J PERS SOC PSYCHOL, V48, P1290, DOI 10.1037/0022-3514.48.5.1290; TRANEL D, 1988, NEUROLOGY, V38, P690, DOI 10.1212/WNL.38.5.690; TRANEL D, 1990, ARCH NEUROL-CHICAGO, V47, P349, DOI 10.1001/archneur.1990.00530030131029; WEISKRANTZ L, 1956, J COMP PHYSIOL PSYCH, V49, P381, DOI 10.1037/h0088009	29	1567	1596	4	217	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					669	672		10.1038/372669a0	http://dx.doi.org/10.1038/372669a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PX307	7990957				2022-12-24	WOS:A1994PX30700084
J	FROLOVA, L; LEGOFF, X; RASMUSSEN, HH; CHEPEREGIN, S; DRUGEON, G; KRESS, M; ARMAN, I; HAENNI, AL; CELIS, JE; PHILIPPE, M; JUSTESEN, J; KISSELEV, L				FROLOVA, L; LEGOFF, X; RASMUSSEN, HH; CHEPEREGIN, S; DRUGEON, G; KRESS, M; ARMAN, I; HAENNI, AL; CELIS, JE; PHILIPPE, M; JUSTESEN, J; KISSELEV, L			A HIGHLY CONSERVED EUKARYOTIC PROTEIN FAMILY POSSESSING PROPERTIES OF POLYPEPTIDE-CHAIN RELEASE FACTOR	NATURE			English	Article							TRANSFER RNA-SYNTHETASE; SACCHAROMYCES-CEREVISIAE; TRANSLATION FIDELITY; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; YEAST; TERMINATION; SUP45; HOMOLOGY; CLONING	THE termination of protein synthesis in ribosomes is governed by termination (stop) codons in messenger RNAs and by polypeptide chain release factors (RFs). Although the primary structure of prokaryotic RFs and yeast mitochrondrial RF is established(1-4), that of the only known eukaryotic RF (eRF)(5) remains obscure. Here we report the assignment of a family of tightly related proteins (designated eRF1) from lower and higher eukaryotes which are structurally and functionally similar to rabbit eRF. Two of these proteins, one from human(6) and the other from Xenopus laevis(7), have been expressed in yeast and Escherichia coli, respectively, purified and shown to be active in the in vitro RF assay. The other protein of this family, sup45 (sup1) of Saccharomyces cerevisiae, is involved in omnipotent suppression during translations(8-12). The amino-acid sequence of the eRF1 family is highly conserved. We conclude that the eRF1 proteins are directly implicated in the termination of translation in eukaryotes.	RUSSIAN ACAD SCI,VA ENGELHARDT MOLEC BIOL INST,MOSCOW 117984,RUSSIA; AARHUS UNIV,DEPT BIOL MOLEC,DK-800 AARHUS C,DENMARK; INST JACQUES MONOD,F-75251 PARIS 05,FRANCE; UNIV RENNES 1,CNRS,URA 256,DEPT BIOL & GENET DEV,F-35042 RENNES,FRANCE; AARHUS UNIV,INST MED BIOCHEM,DK-8000 AARHUS C,DENMARK; AARHUS UNIV,DANISH CTR HUMAN GENOME RES,DK-8000 AARHUS C,DENMARK; RUSSIAN ACAD SCI,INST MOLEC GENET,MOSCOW 123182,RUSSIA; CNRS,ERS0048,MOLEC ONCOL LAB,F-94802 VILLEJUIF,FRANCE	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Aarhus University; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; Aarhus University; Aarhus University; Russian Academy of Sciences; Centre National de la Recherche Scientifique (CNRS)			Cheperegin, Sergey/R-6594-2018	LE GOFF, Xavier/0000-0002-5297-2421				BEAUDET AL, 1971, P NATL ACAD SCI USA, V68, P619, DOI 10.1073/pnas.68.3.619; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BREINING P, 1986, NUCLEIC ACIDS RES, V14, P5187, DOI 10.1093/nar/14.13.5187; Caskey C T, 1974, Methods Enzymol, V30, P293; CRAIGEN WJ, 1990, MOL MICROBIOL, V4, P861, DOI 10.1111/j.1365-2958.1990.tb00658.x; FROLOVA LY, 1991, GENE, V109, P291, DOI 10.1016/0378-1119(91)90624-K; FROLOVA LY, 1993, EMBO J, V12, P4013; GARRET M, 1991, BIOCHEMISTRY-US, V30, P7809, DOI 10.1021/bi00245a021; GOLDSTEIN JL, 1970, P NATL ACAD SCI USA, V67, P99, DOI 10.1073/pnas.67.1.99; GRENETT HE, 1992, GENE, V110, P239, DOI 10.1016/0378-1119(92)90655-9; GRENTZMANN G, 1994, P NATL ACAD SCI USA, V91, P5848, DOI 10.1073/pnas.91.13.5848; HIMMELFARB HJ, 1985, MOL CELL BIOL, V5, P816, DOI 10.1128/MCB.5.4.816; INGE-VECHTOMOV S G, 1970, Genetika, V6, P103; KONECKI DS, 1977, J BIOL CHEM, V252, P4514; LEE CC, 1990, P NATL ACAD SCI USA, V87, P3508, DOI 10.1073/pnas.87.9.3508; MUKINI O, 1994, P NATL ACAD SCI USA, V91, P5798; PEL HJ, 1992, NUCLEIC ACIDS RES, V20, P4423, DOI 10.1093/nar/20.17.4423; PEL HJ, 1992, NUCLEIC ACIDS RES, V20, P6339, DOI 10.1093/nar/20.23.6339; RASMUSSEN HH, 1991, ELECTROPHORESIS, V12, P873, DOI 10.1002/elps.1150121107; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; STANSFIELD I, 1992, MOL MICROBIOL, V6, P3469, DOI 10.1111/j.1365-2958.1992.tb01782.x; Surguchovs AP, 1984, PHYSICOCHEMICAL BIOL, V4, P147; TASSAN JP, 1993, MOL CELL BIOL, V13, P2815, DOI 10.1128/MCB.13.5.2815; TATE WP, 1990, RIBOSOMES PROTEIN SY, P81; TUITE MF, 1993, BIOCHEM SOC T, V21, P857, DOI 10.1042/bst0210857	25	349	371	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					701	703		10.1038/372701a0	http://dx.doi.org/10.1038/372701a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990965				2022-12-24	WOS:A1994PX30700093
J	ERICKSON, SL; DESAUVAGE, FJ; KIKLY, K; CARVERMOORE, K; PITTSMEEK, S; GILLETT, N; SHEEHAN, KCF; SCHREIBER, RD; GOEDDEL, DV; MOORE, MW				ERICKSON, SL; DESAUVAGE, FJ; KIKLY, K; CARVERMOORE, K; PITTSMEEK, S; GILLETT, N; SHEEHAN, KCF; SCHREIBER, RD; GOEDDEL, DV; MOORE, MW			DECREASED SENSITIVITY TO TUMOR-NECROSIS-FACTOR BUT NORMAL T-CELL DEVELOPMENT IN TNF RECEPTOR-2-DEFICIENT MICE	NATURE			English	Article							FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; ENDOTOXIC-SHOCK; MONOCYTOGENES; RESISTANT; INFECTION; BINDING; DOMAIN; LINES	TUMOUR necrosis factor (TNF) elicits multiple biological effects through two distinct cell surface receptors, TNF-R1 (p55) and TNF-R2 (p75). Most TNF-mediated biological responses, such as cell death, gene induction, antiviral activity and cytokine production, have been attributed to TNF-R1 (refs 1-5). Gene targeting of this receptor confirms its role in the lethality attributable to low doses of lipopolysaccharide after sensitization with D-galactosamine(6,7); surprisingly, the toxicity of high doses of lipopolysaccharide was unaffected. The function of TNF-R2 is less well understood, although there are data supporting a role in T-cell development and the proliferation of cytotoxic T lymphocytes(8,9). To clarify the physiological role of TNF-R2, we have generated mice deficient in this receptor by gene targeting. The TNF-R2(-/-) mice show normal T-cell development and activity, but we find that they have increased resistance to TNF-induced death. Additionally, such mice injected subcutaneously with TNF show a dramatic decrease in tissue necrosis, indicating that this receptor plays a role in the necrotic effects of TNF.	GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT ENDOCRINE RES & PHARMACOL,S SAN FRANCISCO,CA 94080; WASHINGTON UNIV,SCH MED,CTR IMMUNOL,DEPT PATHOL,ST LOUIS,MO 63110	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Washington University (WUSTL)			Schreiber, Robert D/A-1276-2013; de Sauvage, Frederic/ABE-8400-2020; Schreiber, Robert/Q-7550-2019	Schreiber, Robert D/0000-0001-6311-0432; de Sauvage, Frederic/0000-0002-5275-2584; Schreiber, Robert/0000-0003-1590-2341				ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542	22	540	557	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					560	563		10.1038/372560a0	http://dx.doi.org/10.1038/372560a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990930				2022-12-24	WOS:A1994PW08200055
J	WILSON, PWF; MYERS, RH; LARSON, MG; ORDOVAS, JM; WOLF, PA; SCHAEFER, EJ				WILSON, PWF; MYERS, RH; LARSON, MG; ORDOVAS, JM; WOLF, PA; SCHAEFER, EJ			APOLIPOPROTEIN-E ALLELES, DYSLIPIDEMIA, AND CORONARY-HEART-DISEASE - THE FRAMINGHAM OFFSPRING STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; E POLYMORPHISM; ARTERY DISEASE; E PHENOTYPE; MYOCARDIAL-INFARCTION; INCREASED PREVALENCE; LOVASTATIN TREATMENT; TRIGLYCERIDE LEVELS; ALZHEIMERS-DISEASE	Objective.-To describe the association between apolipoprotein E alleles (epsilon 2, epsilon 3, and epsilon 4), dyslipidemias, and coronary heart disease (CHD). Design.-Cross-sectional prevalence study. Setting and Participants.-Community-based sample of men (n=1034) and women (n=916) aged 40 to 77 years who are participating in a long-term study of cardiovascular disease. Study participants underwent fasting lipid measurements, coronary risk factor determinations, and a comprehensive evaluation for the presence of current or previous CHD. Results.-Compared with the epsilon 3 allele, the epsilon 4 allele was associated with elevated low-density lipoprotein cholesterol values (greater than or equal to 4.14 mmol/L [160 mg/dL]) in women, the epsilon 2 and epsilon 4 alleles were associated with moderately elevated triglyceride values (greater than or equal to 2.82 mmol/L [250 mg/dL]) in men, and the epsilon 2 allele was associated with severely elevated triglyceride values (greater than or equal to 5.64 mmol/L [500 mg/dL]) in men. The apolipoprotein E alleles were not associated with hypertension, obesity, smoking, or diabetes, but the epsilon 4 allele frequency was reduced in women after 60 years of age. The age-adjusted prevalence of CHD was associated with the epsilon 4 allele in both men (relative odds=1.53, P=.04) and women (relative odds=1.99, P=.05). In analyses for women and for both sexes combined, this relation persisted after adjustment by hypertension, smoking, obesity, diabetes, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol. Conclusions.-Apolipoprotein E alleles are important genetic markers for dyslipidemia and CHD. The estimated CHD odds associated with the epsilon 4 allele appears to be greater than that for any other known genetic lipid abnormality, and the association of the epsilon 4 allele with CHD remains significant in women and both sexes combined after adjustment by traditional coronary risk factors and lipids.	BOSTON UNIV,MED CTR,BOSTON,MA; TUFTS UNIV,USDA,HUMAN NUTR RES CTR,BOSTON,MA 02111	Boston University; Tufts University; United States Department of Agriculture (USDA)	WILSON, PWF (corresponding author), FRAMINGHAM HEART DIS EPIDEMIOL STUDY,5 THURBER ST,FRAMINGHAM,MA 01701, USA.		Wilson, Peter W.F./J-2455-2016; Ordovas, Jose/B-8727-2013	Wolf, Philip/0000-0002-3628-301X; Larson, Martin/0000-0002-9631-1254; Myers, Richard/0000-0002-8365-2674; Ordovas, Jose/0000-0002-7581-5680				ASSMANN G, 1984, CLIN CHEM, V30, P641; BOEMI M, 1993, DIABETOLOGIA, V36, P229, DOI 10.1007/BF00399955; BOERWINKLE E, 1987, ANN HUM GENET, V51, P211, DOI 10.1111/j.1469-1809.1987.tb00874.x; BOERWINKLE E, 1988, AM J HUM GENET, V42, P104; BREWER HB, 1983, ANN INTERN MED, V98, P623, DOI 10.7326/0003-4819-98-5-623; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CARMENA R, 1993, METABOLISM, V42, P895, DOI 10.1016/0026-0495(93)90066-W; CHIVOT L, 1990, ATHEROSCLEROSIS, V82, P205, DOI 10.1016/0021-9150(90)90042-H; COBB MM, 1992, CIRCULATION, V86, P849, DOI 10.1161/01.CIR.86.3.849; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CUMMING AM, 1984, CLIN GENET, V25, P310; CUPPPLES LA, 1987, FRAMINGHAM STUDY EPI; DALLONGEVILLE J, 1992, J LIPID RES, V33, P447; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DEKNIJFF P, 1990, ATHEROSCLEROSIS, V83, P89; DESPRES JP, 1993, DIABETES, V42, P1474, DOI 10.2337/diabetes.42.10.1474; EHNHOLM C, 1986, J LIPID RES, V27, P227; EICHNER JE, 1990, ARTERIOSCLEROSIS, V10, P379, DOI 10.1161/01.ATV.10.3.379; EICHNER JE, 1993, AM J CARDIOL, V71, P160, DOI 10.1016/0002-9149(93)90732-R; ETO M, 1989, CLIN GENET, V36, P183; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Funke Harald, 1993, Current Opinion in Lipidology, V4, P453, DOI 10.1097/00041433-199312000-00006; GHISELLI G, 1982, J CLIN INVEST, V70, P474, DOI 10.1172/JCI110638; GLUECK CJ, 1976, METABOLISM, V25, P1269, DOI 10.1016/S0026-0495(76)80010-8; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1533, DOI 10.1172/JCI107331; HIXSON JE, 1991, ARTERIOSCLER THROMB, V11, P1237, DOI 10.1161/01.ATV.11.5.1237; JANUS ED, 1985, ATHEROSCLEROSIS, V57, P249, DOI 10.1016/0021-9150(85)90038-3; KAMBOH MI, 1993, ATHEROSCLEROSIS, V98, P201, DOI 10.1016/0021-9150(93)90129-I; KUUSI T, 1989, ARTERIOSCLEROSIS, V9, P237, DOI 10.1161/01.ATV.9.2.237; LENZEN HJ, 1986, CLIN CHEM, V32, P778; LOUHIJA J, 1994, ARTERIOSCLER THROMB, V14, P1084, DOI 10.1161/01.ATV.14.7.1084; MAHLEY RW, 1991, JAMA-J AM MED ASSOC, V265, P78, DOI 10.1001/jama.265.1.78; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; MENZEL HJ, 1983, ARTERIOSCLEROSIS, V3, P310, DOI 10.1161/01.ATV.3.4.310; NIEMINEN MS, 1992, ARTERIOSCLER THROMB, V12, P58, DOI 10.1161/01.ATV.12.1.58; OJALA JP, 1991, J INTERN MED, V230, P397, DOI 10.1111/j.1365-2796.1991.tb00464.x; OMALLEY JP, 1990, METABOLISM, V39, P150, DOI 10.1016/0026-0495(90)90068-N; ORDOVAS JM, 1987, J LIPID RES, V28, P371; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; RUST S, 1992, CIRCULATION, V86, P420; SCHAEFER EJ, 1994, ARTERIOSCLER THROMB, V14, P1105, DOI 10.1161/01.ATV.14.7.1105; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P234; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SCHMITZ G, 1993, ARTERIOSCLER THROMB, V13, P1053, DOI 10.1161/01.ATV.13.7.1053; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SING CF, 1985, AM J HUM GENET, V37, P268; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1993, NEUROLOGY, V43, P1467; STUYT PMJ, 1991, SCAND J CLIN LAB INV, V51, P425, DOI 10.3109/00365519109091636; UKKOLA O, 1993, ATHEROSCLEROSIS, V101, P9, DOI 10.1016/0021-9150(93)90096-D; UTERMANN G, 1984, HUM GENET, V65, P237, DOI 10.1007/BF00286509; UTERMANN G, 1979, CLIN GENET, V15, P37; UTERMANN G, 1979, CLIN GENET, V15, P63; VANBOCKXMEER FM, 1992, LANCET, V340, P879, DOI 10.1016/0140-6736(92)93288-X; WALDEN CC, 1994, ANN INTERN MED, V120, P1026, DOI 10.7326/0003-4819-120-12-199406150-00009; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; WILSON PWF, 1980, ACCEL TAPES, V12, P1; YAMAMOTO A, 1990, ANN NY ACAD SCI, V598, P58, DOI 10.1111/j.1749-6632.1990.tb42276.x; YAMAMURA T, 1990, JPN CIRC J, V54, P448, DOI 10.1253/jcj.54.448; 1993, JAMA-J AM MED ASSOC, V269, P505; 1974, NIH75628 LIP RES CLI; 1993, JAMA-J AM MED ASSOC, V269, P3015	64	423	428	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1666	1671		10.1001/jama.272.21.1666	http://dx.doi.org/10.1001/jama.272.21.1666			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU759	7966894				2022-12-24	WOS:A1994PU75900025
J	BOTTASSO, OA; INGLEDEW, N; KENI, M; MORINI, J; PIVIDORI, JF; ROOK, GAW; STANFORD, JL				BOTTASSO, OA; INGLEDEW, N; KENI, M; MORINI, J; PIVIDORI, JF; ROOK, GAW; STANFORD, JL			CELLULAR IMMUNE-RESPONSE TO COMMON MYCOBACTERIAL ANTIGENS IN SUBJECTS SEROPOSITIVE FOR TRYPANOSOMA-CRUZI	LANCET			English	Note							CHAGAS-DISEASE; TUBERCULOSIS; SUPPRESSION; LEPROSY	The immune response is impaired in the silent stage of Chagas' disease. We used quadruple skin-testing with new tuberculins in 37 adults who were symptom-free but seropositive for Trypanosoma cruzi and in 37 matched seronegative controls. Whereas 19% of controls responded to common mycobacterial antigens, none of the Chagas' seropositive group responded to them (p<0.006), demonstrating specificity in their unresponsiveness. The enhanced tuberculin reactivity after BCG vaccination in the control group was suppressed in seropositive subjects (p<0.002). Selective loss of response to common mycobacterial antigens may have implications for the autoimmune pathology of Chagas' disease, and for susceptibility to tuberculosis, leprosy, and HIV disease.	UCL, SCH MED, DEPT MED MICROBIOL, LONDON W1P 7LD, ENGLAND; UNIV NACL ROSARIO, FAC CIENCIAS MED, DIV INMUNOL, RA-2000 ROSARIO, SANTA FE, ARGENTINA; PROGRAMA PROV LUCHA CONTRA ENFERMADAD CHAGAS, RECONQUISTA, SANTA FE, ARGENTINA	University of London; University College London; UCL Medical School; National University of Rosario				Rook, Graham/0000-0002-8041-8110				BOTTASSO OA, 1982, MEDICINA-BUENOS AIRE, V42, P136; CUNNINGHAM DS, 1980, INFECT IMMUN, V30, P496; HERNANDEZPANDO R, 1994, IMMUNOLOGY, V82, P591; KHOO SH, 1993, 9 INT C AIDS BERL; LOCKWOOD DNJ, 1987, EUR J RESPIR DIS, V71, P348; MOSCA W, 1991, MEM I OSWALDO CRUZ, V86, P147, DOI 10.1590/S0074-02761991000200002; SHIELD MJ, 1977, J HYG-CAMBRIDGE, V78, P331, DOI 10.1017/S0022172400056230; STANFORD JL, 1974, TUBERCLE, V55, P143, DOI 10.1016/0041-3879(74)90008-7; VOLTARELLI JC, 1987, T ROY SOC TROP MED H, V81, P169, DOI 10.1016/0035-9203(87)90324-5; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P4267, DOI 10.1073/pnas.85.12.4267	10	14	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1540	1541		10.1016/S0140-6736(94)90351-4	http://dx.doi.org/10.1016/S0140-6736(94)90351-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983955				2022-12-24	WOS:A1994PV01700011
J	ROSENBLUM, LS; CASTRO, KG; DOOLEY, S; MORGAN, M; COLBERT, G				ROSENBLUM, LS; CASTRO, KG; DOOLEY, S; MORGAN, M; COLBERT, G			EFFECT OF HIV-INFECTION AND TUBERCULOSIS ON HOSPITALIZATIONS AND COST OF CARE FOR YOUNG-ADULTS IN THE UNITED-STATES, 1985 TO 1990	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; INTRAVENOUS DRUG-USERS; CLINICAL-FEATURES; MEDICAL-CARE; OUTBREAK; AIDS; TRANSMISSION; MANAGEMENT; IMPACT	Objective: To evaluate the effect of human immunodeficiency virus (HIV) infection and tuberculosis on hospitalizations and the cost of care. Design: National Hospital Discharge Survey, a nationally representative survey of discharges from U.S. nonfederal short-stay hospitals, and statewide billing information. Patients: Patients 15 to 44 years of age with a listed diagnosis of HIV infection (n = 418 200) or active tuberculosis (n = 77 700) during 1985-1990. Results: During 1985-1990, hospitalizations related to HIV infection increased sixfold, from 18 to 102 per 100 000 persons; during 1988-1990, hospitalizations related to-tuberculosis increased twofold, from 8 to 16 per 100 000 persons. The prevalence of tuberculosis among HIV-infected patients increased from 2.4% in 1985-1988 to 5.1% in 1989-1990 (P = 0.003). The prevalence of HIV infection among patients with tuberculosis increased from 11% in 1985-1988 to 28% in 1989 to 39% in 1990 (P < 0.001). Infection with HIV was more prevalent among patients with extrapulmonary tuberculosis (31%) than among those with pulmonary tuberculosis (18%) (P = 0.01). An increase in the duration of hospital stay was associated with both tuberculosis and HIV infection. From 1985 to 1990, inpatient care costs increased 7.7-fold and 3.2-fold for HIV and tuberculosis hospitalizations, respectively. During this period, HIV and tuberculosis hospitalizations resulted in 5 793 000 and 1 107 900 days of care, respectively, with an estimated direct cost of $5.7 to $7.4 billion and $0.89 to $1.07 billion, respectively. Estimated national costs of inpatient care for HIV infection or tuberculosis or both totaled $6.4 to $8.1 billion, 5% of which was for patients with both HIV infection and tuberculosis. Conclusions: This is the first study to use a nationally representative sample of hospitals, combined with cost data, to estimate hospitalizations and their costs for HIV and tuberculosis care. Our findings suggest that the convergence of the HIV and tuberculosis epidemics has had an increasing effect on morbidity and the cost of care among young adults in the United States. The increasing prevalence of comorbidity of HIV infection and tuberculosis in inpatients underscores the need for strict infection control of tuberculosis on the part of hospitals, increased attention to prevention, and early identification and treatment of HIV infection and tuberculosis to reduce morbidity, hospitalizations, and the cost of care.	CTR DIS CONTROL & PREVENT, DIV HIV AIDS, SURVEILLANCE BRANCH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA			Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				ANDRULIS DP, 1992, JAMA-J AM MED ASSOC, V267, P2482, DOI 10.1001/jama.267.18.2482; ANDRULIS DP, 1989, JAMA-J AM MED ASSOC, V262, P784, DOI 10.1001/jama.262.6.784; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; [Anonymous], 1994, MMWR MORB MORTAL WKL; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BURWEN D, 1993, MAY AM LUNG ASS AM T; Centers for Disease Control and Prevention, 1987, MMWR-MORBID MORTAL W, V36, p1S; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P718; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FARNHAM PG, 1994, IN PRESS READINGS PU; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; HAUPT BJ, 1992, VITAL HLTH STATI 111, V13; HELLINGER FJ, 1991, INQUIRY-J HEALTH CAR, V28, P213; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RAVIGLIONE MC, 1992, B WORLD HEALTH ORGAN, V70, P515; ROSENBLUM L, 1993, AM J PUBLIC HEALTH, V83, P1457, DOI 10.2105/AJPH.83.10.1457; ROSENBLUM LS, 1992, J ACQ IMMUN DEF SYND, V5, P497; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, AIDS, V3, pS201, DOI 10.1097/00002030-198901001-00029; SHAH BY, 1981, SESUDAAN STANDARD ER, P1; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; 1980, DHHS PHS801260 PUB; 1992, TUBERCULOSIS STATIST, P14; 1990, MMWR-MORBID MORTAL W, V39, P110; 1990, MMWR-MORBID MORTAL W, V39, P9; 1993, MMWR-MORBID MORTAL W, V42, P696; 1989, MMWR-MORBID MORTAL W, V38, P243; 1989, AIDS PUBLIC INFORMAT; 1993, MMWR-MORBID MORTAL W, V42, P11; 1989, MMWR-MORBID MORTAL W, V38, P236; 1993, MMWR-MORBID MORTAL W, V42, P703; 1989, CURRENT POPULATI P25, V1044, P13; 1986, SUGI SUPPLEMENTAL LI, P269; 1992, STATISTICAL ABSTRACT, P471	45	40	40	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					786	792		10.7326/0003-4819-121-10-199411150-00009	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944056				2022-12-24	WOS:A1994PQ92800009
J	AMOUYEL, P; VIDAL, O; LAUNAY, JM; LAPLANCHE, JL				AMOUYEL, P; VIDAL, O; LAUNAY, JM; LAPLANCHE, JL			THE APOLIPOPROTEIN-E ALLELES AS MAJOR SUSCEPTIBILITY FACTORS FOR CREUTZFELDT-JAKOB-DISEASE	LANCET			English	Article							FAMILIAL ALZHEIMER-DISEASE; TYPE-4 ALLELE; GENE; REGENERATION; EXPRESSION; RECEPTORS; NERVE	Creutzfeldt-Jakob disease (CJD) is a rapid progressive mental and neurological disorder characterised by dementia and is both infectious and genetic. Pathogenic mutations and a predisposing polymorphism have been described in the prion protein gene and an abnormal prion product accumulates in the brain of affected patients. Apolipoprotein E (APOE), a protein of lipid metabolism, has been detected in some prion protein deposits. This ApoE exists as three common isoforms, coded by specific allele (epsilon 2, epsilon 3, epsilon 4). The presence of at least one epsilon 4 allele was described as a major risk factor for Alzheimer's disease, another neurodegenerative disorder. From a series of 61 patients with CJD we found that epsilon 4 allele of the APOE gene was a risk factor for the disease (p < 0.01). This association was observed in both definite and probable cases, and for patients with and without prion protein gene mutations. Moreover, in affected subjects, epsilon 2 allele of the APOE gene delayed occurrence of death (p < 0.01) independently of other known mutations influencing the phenotype of the disease. These effects on neurodegenerative disease associated with APOE alleles suggest a strong involvement of the APOE locus in brain metabolism.	INST PASTEUR, INSERM, U325, F-59019 LILLE, FRANCE; HOP ST LOUIS, SERV BIOCHIM, PARIS, FRANCE; HOP ST LOUIS, FRA CLAUDE BERNARD, PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	AMOUYEL, P (corresponding author), INST PASTEUR, SERV EPIDEMIOL & SANTE PUBL, 1 RUE CALMETTE, F-59019 LILLE, FRANCE.		LAPLANCHE, Jean-Louis/S-8707-2016	Amouyel, Philippe/0000-0001-9088-234X; LAPLANCHE, Jean-Louis/0000-0003-2836-2903				AMOUYEL P, 1993, LANCET, V342, P1309; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BROUSSEAU T, 1994, NEUROLOGY, V44, P342, DOI 10.1212/WNL.44.2.342; BROWN P, 1991, EUR J EPIDEMIOL, V7, P469, DOI 10.1007/BF00143124; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DIEDRICH JF, 1991, J VIROL, V65, P4759, DOI 10.1128/JVI.65.9.4759-4768.1991; DOHURA K, 1991, NATURE, V353, P801, DOI 10.1038/353801b0; HIXSON JE, 1990, J LIPID RES, V31, P545; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; LAPLANCHE JL, IN PRESS NEUROLOGY; LUC G, 1994, ARTERIOSCLER THROMB, V14, P1412, DOI 10.1161/01.ATV.14.9.1412; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PITAS RE, 1987, J BIOL CHEM, V262, P14352; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1993, ARCH NEUROL-CHICAGO, V50, P1129, DOI 10.1001/archneur.1993.00540110011002; REBECK GW, 1993, NEURON, V11, P575; RIPOLL L, 1993, NEUROLOGY, V43, P1934, DOI 10.1212/WNL.43.10.1934; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SCHELLENBERG GD, 1987, J NEUROGENET, V4, P97, DOI 10.3109/01677068709102337; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P537, DOI 10.1126/science.8290965; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; 1988, SAS P179 SAS I INC T, P49; 1993, LANCET, V342, P737	29	139	145	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	1994	344	8933					1315	1318		10.1016/S0140-6736(94)90691-2	http://dx.doi.org/10.1016/S0140-6736(94)90691-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968026				2022-12-24	WOS:A1994PQ92600007
J	JIANG, XX; KHURSIGARA, G; RUBIN, RL				JIANG, XX; KHURSIGARA, G; RUBIN, RL			TRANSFORMATION OF LUPUS-INDUCING DRUGS TO CYTOTOXIC PRODUCTS BY ACTIVATED NEUTROPHILS	SCIENCE			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; HYDRALAZINE-INDUCED LUPUS; REACTIVE METABOLITES; PROCAINAMIDE; MYELOPEROXIDASE; HYDROXYLAMINE; RAT; PROPYLTHIOURACIL; CHLORPROMAZINE; ERYTHEMATOSUS	Drug-induced lupus is a serious side effect of certain medications, but the chemical features that confer this property and the underlying pathogenesis are puzzling. Prototypes of all six therapeutic classes of lupus-inducing drugs were highly cytotoxic only in the presence of activated neutrophils. Removal of extracellular hydrogen peroxide before, but not after, exposure of the drug to activated neutrophils prevented cytotoxicity. Neutrophil-dependent cytotoxicity required the enzymatic action of myeloperoxidase, resulting in the chemical transformation of the drug to a reactive product. The capacity of drugs to serve as myeloperoxidase substrates in vitro was associated with the ability to induce lupus in vivo.	SCRIPPS RES INST, WM KECK AUTOIMMUNE DIS CTR, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009574] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00833] Funding Source: Medline; NIA NIH HHS [R01 AG09574] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS LE, 1989, J LAB CLIN MED, V113, P482; ADAMS LE, 1993, LUPUS, V2, P89, DOI 10.1177/096120339300200205; ANDREAE WA, 1955, NATURE, V175, P859, DOI 10.1038/175859a0; AUCOIN DP, 1985, J PHARMACOL EXP THER, V234, P13; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BARR DP, 1993, ARCH BIOCHEM BIOPHYS, V303, P377, DOI 10.1006/abbi.1993.1298; BLOMGREN SE, 1973, SEMIN HEMATOL, V10, P345; BRETZ U, 1974, J CELL BIOL, V63, P251, DOI 10.1083/jcb.63.1.251; BUDINSKY RA, 1987, DRUG METAB DISPOS, V15, P37; CAMBRIDGE G, 1994, BRIT J RHEUMATOL, V33, P109; CLARK RA, 1983, ADV INFLAMMAT RES, V5, P107; DIXON M, 1979, ENZYMES, P345; EASTMOND DA, 1990, METHOD ENZYMOL, V186, P579; HARMON CE, 1982, CLIN RHEUM DIS, V8, P121; HEIN DW, 1989, AUTOIMMUNITY TOXICOL, P239; HOFSTRA AH, 1991, J RHEUMATOL, V18, P1673; HOFSTRA AH, 1992, DRUG METAB DISPOS, V20, P205; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; KELDER PP, 1991, CHEM-BIOL INTERACT, V79, P15, DOI 10.1016/0009-2797(91)90049-D; KUBICKAMURANYI M, 1993, TOXICOL APPL PHARM, V122, P88, DOI 10.1006/taap.1993.1175; LAHITA R, 1979, NEW ENGL J MED, V301, P1382, DOI 10.1056/NEJM197912203012506; NAKASHIMA I, 1994, J IMMUNOL, V152, P1064; NASSBERGER L, 1990, CLIN EXP IMMUNOL, V81, P380; NELSON SD, 1981, MOL PHARMACOL, V20, P195; RUBIN RL, 1989, J CLIN INVEST, V83, P1336, DOI 10.1172/JCI114020; RUBIN RL, 1987, J PHARMACOL EXP THER, V242, P833; RUBIN RL, UNPUB; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; SMOLEN JE, 1979, ARTHRITIS ALLIED CON, P282; STREETER AJ, 1983, DRUG METAB DISPOS, V11, P184; UETRECHT JP, 1984, DRUG METAB DISPOS, V12, P77; VANZYL JM, 1989, BIOCHEM PHARMACOL, V38, P2363, DOI 10.1016/0006-2952(89)90477-2; VANZYL JM, 1990, BIOCHEM PHARMACOL, V40, P947, DOI 10.1016/0006-2952(90)90478-4; WALDHAUSER L, 1991, DRUG METAB DISPOS, V19, P354; Weinstein A, 1980, Prog Clin Immunol, V4, P1; WHEELER JF, 1991, DRUG METAB DISPOS, V19, P691; WOODHOUSE KW, 1990, BRIT MED BULL, V46, P22, DOI 10.1093/oxfordjournals.bmb.a072387; WOOSLEY RL, 1978, NEW ENGL J MED, V298, P1157, DOI 10.1056/NEJM197805252982101; Worthington C.C., 1988, WORTHINGTON MANUAL E, P254; YAMAMOTO K, 1991, BIOCHEM PHARMACOL, V41, P905; YUNG RL, 1994, RHEUM DIS CLIN N AM, V20, P61; 1994, US STATES PHARMACOPE, V1, P417	42	185	206	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	1994	266	5186					810	813		10.1126/science.7973636	http://dx.doi.org/10.1126/science.7973636			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973636				2022-12-24	WOS:A1994PP75300042
J	STEEN, N; HUTCHINSON, A; MCCOLL, E; ECCLES, MP; HEWISON, J; MEADOWS, KA; BLADES, SM; FOWLER, P				STEEN, N; HUTCHINSON, A; MCCOLL, E; ECCLES, MP; HEWISON, J; MEADOWS, KA; BLADES, SM; FOWLER, P			DEVELOPMENT OF A SYMPTOM BASED OUTCOME MEASURE FOR ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE; CARE	Measuring symptom specific health outcome is complex, but the methodologies now exist to develop measures with the appropriate properties. As one element of a major programme to develop multidomain health outcome measures for chronic disease, a symptom based measure for asthma care has been developed for use in general practice and outpatient departments. This article outlines the development process, which used a framework recently described in the theoretical literature to show the constraints that scientific criteria place on the development of outcome measures and the means of overcoming such limiting factors. Although substantial effort is required to undertake a rigorous process of development, useful tools are the result. Two five item, symptom based outcome measures for adult asthma are described.	UNIV HULL,DEPT PUBL HLTH MED,KINGSTON HULL,N HUMBERSIDE,ENGLAND; UNIV NEWCASTLE UPON TYNE,CTR HLTH SERV RES,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND; UNIV LEEDS,LEEDS,W YORKSHIRE,ENGLAND	University of Hull; Newcastle University - UK; University of Leeds			Eccles, Martin P/AAD-4029-2020					AITKIN M, 1989, STATISTICAL MODELLIN; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Deyo RA, 1991, CONTROLLED CLIN TRIA, V12, P142; FITZPATRICK R, 1992, BRIT MED J, V305, P1074, DOI 10.1136/bmj.305.6861.1074; Fletcher Astrid, 1992, British Medical Journal, V305, P1145; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; KINSMAN RA, 1973, PSYCHOSOM MED, V35, P250, DOI 10.1097/00006842-197305000-00008; KIRKWOOD BR, 1988, ESSENTIALS MED STATI; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCCOLL AJ, 1993, POPULATION HLTH OUTC; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; PARKERSON GR, 1993, J CLIN EPIDEMIOL, V46, P379, DOI 10.1016/0895-4356(93)90153-R; Streiner DL., 2001, HLTH MEASUREMENT SCA, V2nd; USHERWOOD TP, 1990, ARCH DIS CHILD, V65, P779, DOI 10.1136/adc.65.7.779; WILKIN D, 1992, MEASURES NEED OUTCOM	16	82	84	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1065	1068		10.1136/bmj.309.6961.1065	http://dx.doi.org/10.1136/bmj.309.6961.1065			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN733	7950742	Green Published			2022-12-24	WOS:A1994PN73300027
J	HAUGWITZ, M; NOEGEL, AA; KARAKESISOGLOU, J; SCHLEICHER, M				HAUGWITZ, M; NOEGEL, AA; KARAKESISOGLOU, J; SCHLEICHER, M			DICTYOSTELIUM AMEBAS THAT LACK G-ACTIN-SEQUESTERING PROFILINS SHOW DEFECTS IN F-ACTIN CONTENT, CYTOKINESIS, AND DEVELOPMENT	CELL			English	Article							BOUND ADENOSINE 5'-TRIPHOSPHATE; HEAVY-CHAIN GENE; POLYMORPHONUCLEAR LEUKOCYTES; BINDING-PROTEINS; HOMOLOGOUS RECOMBINATION; MONOCLONAL-ANTIBODIES; CELL MOTILITY; DISCOIDEUM; MYOSIN; THYMOSIN-BETA-4	To study in vivo functions of the ubiquitous actin-binding protein profilin, we generated by antisense and gene disruption techniques Dictyostelium mutants that lack one or both of the profilin isoforms. Whereas the single mutants showed an essentially unchanged phenotype, the behavior of the double mutant was drastically altered. Motility was significantly reduced, single cells were up to 10 times larger than wild-type cells and showed a broad rim of filamentous actin below the plasma membrane, the filamentous actin concentration was increased by about 60%-70%, and development was blocked prior to fruiting body formation. Furthermore, double mutants could not be grown in shaking culture under normal conditions, reflecting an impaired cytokinesis. The aberrant phenotype could be rescued by reintroducing a functional profilin I or profilin II gene. The data in this study suggest that profilin functions in Dictyostelium amoebae primarily as an actin-sequestering protein.	UNIV MUNICH, INST ZELLBIOL, D-80366 MUNICH, GERMANY; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	University of Munich; Max Planck Society								ADAMS AEM, 1993, MOL BIOL CELL, V4, P459, DOI 10.1091/mbc.4.5.459; Brown SS, 1993, CURR OPIN CELL BIOL, V5, P129, DOI 10.1016/S0955-0674(05)80018-3; BUSS F, 1992, CELL MOTIL CYTOSKEL, V22, P51, DOI 10.1002/cm.970220106; CANO ML, 1992, J CELL BIOL, V116, P1123, DOI 10.1083/jcb.116.5.1123; CAO LG, 1992, J CELL BIOL, V117, P1023, DOI 10.1083/jcb.117.5.1023; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; CLAVIEZ M, 1982, EMBO J, V1, P1017, DOI 10.1002/j.1460-2075.1982.tb01287.x; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DHARMAWARDHANE S, 1989, CELL MOTIL CYTOSKEL, V13, P57, DOI 10.1002/cm.970130107; EARLY A, 1988, DEV GENET, V9, P383, DOI 10.1002/dvg.1020090419; EDAMATSU M, 1992, J BIOCHEM-TOKYO, V112, P637, DOI 10.1093/oxfordjournals.jbchem.a123952; EGELHOFF TT, 1989, MOL CELL BIOL, V9, P1965, DOI 10.1128/MCB.9.5.1965; FAIX J, 1992, J CELL SCI, V102, P203; FECHHEIMER M, 1993, J CELL BIOL, V123, P1, DOI 10.1083/jcb.123.1.1; FINKEL T, 1994, P NATL ACAD SCI USA, V91, P1510, DOI 10.1073/pnas.91.4.1510; FISHER PR, 1989, J CELL BIOL, V108, P973, DOI 10.1083/jcb.108.3.973; FUKUI Y, 1993, INT REV CYTOL, V144, P85, DOI 10.1016/S0074-7696(08)61514-4; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GREGG JH, 1982, EXP CELL RES, V142, P229, DOI 10.1016/0014-4827(82)90427-X; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; HARTWIG JH, 1989, J CELL BIOL, V109, P1571, DOI 10.1083/jcb.109.4.1571; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HAUGWITZ M, 1991, J CELL SCI, V100, P481; ISENBERG G, 1991, J MUSCLE RES CELL M, V12, P136, DOI 10.1007/BF01774032; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; MAGDOLEN V, 1993, FEBS LETT, V316, P41, DOI 10.1016/0014-5793(93)81733-G; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; NOEGEL A, 1985, J MOL BIOL, V185, P447, DOI 10.1016/0022-2836(85)90416-4; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PODOLSKI JL, 1990, J BIOL CHEM, V265, P1312; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLENZ RS, 1992, CELL, V69, P951, DOI 10.1016/0092-8674(92)90614-I; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SCHLEICHER M, 1992, NEW BIOL, V4, P461; SCHLEICHER M, 1984, EMBO J, V3, P2095, DOI 10.1002/j.1460-2075.1984.tb02096.x; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965; STAIGER CJ, 1994, CURR BIOL, V4, P215, DOI 10.1016/S0960-9822(00)00050-6; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; VANHAASTERT PJM, 1991, EUR J BIOCHEM, V195, P289; VINSON VK, 1993, J CELL BIOL, V122, P1277, DOI 10.1083/jcb.122.6.1277; WADDELL DR, 1988, DEV GENET, V9, P673, DOI 10.1002/dvg.1020090443; WILCZYNSKA Z, 1994, IN PRESS PLASMID; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS KL, 1976, GENETICS, V82, P287; Witke W., 1993, Molecular Biology of the Cell, V4, p149A; WITKE W, 1987, EMBO J, V6, P4143, DOI 10.1002/j.1460-2075.1987.tb02760.x; WITKE W, 1992, CELL, V68, P53, DOI 10.1016/0092-8674(92)90205-Q; ZARBOCK J, 1990, BIOCHEMISTRY-US, V29, P7814, DOI 10.1021/bi00486a006	72	194	199	2	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					303	314		10.1016/0092-8674(94)90199-6	http://dx.doi.org/10.1016/0092-8674(94)90199-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954798				2022-12-24	WOS:A1994PN63000014
J	DELONG, EF; WU, KY; PREZELIN, BB; JOVINE, RVM				DELONG, EF; WU, KY; PREZELIN, BB; JOVINE, RVM			HIGH ABUNDANCE OF ARCHAEA IN ANTARCTIC MARINE PICOPLANKTON	NATURE			English	Article							MICROBIAL ECOLOGY; RIBOSOMAL-RNA; DIVERSITY; ARCHAEBACTERIA; EVOLUTION	ARCHAEA (archaebacteria) constitute one of the three major evolutionary lineages of life on Earth(1-3). Previously these prokaryotes were thought to predominate in only a few unusual and disparate niches, characterized by hypersaline, extremely hot, or strictly anoxic conditions(4-7). Recently, novel (uncultivated) phylotypes of Archaea have been detected in coastal(8) and subsurface(9,10) marine waters, but their abundance, distribution, physiology and ecology remain largely undescribed. Here we report exceptionally high archaeal abundance in frigid marine surface waters of Antarctica. Pelagic Archaea constituted up to 34% of the prokaryotic biomass in coastal Antarctic surface waters, and they were also abundant in a variety of other cold, pelagic marine environments. Because they can make up a significant fraction of picoplankton biomass in the vast habitats encompassed by cold and deep marine waters, these pelagic Archaea represent an unexpectedly abundant component of the Earth's biota.			DELONG, EF (corresponding author), UNIV CALIF SANTA BARBARA,DEPT BIOL,DIV ECOL EVOLUT & MARINE BIOL,SANTA BARBARA,CA 93106, USA.							BARNS SM, 1994, P NATL ACAD SCI USA, V91, P1609, DOI 10.1073/pnas.91.5.1609; DELONG EF, 1992, P NATL ACAD SCI USA, V89, P5585; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; FUHRMAN JA, 1992, NATURE, V356, P148, DOI 10.1038/356148a0; FUHRMAN JA, 1993, APPL ENVIRON MICROB, V59, P1294, DOI 10.1128/AEM.59.5.1294-1302.1993; GIOVANNONI SJ, 1990, NATURE, V345, P60, DOI 10.1038/345060a0; HUBER R, 1990, NATURE, V345, P179, DOI 10.1038/345179a0; JONES WJ, 1987, MICROBIOL REV, V51, P135, DOI 10.1128/MMBR.51.1.135-177.1987; LARSEN N, 1993, NUCLEIC ACIDS RES, V21, P2021; MEDLIN L, 1988, GENE, V71, P491, DOI 10.1016/0378-1119(88)90066-2; OLSEN GJ, 1986, ANNU REV MICROBIOL, V40, P337, DOI 10.1146/annurev.mi.40.100186.002005; OLSEN GJ, 1993, FASEB J, V7, P113, DOI 10.1096/fasebj.7.1.8422957; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; RASKIN L, 1994, APPL ENVIRON MICROB, V60, P1232, DOI 10.1128/AEM.60.4.1232-1240.1994; SAKAI RK, 1988, SCIENCE, V239, P487; Stahl D.A., 1991, NUCL ACID TECHNIQUES, P205; STAHL DA, 1988, APPL ENVIRON MICROB, V54, P1079, DOI 10.1128/AEM.54.5.1079-1084.1988; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; STETTER KO, 1993, NATURE, V365, P743, DOI 10.1038/365743a0; TINDALL BJ, 1992, PROKARYOTES HDB BIOL, P768; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOESE CR, 1994, MICROBIOL REV, V58, P1; [No title captured]	24	424	446	1	58	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					695	697		10.1038/371695a0	http://dx.doi.org/10.1038/371695a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935813				2022-12-24	WOS:A1994PM77300053
J	ROBERTS, SGE; GREEN, MR				ROBERTS, SGE; GREEN, MR			ACTIVATOR-INDUCED CONFORMATIONAL CHANGE IN GENERAL TRANSCRIPTION FACTOR TFIIB	NATURE			English	Article							RNA POLYMERASE-II; FUNCTIONAL DOMAINS; DNA-BINDING	TRANSCRIPTIONAL activator proteins (activators) function, at least in part, by increasing preinitiation complex assembly (for reviews see refs 1-4). Previous studies have shown that an acidic activator forms a contact with the general transcription factor TFIIB (refs 5-7) and recruits it into the preinitiation complex(5,8,9). Mutational studies indicate that this interaction between the acidic activator and TFIIB is required for transcriptional stimulation(5-7,10,11). We show here that the acidic activator-TFIIB interaction has an additional function in preinitiation complex assembly. We provide evidence that in native TFIIB the amino- and carboxy-terminal domains are engaged in an intramolecular interaction. The acidic activator disrupts this intramolecular interaction to expose binding sites for general transcription factors that enter the preinitiation complex through association with TFIIB. Thus, the acidic activator induces a conformational change in TFIIB that drives preinitiation complex assembly forward.			ROBERTS, SGE (corresponding author), UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605, USA.		Roberts, Stefan GE/R-5537-2016	Roberts, Stefan GE/0000-0002-7535-6365				BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; JIANG Y, 1994, J BIOL CHEM, V269, P5505; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KINGSTON RE, 1994, CURR BIOL, V4, P325, DOI 10.1016/S0960-9822(00)00071-3; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	24	155	158	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					717	720		10.1038/371717a0	http://dx.doi.org/10.1038/371717a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935820				2022-12-24	WOS:A1994PM77300061
J	SMITH, DK; SHAW, RW; MARTEAU, TM				SMITH, DK; SHAW, RW; MARTEAU, TM			INFORMED CONSENT TO UNDERGO SERUM SCREENING FOR DOWNS-SYNDROME - THE GAP BETWEEN POLICY AND PRACTICE	BRITISH MEDICAL JOURNAL			English	Article									UNITED MED & DENT SCH,PSYCHOL & GENET RES GRP,LONDON SE1 9RT,ENGLAND; UNIV WALES COLL MED,CARDIFF CF4 4XN,S GLAM,WALES	University of London; King's College London; Cardiff University				Marteau, Theresa/0000-0003-3025-1129	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		MARTEAU TM, 1992, PUBLIC HEALTH, V106, P131, DOI 10.1016/S0033-3506(05)80390-7; ROUND A, 1993, BRIT MED J, V307, P1211, DOI 10.1136/bmj.307.6913.1211-c; SMITH DK, IN PRESS PRENAT DIAG; Weinman J, 1988, TOPICS HLTH PSYCHOL, P205; 1993, REPORT RCOG WORKING	5	89	89	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					776	776		10.1136/bmj.309.6957.776	http://dx.doi.org/10.1136/bmj.309.6957.776			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PJ282	7950565	Green Published			2022-12-24	WOS:A1994PJ28200022
J	BOUVET, P; WOLFFE, AP				BOUVET, P; WOLFFE, AP			A ROLE FOR TRANSCRIPTION AND FRGY2 IN MASKING MATERNAL MESSENGER-RNA WITHIN XENOPUS-OOCYTES	CELL			English	Article							RNA-BINDING-PROTEINS; MESSENGER-RIBONUCLEOPROTEIN PARTICLES; HISTONE GENE CLUSTERS; POLYMERASE-III; LAEVIS OOCYTES; TRANSLATION; NUCLEAR; EMBRYOS; DNA; IDENTIFICATION	We find that mRNA synthesized within the Xenopus oocyte nucleus is translated with an efficiency 50 times less than that of mRNA injected into the oocyte cytoplasm. For histone H1 mRNA this effect is independent of mRNA splicing, nuclear export, and the promoter driving transcription. The mRNA synthesized in vivo is translationally competent but is masked from the translational machinery in the cytoplasm through association with proteins including frog Y-box protein 2 (FRGY2). We find that overexpression of FRGY2 facilitates the translational repression of mRNA synthesized within Xenopus oocytes. The requirement for transcription to occur in vivo before a translationally repressed state can be established suggests that these two events are functionally coupled in Xenopus oocytes.			BOUVET, P (corresponding author), NICHHD, MOLEC EMBRYOL LAB, BETHESDA, MD 20892 USA.		, Bouvet/AAC-8779-2020	Bouvet, Philippe/0000-0003-4524-2233				ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; ANDREWS MT, 1987, CELL, V51, P445, DOI 10.1016/0092-8674(87)90640-4; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BIENZ M, 1984, EMBO J, V3, P2477, DOI 10.1002/j.1460-2075.1984.tb02159.x; BOUVET P, 1994, MOL CELL BIOL, V14, P1893, DOI 10.1128/MCB.14.3.1893; BRADDOCK M, 1990, CELL, V62, P1123, DOI 10.1016/0092-8674(90)90389-V; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CALDWELL DC, 1985, CELL, V42, P691, DOI 10.1016/0092-8674(85)90126-6; CHO H, 1994, IN PRESS GENE; CRAWFORD DR, 1987, DEVELOPMENT, V101, P741; DARNBROUGH CH, 1981, EUR J BIOCHEM, V113, P415, DOI 10.1111/j.1432-1033.1981.tb05081.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; DELAPENA P, 1987, CELL, V50, P613, DOI 10.1016/0092-8674(87)90034-1; DESCHAMPS S, 1991, FEBS LETT, V282, P110, DOI 10.1016/0014-5793(91)80456-D; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DWORKIN MB, 1985, P NATL ACAD SCI USA, V82, P7636, DOI 10.1073/pnas.82.22.7636; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HARFORD JB, 1990, ENZYME, V44, P28, DOI 10.1159/000468745; HARLAND R, 1988, DEVELOPMENT, V102, P837; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JANSENDURR P, 1992, NUCLEIC ACIDS RES, V20, P1243, DOI 10.1093/nar/20.6.1243; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; MARELLO K, 1992, NUCLEIC ACIDS RES, V20, P5593, DOI 10.1093/nar/20.21.5593; MUNROE SH, 1992, P NATL ACAD SCI USA, V89, P895, DOI 10.1073/pnas.89.3.895; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; OLD RW, 1982, NUCLEIC ACIDS RES, V10, P7561, DOI 10.1093/nar/10.23.7561; OSBORNE HB, 1991, EUR J BIOCHEM, V202, P575, DOI 10.1111/j.1432-1033.1991.tb16410.x; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PERRY M, 1985, J MOL BIOL, V185, P479, DOI 10.1016/0022-2836(85)90065-8; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; RICHTER JD, 1988, TRENDS BIOCHEM SCI, V13, P483, DOI 10.1016/0968-0004(88)90236-8; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; RUDERMAN JV, 1979, DEV BIOL, V71, P71, DOI 10.1016/0012-1606(79)90083-6; SOMMERVILLE J, 1993, J CELL BIOL, V120, P277, DOI 10.1083/jcb.120.2.277; Spirin A. S., 1966, Current Topics in Developmental Biology, V1, P1; SPIRIN AS, 1969, EUR J BIOCHEM, V10, P20; Standart Nancy, 1992, Seminars in Developmental Biology, V3, P367; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; STRICKLAND S, 1988, SCIENCE, V241, P680, DOI 10.1126/science.2456615; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; WOODLAND HR, 1979, CELL, V18, P165, DOI 10.1016/0092-8674(79)90365-9; WORMINGTON M, 1991, METHOD CELL BIOL, V36, P167	70	175	183	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					931	941		10.1016/0092-8674(94)90141-4	http://dx.doi.org/10.1016/0092-8674(94)90141-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004679				2022-12-24	WOS:A1994NT33100017
J	PHILLIPS, DM				PHILLIPS, DM			ENTEROCOCCUS-FAECALIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PHILLIPS, DM (corresponding author), POPULAT COUNCIL,1230 YORK AVE,NEW YORK,NY 10021, USA.								0	0	0	2	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					26	26		10.1056/NEJM199501053320105	http://dx.doi.org/10.1056/NEJM199501053320105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990862				2022-12-24	WOS:A1995PZ49700005
J	JOHNSON, RL; LAUFER, E; RIDDLE, RD; TABIN, C				JOHNSON, RL; LAUFER, E; RIDDLE, RD; TABIN, C			ECTOPIC EXPRESSION OF SONIC HEDGEHOG ALTERS DORSAL-VENTRAL PATTERNING OF SOMITES	CELL			English	Article							FLOOR PLATE; CHICK-EMBRYO; CELL PATTERN; NEURAL-TUBE; DIFFERENTIATION; NOTOCHORD; SIGNALS; GENE; MORPHOGENESIS; SPECIFICATION	Differentiation of somites into sclerotome, dermatome, and myotome is controlled by a complex set of inductive interactions. The ability of axial midline tissues, the notochord and floor plate, to induce sclerotome has been well documented and has led to models in which ventral somite identity is specified by signals derived from the notochord and floor plate. Herein, we provide evidence that Sonic hedgehog, a vertebrate homolog of the Drosophila segment polarity gene hedgehog, is a signal produced by the notochord and floor plate that directs ventral somite differentiation. Sonic hedgehog is expressed in ventral midline tissues at critical times during somite specification and has the ability, when ectopically expressed, to enhance the formation of sclerotome and antagonize the development of dermatome.			JOHNSON, RL (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.			Laufer, Edward/0000-0002-4933-1017				AOYAMA H, 1988, DEVELOPMENT, V104, P15; BOBER E, 1994, DEVELOPMENT, V120, P603; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; BUFFINGER N, 1994, DEVELOPMENT, V120, P1443; CHRIST B, 1992, ANAT EMBRYOL, V186, P505; DANTO SI, 1984, J CELL BIOL, V98, P2179, DOI 10.1083/jcb.98.6.2179; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DIETRICH S, 1993, MECH DEVELOP, V44, P189, DOI 10.1016/0925-4773(93)90067-8; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FAN CM, 1994, CELL, V79; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; Gallera J., 1966, Revue Suisse de Zoologie, V73, P492; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; JACOB H J, 1974, Verhandlungen der Anatomischen Gesellschaft, V68, P581; JEFFS P, 1992, ANAT EMBRYOL, V185, P589; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KENNYMOBBS T, 1987, DEVELOPMENT, V100, P449; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOSEKI H, 1993, DEVELOPMENT, V119, P649; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; ORDAHL CP, 1993, MOL BASIS MORPHOGENE, P165; PACKARD DS, 1976, DEV BIOL, V53, P36, DOI 10.1016/0012-1606(76)90207-4; PLACZEK M, 1993, DEVELOPMENT, V117, P205; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RONG PM, 1992, DEVELOPMENT, V115, P657; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; TAM PPL, 1994, ANAT EMBRYOL, V189, P275; THEILER K, 1988, ADV ANAT EMBRYOL CEL, V112, P1; WATTERSON RL, 1954, AM J ANAT, V95, P337, DOI 10.1002/aja.1000950302; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	46	380	406	0	12	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 30	1994	79	7					1165	1173		10.1016/0092-8674(94)90008-6	http://dx.doi.org/10.1016/0092-8674(94)90008-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001152				2022-12-24	WOS:A1994PZ86000008
J	LAUFER, E; NELSON, CE; JOHNSON, RL; MORGAN, BA; TABIN, C				LAUFER, E; NELSON, CE; JOHNSON, RL; MORGAN, BA; TABIN, C			SONIC HEDGEHOG AND FGF-4 ACT THROUGH A SIGNALING CASCADE AND FEEDBACK LOOP TO INTEGRATE GROWTH AND PATTERNING OF THE DEVELOPING LIMB BUD	CELL			English	Article							APICAL ECTODERMAL RIDGE; POLARITY GENE HEDGEHOG; RETROVIRAL VECTORS; HOX-4 GENES; EXPRESSION; CELLS; ACTIVATION; HOMOLOG	Proper limb growth and patterning requires signals from the zone of polarizing activity in the posterior mesoderm and from the overlying apical ectodermal ridge (AER). Sonic hedgehog and Fgf-4, respectively, have recently been identified as candidates for these signals. We have dissected the roles of these secreted proteins in early limb development by ectopically regulating their activities in a number of surgical contexts. Our results indicate that Sonic hedgehog initiates expression of secondary signaling molecules, including Bmp-2 in the mesoderm and Fgf-4 in the ectoderm. The mesoderm requires ectodermally derived competence factors, which include Fgf-4, to activate target gene expression in response to Sonic hedgehog. The expression of Sonic hedgehog and Fgf-4 is coordinately regulated by a positive feedback loop operating between the posterior mesoderm and the overlying AER. Taken together, these data provide a basis for understanding the integration of growth and patterning in the developing limb.			LAUFER, E (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.			Laufer, Edward/0000-0002-4933-1017				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON R, 1993, DEVELOPMENT, V117, P1421; Ausubel F, 1989, MOL REPROD DEV, V1, P146; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CORNELL RA, 1994, DEVELOPMENT, V120, P453; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; FIETZ M, 1995, IN PRESS DEVELOPME S; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GERARD M, 1993, EMBO J, V12, P3539, DOI 10.1002/j.1460-2075.1993.tb06028.x; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IZPISUABELMONTE JC, 1992, EMBO J, V11, P1451, DOI 10.1002/j.1460-2075.1992.tb05189.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KOYAMA E, 1993, PROG CLIN BIOL RES, V383, P51; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LABONNE C, 1994, DEVELOPMENT, V120, P463; LAUFER E, 1993, CURR BIOL, V3, P306, DOI 10.1016/0960-9822(93)90187-S; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MACCABE JA, 1979, J EMBRYOL EXP MORPH, V53, P67; MAVILIO F, 1988, DIFFERENTIATION, V37, P73, DOI 10.1111/j.1432-0436.1988.tb00798.x; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RILEY BB, 1993, DEVELOPMENT, V118, P95; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; TICKLE C, 1991, DEVELOPMENT, P113; TODT WL, 1987, DEVELOPMENT, V101, P501; VOGEL A, 1993, DEVELOPMENT, V119, P199; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	48	708	730	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 16	1994	79	6					993	1003		10.1016/0092-8674(94)90030-2	http://dx.doi.org/10.1016/0092-8674(94)90030-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001146				2022-12-24	WOS:A1994PY08600009
J	ZANARIA, E; MUSCATELLI, F; BARDONI, B; STROM, TM; GUIOLI, S; GUO, WW; LALLI, E; MOSER, C; WALKER, AP; MCCABE, ERB; MEITINGER, T; MONACO, AP; SASSONECORSI, P; CAMERINO, G				ZANARIA, E; MUSCATELLI, F; BARDONI, B; STROM, TM; GUIOLI, S; GUO, WW; LALLI, E; MOSER, C; WALKER, AP; MCCABE, ERB; MEITINGER, T; MONACO, AP; SASSONECORSI, P; CAMERINO, G			AN UNUSUAL MEMBER OF THE NUCLEAR HORMONE-RECEPTOR SUPERFAMILY RESPONSIBLE FOR X-LINKED ADRENAL HYPOPLASIA CONGENITA	NATURE			English	Article							COUP TRANSCRIPTION FACTOR; DNA-BINDING DOMAINS; RETINOIC ACID; GENE SUPERFAMILY; GLYCEROL KINASE; GENOMIC ORGANIZATION; EXPRESSION; CLONING; PROTEIN; XP21	X-linked adrenal hypoplasia congenita is a developmental disorder of the human adrenal gland that results in profound hormonal deficiencies and is,lethal if untreated. We have isolated the gene responsible for the disease, DAX-1, which is deleted or mutated in X-linked adrenal hypoplasia patients. DAX-1 encodes a new member of the nuclear hormone receptor superfamily displaying a novel DNA-binding domain. The DAX-1 product acts as a dominant negative regulator of transcription mediated by the retinoic acid receptor.	UNIV PAVIA,I-27100 PAVIA,ITALY; JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND; LMU,KINDERPOLIKLIN,PADIAT GENET ABT,D-80336 MUNICH,GERMANY; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; ULP,CNRS,INSERM,INST GENET & BIOL MOLEC CELLULAIRE,IGBMC,F-67404 ILLKIRCH GRAFFENS,FRANCE; UNIV SASSARI,IST ISTOL & EMBRIOL,I-07100 SASSARI,ITALY	University of Pavia; Cancer Research UK; University of Oxford; University of Munich; Baylor College of Medicine; Baylor College of Medicine; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Sassari			Lalli, Enzo/F-7052-2013; Bardoni, Barbara/F-9918-2013; Monaco, Anthony P/A-4495-2010; Muscatelli, Françoise/P-4650-2016; Walker, Ann P/C-1628-2008; Moser, Claudio/B-4686-2010	Lalli, Enzo/0000-0002-0584-5681; Monaco, Anthony P/0000-0001-7480-3197; Muscatelli, Françoise/0000-0003-4001-6528; Moser, Claudio/0000-0002-9141-7850; Meitinger, Thomas/0000-0002-8838-8403; Bardoni, Barbara/0000-0001-6411-1517; Guioli, Silvana/0000-0002-4920-7745	Telethon [B.05] Funding Source: Medline	Telethon(Fondazione Telethon)		BALLABIO A, 1990, GENOMICS, V8, P263, DOI 10.1016/0888-7543(90)90281-X; BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; GOONEWARDENA P, 1989, CLIN GENET, V35, P5; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Kastner P., 1994, Vitamin A in health and disease., P189; Kelch RP, 1984, PEDIATR ADOLESC ENDO, V13, P156; KLETTER GB, 1991, TRENDS ENDOCRIN MET, V2, P123, DOI 10.1016/1043-2760(91)90001-4; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIU C, 1992, MOL ENDOCRIN, V7, P651; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Martin M.M., 1985, INT J ADOLESC MED HL, V1, P119; MATHARU PJ, 1992, BIOCHIM BIOPHYS ACTA, V1129, P331, DOI 10.1016/0167-4781(92)90512-X; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; McKusick V.A., 1992, MENDELIAN INHERITANC; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; Sambrook J., 1989, MOL CLONING LAB MANU; STEPHEN F, 1990, J MOL BIOL, V215, P403, DOI DOI 10.1006/JMBI.1990.9999; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANDERLEEDE BM, 1992, BIOCHEM BIOPH RES CO, V188, P695, DOI 10.1016/0006-291X(92)91112-4; WALKER AP, 1992, HUM MOL GENET, V1, P579, DOI 10.1093/hmg/1.8.579; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WORLEY KC, 1992, GENOMICS, V13, P957, DOI 10.1016/0888-7543(92)90007-F; WORLEY KC, 1993, GENOMICS, V16, P407, DOI 10.1006/geno.1993.1204	45	691	720	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					635	641		10.1038/372635a0	http://dx.doi.org/10.1038/372635a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990953				2022-12-24	WOS:A1994PX30700075
J	GORLICH, D; PREHN, S; LASKEY, RA; HARTMANN, E				GORLICH, D; PREHN, S; LASKEY, RA; HARTMANN, E			ISOLATION OF A PROTEIN THAT IS ESSENTIAL FOR THE FIRST STEP OF NUCLEAR-PROTEIN IMPORT	CELL			English	Article							GTP-BINDING PROTEIN; 2 STEPS; SEQUENCE; PORE; TRANSLOCATION; IDENTIFICATION; LOCALIZATION; REPLICATION; ENVELOPE; SIGNALS	We have purified a cytosolic protein from Xenopus eggs that is essential for selective protein import into the cell nucleus. The purified protein, named importin, promotes signal-dependent binding of karyophilic proteins to the nuclear envelope. We have cloned, sequenced, and expressed a corresponding cDNA. Importin shows 44% sequence identity with SRP1p, a protein associated with the yeast nuclear pore complex. Complete, signal-dependent import into HeLa nuclei can be reconstituted by combining importin purified from Xenopus eggs or expressed in E. coli with Ran/TC4. Evidence for additional stimulatory factors is provided.	UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND; HUMBOLDT UNIV BERLIN, INST BIOCHEM, D-10115 BERLIN, GERMANY; MAX DELBRUCK CTR MOLEC MED, D-13125 BERLIN, GERMANY	University of Cambridge; Humboldt University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	GORLICH, D (corresponding author), WELLCOME CRC INST, TENNIS COURT RD, CAMBRIDGE CB2 1QR, ENGLAND.		Hartmann, Enno/C-5687-2013; Görlich, Dirk/B-8296-2017	Görlich, Dirk/0000-0002-4343-5210	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; DUPREE P, 1992, GENE, V120, P325, DOI 10.1016/0378-1119(92)90118-9; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FABRE E, 1994, CURR OPIN CELL BIOL, V6, P335, DOI 10.1016/0955-0674(94)90023-X; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; LENO GH, 1991, METHOD CELL BIOL, V36, P561; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NEWMEYER DD, 1990, J CELL BIOL, V110, P547, DOI 10.1083/jcb.110.3.547; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Yamasaki L, 1992, Trends Cell Biol, V2, P123, DOI 10.1016/0962-8924(92)90083-Y; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	33	627	635	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					767	778		10.1016/0092-8674(94)90067-1	http://dx.doi.org/10.1016/0092-8674(94)90067-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001116				2022-12-24	WOS:A1994PW05400005
J	SUN, XH				SUN, XH			CONSTITUTIVE EXPRESSION OF THE ID1 GENE IMPAIRS MOUSE B-CELL DEVELOPMENT	CELL			English	Article							NF-KAPPA-B; IMMUNOGLOBULIN LIGHT CHAIN; DNA-BINDING SUBUNIT; LOOP-HELIX PROTEINS; HEAVY-CHAIN; BONE-MARROW; TARGETED DISRUPTION; V(D)J RECOMBINATION; MEMBRANE EXON; TRANSCRIPTION	The Id proteins are inhibitors of the basic-helix-loop-helix (bHLH) transcription factors. In the B cell lineage, the Id1 and Id2 genes are expressed in pro-B cells and down-regulated during differentiation. To determine the role of bHLH proteins and the significance of downregulation of ld genes in B cell development, transgenic mice constitutively expressing the Id1 gene were generated. Their phenotype suggests that B cell development is impaired at an early stage. Primarily, these mice have few B220(+) IgM(+) mature B or B220(+) CD43(-) pre-B cells in the bone marrow, reduced frequencies of V(D)J and V(kappa)J(kappa) recombination of the immunoglobulin loci, and lower expression levels of the immunoglobulin, RAG-1, RAG-2, and lambda 5 genes.			SUN, XH (corresponding author), NYU,MED CTR,KAPLAN COMPREHENSIVE CANC CTR,DEPT CELL BIOL,NEW YORK,NY 10016, USA.							ALESSANDRINI A, 1991, MOL CELL BIOL, V11, P2096, DOI 10.1128/MCB.11.4.2096; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Blackwell T. K., 1988, Molecular Immunology., P1; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; HARA E, 1994, J BIOL CHEM, V269, P2139; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P678, DOI 10.1093/nar/18.3.678; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; IGLESIAS A, 1991, EMBO J, V10, P2147, DOI 10.1002/j.1460-2075.1991.tb07749.x; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MISENER V, 1991, INT IMMUNOL, V3, P1129, DOI 10.1093/intimm/3.11.1129; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHLISSEL MS, 1994, J IMMUNOL, V153, P1645; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SHAPIRO AM, 1993, MOL CELL BIOL, V13, P5679, DOI 10.1128/MCB.13.9.5679; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; SU LK, 1990, MOL CELL BIOL, V10, P2619, DOI 10.1128/MCB.10.6.2619; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; XIN XQ, 1993, J IMMUNOL, V151, P5398; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	57	250	255	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 2	1994	79	5					893	900		10.1016/0092-8674(94)90078-7	http://dx.doi.org/10.1016/0092-8674(94)90078-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001126				2022-12-24	WOS:A1994PW05400016
J	MOSER, RH				MOSER, RH			ASPARTAME AND MEMORY LOSS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											MOSER, RH (corresponding author), UNIV NEW MEXICO,SCH MED,ALBUQUERQUE,NM 87131, USA.							TOLLEFSON L, 1993, REGUL TOXICOL PHARM, V18, P32, DOI 10.1006/rtph.1993.1042	1	10	10	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1543	1543						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966850				2022-12-24	WOS:A1994PQ90000037
J	STAMLER, JF				STAMLER, JF			THE SILENT MAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1475	1475						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966826				2022-12-24	WOS:A1994PQ90000001
J	KESSLER, F; BLOBEL, G; PATEL, HA; SCHNELL, DJ				KESSLER, F; BLOBEL, G; PATEL, HA; SCHNELL, DJ			IDENTIFICATION OF 2 GTP-BINDING PROTEINS IN THE CHLOROPLAST PROTEIN IMPORT MACHINERY	SCIENCE			English	Article							PRECURSOR PROTEINS; SEQUENCE-ANALYSIS; ENVELOPE; LOCALIZATION; MEMBRANES; REQUIRES; PATHWAY	Two of four proteins that associated with translocation intermediates during protein import across the outer chloroplast envelope membrane were identified as guanosine triphosphate (GTP)-binding proteins. Both proteins are integral membrane proteins of the outer chloroplast membrane, and both are partially exposed on the chloroplast surface where they were accessible to thermolysin digestion. Engagement of the outer membrane's import machinery by an import substrate was inhibited by slowly hydrolyzable or non-hydrolyzable GTP analogs. Thus, these GTP-binding proteins may function in protein import into chloroplasts.	RUTGERS STATE UNIV,DEPT BIOL SCI,NEWARK,NJ 07102; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021	Rutgers State University Newark; Rutgers State University New Brunswick; Howard Hughes Medical Institute; Rockefeller University			Kessler, Felix Henrique/AAO-1722-2020	Kessler, Felix/0000-0001-6409-5043				ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; MARSTON FAO, 1987, DNA CLONING PRACTICA, V3; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNELL D, UNPUB; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1994, SCIENCE, V266, P100; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x	22	251	264	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1035	1039		10.1126/science.7973656	http://dx.doi.org/10.1126/science.7973656			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973656				2022-12-24	WOS:A1994PQ92400042
J	SCHUMACHER, MA; CHOI, KY; ZALKIN, H; BRENNAN, RG				SCHUMACHER, MA; CHOI, KY; ZALKIN, H; BRENNAN, RG			CRYSTAL-STRUCTURE OF LACI MEMBER, PURR, BOUND TO DNA - MINOR-GROOVE BINDING BY ALPHA-HELICES	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ESCHERICHIA-COLI; REPRESSOR PROTEIN; NUCLEOTIDE-SEQUENCE; REGULATORY PROTEINS; MOLECULAR-DYNAMICS; PURINE REPRESSOR; ACID INTERACTION; OPERATOR; GENE	The three-dimensional structure of a ternary complex of the purine repressor, PurR, bound to both its corepressor, hypoxanthine, and the 16-base pair purF operator site has been solved at 2.7 Angstrom resolution by x-ray crystallography. The bipartite Structure of PurR consists of an amino-terminal DNA-binding domain and a larger carboxyl-terminal corepressor binding and dimerization domain that is similar to that of the bacterial periplasmic binding proteins. The DNA-binding domain contains alpha helix-turn-helix motif that makes base-specific contacts in the major groove of the DNA. Base contacts are also made by residues of symmetry-related a helices, the ''hinge'' helices, which bind deeply in the minor groove, Critical to hinge helix-minor groove binding is the intercalation of the side chains of Leu(54) and its symmetry-related mate, Leu(54'), into the central CpG-base pair step. These residues thereby act as ''leucine levers'' to pry open the minor groove and kink the purF operator by 45 degrees.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Oregon Health & Science University; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Brennan, Richard/0000-0001-7647-485X	NIGMS NIH HHS [GM 24658, GM 49244] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024658, R37GM024658, R01GM049244] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; ALBERTI S, 1991, NEW BIOL, V3, P57; BARBIER CS, 1992, J BACTERIOL, V174, P2881, DOI 10.1128/JB.174.9.2881-2890.1992; BARKLEY MD, 1974, NATURE, V251, P247, DOI 10.1038/251247a0; BIN H, 1993, J BACTERIOL, V175, P3598, DOI 10.1128/jb.175.11.3598-3606.1993; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; Brennan RG, 1991, CURR OPIN STRUC BIOL, V1, P80, DOI 10.1016/0959-440X(91)90015-L; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG WI, 1994, BIOCHEMISTRY-US, V33, P3607, DOI 10.1021/bi00178a018; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; CHOI KY, 1994, J BIOL CHEM, V269, P24066; CHOI KY, 1994, J BACTERIOL, V176, P1767, DOI 10.1128/jb.176.6.1767-1772.1994; CHUPRINA VP, 1993, J MOL BIOL, V234, P446, DOI 10.1006/jmbi.1993.1598; CORTAY JC, 1994, J BIOL CHEM, V269, P14885; GORDON AJE, 1988, J MOL BIOL, V200, P239, DOI 10.1016/0022-2836(88)90237-9; GRALLA JD, 1992, TRANSCRIPTIONAL REGU, V2, P629; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HE B, 1990, J BACTERIOL, V172, P4555, DOI 10.1128/jb.172.8.4555-4562.1990; HE B, 1994, J BACTERIOL, V176, P1009, DOI 10.1128/JB.176.4.1009-1013.1994; HE B, 1992, J BACTERIOL, V174, P130, DOI 10.1128/jb.174.1.130-136.1992; HE B, 1992, J BACTERIOL, V174, P7121, DOI 10.1128/jb.174.22.7121-7127.1992; HSIEH M, 1994, J BIOL CHEM, V269, P13825; JAENICKE R, 1990, FEBS LETT, V260, P233, DOI 10.1016/0014-5793(90)80111-U; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAPTEIN R, 1985, J MOL BIOL, V182, P179, DOI 10.1016/0022-2836(85)90036-1; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LAMERICHS RMJN, 1989, BIOCHEMISTRY-US, V28, P2985, DOI 10.1021/bi00433a037; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LEHMING N, 1988, P NATL ACAD SCI USA, V85, P7947, DOI 10.1073/pnas.85.21.7947; LU FH, UNPUB; MARKIEWICZ P, 1994, J MOL BIOL, V240, P421, DOI 10.1006/jmbi.1994.1458; MAUZY CA, 1992, PROTEIN SCI, V1, P843, DOI 10.1002/pro.5560010702; MENG LM, 1990, EUR J BIOCHEM, V187, P373, DOI 10.1111/j.1432-1033.1990.tb15314.x; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; NICHOLS JC, 1993, J BIOL CHEM, V268, P17602; OH BH, 1993, J BIOL CHEM, V268, P11348; OLAH GA, 1993, J BIOL CHEM, V268, P16241; ORNSTEIN RL, 1978, BIOPOLYMERS, V17, P2341, DOI 10.1002/bip.1978.360171005; PABO CO, 1990, SCIENCE, V247, P1210, DOI 10.1126/science.2315694; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; RAVISHANKER G, 1989, J BIOMOL STRUCT DYN, V6, P669, DOI 10.1080/07391102.1989.10507729; ROLFES RJ, 1988, J BIOL CHEM, V263, P19653; ROLFES RJ, 1990, J BACTERIOL, V172, P5758, DOI 10.1128/jb.172.10.5758-5766.1990; SADLER JR, 1983, P NATL ACAD SCI-BIOL, V80, P6785, DOI 10.1073/pnas.80.22.6785; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1994, J MOL BIOL, V242, P302, DOI 10.1006/jmbi.1994.1580; SCHUMACHER MA, 1993, J BIOL CHEM, V268, P12282; SCHUMACHER MA, UNPUB; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SIMONS A, 1984, P NATL ACAD SCI-BIOL, V81, P1624, DOI 10.1073/pnas.81.6.1624; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SPOTTS RO, 1991, J BIOL CHEM, V266, P22998; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TRAVERS AA, 1992, CURR OPIN STRUC BIOL, V2, P71; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VARTAK NB, 1991, RES MICROBIOL, V142, P951, DOI 10.1016/0923-2508(91)90005-U; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4; ZUIDERWEG ERP, 1983, P NATL ACAD SCI-BIOL, V80, P5837, DOI 10.1073/pnas.80.19.5837; ZWIEB C, 1989, GENE DEV, V3, P606, DOI 10.1101/gad.3.5.606	78	342	350	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	1994	266	5186					763	770		10.1126/science.7973627	http://dx.doi.org/10.1126/science.7973627			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973627				2022-12-24	WOS:A1994PP75300028
J	DAVIS, G; DRIVER, J				DAVIS, G; DRIVER, J			PARALLEL DETECTION OF KANIZSA SUBJECTIVE FIGURES IN THE HUMAN VISUAL-SYSTEM	NATURE			English	Article							ILLUSORY CONTOURS; APPARENT DEPTH; SEARCH	SUBJECTIVE figures, seen in the absence of luminance gradients (Fig. 1), provide a phenomenal illusion that can be related to the properties of single cells in the visual cortex(1), offering a rare bridge between brain function and visual awareness. It remains controversial whether subjective figures arise from intelligent cognitive mechanisms(2-4), or from lower-level processes in early vision(5,6). The cognitive account implies that the perception of subjective figures may require serial attentive processing, whereas on the low-level account they should arise in parallel at earlier visual stages. Physiological evidence apparently fits a low-level account(7,8) and indicates that some types of subjective contour may be detected earlier than the conventional Kanizsa(9) type. Here we report that even Kanizsa subjective figures can be detected without focal attention at parallel stages of the human visual system.			DAVIS, G (corresponding author), UNIV CAMBRIDGE,DEPT EXPTL PSYCHOL,DOWNING ST,CAMBRIDGE CB2 3EA,ENGLAND.		Driver, Jon/A-4779-2010; Davis, Gregory/G-9954-2012					BRIGNER WL, 1974, PERCEPT MOTOR SKILL, V38, P1047, DOI 10.2466/pms.1974.38.3c.1047; BROADBENT DE, 1985, MODELLING COGNITION, P169; COREN S, 1972, PSYCHOL REV, V79, P359, DOI 10.1037/h0032940; DeValois RL, 1990, SPATIAL VISION; DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037/0033-295X.96.3.433; ENNS JT, 1990, SCIENCE, V247, P721, DOI 10.1126/science.2300824; ENNS JT, 1990, BEHAV RES METH INSTR, V22, P118, DOI 10.3758/BF03203130; GINSBURG AP, 1975, NATURE, V257, P219, DOI 10.1038/257219a0; GINSBURG AP, 1987, PERCEPTION ILLUSORY, P126; GRABOWECKY M, 1989, Investigative Ophthalmology and Visual Science, V30, P457; GREGORY RL, 1972, NATURE, V238, P51, DOI 10.1038/238051a0; GROSOF DH, 1993, NATURE, V365, P550, DOI 10.1038/365550a0; GURNSEY R, 1992, PERCEPT PSYCHOPHYS, V52, P263, DOI 10.3758/BF03209144; Kanizsa G., 1955, RIV PSICOL, V49, P7; PETERHANS E, 1991, TRENDS NEUROSCI, V14, P112, DOI 10.1016/0166-2236(91)90072-3; PRADZNY K, 1983, PERCEPT PSYCHOPHYS, V34, P403; Ramachandran V. S., 1987, PERCEPTION ILLUSORY, P93, DOI 10.1007/978-1-4612-4760-9_10; ROCK I, 1979, PERCEPTION, V8, P665, DOI 10.1068/p080665; SMITH AT, 1977, NATURE, V257, P581; TOWNSEND JT, 1971, PERCEPT PSYCHOPHYS, V10, P161, DOI 10.3758/BF03205778; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; WARM JS, 1986, PERCEPT PSYCHOPHYS, V39, P219	23	127	128	2	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					791	793		10.1038/371791a0	http://dx.doi.org/10.1038/371791a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PP018	7935838				2022-12-24	WOS:A1994PP01800057
J	PAUSE, A; BELSHAM, GJ; GINGRAS, AC; DONZE, O; LIN, TA; LAWRENCE, JC; SONENBERG, N				PAUSE, A; BELSHAM, GJ; GINGRAS, AC; DONZE, O; LIN, TA; LAWRENCE, JC; SONENBERG, N			INSULIN-DEPENDENT STIMULATION OF PROTEIN-SYNTHESIS BY PHOSPHORYLATION OF A REGULATOR OF 5'-CAP FUNCTION	NATURE			English	Article							5' NONCODING REGION; SECONDARY STRUCTURE; INITIATION; TRANSLATION; MECHANISM; CELLS; EXPRESSION; VIRUS	The cloning is described of two related human complementary DNAs encoding polypeptides that interact specifically with the translation initiation factor eIF-4E, which binds to the messenger RNA 5'-cap structure. Interaction of these proteins with eIF-4E inhibits translation but treatment of cells with insulin causes one of them to become hyperphosphorylated and dissociate from eIF-4E, thereby relieving the translational inhibition. The action of this new regulator of protein synthesis is therefore modulated by insulin, which acts to stimulate the overall rate of translation and promote cell growth.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL H3G 1Y6,PQ,CANADA; BBSRC,INST ANIM HLTH,WOKING GU24 0NF,SURREY,ENGLAND; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	McGill University; McGill University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Washington University (WUSTL)			Belsham, Graham J./H-8589-2019; Belsham, Graham/J-3132-2019; Gingras, Anne-Claude/E-9982-2010; Gingras, Anne-Claude/ABA-8341-2020	Belsham, Graham J./0000-0003-1187-4873; Belsham, Graham/0000-0003-1187-4873; Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437				AVRUCH J, 1985, MOL BASIS INSULIN AC, P67; BELSHAM GJ, 1980, DIABETOLOGIA, V18, P307; BELSHAM GJ, 1982, BIOCHEM J, V204, P345, DOI 10.1042/bj2040345; BELSHAM GJ, 1990, J VIROL, V64, P5389, DOI 10.1128/JVI.64.11.5389-5395.1990; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; DENTON RM, 1981, DIABETOLOGIA, V21, P347; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLIE DR, 1994, J BIOL CHEM, V269, P7174; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, REV BIOCH, V60, P717; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; LARARISKARATZAS A, 1990, NATURE, V345, P544; LYONS RT, 1980, J BIOL CHEM, V255, P6330; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; MORGAN HE, 1971, J BIOL CHEM, V246, P2163; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; SHANTZ LM, 1994, CANCER RES, V54, P2313; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; Sonenberg Nahum, 1993, Gene Expression, V3, P317; STIREWAL.WS, 1967, P NATL ACAD SCI USA, V57, P1885, DOI 10.1073/pnas.57.6.1885	31	1031	1058	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					762	767		10.1038/371762a0	http://dx.doi.org/10.1038/371762a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935836				2022-12-24	WOS:A1994PP01800049
J	COUSO, JP; ARIAS, AM				COUSO, JP; ARIAS, AM			NOTCH IS REQUIRED FOR WINGLESS SIGNALING IN THE EPIDERMIS OF DROSOPHILA	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; GENE SERRATE ENCODES; NEUROGENIC GENES; CELL FATE; TRANSMEMBRANE PROTEIN; EXPRESSION; LOCUS; MELANOGASTER; MUTATIONS; RECEPTOR	Mutations in the Notch (N) gene affect many processes during the development of Drosophila. Some alleles of Notch affect only particular processes, suggesting that the Notch protein (N) has more than one functional domain. We have found a series of N mutant phenotypes that are similar to those produced by the loss of function of the segment polarity gene wingless (wg) in the embryo and the adult. In addition, we observe that mutations in N behave as dominant enhancers of wg and that there exist allele-specific interactions between the two loci. Our results suggest that the product of wg is a ligand for N.			COUSO, JP (corresponding author), UNIV CAMBRIDGE,DEPT ZOOL,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.		Martinez Arias, Alfonso/F-1966-2010; Couso, Juan Pablo/ABH-5860-2020		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHBURNER M, 1989, DROSOPHILA LABORATO; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BATE M, 1993, DEVELOPMENT S, V119, P149; BLAIR SS, 1994, DEV BIOL, V162, P229, DOI 10.1006/dbio.1994.1081; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; CHOU TB, 1992, GENETICS, V131, P643; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DECELIS JF, 1993, P NATL ACAD SCI USA, V90, P4037, DOI 10.1073/pnas.90.9.4037; DECELIS JF, 1994, GENETICS, V136, P183; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HEITZLER P, 1993, DEVELOPMENT, V117, P1113; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; JACK J, 1992, GENETICS, V131, P353; JIMENEZ F, 1982, ROUX ARCH DEV BIOL, V191, P191, DOI 10.1007/BF00848335; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LIEBER T, 1992, NEURON, V9, P847, DOI 10.1016/0896-6273(92)90238-9; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lindsley D.L., 1992, GENOME DROSOPHILA ME; Muller H.J, 1932, P 6 INT C GEN, V1, P213; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; ORTEGA JAC, 1993, DEV DROSOPHILA MELAN, P1091; PEIFER M, 1994, DEVELOPMENT, V120, P369; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; PORTIN P, 1981, HEREDITAS, V95, P247; PORTIN P, 1977, HEREDITAS, V87, P77; Poulson DF, 1940, J EXP ZOOL, V83, P271, DOI 10.1002/jez.1400830207; RABINOW L, 1990, GENETICS, V125, P41; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SIMPSON P, 1993, DEVELOPMENT S, V119, P29; STERN CURT, 1954, AMER SCI, V42, P213; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; THOMAS U, 1991, DEVELOPMENT, V111, P749; TSAKONAS SA, 1991, TRENDS GENET, V7, P403; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Wigglesworth VB, 1940, J EXP BIOL, V17, P180; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; XU T, 1992, DEVELOPMENT, V115, P913	63	168	176	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					259	272		10.1016/0092-8674(94)90195-3	http://dx.doi.org/10.1016/0092-8674(94)90195-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954794				2022-12-24	WOS:A1994PN63000010
J	FORTINI, ME; ARTAVANISTSAKONAS, S				FORTINI, ME; ARTAVANISTSAKONAS, S			THE SUPPRESSOR OF HAIRLESS PROTEIN PARTICIPATES IN NOTCH RECEPTOR SIGNALING	CELL			English	Article							DEVELOPING DROSOPHILA EYE; CELL-FATE; BINDING-PROTEIN; NEGATIVE COMPLEMENTATION; NEUROGENIC GENES; LOCUS; MELANOGASTER; SEQUENCE; ENCODES; DELTA	In a genetic screen for mutations that attenuate Notch signaling in the developing Drosophila eye, we isolated rare, gain-of-function alleles of Suppressor of Hairless (Su(H)), the fly homolog of the mammalian C promoter-binding factor 1 (CBF1) gene. Su(H) exhibits numerous allele-specific genetic interactions with Notch as well as with Delta, deltex, and mastermind. In cultured Drosophila cells, the Su(H) protein is sequestered in the cytoplasm when coexpressed with Notch protein and is translocated to the nucleus when Notch binds to its ligand Delta. Cytoplasmic retention of Su(H) requires the intracellular cdc10/ankyrin repeats of Notch, which associate with SU(H) protein in the yeast interaction trap assay. These results indicate that Notch activity may regulate nuclear events by controlling the activity of a DNA-binding protein.	YALE UNIV,HOWARD HUGHES MED INST,DEPT CELL BIOL,NEW HAVEN,CT 06536	Howard Hughes Medical Institute; Yale University	FORTINI, ME (corresponding author), YALE UNIV,HOWARD HUGHES MED INST,DEPT BIOL,NEW HAVEN,CT 06536, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026084, R01NS026084] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26084] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; ASHBURNER M, 1982, GENETICS, V101, P447; BANG AG, 1992, GENE DEV, V6, P1752, DOI 10.1101/gad.6.9.1752; BUSSEAU I, 1994, GENETICS, V136, P585; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; DELACONCHA A, 1988, GENETICS, V118, P499; DELIDAKIS C, 1991, GENETICS, V129, P803; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; DOU SB, 1994, MOL CELL BIOL, V14, P3310, DOI 10.1128/MCB.14.5.3310; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FOSTER GG, 1975, GENETICS, V81, P99; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; FURUKAWA T, 1991, J BIOL CHEM, V266, P23334; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KOOH PJ, 1993, DEVELOPMENT, V117, P493; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MAIER D, 1992, MECH DEVELOP, V38, P143, DOI 10.1016/0925-4773(92)90006-6; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; NASH D, 1970, GENETICS, V64, P471; NASH D, 1965, GENET RES, V6, P175, DOI 10.1017/S0016672300004079; PARODY TR, 1993, GENETICS, V135, P527; Plunkett CR, 1926, J EXP ZOOL, V46, P181, DOI 10.1002/jez.1400460204; PORTIN P, 1975, GENETICS, V81, P121; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; SHELLENBARGER DL, 1975, GENETICS, V81, P143; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Thummel CS, 1992, DROS INF SERV, V71, P150; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	48	473	482	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					273	282		10.1016/0092-8674(94)90196-1	http://dx.doi.org/10.1016/0092-8674(94)90196-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954795				2022-12-24	WOS:A1994PN63000011
J	SYM, M; ROEDER, GS				SYM, M; ROEDER, GS			CROSSOVER INTERFERENCE IS ABOLISHED IN THE ABSENCE OF A SYNAPTONEMAL COMPLEX PROTEIN	CELL			English	Article							MEIOTIC CHROMOSOME SYNAPSIS; CHIASMA MAINTENANCE; ELECTROPHORETIC KARYOTYPE; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; RECOMBINATION NODULES; ASPERGILLUS-NIDULANS; GEL-ELECTROPHORESIS; DESYNAPTIC MUTANT; FISSION YEAST	In the zip1 mutant, meiotic chromosomes fail to synapse, owing to the absence of a structural component of the synaptonemal complex (SC). This mutant has been analyzed for the ability to carry out several functions that have been proposed for the SC. The data presented show that the zip1 mutation does not affect chiasma function and confers only modest defects in meiotic recombination and sister chromatid cohesion. In contrast, crossover interference is completely abolished in the absence of Zip1. These data are the first to establish a molecular link between cytological observations of the SC and the genetic phenomenon of interference.			SYM, M (corresponding author), YALE UNIV, DEPT BIOL, POB 6666, NEW HAVEN, CT 06520 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904, T32GM007223] Funding Source: NIH RePORTER; NIGMS NIH HHS [2 T32 GM07223-18, GM28904] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BAHLER J, 1993, J CELL BIOL, V121, P241, DOI 10.1083/jcb.121.2.241; BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; BHARGAVA J, 1992, GENETICS, V130, P59; BRODY H, 1989, P NATL ACAD SCI USA, V86, P6260, DOI 10.1073/pnas.86.16.6260; CARPENTER ATC, 1979, CHROMOSOMA, V75, P259, DOI 10.1007/BF00293472; CARPENTER ATC, 1975, P NATL ACAD SCI USA, V72, P3186, DOI 10.1073/pnas.72.8.3186; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; CLARKE L, 1983, NATURE, V305, P23, DOI 10.1038/305023a0; CLUTTERBUCK AJ, 1992, ASPERGILLUS BIOL IND, P3; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; EGEL R, 1978, HEREDITY, V41, P233, DOI 10.1038/hdy.1978.92; EGELMITANI M, 1982, HEREDITAS, V97, P179, DOI 10.1111/j.1601-5223.1982.tb00870.x; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; ENGEBRECHT JA, 1989, GENETICS, V121, P237; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; FOSS E, 1993, GENETICS, V133, P681; GAME JC, 1980, GENETICS, V94, P51; HALDANE J. B. S., 1931, CYTOLOGIA, V3, P54; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; HOLM PB, 1980, CARLSBERG RES COMMUN, V45, P483, DOI 10.1007/BF02932921; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES G H, 1987, P213; JONES GH, 1974, HEREDITY, V32, P375, DOI 10.1038/hdy.1974.45; JONES GH, 1967, CHROMOSOMA, V22, P69, DOI 10.1007/BF00291287; KABACK DB, 1989, P NATL ACAD SCI USA, V86, P3694, DOI 10.1073/pnas.86.10.3694; KABACK DB, 1992, SCIENCE, V256, P228, DOI 10.1126/science.1566070; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; KING JS, 1990, GENETICS, V126, P1127; KLAPHOLZ S, 1985, GENETICS, V110, P187; LAURIE DA, 1981, HEREDITY, V47, P409, DOI 10.1038/hdy.1981.102; MAGUIRE M P, 1978, Chromosoma (Berlin), V65, P173, DOI 10.1007/BF00329469; MAGUIRE MP, 1979, CHROMOSOMA, V70, P313, DOI 10.1007/BF00328769; MAGUIRE MP, 1978, EXP CELL RES, V112, P297, DOI 10.1016/0014-4827(78)90213-6; MAGUIRE MP, 1988, J THEOR BIOL, V134, P565, DOI 10.1016/S0022-5193(88)80058-4; MAGUIRE MP, 1993, GENOME, V36, P797, DOI 10.1139/g93-105; MAGUIRE MP, 1991, GENOME, V34, P879, DOI 10.1139/g91-135; Mather K, 1940, J GENET, V39, P205, DOI 10.1007/BF02982836; MENEES TM, 1992, MOL CELL BIOL, V12, P1340, DOI 10.1128/MCB.12.3.1340; MENEES TM, 1989, GENETICS, V123, P675; MOENS PB, 1994, BIOESSAYS, V16, P101, DOI 10.1002/bies.950160206; Mortimer R.R., 1974, MECH RECOMBINATION, P263, DOI [10.1007/978-1-4684-2133-0_23, DOI 10.1007/978-1-4684-2133-0_23]; MORTIMER RK, 1991, MOL CELLULAR BIOL YE, P737; Muller HJ, 1916, AM NAT, V50, P193, DOI 10.1086/279534; Munz P, 1989, MOL BIOL FISSION YEA, P1; NICKLAS RB, 1974, GENETICS, V78, P205; OLSON LW, 1978, HEREDITAS, V89, P189; Olson M., 1991, MOL CELLULAR BIOL YE, P1; PAPAZIAN HP, 1952, GENETICS, V37, P175; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; ROCKMILL B, 1990, GENETICS, V126, P563; ROCKMILL B, 1994, GENETICS, V136, P65; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sherman F., 1986, METHODS YEAST GENETI; SMITH CL, 1987, NUCLEIC ACIDS RES, V15, P4481, DOI 10.1093/nar/15.11.4481; SNOW R, 1979, GENETICS, V92, P231; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRICKLAND WN, 1958, PROC R SOC SER B-BIO, V149, P82, DOI 10.1098/rspb.1958.0053; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; THOMPSON EA, 1989, MOL GEN GENET, V218, P293, DOI 10.1007/BF00331281; VOLLRATH D, 1987, NUCLEIC ACIDS RES, V15, P7865, DOI 10.1093/nar/15.19.7865; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6	64	233	236	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					283	292		10.1016/0092-8674(94)90197-X	http://dx.doi.org/10.1016/0092-8674(94)90197-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954796				2022-12-24	WOS:A1994PN63000012
J	FENTON, WA; KASHI, Y; FURTAK, K; HORWICH, AL				FENTON, WA; KASHI, Y; FURTAK, K; HORWICH, AL			RESIDUES IN CHAPERONIN GROEL REQUIRED FOR POLYPEPTIDE BINDING AND RELEASE	NATURE			English	Article							MOLECULAR CHAPERONE; ATP HYDROLYSIS; PROTEINS; COOPERATIVITY; CELL	CHAPERONINS are king-shaped protein complexes that are essential in the cell, mediating ATP-dependent polypeptide folding in a variety of compartments(1-3). Recent studies suggest that they function through multiple rounds of binding and release of non-native proteins: with each round of ATP-driven release into the bulk solution, a substrate protein kinetically partitions between folding to the native state or rebinding to another chaperonin molecule(4-6). To gain further insight into the mechanism of polypeptide binding and release by the chaperonin GroEL from Escherichia coli, we have undertaken a mutational analysis that relates the functional properties of GroEL to its crystal structure(7). Our functional tests identify a putative polypeptide-binding site on the inside surface of the apical domain, facing the central channel, consisting of hydrophobic residues. These same residues are essential for binding of the co-chaperonin GroES, which is required for productive polypeptide release. A highly conserved residue, Asp 87, positioned within a putative nucleotide-binding pocket in the top of the equatorial domain, is essential for ATP hydrolysis and polypeptide release.	YALE UNIV,SCH MED,BOYER CTR,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,BOYER CTR,DEPT GENET,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University			Kashi, Yechezkel/D-5433-2013					AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	22	576	588	0	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					614	619		10.1038/371614a0	http://dx.doi.org/10.1038/371614a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935796				2022-12-24	WOS:A1994PL55900055
J	CROFT, P; SCHOLLUM, J; SILMAN, A				CROFT, P; SCHOLLUM, J; SILMAN, A			POPULATION STUDY OF TENDER POINT COUNTS AND PAIN AS EVIDENCE OF FIBROMYALGIA	BRITISH MEDICAL JOURNAL			English	Article							FATIGUE; SLEEP; FIBROSITIS; SCALE	Objective-To determine the relation between tender points, complaints of pain, and symptoms of depression, fatigue, and sleep quality in the general population. Design-Two stage cross sectional study with an initial questionnaire about pain to classify those eligible for an examination oftender points. Setting-Two general practices in north west England. Subjects-Stratified random sample of adults from age-sex registers. Of the responders, 250 were selected for examination of tender points on the basis of their reported pain complaints; 177 subsequently participated. Main outcome measures-Tender point count (0 to 18) grouped into four categories with the highest (greater than or equal to 11) corresponding to the criteria of the American College of Rheumatology for fibromyalgia. Assessment of pain (chronic widespread, regional, none). Measures of depression, fatigue, and difficulty with sleeping. Results-Women had a higher median tender point count (six) than did men (three). Counts were higher in those with pain than in those who had no pain and in those with widespread compared with regional pain. Most subjects with chronic widespread pain, however, had fewer than 11 tender points (27/45; 60%). Two people with counts of 11 or more were in the group reporting no pain. Mean symptom scores for depression, fatigue, and sleep problems increased as the tender point count rose (P value for trend < 0.001). These trends were independent of pain complaints. Conclusions-Tender points are a measure of general distress. They are related to pain complaints but are separately associated with fatigue and depression. Sleep problems are associated with tender points, although prospective studies are needed to determine whether they cause tenderness to develop. Fibromyalgia does not seem to be a distinct disease entity.			CROFT, P (corresponding author), UNIV MANCHESTER,ARTHRITIS & RHEUMATISM COUNCIL,EPIDEMIOL RES UNIT,STOPFORD BLDG,MANCHESTER M13 9PT,ENGLAND.							CAMPBELL SM, 1983, ARTHRITIS RHEUM, V26, P817, DOI 10.1002/art.1780260701; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; COHEN ML, 1993, LANCET, V342, P906, DOI 10.1016/0140-6736(93)91950-Q; CROFT P, 1993, J RHEUMATOL, V20, P710; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; GOLDENBERG DL, 1990, ARTHRITIS RHEUM, V33, P381, DOI 10.1002/art.1780330311; JENKINS CD, 1988, J CLIN EPIDEMIOL, V41, P313, DOI 10.1016/0895-4356(88)90138-2; LEIGH TJ, 1990, SCAND J RHEUMATOL, V19, P5, DOI 10.3109/03009749009092616; MOLDOFSKY H, 1976, PSYCHOSOM MED, V38, P35, DOI 10.1097/00006842-197601000-00006; REILLY PA, 1993, ANN RHEUM DIS, V52, P249, DOI 10.1136/ard.52.4.249; RIDSDALE L, 1993, BMJ-BRIT MED J, V307, P103, DOI 10.1136/bmj.307.6896.103; SMYTHE H A, 1977, Bulletin on the Rheumatic Diseases, V28, P928; WALL PD, 1993, PROGR FIBROMYALGIA M; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; WOLFE F, 1990, RHEUM DIS CLIN N AM, V16, P681; YUNUS M, 1981, SEMIN ARTHRITIS RHEU, V11, P151, DOI 10.1016/0049-0172(81)90096-2; YUNUS MB, 1992, J RHEUMATOL, V19, P846; YUNUS MB, 1991, ARTHRITIS RHEUM, V34, P15, DOI 10.1002/art.1780340104	18	244	248	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					696	699		10.1136/bmj.309.6956.696	http://dx.doi.org/10.1136/bmj.309.6956.696			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7950521	Green Published			2022-12-24	WOS:A1994PH40700014
J	SIMOONS, ML				SIMOONS, ML			MYOCARDIAL-INFARCTION - ACE-INHIBITORS FOR ALL - FOR EVER	LANCET			English	Editorial Material							LEFT-VENTRICULAR DYSFUNCTION; CAPTOPRIL; THERAPY; ENALAPRIL; REPERFUSION; DILATATION; TRIAL				SIMOONS, ML (corresponding author), ERASMUS UNIV ROTTERDAM,THORAXCTR,3000 DR ROTTERDAM,NETHERLANDS.							[Anonymous], 1993, LANCET, V342, P821; BALL SG, 1994, LANCET, V343, P1632, DOI 10.1016/S0140-6736(94)93083-X; BONARJEE VVS, 1993, AM J CARDIOL, V72, P1004, DOI 10.1016/0002-9149(93)90853-5; DEGRAEFF PA, 1987, J CARDIOVASC PHARM, V9, pS37, DOI 10.1097/00005344-198700002-00009; Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico, 1994, LANCET, V343, P1115; HOCK CE, 1985, AM HEART J, V109, P222, DOI 10.1016/0002-8703(85)90587-3; KINGMA JH, IN PRESS EUR HEART J; KINGMA JH, 1989, CURRENT ADV ACE INHI, P291; NABEL EG, 1991, J AM COLL CARDIOL, V17, P467, DOI 10.1016/S0735-1097(10)80117-2; OLDROYD KG, 1991, AM J CARDIOL, V68, P713, DOI 10.1016/0002-9149(91)90641-W; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; PFEFFER MA, 1992, NEW ENGL J MED, V327, P369; SCHOEMAKER RG, 1991, J MOL CELL CARDIOL, V23, P187, DOI 10.1016/0022-2828(91)90105-U; SHARPE N, 1988, LANCET, V1, P255; SHARPE N, 1991, LANCET, V337, P872, DOI 10.1016/0140-6736(91)90202-Z; SIGURDSSON A, 1991, INT J CARDIOL, V33, P115, DOI 10.1016/0167-5273(91)90159-M; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; TOGNONI G, 1994, LANCET, V343, P1633; VANGILST WH, 1986, J CARDIOVASC PHARM, V8, P722; 1991, NEW ENGL J MED, V325, P293; 1987, NEW ENGL J MED, V316, P1429; 1991, AM J CARDIOL, V68, pD87	23	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					279	281		10.1016/S0140-6736(94)91333-1	http://dx.doi.org/10.1016/S0140-6736(94)91333-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7980780	Green Submitted			2022-12-24	WOS:A1994NZ23300002
J	TANAKA, N; ISHIHARA, M; KITAGAWA, M; HARADA, H; KIMURA, T; MATSUYAMA, T; LAMPHIER, MS; AIZAWA, S; MAK, TW; TANIGUCHI, T				TANAKA, N; ISHIHARA, M; KITAGAWA, M; HARADA, H; KIMURA, T; MATSUYAMA, T; LAMPHIER, MS; AIZAWA, S; MAK, TW; TANIGUCHI, T			CELLULAR COMMITMENT TO ONCOGENE-INDUCED TRANSFORMATION OR APOPTOSIS IS DEPENDENT ON THE TRANSCRIPTION FACTOR IRF-1	CELL			English	Article							REGULATORY FACTOR-I; ACUTE NONLYMPHOCYTIC LEUKEMIA; TUMOR-SUPPRESSOR GENES; ACUTE MYELOID-LEUKEMIA; IFN-INDUCIBLE GENES; INTERFERON SYSTEM; PROTEIN-KINASE; P53 GENE; MALIGNANT TRANSFORMATION; MYELOGENOUS LEUKEMIA	The transcriptional activator interferon regulatory factor 1 (IRF-1) and its antagonistic repressor IRF-2 are regulators of the interferon (IFN) system and of cell growth. Here we report that embryonic fibroblasts (EFs) from mice with a null mutation in the IRF-1 gene (IRF-1(-/-) mice) can be transformed by expression of an activated c-Ha-ras oncogene. This property is not observed in EFs from wild-type or IRF-2(-/-) mice but is still observed in EFs from mice deficient in both genes. The transformed phenotype of ras-expressing IRF-1(-/-) EFs could be suppressed by the expression of the IRF-1 cDNA. Thus, IRF-1 functions as a tumor suppressor. Furthermore, expression of the c-Ha-ras oncogene causes wild-type but not IRF-1(-/-) EFs to undergo apoptosis when combined with a block to cell proliferation or treated by anticancer drugs or ionizing radiation. Hence, IRF-1 may be a critical determinant of oncogene-induced cell transformation or apoptosis.	UNIV TORONTO,ONTARIO CANC INST,DEPT IMMUNOL & MED BIOPHYS,AMGEN INST,TORONTO M4X 1K9,ON,CANADA; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,TSUKUBA,IBARAKI 305,JAPAN	University of Toronto; University Toronto Affiliates; University Health Network Toronto; RIKEN	TANAKA, N (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADA OKA,SUITA,OSAKA 565,JAPAN.		Harada, Hisashi/H-2815-2019; Kitagawa, Motoo/W-8468-2019	Harada, Hisashi/0000-0001-5993-1289; Kitagawa, Motoo/0000-0003-1036-840X; Tanaka, Nobuyuki/0000-0002-6373-2220; Kimura, Tohru/0000-0001-9227-0996				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BOS JL, 1989, CANCER RES, V49, P4682; BOULTWOOD J, 1993, BLOOD, V82, P2611; Carter Graham, 1992, Critical Reviews in Oncogenesis, V3, P339; CLRKE AR, 1993, NATURE, V362, P849; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Demaeyer E., 1988, INTERFERONS OTHER RE; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FENAUX P, 1991, BLOOD, V78, P1652; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; ITOH S, 1991, GENOMICS, V10, P1097, DOI 10.1016/0888-7543(91)90208-V; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1991, ORIGINS OF HUMAN CANCER, P423; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KASTAN MB, 1991, CANCER RES, V51, P6304; KERIM S, 1990, LEUKEMIA, V4, P12; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEBEAU MM, 1992, CANCER SURV, V15, P143; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUYAMA T, 1993, WATA, V75, P83; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYASHITA K, 1975, CELL, V5, P131, DOI 10.1016/0092-8674(75)90021-5; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RUFNER H, 1993, P NATL ACAD SCI USA, V90, P11503; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SEN GC, 1992, J BIOL CHEM, V267, P5017; Shin S, 1979, Methods Enzymol, V58, P370; SHIRAYOSHI Y, 1987, MOL CELL BIOL, V7, P4542, DOI 10.1128/MCB.7.12.4542; SLINGERLAND JM, 1991, BLOOD, V77, P1500; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; SUGIMOTO K, 1993, BLOOD, V81, P3022; SUGIMOTO K, 1991, BLOOD, V77, P1153; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSUKADA T, 1993, ONCOGENE, V8, P3313; VILCEK J, 1990, PEPTIDE GROWTH FACTO, V2, P3; VOGELSTEIN B, 1992, CELL, V70, P623; WATANABE N, CELL, V83, P93; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERG RA, 1989, CANCER RES, V49, P3713; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA G, 1990, P NATL ACAD SCI USA, V88, P532; YAMAMOTO H, 1994, IN PRESS ONCOGENE; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YOSHIDA K, 1988, CANCER RES, V48, P5503; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	92	474	487	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					829	839		10.1016/0092-8674(94)90132-5	http://dx.doi.org/10.1016/0092-8674(94)90132-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004672				2022-12-24	WOS:A1994NT33100008
J	FUCHS, CS; GIOVANNUCCI, EL; COLDITZ, GA; HUNTER, DJ; SPEIZER, FE; WILLETT, WC				FUCHS, CS; GIOVANNUCCI, EL; COLDITZ, GA; HUNTER, DJ; SPEIZER, FE; WILLETT, WC			A PROSPECTIVE-STUDY OF FAMILY HISTORY AND THE RISK OF COLORECTAL-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SELF-ADMINISTERED QUESTIONNAIRE; CORONARY HEART-DISEASE; ALCOHOL-CONSUMPTION; COLON; REPRODUCIBILITY; FREQUENCY; RECTUM; POLYPS	Background. A family history of colorectal cancer is recognized as a risk factor for the disease. However, as a result of the retrospective design of prior studies, the strength of this association is uncertain, particularly as it is influenced by characteristics of the person at risk and the affected family members. Methods. We conducted a prospective study of 32,085 men and 87,031 women who had not previously been examined by colonoscopy or sigmoidoscopy and who provided data on first-degree relatives with colorectal cancer, diet, and other risk factors for the disease. During the follow-up period, colorectal cancer was diagnosed in 148 men and 315 women. Results. The age-adjusted relative risk of colorectal cancer for men and women with affected first-degree relatives, as compared with those without a family history of the disease, was 1.72 (95 percent confidence interval, 1.34 to 2.19). The relative risk among study participants with two or more affected first-degree relatives was 2.75 (95 percent confidence interval, 1.34 to 5.63). For participants under the age of 45 years who had one or more affected first-degree relatives, the relative risk was 5.37 (95 percent confidence interval, 1.98 to 14.6), and the risk decreased with increasing age (P for trend, <0.001). Conclusions. A family history of colorectal cancer is associated with an increased risk of the disease, especially among younger people.	HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	FUCHS, CS (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DANA FARBER CANC INST,DIV MED ONCOL,44 BINNEY ST,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [P01CA055075, R01CA040935] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONELLI L, 1988, INT J CANCER, V41, P513; CANNONALBRIGHT LA, 1989, CANCER, V64, P1971, DOI 10.1002/1097-0142(19891101)64:9<1971::AID-CNCR2820640935>3.0.CO;2-L; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COLDITZ GA, 1987, INT J EPIDEMIOL, V16, P392, DOI 10.1093/ije/16.3.392; COX DR, 1972, J R STAT SOC B, V34, P187; DELEON MP, 1987, CANCER, V60, P2848, DOI 10.1002/1097-0142(19871201)60:11<2848::AID-CNCR2820601141>3.0.CO;2-F; DUNCAN JL, 1982, GUT, V23, P169, DOI 10.1136/gut.23.2.169; FISHER G, 1989, MED J AUSTRALIA, V150, P22, DOI 10.5694/j.1326-5377.1989.tb136314.x; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; KUNE GA, 1989, WORLD J SURG, V13, P124, DOI 10.1007/BF01671173; LEVIN B, 1992, CA-CANCER J CLIN, V42, P296, DOI 10.3322/canjclin.42.5.296; LOVETT E, 1976, BRIT J SURG, V63, P13, DOI 10.1002/bjs.1800630103; MACKLIN MT, 1960, J NATL CANCER I, V24, P551, DOI 10.1093/jnci/24.3.551; MAIRE P, 1984, GASTROEN CLIN BIOL, V8, P22; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Rothman K, 1986, MODERN EPIDEMIOLOGY; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SONDERGAARD JO, 1991, INT J CANCER, V47, P202, DOI 10.1002/ijc.2910470207; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STEPHENSON BM, 1991, BRIT J SURG, V78, P1162, DOI 10.1002/bjs.1800781005; STJOHN DJB, 1993, ANN INTERN MED, V118, P785, DOI 10.7326/0003-4819-118-10-199305150-00005; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; WOOLF CM, 1958, AM J HUM GENET, V10, P42	28	586	593	2	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	1994	331	25					1669	1674		10.1056/NEJM199412223312501	http://dx.doi.org/10.1056/NEJM199412223312501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX382	7969357				2022-12-24	WOS:A1994PX38200001
J	PEREGO, M; HANSTEIN, C; WELSH, KM; DJAVAKHISHVILI, T; GLASER, P; HOCH, JA				PEREGO, M; HANSTEIN, C; WELSH, KM; DJAVAKHISHVILI, T; GLASER, P; HOCH, JA			MULTIPLE PROTEIN ASPARTATE PHOSPHATASES PROVIDE A MECHANISM FOR THE INTEGRATION OF DIVERSE SIGNALS IN THE CONTROL OF DEVELOPMENT IN BACILLUS-SUBTILIS	CELL			English	Article							BACILLUS-SUBTILIS; SPORULATION GENE; PHOSPHORYLATION; INITIATION; EXPRESSION; SYSTEM; TRANSCRIPTION; PHOSPHORELAY; CHROMOSOME; MUTATIONS	The initiation of sporulation in B. subtilis is regulated by the SpoOA transcription factor, which is activated by phosphorylation to central developmental switching from the vegetative to the sporulation state. The level of phosphorylation of SpoOA is regulated by the phosphorelay, a signal transduction system based on the protein-histidine kinase-response regulator two-component paradigm. To initiate sporulation, the cell must recognize and interpret a large variety of environmental, metabolic, and cell cycle signals that influence the phosphorylation level of SpoOA. We describe here a family of protein-aspartate phosphatases with activity on SpoOF similar to P, a response regulator component of the phosphorelay, that provide a mechanism for signal recognition and interpretation. These phosphatases function to drain the phosphorelay, lower SpoOA similar to P levels, and prevent sporulation, The integration of diverse environmental signals that affect the initiation of sporulation likely occurs through the competition between opposing activities of protein kinases and protein phosphatases.	UNIV PAVIA, DIPARTIMENTO GENET & MICROBIOL A BUZZATI TRAV, I-27100 PAVIA, ITALY; INST PASTEUR, DEPT REGULAT GENET EXPRESS, F-75724 PARIS, FRANCE; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	University of Pavia; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Scripps Research Institute	PEREGO, M (corresponding author), UNIV PARMA, DIPARTIMENTO FARMACEUT, VIA SCI, I-43100 PARMA, ITALY.		Glaser, Philippe/O-2641-2015	Glaser, Philippe/0000-0003-4156-2782	NIGMS NIH HHS [GM45727, GM19416] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045727, R37GM019416, R01GM019416] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; DEDONDER RA, 1977, APPL ENVIRON MICROB, V33, P989, DOI 10.1128/AEM.33.4.989-993.1977; DUBNAU D, 1991, MOL MICROBIOL, V5, P11, DOI 10.1111/j.1365-2958.1991.tb01820.x; FERRARI E, 1988, J BACTERIOL, V170, P289, DOI 10.1128/JB.170.1.289-295.1988; GRIMSLEY JK, 1994, J BIOL CHEM, V269, P16977; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; HOCH JA, 1976, ADV GENET, V18, P69, DOI 10.1016/S0065-2660(08)60437-X; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANDELSTAM J, 1974, J BACTERIOL, V120, P38, DOI 10.1128/JB.120.1.38-42.1974; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Miller J.H., 1972, EXPT MOL GENETICS; MUELLER JP, 1992, J BACTERIOL, V174, P4361, DOI 10.1128/JB.174.13.4361-4373.1992; MUELLER JP, 1992, J BACTERIOL, V174, P4374, DOI 10.1128/JB.174.13.4374-4383.1992; OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/pnas.91.5.1756; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEREGO M, 1988, MOL MICROBIOL, V2, P689, DOI 10.1111/j.1365-2958.1988.tb00079.x; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; PEREGO M, 1991, J BACTERIOL, V173, P2514, DOI 10.1128/jb.173.8.2514-2520.1991; Perego Marta, 1993, P615; SANDMAN K, 1987, GENETICS, V117, P603; SPIEGELMAN G, 1990, J BACTERIOL, V172, P5011, DOI 10.1128/jb.172.9.5011-5019.1990; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STRAUCH MA, 1993, MOL MICROBIOL, V7, P337, DOI 10.1111/j.1365-2958.1993.tb01125.x; STRAUCH MA, 1993, MOL MICROBIOL, V7, P967, DOI 10.1111/j.1365-2958.1993.tb01188.x; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TRACH K, 1988, J BACTERIOL, V170, P4194, DOI 10.1128/jb.170.9.4194-4208.1988; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; YOUNGMAN P, 1984, MOL GEN GENET, V195, P424, DOI 10.1007/BF00341443	35	254	257	2	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1047	1055		10.1016/0092-8674(94)90035-3	http://dx.doi.org/10.1016/0092-8674(94)90035-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001132				2022-12-24	WOS:A1994PY08600014
J	MILLINER, DS; EICKHOLT, JT; BERGSTRALH, EJ; WILSON, DM; SMITH, LH				MILLINER, DS; EICKHOLT, JT; BERGSTRALH, EJ; WILSON, DM; SMITH, LH			RESULTS OF LONG-TERM TREATMENT WITH ORTHOPHOSPHATE AND PYRIDOXINE IN PATIENTS WITH PRIMARY HYPEROXALURIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOMERULAR-FILTRATION RATE; GLYOXYLATE AMINOTRANSFERASE; KIDNEY-TRANSPLANTATION; RENAL-TRANSPLANTATION; PEROXISOMAL ALANINE; OXALATE DYNAMICS; PRIMARY OXALOSIS; HEPATIC ALANINE; TYPE-1; URINARY	Background. The prognosis for patients with primary hyperoxaluria has been ominous, with the expectation of renal failure, poor results with transplantation, and early death. Methods. We studied the long-term effects of orthophosphate and pyridoxine therapy in 25 patients with primary hyperoxaluria who were treated for an average of 10 years (range, 0.3 to 26). Their mean age at the start of treatment was 12 years (median, 6; range, 0.5 to 32). We also studied the effect of orthophosphate and pyridoxine on urinary supersaturation with calcium oxalate, crystal inhibition using a seeded growth system, and crystal formation using scanning electron microscopy in 12 patients during three-day stays in the clinical research center. Results. The mean (+/-SD) glomerular filtration rate at the start of treatment was 91+/-26 ml per minute per 1.73 m(2). The median decline in glomerular filtration rates was 1.4 ml per minute per 1.73 m(2) of body-surface area per year. The actuarial survival free of end-stage renal disease was 96, 89, 74, and 74 percent at 5, 10, 15, and 20 years, respectively. Treatment with orthophosphate and pyridoxine reduced urinary supersaturation with calcium oxalate from 8.3+/-3.0 to 2.1+/-1.7 kJ per mole at 38 degrees C (P<0.001), increased the inhibition of calcium oxalate formation from 63+/-11 to 108+/-10 inhibitor units per 24 hours (P<0.001), and improved the crystalluria score from 2.6+/-0.3 to 0.6+/-0.1 (P<0.001). Conclusions. Treatment of patients with primary hyperoxaluria with orthophosphate and pyridoxine decreases urinary calcium oxalate crystallization and appears to preserve renal function.	MAYO CLIN & MAYO FDN,DEPT PEDIAT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	MILLINER, DS (corresponding author), MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,DIV NEPHROL,ROCHESTER,MN 55905, USA.				NCRR NIH HHS [5M01-RR0585-23] Funding Source: Medline; NIADDK NIH HHS [AM20605] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000585] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLSOP J, 1987, CLIN CHIM ACTA, V170, P187, DOI 10.1016/0009-8981(87)90127-6; BARRATT TM, 1988, OXALATE METABOLISM R, P84; BRIGMAN J, 1978, INVEST UROL, V15, P496; BROYER M, 1990, NEPHROL DIAL TRANSPL, V5, P332, DOI 10.1093/ndt/5.5.332; CHALMERS RA, 1972, ANALYST, V97, P958, DOI 10.1039/an9729700958; CHLEBECK PT, 1994, AM J KIDNEY DIS, V23, P255, DOI 10.1016/S0272-6386(12)80981-4; COOPER PJ, 1988, J HISTOCHEM CYTOCHEM, V36, P1285, DOI 10.1177/36.10.3418107; DANPURE CJ, 1987, LANCET, V1, P289; DANPURE CJ, 1989, J INHERIT METAB DIS, V12, P210, DOI 10.1007/BF01800727; DANPURE CJ, 1991, AM J KIDNEY DIS, V17, P366, DOI 10.1016/S0272-6386(12)80624-X; DANPURE CJ, 1986, FEBS LETT, V201, P20, DOI 10.1016/0014-5793(86)80563-4; DANPURE CJ, 1989, J CELL BIOL, V108, P1345, DOI 10.1083/jcb.108.4.1345; DENT CE, 1970, ARCH DIS CHILD, V45, P735, DOI 10.1136/adc.45.244.735; FOLIN O, 1905, J BIOL CHEM, V1, P131; FREDERICK EW, 1963, NEW ENGL J MED, V269, P821, DOI 10.1056/NEJM196310172691601; GIBBS DA, 1969, J LAB CLIN MED, V73, P901; GIBBS DA, 1970, CLIN SCI, V38, P277, DOI 10.1042/cs0380277; HELIN I, 1980, SCAND J UROL NEPHROL, V14, P61, DOI 10.3109/00365598009181192; HOCKADAY TD, 1964, MEDICINE, V43, P315, DOI 10.1097/00005792-196405000-00010; HOLMGREN G, 1978, UPSALA J MED SCI, V83, P65, DOI 10.3109/03009737809179114; KATZ A, 1992, KIDNEY INT, V42, P1408, DOI 10.1038/ki.1992.434; KOEHL C, 1976, CLIN CHIM ACTA, V70, P71, DOI 10.1016/0009-8981(76)90006-1; LATTA K, 1990, EUR J PEDIATR, V149, P518, DOI 10.1007/BF01957682; LEUMANN E, 1993, PEDIATR NEPHROL, V7, P207, DOI 10.1007/BF00864405; MCDONALD JC, 1989, NEW ENGL J MED, V321, P1100, DOI 10.1056/NEJM198910193211607; MEYER JL, 1975, INVEST UROL, V13, P36; MISTRY J, 1988, BIOCHEM SOC T, V16, P626, DOI 10.1042/bst0160626; NATELSON S, 1948, J BIOL CHEM, V175, P745; OLTHUIS FMFG, 1977, CLIN CHIM ACTA, V75, P123, DOI 10.1016/0009-8981(77)90507-1; OTT NT, 1975, MAYO CLIN PROC, V50, P664; SCHEINMAN JI, 1984, KIDNEY, V17, P13; SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259; SCHWARTZ GJ, 1985, J PEDIATR-US, V106, P522, DOI 10.1016/S0022-3476(85)80697-1; SLACK TK, 1976, MAYO CLIN PROC, V51, P296; SMITH LH, 1967, MOD TREAT, V4, P522; SMITH LH, 1976, UROLITHIASIS RES, P199; WATTS RWE, 1987, LANCET, V2, P474; WATTS RWE, 1991, AM J MED, V90, P179; WATTS RWE, 1985, CLIN SCI, V69, P87, DOI 10.1042/cs0690087; WATTS RWE, 1984, CLIN SCI, V66, P591, DOI 10.1042/cs0660591; WERNESS PG, 1981, J CRYST GROWTH, V53, P166, DOI 10.1016/0022-0248(81)90063-4; WERNESS PG, 1985, J UROLOGY, V134, P1242, DOI 10.1016/S0022-5347(17)47703-2; WILL EJ, 1979, METABOLISM, V28, P542, DOI 10.1016/0026-0495(79)90195-1; WILLIAMS HE, 1968, NEW ENGL J MED, V278, P233, DOI 10.1056/NEJM196802012780502; WILLIAMS HE, 1978, METABOLIC BASIS INHE, P182; WILSON DM, 1991, CLIN CHEM, V37, P1229	46	147	148	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1553	1558		10.1056/NEJM199412083312304	http://dx.doi.org/10.1056/NEJM199412083312304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV292	7969325	Bronze			2022-12-24	WOS:A1994PV29200004
J	BAIN, G; MAANDAG, ECR; IZON, DJ; AMSEN, D; KRUISBEEK, AM; WEINTRAUB, BC; KROP, I; SCHLISSEL, MS; FEENEY, AJ; VANROON, M; VANDERVALK, M; TERIELE, HPJ; BERNS, A; MURRE, C				BAIN, G; MAANDAG, ECR; IZON, DJ; AMSEN, D; KRUISBEEK, AM; WEINTRAUB, BC; KROP, I; SCHLISSEL, MS; FEENEY, AJ; VANROON, M; VANDERVALK, M; TERIELE, HPJ; BERNS, A; MURRE, C			E2A PROTEINS ARE REQUIRED FOR PROPER B-CELL DEVELOPMENT AND INITIATION OF IMMUNOGLOBULIN GENE REARRANGEMENTS	CELL			English	Article							TRANSCRIPTION FACTOR BSAP; DNA-BINDING PROTEINS; HEAVY-CHAIN ENHANCER; FUNCTIONAL-ANALYSIS; LYMPHOCYTES-B; IGH ENHANCER; STEM-CELLS; EXPRESSION; PROMOTER; SEQUENCE	E12 and E47 are two helix-loop-helix transcription factors that arise by alternative splicing of the E2A gene. Both have been implicated in the regulation of immunoglobulin gene expression. We have now generated E2A (-/-) mice by gene targeting. E2A-null mutant mice fail to generate mature B cells. The arrest of B cell development occurs at an early stage, since no immunoglobulin DJ rearrangements can be detected in homozygous mutant mice. While immunoglobulin germline I-mu RAG-1, mb-1, CD19, and lambda 5 transcripts are dramatically reduced in fetal livers of E2A (-/-) mice, B29 and mu degrees transcripts are present, but at lower levels. In addition, we show that Pax-5 transcripts are significantly reduced in fetal livers of E2A (-/-) mice. These data suggest a crucial role for E2A products as central regulators in early B cell differentiation.	NETHERLANDS CANC INST, DEPT IMMUNOL, 1066 CX AMSTERDAM, NETHERLANDS; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; NETHERLANDS CANC INST, DEPT MOLEC GENET, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute; Scripps Research Institute; Johns Hopkins University; Johns Hopkins University; Netherlands Cancer Institute	BAIN, G (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL 0116, LA JOLLA, CA 92130 USA.				NCI NIH HHS [CA54198-01] Funding Source: Medline; NHLBI NIH HHS [HL48702] Funding Source: Medline; NIAID NIH HHS [R01 AI34088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054198, R37CA054198] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ALESSANDRINI A, 1991, MOL CELL BIOL, V11, P2096, DOI 10.1128/MCB.11.4.2096; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FEENEY AJ, 1991, J IMMUNOL, V147, P4343; FEENEY AJ, 1992, J IMMUNOL, V149, P222; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KUBO RT, 1989, J IMMUNOL, V142, P2736; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OKABE T, 1992, EUR J IMMUNOL, V22, P37, DOI 10.1002/eji.1830220107; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; SU LK, 1990, MOL CELL BIOL, V10, P2619, DOI 10.1128/MCB.10.6.2619; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; TAKEDA J, 1990, MOL CELL BIOL, V10, P5027, DOI 10.1128/MCB.10.10.5027; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TSAO BP, 1988, NUCLEIC ACIDS RES, V16, P3239, DOI 10.1093/nar/16.8.3239; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	53	636	643	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					885	892		10.1016/0092-8674(94)90077-9	http://dx.doi.org/10.1016/0092-8674(94)90077-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001125				2022-12-24	WOS:A1994PW05400015
J	ERIE, DA; YANG, GL; SCHULTZ, HC; BUSTAMANTE, C				ERIE, DA; YANG, GL; SCHULTZ, HC; BUSTAMANTE, C			DNA BENDING BY CRO PROTEIN IN SPECIFIC AND NONSPECIFIC COMPLEXES - IMPLICATIONS FOR PROTEIN SITE RECOGNITION AND SPECIFICITY	SCIENCE			English	Article							SCANNING FORCE MICROSCOPY; TATA-BOX COMPLEX; CRYSTAL-STRUCTURE; GEL-ELECTROPHORESIS; RNA-POLYMERASE; OPERATOR DNA; TRANSCRIPTION; ENDONUCLEASE; REPRESSOR; BINDING	Scanning force microscopy was used to resolve lambda Cro protein when bound as a single dimer or multiple dimers to its three operator (O-R) sites. The bend angles induced by binding of Cro to specific and nonspecific sites were determined and are 69 degrees +/- 11 degrees for specific and 62 degrees +/- 23 degrees for nonspecific complexes. Bending of the nonspecific sites is advantageous for a protein such as Cro that bends its specific site, because it increases the binding specificity of the protein and it can be used by the protein to sample contacts required for the recognition of its target sequence. It is proposed here that bending of nonspecific DNA may be a general property among DNA binding proteins that bend their specific sites.	UNIV OREGON,HOWARD HUGHES MED INST,EUGENE,OR 97403; UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403	Howard Hughes Medical Institute; University of Oregon; University of Oregon				Bustamante, Carlos/0000-0002-2970-0073	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R37GM032543, R01GM032543, R37GM015792, R01GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-32543, GM-15792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BUSTAMANTE C, 1992, BIOCHEMISTRY-US, V31, P22, DOI 10.1021/bi00116a005; BUSTAMANTE C, 1993, CURR OPIN STRUC BIOL, V3, P363, DOI 10.1016/S0959-440X(05)80107-1; BUSTAMANTE JF, 1994, SCIENCE, V265, P1599; CROTHERS DM, 1991, METHOD ENZYMOL, V208, P118; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FICKERT R, 1992, J MOL BIOL, V226, P59, DOI 10.1016/0022-2836(92)90124-3; GARCIA R, UNPUB; HATS JB, 1969, BIOPOLYMERS, V8, P531; HERMAN S, UNPUB; Hermann S., UNPUB; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; JOANICOT M, 1987, BIOPOLYMERS, V26, P315, DOI 10.1002/bip.360260211; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KELLER DJ, 1992, SURF SCI, V268, P333, DOI 10.1016/0039-6028(92)90973-A; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM JG, 1987, J MOL BIOL, V196, P149, DOI 10.1016/0022-2836(87)90517-1; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOUDELKA GB, 1991, NUCLEIC ACIDS RES, V19, P4115, DOI 10.1093/nar/19.15.4115; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; Landau L D., 1980, STATISTICAL PHYSIC 1, V5, P396; LANDAU LD, 1970, THEORY ELASTICITY, V7, P82; LECAM E, 1994, J MOL BIOL, V235, P1062, DOI 10.1006/jmbi.1994.1057; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LYUBCHENKO Y, 1991, P NATL ACAD SCI USA, V88, P5331, DOI 10.1073/pnas.88.12.5331; MATTHEW JB, 1985, J BIOL CHEM, V260, P5860; MEYERALMES FJ, 1994, J MOL BIOL, V236, P1, DOI 10.1006/jmbi.1994.1112; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PRENTKI P, 1987, EMBO J, V6, P2479, DOI 10.1002/j.1460-2075.1987.tb02529.x; PTASHNE M, 1992, GENETIC SWITCH GENE; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; SCHELLMAN JA, 1974, BIOPOLYMERS, V13, P217, DOI 10.1002/bip.1974.360130115; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STARR DE, UNPUB; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STOVER T, 1993, J BIOL CHEM, V268, P8645; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439; TAKEDA Y, 1992, P NATL ACAD SCI USA, V89, P8180, DOI 10.1073/pnas.89.17.8180; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; VANDERVLIET PC, 1993, BIOESSAYS, V15, P25, DOI 10.1002/bies.950150105; VESENKA J, 1992, ULTRAMICROSCOPY, V42, P1243, DOI 10.1016/0304-3991(92)90430-R; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; VONHIPPEL PH, 1994, SCIENCE, V263, P769, DOI 10.1126/science.8303292; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; ZAUG AJ, 1985, BIOCHEMISTRY-US, V24, P6211, DOI 10.1021/bi00343a027; ZINKEL SS, 1990, BIOPOLYMERS, V29, P29, DOI 10.1002/bip.360290106	54	158	160	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1562	1566		10.1126/science.7985026	http://dx.doi.org/10.1126/science.7985026			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985026				2022-12-24	WOS:A1994PV01500044
J	BLUMENFELD, JD; SEALEY, JE; SCHLUSSEL, Y; VAUGHAN, ED; SOS, TA; ATLAS, SA; MULLER, FB; ACEVEDO, R; ULICK, S; LARAGH, JH				BLUMENFELD, JD; SEALEY, JE; SCHLUSSEL, Y; VAUGHAN, ED; SOS, TA; ATLAS, SA; MULLER, FB; ACEVEDO, R; ULICK, S; LARAGH, JH			DIAGNOSIS AND TREATMENT OF PRIMARY HYPERALDOSTERONISM	ANNALS OF INTERNAL MEDICINE			English	Review							ATRIAL NATRIURETIC FACTOR; ALDOSTERONE-PRODUCING ADENOMA; CALCIUM-CHANNEL BLOCKADE; PLASMA-RENIN ACTIVITY; ESSENTIAL-HYPERTENSION; PEPTIDE; RADIOIMMUNOASSAY; RESPONSES	Objective: To characterize the clinical and laboratory features of primary aldosteronism and to evaluate which diagnostic tests can discriminate surgically curable forms of this syndrome. Design: Retrospective analysis of the following data from 82 patients with primary aldosteronism: blood pressure, serum electrolytes, urinary aldosterone anti electrolytes, computed tomographic scans, plasma renin and aldosterone before and during upright posture, atrial natriuretic peptide, and adrenal vein aldosterone and cortisol. Clinical outcomes assessed after treatment included blood pressure, serum electrolytes, anti plasma renin activity. Results: Drug therapy was discontinued before diagnostic tests were done in 56 of 82 patients (34 with adenomas and 22 with hyperplasia). Compared with patients with hyperplasia, those with adenomas had higher systolic (184 mm Hg and 161 mm Hg, respectively; P < 0.001) and diastolic blood pressures (112 mm Hg and 105 mm Hg; P = 0.03), lower serum potassium levels (3.0 mmol/L and 3.5 mmol/L; P < 0.001), and higher serum CO, (P = 0.001), atrial natriuretic peptide (P = 0.008), and urinary 18-methyl oxygenated cortisol metabolite levels (P = 0.02). In patients with adenomas, aldosterone secretion lateralized to one adrenal gland and did not increase during the postural stimulation test; preoperative urinary aldosterone levels were correlated with diastolic pressures (r = 0.58; P = 0.001). Hypertension was ''cured'' postoperatively in approximately 35% of patients with adenomas and those with hyperplasia (P > 0.2) but was ''improved'' more frequently in those with adenomas (P= 0.002). Cured patients from both groups were younger than those not cured (mean ages, 43 years anti 54 years, respectively; P = 0.002) and had lower preoperative mean plasma renin activity (0.17 ng/mL per hour and 0.50 ng/mL per hour; P < 0.001). All patient!; with adenomas in whom aldosterone secretion lateralized were either cured or improved. Conclusion: Of the 51 patients with primary aldosteronism who had adrenalectomy (43 patients with adenomas and 8 with hyperplasia), those most likely to be cured were younger and had lower plasma renin activity. In patients with adenomas who were cured or improved, aldosterone secretion was more likely to lateralize. Tests that distinguished adenomas from adrenal hyperplasia included the postural stimulation test, urinary excretion rates of 18-oxocortisol and 18-hydroxycortisol, and adrenal vein sampling.	VET AFFAIRS MED CTR, HYPERTENS RES LAB 151, BRONX, NY 10468 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	BLUMENFELD, JD (corresponding author), CORNELL UNIV, MED CTR,NEW YORK HOSP,CTR CARDIOVASC, 520 E 70TH ST, STARR 4, NEW YORK, NY 10021 USA.		Acevedo, Romina/HCI-4706-2022; Blumenfeld, Jon/ABC-1107-2021; Sealey, Jean/A-9562-2009		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000047] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00047] Funding Source: Medline; NHLBI NIH HHS [HL 18323] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEEVERS DG, 1976, Q J MED, V45, P401; BOLLI P, 1980, J CARDIOVASC PHARM, V2, pS399, DOI 10.1097/00005344-198002003-00013; BRAVO EL, 1983, AM J MED, V74, P641, DOI 10.1016/0002-9343(83)91022-7; BRAVO EL, 1988, HYPERTENSION, V11, P207; BRAVO EL, 1986, HYPERTENSION, V8, P191; BRAVO EL, 1985, HYPERTENSION, V7, P90, DOI 10.1161/01.HYP.7.1.90; BRUNNER HR, 1972, NEW ENGL J MED, V286, P441, DOI 10.1056/NEJM197203022860901; BUHLER FR, 1972, NEW ENGL J MED, V287, P1209, DOI 10.1056/NEJM197212142872401; BUHLER FR, 1974, HYPERTENSION MANUAL, P655; BURSZTYN M, 1988, AM J HYPERTENS, V1, pS88, DOI 10.1093/ajh/1.3.88S; CODY RJ, 1986, J CLIN INVEST, V78, P1362, DOI 10.1172/JCI112723; Conn JW., 1968, HARVEY LECT, V62, P257; FARMER RW, 1974, CLIN CHEM, V20, P411; FONTES RG, 1991, AM J HYPERTENS, V4, P786, DOI 10.1093/ajh/4.9.786; GANGULY A, 1973, J CLIN ENDOCR METAB, V36, P401, DOI 10.1210/jcem-36-2-401; Gordon R D, 1987, J Hypertens Suppl, V5, pS103; HAMLET SM, 1985, CLIN EXP PHARMACOL P, V12, P249, DOI 10.1111/j.1440-1681.1985.tb02641.x; HIRAMATSU K, 1981, ARCH INTERN MED, V141, P1589, DOI 10.1001/archinte.141.12.1589; IRONY I, 1990, AM J HYPERTENS, V3, P576, DOI 10.1093/ajh/3.7.576; IWAOKA T, 1990, ENDOCRINOL JAPON, V37, P151; LJUNGMAN S, 1990, AM J HYPERTENS, V3, P956, DOI 10.1093/ajh/3.12.956; MCLEOD MK, 1989, SURGERY, V106, P1161; MELBY JC, 1984, KIDNEY INT, V26, P769, DOI 10.1038/ki.1984.215; MELBY JC, 1967, NEW ENGL J MED, V277, P1050, DOI 10.1056/NEJM196711162772002; NADLER JL, 1985, J CLIN ENDOCR METAB, V60, P896, DOI 10.1210/jcem-60-5-896; NAKADA T, 1989, J UROLOGY, V142, P13, DOI 10.1016/S0022-5347(17)38650-0; PEDRINELLI R, 1988, HYPERTENSION, V12, P192, DOI 10.1161/01.HYP.12.2.192; RADIN DR, 1992, AM J ROENTGENOL, V158, P553, DOI 10.2214/ajr.158.3.1738993; SCOGGINS BA, 1972, ANN INTERN MED, V76, P891, DOI 10.7326/0003-4819-76-6-391; SEALEY JE, 1991, CLIN CHEM, V37, P1811; SEALEY JE, 1972, CIRC RES, V31, P367, DOI 10.1161/01.RES.31.3.367; STREETEN DHP, 1990, AM J HYPERTENS, V3, P360, DOI 10.1093/ajh/3.5.360; TORRES VE, 1990, NEW ENGL J MED, V322, P345, DOI 10.1056/NEJM199002083220601; TUNNY TJ, 1991, CLIN ENDOCRINOL, V34, P363, DOI 10.1111/j.1365-2265.1991.tb00306.x; TUNNY TJ, 1986, CLIN EXP PHARMACOL P, V13, P341, DOI 10.1111/j.1440-1681.1986.tb00360.x; ULICK S, 1993, J CLIN ENDOCR METAB, V76, P873, DOI 10.1210/jc.76.4.873; ULICK S, 1989, ADRENAL HYPERTENSION, P313; WEIBNERGER MH, 1984, ANN INTERN MED, V90, P386; YAMAJI T, 1986, J CLIN ENDOCR METAB, V63, P815, DOI 10.1210/jcem-63-4-815; 1990, NEW ENGL J MED, V323, P29	40	213	224	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					877	885		10.7326/0003-4819-121-11-199412010-00010	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978702				2022-12-24	WOS:A1994PT62800010
J	PARSELL, DA; KOWAL, AS; SINGER, MA; LINDQUIST, S				PARSELL, DA; KOWAL, AS; SINGER, MA; LINDQUIST, S			PROTEIN DISAGGREGATION MEDIATED BY HEAT-SHOCK PROTEIN HSP104	NATURE			English	Article							RNA-POLYMERASE; YEAST-CELLS; DNAK; BINDING; HSP70; CHAPERONES; ORIGIN; REPA	THE heat-inducible members of the Hsp100 (or Clp) family of proteins share a common function in helping organisms to survive extreme stress, but the basic mechanism through which these proteins function is not understood(1-5) Hsp104 protects cells against a variety of stresses, under many physiological conditions(6,7) and its function has been evolutionarily conserved, at least from Saccharomyces cerevisiae to Arabidopsis thaliana(25). Homology with the Escherichia coli ClpA protein suggests that Hsp104 may provide stress tolerance by helping to rid the tell of heat-denatured proteins through proteolysis(1). But genetic analysis indicates that Hsp104 may function like Hsp70 as a molecular chaperones(8). Here we investigate the role of Hsp104 in vivo using a temperature-sensitive Vibrio harveyi luciferase-fusion protein as a test substrate(9). We find that Hsp104 does not protect luciferase from thermal denaturation, nor does it promote proteolysis of luciferase. Rather, Hsp104 functions in a manner not previously described for other heat-shock proteins: it mediates the resolubilization of heat-inactivated luciferase from insoluble aggregates.	UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PATHOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago								BYERS B, 1991, METHOD ENZYMOL, V194, P602; ESCHER A, 1989, P NATL ACAD SCI USA, V86, P6528, DOI 10.1073/pnas.86.17.6528; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; KRUGER E, 1994, J BACTERIOL, V176, P3360; KURTZ S, 1985, SEQUENCE SPECIFICITY, P611; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SCHIRMER E, IN PRESS PL CELL; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHANER SL, 1982, BIOCHEMISTRY-US, V21, P5539, DOI 10.1021/bi00265a025; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; TRECO DA, 1989, CURRENT PROTOCOLS MO; VANTUINEN E, 1987, J HISTOCHEM CYTOCHEM, V35, P327, DOI 10.1177/35.3.3546482; WEBSTER DL, 1993, YEAST, V9, P1165, DOI 10.1002/yea.320091103; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WRIGHT R, 1989, METHOD CELL BIOL, V31, P473	25	727	743	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 1	1994	372	6505					475	478		10.1038/372475a0	http://dx.doi.org/10.1038/372475a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984243				2022-12-24	WOS:A1994PV01200060
J	BANERJEE, A; JONES, R				BANERJEE, A; JONES, R			WHITHER IMMEDIATE FLUID RESUSCITATION	LANCET			English	Editorial Material											BANERJEE, A (corresponding author), ROTHERHAM DIST GEN HOSP,DEPT GEN SURG,ROTHERHAM,S YORKSHIRE,ENGLAND.		Banerjee, Anjan Kumar/AAL-6375-2020	Banerjee, Anjan Kumar/0000-0002-5935-3404				BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BICKELL WH, 1992, ANN EMERG MED, V21, P1077, DOI 10.1016/S0196-0644(05)80648-1; CRAWFORD ES, 1991, J VASC SURG, V13, P348; DEMETRIADES D, 1993, BRIT J SURG, V80, P1534, DOI 10.1002/bjs.1800801213; DILLON J, 1966, ARCH SURG-CHICAGO, V93, P537; JACOBS LM, 1994, NEW ENGL J MED, V331, P1153, DOI 10.1056/NEJM199410273311710; SHIRES T, 1964, ARCH SURG-CHICAGO, V88, P688; SIRINEK KR, 1990, ARCH SURG-CHICAGO, V125, P844; 1993, ADV TRAUMA LIFE SUPP, P75	9	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1450	1451		10.1016/S0140-6736(94)90283-6	http://dx.doi.org/10.1016/S0140-6736(94)90283-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968115				2022-12-24	WOS:A1994PT99500002
J	LEVINE, A; TENHAKEN, R; DIXON, R; LAMB, C				LEVINE, A; TENHAKEN, R; DIXON, R; LAMB, C			H2O2 FROM THE OXIDATIVE BURST ORCHESTRATES THE PLANT HYPERSENSITIVE DISEASE RESISTANCE RESPONSE	CELL			English	Article							CELL-SUSPENSION CULTURES; DNA-BINDING ACTIVITY; PHASEOLUS-VULGARIS; DEFENSE RESPONSE; MESSENGER-RNA; INDUCTION; ELICITOR; GENE; PROTEIN; ELICITATION	Microbial elicitors or attempted infection with an avirulent pathogen strain causes the rapid production of reactive oxygen intermediates. We report here that H2O2 from this oxidative bu rst not only drives the crosslinking of cell wall structural proteins, but also functions as a local trigger of programmed death in challenged cells and as a diffusible signal for the induction in adjacent cells of genes encoding cellular protectants such as glutathione S-transferase and glutathione peroxidase. Thus, H2O2 from the oxidative burst plays a key role in the orchestration of a localized hypersensitive response during the expression of plant disease resistance.	SALK INST BIOL STUDIES, PLANT BIOL LAB, LA JOLLA, CA 92037 USA; SAMUEL ROBERTS NOBLE FDN INC, DIV PLANT BIOL, ARDMORE, OK 73402 USA	Salk Institute; Noble Research Institute			Tenhaken, Raimund/O-6556-2019; Levine, Alex/A-6867-2008	Tenhaken, Raimund/0000-0002-6764-4826; 				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; ATKINSON MM, 1990, PLANT PHYSIOL, V92, P215, DOI 10.1104/pp.92.1.215; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BABIYCHUK E, 1994, P NATL ACAD SCI USA, V91, P3299, DOI 10.1073/pnas.91.8.3299; BAKER CJ, 1993, PHYSIOL MOL PLANT P, V43, P81, DOI 10.1006/pmpp.1993.1042; BECKER F, 1993, PLANT J, V3, P875, DOI 10.1111/j.1365-313X.1993.00875.x; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; BRISSON LF, 1994, IN PRESS PLANT CELL; BULTKE TM, 1994, TODAY, V15, P7; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; CREELMAN RA, 1992, P NATL ACAD SCI USA, V89, P4938, DOI 10.1073/pnas.89.11.4938; CRIQUI MC, 1992, PLANT MOL BIOL, V18, P623, DOI 10.1007/BF00040684; CZARNECKA E, 1988, MOL CELL BIOL, V8, P1113, DOI 10.1128/MCB.8.3.1113; DAVIS D, 1993, PHYTOCHEMISTRY, V32, P607, DOI 10.1016/S0031-9422(00)95144-6; DEVLIN WS, 1992, PLANT PHYSIOL, V100, P1189, DOI 10.1104/pp.100.3.1189; DIETRICH A, 1990, J BIOL CHEM, V265, P6360; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DIXON RA, 1983, PLANT PHYSIOL, V71, P251, DOI 10.1104/pp.71.2.251; EDWARDS K, 1985, P NATL ACAD SCI USA, V82, P6731, DOI 10.1073/pnas.82.20.6731; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; FELIX G, 1994, P NATL ACAD SCI USA, V91, P952, DOI 10.1073/pnas.91.3.952; GREENBERG JT, 1993, PLANT J, V4, P327, DOI 10.1046/j.1365-313X.1993.04020327.x; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; HAHN MG, 1992, MOL PLANT PATHOL, V2, P231; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAVIR EA, 1992, PLANT PHYSIOL, V99, P533, DOI 10.1104/pp.99.2.533; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HEROUART D, 1993, P NATL ACAD SCI USA, V90, P3108, DOI 10.1073/pnas.90.7.3108; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ITZHAKI H, 1993, PLANT MOL BIOL, V22, P43, DOI 10.1007/BF00038994; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KEEN NT, 1991, THEOR APPL GENET, V81, P133, DOI 10.1007/BF00226123; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KIEDROWSKI S, 1992, EMBO J, V11, P4677, DOI 10.1002/j.1460-2075.1992.tb05572.x; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LAMB CJ, 1994, CELL, V76, P419, DOI 10.1016/0092-8674(94)90106-6; LI YM, 1992, P NATL ACAD SCI USA, V89, P11867, DOI 10.1073/pnas.89.24.11867; MAUCH F, 1993, PLANT PHYSIOL, V102, P1193, DOI 10.1104/pp.102.4.1193; MCGURL B, 1992, SCIENCE, V255, P1570, DOI 10.1126/science.1549783; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; OLSON PD, 1993, PLANT J, V4, P887, DOI 10.1046/j.1365-313X.1993.04050887.x; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; ROOT RK, 1975, J CLIN INVEST, V55, P945, DOI 10.1172/JCI108024; RYALS J, 1994, PLANT PHYSIOL, V104, P1109, DOI 10.1104/pp.104.4.1109; RYDER TB, 1984, P NATL ACAD SCI-BIOL, V81, P5724, DOI 10.1073/pnas.81.18.5724; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SUTHERLAND MW, 1991, PHYSIOL MOL PLANT P, V39, P79, DOI 10.1016/0885-5765(91)90020-I; TURNER JG, 1974, PHYTOPATHOLOGY, V64, P885, DOI 10.1094/Phyto-64-885; VARNER JE, 1989, CELL, V56, P231, DOI 10.1016/0092-8674(89)90896-9; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VERNOOIJ B, 1994, PLANT CELL, V6, P959, DOI 10.1105/tpc.6.7.959; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	59	2168	2366	6	271	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 18	1994	79	4					583	593		10.1016/0092-8674(94)90544-4	http://dx.doi.org/10.1016/0092-8674(94)90544-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954825				2022-12-24	WOS:A1994PT48100006
J	SONDEK, J; LAMBRIGHT, DG; NOEL, JP; HAMM, HE; SIGLER, PB				SONDEK, J; LAMBRIGHT, DG; NOEL, JP; HAMM, HE; SIGLER, PB			GTPASE MECHANISM OF GPROTEINS FROM THE 1.7-ANGSTROM CRYSTAL-STRUCTURE OF TRANSDUCIN ALPHA-CENTER-DOT-GDP-CENTER-DOT-ALF4(-)	NATURE			English	Article							H-RAS P21; X-RAY; HYDROLYSIS; PROTEIN; MUTANTS; ACTIVATION; INHIBITION; MUTATIONS; ALUMINUM; FLUORIDE	ALUMINIUM fluoride (AlF4-) activates members of the heterotrimeric G-protein (G(alpha beta gamma)) family(1,2) by binding to inactive G(alpha).GDP near the site occupied by the gamma-phosphate in G(alpha).GTP (ref. 3). Here we describe the crystal structure of transducin alpha.GDP activated with aluminium fluoride (G(t alpha).GDP.AlF4-.H2O) at 1.7 Angstrom, a resolution sufficient to establish the coordination geometry of the bound aluminium fluoride as well as the extensive network of direct and water-mediated interactions that stabilize it. These observations are derived from three independent representations in the asymmetric unit, eliminating any chance of drawing conclusions based on stereochemistry imposed by crystal packing. Surprisingly, aluminium fluoride activates G(alpha).GDP by binding with a geometry resembling a pentavalent intermediate for GTP hydrolysis. The stabilizing interactions involve not only residues that interact with the gamma-phosphate in G(t alpha).GTP gamma S, but also conserved residues essential for GTPase activity. Thus the G(t alpha).GDP.AlF4-.H2O structure provides new insight into the mechanism of GTP hydrolysis.	YALE UNIV,BOYER CTR MOLEC MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60680; UNIV SASSARI,IST FISIOL GEN & CHIM BIOL,I-07100 SASSARI,ITALY	Yale University; Howard Hughes Medical Institute; Yale University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Sassari			Hamm, Heidi E/G-2374-2014; Noel, Joseph P/A-9459-2009	Sondek, John/0000-0002-1127-8310				ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHUNG HH, 1993, SCIENCE, V259, P806, DOI 10.1126/science.8430333; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DUPUIS A, 1989, FEBS LETT, V255, P47, DOI 10.1016/0014-5793(89)81058-0; FOURQUET JL, 1986, REV CHIM MINER, V23, P183; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GOODY RS, 1992, PHILOS T ROY SOC B, V336, P3, DOI 10.1098/rstb.1992.0037; GROTTEL M, 1992, J PHYS-CONDENS MAT, V4, P1837, DOI 10.1088/0953-8984/4/7/022; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARUTA S, 1993, J BIOL CHEM, V268, P7093; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; SCHEPARTZ A, 1987, J AM CHEM SOC, V109, P1814, DOI 10.1021/ja00240a036; SCHWEINS T, 1994, NAT STRUCT BIOL, V1, P476, DOI 10.1038/nsb0794-476; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STRYER L, 1983, METHOD ENZYMOL, V96, P617; SUAREZ HG, 1991, ONCOGENE, V6, P677; SWAIN CG, 1952, J AM CHEM SOC, V74, P2538, DOI 10.1021/ja01130a024; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996	30	539	546	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					276	279		10.1038/372276a0	http://dx.doi.org/10.1038/372276a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969474				2022-12-24	WOS:A1994PR88900054
J	MADDOX, J				MADDOX, J			FRONTIERS OF IGNORANCE - IS THE BRAIN A COMPUTER	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					35	36						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969413				2022-12-24	WOS:A1994PQ34800048
J	VU, TH; HOFFMAN, AR				VU, TH; HOFFMAN, AR			PROMOTER-SPECIFIC IMPRINTING OF THE HUMAN INSULIN-LIKE GROWTH FACTOR-II GENE	NATURE			English	Article							ALLELE-SPECIFIC METHYLATION; BECKWITH-WIEDEMANN SYNDROME; WILMS-TUMOR; IGF2 GENE; MOUSE; RELAXATION; EMBRYOGENESIS; CANCER	GENOMIC imprinting is a mechanism whereby only one of the two parental alleles is expressed. Loss or relaxation of genomic imprinting has been proposed as an epigenetic mechanism for oncogenesis in a variety of human tumours(1-6). Although the mechanism of imprinting is unknown, differential CpG methylation of the parental alleles has been implicated(7-12). The human insulinlike growth factor-II (IGF2) gene, which is transcribed from four promoters, P1-P4 (ref. 13), is imprinted in fetal liver(14,15) but biallelic expression occurs in adult liver(16). Like most tissues, fetal liver uses primarily promoters P3 and P4 (ref. 17). Adult liver, however, transcribes IGF2 from promoter P1, and it has been suggested that the recruitment of P1 may be responsible for the absence of imprinting in human liver, and in choroid plexus and leptomeninges(18). We report here that in liver and chondrocytes, IGF2 transcripts from promoter P1 are always derived from both parental alleles, whereas transcripts from promoters P2, P3 and P4 are always from one parental allele. These findings demonstrate that imprinting and a lack of imprinting can both occur within a single gene in a single tissue, suggesting that regional imprinting factors may be important.	STANFORD UNIV,DEPT MED,PALO ALTO,CA 94304	Stanford University	VU, TH (corresponding author), VET ADM MED CTR,MED SERV,3801 MIRANDA AVE,PALO ALTO,CA 94304, USA.			Hoffman, Andrew/0000-0002-0145-1917				BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; CATTANACH BM, 1990, DEVELOPMENT, P63; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EKSBERG R, 1993, NAT GENET, V5, P143; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SCHNEID H, 1993, J MED GENET, V30, P353, DOI 10.1136/jmg.30.5.353; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9	24	208	212	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					714	717		10.1038/371714a0	http://dx.doi.org/10.1038/371714a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935819				2022-12-24	WOS:A1994PM77300060
J	COHEN, J				COHEN, J			LABORATORY WASTES - TOXIC DISPUTE COSTS STANFORD 1-MILLION-DOLLARS	SCIENCE			English	Editorial Material																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					213	213		10.1126/science.7939653	http://dx.doi.org/10.1126/science.7939653			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939653				2022-12-24	WOS:A1994PM13400013
J	MOY, VT; FLORIN, EL; GAUB, HE				MOY, VT; FLORIN, EL; GAUB, HE			INTERMOLECULAR FORCES AND ENERGIES BETWEEN LIGANDS AND RECEPTORS	SCIENCE			English	Article							SCANNING TUNNELING MICROSCOPY; ACTIN FILAMENT; STREPTAVIDIN; CELLS	The recognition mechanisms and dissociation pathways of the avidin-biotin complex and of actin monomers in actin filaments were investigated. The unbinding forces of discrete complexes of avidin or streptavidin with biotin analogs are proportional to the enthalpy change of the complex formation but independent of changes in the free energy. This result indicates that the unbinding process is adiabatic and that entropic changes occur after unbinding. On the basis of the measured forces and binding energies, an effective rupture length of 9.5 +/- 1 angstroms was calculated for all biotin-avidin pairs and approximately 1 to 3 angstroms for the actin monomer-monomer interaction. A model for the correlation among binding forces, intermolecular potential, and molecular function is proposed.	TECH UNIV MUNICH,DEPT PHYS,D-85748 GARCHING,GERMANY	Technical University of Munich								[Anonymous], 1992, INTERMOLECULAR SURFA; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BINNIG G, 1987, REV MOD PHYS, V59, P615, DOI 10.1103/RevModPhys.59.615; EVANS E, 1991, BIOPHYS J, V59, P838, DOI 10.1016/S0006-3495(91)82296-2; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GREEN NM, 1966, BIOCHEM J, V101, P774, DOI 10.1042/bj1010774; HANSMA PK, 1988, SCIENCE, V242, P209, DOI 10.1126/science.3051380; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUTTER JL, 1993, REV SCI INSTRUM, V64, P1868, DOI 10.1063/1.1143970; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; LECKBAND DE, 1994, BIOCHEMISTRY-US, V33, P4611, DOI 10.1021/bi00181a023; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; MIYAMOTO S, 1993, PROTEINS, V16, P226, DOI 10.1002/prot.340160303; MOY VT, 1993, REV SCI INSTRUM, V64, P403; OOSAWA F, 1977, BIORHEOLOGY, V14, P11; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; SENDEN TJ, 1994, LANGMUIR, V10, P1003, DOI 10.1021/la00016a600; SHETERLINE P, 1994, ACTIN, V1; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WEBER PC, 1992, J AM CHEM SOC, V114, P3197, DOI 10.1021/ja00035a004	24	763	784	2	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					257	259		10.1126/science.7939660	http://dx.doi.org/10.1126/science.7939660			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939660				2022-12-24	WOS:A1994PM13400027
J	STEINHOFF, HJ; MOLLAAGHABABA, R; ALTENBACH, C; HIDEG, K; KREBS, M; KHORANA, HG; HUBBELL, WL				STEINHOFF, HJ; MOLLAAGHABABA, R; ALTENBACH, C; HIDEG, K; KREBS, M; KHORANA, HG; HUBBELL, WL			TIME-RESOLVED DETECTION OF STRUCTURAL-CHANGES DURING THE PHOTOCYCLE OF SPIN-LABELED BACTERIORHODOPSIN	SCIENCE			English	Article							HALOBACTERIUM-HALOBIUM; CONFORMATIONAL-CHANGES; PROTON TRANSLOCATION; LIGHT; DIFFRACTION; PROTEIN; MUTANTS; SPECTROSCOPY; MECHANISM; RHODOPSIN	Bacteriorhodopsin was selectively spin labeled at residues 72, 101, or 105 after replacement of the native amino acids by cysteine. Only the electron paramagnetic resonance spectrum of the label at 101 was time-dependent during the photocycle. The spectral change rose with the decay of the M intermediate and fell with recovery of the ground state. The transient signal is interpreted as the result of movement in the C-D or E-F interhelical loop, or in both, coincident with protonation changes at the key aspartate 96 residue. These results link the optically characterized intermediates with localized conformational changes in bacteriorhodopsin during the photocycle.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139; RUHR UNIV BOCHUM,INST BIOPHYS,D-44780 BOCHUM,GERMANY; UNIV CALIF LOS ANGELES,JULES STEIN EYE INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV PECS,CENT RES LAB,H-7643 PECS,HUNGARY	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Ruhr University Bochum; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Pecs			Steinhoff, Heinz-Juergen/H-3791-2014	Steinhoff, Heinz-Juergen/0000-0002-5888-0157; Krebs, Mark/0000-0001-9017-6066	NATIONAL EYE INSTITUTE [R37EY005216, R01EY005216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028289, R01GM028289] Funding Source: NIH RePORTER; NEI NIH HHS [EY05216] Funding Source: Medline; NIGMS NIH HHS [GM28289] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXIEV U, 1994, BIOPHYS J, V66, pA44; ALEXIEV U, UNPUB; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; DENCHER NA, 1989, P NATL ACAD SCI USA, V86, P7876, DOI 10.1073/pnas.86.20.7876; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; GERWERT K, 1990, P NATL ACAD SCI USA, V87, P9774, DOI 10.1073/pnas.87.24.9774; GREENHALGH DA, 1991, P NATL ACAD SCI USA, V88, P8626, DOI 10.1073/pnas.88.19.8626; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON RD, COMMUNICATION; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; KREBS MP, 1993, J BACTERIOL, V175, P1555, DOI 10.1128/JB.175.6.1555-1560.1993; KREBS MP, 1993, P NATL ACAD SCI USA, V90, P1987, DOI 10.1073/pnas.90.5.1987; LOZIER RH, 1975, BIOPHYS J, V15, P955, DOI 10.1016/S0006-3495(75)85875-9; OESTERHELT D, 1991, Q REV BIOPHYS, V24, P425, DOI 10.1017/S0033583500003863; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; ROTHSCHILD KJ, 1993, J BIOL CHEM, V268, P27046; SOUVIGNIER G, 1992, BIOPHYS J, V63, P1393, DOI 10.1016/S0006-3495(92)81722-8; STOECKENIUS W, 1979, BIOCHIM BIOPHYS ACTA, V505, P215, DOI 10.1016/0304-4173(79)90006-5; SUBRAMANIAM S, 1993, EMBO J, V12, P1; TODD AP, 1989, PROTEINS, V6, P294, DOI 10.1002/prot.340060312	22	148	149	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					105	107		10.1126/science.7939627	http://dx.doi.org/10.1126/science.7939627			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939627				2022-12-24	WOS:A1994PK58200033
J	LI, R; WAGA, S; HANNON, GJ; BEACH, D; STILLMAN, B				LI, R; WAGA, S; HANNON, GJ; BEACH, D; STILLMAN, B			DIFFERENTIAL-EFFECTS BY THE P21 CDK INHIBITOR ON PCNA-DEPENDENT DNA-REPLICATION AND REPAIR	NATURE			English	Article							LAGGING STRAND SYNTHESIS; CELL NUCLEAR ANTIGEN; POLYMERASE-DELTA; EXCISION REPAIR; AUXILIARY PROTEIN; INVITRO; KINASES; P53; SUBUNIT; EPSILON	IN mammalian cells, DNA damage increases the levels of the nuclear tumour-suppressor p53, resulting io elevated synthesis of p21, an inhibitor oi cyclin-dependent kinases (CDK)(1-6). p21 may also directly block DNA replication by inhibiting the proliferating-cell nuclear antigen (PCNA)(7), an essential DNA replication protein. However PCNA is also required for nucleotide-excision repair of DNA(8), an intrinsic part of the cellular response to ultraviolet irradiation. Using an in vitro system(9) we now show that p21 does not block PCNA-dependent nucleotide-excision repair, in contrast to its inhibition of simian virus 40 DNA replication(7) Furthermore, the short gap-filling DNA synthesis by PCNA-dependent DNA polymerases delta and epsilon is less sensitive to inhibition by p21 than is long primer-extension synthesis. The ability of p21 to inhibit the role of PCNA in DNA replication but not in DNA repair rationalizes in vivo data showing that genetic damage leads to inactivation of chromosomal replication while allowing damage-responsive repair.			LI, R (corresponding author), COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,POB 100,COLD SPRING HARBOR,NY 11724, USA.		Hannon, Gregory/AAB-3568-2019	Stillman, Bruce/0000-0002-9453-4091; Waga, Shou/0000-0003-4986-8735				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; [Anonymous], 1985, DNA REPAIR; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LEE SH, 1991, J BIOL CHEM, V266, P2207; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MELENDY T, 1992, NUCLEIC ACIDS MOL BI, V6, P129; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WELSER T, 1991, J BIOL CHEM, V266, P10420; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; ZENG XR, 1994, J BIOL CHEM, V269, P13748	29	634	656	4	52	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					534	537		10.1038/371534a0	http://dx.doi.org/10.1038/371534a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935768				2022-12-24	WOS:A1994PK58900061
J	WRAY, J; POTMEES, C; ZEITLIN, H; RADLEYSMITH, R; YACOUB, M				WRAY, J; POTMEES, C; ZEITLIN, H; RADLEYSMITH, R; YACOUB, M			COGNITIVE FUNCTION AND BEHAVIORAL STATUS IN PEDIATRIC HEART AND HEART-LUNG TRANSPLANT RECIPIENTS - THE HAREFIELD EXPERIENCE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; ADJUSTMENT; DEFECTS; DISEASE	Objective-To assess the psychological impact of cardiac and cardiopulmonary transplantation on children. Design-Retrospective cross sectional study. Setting-One British centre performing paediatric heart and heart-lung transplant operations, four cardiac units in London, three London schools, two London health centres, and the dental department of a London children's hospital. Subjects-65 children who had been given heart or heart-lung transplants and two reference groups of 52 children who had had other types of cardiac surgery and 45 healthy children. Main outcome measures-Development, cognition, and behaviour at home and at school as assessed by measures with proved validity and reliability. Results-Developmental and cognitive measures indicated that children given transplants had significantly lower scores on several parameters, particularly in terms of development in children under 41/2 years of age. Performance on all tests, however, was within the normal range. There were no significant differences in behavioural ratings between the transplant and reference groups, though problem behaviour at home was more prevalent in the transplant group. Conclusions-Though cognitive development may be within the normal range, there are adverse psychological effects associated with cardiac and cardiopulmonary transplantation. These data indicate the need for a controlled prospective study in which children and their families are seen before and at regular intervals after transplantation. Interventions should he-developed that are tailored to the particular needs of this very specialised group of paediatric patients and their families.	WESTMINSTER MED SCH & HOSP, CHARING CROSS & WESTMINSTER MED SCH, DEPT PSYCHIAT, LONDON SW1P 2NS, ENGLAND	Imperial College London	WRAY, J (corresponding author), HAREFIELD HOSP, CARDIOTHORAC UNIT, HAREFIELD UB9 6UJ, MIDDX, ENGLAND.			Wray, Jo/0000-0002-4769-1211				APLEY J, 1967, BMJ-BRIT MED J, V1, P103, DOI 10.1136/bmj.1.5532.103; ARAM DM, 1985, J AM COLL CARDIOL, V6, P889; Banner, 1989, TRANSPLANT REV, V3, P1, DOI [10.1016/S0955-470X(89)80003-5, DOI 10.1016/S0955-470X(89)80003-5]; BANNER NR, 1989, ASSISTED CIRCULATION, V3, P448; BERNSTEIN DM, 1977, GIFT LIFE SOCIAL PSY, P119; DANILOWICZ DA, 1971, AM J PSYCHIAT, V128, P185, DOI 10.1176/ajp.128.2.185; Elliot C. D., 1983, BRIT ABILITY SCALES; FRICKER FJ, 1987, PEDIATRICS, V79, P138; FULTON M, 1987, LANCET, V1, P1221; GARRALDA ME, 1988, J CHILD PSYCHOL PSYC, V29, P79, DOI 10.1111/j.1469-7610.1988.tb00691.x; Griffiths R., 1970, ABILITIES YOUNG CHIL; HELLER A, 1985, AM J DIS CHILD, V139, P257, DOI 10.1001/archpedi.1985.02140050051021; KONG SG, 1986, AUST PAEDIATR J, V22, P101; KORSCH BM, 1973, J PEDIATR-US, V83, P399, DOI 10.1016/S0022-3476(73)80262-8; LAWRENCE KS, 1987, J HEART TRANSPLANT, V6, P329; LINDE LM, 1970, ACTA PAEDIATR SCAND, V59, P169, DOI 10.1111/j.1651-2227.1970.tb08984.x; LINDE LM, 1967, J PEDIATR-US, V71, P198, DOI 10.1016/S0022-3476(67)80072-6; NEWBURGER JW, 1984, NEW ENGL J MED, V310, P1495, DOI 10.1056/NEJM198406073102303; ODOUGHERTY M, 1983, CHILD DEV, V54, P1129, DOI 10.1111/j.1467-8624.1983.tb00534.x; PAHL E, 1988, TRANSPLANT P, V20, P743; PENNINGTON DG, 1985, HEART TRANSPLANT, V4, P441; PLESS IB, 1975, CHILD HLTH COMMUNITY, P41; POTMEES C, 1989, PSYCHOSOCIAL AFFECTS; RICHMAN N, 1971, J CHILD PSYCHOL PSYC, V12, P5, DOI 10.1111/j.1469-7610.1971.tb01047.x; ROSENTHAL A, 1975, PROG CARDIOVASC DIS, V18, P27, DOI 10.1016/0033-0620(75)90005-5; RUTTER M, 1970, ED HLTH BEHAVIOR; SCHONELL FJ, 1949, DIAGNOSTIC ATTAINMEN; UZARK K, 1989, PROG CARDIOVASC NURS, V46, P382	28	39	39	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	1994	309	6958					837	841		10.1136/bmj.309.6958.837	http://dx.doi.org/10.1136/bmj.309.6958.837			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7950613	Green Published			2022-12-24	WOS:A1994PK50100019
J	BARLOWE, C; ORCI, L; YEUNG, T; HOSOBUCHI, M; HAMAMOTO, S; SALAMA, N; REXACH, MF; RAVAZZOLA, M; AMHERDT, M; SCHEKMAN, R				BARLOWE, C; ORCI, L; YEUNG, T; HOSOBUCHI, M; HAMAMOTO, S; SALAMA, N; REXACH, MF; RAVAZZOLA, M; AMHERDT, M; SCHEKMAN, R			COPII - A MEMBRANE COAT FORMED BY SEC PROTEINS THAT DRIVE VESICLE BUDDING FROM THE ENDOPLASMIC-RETICULUM	CELL			English	Article							YEAST SECRETORY PATHWAY; GOLGI TRANSPORT VESICLES; ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; VESICULAR TRANSPORT; BETA-COP; ESCHERICHIA-COLI; COMPLEX; CLATHRIN; ER	In vitro synthesis of endoplasmic reticulum-derived transport vesicles has been reconstituted with washed membranes and th ree soluble proteins (Sar1p, Sec13p complex, and Sec23p complex). Vesicle formation requires GTP but can be driven by nonhydrolyzable analogs such as GMP-PNP. However, GMP-PNP vesicles fail to target and fuse with the Golgi complex whereas GTP vesicles are functional. All the cytosolic proteins required for vesicle formation are retained on GMP-PNP vesicles, while Sar1p dissociates from GTP vesicles. Thin section electron microscopy of purified preparations reveals a uniform population of 60-65 nm vesicles with a 10 nm thick electron dense coat. The subunits of this novel coat complex are molecularly distinct from the constituents of the nonclathrin coatomer involved in intra-Golgi transport. Because the overall cycle of budding driven by these two types of coats appears mechanistically similar, we propose that the coat structures be called COPI and COPII.	UNIV GENEVA, SCH MED, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva	BARLOWE, C (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.		Salama, Nina Reda/AAG-2437-2019	Salama, Nina Reda/0000-0003-2762-1424				BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; BARLOWE C, J BIOL CHEM, V268, P87393; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; KUGE O, 1993, J CELL BIOL, V123, P1727, DOI 10.1083/jcb.123.6.1727; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OKA T, 1994, J CELL BIOL, V124, P425, DOI 10.1083/jcb.124.4.425; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PAYNE GS, 1985, SCIENCE, V230, P1009, DOI 10.1126/science.2865811; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	60	1042	1057	0	135	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					895	907		10.1016/0092-8674(94)90138-4	http://dx.doi.org/10.1016/0092-8674(94)90138-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004676				2022-12-24	WOS:A1994NT33100014
J	TONTONOZ, P; HU, ED; SPIEGELMAN, BM				TONTONOZ, P; HU, ED; SPIEGELMAN, BM			STIMULATION OF ADIPOGENESIS IN FIBROBLASTS BY PPAR-GAMMA-2, A LIPID-ACTIVATED TRANSCRIPTION FACTOR	CELL			English	Article							ENHANCER-BINDING-PROTEIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; HORMONE RECEPTOR SUPERFAMILY; PEROXISOME PROLIFERATOR; GENE-EXPRESSION; RETINOIC ACID; FATTY-ACIDS; ADIPOCYTE DIFFERENTIATION; 3T3-L1 PREADIPOCYTES; NUCLEAR RECEPTORS	Peroxisome proliferator-activated receptor gamma 2 (PPAR gamma 2) is an adipocyte-specific nuclear hormone receptor that has recently been identified as a key regulator of two fat cell enhancers. Transcriptional activation by PPAR gamma 2 is potentiated by a variety of lipids and lipid-like compounds, including naturally occurring polyunsaturated fatty acids. We demonstrate here that retroviral expression of PPAR gamma 2 stimulates adipose differentiation of cultured fibroblasts. PPAR activators promote the differentiation of PPAR gamma 2-expressing cells in a dose-dependent manner. C/EBP alpha, a second transcription factor induced during adipocyte differentiation, can cooperate with PPAR gamma 2 to stimulate the adipocyte program dramatically. Our results suggest that the physiologic role of PPAR gamma 2 is to regulate development of the adipose lineage in response to endogenous activators and that this factor may serve to link the process of adipocyte differentiation to systemic lipid metabolism.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	TONTONOZ, P (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.				NIDDK NIH HHS [DK31405] Funding Source: Medline; NIGMS NIH HHS [T32 GM007753, T32 GM07753] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031405, R37DK031405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; BENNETT PH, 1990, DIABETES MELLITUS TH, P357; BRANDES R, 1987, LIFE SCI, V40, P935, DOI 10.1016/0024-3205(87)90312-2; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; ENERBACK S, 1992, MOL CELL BIOL, V12, P4622, DOI 10.1128/MCB.12.10.4622; FINEBERG AP, 1984, ANAL BIOCHEM, V137, P266; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GHARBICHIHI J, 1993, BIOCHIM BIOPHYS ACTA, V1177, P8, DOI 10.1016/0167-4889(93)90150-N; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GRAVES RA, 1992, MOL CELL BIOL, V12, P1202, DOI 10.1128/MCB.12.3.1202; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KELLER H, 1993, TRENDS ENDOCRIN MET, V4, P291, DOI 10.1016/1043-2760(93)90048-J; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T, 1989, DECONTAMINATION DILU; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1995, IN PRESS NUCL ACIDS; TONTONOZ P, 1909, IN PRESS MOL CELL BI; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	49	3020	3148	6	189	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1147	1156		10.1016/0092-8674(94)90006-X	http://dx.doi.org/10.1016/0092-8674(94)90006-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001151				2022-12-24	WOS:A1994PZ86000006
J	COVINSKY, KE; GOLDMAN, L; COOK, EF; OYE, R; DESBIENS, N; REDING, D; FULKERSON, W; CONNORS, AF; LYNN, J; PHILLIPS, RS				COVINSKY, KE; GOLDMAN, L; COOK, EF; OYE, R; DESBIENS, N; REDING, D; FULKERSON, W; CONNORS, AF; LYNN, J; PHILLIPS, RS			THE IMPACT OF SERIOUS ILLNESS ON PATIENTS FAMILIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADULTS; SYSTEM; SERVICES	Objective.-To examine the impact of illness on the families of seriously ill adults and to determine the correlates of adverse economic impact. Design.-Data were collected during the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment (SUPPORT), a prospective cohort study of outcomes, preferences, and decision making in seriously ill hospitalized adults and their families. Setting.-Five tertiary care hospitals in the United States. Participants.-The 2661 seriously ill patients in nine diagnostic categories who survived their index hospitalization and were discharged home were eligible for this analysis, Surrogate and/or patient interviews about the impact of illness on the family were obtained for 2129 (80%) of these patients (mean age, 62 years; 43% women; 6-month survival, 75%). Outcome Measures.-Surrogates and patients were surveyed to determine the frequency of adverse caregiving and economic burdens, Multivariable analyses were performed to determine correlates of loss of family savings. Results.-One third (34%) of patients required considerable caregiving assistance from a family member. In 20% of cases, a family member had to quit work or make another major life change to provide care for the patient. Loss of most or all of the family savings was reported by 31% of families, whereas 29% reported loss of the major source of income. Patient factors independently associated with loss of the family's savings on multivariable analysis included poor functional status (odds ratio [OR], 1.40; 95% confidence interval [CI], 1.10 to 1.78 for patients needing assistance with three or more activities of daily living), lower family income (OR, 1.74; 95% CI, 1.37 to 2.21 for those with annual incomes below $25 000), and young age (OR, 2.85; 95% CI, 2.13 to 3.82 for those younger than 45 years compared with those 65 years or older). Conclusions.-Many families of seriously ill patients experience severe caregiving and financial burdens. Families of younger, poorer, and more functionally dependent patients are most likely to report loss of most or all of the family's savings.	BETH ISRAEL HOSP,DEPT MED,DIV GEN MED & PRIMARY CARE,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,DIV CLIN EPIDEMIOL,BOSTON,MA 02215; UNIV CALIF LOS ANGELES,MED CTR,SCH MED,LOS ANGELES,CA 90024; MARSHFIELD CLIN FDN MED RES & EDUC,MARSHFIELD,WI 54449; DUKE UNIV,MED CTR,DURHAM,NC; METROHLTH MED CTR,CASE WESTERN RESERVE UNIV,CLEVELAND,OH; DARTMOUTH HITCHCOCK MED CTR,HANOVER,NH; GEORGE WASHINGTON UNIV,CTR SUPPORT COORDINATION,WASHINGTON,DC	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Marshfield Clinic; Duke University; Case Western Reserve University; MetroHealth System; Dartmouth College; George Washington University				Connors, Alfred F./0000-0001-7123-3360				ALTMAN B, 1993, 930040 AG HLTH CAR P; ANDOLSEK KM, 1988, ARCH INTERN MED, V148, P2177, DOI 10.1001/archinte.148.10.2177; BODKIN CM, 1982, BRIT MED J, V284, P1542, DOI 10.1136/bmj.284.6328.1542; Hamel M., 1994, Journal of General Internal Medicine, V9, P43; HAYWARD RA, 1988, NEW ENGL J MED, V318, P1507, DOI 10.1056/NEJM198806093182305; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KATZ S, 1976, INT J HEALTH SERV, V6, P493, DOI 10.2190/UURL-2RYU-WRYD-EY3K; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; MUI AC, 1992, GERONTOLOGIST, V32, P205; MURPHY DJ, 1990, J CLIN EPIDEMIOL S, V43, pS1; PATRICK C, 1992, GEN HOSP PSYCHIAT, V14, P219, DOI 10.1016/0163-8343(92)90091-N; PRUNCHO RA, 1989, J AM GERIATR SOC, V37, P697; Rosner B., 2015, FUNDAMENTALS BIOSTAT; RUBENSTEIN LZ, 1984, J GERONTOL, V39, P686, DOI 10.1093/geronj/39.6.686; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; STANLEY MJB, 1988, HEART LUNG, V17, P677; TAYLOR RJ, 1991, J GERONTOL, V46, pS210, DOI 10.1093/geronj/46.4.S210; ZWEIBEL NR, 1989, GERONTOLOGIST, V29, P615, DOI 10.1093/geront/29.5.615	20	372	379	1	36	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1839	1844		10.1001/jama.272.23.1839	http://dx.doi.org/10.1001/jama.272.23.1839			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW980	7990218				2022-12-24	WOS:A1994PW98000032
J	ORRELL, RW; DEBELLEROCHE, JS				ORRELL, RW; DEBELLEROCHE, JS			SUPEROXIDE-DISMUTASE AND ALS	LANCET			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS		CHARING CROSS & WESTMINSTER MED SCH,DEPT BIOCHEM,LONDON W6 8RF,ENGLAND	Imperial College London	ORRELL, RW (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,ACAD UNIT NEUROSCI,LONDON,ENGLAND.		Orrell, Richard/L-2123-2013					BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; ELSHAFEY A, 1994, HUM MOL GENET, V3, P363, DOI 10.1093/hmg/3.2.363; ESTEBAN J, 1994, HUM MOL GENET, V3, P997, DOI 10.1093/hmg/3.6.997; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HENTATI A, 1994, NAT GENET, V7, P425, DOI 10.1038/ng0794-425; JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7; JONES CT, 1994, HUM MOL GENET, V3, P649, DOI 10.1093/hmg/3.4.649; KING AW, 1994, BIOCHEM SOC T, V22, pS149, DOI 10.1042/bst022149s; NAKANO R, 1994, BIOCHEM BIOPH RES CO, V200, P695, DOI 10.1006/bbrc.1994.1506; OGASAWARA M, 1993, NAT GENET, V5, P323, DOI 10.1038/ng1293-323; ROBBERECHT W, 1994, J NEUROCHEM, V62, P384; ROSEN DR, 1994, HUM MOL GENET, V3, P981, DOI 10.1093/hmg/3.6.981; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0	15	13	13	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1651	1652		10.1016/S0140-6736(94)90452-9	http://dx.doi.org/10.1016/S0140-6736(94)90452-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996955				2022-12-24	WOS:A1994PX30200003
J	LIEBERMAN, EH; GERHARD, MD; UEHATA, A; WALSH, BW; SELWYN, AP; GANZ, P; YEUNG, AC; CREAGER, MA				LIEBERMAN, EH; GERHARD, MD; UEHATA, A; WALSH, BW; SELWYN, AP; GANZ, P; YEUNG, AC; CREAGER, MA			ESTROGEN IMPROVES ENDOTHELIUM-DEPENDENT, FLOW-MEDIATED VASODILATION IN POSTMENOPAUSAL WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						ESTROGEN REPLACEMENT THERAPY; MENOPAUSE; ENDOTHELIUM; VASODILATION; CORONARY DISEASE	ATHEROSCLEROTIC CORONARY-ARTERIES; SMOOTH-MUSCLE CELLS; NITRIC-OXIDE; RELAXING FACTOR; HEART-DISEASE; FOLLOW-UP; ESSENTIAL-HYPERTENSION; PLASMA-LIPOPROTEINS; RELAXANT FACTOR; ACETYLCHOLINE	Objective: To assess the effect of estrogen replacement therapy on endothelium-dependent vasodilation in postmenopausal women. Design: Double-blind, placebo-controlled, crossover trial. Setting: University medical center. Patients: 13 postmenopausal women aged 44 to 69 years (average age, 55 +/- 7 years). Intervention: Patients were randomly assigned to receive placebo, oral estradiol at a dose of 1 mg/d, and oral estradiol at a dose of 2 mg/d. Each treatment phase lasted 9 weeks. Measurements: High-resolution ultrasonography was used to measure vascular reactivity in a peripheral conduit vessel, the brachial artery. Endothelium-dependent vasodilation was determined by measuring the change in brachial artery diameter during increases in flow induced by reactive hyperemia. Endothelium-independent vasodilation was measured after sublingual nitroglycerin was administered. Results: Flow-mediated, endothelium-dependent vasodilation of the brachial artery was greater when patients received estradiol (13.5% and 11.6% for I-mg and 2-mg doses, respectively) than when patients received placebo (6.8%; P < 0.05 for each dose compared with placebo). In contrast, estrogen administration had no effect on endothelium-independent vasodilation as assessed by sublingual nitroglycerin. Conclusion: Short-term estrogen replacement therapy improves flow-mediated endothelium-dependent vasodilation in postmenopausal women. This improvement may be mediated by a direct effect of estrogen on vascular function or may be induced through modification of lipoprotein metabolism.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA; MT SINAI HOSP, MIAMI, FL USA; NATL DEF MED COLL, TOKOROZAWA, SAITAMA 359, JAPAN; STANFORD UNIV, MED CTR, DIV CARDIOVASC, STANFORD, CA 94305 USA; BRIGHAM & WOMENS HOSP, DEPT OBSTET GYNECOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; National Defense Medical College - Japan; Stanford University; Harvard University; Brigham & Women's Hospital				Ganz, Peter/0000-0002-0437-8882	NHLBI NIH HHS [HL02566, HL02663, HL38780] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038780, K04HL002566] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; BUSSE R, 1987, N-S ARCH PHARMACOL, V336, P566; CELERMAJER DS, 1993, CIRCULATION, V88, P2149, DOI 10.1161/01.CIR.88.5.2149; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; CHANG WC, 1980, BIOCHIM BIOPHYS ACTA, V619, P107; COLBURN P, 1978, SCIENCE, V201, P817, DOI 10.1126/science.684408; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; COX DA, 1989, CIRCULATION, V80, P458, DOI 10.1161/01.CIR.80.3.458; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GISCLARD V, 1988, J PHARMACOL EXP THER, V244, P19; GRIFFITH TM, 1984, NATURE, V308, P645, DOI 10.1038/308645a0; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; HONG MK, 1992, AM J CARDIOL, V69, P176, DOI 10.1016/0002-9149(92)91300-S; HORWITZ KB, 1982, J CLIN INVEST, V69, P750, DOI 10.1172/JCI110513; JIANG CW, 1992, AM J PHYSIOL, V263, pH271, DOI 10.1152/ajpheart.1992.263.1.H271; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; KEANEY JF, 1994, CIRCULATION, V89, P2251, DOI 10.1161/01.CIR.89.5.2251; KLEINMAN DG, 1988, APPLIED REGRESSION A; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUHN FE, 1991, AM J CARDIOL, V68, P1425, DOI 10.1016/0002-9149(91)90274-O; KUSHWAHA RS, 1991, ARTERIOSCLER THROMB, V11, P23, DOI 10.1161/01.ATV.11.1.23; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; LIAO JK, 1991, CIRC RES, V68, P1027, DOI 10.1161/01.RES.68.4.1027; LIEBERMAN EH, 1993, CIRCULATION, V88, P79; LINDER L, 1990, CIRCULATION, V81, P1762, DOI 10.1161/01.CIR.81.6.1762; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MACK TM, 1976, NEW ENGL J MED, V294, P1262, DOI 10.1056/NEJM197606032942304; MCDONALD TW, 1977, AM J OBSTET GYNECOL, V127, P572, DOI 10.1016/0002-9378(77)90351-9; MCGILL HC, 1981, CIRC RES, V48, P238, DOI 10.1161/01.RES.48.2.238; MILLER VM, 1990, AM J PHYSIOL, V258, pR1502, DOI 10.1152/ajpregu.1990.258.6.R1502; MILLER VM, 1988, PHLEBOLOGY, V3, P63; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; RAINBOW TC, 1980, BRAIN RES, V198, P239, DOI 10.1016/0006-8993(80)90362-5; REIS SE, 1994, CIRCULATION, V89, P52, DOI 10.1161/01.CIR.89.1.52; SIMON DI, 1993, ARTERIOSCLER THROMB, V13, P791, DOI 10.1161/01.ATV.13.6.791; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; UEHATA A, 1993, CIRCULATION, V88, P618; UEHATA A, 1992, CIRCULATION, V86, P620; VANHOUTTE PM, 1985, CIRCULATION, V72, P728, DOI 10.1161/01.CIR.72.4.728; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WILLIAMS JK, 1992, J AM COLL CARDIOL, V20, P452, DOI 10.1016/0735-1097(92)90116-5; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680; YAGI K, 1986, BIOCHEM INT, V13, P1051; ZEIHER AM, 1991, CIRCULATION, V84, P1984, DOI 10.1161/01.CIR.84.5.1984; 1986, MMWR-MORBID MORTAL W, V35, P653	54	605	614	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					936	941		10.7326/0003-4819-121-12-199412150-00005	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978718				2022-12-24	WOS:A1994PW08300005
J	KARLSSON, L; PELERAUX, A; LINDSTEDT, R; LILJEDAHL, M; PETERSON, PA				KARLSSON, L; PELERAUX, A; LINDSTEDT, R; LILJEDAHL, M; PETERSON, PA			RECONSTITUTION OF AN OPERATIONAL MHC CLASS-II COMPARTMENT IN NONANTIGEN-PRESENTING CELLS	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; INVARIANT CHAIN; MICE LACKING; MOLECULES; PEPTIDE; ANTIGENS; TRANSPORT; BIOSYNTHESIS; ASSOCIATION; EXPRESSION	Professional antigen-presenting cells (APCs) have a distinct compartment in which class II molecules are proposed to acquire antigenic peptides. Genetic evidence suggests that human leukocyte antigen (HLA)-DM, an unusual class II molecule, participates in this process. Peptide acquisition was reconstituted in nonprofessional APCs by transfection of class II, invariant chain (Ii), and H-2M, the murine equivalent of DM. The H-2M heterodimer appeared in an endosomal compartment, not at the cell surface, and the localization was independent of Ii. The data presented show that H-2M, class II, and Ii are the minimally required components for efficient formation of stable class II-peptide complexes, and thus for a functional class II compartment.			KARLSSON, L (corresponding author), SCRIPPS RES INST, RW JOHNSON PHARMACEUT RES INST, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026610] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26610] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; CALAFAT J, 1994, J CELL BIOL, V126, P967, DOI 10.1083/jcb.126.4.967; CARRINGTON M, 1993, IMMUNOGENETICS, V38, P446; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; CHO SG, 1991, P NATL ACAD SCI USA, V88, P5197, DOI 10.1073/pnas.88.12.5197; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; KARLSSON L, 1991, NATURE, V351, P485, DOI 10.1038/351485a0; KARLSSON L, UNPUB; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; OWEN MJ, 1981, J BIOL CHEM, V256, P8987; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; RIBERDY JM, 1994, J CELL BIOL, V125, P1225, DOI 10.1083/jcb.125.6.1225; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; SADEGHNASSERI S, 1994, NATURE, V370, P647, DOI 10.1038/370647a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SALAMERO J, 1990, EMBO J, V9, P3489, DOI 10.1002/j.1460-2075.1990.tb07557.x; SANDERSON F, 1994, IMMUNOGENETICS, V39, P56; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; SYMINGTON FW, 1981, IMMUNOGENETICS, V14, P53, DOI 10.1007/BF00344299; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0	42	137	138	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1569	1573		10.1126/science.7985028	http://dx.doi.org/10.1126/science.7985028			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985028				2022-12-24	WOS:A1994PV01500046
J	DESJARLAIS, DC; PADIAN, NS; WINKELSTEIN, W				DESJARLAIS, DC; PADIAN, NS; WINKELSTEIN, W			TARGETED HIV-PREVENTION PROGRAMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN IMMUNODEFICIENCY VIRUS; 2 DIVISIVE ISSUES; AIDS POLICY; DRUG-USERS; INFECTION; HEALTH; RISK		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94105; UNIV CALIF BERKELEY,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California Berkeley	DESJARLAIS, DC (corresponding author), NATL DEV & RES INST INC,BETH ISRAEL MED CTR,11 BEACH ST,NEW YORK,NY 10013, USA.							[Anonymous], 1988, RATIONAL CHOICE UNCE; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DESJARLAIS DC, 1993, 9 INT C AIDS BERL; DICLEMENTE RJ, 1994, PREVENTING AIDS THEO; EDLIN BR, 1994, NEW ENGL J MED, V331, P1422, DOI 10.1056/NEJM199411243312106; FENNER F, 1982, REV INFECT DIS, V4, P916; FIFE D, 1992, J ACQ IMMUN DEF SYND, V5, P1111; GAGNON J, 1994, NY TIMES        0106, pA23; HEATHCOTE H, 1984, LECTURE NOTES BIOMAT, V56; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HU DJ, 1993, 9TH INT C AIDS BERL; JONSON AR, 1993, SOCIAL IMPACT AIDS U; KELLY JA, 1991, AM J PUBLIC HEALTH, V81, P168, DOI 10.2105/AJPH.81.2.168; Lurie P, 1993, PUBLIC HLTH IMPACT N; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; ROGERS DE, 1993, JAMA-J AM MED ASSOC, V270, P494; Rogers R. W., 1983, SOCIAL PSYCHOPHYSIOL, P153, DOI DOI 10.1002/9780470479216.CORPSY0897; ROJANAPITHAYAKO.W, 1994, MAY AD HOC TECHN ADV; STRYKER J, 1993, JAMA-J AM MED ASSOC, V270, P2436, DOI 10.1001/jama.270.20.2436; VANWIJNGAARDEN JK, 1992, AIDS IND DEMOCRACIES, P252; WALLACE R, IN PRESS SOC SCI MED; WASSER SC, 1993, J ACQ IMMUN DEF SYND, V6, P1035; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; 1993, AIDS EXPANDING TRAGE; 1994, HIV AIDS SURVEILLANC	26	43	44	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1451	1453		10.1056/NEJM199411243312112	http://dx.doi.org/10.1056/NEJM199411243312112			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7969287				2022-12-24	WOS:A1994PU53300012
J	KINOSHITA, J				KINOSHITA, J			AGRICULTURAL BIOTECH BLOOMS LATE	SCIENCE			English	Editorial Material																			0	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1184	1185		10.1126/science.7973697	http://dx.doi.org/10.1126/science.7973697			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973697				2022-12-24	WOS:A1994PT13200035
J	UNGERMANN, C; NEUPERT, W; CYR, DM				UNGERMANN, C; NEUPERT, W; CYR, DM			THE ROLE OF HSP70 IN CONFERRING UNIDIRECTIONALITY ON PROTEIN TRANSLOCATION INTO MITOCHONDRIA	SCIENCE			English	Article							YEAST MITOCHONDRIA; MEMBRANE TRANSLOCATION; INTERMEMBRANE SPACE; PRECURSOR PROTEIN; INNER MEMBRANE; IMPORT; CYTOCHROME-B2; RECOGNITION; PREPROTEINS; REQUIREMENT	The entry of segments of preproteins of defined lengths into the matrix space of mitochondria was studied. The mitochondrial chaperone Hsp70 (mtHsp70) interacted with proteins emerging from the protein import channel and stabilized translocation intermediates across the membranes in an adenosine triphosphate-dependent fashion. The chaperone bound to the presequence and mature parts of preproteins. In the absence of mtHsp70 binding, preproteins with less than 30 to 40 residues in the matrix diffused out of mitochondria. Thus, protein translocation was reversible up to a late stage. The import channels in both mitochondrial membranes constitute a passive pore that interacts weakly with polypeptide chains entering the matrix.	UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY	University of Munich				Cyr, Douglas/0000-0002-4928-3414				BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; CYR DM, 1993, J BIOL CHEM, V268, P23751; DAUM G, 1982, J BIOL CHEM, V257, P3028; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HANNAVY K, 1993, CURR OPIN CELL BIOL, V5, P594; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HORST M, 1993, EMBO J, V12, P3035, DOI 10.1002/j.1460-2075.1993.tb05972.x; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; SANDERS SL, 1992, J BIOL CHEM, V267, P9881; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHNEIDER HC, IN PRESS NATURE; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; Theg Steven M., 1993, Trends in Cell Biology, V3, P186, DOI 10.1016/0962-8924(93)90212-J; VIEBROCK A, 1982, EMBO J, V1, P565, DOI 10.1002/j.1460-2075.1982.tb01209.x; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	30	222	224	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1250	1253		10.1126/science.7973708	http://dx.doi.org/10.1126/science.7973708			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973708				2022-12-24	WOS:A1994PT13200056
J	MIYAZAKI, T; KAWAHARA, A; FUJII, H; NAKAGAWA, Y; MINAMI, Y; LIU, ZJ; OISHI, I; SILVENNOINEN, O; WITTHUHN, BA; IHLE, JN; TANIGUCHI, T				MIYAZAKI, T; KAWAHARA, A; FUJII, H; NAKAGAWA, Y; MINAMI, Y; LIU, ZJ; OISHI, I; SILVENNOINEN, O; WITTHUHN, BA; IHLE, JN; TANIGUCHI, T			FUNCTIONAL ACTIVATION OF JAK1 AND JAK3 BY SELECTIVE ASSOCIATION WITH IL-2 RECEPTOR SUBUNITS	SCIENCE			English	Article							INTERLEUKIN-2 RECEPTOR; SIGNAL-TRANSDUCTION; GAMMA-CHAIN; TYROSINE KINASE; CYTOPLASMIC REGION; LIGAND-BINDING; BETA-SUBUNIT; COMPONENT; FAMILY; SUPERFAMILY	The interleukin-2 receptor (IL-2) consists of three subunits: the IL-2R alpha, IL-2R beta, and IL-2R gamma chains, the last of which is also used in the receptors for IL-4, IL-7, and IL-9. Stimulation with IL-2 induces the tyrosine phosphorylation and activation of the Janus kinases Jak1 and Jak3. Jak1 and Jak3 were found to be selectively associated with the ''serine-rich'' region of IL-2R beta and the carboxyl-terminal region of IL-2R gamma, respectively. Both regions were necessary for IL-2 signaling. Furthermore, Jak3-negative fibroblasts expressing reconstituted IL-2R became responsive to IL-2 after the additional expression of Jak3 complementary DNA. Thus, activation of Jak1 and Jak3 may be a key event in IL-2 signaling.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital	MIYAZAKI, T (corresponding author), OSAKA UNIV, INST MOLEC & CELLULAR BIOL, 1-3 YAMADA OKA, SUITA, OSAKA 565, JAPAN.		Fujii, Hodaka/N-9792-2019; Oishi, Isao/L-8639-2018; witthuhn, bruce/GSE-3193-2022; Miyazaki, Tadaaki/D-9368-2012; Fujii, Hodaka/A-2420-2008	Fujii, Hodaka/0000-0003-1296-4256; Oishi, Isao/0000-0003-3682-5349; Fujii, Hodaka/0000-0003-1296-4256	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUNG MR, 1991, J IMMUNOL, V147, P1253; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAHARA A, 1994, MOL CELL BIOL, V14, P5433, DOI 10.1128/MCB.14.8.5433; KAWAHARA A, UNPUB; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; MINAMI Y, 1994, J IMMUNOL, V152, P5680; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; Minami Y., UNPUB; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WITTHUHN BA, UNPUB; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	36	521	533	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1045	1047		10.1126/science.7973659	http://dx.doi.org/10.1126/science.7973659			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973659				2022-12-24	WOS:A1994PQ92400045
J	MADDOX, J				MADDOX, J			FRONTIERS OF IGNORANCE - MOLECULES IN EMBRYOLOGY	NATURE			English	Editorial Material																			0	0	0	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					36	36						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969414				2022-12-24	WOS:A1994PQ34800049
J	AIBA, A; CHEN, C; HERRUP, K; ROSENMUND, C; STEVENS, CF; TONEGAWA, S				AIBA, A; CHEN, C; HERRUP, K; ROSENMUND, C; STEVENS, CF; TONEGAWA, S			REDUCED HIPPOCAMPAL LONG-TERM POTENTIATION AND CONTEXT-SPECIFIC DEFICIT IN ASSOCIATIVE LEARNING IN MGLUR1 MUTANT MICE	CELL			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; CENTRAL-NERVOUS-SYSTEM; CALCIUM CURRENTS; BRAIN-FUNCTION; NEURONS; RAT; DEPRESSION; INDUCTION; BLOCKADE; CHANNELS	We generated a novel strain of mutant mouse with a deletion in the gene encoding metabotropic glutamate receptor 1 (mGluR1). Gross anatomy of the hippocampus, excitatory synaptic transmission, long-term depression, and short-term potentiation in the hippocampal CA1 region are all apparently normal in the mutant mice. In contrast, long-term potentiation (LTP) is substantially reduced, and a moderate level of impairment is observed in context-specific associative learning. We propose that mGluR1 is not ''in line'' in LTP production, but rather modulates the plasticity process, and hence affects context-specific associative learning.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; CASE WESTERN RESERVE UNIV,SCH MED,ALZHEIMERS RES LABS,CLEVELAND,OH 44106; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Massachusetts Institute of Technology (MIT); Case Western Reserve University; Howard Hughes Medical Institute; Salk Institute	AIBA, A (corresponding author), MIT,HOWARD HUGHES MED INST,CTR LEARNING & MEMORY,CAMBRIDGE,MA 02139, USA.		Rosenmund, Christian/AAC-3596-2020; Herrup, Karl/C-5313-2014	Rosenmund, Christian/0000-0002-3905-2444; Herrup, Karl/0000-0001-7786-5844; Aiba, Atsu/0000-0002-8192-0778	NINDS NIH HHS [R01 NS32925, NS20591] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925, R01NS020591] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; BASHIR ZI, 1993, EUR J PHARMACOL, V239, P265, DOI 10.1016/0014-2999(93)91009-C; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; BIRSE EF, 1993, NEUROSCIENCE, V52, P481, DOI 10.1016/0306-4522(93)90400-A; BLANTON M, 1990, J NEUROSCI METH, V30, P203; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BONHOEFFER T, 1990, COLD SH Q B, V55, P137; BORTOLOTTO ZA, 1994, NATURE, V368, P740, DOI 10.1038/368740a0; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CHARPAK S, 1991, P ROY SOC B-BIOL SCI, V243, P221, DOI 10.1098/rspb.1991.0035; CHINESTRA P, 1993, J NEUROPHYSIOL, V70, P2684, DOI 10.1152/jn.1993.70.6.2684; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORMIER RJ, 1993, NEURON, V10, P907, DOI 10.1016/0896-6273(93)90206-7; DESAI MA, 1991, J NEUROPHYSIOL, V66, P40, DOI 10.1152/jn.1991.66.1.40; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; FOTUHI M, 1993, J NEUROSCI, V13, P2001; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; Hogan B., 1986, MANIPULATING MOUSE E; KIM JJ, 1991, BEHAV NEUROSCI, V105, P126, DOI 10.1037/0735-7044.105.1.126; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; MANZONI OJ, 1994, EUR J NEUROSCI, V6, P1050, DOI 10.1111/j.1460-9568.1994.tb00599.x; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MUSGRAVE MA, 1993, NEUROREPORT, V4, P712; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; RIEDEL G, 1994, NEUROSCI LETT, V167, P141, DOI 10.1016/0304-3940(94)91047-2; ROSENMUND C, 1993, J PHYSIOL-LONDON, V470, P705, DOI 10.1113/jphysiol.1993.sp019884; SAHARA Y, 1993, J NEUROSCI, V13, P3041; SAYER RJ, 1992, J NEUROPHYSIOL, V68, P833, DOI 10.1152/jn.1992.68.3.833; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SWARTZ KJ, 1992, J NEUROSCI, V12, P4358; Westbrook Gary L., 1994, Current Opinion in Neurobiology, V4, P337, DOI 10.1016/0959-4388(94)90094-9; WYLLIE DJA, 1994, NEURON, V12, P127, DOI 10.1016/0896-6273(94)90158-9; ZHENG F, 1992, NEURON, V9, P163, DOI 10.1016/0896-6273(92)90231-2	53	349	364	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					365	375		10.1016/0092-8674(94)90204-6	http://dx.doi.org/10.1016/0092-8674(94)90204-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954802				2022-12-24	WOS:A1994PN63000019
J	NEWMEYER, DD; FARSCHON, DM; REED, JC				NEWMEYER, DD; FARSCHON, DM; REED, JC			CELL-FREE APOPTOSIS IN XENOPUS EGG EXTRACTS - INHIBITION BY BCL-2 AND REQUIREMENT FOR AN ORGANELLE FRACTION ENRICHED IN MITOCHONDRIA	CELL			English	Article							DEATH GENE CED-3; NUCLEAR-ENVELOPE; GRANULOSA-CELLS; PORE COMPLEX; MAP KINASE; RAT-LIVER; PROTEIN; ONCOPROTEIN; INVITRO; DNA	Apoptotic cell death involves a ritual series of morphological changes, presumably reflecting a conserved molecular pathway. We now report that the nuclear events typical of apoptosis can be reproduced in ''apoptotic'' Xenopus egg extracts. In this cell-free system, nuclear assembly and protein import are initially normal; after 2-4 hr, however, a process of nuclear destruction ensues involving chromatin condensation and the shrinkage and fragmentation of the nuclei. This apoptotic process, which also occurs in nuclei added exogenously, is blocked by the addition of baculovirus-expressed Bcl-2 protein. To block the disintegration of nuclei that are added later, Bcl-2 must be present during this latent period. ''Apoptosis'' in these extracts requires a dense organelle fraction enriched in mitochondria. The cell-free system described here provides a novel tool for understanding intracellular events in apoptosis and the inhibitory function of Bcl-2.	LA JOLLA INST ALLERGY & IMMUNOL, LA JOLLA, CA 92037 USA	La Jolla Institute for Immunology	NEWMEYER, DD (corresponding author), LA JOLLA CANC RES FDN, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA047956, R01CA060181] Funding Source: NIH RePORTER; NCI NIH HHS [CA-60181, CA-47956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; CROMPTON M, 1988, BIOCHEM J, V255, P357; DABAUVALLE MC, 1991, J CELL BIOL, V112, P1073, DOI 10.1083/jcb.112.6.1073; DEJONG D, 1994, CANCER RES, V54, P256; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GONG JP, 1993, J CELL PHYSIOL, V157, P263; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HENNET T, 1993, CANCER RES, V53, P1456; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUGHES FM, 1991, ENDOCRINOLOGY, V129, P2415, DOI 10.1210/endo-129-5-2415; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1993, BLOOD, V81, P151; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAN BT, 1994, J BIOL CHEM, V269, P5968; REED JC, 1992, ANAL BIOCHEM, V205, P70, DOI 10.1016/0003-2697(92)90580-Z; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REINHART PH, 1982, BIOCHEM J, V204, P731, DOI 10.1042/bj2040731; RICHTER C, 1993, TOXICOL LETT, V67, P119, DOI 10.1016/0378-4274(93)90050-8; SANDSTROM PA, 1994, J BIOL CHEM, V269, P798; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SATO T, 1994, IN PRESS P NATL ACAD; SCHLEGEL J, 1992, BIOCHEM J, V285, P65, DOI 10.1042/bj2850065; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHWARTZMAN RA, 1991, ENDOCRINOLOGY, V128, P1190, DOI 10.1210/endo-128-2-1190; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SMITH LD, 1991, METHOD CELL BIOL, V36, P45; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TILLY JL, 1992, MOL ENDOCRINOL, V6, P1942, DOI 10.1210/me.6.11.1942; TONKS NK, 1991, METHOD ENZYMOL, V201, P442; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WANG HG, 1994, ONCOGENE, V9, P2751; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929	60	490	511	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					353	364		10.1016/0092-8674(94)90203-8	http://dx.doi.org/10.1016/0092-8674(94)90203-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954801				2022-12-24	WOS:A1994PN63000018
J	KILPATRICK, ES; RUMLEY, AG; DOMINICZAK, MH; SMALL, M				KILPATRICK, ES; RUMLEY, AG; DOMINICZAK, MH; SMALL, M			GLYCATED HEMOGLOBIN VALUES - PROBLEMS IN ASSESSING BLOOD-GLUCOSE CONTROL IN DIABETES-MELLITUS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FETAL HEMOGLOBIN	Objective-To see whether two measures of glycated haemoglobin concentration-the haemoglobin A(1) (HbA(1)) value and the haemoglobin A1c (HbA(1c) value-assess blood glucose control differently in diabetes. Design-Diabetic patients had glycaemic control assessed on the basis of HbA(1) and HbA(1c) values measured by the same high performance liquid chromatography instrument and on the basis of HbA(1) measured by electrophoresis. Setting-A diabetic outpatient clinic. Subjects-208 diabetic patients and 106 nondiabetic controls. Main outcome measures-Glycated haemoglobin concentrations classified according to European guidelines as representing good, borderline, or poor glycaemic control by using standard deviations from a reference mean. Results-Fewer patients were in good control (25;12%) and more poorly controlled (157;75%) as assessed by the HbA(1c) value compared with both HbA(1) assays (39 (19%) and 130 (63%) respectively when using highperformance liquid chromatography; 63 (30%) acid 74 (36%) when using electrophoresis). The median patient value was 8.0 SD from the reference mean when using HbA(1c), 5.9 when using HbA(1) measured by the same high performance liquid chromatography method, and 4.1 when using HbA(1) measured by electrophoresis. Conclusions-Large differences exist between HbA(1) and HbA(1c) in the classification of glycaemic control in diabetic patients. The HbA(1c) value may suggest a patient is at a high risk of long term diabetic complications when the HbA(1) value may not. Better standardisation of glycated haemoglobin measurements is advisable.	GARTNAVEL ROYAL HOSP, DIABET UNIT, GLASGOW G12 0YN, LANARK, SCOTLAND	Gartnavel Royal Hospital	KILPATRICK, ES (corresponding author), GARTNAVEL ROYAL HOSP, DEPT PATHOL BIOCHEM, LIPID & DIABET LAB, GLASGOW G12 0YN, LANARK, SCOTLAND.							ALBERTI KGMM, 1988, DIABETIC MED, V5, P275, DOI 10.1111/j.1464-5491.1988.tb00984.x; AMER DIABET ASSOC, 1993, DIABETES, V42, P1555; ANTSIFEROV M, 1993, DIABETIC MED, V10, P990; GOLDSTEIN DE, 1986, CLIN CHEM, V32, pB64; JOHN WG, 1992, DIABETIC MED, V9, P15, DOI 10.1111/j.1464-5491.1992.tb01708.x; KILPATRICK ES, 1993, CLIN CHEM, V39, P833; PAGE SR, 1993, DIABETIC MED, V10, P793, DOI 10.1111/j.1464-5491.1993.tb00168.x; RUMLEY AG, 1993, DIABETIC MED, V10, P976, DOI 10.1111/j.1464-5491.1993.tb00016.x; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; WYSOCKI T, 1989, J BEHAV MED, V12, P183, DOI 10.1007/BF00846550; YATSCOFF RW, 1983, CLIN CHEM, V29, P543	11	36	36	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 15	1994	309	6960					983	986		10.1136/bmj.309.6960.983	http://dx.doi.org/10.1136/bmj.309.6960.983			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950717	Green Published			2022-12-24	WOS:A1994PM41700019
J	JIMENEZ, JA; HUGHES, KA; ALAKS, G; GRAHAM, L; LACY, RC				JIMENEZ, JA; HUGHES, KA; ALAKS, G; GRAHAM, L; LACY, RC			AN EXPERIMENTAL-STUDY OF INBREEDING DEPRESSION IN A NATURAL HABITAT	SCIENCE			English	Article							POPULATIONS	Inbreeding is known to lead to decreased survival and reproduction in captive populations of animals. It is also important to know whether inbreeding has deleterious effects in natural habitats. An estimate was made of the effects of inbreeding in white-footed mice, Peromyscus leucopus noveboracensis, derived from a wild population. This study demonstrates that inbreeding had a significant detrimental effect on the survivorship of mice reintroduced into a natural habitat. This effect was more severe than the effect observed in laboratory studies of the population.	CHICAGO ZOOL SOC, DEPT CONSERVAT BIOL, BROOKFIELD, IL 60513 USA; UNIV ILLINOIS, DEPT BIOL SCI, CHICAGO, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Peng, Bo/A-6920-2009	Peng, Bo/0000-0001-8225-2284				Akaike H., 1998, P 2 INT S INF THEOR, DOI DOI 10.1007/978-1-4612-1694-0_15; [Anonymous], 1982, ESTIMATION ANIMAL AB; BARRETT SCH, 1991, GENETICS AND CONSERVATION OF RARE PLANTS, P3; BREWER BA, 1990, J HERED, V81, P257, DOI 10.1093/oxfordjournals.jhered.a110988; CHARLESWORTH D, 1987, ANNU REV ECOL SYST, V18, P237, DOI 10.1146/annurev.ecolsys.18.1.237; CHEN XF, 1993, HEREDITY, V71, P456, DOI 10.1038/hdy.1993.163; CLARK TW, 1989, CONSERVATION BIOL BL; Falconer D. S., 1989, Introduction to quantitative genetics.; GILBERT DG, 1989, IUBIO ARCH MOL GENER; Kleiman D.G., 1986, P959; LACY RC, 1993, NATURAL HIST INBREED, P252; LEBRETON JD, 1992, ECOL MONOGR, V62, P67, DOI 10.2307/2937171; LIVELY CM, 1990, NATURE, V344, P864, DOI 10.1038/344864a0; MORTON NE, 1956, P NATL ACAD SCI USA, V42, P855, DOI 10.1073/pnas.42.11.855; Pradel R., 1993, USERS MANUAL PROGRAM; QUATTRO JM, 1989, SCIENCE, V245, P976, DOI 10.1126/science.2772650; Ralls K., 1983, P164; RALLS K, 1988, Conservation Biology, V2, P185, DOI 10.1111/j.1523-1739.1988.tb00169.x; RYMAN N, 1970, HEREDITAS-GENETISK A, V65, P159; SEAL US, 1989, CONSERVATION BIOL BL; Shields William M., 1993, P143; SHIELDS WM, 1979, PHILOPATRY INBREEDIN; SITTMANN K, 1966, GENETICS, V54, P371; Templeton A.R., 1983, P241; Wright S, 1977, EXPT RESULTS EVOLUTI, V3	25	291	300	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	1994	266	5183					271	273		10.1126/science.7939661	http://dx.doi.org/10.1126/science.7939661			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939661				2022-12-24	WOS:A1994PM13400032
J	SUN, H; TONKS, NK; BARSAGI, D				SUN, H; TONKS, NK; BARSAGI, D			INHIBITION OF RAS-INDUCED DNA-SYNTHESIS BY EXPRESSION OF THE PHOSPHATES MKP-1	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASES; IMMEDIATE-EARLY GENE; MAP KINASE; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; PROLIFERATION; PATHWAY; DOMAIN	Mitogen-activated protein kinases (MAP kinases) are common components of signaling pathways induced by diverse growth stimuli. Although the guanidine nucleotide-binding Ras proteins are known to be upstream activators of MAP kinases, the extent to which MAP kinases directly contribute to the mitogenic effect of Ras is as yet undefined. In this study, inhibition of MAP kinases by the MAP kinase phosphatase MKP-1 blocked the induction of DNA synthesis in quiescent rat embryonic fibroblast REF-52 cells by an activated mutant of Ras, V(12)Ras. These results suggest an essential role for activation of MAP kinases in the transition from the quiescent to the DNA replication phase of the eukaryotic cell cycle.			SUN, H (corresponding author), COLD SPRING HARBOR LAB,1 BUNGTOWN RD,POB 100,COLD SPRING HARBOR,NY 11724, USA.			Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA53840, CA55360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053840, R01CA055360, R01CA053840, R37CA055360, R56CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ALESSI DR, 1993, ONCOGENE, V8, P2015; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHARLES CH, 1992, ONCOGENE, V7, P187; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MINSHULL J, IN PRESS CELL; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Sun H., UNPUB; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	30	223	234	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					285	288		10.1126/science.7939666	http://dx.doi.org/10.1126/science.7939666			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939666				2022-12-24	WOS:A1994PM13400037
J	PAPAVASSILIOU, AG				PAPAVASSILIOU, AG			TRANSCRIPTION FACTORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											PAPAVASSILIOU, AG (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAM,POSTFACH 102209,D-69012 HEIDELBERG,GERMANY.		Karamouzis, Michalis/AAD-2860-2020					LATCHMAN DS, 1991, EUKARYOTIC TRANSCRIP; ROSENTHAL N, 1994, NEW ENGL J MED, V331, P931, DOI 10.1056/NEJM199410063311408; Travers A., 1993, DNA PROTEIN INTERACT	3	79	84	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					45	47		10.1056/NEJM199501053320108	http://dx.doi.org/10.1056/NEJM199501053320108			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990864				2022-12-24	WOS:A1995PZ49700008
J	SANCHEZ, I; HUGHES, RT; MAYER, BJ; YEE, K; WOODGETT, JR; AVRUCH, J; KYRIAKIS, JM; ZON, LI				SANCHEZ, I; HUGHES, RT; MAYER, BJ; YEE, K; WOODGETT, JR; AVRUCH, J; KYRIAKIS, JM; ZON, LI			ROLE OF SAPK/ERK KINASE-1 IN THE STRESS-ACTIVATED PATHWAY REGULATING TRANSCRIPTION FACTOR C-JUN	NATURE			English	Article							MAP KINASE; PROTEIN-KINASE; PHOSPHORYLATION; EXPRESSION; TYROSINE; CLONING; FAMILY; MEK	THE stress-activated protein kinases (SAPKs), which are distantly related to the MAP kinases, are the dominant c-Jun amino-terminal protein kinases activated in response to a variety of cellular stresses, including treatment with tumour-necrosis factor-a and interleukin-beta (refs 1, 2). SAPK phosphorylation of c-Jun probably activates the c-Jun transactivation function(3). SAPKs are part of a signal transduction cascade related to, but distinct from, the MAPK pathway(1). We have now identified a novel protein kinase, called SAPK/ERK kinase-1 (SEK1), which is structurally related to the MAP kinase kinases (MEKs)(4). SEK1 is a potent activator of the SAPKs in vitro and in vivo. An inactive SEK1 mutant blocks SAPK activation by extracellular stimuli without interfering with the MAPK pathway. Although alternative mechanisms of SAPK activation may exist, as an immediate upstream activator of the SAPKs, SEK1 further defines a signalling cascade that couples cellular stress agonists to the c-Jun transcription factor.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; PRINCESS MARGARET HOSP, ONTARIO CANC INST, TORONTO M4X 1K9, ON, CANADA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	SANCHEZ, I (corresponding author), MASSACHUSETTS GEN HOSP E, MED SERV, DIABET RES LAB, 149 13TH ST, BOSTON, MA 02129 USA.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	28	961	982	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					794	798						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997269				2022-12-24	WOS:A1994PY21200057
J	WHITCOMB, DC; BLOCK, GD				WHITCOMB, DC; BLOCK, GD			ASSOCIATION OF ACETAMINOPHEN HEPATOTOXICITY WITH FASTING AND ETHANOL USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCED HEPATIC NECROSIS; ENHANCED TOXICITY; N-ACETYLCYSTEINE; PROTECTIVE ROLE; FREE-RADICALS; HUMAN-LIVER; METABOLISM; PARACETAMOL; ALCOHOL; OVERDOSE	Objectives.-To evaluate the association of fasting and alcohol use with hepatotoxicity from acetaminophen ingested for therapeutic reasons. Design.-Retrospective case series. Setting.-Hospitals of the University of Pittsburgh (Pa) Medical Center. Patients.-A total of 126779 discharge summaries from January 1987 to July 1993 were reviewed using a comprehensive, whole-text-indexed medical database to identify all patients with acetaminophen ingestion and hepatotoxicity. These patients were categorized according to the intended acetaminophen use and dose of acetaminophen ingested. Main Outcomes Measured.-The independent variables of chronic alcohol use, recent alcohol use, and recent fasting were determined for all patients. Results.-Forty-nine patients with acetaminophen hepatotoxicity (aspartate aminotransferase > 1000 U/L) were identified. Twenty-one patients (43%) ingested acetaminophen for therapeutic purposes. All patients with hepatotoxicity took more than the recommended limit of 4 g/d. Recent fasting was more common than recent alcohol use among those who suffered hepatotoxicity after a dose of 4 to 10 g of acetaminophen per day (P=.02). Recent alcohol use was more common in the group who took more than 10 g/d than in those who took 4 to 10 g/d (P=.004). Conclusion.-Acetaminophen hepatotoxicity after a dose of 4 to 10 g/d was associated with fasting and less commonly with alcohol use. Patients who developed hepatoxicity after taking acetaminophen doses of greater than 10 g/d for therapeutic purposes were alcohol users. Acetaminophen hepatotoxicity after an overdose appears to be enhanced by fasting in addition to alcohol ingestion.	UNIV PITTSBURGH,DEPT MED,DIV GASTROENTEROL & HEPATOL,PITTSBURGH,PA; UNIV PITTSBURGH,DEPT PATHOL,PITTSBURGH,PA; UNIV PITTSBURGH,DEPT PHYSIOL & CELL BIOL,PITTSBURGH,PA; DEPT VET AFFAIRS MED CTR,PITTSBURGH,PA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ALTOMARE E, 1984, ALCOHOL CLIN EXP RES, V8, P405, DOI 10.1111/j.1530-0277.1984.tb05688.x; ALTOMARE E, 1984, BIOCHEM PHARMACOL, V33, P2207, DOI 10.1016/0006-2952(84)90655-5; BARKER JD, 1977, ANN INTERN MED, V87, P299, DOI 10.7326/0003-4819-87-3-299; BENSON GD, 1983, CLIN PHARMACOL THER, V33, P95, DOI 10.1038/clpt.1983.14; BRENT JA, 1993, J TOXICOL-CLIN TOXIC, V31, P139, DOI 10.3109/15563659309000383; BRENT JA, 1993, J TOXICOL-CLIN TOXIC, V31, P173, DOI 10.3109/15563659309000384; CLARK R, 1973, LANCET, V1, P66; CRITCHLEY JAJH, 1986, BRIT J CLIN PHARMACO, V22, P649, DOI 10.1111/j.1365-2125.1986.tb02953.x; DEMORAIS SMF, 1992, GASTROENTEROLOGY, V102, P577, DOI 10.1016/0016-5085(92)90106-9; DEMORAIS SMF, 1989, HEPATOLOGY, V10, P163, DOI 10.1002/hep.1840100207; EDWARDS D, 1986, ANN EMERG MED, V5, P1314; EMBY DJ, 1977, S AFR MED J, V51, P208; GOLDFINGER R, 1978, AM J GASTROENTEROL, V70, P385; GREGUS Z, 1988, DRUG METAB DISPOS, V16, P527; GREGUS Z, 1990, DRUG METAB DISPOS, V18, P10; HALL AH, 1986, JAMA-J AM MED ASSOC, V256, P1893, DOI 10.1001/jama.1986.03380140063015; HALL AH, 1986, ANN INTERN MED, V105, P624, DOI 10.7326/0003-4819-105-4-624_2; HALL AH, 1987, DIGEST DIS SCI, V32, P558, DOI 10.1007/BF01296042; HONG JY, 1987, BIOCHEM BIOPH RES CO, V142, P1077, DOI 10.1016/0006-291X(87)91525-7; JOHNSON MW, 1981, AM J GASTROENTEROL, V76, P530; JOLLOW DJ, 1974, PHARMACOLOGY, V12, P251, DOI 10.1159/000136547; JOLLOW DJ, 1973, J PHARMACOL EXP THER, V187, P195; KARTSONIS A, 1986, ANN INTERN MED, V105, P138, DOI 10.7326/0003-4819-105-1-138_2; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; LEIST MH, 1985, J CLIN GASTROENTEROL, V7, P55, DOI 10.1097/00004836-198502000-00008; LICHT H, 1980, ANN INTERN MED, V92, P511, DOI 10.7326/0003-4819-92-4-511_1; LIEBER CS, 1991, J AM COLL NUTR, V10, P602; MADDREY WC, 1987, J CLIN GASTROENTEROL, V9, P180, DOI 10.1097/00004836-198704000-00014; MADHU C, 1989, J PHARMACOL EXP THER, V248, P1069; MCCLAIN CJ, 1980, JAMA-J AM MED ASSOC, V244, P251, DOI 10.1001/jama.244.3.251; MITCHELL JR, 1974, CLIN PHARMACOL THER, V16, P676; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P185; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; MROCHEK JE, 1974, CLIN CHEM, V20, P1086; PATEL M, 1992, PHARMACOGENETICS, V2, P28; PERROT N, 1989, EUR J CLIN INVEST, V19, P549, DOI 10.1111/j.1365-2362.1989.tb00273.x; PESSAYRE D, 1979, GASTROENTEROLOGY, V77, P264; PESSAYRE D, 1980, BIOCHEM PHARMACOL, V29, P2219, DOI 10.1016/0006-2952(80)90201-4; PETERSON RG, 1977, JAMA-J AM MED ASSOC, V237, P2406, DOI 10.1001/jama.237.22.2406; PRESCOTT LF, 1971, LANCET, V1, P519; PRESCOTT LF, 1983, AM J MED, V75, P113, DOI 10.1016/0002-9343(83)90241-3; PRESCOTT LF, 1977, LANCET, V2, P432; PRESCOTT LF, 1980, BR J CLIN PHARM, V10, P2915; PRICE VF, 1989, BIOCHEM PHARMACOL, V38, P289, DOI 10.1016/0006-2952(89)90039-7; PRICE VF, 1987, BIOCHEM PHARMACOL, V36, P427, DOI 10.1016/0006-2952(87)90346-7; PRICE VF, 1988, BIOCHEM PHARMACOL, V37, P1067, DOI 10.1016/0006-2952(88)90512-6; PRICE VF, 1984, XENOBIOTICA, V7, P533; READ RB, 1986, HUM TOXICOL, V5, P201, DOI 10.1177/096032718600500309; REINKE LA, 1979, RES COMMUN CHEM PATH, V23, P185; RUMACK BH, 1981, ARCH INTERN MED, V141, P380, DOI 10.1001/archinte.141.3.380; RUMACK BH, 1983, AM J MED, V75, P104, DOI 10.1016/0002-9343(83)90240-1; SEEFF LB, 1986, ANN INTERN MED, V104, P399, DOI 10.7326/0003-4819-104-3-399; SEEFF LB, 1986, ANN INTERN MED, V105, P624; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; TAKAHASHI T, 1993, HEPATOLOGY, V17, P236, DOI 10.1016/0270-9139(93)90083-Y; Thurman R. G, 1980, PHARMACOL REV, V31, P229; TREDGER JM, 1985, TOXICOLOGY, V36, P341, DOI 10.1016/0300-483X(85)90035-6; TREDGER JM, 1986, XENOBIOTICA, V16, P661, DOI 10.3109/00498258609043556; YANG CS, 1992, FASEB J, V6, P737, DOI 10.1096/fasebj.6.2.1537464; ZIMMERMAN HJ, 1986, ALCOHOL CLIN EXP RES, V10, P3, DOI 10.1111/j.1530-0277.1986.tb05605.x	60	322	334	0	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1845	1850		10.1001/jama.272.23.1845	http://dx.doi.org/10.1001/jama.272.23.1845			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW980	7990219				2022-12-24	WOS:A1994PW98000033
J	MILLER, HI				MILLER, HI			A NEED TO REINVENT BIOTECHNOLOGY REGULATION AT THE EPA	SCIENCE			English	Editorial Material									STANFORD UNIV,INST INT STUDIES,STANFORD,CA 94305	Stanford University	MILLER, HI (corresponding author), STANFORD UNIV,HOOVER INST,STANFORD,CA 94305, USA.							BIDINOTTO RJ, 1990, READERS DIGEST   OCT, P55; COOK RJ, 1992, COMMUNICATION   0917; FALK BW, 1994, SCIENCE, V263, P1395, DOI 10.1126/science.8179685; FISHER LJ, 1992, COMMUNICATION   0821; Fumento M., 1993, SCI SIEGE BALANCING, P19; GOODMAN RM, 1987, SCIENCE, V236, P48, DOI 10.1126/science.236.4797.48; HOYLE R, 1992, BIO-TECHNOL, V10, P742; HUTTNER SL, IN PRESS BIOTECHNOLO; MILLER HI, 1990, SCIENCE, V250, P490, DOI 10.1126/science.2237398; MILLER HI, IN PRESS BIOTECHNOLO; MOFFAT AS, 1994, SCIENCE, V265, P1804, DOI 10.1126/science.8091208; NAJ AK, 1989, WALL STREET J   0130; National Academy of Science Committee on the Introduction of Genetically Engineered Organisms into the Environment, 1987, INTRO RECOMBINANT DN; SEIDLER RJ, 1988, SPECIAL REPORT RELEA; STEWART RB, 1991, GENETIC REVOLUTION, P219; 1994, FINAL RULE TESTING M; 1992, EPA600991050 DOC; 1992, NATIONAL BIOTECHNOLO; 1989, FIELD TESTING GENETI; 1989, NY TIMES        0202, pA1; 1989, APPL MICROBIOL BIOT, V30, P541; 1994, FED REGISTER, V59, P45600; 1988, BIOSAFETY MICROBIOLO; 1992, FED REGISTER, V57, P6753	24	11	11	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1815	1818		10.1126/science.7997875	http://dx.doi.org/10.1126/science.7997875			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997875				2022-12-24	WOS:A1994PX38300024
J	VONARNIM, AG; DENG, XW				VONARNIM, AG; DENG, XW			LIGHT INACTIVATION OF ARABIDOPSIS PHOTOMORPHOGENIC REPRESSOR COP1 INVOLVES A CELL-SPECIFIC REGULATION OF ITS NUCLEOCYTOPLASMIC PARTITIONING	CELL			English	Article							NF-KAPPA-B; NUCLEAR-LOCALIZATION; GENE-EXPRESSION; PROTEIN-KINASE; BINDING-PROTEIN; PHYTOCHROME; THALIANA; ENCODES; TRANSDUCTION; DROSOPHILA	Arabidopsis COP1 acts as a repressor of photomorphogenesis in darkness, and light stimuli abrogate this suppressive action. COP1, when fused to beta-glucuronidase (GUS), is enriched in the nucleus in darkness, but not in the light, in hypocotyl cells of Arabidopsis seedlings and epidermal cells of onion bulbs. In Arabidopsis hypocotyl cells, the nuclear GUS-COP1 level changes in response to dark-light transitions and quantitatively correlates with the extent of repression of photomorphogenic development. In root cells, GUS-COP1 is constitutively nuclear, consistent with an established role of COP1 in suppressing root chloroplast development in both light and darkness. We conclude that COP1 acts inside the nucleus to suppress photomorphogenesis and that light inactivation of COP1 involves a cell type-specific control of its nucleocytoplasmic partitioning.	YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06520 USA	Yale University			Deng, Xing Wang/ABF-4107-2020	von Arnim, Albrecht/0000-0003-3472-3357	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047850] Funding Source: NIH RePORTER; NIGMS NIH HHS [1-R29-GM47850] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUTTER PS, 1994, BIOCHEM J, V300, P609, DOI 10.1042/bj3000609; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; ANG LH, 1994, PLANT CELL, V6, P613, DOI 10.1105/tpc.6.5.613; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CITOVSKY V, 1994, P NATL ACAD SCI USA, V91, P3210, DOI 10.1073/pnas.91.8.3210; DENG XW, 1992, PLANT J, V2, P83, DOI 10.1111/j.1365-313X.1992.00083.x; DENG XW, 1994, CELL, V76, P423, DOI 10.1016/0092-8674(94)90107-4; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; FURUYA M, 1993, ANNU REV PLANT PHYS, V44, P617, DOI 10.1146/annurev.pp.44.060193.003153; GOPLDFARB DS, 1994, CURR BIOL, V4, P57; HARTER K, 1994, PLANT CELL, V6, P545, DOI 10.1105/tpc.6.4.545; HARTER K, 1994, P NATL ACAD SCI USA, V91, P5038, DOI 10.1073/pnas.91.11.5038; ISOMURA T, 1992, NUCLEIC ACIDS RES, V20, P5305, DOI 10.1093/nar/20.20.5305; KAUFMAN LS, 1993, PLANT PHYSIOL, V102, P333, DOI 10.1104/pp.102.2.333; Kendrick RE, 1993, PHOTOMORPHOGENESIS P; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MCCURDY DW, 1986, J CELL BIOL, V103, P2541, DOI 10.1083/jcb.103.6.2541; MCNELLIS T, 1994, IN PRESS PLANT CEL; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MISERA S, 1994, MOL GEN GENET, V244, P242, DOI 10.1007/BF00285451; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; Newmeyer DD, 1993, CURR OPIN CELL BIOL, V5, P395, DOI 10.1016/0955-0674(93)90003-9; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; REYMOND P, 1992, PLANT PHYSIOL, V100, P655, DOI 10.1104/pp.100.2.655; ROMERO LC, 1993, P NATL ACAD SCI USA, V90, P1465, DOI 10.1073/pnas.90.4.1465; ROMERO LC, 1991, FEBS LETT, V282, P342; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SHELDON LA, 1993, GENE DEV, V7, P1549, DOI 10.1101/gad.7.8.1549; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213; VIERSTRA RD, 1993, PLANT PHYSIOL, V103, P679, DOI 10.1104/pp.103.3.679; VONARNIM AG, 1993, J BIOL CHEM, V268, P19626; WARPEHA KMF, 1991, P NATL ACAD SCI USA, V88, P8925, DOI 10.1073/pnas.88.20.8925; WEI N, 1994, PLANT CELL, V6, P629, DOI 10.1105/tpc.6.5.629; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523	51	364	376	0	52	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 16	1994	79	6					1035	1045		10.1016/0092-8674(94)90034-5	http://dx.doi.org/10.1016/0092-8674(94)90034-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001131				2022-12-24	WOS:A1994PY08600013
J	HINKLE, G; WETTERER, JK; SCHULTZ, TR; SOGIN, ML				HINKLE, G; WETTERER, JK; SCHULTZ, TR; SOGIN, ML			PHYLOGENY OF THE ATTINE ANT FUNGI BASED ON ANALYSIS OF SMALL-SUBUNIT RIBOSOMAL-RNA GENE-SEQUENCES	SCIENCE			English	Article								Complete 16S-like ribosomal RNA coding regions were obtained from the fungal symbiont of five genera of attine (leaf-cutting) ants and two free-living fungi. Phylogenetic analyses with distance matrix, maximum likelihood, and parsimony methods revealed that the attine fungal symbionts are homobasidiomycetes in the order Agaricales. Comparison of the topology of the attine fungal symbiont phylogenetic tree with a tree based on attine ant morphology revealed a congruent branching pattern of the more derived attine ants and their fungal symbionts. The parallel branching pattern suggests a long-term coevolution of derived leaf-cutting attine ants and their fungal symbionts.	MARINE BIOL LAB, WOODS HOLE, MA 02543 USA; HARVARD UNIV, MUSEUM COMPARAT ZOOL, CAMBRIDGE, MA 02138 USA; CORNELL UNIV, DEPT ENTOMOL, ITHACA, NY 14853 USA	Marine Biological Laboratory - Woods Hole; Harvard University; Cornell University			Sogin, Mitchell/AAE-7186-2019		NIGMS NIH HHS [GM32964] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032964] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baroni Urbani C., 1980, STUTTGARTER BEITRA B, V54, P1; CHAPELA IH, 1994, SCIENCE, V266, P1691, DOI 10.1126/science.266.5191.1691; Cherrett J.M., 1989, P93; ELWOOD HJ, 1985, MOL BIOL EVOL, V2, P399; HERVEY A, 1977, BRITTONIA, V29, P226, DOI 10.2307/2805856; Holldobler B., 1990, pi; Kermarrec A., 1986, P231; KREISEL H, 1975, INDEX FUNGI 10, V4; Lee S.B., 1990, PCR PROTOCOLS GUIDE, P282, DOI DOI 10.1016/B978-0-12-372180-8.50038-X; MARTIN MM, 1987, INVERTEBRATE MICROBI, P91; MEDLIN L, 1988, GENE, V71, P491, DOI 10.1016/0378-1119(88)90066-2; Mitter C., 1983, P65; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; POWELL RJ, 1986, T BRIT MYCOL SOC, V87, P205, DOI 10.1016/S0007-1536(86)80022-5; SCHULTZ TR, IN PRESS SYSTEM ENTO; STRADLING DJ, 1986, EXPERIENTIA, V42, P962, DOI 10.1007/BF01941781; Swofford D., 1990, B ILL NAT HIST SURV; Weber N.A., 1972, Memoirs Am phil Soc, V92, P1; Weber N.A., 1979, P77; WEBER NA, 1966, SCIENCE, V153, P587, DOI 10.1126/science.153.3736.587; Weber NA, 1958, P 10 INT C ENT, V2, P459; Weber NA., 1938, REV ENTOMOLOGIA, V9, P154; Wetterer James K., 1994, P309; Wilson E.O., 1986, P1; WILSON EO, 1985, SCIENCE, V229, P265, DOI 10.1126/science.229.4710.265	26	68	72	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	1994	266	5191					1695	1697		10.1126/science.7992052	http://dx.doi.org/10.1126/science.7992052			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992052				2022-12-24	WOS:A1994PW30800037
J	WECHSLER, H; DAVENPORT, A; DOWDALL, G; MOEYKENS, B; CASTILLO, S				WECHSLER, H; DAVENPORT, A; DOWDALL, G; MOEYKENS, B; CASTILLO, S			HEALTH AND BEHAVIORAL CONSEQUENCES OF BINGE-DRINKING IN COLLEGE - A NATIONAL SURVEY OF STUDENTS AT 140 CAMPUSES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOL-USE; PATTERNS; VALIDITY	Objective.-To examine the extent of binge drinking by college students and the ensuing health and behavioral problems that binge drinkers create for themselves and others on their campus. Design.-Self-administered survey mailed to a national representative sample of US 4-year college students. Setting.-One hundred forty US 4-year colleges in 1993. Participants.-A total of 17 592 college students. Main Outcome Measures.-Self-reports of drinking behavior, alcohol-related health problems, and other problems. Results.-Almost half (44%) of college students responding to the survey were binge drinkers, including almost one fifth (19%) of the students who were frequent binge drinkers. Frequent binge drinkers are more likely to experience serious health and other consequences of their drinking behavior than other students. Almost half (47%) of the frequent binge drinkers experienced five or more different drinking-related problems, including injuries and engaging in unplanned sex, since the beginning of the school year. Most binge drinkers do not consider themselves to be problem drinkers and have not sought treatment for an alcohol problem. Binge drinkers create problems for classmates who are not binge drinkers. Students who are not binge drinkers at schools with higher binge rates were more likely than students at schools with lower binge rates to experience problems such as being pushed, hit, or assaulted or experiencing an unwanted sexual advance. Conclusions.-Binge drinking is widespread on college campuses. Programs aimed at reducing this problem should focus on frequent binge drinkers, refer them to treatment or educational programs, and emphasize the harm they cause for students who are not binge drinkers.	HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	WECHSLER, H (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH & SOCIAL BEHAV, 667 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Fahimifar, Sepideh/M-5303-2019					Berkowitz A D, 1986, J Am Coll Health, V35, P21; BRENNAN AF, 1986, INT J ADDICT, V21, P449, DOI 10.3109/10826088609083536; COOPER AM, 1981, INT J ADDICT, V16, P401, DOI 10.3109/10826088109038841; ENGS RC, 1985, J ALCOHOL DRUG EDUC, V31, P65; HANSON DJ, 1992, PSYCHOL REP, V71, P39, DOI 10.2466/PR0.71.5.39-39; HAWORTHHOEPPNER S, 1989, INT J ADDICT, V24, P829, DOI 10.3109/10826088909047315; HUGHES S, 1983, J COLL STUDENT PERS, V20, P257; JOHNSTON LD, 1991, ADM911835 US DEP HLT; LILJESTRAND P, 1993, J ALCOHOL DRUG EDUC, V38, P1; MIDANIK LT, 1988, BRIT J ADDICT, V83, P1019; OHARE TM, 1990, J STUD ALCOHOL, V51, P536, DOI 10.15288/jsa.1990.51.536; Presley CA., 1993, ALCOHOL DRUGS AM COL, VI; REINISCH OJ, 1991, RAND N3189CHF PUBL; ROOM R, 1971, DRINKING DRUG PRACTI, V3, P15; ROOM R, 1991, ALCOHOL AM DRINKING, P26; Saltz R, 1986, CONTEMP DRUG PROBL, V13, P117; Straus R, 1953, DRINKING IN COLLEGE; WECHSLER H, 1992, Journal of the American Medical Association, V267, P2929, DOI 10.1001/jama.267.21.2929; WECHSLER H, 1979, J STUD ALCOHOL, V40, P969, DOI 10.15288/jsa.1979.40.969; 1990, ALCOHOL HLTH; 1992, BARRONS PROFILES AM; 1994, RETHINKING RITES PAS; 1993, DIGEST ED STATISTICS, P180; 1993, SUBSTANCE ABUSE NATI; 1988, SAS STAT USERS GUIDE; 1990, CAMPUS LIFE SEARCH C	26	1339	1346	1	191	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1672	1677		10.1001/jama.272.21.1672	http://dx.doi.org/10.1001/jama.272.21.1672			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU759	7966895				2022-12-24	WOS:A1994PU75900026
J	MULLER, U; CRISTINA, N; LI, ZW; WOLFER, DP; LIPP, HP; RULICKE, T; BRANDNER, S; AGUZZI, A; WEISSMANN, C				MULLER, U; CRISTINA, N; LI, ZW; WOLFER, DP; LIPP, HP; RULICKE, T; BRANDNER, S; AGUZZI, A; WEISSMANN, C			BEHAVIORAL AND ANATOMICAL DEFICITS IN MICE HOMOZYGOUS FOR A MODIFIED BETA-AMYLOID PRECURSOR PROTEIN GENE	CELL			English	Article							ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; STEM-CELLS; TARGETED DISRUPTION; TYPE-4 ALLELE; MESSENGER-RNA; MOUSE HOMOLOG; WATER-MAZE; RAT; PROTOONCOGENE	The beta-amyloid precursor protein (beta APP) gene of the mouse was disrupted by inserting into exon 2 a cassette containing a neomycin resistance gene and a putative transcription termination sequence. Contrary to expectation, brain and other tissues from mice homozygous for the insertion still contained beta APP-specific RNA, albeit at a level 5- to 10-fold lower than wild type and lacking the disrupted exon, which had been spliced out. The brain contained shortened beta APP-specific protein at a low level. Mutant mice were severely impaired in spatial learning and exploratory behavior and showed increased incidence of agenesis of the corpus callosum.	UNIV ZURICH, INST ANAT, CH-8057 ZURICH, SWITZERLAND; UNIV SPITAL ZURICH, INST NEUROPATHOL, BIOL ZENT LAB, CH-8091 ZURICH, SWITZERLAND	University of Zurich; University of Zurich; University Zurich Hospital	MULLER, U (corresponding author), UNIV ZURICH, INST MOLEK BIOL 1, CH-8093 ZURICH, SWITZERLAND.		; Brandner, Sebastian/J-4562-2014	Aguzzi, Adriano/0000-0002-0344-6708; Brandner, Sebastian/0000-0002-9821-0342				ASHALL F, 1994, TRENDS BIOCHEM SCI, V19, P42, DOI 10.1016/0968-0004(94)90173-2; BERNASCONIGUASTALLA S, 1994, HIPPOCAMPUS, V4, P53, DOI 10.1002/hipo.450040107; BEYREUTHER K, 1991, ANN NY ACAD SCI, V640, P129; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CLARK RF, 1993, ARCH NEUROL-CHICAGO, V50, P1164, DOI 10.1001/archneur.1993.00540110044004; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; DOYLE E, 1990, NEUROSCI LETT, V115, P97, DOI 10.1016/0304-3940(90)90524-D; Gallyas F, 1979, Neurol Res, V1, P203; GANDY S, 1992, TRENDS PHARMACOL SCI, V13, P108, DOI 10.1016/0165-6147(92)90039-9; GENNARINI G, 1984, EUR J BIOCHEM, V142, P65, DOI 10.1111/j.1432-1033.1984.tb08251.x; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HARDY J, 1994, SCIENCE, V263, P454, DOI 10.1126/science.8290946; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; HESS DT, 1983, J NEUROSCI METH, V8, P95, DOI 10.1016/0165-0270(83)90055-9; HILBICH C, 1993, J BIOL CHEM, V268, P26571; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEITINGER B, 1994, BEHAV GENET, V24, P273, DOI 10.1007/BF01067194; Lipp H.-P., 1993, Society for Neuroscience Abstracts, V19, P799; Lipp H.-P., 1992, GENETICALLY DEFINED, P217; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MONTAG D, 1994, NEURON, V13, P229, DOI 10.1016/0896-6273(94)90472-3; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; NOGUCHI S, 1993, LANCET, V342, P737, DOI 10.1016/0140-6736(93)91728-5; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; REBECK GW, 1993, NEURON, V11, P575; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; Schopke R, 1991, Hippocampus, V1, P315, DOI 10.1002/hipo.450010322; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SMALL DH, 1994, J NEUROSCI, V14, P2117; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P537, DOI 10.1126/science.8290965; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WEHNER JM, 1990, BRAIN RES, V523, P181, DOI 10.1016/0006-8993(90)91485-Y; WOLFER DP, 1992, J NEUROSCI METH, V41, P65, DOI 10.1016/0165-0270(92)90124-V; YAMADA T, 1989, BIOCHEM BIOPH RES CO, V158, P906, DOI 10.1016/0006-291X(89)92808-8; YAMADA T, 1987, BIOCHEM BIOPH RES CO, V149, P665, DOI 10.1016/0006-291X(87)90419-0; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	55	271	282	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					755	765		10.1016/0092-8674(94)90066-3	http://dx.doi.org/10.1016/0092-8674(94)90066-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001115				2022-12-24	WOS:A1994PW05400004
J	RAE, D; PORTER, J; BEECHEYNEWMAN, N; SUMAR, N; BENNETT, D; HERMONTAYLOR, J				RAE, D; PORTER, J; BEECHEYNEWMAN, N; SUMAR, N; BENNETT, D; HERMONTAYLOR, J			TYPE-1 PROPHOSPHOLIPASE A(2) PROPEPTIDE IN ACUTE LUNG INJURY	LANCET			English	Note							RESPIRATORY-DISTRESS SYNDROME; NEUTROPHILS	Neutrophil sequestration and activation in the pulmonary vasculature and interstitium are important in acute lung injury. Phospholipase A(2) plays an important part in the production of potent inflammatory mediators in this syndrome. We used our ELISA for type 1 prophospholipase A(2) activation peptides, which have the aminoacid sequence Asp-Ser-Gly-Ile-Ser-Pro-Arg (DSGISPR), to show that DSGISPR concentrations in plasma and urine are a sensitive and specific marker of acute lung injury in patients admitted to intensive care. The detection of DSGISPR in the plasma of 11 of 50 unselected patients had a sensitivity of 100% and a specificity of 93% for the presence or future development of acute lung injury.	ST GEORGE HOSP,SCH MED,DEPT SURG,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,INTENS CARE UNIT,LONDON SW17 0RE,ENGLAND	St Georges University London; St Georges University London			Porter, Joanna/C-7162-2009	Porter, Joanna/0000-0002-7307-169X				CHANG SW, 1987, J CLIN INVEST, V79, P1498, DOI 10.1172/JCI112980; GRATAROLI R, 1982, EUR J BIOCHEM, V122, P111, DOI 10.1111/j.1432-1033.1982.tb05855.x; HEFFNER JE, 1987, AM REV RESPIR DIS, V135, P482; OFFENSTADT G, 1981, INTENS CARE MED, V7, P285, DOI 10.1007/BF01709723; RAE D, IN PRESS CLIN BIOCH; RINTALA EM, 1993, CLIN INFECT DIS, V17, P864, DOI 10.1093/clinids/17.5.864; ROMASCHIN AD, 1992, CLIN BIOCHEM, V25, P55, DOI 10.1016/0009-9120(92)80046-J; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218; WEINBERG PF, 1984, AM REV RESPIR DIS, V130, P791; WEISS SJ, 1989, NEW ENGL J MED, V320, P365	10	45	45	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1472	1473		10.1016/S0140-6736(94)90291-7	http://dx.doi.org/10.1016/S0140-6736(94)90291-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968121				2022-12-24	WOS:A1994PT99500010
J	FISHEL, R; EWEL, A; LEE, S; LESCOE, MK; GRIFFITH, J				FISHEL, R; EWEL, A; LEE, S; LESCOE, MK; GRIFFITH, J			BINDING OF MISMATCHED MICROSATELLITE DNA-SEQUENCES BY THE HUMAN MSH2 PROTEIN	SCIENCE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; ESCHERICHIA-COLI; SPONTANEOUS MUTATION; GENETIC INSTABILITY; REPAIR; CARCINOGENESIS; HETERODUPLEXES; TUMORIGENESIS; CARCINOMA; HOMOLOG	Alteration of the human mismatch repair gene hMSH2 has been linked to the microsatellite DNA instability found in hereditary nonpolyposis colon cancer and several sporadic cancers. This microsatellite DNA instability is thought to arise from defective repair of DNA replication errors that create insertion-deletion loop-type (IDL) mismatched nucleotides. Here, it is shown that purified hMSH2 protein efficiently and specifically binds DNA containing IDL mismatches of up to 14 nucleotides. These results support a direct role for hMSH2 in mutation avoidance and microsatellite stability in human cells.	UNIV N CAROLINA,LINEBERGER CANC RES CTR,DEPT MICROBIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	FISHEL, R (corresponding author), UNIV VERMONT,MARKEY CTR MOLEC GENET,SCH MED,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05405, USA.				NCI NIH HHS [CA56542, R01 CA067007] Funding Source: Medline; NIGMS NIH HHS [GM31819, GM42342] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056542, R01CA067007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALANI E, UNPUB; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BISHOP DT, 1990, CANCER SURV, V9, P585; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURKS RT, 1994, ONCOGENE, V9, P1163; CHI W, IN PRESS J BIOL CHEM; COX EC, 1976, ANNU REV GENET, V10, P135, DOI 10.1146/annurev.ge.10.120176.001031; DRAKE JW, 1976, ANNU REV BIOCHEM, V45, P11, DOI 10.1146/annurev.bi.45.070176.000303; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FISHEL R, UNPUB; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P10; GRIFFITH JP, UNPUB; HAN HJ, 1993, CANCER RES, V53, P5087; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEARN BA, 1989, J BACTERIOL, V171, P6473, DOI 10.1128/jb.171.12.6473-6481.1989; LEONG PM, 1986, J BACTERIOL, V168, P412, DOI 10.1128/jb.168.1.412-416.1986; LOEB LA, 1991, CANCER RES, V51, P3075; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; LYNCH HT, 1991, SEMIN ONCOL, V18, P337; MERLO A, 1994, CANCER RES, V54, P2098; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1989, J BIOL CHEM, V264, P6597; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; RENAN MJ, 1993, MOL CARCINOGEN, V7, P139; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SCHOENBERG MP, 1994, BIOCHEM BIOPH RES CO, V198, P74, DOI 10.1006/bbrc.1994.1011; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, IN PRESS SCIENCE; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WANG YH, 1992, J BIOL CHEM, V267, P4911; WETNUR JG, 1968, J MOL BIOL, V31, P349; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YEE CJ, 1994, CANCER RES, V54, P1641; YOUNG J, 1993, HUM MUTAT, V2, P351, DOI 10.1002/humu.1380020505	54	162	173	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1403	1405		10.1126/science.7973733	http://dx.doi.org/10.1126/science.7973733			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973733				2022-12-24	WOS:A1994PT63200049
J	OFVERSTEDT, LG; ZHANG, K; TAPIO, S; SKOGLUND, U; ISAKSSON, LA				OFVERSTEDT, LG; ZHANG, K; TAPIO, S; SKOGLUND, U; ISAKSSON, LA			STARVATION IN-VIVO FOR AMINOACYL-TRANSFER-RNA INCREASES THE SPATIAL SEPARATION BETWEEN THE 2 RIBOSOMAL-SUBUNITS	CELL			English	Article							ESCHERICHIA-COLI RIBOSOME; ELECTRON-MICROSCOPE TOMOGRAPHY; 3-DIMENSIONAL IMAGE-RECONSTRUCTION; ELONGATION-FACTOR TU; TRANSFER-RNA BINDING; X-RAY; IMMUNOELECTRON MICROSCOPY; CONFORMATIONAL CHANGE; PUROMYCIN BINDING; SINGLE PARTICLES	Structures in situ of individual ribosomes in E. coli have been determined by computer-aided electron microscope tomography using a tilt series of positively stained embedded cellular sections. Amino acid starvation of a bacterial culture, causing a deficiency for aminoacyl-tRNA, induces a spatial separation between the ribosomal subunits compared with ribosomes in exponentially growing cells. Eight ribosomes from each growth condition were aligned to each other, and the two average structures were determined. Comparison of these suggests that the distance between the two subunits increases by similar to 3 nm upon starvation for aminoacyl-tRNA during protein synthesis. Ribosomes in most other states of the translational elongation cycle in exponentially growing cells show a more compact structure than previously realized.	UNIV STOCKHOLM,DEPT MICROBIOL,S-10691 STOCKHOLM,SWEDEN	Stockholm University	OFVERSTEDT, LG (corresponding author), KAROLINSKA INST,MED NOBEL INST,DEPT CELL & MOLEC BIOL,S-17177 STOCKHOLM,SWEDEN.		Öfverstedt, Lars-Göran/J-3518-2013; Tapio, Soile/CAJ-5871-2022; Tapio, Soile/M-7358-2014; Skoglund, Ulf/B-5829-2015	Öfverstedt, Lars-Göran/0000-0002-1796-2199; Tapio, Soile/0000-0001-9860-3683; Skoglund, Ulf/0000-0002-3407-0053				ARAD T, 1987, BIOCHIMIE, V69, P1001, DOI 10.1016/0300-9084(87)90234-3; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERKOVITCHYELLIN Z, 1992, CRIT REV BIOCHEM MOL, V27, P403, DOI 10.3109/10409239209082568; BRACEWELL RN, 1967, ASTROPHYS J, V150, P427, DOI 10.1086/149346; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; FRANK J, 1988, TRENDS BIOCHEM SCI, V13, P123, DOI 10.1016/0968-0004(88)90063-1; FRANK J, 1990, RIBOSOME, P107; GILBERT PFC, 1972, PROC R SOC SER B-BIO, V182, P89, DOI 10.1098/rspb.1972.0068; GIRSHOVICH AS, 1981, FEBS LETT, V130, P54, DOI 10.1016/0014-5793(81)80664-3; GIRSHOVICH AS, 1986, FEBS LETT, V197, P192, DOI 10.1016/0014-5793(86)80325-8; GLAUERT AM, 1958, J BIOPHYS BIOCHEM CY, V4, P191, DOI 10.1083/jcb.4.2.191; GORNICKI P, 1984, J BIOL CHEM, V259, P493; GUDKOV AT, 1989, BIOCHIMIE, V71, P779, DOI 10.1016/0300-9084(89)90040-0; HART RG, 1968, SCIENCE, V159, P1464, DOI 10.1126/science.159.3822.1464; HOPPE W, 1986, J MOL BIOL, V192, P291, DOI 10.1016/0022-2836(86)90366-9; ISAKSSON LA, 1977, MOL GEN GENET, V156, P223; KIRSEBOM LA, 1986, MOL GEN GENET, V205, P240, DOI 10.1007/BF00430434; KLUG A, 1972, NATURE, V238, P435, DOI 10.1038/238435a0; KNAUER V, 1983, J MOL BIOL, V163, P409, DOI 10.1016/0022-2836(83)90066-9; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAKE JA, 1977, P NATL ACAD SCI USA, V74, P1903, DOI 10.1073/pnas.74.5.1903; LAKE JA, 1985, ANNU REV BIOCHEM, V54, P507, DOI 10.1146/annurev.biochem.54.1.507; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; LAUGHREA M, 1992, BIOCHEMISTRY-US, V31, P12035, DOI 10.1021/bi00163a011; LAUGHREA M, 1994, IN PRESS MOL MICROBI, V11; LILJAS A, 1982, PROG BIOPHYS MOL BIO, V40, P161, DOI 10.1016/0079-6107(82)90013-X; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; LODMELL JS, 1993, BIOCHEMISTRY-US, V32, P4067, DOI 10.1021/bi00066a030; LONNROTH A, 1993, J MICROSC-OXFORD, V170, P173; LUFT JH, 1972, P ELECTRON MICROSC S, V30, P132; LUHRMANN R, 1981, P NATL ACAD SCI-BIOL, V78, P7276, DOI 10.1073/pnas.78.12.7276; LUTHER PK, 1988, ULTRAMICROSCOPY, V24, P7, DOI 10.1016/0304-3991(88)90322-1; MAUGUEN Y, 1982, NATURE, V297, P162, DOI 10.1038/297162a0; MCEWEN BF, 1986, P NATL ACAD SCI USA, V83, P9040, DOI 10.1073/pnas.83.23.9040; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MEISENBERGER O, 1984, BIOCHIM BIOPHYS ACTA, V781, P225, DOI 10.1016/0167-4781(84)90087-3; Miller JH, 1972, EXPT MOL GENETICS; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; NORDESTGAARD BG, 1985, MICRON MICROSC ACTA, V16, P65, DOI 10.1016/0739-6260(85)90035-8; ODOM OW, 1990, BIOCHEMISTRY-US, V29, P10734, DOI 10.1021/bi00500a004; OETTL H, 1983, J MOL BIOL, V163, P431, DOI 10.1016/0022-2836(83)90067-0; OFENGAND J, 1986, STRUCTURE FUNCTION G, P473; OLSON HM, 1982, J BIOL CHEM, V257, P2649; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; RADERMACHER M, 1987, EMBO J, V6, P1107, DOI 10.1002/j.1460-2075.1987.tb04865.x; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; SERDYUK I, 1992, BIOCHIMIE, V74, P299, DOI 10.1016/0300-9084(92)90107-P; SKOGLUND U, 1986, TRENDS BIOCHEM SCI, V11, P499, DOI 10.1016/0968-0004(86)90077-0; SKOGLUND U, 1986, NATURE, V319, P560, DOI 10.1038/319560a0; SPIRIN A, 1987, BIOCHIMIE, V69, P949, DOI 10.1016/0300-9084(87)90228-8; SPIRIN AS, 1987, J MOL BIOL, V194, P119, DOI 10.1016/0022-2836(87)90720-0; SPIRIN AS, 1983, FEBS LETT, V156, P217, DOI 10.1016/0014-5793(83)80499-2; SPIRIN AS, 1989, BIOL CELL, V66, P215, DOI 10.1016/0248-4900(89)90174-3; SRIVASTAVA S, 1985, FEBS LETT, V186, P17, DOI 10.1016/0014-5793(85)81330-2; STOFFLER G, 1984, ANNU REV BIOPHYS BIO, V13, P303, DOI 10.1146/annurev.bb.13.060184.001511; STOFFLER G, 1980, RIBOSOMES STRUCTURE, P171; TARDIEU A, 1982, EMBO J, V1, P35, DOI 10.1002/j.1460-2075.1982.tb01120.x; VASILIEV VD, 1983, FEBS LETT, V155, P167, DOI 10.1016/0014-5793(83)80232-4; WAGENKNECHT T, 1989, BIOPHYS J, V55, P455, DOI 10.1016/S0006-3495(89)82839-5; WILLIAMS RC, 1970, J MOL BIOL, V52, P121, DOI 10.1016/0022-2836(70)90181-6; WITTMANN HG, 1983, ANNU REV BIOCHEM, V52, P35, DOI 10.1146/annurev.bi.52.070183.000343; WOWER J, 1991, BIOCHIMIE, V73, P961, DOI 10.1016/0300-9084(91)90137-P; YONATH A, 1993, CURR OPIN STRUC BIOL, V3, P175, DOI 10.1016/S0959-440X(05)80149-6; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200; YONATH A, 1990, RIBOSOME, P134	69	39	39	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					629	638		10.1016/0092-8674(94)90548-7	http://dx.doi.org/10.1016/0092-8674(94)90548-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954829				2022-12-24	WOS:A1994PT48100010
J	CONQUET, F; BASHIR, ZI; DAVIES, CH; DANIEL, H; FERRAGUTI, F; BORDI, F; FRANZBACON, K; REGGIANI, A; MATARESE, V; CONDE, F; COLLINGRIDGE, GL; CREPEL, F				CONQUET, F; BASHIR, ZI; DAVIES, CH; DANIEL, H; FERRAGUTI, F; BORDI, F; FRANZBACON, K; REGGIANI, A; MATARESE, V; CONDE, F; COLLINGRIDGE, GL; CREPEL, F			MOTOR DEFICIT AND IMPAIRMENT OF SYNAPTIC PLASTICITY IN MICE LACKING MGLUR1	NATURE			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; CEREBELLAR PURKINJE-CELLS; LONG-TERM POTENTIATION; RAT-BRAIN; INVITRO; MOUSE; HIPPOCAMPUS; EXPRESSION; INDUCTION; ACTIVATION	Metabotropic glutamate receptor 1 (mGluR1) is a member of a large family of G-protein-coupled glutamate receptors, the physiological functions of which are largely unknown. Mice deficient in mGluR1 have severe motor coordination and spatial learning deficits. They have no gross anatomical or basic electrophysiological abnormalities in either the cerebellum or hippocampus, but they show impaired cerebellar long-term depression and hippocampal messy fibre long-term potentiation, mGluR1-deficient mice should therefore be valuable models for studying synaptic plasticity.	GLAXO SPA,GLAXO RES LABS,DEPT PHARMACOL,I-37100 VERONA,ITALY; UNIV PARIS 11,F-91405 ORSAY,FRANCE; CNRS,DEPT NEUROBIOL,F-91405 ORSAY,FRANCE; UNIV BIRMINGHAM,DEPT PHARMACOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	GlaxoSmithKline; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); University of Birmingham	CONQUET, F (corresponding author), GLAXO INST MOLEC BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND.		Francesco, Ferraguti/AAD-3422-2020; Collingridge, Graham L/C-4605-2015; collingridge, graham/AAI-8362-2020; Matarese, Valerie/ABE-1606-2020	Francesco, Ferraguti/0000-0002-3843-5857; Collingridge, Graham L/0000-0002-9572-5359; Matarese, Valerie/0000-0003-2687-194X; Bashir, Zafar/0000-0003-3650-2136				AGNATI LF, 1988, NEUROSCIENCE, V27, P785, DOI 10.1016/0306-4522(88)90183-2; BASHIR ZI, 1993, EUR J PHARMACOL, V239, P265, DOI 10.1016/0014-2999(93)91009-C; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BORTOLOTTO ZA, 1994, NATURE, V368, P740, DOI 10.1038/368740a0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1986, J PHYSIOL-LONDON, V372, P1; DANIEL H, 1992, EXP BRAIN RES, V90, P327; Eccles JC, 1967, CEREBELLUM NEURONAL; FOTUHI M, 1993, J NEUROSCI, V13, P2001; HANSE E, 1992, EUR J NEUROSCI, V4, P1191, DOI 10.1111/j.1460-9568.1992.tb00144.x; HARTELL NA, 1994, NEUROREPORT, V5, P913, DOI 10.1097/00001756-199404000-00015; HAYASHI T, 1994, J NEUROSCI, V14, P3370; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; IRWIN S, 1959, ARCH INT PHARMACOD T, V188, P358; Ito M, 1990, Neuroreport, V1, P129; KABA H, 1994, SCIENCE, V265, P262, DOI 10.1126/science.8023145; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MANZONI OJ, 1994, EUR J NEUROSCI, V6, P1050, DOI 10.1111/j.1460-9568.1994.tb00599.x; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OCONNOR JJ, 1994, NATURE, V367, P557, DOI 10.1038/367557a0; PERKEL DJ, 1990, P ROY SOC B-BIOL SCI, V241, P116, DOI 10.1098/rspb.1990.0074; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; REIDEL G, 1993, NEUROPHARMACOLOGY, V32, P929; RICHTER-LEVIN G, 1994, NEUROPHARMACOLOGY, V33, P853, DOI 10.1016/0028-3908(94)90181-3; RIDEL G, 1994, NEUROSCI LETT, V167, P141; RYO Y, 1993, J NEUROSCI RES, V36, P19, DOI 10.1002/jnr.490360104; SANDBERG PR, 1985, NEUROBEHAV TOXICOL T, V7, P87; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; STAUB C, 1992, EUR J NEUROSCI, V4, P832, DOI 10.1111/j.1460-9568.1992.tb00193.x	39	639	646	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					237	243		10.1038/372237a0	http://dx.doi.org/10.1038/372237a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969468				2022-12-24	WOS:A1994PR88900041
J	BOUSSIOTIS, VA; BARBER, DL; NAKARAI, T; FREEMAN, GJ; GRIBBEN, JG; BERNSTEIN, GM; DANDREA, AD; RITZ, J; NADLER, LM				BOUSSIOTIS, VA; BARBER, DL; NAKARAI, T; FREEMAN, GJ; GRIBBEN, JG; BERNSTEIN, GM; DANDREA, AD; RITZ, J; NADLER, LM			PREVENTION OF T-CELL ANERGY BY SIGNALING THROUGH THE GAMMA(C) CHAIN OF THE IL-2 RECEPTOR	SCIENCE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; CTLA-4 COUNTER-RECEPTOR; HUMAN LYMPHOCYTES-T; CLONAL ANERGY; FUNCTIONAL COMPONENT; INTERLEUKIN-2; INDUCTION; ANTIGEN; MICE; PROLIFERATION	When stimulated through their antigen receptor without requisite costimulation, T cells enter a state of antigen-specific unresponsiveness, termed anergy. In this study, signaling through the common gamma chain of the interleukin-2 (IL-2), IL-4, and IL-7 receptors in the presence of antigen was found to be sufficient to prevent the induction of anergy. After culture with IL-2, IL-4, or IL-7, Jak3 kinase was tyrosine-phosphorylated, which correlated with the prevention of anergy. Therefore, a signal through the common gamma chain may regulate the decision of T cells to either clonally expand or enter a state of anergy.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	BOUSSIOTIS, VA (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,44 BINNEY ST,BOSTON,MA 02115, USA.		Freeman, Gordon/AAC-5380-2019; Ritz, Jerome/C-7929-2009	Freeman, Gordon/0000-0002-7210-5616; Ritz, Jerome/0000-0001-5526-4669; Barber, Dwayne/0000-0001-5528-8150	NCI NIH HHS [CA 40216] Funding Source: Medline; NIAID NIH HHS [AI 35225] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BHANDOOLA A, 1993, J IMMUNOL, V151, P2355; BOUSSIOTIS VA, 1993, J EXP MED, V178, P1753, DOI 10.1084/jem.178.5.1753; BOUSSIOTIS VA, UNPUB; BOUSSIOTIS VA, IN PRESS J EXP MED; DALLMAN MJ, 1991, J EXP MED, V173, P79, DOI 10.1084/jem.173.1.79; DISANTO JP, 1994, EUR J IMMUNOL, V24, P475, DOI 10.1002/eji.1830240232; ESSERY G, 1988, IMMUNOLOGY, V64, P413; FANSLOW WC, 1993, BLOOD, V81, P2998; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FOX DA, 1984, J IMMUNOL, V133, P1250; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1993, J EXP MED, V178, P2185, DOI 10.1084/jem.178.6.2185; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GO C, 1992, J EXP MED, V175, P1327, DOI 10.1084/jem.175.5.1327; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HARPUR AG, 1992, ONCOGENE, V7, P1347; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAMIO M, 1990, INT IMMUNOL, V2, P521, DOI 10.1093/intimm/2.6.521; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LIN H, 1993, J EXP MED, V178, P1801, DOI 10.1084/jem.178.5.1801; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LOMBARDI G, 1994, J EXP MED, V264, P1587; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NAKARAI T, 1994, J EXP MED, V180, P241, DOI 10.1084/jem.180.1.241; NELSON JD, 1994, NATURE, V369, P333; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; WHITTHUHN BA, 1994, NATURE, V370, P153; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	51	318	325	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1039	1042		10.1126/science.7973657	http://dx.doi.org/10.1126/science.7973657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973657				2022-12-24	WOS:A1994PQ92400043
J	RUSSELL, SM; JOHNSTON, JA; NOGUCHI, M; KAWAMURA, M; BACON, CM; FRIEDMANN, M; BERG, M; MCVICAR, DW; WITTHUHN, BA; SILVENNOINEN, O; GOLDMAN, AS; SCHMALSTIEG, FC; IHLE, JN; OSHEA, JJ; LEONARD, WJ				RUSSELL, SM; JOHNSTON, JA; NOGUCHI, M; KAWAMURA, M; BACON, CM; FRIEDMANN, M; BERG, M; MCVICAR, DW; WITTHUHN, BA; SILVENNOINEN, O; GOLDMAN, AS; SCHMALSTIEG, FC; IHLE, JN; OSHEA, JJ; LEONARD, WJ			INTERACTION OF IL-2R-BETA AND GAMMA(C) CHAINS WITH JAK1 AND JAK3 - IMPLICATIONS FOR XSCID AND XCID	SCIENCE			English	Article							HUMAN INTERLEUKIN-2 RECEPTOR; COMBINED IMMUNODEFICIENCY DISEASE; IL-2 RECEPTOR; TYROSINE PHOSPHORYLATION; FUNCTIONAL COMPONENT; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; LYMPHOCYTES-T; BETA; EXPRESSION	Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta (IL-2R beta) and common gamma (gamma(c)) chains. Mutations of gamma(c) can result in X-linked severe combined immunodeficiency (XSCID). IL-2, IL-4, IL-7 (whose receptors are known to contain gamma(c)) and IL-9 (whose receptor is shown here to contain gamma(c)) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3. Jak1 and Jak3 associated with IL-2R beta and gamma(c), respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma(c) associations. Truncations of gamma(c), and a gamma(c), point mutation causing moderate X-linked combined immunodeficiency (XCID), decreased gamma(c)-Jak3 association. Thus, gamma(c) mutations in at least some XSCID and XCID patients prevent normal Jak3 activation, suggesting that mutations of Jak3 may result in an XSCID-like phenotype.	NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, EXPTL IMMUNOL LAB, FREDERICK, MD 21702 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; UNIV TEXAS, MED BRANCH, DEPT PEDIAT, DIV IMMUNOL & ALLERGY, GALVESTON, TX 77555 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; St Jude Children's Research Hospital; University of Texas System; University of Texas Medical Branch Galveston	RUSSELL, SM (corresponding author), NHLBI, MOLEC IMMUNOL LAB, BLDG 10, BETHESDA, MD 20892 USA.		Russell, Sarah M/B-9341-2009; witthuhn, bruce/GSE-3193-2022; Leonard, Warren/AAA-1397-2022; McVicar, Daniel/G-1970-2015	Russell, Sarah M/0000-0001-5826-9641; Bacon, Chris/0000-0002-8268-2812; McVicar, Daniel/0000-0002-1112-5111	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASAO H, 1992, FEBS LETT, V304, P141, DOI 10.1016/0014-5793(92)80605-G; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BROOKS EG, 1990, J CLIN INVEST, V86, P1623, DOI 10.1172/JCI114884; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOLDMAN AS, 1992, EUR J IMMUNOL, V22, P1103, DOI 10.1002/eji.1830220435; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEONARD WJ, 1994, CURR OPIN IMMUNOL, V6, P631, DOI 10.1016/0952-7915(94)90152-X; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NAKARAI T, 1994, J EXP MED, V180, P241, DOI 10.1084/jem.180.1.241; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; RUSSELL SM, UNPUB; SALTZMAN EM, 1990, J BIOL CHEM, V265, P10138; SCHMALSTIEG FC, 1992, CLIN IMMUNOL IMMUNOP, V64, P71, DOI 10.1016/0090-1229(92)90061-R; SCHMALSTIEG FC, UNPUB; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	41	617	648	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1042	1045		10.1126/science.7973658	http://dx.doi.org/10.1126/science.7973658			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973658	Green Submitted			2022-12-24	WOS:A1994PQ92400044
J	CHEN, XS; SHELLER, JR; JOHNSON, EN; FUNK, CD				CHEN, XS; SHELLER, JR; JOHNSON, EN; FUNK, CD			ROLE OF LEUKOTRIENES REVEALED BY TARGETED DISRUPTION OF THE 5-LIPOXYGENASE GENE	NATURE			English	Article							PLATELET-ACTIVATING-FACTOR; MOUSE EAR EDEMA; MAST-CELLS; MICE; STIMULATION; PERITONITIS; MODULATION; MEDIATORS; PRODUCTS; INVITRO	LEUKOTRIENES constitute a class of potent biological mediators of inflammation and anaphylaxis (for reviews see refs 1 and 2). Their biosynthesis derives from 5-lipoxygenase-catalysed oxygenation of arachidonic acid in granulocytes, macrophages and mast cells. To examine the physiological importance of leukotrienes, we have disrupted the 5-lipoxygenase gene by homologous recombination in embryonic stem cells. 5-Lipoxygenase-deficient (5LX(-/-)) mice develop normally and are healthy. They show a selective opposition to certain inflammatory insults. Although there is no difference in their reaction to endotoxin shock, the 5LX(-/-) animals resist the lethal effects of shock induced by platelet-activating factor. Reaction to ear inflammation induced by phorbol ester is normal, whereas inflammation induced by arachidonic acid is markedly reduced. Contrasts mere also found in two models of leukocyte chemotaxis in vivo. The phenotype of 5LX(-/-) mice under injurious insult identifies the role for leukotrienes in the pathophysiology of select inflammatory states.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University			Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233				BARBEE RW, 1994, CIRC RES, V74, P747, DOI 10.1161/01.RES.74.4.747; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRAQUET P, 1987, PHARMACOL REV, V39, P97; CARLSON RP, 1985, AGENTS ACTIONS, V17, P197, DOI 10.1007/BF01966592; CLAESSON HE, 1985, BIOCHEM BIOPH RES CO, V131, P579, DOI 10.1016/0006-291X(85)91276-8; CRUMMEY A, 1987, AGENTS ACTIONS, V20, P69, DOI 10.1007/BF01965627; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FUNK CD, 1991, J BIOL CHEM, V266, P12508; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; INOUE H, 1988, PROSTAGLANDINS, V36, P731, DOI 10.1016/0090-6980(88)90016-0; LANARA E, 1982, BIOCHEM BIOPH RES CO, V109, P1148, DOI 10.1016/0006-291X(82)91897-6; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MARTIN TR, 1988, J APPL PHYSIOL, V64, P2318, DOI 10.1152/jappl.1988.64.6.2318; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; OGATA M, 1992, INFECT IMMUN, V60, P2432, DOI 10.1128/IAI.60.6.2432-2437.1992; PEMBER SO, 1983, BLOOD, V61, P1105; PIPER PJ, 1986, BRIT J PHARMACOL, V88, P595, DOI 10.1111/j.1476-5381.1986.tb10240.x; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; RAMOS BF, 1990, J IMMUNOL, V145, P1868; RAZIN E, 1982, P NATL ACAD SCI-BIOL, V79, P4665, DOI 10.1073/pnas.79.15.4665; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; STAHL GL, 1987, CIRC SHOCK, V23, P165; SUN XM, 1991, J IMMUNOL, V147, P509; VOELKEL NF, 1982, SCIENCE, V218, P286, DOI 10.1126/science.7123233; ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922; ZHANG YY, 1992, P NATL ACAD SCI USA, V89, P485, DOI 10.1073/pnas.89.2.485; ZIBOH VA, 1986, CANCER RES, V46, P600	28	329	339	2	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					179	182		10.1038/372179a0	http://dx.doi.org/10.1038/372179a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969451				2022-12-24	WOS:A1994PQ68800056
J	KINLEN, LJ; JOHN, SM				KINLEN, LJ; JOHN, SM			WARTIME EVACUATION AND MORTALITY FROM CHILDHOOD LEUKEMIA IN ENGLAND AND WALES IN 1945-9	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA; EXCESS	Objective-To discover whether the wartime government evacuation of children from London and other population centres to rural districts was associated with any increase in childhood leukaemia. Design-Observational study of mortality from leukaemia among the childhood population of England and Wales in relation to the unique population movements during the second world war. The 476 rural districts of England and Wales were ranked according to the ratio of government evacuees (two thirds of them children) to local children in September 1941. The districts were divided into three categories, each with similar numbers of children in 1947 but with different ratios of evacuees to local children (''low,'' ''intermediate,'' ''high''). Mortality from childhood leukaemia was examined in these three rural categories in 1945-9. Urban areas were also examined according to their exposure to evacuees. Setting-Local authority areas of England and Wales. Subjects-Children aged under 15. Results-47% excess of leukaemia at ages 0-14 years occurred in 1945-9 in the rural ''high'' category for evacuees relative to the ''low'' category, with a significant trend across the three categories. There were increases in both the 0-4 and 5-14 year age groups, but these were larger in the older age group. Rates 25% lower than average occurred in rural areas with few evacuees. Conclusion-These findings suggest that wartime evacuation increased the incidence of childhood leukaemia in rural areas and that other forms of population mixing may have contributed to the increases in past decades. Overall, they add to the appreciable evidence for an infective basis in childhood leukaemia.			KINLEN, LJ (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND.							BRADBEER G, 1993, LAND CHANGED ITS FAC; BROWN WMC, 1960, BRIT MED J, V2, P1539, DOI 10.1136/bmj.2.5212.1539; CALDER A, 1986, PEOPLES WAR BRITAIN; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1993, BRIT MED J, V306, P743, DOI 10.1136/bmj.306.6880.743; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; KNEALE GW, 1971, BRIT J PREV SOC MED, V25, P152; LANGFORD I, 1991, SOC SCI MED, V33, P435, DOI 10.1016/0277-9536(91)90325-7; ROOTES A, 1980, FRONT LINE COUNTY; Stocks P, 1941, J R STAT SOC, V104, P311, DOI 10.2307/2980120; Stocks P, 1942, J R STAT SOC, V105, P259, DOI 10.2307/2980435; TITMUSS RM, 1950, HIST 2ND WORLD WAR U; WOLFF SP, 1991, NATURE, V349, P23, DOI 10.1038/349023a0; 1951, STATISTICAL REV ENGL, V2; 1940, STATISTICS POPULATIO; 1949, ESTIMATES SEX AGE DI; 1947, STATISTICAL REV EN 1	19	42	42	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 5	1994	309	6963					1197	1202		10.1136/bmj.309.6963.1197	http://dx.doi.org/10.1136/bmj.309.6963.1197			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7987150	Green Published			2022-12-24	WOS:A1994PQ66200019
J	GEIERSTANGER, BH; MRKSICH, M; DERVAN, PB; WEMMER, DE				GEIERSTANGER, BH; MRKSICH, M; DERVAN, PB; WEMMER, DE			DESIGN OF A G-CENTER-DOT-C-SPECIFIC DNA MINOR GROOVE-BINDING PEPTIDE	SCIENCE			English	Article							SEQUENCE-SPECIFIC RECOGNITION; TWO-DIMENSIONAL NMR; MOLECULAR RECOGNITION; DISTAMYCIN-A; N-METHYLPYRROLECARBOXAMIDE; 2-DIMENSIONAL NMR; DYNAMIC ASPECTS; NUCLEIC-ACIDS; NETROPSIN; COMPLEX	A four-ring tripeptide containing alternating imidazole and pyrrole carboxamides specifically binds six-base pair 5'-(A,T)GCGC(A,T)-3' sites in the minor groove of DNA. The designed peptide has a specificity completely reversed from that of the tripyrrole distamycin, which binds A,T sequences. Structural studies with nuclear magnetic resonance revealed that two peptides bound side-by-side and in an antiparallel orientation in the minor groove. Each of the four imidazoles in the 2:1 ligand-DNA complex recognized a specific guanine amino group in the GCGC core through a hydrogen bond. Targeting a designated four- base pair G-C tract by this synthetic ligand supports the generality of the 2:1 peptide-DNA motif for sequence-specific minor groove recognition of DNA.	CALTECH,ARNOLD & MABEL BECKMAN LABS CHEM SYNTHESIS,PASADENA,CA 91125; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,GRAD GRP BIOPHYS,BERKELEY,CA 94720	California Institute of Technology; University of California System; University of California Berkeley; University of California System; University of California Berkeley			Mrksich, Milan/G-2469-2011	Mrksich, Milan/0000-0002-4964-796X	NIGMS NIH HHS [GM-27681, GM-43129] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043129, R37GM027681, R01GM027681] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOELENS R, 1985, J MAGN RESON, V62, P378, DOI 10.1016/0022-2364(85)90207-0; BURCKHARDT G, 1989, BIOCHIM BIOPHYS ACTA, V1009, P11, DOI 10.1016/0167-4781(89)90072-9; CHEN X, 1994, NAT STRUCT BIOL, V1, P169, DOI 10.1038/nsb0394-169; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408; DWYER TJ, 1993, J AM CHEM SOC, V115, P9900, DOI 10.1021/ja00075a005; DWYER TJ, 1992, J AM CHEM SOC, V114, P5911, DOI 10.1021/ja00041a001; GEIERSTANGER BH, 1993, J AM CHEM SOC, V115, P4474, DOI 10.1021/ja00064a009; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P3055, DOI 10.1021/bi00176a039; GEIERSTANGER BH, UNPUB; HARTLEY JA, 1988, ACTA ONCOL, V27, P503, DOI 10.3109/02841868809093578; KISSINGER K, 1987, BIOCHEMISTRY-US, V26, P5590, DOI 10.1021/bi00392a002; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P3296, DOI 10.1021/bi00359a032; KOPKA ML, 1985, J MOL BIOL, V183, P553, DOI 10.1016/0022-2836(85)90171-8; KOPKA ML, 1985, P NATL ACAD SCI USA, V82, P1376, DOI 10.1073/pnas.82.5.1376; LEE M, 1993, BIOCHEMISTRY-US, V32, P4237, DOI 10.1021/bi00067a011; LEE M, 1988, J BIOMOL STRUCT DYN, V5, P1059, DOI 10.1080/07391102.1988.10506449; LEE M, 1988, BIOCHEMISTRY-US, V27, P445, DOI 10.1021/bi00401a066; Lee M, 1989, J Mol Recognit, V2, P84, DOI 10.1002/jmr.300020206; LOWN JW, 1986, BIOCHEMISTRY-US, V25, P7408, DOI 10.1021/bi00371a024; MRKSICH M, 1994, J AM CHEM SOC, V116, P3663, DOI 10.1021/ja00087a088; MRKSICH M, 1993, J AM CHEM SOC, V115, P9892, DOI 10.1021/ja00075a004; MRKSICH M, 1993, J AM CHEM SOC, V115, P2572, DOI 10.1021/ja00060a004; MRKSICH M, 1992, P NATL ACAD SCI USA, V89, P7586, DOI 10.1073/pnas.89.16.7586; MRKSICH M, UNPUB; PELTON JG, 1988, BIOCHEMISTRY-US, V27, P8088, DOI 10.1021/bi00421a018; PELTON JG, 1989, P NATL ACAD SCI USA, V86, P5723, DOI 10.1073/pnas.86.15.5723; PELTON JG, 1990, J AM CHEM SOC, V112, P1393, DOI 10.1021/ja00160a016; SCHULTZ PG, 1984, J BIOMOL STRUCT DYN, V1, P1133, DOI 10.1080/07391102.1984.10507508; SKLENAR V, 1987, FEBS LETT, V216, P249, DOI 10.1016/0014-5793(87)80699-3; TAYLOR JS, 1984, TETRAHEDRON, V40, P457, DOI 10.1016/0040-4020(84)85050-4; WADE WS, 1992, J AM CHEM SOC, V114, P8783, DOI 10.1021/ja00049a006; WADE WS, 1993, BIOCHEMISTRY-US, V32, P11385, DOI 10.1021/bi00093a015; WADE WS, 1987, J AM CHEM SOC, V109, P1574, DOI 10.1021/ja00239a050; WEMMER DE, 1994, STRUCTURAL BIOL STAT, V2, P301; YOUNGQUIST RS, 1985, P NATL ACAD SCI USA, V82, P2565, DOI 10.1073/pnas.82.9.2565; ZIMMER C, 1986, PROG BIOPHYS MOL BIO, V47, P31, DOI 10.1016/0079-6107(86)90005-2	37	208	218	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					646	650		10.1126/science.7939719	http://dx.doi.org/10.1126/science.7939719			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939719				2022-12-24	WOS:A1994PN80700047
J	FANTL, WJ; MUSLIN, AJ; KIKUCHI, A; MARTIN, JA; MACNICOL, AM; GROSS, RW; WILLIAMS, LT				FANTL, WJ; MUSLIN, AJ; KIKUCHI, A; MARTIN, JA; MACNICOL, AM; GROSS, RW; WILLIAMS, LT			ACTIVATION OF RAF-1 BY 14-3-3-PROTEINS	NATURE			English	Article							KINASE-KINASE; OOCYTE MATURATION; EXPRESSION; INDUCTION; PATHWAY; CLONING; GROWTH; CYCLIN; FAMILY; CELLS	THE protein Raf-1, a key mediator of mitogenesis and differentiation, associates with p21(ras) (refs 1-3). However, the regulation of the serine/threonine kinase activity of Raf-1 is still not understood(4-13). Using the yeast two-hybrid systems(8,14-16), we identified two structurally related proteins that interact with the aminoterminal region of Raf-1. These proteins, 14-3-3 zeta (PLA(2)) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins(17-23). Expression of 14-3-3 proteins in Xenopus oocytes enhanced Raf-1 activity and promoted Raf-1-dependent oocyte maturation. A dominant negative mutant of Raf-1 blocked the effects of 14-3-3 protein.	WASHINGTON UNIV, SCH MED, DIV BIOORGAN CHEM & MOLEC PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	FANTL, WJ (corresponding author), UNIV CALIF SAN FRANCISCO, DAIICHI RES CTR, INST CARDIOVASC RES, DEPT MED, SAN FRANCISCO, CA 94143 USA.							AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DU XP, 1994, J BIOL CHEM, V269, P18287; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARPER JW, 1993, CELL, V75, P805; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NIELSEN PJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P425, DOI 10.1016/0167-4781(91)90136-A; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; RAPP UR, 1991, ONCOGENE, V6, P495; SMITH LD, 1989, DEVELOPMENT, V107, P685; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P9213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	30	326	331	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					612	614		10.1038/371612a0	http://dx.doi.org/10.1038/371612a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935795				2022-12-24	WOS:A1994PL55900054
J	JARVIS, WR; BOLYARD, EA; BOZZI, CJ; BURWEN, DR; DOOLEY, SW; MARTIN, LS; MULLAN, RJ; SIMONE, PM				JARVIS, WR; BOLYARD, EA; BOZZI, CJ; BURWEN, DR; DOOLEY, SW; MARTIN, LS; MULLAN, RJ; SIMONE, PM			RESPIRATORS, RECOMMENDATIONS, AND REGULATIONS - THE CONTROVERSY SURROUNDING PROTECTION OF HEALTH-CARE WORKERS FROM TUBERCULOSIS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HIV-INFECTED PATIENTS; NOSOCOMIAL TRANSMISSION; OUTBREAK	Recent nosocomial outbreaks of tuberculosis have increased concern about the occupational acquisition of tuberculosis by health care workers. The Centers for Disease Control and Prevention (CDC), Department of Health and Human Services, and the Occupational Safety and Health Administration, Department of Labor, have issued recommendations and regulations in an effort to decrease health care workers' risk for exposure to patients with infectious tuberculosis. Within the CDC, the National Center for Infectious Diseases, the National Center for Prevention Services, and the National Institute for Occupational Safety and Health collaborated to produce the 1994 Guidelines for Preventing the Transmission of Tuberculosis in Health-Care Facilities. As stated in the Draft Guidelines, the major components of health care worker protection from Mycobacterium tuberculosis infection include administration or source controls, engineering controls, and respiratory protective devices. We review the evolution of the seemingly conflicting recommendations for respiratory protective devices made by these Centers of the CDC and explain how the recommendations in the current CDC Guidelines were reached.	CTR DIS CONTROL & PREVENT, DIV TB ELIMINAT, NCPS, ATLANTA, GA 30333 USA; CTR DIS CONTROL & PREVENT, NIOSH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	JARVIS, WR (corresponding author), CTR DIS CONTROL & PREVENT, HOSP INFECT PROGRAM, 1600 CLIFTON RD NE, MS E-69, ATLANTA, GA 30333 USA.							Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; JARVIS WR, 1993, RES MICROBIOL, V144, P117, DOI 10.1016/0923-2508(93)90025-W; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; LEIDEL NA, 1992, NIOSH RECOMMENDED GU; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; WENGER P, 1992, 1ST WORLD C TUB ROCK; 1982, CDC828371 US DEP HLT; 1993, MMWR-MORBID MORTAL W, V42, P696; 1987, DHHS NIOSH87116 PUBL; 1994, FED REG         0524, P26850; 1972, FED REGISTER, V37, P1910; 1993, DRAFT GUIDELINES PRE	18	43	44	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					142	146		10.7326/0003-4819-122-2-199501150-00011	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7992989				2022-12-24	WOS:A1995QC05900011
J	CHANG, Y; CESARMAN, E; PESSIN, MS; LEE, F; CULPEPPER, J; KNOWLES, DM; MOORE, PS				CHANG, Y; CESARMAN, E; PESSIN, MS; LEE, F; CULPEPPER, J; KNOWLES, DM; MOORE, PS			IDENTIFICATION OF HERPESVIRUS-LIKE DNA-SEQUENCES IN AIDS-ASSOCIATED KAPOSIS-SARCOMA	SCIENCE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; EPSTEIN-BARR-VIRUS; HOMOSEXUAL MEN; CYTOMEGALO-VIRUS; BISEXUAL MEN; COHORT; INFECTION; COFACTORS; DISEASE; GENOME	Representational difference analysis was used lo isolate unique sequences present in more than 90 percent of Kaposi's sarcoma (KS) tissues obtained from patients with acquired immunodeficiency syndrome (AIDS). These sequences were not present in tissue DNA from non-AIDS patients, but were present in 15 percent of non-KS tissue DNA samples from AIDS patients. The sequences are homologous to, but distinct from, capsid and tegument protein genes of the Gammaherpesvirinae, herpesvirus saimiri and Epstein-Barr virus. These KS-associated herpesvirus-like (KSHV) sequences appear to define a new human herpesvirus.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT BIOL MOLEC,PALO ALTO,CA 94304; NEW YORK CITY DEPT HLTH,DIS INTERVENT COMMISS,NEW YORK,NY 10013; COLUMBIA UNIV,SCH PUBL HLTH,DIV EPIDEMIOL,NEW YORK,NY 10013	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; New York City Department of Health & Mental Hygiene; Columbia University	CHANG, Y (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,630 W 168TH ST,NEW YORK,NY 10032, USA.		Moore, Patrick/GVR-8294-2022; Chang, Yuan/F-4146-2011; Moore, Patrick S./F-3960-2011	Chang, Yuan/0000-0003-1125-4041; Moore, Patrick S./0000-0002-8132-858X; Pessin, Melissa/0000-0003-3990-6494				ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARCHIBALD CP, 1992, EPIDEMIOLOGY, V3, P203, DOI 10.1097/00001648-199205000-00004; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BENDSOE N, 1990, EUR J CANCER, V26, P699, DOI 10.1016/0277-5379(90)90120-I; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1992, LANCET, V339, P632, DOI 10.1016/0140-6736(92)90793-3; BERAL V, 1991, BRIT MED J, V302, P624, DOI 10.1136/bmj.302.6777.624; BIGGAR RJ, 1994, AM J EPIDEMIOL, V139, P362, DOI 10.1093/oxfordjournals.aje.a117008; BOVENZI P, 1993, LANCET, V341, P1288, DOI 10.1016/0140-6736(93)91198-U; DREW WL, 1982, LANCET, V2, P125; Giraldo G, 1983, Antibiot Chemother (1971), V32, P1; HAVERKOS HW, 1985, SEX TRANSM DIS, V12, P203, DOI 10.1097/00007435-198510000-00007; HOLMBERG SD, 1990, CANCER DETECT PREV, V14, P331; JAHAN N, 1989, AIDS RES HUM RETROV, V5, P225, DOI 10.1089/aid.1989.5.225; JOHNSTON GS, 1990, CANCER DETECT PREV, V14, P337; KATZ MH, 1994, J INFECT DIS, V170, P198, DOI 10.1093/infdis/170.1.198; KINGSLEY L, UNPUB; LIFSON AR, 1990, AM J EPIDEMIOL, V131, P221, DOI 10.1093/oxfordjournals.aje.a115492; LIN JC, 1993, BLOOD, V81, P3372; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LO SC, 1992, INT J SYST BACTERIOL, V42, P357, DOI 10.1099/00207713-42-3-357; PELLICI PG, 1985, J EXP MED, V162, P1015; PETERMAN TA, 1991, CANCER SURV, V10, P23; SAFAI B, 1980, CANCER, V45, P1472, DOI 10.1002/1097-0142(19800315)45:6<1472::AID-CNCR2820450629>3.0.CO;2-A; SCHECHTER MT, 1991, AM J EPIDEMIOL, V134, P485, DOI 10.1093/oxfordjournals.aje.a116120; SIDDIQUI A, 1983, P NATL ACAD SCI-BIOL, V80, P4861, DOI 10.1073/pnas.80.15.4861; VANDENBERG F, 1989, J CLIN PATHOL, V42, P128, DOI 10.1136/jcp.42.2.128; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WANG RYH, 1993, CLIN INFECT DIS, V17, P724, DOI 10.1093/clinids/17.4.724	30	4581	4792	5	201	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1865	1869		10.1126/science.7997879	http://dx.doi.org/10.1126/science.7997879			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997879	Green Submitted			2022-12-24	WOS:A1994PX38300036
J	DICKEY, W				DICKEY, W			EPILEPSY, CEREBRAL CALCIFICATIONS, AND CELIAC-DISEASE	LANCET			English	Editorial Material							CELIAC-DISEASE				DICKEY, W (corresponding author), ANTRIM HOSP,ANTRIM,NORTH IRELAND.							AMBROSETTO G, 1992, EPILEPSIA, V33, P476, DOI 10.1111/j.1528-1157.1992.tb01695.x; BARDELLA MT, 1994, ARCH DIS CHILD, V70, P211, DOI 10.1136/adc.70.3.211; CHAPMAN RWG, 1978, BRIT MED J, V2, P250, DOI 10.1136/bmj.2.6132.250; COOKE WT, 1966, BRAIN, V89, P683, DOI 10.1093/brain/89.4.683; ERRANZ E, 1994, GUT, V35, P476; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; Garwicz S, 1976, Pediatr Radiol, V5, P5, DOI 10.1007/BF00988654; GOBBI G, 1992, LANCET, V340, P439; MAGAUDDA A, 1993, J NEUROL NEUROSUR PS, V56, P885, DOI 10.1136/jnnp.56.8.885; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; PIATTELLA L, 1993, CHILD NERV SYST, V9, P172; SAMMARITANO M, 1988, Neurology, V38, P239; TIACCI C, 1993, EPILEPSIA, V34, P528, DOI 10.1111/j.1528-1157.1993.tb02592.x; TORTORELLA G, 1993, NEUROPEDIATRICS, V24, P341, DOI 10.1055/s-2008-1071569	14	17	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1585	1586		10.1016/S0140-6736(94)90400-6	http://dx.doi.org/10.1016/S0140-6736(94)90400-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983988				2022-12-24	WOS:A1994PW05100003
J	URBANEK, P; WANG, ZQ; FETKA, I; WAGNER, EF; BUSSLINGER, M				URBANEK, P; WANG, ZQ; FETKA, I; WAGNER, EF; BUSSLINGER, M			COMPLETE BLOCK OF EARLY B-CELL DIFFERENTIATION AND ALTERED PATTERNING OF THE POSTERIOR MIDBRAIN IN MICE LACKING PAX5/BSAP	CELL			English	Article							TRANSCRIPTION FACTOR BSAP; HOMEOBOX-CONTAINING GENE; PROTO-ONCOGENE INT-1; DNA-BINDING PROTEIN; IMMUNOGLOBULIN HEAVY; PAIRED BOX; CHAIN GENE; WAARDENBURG SYNDROME; TARGETED DISRUPTION; HINDBRAIN BOUNDARY	The Pax5 gene, coding for the transcription factor BSAP, was mutated in the mouse germline by targeted disruption. Homozygous mutant mice were born alive, became growth retarded, and usually died within three weeks. About 5% of mutants survived to adulthood and were fertile, but severely runted. Morphogenesis of the posterior midbrain was affected as early as embryonic day 16.5, leading to a reduction of the inferior colliculus near the midline and to altered foliation of the anterior cerebellum. Moreover, all mutants failed to produce small pre-B, B, and plasma cells owing to a complete arrest of B cell development at an early precursor stage. These data define a key role for Pax5 in early a lymphopoiesis and midbrain patterning.	RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Busslinger, Meinrad J./J-1249-2016	Busslinger, Meinrad J./0000-0002-9111-9351; Wagner, Erwin F/0000-0001-7872-0196				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ASANO M, 1992, MECH DEVELOP, V39, P29, DOI 10.1016/0925-4773(92)90023-D; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BOBER E, 1994, DEVELOPMENT, V120, P603; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BUCKWALTER MS, 1993, GENOMICS, V17, P279, DOI 10.1006/geno.1993.1322; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DUCHEN LW, 1964, BRAIN, V87, P367, DOI 10.1093/brain/87.2.367; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; GOULDING M, 1993, GENOMICS, V17, P355, DOI 10.1006/geno.1993.1332; GOULDING M, 1994, DEVELOPMENT, V120, P957; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HAGMAN J, 1994, CURR OPIN IMMUNOL, V6, P222, DOI 10.1016/0952-7915(94)90095-7; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; INOUYE M, 1980, J COMP NEUROL, V190, P357, DOI 10.1002/cne.901900209; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.immunol.11.1.501; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KRAUSS S, 1992, NATURE, V360, P87, DOI 10.1038/360087a0; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LIAO F, 1992, J IMMUNOL, V148, P2909; MARTINEZ S, 1989, EUR J NEUROSCI, V1, P549, DOI 10.1111/j.1460-9568.1989.tb00362.x; MASTERTON RB, 1992, TRENDS NEUROSCI, V15, P280, DOI 10.1016/0166-2236(92)90077-L; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; OKABE T, 1992, EUR J IMMUNOL, V22, P37, DOI 10.1002/eji.1830220107; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROTHMAN P, 1991, MOL CELL BIOL, V11, P5551, DOI 10.1128/MCB.11.11.5551; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; WALLIN J, 1994, DEVELOPMENT, V120, P1109; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WATERS SH, 1989, MOL CELL BIOL, V9, P5594, DOI 10.1128/MCB.9.12.5594; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WURST W, 1994, DEVELOPMENT, V120, P2065; XU LZ, 1992, INT IMMUNOL, V4, P875, DOI 10.1093/intimm/4.8.875; YOON C. H., 1957, JOUR HEREDITY, V48, P176; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	66	660	666	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					901	912		10.1016/0092-8674(94)90079-5	http://dx.doi.org/10.1016/0092-8674(94)90079-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001127				2022-12-24	WOS:A1994PW05400017
J	DOWNES, CS; CLARKE, DJ; MULLINGER, M; GIMENEZABIAN, JF; CREIGHTON, AM; JOHNSON, RT				DOWNES, CS; CLARKE, DJ; MULLINGER, M; GIMENEZABIAN, JF; CREIGHTON, AM; JOHNSON, RT			A TOPOISOMERASE II-DEPENDENT G2 CYCLE CHECKPOINT IN MAMMALIAN-CELLS	NATURE			English	Article							PREMATURE CHROMOSOME CONDENSATION; ULTRAVIOLET-IRRADIATION; MITOTIC CHROMOSOMES; STRAND BREAKS; EGG EXTRACTS; DNA; REPLICATION; SEPARATION; INHIBITION; CAFFEINE	THE enzyme DNA topoisomerase II, which removes the catenations formed between the DNA molecules of sister chromatids during replication(1) and is a structural component of chromosome cores(2), is needed for chromosome condensation in yeast(3) and in Xenopus extracts(4-6). Inhibitors of topoisomerase II arrest mammalian cells before mitosis in the G2 phase of the cell cycle(7), but also produce DNA damage, which causes arrest through established checkpoint controls(8). It is open to question whether cells need topoisomerase II to leave G2, or control late-cycle progression in response to its activity. Bisdioxopiperazines are topoisomerase II inhibitors that act without producing direct DNA damage(9); the most potent, ICRF-193, blocks mammalian entry into but not exit from mitosis. Here we show that checkpoint-evading agents such as caffeine override this block to produce abortively condensed chromosomes, indicating that topoisomerase II is needed for complete condensation. We find that exit from G2 is regulated by a catenation-sensitive checkpoint mechanism which is distinct from the G2-damage checkpoint.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT REPROD PHYSIOL,MED CHEM LAB,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London	DOWNES, CS (corresponding author), UNIV CAMBRIDGE,DEPT ZOOL,CRC,MAMMALIAN CELL DNA REPAIR RES GRP,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.		Abián, Juan F Giménez/E-6372-2015	Abián, Juan F Giménez/0000-0002-9220-286X; Clarke, Duncan/0000-0002-7795-3294				ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AHNSTROM G, 1974, INT J RADIAT BIOL, V26, P493, DOI 10.1080/09553007414551511; CLARKE DJ, 1993, J CELL SCI, V105, P563; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; CREIGHTON AM, 1969, NATURE, V222, P384, DOI 10.1038/222384a0; CREIGHTON AM, 1979, ADV MED ONCOL RES ED, V5, P83; Downes CS, 1991, P NATL ACAD SCI USA, V88, P2616; GORBSKY GJ, 1994, CANCER RES, V54, P1042; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; ISHIDA R, 1991, CANCER RES, V51, P4909; ISHIMI Y, 1992, MOL CELL BIOL, V12, P4007, DOI 10.1128/MCB.12.9.4007; Johnson Robert David, 1994, CELL CYCLE PRACTICAL, P1; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; KALWINSKY DK, 1983, CANCER RES, V43, P1592; LOCK RB, 1990, CANCER RES, V50, P3761; MA XJ, 1993, J BIOL CHEM, V268, P6182; MORGAN TL, 1991, EXP CELL RES, V197, P125, DOI 10.1016/0014-4827(91)90489-H; MUSK SRR, 1990, BIOCHIM BIOPHYS ACTA, V1052, P53, DOI 10.1016/0167-4889(90)90057-K; MUSK SRR, 1988, J CELL SCI, V90, P591; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; RUFAS JS, 1987, GENOME, V29, P706, DOI 10.1139/g87-121; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SHARPE HBA, 1970, NATURE, V226, P524, DOI 10.1038/226524a0; SQUIRES S, 1982, MUTAT RES, V95, P389, DOI 10.1016/0027-5107(82)90273-1; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; TOLMACH LJ, 1980, RADIAT RES, V82, P374, DOI 10.2307/3575387; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	30	281	287	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					467	470		10.1038/372467a0	http://dx.doi.org/10.1038/372467a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984241				2022-12-24	WOS:A1994PV01200058
J	HOOPER, JE				HOOPER, JE			DISTINCT PATHWAYS FOR AUTOCRINE AND PARACRINE WINGLESS SIGNALING IN DROSOPHILA EMBRYOS	NATURE			English	Article							CELL-CELL COMMUNICATION; HEDGEHOG GENE; PATCHED GENE; PROTEIN; TRANSCRIPTION; SECRETION; PRODUCT; EXPRESSION; EPIDERMIS; MUTATIONS	Two secreted proteins, Wingless(1,2) and Hedgehog(3,4), instruct cell fates within the segmented epidermis of Drosophila embryos (reviewed in ref. 5). Wingless (Wg) is expressed by the most posterior cells in each parasegment; Hedgehog (Hh) is expressed in the most anterior cells of the next parasegment. Immediately after gastrulation, the two cell types are mutually dependent(6,7). Local Wg signalling stabilizes Hh expression(8-10) and local Hh signalling stabilizes Wg expression(11,12). Direct Wg autoregulation (autocrine signalling) is masked by its paracrine role in maintaining hh, which in turn maintains wg. I have used zeste-white3 (zw3)(13) and patched (ptc)(11,14) mutant backgrounds to uncouple genetically this positive-feedback loop and to study autocrine Wg signalling. I report here that direct Wg autoregulation differs from Wg signalling to adjacent cells in the importance of fused (fu), smoothened (smo) and cubitus interruptus (ci) relative to zw3 and armadillo (arm). I also find that Wg autoregulation during this early hh-dependent phase differs from later Wg autoregulation(15) by lack of gooseberry (gsb) participation.			HOOPER, JE (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT CELLULAR & STRUCT BIOL, DENVER, CO 80262 USA.							ARIAS AM, 1988, DEVELOPMENT, V103, P157; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; CAMPOSORTEGA JA, 1985, EMBRYONIC DEV DROSOP, P1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FORBES AJ, 1993, DEVELOPMENT, P115; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LI XL, 1993, EMBO J, V12, P1427, DOI 10.1002/j.1460-2075.1993.tb05786.x; MOHLER J, 1992, DEVELOPMENT, V115, P957; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, J CELL SCI, V105, P993; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WIESCHAUS E, 1986, ROUX ARCH DEV BIOL, V195, P63, DOI 10.1007/BF00444042	31	118	122	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 1	1994	372	6505					461	464		10.1038/372461a0	http://dx.doi.org/10.1038/372461a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984239				2022-12-24	WOS:A1994PV01200056
J	OUBRIDGE, C; ITO, N; EVANS, PR; TEO, CH; NAGAI, K				OUBRIDGE, C; ITO, N; EVANS, PR; TEO, CH; NAGAI, K			CRYSTAL-STRUCTURE AT 1.92 ANGSTROM RESOLUTION OF THE RNA-BINDING DOMAIN OF THE U1A SPLICEOSOMAL PROTEIN COMPLEXED WITH AN RNA HAIRPIN	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; X-RAY-DIFFRACTION; HNRNP-C-PROTEINS; A-PROTEIN; PREMESSENGER RNA; SYNTHETASE; SNRNA; RECOGNITION; POLYADENYLATION; CRYSTALLOGRAPHY	The crystal structure of the RNA-binding domain of the small nuclear ribonucleoprotein U1A bound to a 21-nucleotide RNA hairpin has been determined at 1.92 Angstrom resolution. The ten-nucleotide RNA loop binds to the surface of the beta-sheet as an open structure, and the AUUGCAC sequence of the loop interacts extensively with the conserved RNP1 and RNP2 motifs and the C-terminal extension of the RNP domain. These interactions include stacking of RNA bases with aromatic side chains of proteins and many direct and water-mediated hydrogen bonds. The structure reveals the stereochemical basis for sequence-specific RNA recognition by the RNP domain.			OUBRIDGE, C (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.			Oubridge, Chris/0000-0001-8492-8305				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACH M, 1990, NUCLEIC ACIDS RES, V18, P449, DOI 10.1093/nar/18.3.449; BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; COSIER J, 1986, J APPL CRYSTALLOGR, V19, P105, DOI 10.1107/S0021889886089835; GALT MJ, 1991, OLIGONUCLEOTIDE SYNT, P25; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; HABETS WJ, 1987, P NATL ACAD SCI USA, V84, P2421, DOI 10.1073/pnas.84.8.2421; HALL KB, 1994, BIOCHEMISTRY-US, V33, P10076, DOI 10.1021/bi00199a035; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOWE PWA, 1994, EMBO J, V13, P3873, DOI 10.1002/j.1460-2075.1994.tb06698.x; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KROL A, 1990, NUCLEIC ACIDS RES, V18, P3803, DOI 10.1093/nar/18.13.3803; LESLIE AGW, 1992, JOINT CCP4 AND ESF E; LINDAHL M, 1994, EMBO J, V13, P1249, DOI 10.1002/j.1460-2075.1994.tb06376.x; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NAGAI K, 1991, ISOMORPHOUS REPLACEM, P141; NAGAI K, 1994, RNA PROTEIN INTERACT, P150; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SHELDRICK GM, 1991, ISOMORPHOUS REPLACEM, P23; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; VANGELDER CWG, 1993, EMBO J, V12, P5191, DOI 10.1002/j.1460-2075.1993.tb06214.x; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013	50	800	816	3	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					432	438		10.1038/372432a0	http://dx.doi.org/10.1038/372432a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984237				2022-12-24	WOS:A1994PV01200047
J	SURRIDGE, C				SURRIDGE, C			FOREWARNED IS 4-ARMED	NATURE			English	Editorial Material							BINDING; P53							Surridge, Christopher/0000-0003-4264-5176				CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581	5	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					482	482		10.1038/372482a0	http://dx.doi.org/10.1038/372482a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984245	Bronze			2022-12-24	WOS:A1994PV01200062
J	WANG, ZQ; FUNG, MR; BARLOW, DP; WAGNER, EF				WANG, ZQ; FUNG, MR; BARLOW, DP; WAGNER, EF			REGULATION OF EMBRYONIC GROWTH AND LYSOSOMAL TARGETING BY THE IMPRINTED IGF2/MPR GENE	NATURE			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; FACTOR-II; TME LOCUS; MOUSE; CELLS; ACTIVATION; DISRUPTION; PROTEINS; BINDING; DEFECTS	THE receptor for insulin-like growth factor type 2, also known as the cation-independent mannose-6-phosphate receptor (Igf2/Mpr), is a multifunctional receptor thought to play a role in lysosomal targeting, cell growth and signal transduction(1-8). Igf2/Mpr has been mapped to the mouse Tme(9) locus and shown to be an imprinted gene(10), which further suggests a role in embryonic growth regulation. To define the functions of Igf2/Mpr, we have generated mice lacking this gene. We report here that maternal inheritance of an Igf2/Mpr null allele (-/+) as well as homozygosity for the inactive allele (-/-) is generally lethal at birth and mutants are about 30% larger, indicating that maternal expression of Igf2/Mpr is essential for late embryonic development and growth regulation. The phenotype is probably caused by an excess of Igf2 because the introduction of an Igf2 null allele rescued the Igf2/Mpr mutant mice. Mutant mice also have organ and skeletal abnormalities and missort mannose-6-phosphate-tagged proteins. A few (-/+) mice reactivated their paternal Igf2/Mpr allele in some tissues and survived to adults. But no (-/-) mice survived, indicating a role for the reactivated paternal allele in postnatal survival.			WANG, ZQ (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Wagner, Erwin F/0000-0001-7872-0196				BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHLARA TM, 1990, CELL, V64, P849; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FILSON A, 1993, DEVELOPMENT, V116, P731; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; FRANKEL HA, 1977, PEDIATR RES, V11, P811, DOI 10.1203/00006450-197707000-00007; HERZOG V, 1987, EMBO J, V6, P555, DOI 10.1002/j.1460-2075.1987.tb04790.x; JOHNSON DR, 1974, GENETICS, V76, P795; Kaufman M.H., 1992, ATLAS MOUSE DEV; KORNFELD S, 1992, REV BIOCH, V61, P307; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LATHAM KE, 1994, GENE DEV, V8, P290, DOI 10.1101/gad.8.3.290; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LUDWIG T, 1993, EMBO J, V12, P5225, DOI 10.1002/j.1460-2075.1993.tb06218.x; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOULLIER P, 1993, TRANSPLANTATION, V56, P427, DOI 10.1097/00007890-199308000-00034; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NOLAN CM, 1989, METABOLIC BASIS INHE, P1589; OKA Y, 1985, J BIOL CHEM, V260, P9435; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; VOGLER C, 1990, AM J PATHOL, V136, P2207; von Figura K, 1991, Curr Opin Cell Biol, V3, P642, DOI 10.1016/0955-0674(91)90035-W; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0	30	397	416	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					464	467		10.1038/372464a0	http://dx.doi.org/10.1038/372464a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984240				2022-12-24	WOS:A1994PV01200057
J	KOFF, WC				KOFF, WC			THE NEXT STEPS TOWARD A GLOBAL AIDS VACCINE	SCIENCE			English	Editorial Material							ENVELOPE; ANTIBODIES; INDUCTION; IMMUNITY; ISSUES				KOFF, WC (corresponding author), UNITED BIOMED,VACCINE RES & DEV,25 DAVIDS DR,HAUPPAUGE,NY 11790, USA.							CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; COHEN J, 1994, SCIENCE, V264, P1839, DOI 10.1126/science.8009201; COONEY EL, 1993, P NATL ACAD SCI USA, V90, P1882, DOI 10.1073/pnas.90.5.1882; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; DIXON DO, 1993, J ACQ IMMUN DEF SYND, V6, P485; ESPARZA J, 1993, CURR OPIN INFECT DIS, V6, P218, DOI 10.1097/00001432-199304000-00014; ESPARZA J, 1993, AIDS RES HUM RETR S1, V9, pS1133; FAST PE, 1993, AIDS, V7, pS147, DOI 10.1097/00002030-199301001-00020; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; HAYNES BF, 1993, SCIENCE, V260, P1279, DOI 10.1126/science.8493572; KARZON DT, 1992, VACCINE, V10, P1039, DOI 10.1016/0264-410X(92)90114-Y; KOFF WC, 1988, SCIENCE, V241, P426, DOI 10.1126/science.3293212; LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; Mariner W K, 1987, Law Med Health Care, V15, P17; MARINER WK, 1992, HEALTH AFFAIR, V11, P255, DOI 10.1377/hlthaff.11.1.255; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MASCOLA JR, 1993, AIDS RES HUM RETROV, V9, P1175, DOI 10.1089/aid.1993.9.1175; MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0; MYERS G, 1993, HUMAN RETROVIRUSES A; PETRICCIANI JC, 1993, VACCINE, V11, P873, DOI 10.1016/0264-410X(93)90364-4; PHILLIPS DM, 1994, AIDS, V8, P719, DOI 10.1097/00002030-199406000-00001; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; SCHWARTZ DH, 1993, LANCET, V342, P69, DOI 10.1016/0140-6736(93)91283-R; STEIN RE, 1992, VACCINE RES DEV, V1, P223; VERMUND SH, 1994, CURR OPIN INFECT DIS, V7, P82, DOI 10.1097/00001432-199402000-00014; VERMUND SH, 1993, EFFICACY HIV VACCINE, P187; WEININGER BG, IN PRESS AIDS; 1994, HIV VACCINES ACCELER; 1993, HUMAN IMMUNODEFICIEN; 1985, VACCINE SUPPLY INNOV; 1991, VACCINE, V9, P703	32	16	17	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1335	1337		10.1126/science.7973724	http://dx.doi.org/10.1126/science.7973724			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973724				2022-12-24	WOS:A1994PT63200030
J	CHIRUVOLU, S; WARRINER, HE; NARANJO, E; IDZIAK, SHJ; RADLER, JO; PLANO, RJ; ZASADZINSKI, JA; SAFINYA, CR				CHIRUVOLU, S; WARRINER, HE; NARANJO, E; IDZIAK, SHJ; RADLER, JO; PLANO, RJ; ZASADZINSKI, JA; SAFINYA, CR			A PHASE OF LIPOSOMES WITH ENTANGLED TUBULAR VESICLES	SCIENCE			English	Article							THERMAL FLUCTUATIONS; MEMBRANES; LECITHIN; TRANSITION; ADHESION; SYSTEM; L3	An equilibrium phase belonging to the family of bilayer liposomes in ternary mixtures of dimyristoylphosphatidylcholine (DMPC), water, and geraniol (a biological alcohol derived from oil-soluble vitamins that acts as a cosurfactant) has been identified. Electron and optical microscopy reveal the phase, labeled L(tv), to be composed of highly entangled tubular vesicles. In situ x-ray diffraction confirms that the tubule walls are multilamellar with the lipids in the chain-melted state. Macroscopic observations show that the L(tv) phase coexists with the well-known L(4) phase of spherical vesicles and a bulk L(alpha) phase. However, the defining characteristic oi the L(tv) phase is the Weissenberg rod climbing effect under shear, which results from its polymer-like entangled microstructure.	UNIV CALIF SANTA BARBARA, DEPT CHEM ENGN,MAT RES LAB, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, DEPT MAT,MAT RES LAB, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, DEPT PHYS, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, BIOCHEM & MOLEC BIOL PROGRAM, SANTA BARBARA, CA 93106 USA; EXXON RES & ENGN CO, ANNANDALE, NJ 08801 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Exxon Mobil Corporation			Rädler, Joachim/AAD-8747-2019	Rädler, Joachim/0000-0002-5846-1489	NIGMS NIH HHS [GM47334] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047334] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1992, INTERMOLECULAR SURFA; Bangham A.D., 1973, METHODS MEMBR BIOL, V1, P1; BELLARE JR, 1988, J ELECTRON MICR TECH, V10, P87, DOI 10.1002/jemt.1060100111; Ben-Shaul A., 1994, MICELLES MEMBRANES M; Bird RB, 1977, DYNAMICS POLYM LIQUI, V1; CANTU L, 1990, EUROPHYS LETT, V13, P561, DOI 10.1209/0295-5075/13/6/015; CATES ME, 1990, J PHYS-CONDENS MAT, V2, P6869, DOI 10.1088/0953-8984/2/33/001; COULON C, 1991, PHYS REV LETT, V66, P1709, DOI 10.1103/PhysRevLett.66.1709; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P7132, DOI 10.1073/pnas.83.19.7132; HARBICH W, 1990, J PHYS-PARIS, V51, P1027, DOI 10.1051/jphys:0199000510100102700; HARBICH W, 1984, CHEM PHYS LIPIDS, V36, P39, DOI 10.1016/0009-3084(84)90089-6; HELFRICH W, 1985, CHEM SCRIPTA, V25, P32; HELFRICH W, 1986, J PHYS-PARIS, V47, P321, DOI 10.1051/jphys:01986004702032100; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; HERVE P, 1993, J PHYS II, V3, P1255, DOI 10.1051/jp2:1993196; HOFFMANN H, 1992, LANGMUIR, V8, P2629, DOI 10.1021/la00047a011; JANIAK MJ, 1979, J BIOL CHEM, V254, P6068; KALER EW, 1989, SCIENCE, V245, P1371, DOI 10.1126/science.2781283; KLOSGEN B, 1993, EUR BIOPHYS J, V22, P340; LASIC DD, 1993, LIPOSOMES PHYSICS AP; MCINTOSH TJ, 1989, BIOPHYS J, V55, P897, DOI 10.1016/S0006-3495(89)82888-7; Papahadjopoulos D., 1978, ANN NY ACAD SCI, V308, P1, DOI [10.1111/j.1749-6632.1978.tb22009.x, DOI 10.1111/J.1749-6632.1978.TB22009.X]; PORTE G, 1988, EUROPHYS LETT, V7, P713, DOI 10.1209/0295-5075/7/8/008; PORTE G, 1989, J PHYS-PARIS, V50, P1335, DOI 10.1051/jphys:0198900500110133500; ROUX D, 1988, J PHYS-PARIS, V49, P307, DOI 10.1051/jphys:01988004902030700; SAFINYA CR, 1986, PHYS REV LETT, V57, P2718, DOI 10.1103/PhysRevLett.57.2718; SAFINYA CR, 1989, PHYS REV LETT, V62, P1134, DOI 10.1103/PhysRevLett.62.1134; Safran S.A., 1994, STAT THERMODYNAMICS; SCHNEIDER MB, 1984, J PHYS-PARIS, V45, P1457, DOI 10.1051/jphys:019840045090145700; SCHNEIDER MB, 1984, BIOPHYS J, V45, P891, DOI 10.1016/S0006-3495(84)84235-6; SERVUSS RM, 1989, J PHYS-PARIS, V50, P809, DOI 10.1051/jphys:01989005007080900; SERVUSS RM, 1987, PHYSICS COMPLEX SUPR; SPECTOR M, UNPUB; STREY R, 1990, J CHEM SOC FARADAY T, V86, P2253, DOI 10.1039/ft9908602253; TARDIEU A, 1973, J MOL BIOL, V75, P711, DOI 10.1016/0022-2836(73)90303-3; WEISSENBERG K, 1947, NATURE, V159, P310, DOI 10.1038/159310a0	36	89	91	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	1994	266	5188					1222	1225		10.1126/science.7973704	http://dx.doi.org/10.1126/science.7973704			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973704	Green Submitted			2022-12-24	WOS:A1994PT13200049
J	ALEXANDER, S				ALEXANDER, S			PREDICTING PROGNOSIS AFTER MYOCARDIAL INFRACTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ALEXANDER, S (corresponding author), LAHEY CLIN MED CTR,BURLINGTON,MA 01803, USA.								0	1	1	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1543	1544						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966851				2022-12-24	WOS:A1994PQ90000038
J	FESKENS, EJM; HAVEKES, LM; KALMIJN, S; DEKNIJFF, P; LAUNER, LJ; KROMHOUT, D				FESKENS, EJM; HAVEKES, LM; KALMIJN, S; DEKNIJFF, P; LAUNER, LJ; KROMHOUT, D			APOLIPOPROTEIN E4 ALLELE AND COGNITIVE DECLINE IN ELDERLY MEN	BRITISH MEDICAL JOURNAL			English	Article							FAMILIAL ALZHEIMER-DISEASE; CORONARY HEART-DISEASE; E POLYMORPHISM; TYPE-4 ALLELE; CHROMOSOME-19; STATE; GENE; APOE; RISK	Objectives-To determine whether polymorphism of apolipoprotein E-notably, the e4 allele- predicts cognitive deterioration in the general population. Design-Population based cohort investigated in 1990 and in 1993. Setting-Zutphen, the Netherlands. Subjects-Representative cohort of 538 Dutch men aged 70-89 at baseline. Main outcome measures-Cognitive function assessed by mini mental state examination, change in cognitive function and incidence of impaired cognitive function at three years. Results-The baseline prevalence of impaired cognitive function (mini mental state examination score less than or equal to 25) was higher among carriers of the e4 allele compared wth men without the allele (41.0% (55) v 31.1% (122) P=0.03), and this result was still valid after adjustment for age, occupation, smoking, alcohol use, and cardiovascular diseases. The decline in cognitive function at three years was largest in men homozygous for e4 (-2.4 points), intermediate in those heterozygous for e4 (-0.7 points), and lowest in men without e4 (-0.1 points), and it was independent of other risk factors (P=0.02). The risk of developing impaired cognitive function during follow up was significantly increased in allele carriers compared with non-carriers (27.6% (16/58) v 15.5% (32/207)). The adjusted odds ratio was 2.87 (95% confidence interval 1.29 to 6.42). Twenty two per cent of the risk of developing impaired cognitive function in this population may be attributable to the e4 allele. Conclusions-The apolipoprotein e4 allele predisposes to cognitive decline in a general population of elderly men.	TNO,INST PREVENT HLTH RES PG TNO,GAUBIUS LAB,LEIDEN,NETHERLANDS; ROTTERDAM MED SCH,DEPT EPIDEMIOL & BIOSTAT,ROTTERDAM,NETHERLANDS	Netherlands Organization Applied Science Research	FESKENS, EJM (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT CHRONIC DIS & ENVIRONM EPIDEMIOL,POB 1,3720 BA BILTHOVEN,NETHERLANDS.		Feskens, Edith/ABI-1446-2020; Kromhout, Daan/A-8566-2014; Feskens, Edith JM/A-3757-2012; de Knijff, Peter/Y-2519-2018	Feskens, Edith/0000-0001-5819-2488; de Knijff, Peter/0000-0002-0899-771X				BLOEMBERG BPM, 1989, AM J EPIDEMIOL, V130, P1047, DOI 10.1093/oxfordjournals.aje.a115405; COLSHER PL, 1991, EPIDEMIOL REV, V13, P1; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DALLONGEVILLE J, 1992, J LIPID RES, V33, P447; DAS HK, 1985, J BIOL CHEM, V260, P6240; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; FILTENBAUM GG, 1988, PSYCHOL MED, V18, P1023; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HAVEKES LM, 1987, J LIPID RES, V28, P445; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; KEYS A, 1967, ACTA MED SCAND, V460, P1; LAUNER LJ, 1992, NEUROEPIDEMIOLOGY, V11, pS12; LAUNER LJ, 1993, J GERONTOL, V48, P271; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NOGUCHI S, 1993, LANCET, V342, P737, DOI 10.1016/0140-6736(93)91728-5; OLAISEN B, 1982, HUM GENET, V62, P233, DOI 10.1007/BF00333526; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PIORIER J, 1993, LANCET, V342, P697; REBECK GW, 1993, NEURON, V11, P575; Rose G, 1968, CARDIOVASCULAR SURVE; Roth M, 1988, CAMDEX CAMBRIDGE EXA; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SHERRILL BC, 1980, J BIOL CHEM, V255, P1804; SIEDEL J, 1981, J CLIN CHEM CLIN BIO, V19, P838; SIU AL, 1991, ANN INTERN MED, V134, P1303; SMIT M, 1988, HUM GENET, V80, P287, DOI 10.1007/BF01790099; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; VANBOCKXMEER FM, 1992, LANCET, V340, P879, DOI 10.1016/0140-6736(92)93288-X; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; 1990, STAT USERS GUIDE; 1993, LANCET, V342, P737; 1978, TECHNICAL REPORT SER, V628	34	151	153	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 5	1994	309	6963					1202	1206		10.1136/bmj.309.6963.1202	http://dx.doi.org/10.1136/bmj.309.6963.1202			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7987151	Green Published			2022-12-24	WOS:A1994PQ66200020
J	REUTHER, GW; FU, H; CRIPE, LD; COLLIER, RJ; PENDERGAST, AM				REUTHER, GW; FU, H; CRIPE, LD; COLLIER, RJ; PENDERGAST, AM			ASSOCIATION OF THE PROTEIN-KINASES C-BCR AND BCR-ABL WITH PROTEINS OF THE 14-3-3-FAMILY	SCIENCE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE; DOMAIN; ONCOGENE; TRANSFORMATION; SEQUENCES; REGION; GENE; IDENTIFICATION; ACTIVATION	In this study, a protein that interacts with sequences encoded by the first exon of the protein kinase Bcr was cloned. The Bcr-associated protein 1 (Bap-1) is a member of the 14-3-3 family of proteins. Bap-1 interacts with full-length c-Bcr and with the chimeric Bcr-Abl tyrosine kinase of Philadelphia chromosome (Ph(1))-positive human leukemias. Bap-1 is a substrate for the Bcr serine-threonine kinase and is also phosphorylated on tyrosine by Bcr-Abl but not by c-Abl. Bap-1 may function in the regulation of c-Bcr and may contribute to the transforming activity of Bcr-Abl in vivo. 14-3-3 proteins are essential for cell proliferation and have a role in determining the timing of mitosis in yeast. Through direct binding to sequences present in Bcr and in other proteins implicated in signaling, the mammalian 14-3-3 proteins may link specific signaling protein components to mitogenic and cell-cycle control pathways.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, SHIPLEY INST MED, BOSTON, MA 02115 USA	Duke University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Reuther, Gary/AFR-2892-2022	Pendergast, Ann Marie/0000-0002-1250-6880; Collier, R John/0000-0002-2427-4239	NATIONAL CANCER INSTITUTE [R01CA061033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K12DK001965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184] Funding Source: NIH RePORTER; NCI NIH HHS [CA61033] Funding Source: Medline; NIDDK NIH HHS [DK01965] Funding Source: Medline; NIGMS NIH HHS [GM07184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NIELSEN PJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P425, DOI 10.1016/0167-4781(91)90136-A; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REUTHER GW, UNPUB; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; RON D, 1991, NEW BIOL, V3, P372; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x	39	218	223	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	1994	266	5182					129	133		10.1126/science.7939633	http://dx.doi.org/10.1126/science.7939633			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939633				2022-12-24	WOS:A1994PK58200041
J	KONDE, M; INGENBLEEK, Y; DAFFE, M; SYLLA, B; BARRY, O; DIALLO, S				KONDE, M; INGENBLEEK, Y; DAFFE, M; SYLLA, B; BARRY, O; DIALLO, S			GOITROUS ENDEMIC IN GUINEA	LANCET			English	Article							NUTRITIONAL-STATUS; DARFUR REGION; GOITER; MILLET; SUDAN; EPIDEMIOLOGY; ETIOLOGY	We identified a major goitrous area in the Republic of Guinea, characterised by an overall goitre prevalence of 70% in adults. Thyroid swelling was sometimes present at birth and affected 55% of schoolchildren. A difference between sexes appeared at puberty. Endemic cretinism, mainly in its myxoedematous form, was found in about 2% of goitrous patients. In this region, iodine deficiency is the primary causative factor (median urinary concentrations of 16 mu g/L, and in 69% of inhabitants below the critical threshold of 20 mu g/L). The diet contained substantial amounts of thiocyanate anions (median 6 mg/L in urine and in 27%, more than 10 mg/L) likely to further depress iodine bioavailability. Other dietary compounds, notably flavonoids were suspected to contribute. Overall nutritional and general health appeared satisfactory. The affected population is borderline euthyroid with a trend towards hypothyroidism in protracted disease. This area of Guinea may be regarded as the epicentre of the west African endemic acid as one of the most severely goitrous regions ever described, requiring urgent public health measures.	UNIV STRASBOURG 1,DEPT FOOD SCI,F-67400 ILLKIRCH GRAFFENS,FRANCE; DIRECT PUBL HLTH,CONAKRY,GUINEA	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ALDRIDGE WN, 1945, ANALYST, V70, P474; BEDIAKO BM, 1985, STUDIES PREVALENCE E, P1; BENMILOUD M, 1983, CASSAVA TOXICITY THY, P49; BENNETT S, 1991, World Health Statistics Quarterly, V44, P98; BOURDOUX P, 1986, PAHO SCI PUBL, V502, P115; COURTOIS P, 1982, NUTR FACTORS INVOLVE, P65; DEVISSCHER M, 1980, THYROID GLAND, P377; Dunn JT, 1990, ICCIDDUNICEFWHO3 TEC, P1; ELTOM M, 1985, ACTA ENDOCRINOL-COP, V108, P356, DOI 10.1530/acta.0.1080356; ELTOM M, 1984, ACTA MED SCAND, V215, P467; GAITAN B, 1986, PAHO WHO SCI PUBL, V502, P28; GAITAN E, 1989, J CLIN ENDOCR METAB, V68, P707, DOI 10.1210/jcem-68-4-707; HERSHMAN JM, 1986, PAHO WHO SCI PUBL, V502, P96; INGENBLEEK Y, 1980, LANCET, V1, P388; INGENBLEEK Y, 1975, METABOLISM, V24, P633, DOI 10.1016/0026-0495(75)90143-2; INGENBLEEK Y, 1985, INT J VITAM NUTR RES, V55, P91; INGENBLEEK Y, 1994, ANNU REV NUTR, V14, P495, DOI 10.1146/annurev.nu.14.070194.002431; INGENBLEEK Y, 1979, METABOLISM, V28, P9, DOI 10.1016/0026-0495(79)90162-8; Ingenbleek Y., 1980, THYROID GLAND, P499; KELLY FC, 1960, WHO MONOGR SER, V44, P117; KLOPFENSTEIN CF, 1983, NUTR REP INT, V27, P1039; KOUTRAS DA, 1980, ENDEMIC GOITER ENDEM, P255; LATAPIE JL, 1981, ANN ENDOCRINOL-PARIS, V42, P517; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; OLIVEIRA AL, 1991, B WORLD HEALTH ORGAN, V63, P347; OSMAN AK, 1981, ECOL FOOD NUTR, V11, P121, DOI 10.1080/03670244.1981.9990666; PEREZ C, 1960, WHO MONOGRAPHS SERIE, V44, P369; ROUX F, 1983, MED NUTR, V19, P339; Sandell E. B., 1937, MICROCHIM ACTA, V1, P9, DOI [10.1007/BF01476194, DOI 10.1007/BF01476194]; Snedecor G. W., 1967, STATISTICAL METHODS, P91; STANBURY JB, 1980, IODINE NUTRITION HLT, P1; WILSON DC, 1954, T ROY SOC TROP MED H, V48, P481, DOI 10.1016/0035-9203(54)90083-8; WOLLMAN SH, 1962, AM J PHYSIOL, V203, P517, DOI 10.1152/ajplegacy.1962.203.3.517	33	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1675	1678		10.1016/S0140-6736(94)90461-8	http://dx.doi.org/10.1016/S0140-6736(94)90461-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996963				2022-12-24	WOS:A1994PX30200012
J	KITCHENS, JM				KITCHENS, JM			DOES THIS PATIENT HAVE AN ALCOHOL PROBLEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAGE QUESTIONNAIRE; SCREENING-TEST; COLLABORATIVE PROJECT; LABORATORY TESTS; RISK-DRINKING; USE DISORDERS; CONSUMPTION; IDENTIFICATION; PREVALENCE; VALIDATION		UNIV TORONTO, DEPT INTERNAL MED, TORONTO, ON, CANADA	University of Toronto	KITCHENS, JM (corresponding author), ST MICHAELS HOSP, DIV GEN INTERNAL MED, 30 BOND ST, TORONTO M5B 1W8, ON, CANADA.							BERESFORD T, 1982, PSYCHOSOMATICS, V23, P713; BERNADT MW, 1982, LANCET, V1, P325; BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; BUCHSBAUM DG, 1992, J GEN INTERN MED, V7, P517, DOI 10.1007/BF02599456; BUCHSBAUM DG, 1992, J AM GERIATR SOC, V40, P662, DOI 10.1111/j.1532-5415.1992.tb01956.x; BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; CHICK J, 1981, LANCET, V1, P1249; CLARK PMS, 1986, BR J ALCOHOL ALCOHOL, V16, P11; CLEARY PD, 1988, AM J MED, V85, P466; CURTIS JR, 1989, J AM GERIATR SOC, V37, P310, DOI 10.1111/j.1532-5415.1989.tb05496.x; DAWSON NV, 1992, J GEN INTERN MED, V7, P38, DOI 10.1007/BF02599100; ECKARDT MJ, 1981, JAMA-J AM MED ASSOC, V246, P648, DOI 10.1001/jama.246.6.648; ERNHART CB, 1988, ALCOHOL CLIN EXP RES, V12, P506, DOI 10.1111/j.1530-0277.1988.tb00233.x; ERNHART CB, 1987, AM J OBSTET GYNECOL, V156, P33, DOI 10.1016/0002-9378(87)90199-2; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; GIBBS LE, 1983, DRUG ALCOHOL DEPEN, V12, P279, DOI 10.1016/0376-8716(83)90071-6; KING M, 1986, PSYCHOL MED, V16, P213, DOI 10.1017/S0033291700002658; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; MARSH CM, 1989, 142ND ANN M AM PSYCH; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; MORROWTLUCAK M, 1989, ALCOHOL CLIN EXP RES, V13, P399, DOI 10.1111/j.1530-0277.1989.tb00343.x; PEQUIGNOT G, 1978, INT J EPIDEMIOL, V7, P113, DOI 10.1093/ije/7.2.113; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; RANKIN JG, 1992, PUBLIC HLTH PREVENTI, pCH43; ROSS HE, 1990, J STUD ALCOHOL, V51, P506, DOI 10.15288/jsa.1990.51.506; ROUNSAVILLE BJ, 1993, ADDICTION, V88, P337, DOI 10.1111/j.1360-0443.1993.tb00821.x; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SAUNDERS JB, 1993, ADDICTION, V88, P349, DOI 10.1111/j.1360-0443.1993.tb00822.x; SCHUCKIT MA, 1985, JAMA-J AM MED ASSOC, V254, P2614, DOI 10.1001/jama.254.18.2614; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SKINNER HA, 1982, J STUD ALCOHOL, V43, P1157, DOI 10.15288/jsa.1982.43.1157; SKINNER HA, 1984, ANN INTERN MED, V101, P847, DOI 10.7326/0003-4819-101-6-847; SOKOL RJ, 1989, AM J OBSTET GYNECOL, V160, P863, DOI 10.1016/0002-9378(89)90302-5; Sox HC, 1988, MED DECISION MAKING; Spitzer RL, 1990, STRUCTURED CLIN INTE; WATERSON EJ, 1989, ALCOHOL ALCOHOLISM, V24, P21; WEST LJ, 1985, OXFORD TXB PUBLIC HL, V2, pCH9; 1992, INT STATISTICAL CLAS, pCH5; 1987, DIAGNOSTIC STATISTIC	44	115	116	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	1994	272	22					1782	1787		10.1001/jama.272.22.1782	http://dx.doi.org/10.1001/jama.272.22.1782			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV815	7966928				2022-12-24	WOS:A1994PV81500029
J	HARRISON, SL; MACLENNAN, R; SPEARE, R; WRONSKI, I				HARRISON, SL; MACLENNAN, R; SPEARE, R; WRONSKI, I			SUN EXPOSURE AND MELANOCYTIC NEVI IN YOUNG AUSTRALIAN CHILDREN	LANCET			English	Article							CUTANEOUS MALIGNANT-MELANOMA; BENIGN PIGMENTED NEVI; DYSPLASTIC NEVI; VANCOUVER MOLE; NEVOCYTIC NEVI; RISK-FACTORS; COMMON; PREVALENCE; SCHOOLCHILDREN; QUEENSLAND	Queensland, Australia, has the highest rates of melanoma in the world and Queensland children have the greatest numbers of melanocytic naevi, the strongest risk factor for melanoma. Although both melanoma and naevi are broadly related to sun exposure in childhood, the relation to individual exposure early in life is difficult to study retrospectively in adults. We surveyed 506 children aged 1-6 years who had been born in Townsville, North Queensland, Sun exposure was assessed by questionnaire and melanocytic naevi were counted using a standard international protocol. Very high counts (upper quarter) of melanocytic naevi were Significantly associated with sun exposure of more than 4 hours per day (adjusted relative risk ratio 3.29; 95% CI 1.12-9.69), and with a history of sunburn (1.89; 1.11-3.21). Melanocytic naevus counts increased with age, light skin reflectance, and freckling. With exposure to intense ultraviolet light in Townsville, children develop melanocytic naevi early in life and in large numbers. We found that both acute and chronic exposure to sun are associated with their development.	QUEENSLAND INST MED RES,EPIDEMIOL UNIT,BRISBANE,QLD 4006,AUSTRALIA	QIMR Berghofer Medical Research Institute	HARRISON, SL (corresponding author), JAMES COOK UNIV N QUEENSLAND,DEPT PUBL HLTH & TROP MED,ANTON BREINI CTR,TOWNSVILLE,QLD 4811,AUSTRALIA.		Harrison, Simone Lee/U-3429-2018; Harrison, Simone Lee/CAF-2591-2022	Harrison, Simone Lee/0000-0001-5309-0773; Harrison, Simone Lee/0000-0001-5309-0773; Speare, Rick/0000-0002-9993-1213				ARMSTRONG BK, 1986, J NATL CANCER I, V77, P329; AUGUSTSSON A, 1991, ACTA DERM-VENEREOL, V71, P512; AUGUSTSSON A, 1991, ACTA DERM-VENEREOL, V71, P518; COOKE KR, 1985, INT J CANCER, V36, P175, DOI 10.1002/ijc.2910360208; ELWOOD JM, 1986, BRIT J CANCER, V53, P65, DOI 10.1038/bjc.1986.10; ENGLISH DR, 1994, AM J EPIDEMIOL, V139, P1; ENGLISH DR, 1990, IARC90002 INT AG RES; GALLAGHER RP, 1990, ARCH DERMATOL, V126, P466, DOI 10.1001/archderm.126.4.466; GALLAGHER RP, 1990, ARCH DERMATOL, V126, P770, DOI 10.1001/archderm.126.6.770; GREEN A, 1989, J AM ACAD DERMATOL, V20, P1054, DOI 10.1016/S0190-9622(89)70131-6; GREEN A, 1985, INT J CANCER, V35, P297, DOI 10.1002/ijc.2910350303; GROB JJ, 1990, CANCER, V66, P387, DOI 10.1002/1097-0142(19900715)66:2<387::AID-CNCR2820660232>3.0.CO;2-J; HALPERN AC, 1991, ARCH DERMATOL, V127, P995, DOI 10.1001/archderm.127.7.995; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P460; HOLMAN CDJ, 1984, JNCI-J NATL CANCER I, V72, P257; HORNBY F, 1986, TOWNSVILLE REGION SO; KELLY JW, 1994, J AM ACAD DERMATOL, V30, P40, DOI 10.1016/S0190-9622(94)70005-2; Kopf A W, 1978, J Dermatol Surg Oncol, V4, P153; KOPF AW, 1986, ARCH DERMATOL, V122, P1003, DOI 10.1001/archderm.122.9.1003; Lund CC., SURG GYNECOL OBSTET, V79, P352; MACKIE RM, 1985, BRIT J DERMATOL, V113, P167, DOI 10.1111/j.1365-2133.1985.tb02060.x; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; MOSTELLER RD, 1987, NEW ENGL J MED, V317, P1098, DOI 10.1056/nejm198710223171717; NICHOLLS EM, 1973, CANCER, V32, P191, DOI 10.1002/1097-0142(197307)32:1<191::AID-CNCR2820320129>3.0.CO;2-W; OSTERLIND A, 1988, INT J CANCER, V42, P200, DOI 10.1002/ijc.2910420210; POPE DJ, 1992, ARCH DERMATOL, V128, P1201, DOI 10.1001/archderm.128.9.1201; RAMPEN FHJ, 1988, J AM ACAD DERMATOL, V18, P679, DOI 10.1016/S0190-9622(88)70090-0; SIGG C, 1989, DERMATOLOGICA, V179, P123, DOI 10.1159/000248337; SORAHAN T, 1990, J AM ACAD DERMATOL, V22, P747, DOI 10.1016/0190-9622(90)70102-N; SWERDLOW AJ, 1986, BRIT MED J, V292, P1555, DOI 10.1136/bmj.292.6535.1555	30	163	164	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1529	1532		10.1016/S0140-6736(94)90348-4	http://dx.doi.org/10.1016/S0140-6736(94)90348-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983952				2022-12-24	WOS:A1994PV01700008
J	ESPINOZA, FH; OGAS, J; HERSKOWITZ, I; MORGAN, DO				ESPINOZA, FH; OGAS, J; HERSKOWITZ, I; MORGAN, DO			CELL-CYCLE CONTROL BY A COMPLEX OF THE CYCLIN HCS26 (PCL1) AND THE KINASE PHO85	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; PHOSPHATASE; SYSTEM; GENE; G1; TRANSCRIPTION; REGULATORS; PHASE; CDC28	The events of the eukaryotic cell cycle are governed by cyclin-dependent kinases (cdk's), whose activation requires association with cyclin regulatory subunits expressed at specific cell cycle stages. In the budding yeast Saccharomyces cerevisiae, the cell cycle is thought to be controlled by a single cdk, CDC28. Passage through the G(1) phase of the cell cycle is regulated by complexes of CDC28 and G(1) cyclins (CLN1, CLN2, and CLN3). A putative G(1) cyclin, HCS26, has recently been identified. In a/alpha diploid cells lacking CLN1 and CLN2, HCS26 is required for passage through G(1). HCS26 does not associate with CDC28, but instead associates with PHO85, a closely related protein kinase. Thus, budding yeast, like higher eukaryotes, use multiple cdk's in the regulation of cell cycle progression.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco				Morgan, David/0000-0001-8753-4416; Ogas, Joe/0000-0002-1332-7729; Espinoza, Francisco/0000-0002-1855-1914	NATIONAL CANCER INSTITUTE [R01CA052481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018738, R01AI018738] Funding Source: NIH RePORTER; NCI NIH HHS [CA52481] Funding Source: Medline; NIAID NIH HHS [AI18738] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; ESPINOZA FH, UNPUB; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; MURPHTY SM, 1993, MOL CELL BIOL, V19, P5290; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; OGAS J, UNPUB; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOHE A, 1988, MOL GEN GENET, V214, P162, DOI 10.1007/BF00340196; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; UEDA Y, 1975, J BACTERIOL, V122, P911, DOI 10.1128/JB.122.3.911-922.1975; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299	22	133	139	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1388	1391		10.1126/science.7973730	http://dx.doi.org/10.1126/science.7973730			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973730				2022-12-24	WOS:A1994PT63200045
J	BOISMENU, R; HAVRAN, WL				BOISMENU, R; HAVRAN, WL			MODULATION OF EPITHELIAL-CELL GROWTH BY INTRAEPITHELIAL GAMMA-DELTA T-CELLS	SCIENCE			English	Article							DENDRITIC EPIDERMAL-CELLS; ANTIGEN RECEPTORS; MURINE EPIDERMIS; EXPRESSION; LYMPHOCYTES; KGF	The role played in immune surveillance by gamma delta T cells residing in various epithelia has not been clear. It is shown here that activated gamma delta T cells obtained from skin and intestine express the epithelial cell mitogen keratinocyte growth factor (KGF). In contrast, intraepithelial alpha beta T cells, as well as all lymphoid alpha beta and gamma delta T cell populations tested, did not produce KGF or promote the growth of cultured epithelial cells. These results suggest that intraepithelial gamma delta T cells function in surveillance and in repair of damaged epithelial tissues.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032751, R29AI032751, R21AI032751] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32751] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON JP, 1991, ANNU REV IMMUNOL, V9, P679, DOI 10.1146/annurev.iy.09.040191.003335; ARSANOW D, 1989, NATURE, V341, P60; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BERGSTRESSER PR, 1984, J INVEST DERMATOL, V83, P83, DOI 10.1111/1523-1747.ep12262587; BERGSTRESSER PR, 1983, J INVEST DERMATOL, V81, P286, DOI 10.1111/1523-1747.ep12518332; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BOISMENU R, UNPUB; BOTTARO DP, 1993, J BIOL CHEM, V268, P9180; FALCO JP, 1988, ONCOGENE, V2, P573; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; HAVRAN WL, 1991, SCIENCE, V252, P1430, DOI 10.1126/science.1828619; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HAVRAN WL, UNPUB; KUZIEL WA, 1987, NATURE, V328, P263, DOI 10.1038/328263a0; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; PANOS RJ, 1993, J CLIN INVEST, V92, P969, DOI 10.1172/JCI116673; PAYER E, 1992, SPRINGER SEMIN IMMUN, V13, P315; RON D, 1993, J BIOL CHEM, V268, P2984; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; STINGL G, 1987, P NATL ACAD SCI USA, V84, P2430, DOI 10.1073/pnas.84.8.2430; ULICH TR, 1994, AM J PATHOL, V144, P862; ULICH TR, 1994, J CLIN INVEST, V93, P1298, DOI 10.1172/JCI117086; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8	26	548	559	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1253	1255		10.1126/science.7973709	http://dx.doi.org/10.1126/science.7973709			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973709				2022-12-24	WOS:A1994PT13200057
J	COLUCCIGUYON, E; PORTIER, MM; DUNIA, I; PAULIN, D; POURNIN, S; BABINET, C				COLUCCIGUYON, E; PORTIER, MM; DUNIA, I; PAULIN, D; POURNIN, S; BABINET, C			MICE LACKING VIMENTIN DEVELOP AND REPRODUCE WITHOUT AN OBVIOUS PHENOTYPE	CELL			English	Article							INTERMEDIATE FILAMENT PROTEIN; TRANSGENIC MICE; MOUSE EMBRYO; CELL-DIFFERENTIATION; MONOCLONAL-ANTIBODY; MESENCHYMAL CELLS; CULTURED-CELLS; GROWTH-FACTOR; EXPRESSION; CYTOKERATINS	To address the biological role of vimentin in the context of the living organism, we have introduced a null mutation of the vimentin gene into the germ line of mice. Surprisingly, animals homozygous for this mutation developed and reproduced without an obvious phenotype. Immunoblotting, immunofluorescence, and immunogold labeling analysis confirmed the absence of vimentin and of the corresponding filament network. Furthermore, no compensatory expression of another intermediate filament could be demonstrated. While these results leave open the question of the possible role of vimentin in unusual situations or pathological conditions, they show that a conspicuous developmental and cell-specific structure that is an integral part of the cytoskeleton can be eliminated without apparent effect on mouse reproduction and development.	BIOCHIM CELLULAIRE COLL FRANCE,F-75005 PARIS,FRANCE; UNIV PARIS 07,CNRS,INST JACQUES MONOD,F-75005 PARIS,FRANCE; INST PASTEUR,SERV CENT MICROSCOPIE ELECTR,F-75005 PARIS 15,FRANCE; UNIV PARIS 07,F-75005 PARIS 15,FRANCE	UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	COLUCCIGUYON, E (corresponding author), INST PASTEUR,UNITE GENET MAMMIFERES,CNRS,URA 361,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P901; BARIBAULT H, 1993, GENE DEV, V7, P1191, DOI 10.1101/gad.7.7a.1191; BENEDETTI EL, 1994, TREATISE CYTOSKELETO; BENZEEV A, 1984, J CELL BIOL, V99, P1424, DOI 10.1083/jcb.99.4.1424; BRADLEY A, 1987, TERATOCARCINOMAS EMB; Brookfield John, 1992, Current Biology, V2, P553, DOI 10.1016/0960-9822(92)90036-A; CAPETANAKI Y, 1990, ONCOGENE, V5, P645; CAPETANAKI Y, 1989, P NATL ACAD SCI USA, V86, P4882, DOI 10.1073/pnas.86.13.4882; CAPETANAKI Y, 1989, J CELL BIOL, V109, P1653, DOI 10.1083/jcb.109.4.1653; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; CHRISTIAN J L, 1990, New Biologist, V2, P700; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; COCHARD P, 1984, J NEUROSCI, V4, P2080; COHENTANNOUDJI M, 1992, MOL REPROD DEV, V33, P149, DOI 10.1002/mrd.1080330206; DELLAGI K, 1982, P NATL ACAD SCI-BIOL, V79, P446, DOI 10.1073/pnas.79.2.446; DELLAGI K, 1983, EMBO J, V2, P1509, DOI 10.1002/j.1460-2075.1983.tb01615.x; DELLAGI K, 1982, NATURE, V298, P284, DOI 10.1038/298284a0; DENT JA, 1989, DEVELOPMENT, V105, P61; DUNIA I, 1990, EUR J CELL BIOL, V53, P59; DUPOUEY P, 1985, DEV NEUROSCI-BASEL, V7, P81, DOI 10.1159/000112279; EDDE B, 1982, BIOCHIMIE, V64, P141, DOI 10.1016/S0300-9084(82)80416-1; FRANKE WW, 1979, EXP CELL RES, V123, P25, DOI 10.1016/0014-4827(79)90418-X; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; FRANKE WW, 1982, DIFFERENTIATION, V23, P43, DOI 10.1111/j.1432-0436.1982.tb01266.x; FUCHS E, 1992, CELL, V69, P899, DOI 10.1016/0092-8674(92)90607-E; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FURST DO, 1989, J CELL BIOL, V109, P517, DOI 10.1083/jcb.109.2.517; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HOULE J, 1983, DEV BRAIN RES, V9, P189, DOI 10.1016/0165-3806(83)90051-2; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLYMKOWSKY MW, 1981, NATURE, V291, P249, DOI 10.1038/291249a0; KLYMKOWSKY MW, 1992, P NATL ACAD SCI USA, V89, P8736, DOI 10.1073/pnas.89.18.8736; LANE EB, 1983, NATURE, V303, P701, DOI 10.1038/303701a0; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LIN JJC, 1981, CELL, V24, P185, DOI 10.1016/0092-8674(81)90514-6; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARKL J, 1989, EUR J CELL BIOL, V50, P1; MARKL J, 1991, J CELL SCI, V98, P261; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; NGAI J, 1987, MOL CELL BIOL, V7, P3955, DOI 10.1128/MCB.7.11.3955; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAULINLEVASSEUR M, 1988, EUR J CELL BIOL, V47, P121; PERREAU J, 1988, GENE, V62, P7, DOI 10.1016/0378-1119(88)90575-6; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; RAMAEKERS FCS, 1983, P NATL ACAD SCI-BIOL, V80, P2618, DOI 10.1073/pnas.80.9.2618; RITTLING SR, 1987, MOL CELL BIOL, V7, P3908, DOI 10.1128/MCB.7.11.3908; Robertson E. J., 1987, TERATOCARCINOMAS EMB; SARRIA AJ, 1992, J BIOL CHEM, V267, P19455; SCHULTHEISS T, 1991, J CELL BIOL, V114, P953, DOI 10.1083/jcb.114.5.953; SEJERSEN T, 1993, J CELL SCI, V106, P1291; SHEA TB, 1993, J NEUROSCI RES, V36, P66, DOI 10.1002/jnr.490360108; SOELLNER P, 1985, P NATL ACAD SCI USA, V82, P7929, DOI 10.1073/pnas.82.23.7929; TORPEY N, 1992, NATURE, V357, P413, DOI 10.1038/357413a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WACKER IU, 1992, J CELL BIOL, V117, P813, DOI 10.1083/jcb.117.4.813; WEBER K, 1991, BIOCHEM SOC T, V19, P1021, DOI 10.1042/bst0191021; [No title captured]	62	479	488	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					679	694		10.1016/0092-8674(94)90553-3	http://dx.doi.org/10.1016/0092-8674(94)90553-3			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954832				2022-12-24	WOS:A1994PT48100015
J	ADAMI, HO; HSIEH, CC; LAMBE, M; TRICHOPOULOS, D; LEON, D; PERSSON, I; EKBOM, A; JANSON, PO				ADAMI, HO; HSIEH, CC; LAMBE, M; TRICHOPOULOS, D; LEON, D; PERSSON, I; EKBOM, A; JANSON, PO			PARITY, AGE AT FIRST CHILDBIRTH, AND RISK OF OVARIAN-CANCER	LANCET			English	Article							STATES CASE-CONTROL; EUROPEAN CASE-CONTROL; COLLABORATIVE ANALYSIS; POOLED ANALYSIS; WHITE WOMEN; PATHOGENESIS; DETERMINANTS	Increasing parity is associated with a reduction in the risk of ovarian cancer, but it is not clear whether this association applies to different histopathological types and to borderline tumours. Moreover, the temporal relations are poorly understood, and the possible role of age at first birth remains unequivocal. We have investigated these issues in a case-control study nested in a nationwide cohort of women born between 1925 and 1960 in Sweden. During follow-up until 1984, 3486 invasive ovarian cancers (2992 epithelial, 330 stromal, 149 germ-cell, 15 not classifiable) and 510 tumours of borderline malignant were diagnosed. 5 individually age-matched (total 19 980) were selected for each case woman. After simultaneous adjustment for parity and age at first birth, increasing parity was associated with a pronounced consistent decrease in relative risk of all invasive cancers (odds ratio for each additional birth 0.81 [95% Cl 0.77-0.85]), epithelial cancer (0.81 [0.77-0.86]), stromal cancer (0.84 [0.72-0.98]), and germ-cell cancer (0.71 [0.48-1.05]), but a less consistent decrease for borderline tumours (0.92 [0.81-1.04]). The risk of ovarian cancer decreased by about 10% for each 5-year increment in age at first childbirth (odds ratios 0.89 [0.84-0.94] epithelial cancer, 0.92 [0.77-1.10] stromal cancer, 0.92 [0.65-1.32] germ-cell cancer, 0.93 [0.80-1.09] borderline tumours). Because our findings cannot be readily explained by theories invoking incessant ovulation or high serum concentrations of gonadotropins, new aetiological hypotheses are needed. Pregnancy-dependent clearance from the ovaries of cells that have undergone malignant transformation could explain the reproductive risk factors for ovarian cancer.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; UNIV UPPSALA HOSP, DEPT SOCIAL MED, S-75185 UPPSALA, SWEDEN; LONDON SCH HYG & TROP MED, LONDON WC1, ENGLAND; SAHLGRENS UNIV HOSP, DEPT OBSTET & GYNECOL, GOTHENBURG, SWEDEN	Harvard University; Harvard T.H. Chan School of Public Health; Uppsala University; Uppsala University Hospital; University of London; London School of Hygiene & Tropical Medicine; Sahlgrenska University Hospital	ADAMI, HO (corresponding author), UNIV UPPSALA HOSP, DEPT CANC EPIDEMIOL, S-75185 UPPSALA, SWEDEN.		Leon, David A/G-2195-2010	Leon, David A/0000-0001-9747-1762; Lambe, Mats/0000-0002-4624-3767				CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; FATHALLA MF, 1971, LANCET, V2, P163; FRANCESCHI S, 1991, INT J CANCER, V49, P57, DOI 10.1002/ijc.2910490111; FRANCESCHI S, 1991, INT J CANCER, V49, P61, DOI 10.1002/ijc.2910490112; GRANAI CO, 1992, NEW ENGL J MED, V327, P197, DOI 10.1056/NEJM199207163270313; HAMILTON TC, 1992, CURR PROB CANCER, V16, P5, DOI 10.1016/0147-0272(92)90047-R; HANKINSON SE, 1993, JAMA-J AM MED ASSOC, V270, P2813, DOI 10.1001/jama.270.23.2813; HARRIS R, 1992, AM J EPIDEMIOL, V136, P1204, DOI 10.1093/oxfordjournals.aje.a116428; HORNROSS PL, 1992, EPIDEMIOLOGY, V3, P490, DOI 10.1097/00001648-199211000-00005; JOHANSSON L, 1983, 14 STAT SWED URV; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; MALIK S, 1991, BRIT J CANCER, V64, P617, DOI 10.1038/bjc.1991.372; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; MORELY JE, 1992, ENDOCRINOL METAB, P322; MUSEY VC, 1987, NEW ENGL J MED, V316, P229, DOI 10.1056/NEJM198701293160501; NEGRI E, 1991, INT J CANCER, V49, P50, DOI 10.1002/ijc.2910490110; Ryan K J, 1980, MATERNAL FETAL ENDOC, P3; Stadel B V, 1975, Am J Obstet Gynecol, V123, P772; TOMATIS L, 1990, IARC SCI PUBLICATION, V100; Walker AM, 1991, OBSERVATION INFERENC; Whelan SL, 1990, IARC SCI PUBLICATION; WHITTEMORE AS, 1989, CANCER RES, V49, P4047; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1175, DOI 10.1093/oxfordjournals.aje.a116426; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1212, DOI 10.1093/oxfordjournals.aje.a116429; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; WILLEMSEN W, 1993, LANCET, V341, P986, DOI 10.1016/0140-6736(93)91071-S; [No title captured]; 1990, SOS1989 NAT BOARD HL, P19; 1962, CENSUS POPULATION 19, V4	30	252	258	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 5	1994	344	8932					1250	1254		10.1016/S0140-6736(94)90749-8	http://dx.doi.org/10.1016/S0140-6736(94)90749-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967985				2022-12-24	WOS:A1994PP70100007
J	MENARD, R; SANSONETTI, P; PARSOT, C; VASSELON, T				MENARD, R; SANSONETTI, P; PARSOT, C; VASSELON, T			EXTRACELLULAR ASSOCIATION AND CYTOPLASMIC PARTITIONING OF THE IPAB AND IPAC INVASINS OF SHIGELLA-FLEXNERI	CELL			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; YERSINIA YOP PROTEINS; B-CELL EPITOPES; SHIGELLA-FLEXNERI; EPITHELIAL-CELLS; SALMONELLA-TYPHIMURIUM; SIGNAL-TRANSDUCTION; NUCLEOTIDE-SEQUENCE; PLASMID ANTIGENS; HELA-CELLS	Shigella species cause bacillary dysentery in humans by invading colonic epithelial cells. IpaB and IpaC, two major invasins of these pathogens, are secreted into the extracellular milieu. We show here that IpaB and IpaC form a complex in the extracellular medium and that each binds independently to a 17 kDa polypeptide, IpgC, in the bacterial cytoplasm. The IpgC polypeptide was found to be necessary for bacterial entry into epithelial cells, to stabilize the otherwise unstable IpaB protein, and to prevent the proteolytic degradation of IpaC that occurs through its association with unprotected IpaB. We propose that IpgC, which is not secreted and thus acts as a molecular chaperone, serves as a receptor that prevents premature oligomerization of IpaB and IpaC within the cytoplasm of Shigella cells.	INST PASTEUR, UNITE PATHOGENIE MICROBIENNE MOLEC, F-75724 PARIS 15, FRANCE; INST PASTEUR, INSERM, U389, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ADLER B, 1989, MOL MICROBIOL, V3, P627, DOI 10.1111/j.1365-2958.1989.tb00210.x; ALLAOUI A, 1992, J BACTERIOL, V174, P7661, DOI 10.1128/JB.174.23.7661-7669.1992; ALLAOUI A, 1992, MOL MICROBIOL, V6, P1605, DOI 10.1111/j.1365-2958.1992.tb00885.x; ALLAOUI A, 1993, MOL MICROBIOL, V7, P59, DOI 10.1111/j.1365-2958.1993.tb01097.x; ANDREWS GP, 1991, INFECT IMMUN, V59, P1997, DOI 10.1128/IAI.59.6.1997-2005.1991; BARZU S, 1993, INFECT IMMUN, V61, P3825, DOI 10.1128/IAI.61.9.3825-3831.1993; BAUDRY B, 1988, MICROB PATHOGENESIS, V4, P345, DOI 10.1016/0882-4010(88)90062-9; BERGMAN T, 1991, J BACTERIOL, V173, P1607, DOI 10.1128/jb.173.5.1607-1616.1991; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; CLERC P, 1987, INFECT IMMUN, V55, P2681, DOI 10.1128/IAI.55.11.2681-2688.1987; DONNENBERG MS, 1992, INFECT IMMUN, V60, P3953, DOI 10.1128/IAI.60.10.3953-3961.1992; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ELSINGHORST EA, 1989, P NATL ACAD SCI USA, V86, P5173, DOI 10.1073/pnas.86.13.5173; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GROISMAN EA, 1993, EMBO J, V12, P3779, DOI 10.1002/j.1460-2075.1993.tb06056.x; HAKANSSON S, 1993, INFECT IMMUN, V61, P71; HARLOW E, 1988, ANTIBODIES LABORATOR; HIGH N, 1992, EMBO J, V11, P1991, DOI 10.1002/j.1460-2075.1992.tb05253.x; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAURELLI AT, 1985, INFECT IMMUN, V49, P164, DOI 10.1128/IAI.49.1.164-171.1985; MENARD R, 1993, J BACTERIOL, V175, P5899; MICHIELS T, 1991, J BACTERIOL, V173, P4994, DOI 10.1128/jb.173.16.4994-5009.1991; MICHIELS T, 1990, INFECT IMMUN, V58, P2840, DOI 10.1128/IAI.58.9.2840-2849.1990; MILLER VL, 1988, INFECT IMMUN, V56, P1242, DOI 10.1128/IAI.56.5.1242-1248.1988; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; NEU HC, 1965, J BIOL CHEM, V240, P3685; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PHALIPON A, 1992, INFECT IMMUN, V60, P1919, DOI 10.1128/IAI.60.5.1919-1926.1992; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; SAKAI T, 1988, MOL MICROBIOL, V2, P589, DOI 10.1111/j.1365-2958.1988.tb00067.x; SANSONETTI PJ, 1982, INFECT IMMUN, V35, P852, DOI 10.1128/IAI.35.3.852-860.1982; SASAKAWA C, 1993, J BACTERIOL, V175, P2334, DOI 10.1128/JB.175.8.2334-2346.1993; SASAKAWA C, 1989, MOL MICROBIOL, V3, P1191, DOI 10.1111/j.1365-2958.1989.tb00269.x; SASAKAWA C, 1988, J BACTERIOL, V170, P2480, DOI 10.1128/jb.170.6.2480-2484.1988; SERENY B., 1957, ACTA MICROBIOL ACAD SCI HUNGARICAE, V4, P367; VANNHIEU GT, 1993, EMBO J, V12, P1887, DOI 10.1002/j.1460-2075.1993.tb05837.x; VENKATESAN MM, 1992, J BACTERIOL, V174, P1990, DOI 10.1128/jb.174.6.1990-2001.1992; WATTIAU P, 1993, MOL MICROBIOL, V8, P123, DOI 10.1111/j.1365-2958.1993.tb01209.x; YANG YX, 1993, INFECT IMMUN, V61, P3907, DOI 10.1128/IAI.61.9.3907-3913.1993	50	248	253	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	1994	79	3					515	525		10.1016/0092-8674(94)90260-7	http://dx.doi.org/10.1016/0092-8674(94)90260-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954817				2022-12-24	WOS:A1994PQ48800014
J	SHIMKETS, RA; WARNOCK, DG; BOSITIS, CM; NELSONWILLIAMS, C; HANSSON, JH; SCHAMBELAN, M; GILL, JR; ULICK, S; MILORA, RV; FINDLING, JW; CANESSA, CM; ROSSIER, BC; LIFTON, RP				SHIMKETS, RA; WARNOCK, DG; BOSITIS, CM; NELSONWILLIAMS, C; HANSSON, JH; SCHAMBELAN, M; GILL, JR; ULICK, S; MILORA, RV; FINDLING, JW; CANESSA, CM; ROSSIER, BC; LIFTON, RP			LIDDLES SYNDROME - HERITABLE HUMAN HYPERTENSION CAUSED BY MUTATIONS IN THE BETA-SUBUNIT OF THE EPITHELIAL SODIUM-CHANNEL	CELL			English	Article							ALDOSTERONE SYNTHASE; GENE; DNA; LINKAGE; CELLS	Liddle's syndrome (pseudoaldosteronism) is an autosomal dominant form of human hypertension characterized by a constellation of findings suggesting constitutive activation of the amiloride-sensitive distal renal epithelial sodium channel. We demonstrate complete linkage of the gene encoding the beta subunit of the epithelial sodium channel to Liddle's syndrome in Liddle's original kindred. Analysis of this gene reveals a premature stop codon that truncates the cytoplasmic carboxyl terminus of the encoded protein in affected subjects. Analysis of subjects with Liddle's syndrome from four additional kindreds demonstrates either premature termination or frameshift mutations in this same carboxy-terminal domain in all four. These findings demonstrate that Liddle's syndrome is caused by mutations in the beta subunit of the epithelial sodium channel and have implications for the regulation of this epithelial ion channel as well as blood pressure homeostasis.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST,DEPT MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT GENET,NEW HAVEN,CT 06510; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; VET AFFAIRS MED CTR,BIRMINGHAM,AL 35294; SAN FRANCISCO GEN HOSP,DEPT MED,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94110; NHLBI,HYPERTENS ENDOCRINE BRANCH,BETHESDA,MD 20892; VET AFFAIRS HOSP,BRONX,NY 10468; CAPITAL DIST RENAL PHYSICIANS,ALBANY,NY 12208; MED COLL WISCONSIN,ST LUKES MED CTR,MILWAUKEE,WI 53215; UNIV LAUSANNE,INST PHARMACOL & TOXICOL,CH-1005 LAUSANNE,SWITZERLAND	Howard Hughes Medical Institute; Yale University; Yale University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Medical College of Wisconsin; University of Lausanne								BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; BUBIEN JK, 1993, AM J PHYSIOL, V265, pC1175, DOI 10.1152/ajpcell.1993.265.4.C1175; BUBIEN JK, 1994, J BIOL CHEM, V269, P17780; CANESSA C, 1994, IN PRESS AM J PHYSL; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; EVANS GA, 1987, METHOD ENZYMOL, V152, P604; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; GARDNER JD, 1971, J CLIN INVEST, V50, P2253, DOI 10.1172/JCI106722; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HATA A, 1990, NUCLEIC ACIDS RES, V18, P5407, DOI 10.1093/nar/18.18.5407; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; KUHNLE U, 1990, J CLIN ENDOCR METAB, V70, P638, DOI 10.1210/jcem-70-3-638; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; LIFTON RP, 1993, J HYPERTENS, V11, P231, DOI 10.1097/00004872-199303000-00002; LIFTON RP, 1992, NAT GENET, V2, P66, DOI 10.1038/ng0992-66; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; RENARD S, 1994, J BIOL CHEM, V269, P12981; ROTIN D, 1994, IN PRESS EMBO J; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WARD R, 1990, HYPERTENSION PATHOPH, P81	29	1084	1101	1	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 4	1994	79	3					407	414		10.1016/0092-8674(94)90250-X	http://dx.doi.org/10.1016/0092-8674(94)90250-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954808				2022-12-24	WOS:A1994PQ48800004
J	VANDENBERG, AV; BRENNER, E				VANDENBERG, AV; BRENNER, E			WHY 2 EYES ARE BETTER THAN ONE FOR JUDGMENTS OF HEADING	NATURE			English	Article							OPTICAL-FLOW; PERCEPTION; MOVEMENTS; MOTION; IMAGE	ARE two eyes needed for judging direction of self-motion? Traditional analyses stress that the pattern of optic flow in one eye is sufficient(1-5). The main difficulty is how to deal with the eye or head rotation. Extraretinal signals help(6-8), but humans can also discount the effect of rotation purely on the basis of monocular flow(6,7,9-12) provided the scene contains depth(6,9,10). Depth differences give rise to changing binocular disparities when the observer moves. These disparities are ignored in monocular theories of judgements of heading. Using computer generated displays, we investigated whether stereoscopic presentation improves heading judgements for conditions that pose problems to the monocular observer. We found that adding disparities to simulated ego-motion through a cloud of dots made heading judgements up to four times more tolerant to motion noise. The same improvement was found when the disparities specify the initial distances throughout the motion sequence. We conclude that binocular disparities improve judgements of heading by imposing a depth order on the elements of the scene, not because they provide additional information on the elements' motion in depth.			VANDENBERG, AV (corresponding author), ERASMUS UNIV ROTTERDAM,FAC MED,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.		van den Berg, Albert/G-3108-2012	van den Berg, Albert Victor/0000-0002-1543-5408				Gibson J. J., 1950, PERCEPTION VISUAL WO; Heeger DJ, 1990, NEURAL COMPUT, V2, P129, DOI 10.1162/neco.1990.2.2.129; KOENDERINK JJ, 1987, BIOL CYBERN, V56, P247, DOI 10.1007/BF00365219; LONGUETHIGGINS HC, 1980, PROC R SOC SER B-BIO, V208, P385, DOI 10.1098/rspb.1980.0057; RIEGER JH, 1985, BIOL CYBERN, V52, P377, DOI 10.1007/BF00449594; RIEGER JH, 1985, J OPT SOC AM A, V2, P354, DOI 10.1364/JOSAA.2.000354; ROYDEN CS, 1992, NATURE, V360, P583, DOI 10.1038/360583a0; VANDENBERG AV, 1992, VISION RES, V32, P1285, DOI 10.1016/0042-6989(92)90223-6; VANDENBERG AV, 1993, NATURE, V365, P497, DOI 10.1038/365497a0; VANDENBERG AV, 1994, VISION RES, V34, P2153, DOI 10.1016/0042-6989(94)90324-7; WARREN WH, 1990, J OPT SOC AM A, V7, P160, DOI 10.1364/JOSAA.7.000160; WARREN WH, 1988, NATURE, V336, P162, DOI 10.1038/336162a0	12	87	87	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					700	702		10.1038/371700a0	http://dx.doi.org/10.1038/371700a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935814	Green Submitted			2022-12-24	WOS:A1994PM77300055
J	SULLENGER, BA; CECH, TR				SULLENGER, BA; CECH, TR			RIBOZYME-MEDIATED REPAIR OF DEFECTIVE MESSENGER-RNA BY TARGETED TRANSSPLICING	NATURE			English	Article							RNA ENZYME; TETRAHYMENA RIBOZYME; ESCHERICHIA-COLI; SEQUENCE; CLEAVAGE; EXPRESSION; BINDING; INVIVO; MODEL; VIRUS	RIBOZYMES can be targeted to cleave specific RNAs(1-8), which has led to much interest in their potential as gene inhibitors(3,9,10). Such trans-cleaving ribozymes join a growing list of agents that stop the flow of genetic information(11,12). Here we describe a different application of ribozymes for which they may be uniquely suited. By targeted trans-splicing, a ribozyme can replace a defective portion of RNA with a functional sequence. The self-splicing intron from Tetrahymena thermophila(13) was previously shown to mediate trans-splicing of oligonucleotides in vitro(14,15). As a model system for messenger RNA repair, this group I intron was re-engineered to regenerate the proper coding capacity of short, truncated lacZ transcripts. Trans-splicing was efficient in vitro and proceeded in Escherichia coli to generate translatable lacZ messages. Targeted trans-splicing represents a general means of altering the sequence of specified transcripts and may provide a new approach to the treatment of many genetic diseases.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; CECH TR, 1992, J BIOL CHEM, V267, P17479; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; FELDSTEIN PA, 1989, GENE, V82, P53, DOI 10.1016/0378-1119(89)90029-2; FORD E, 1994, P NATL ACAD SCI USA, V91, P3117, DOI 10.1073/pnas.91.8.3117; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; GILBOA E, 1994, TRENDS GENET, V10, P139, DOI 10.1016/0168-9525(94)90216-X; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERSCHLAG D, 1991, P NATL ACAD SCI USA, V88, P6921, DOI 10.1073/pnas.88.16.6921; INOUE T, 1985, CELL, V43, P431, DOI 10.1016/0092-8674(85)90173-4; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; Miller JH, 1972, EXPT MOL GENETICS; MORGAN RA, 1993, ANNU REV BIOCHEM, V62, P191; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PRICE JV, 1985, SCIENCE, V228, P719, DOI 10.1126/science.2986286; ROSSI J J, 1992, Current Opinion in Biotechnology, V3, P3, DOI 10.1016/0958-1669(92)90117-2; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABOR S, 1990, CURRENT PROTOCOLS MO; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; WARING RB, 1985, CELL, V40, P371, DOI 10.1016/0092-8674(85)90151-5; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YU M, 1994, GENE THER, V1, P13; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	30	196	225	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					619	622		10.1038/371619a0	http://dx.doi.org/10.1038/371619a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935797				2022-12-24	WOS:A1994PL55900056
J	MORGAN, R; KING, D; PRAJAPATI, C; ROWE, J				MORGAN, R; KING, D; PRAJAPATI, C; ROWE, J			VIEWS OF ELDERLY PATIENTS AND THEIR RELATIVES ON CARDIOPULMONARY-RESUSCITATION	BRITISH MEDICAL JOURNAL			English	Article							ATTITUDES; DECISIONS		BROADGREEN HOSP,DEPT MED,LIVERPOOL L14 3LB,MERSEYSIDE,ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; University of Liverpool								DAVIES KN, 1993, J ROY COLL PHYS LOND, V27, P127; DOYAL L, 1993, BRIT MED J, V306, P1593, DOI 10.1136/bmj.306.6892.1593; SCHADE SG, 1989, J MED ETHICS, V15, P186, DOI 10.1136/jme.15.4.186; STEWART K, 1990, BRIT MED J, V300, P785, DOI 10.1136/bmj.300.6727.785; STOLMAN CJ, 1990, ARCH INTERN MED, V150, P653, DOI 10.1001/archinte.150.3.653	5	70	70	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1677	1678		10.1136/bmj.308.6945.1677a	http://dx.doi.org/10.1136/bmj.308.6945.1677a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	7993423	Green Published			2022-12-24	WOS:A1994NU48300022
J	BEHL, C; DAVIS, JB; LESLEY, R; SCHUBERT, D				BEHL, C; DAVIS, JB; LESLEY, R; SCHUBERT, D			HYDROGEN-PEROXIDE MEDIATES AMYLOID-BETA PROTEIN TOXICITY	CELL			English	Article							SUPEROXIDE-GENERATING OXIDASE; FAMILIAL ALZHEIMERS-DISEASE; CENTRAL-NERVOUS-SYSTEM; PRECURSOR PROTEIN; GLUTAMATE TOXICITY; GROWTH-FACTOR; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; CORTICAL-NEURONS; CELLS	Amyloid beta protein (A beta) is a 40-43 amino acid peptide that is associated with plaques in the brains of Alzheimer's patients and is cytotoxic to cultured neurons. Using both primary central nervous system cultures and clonal cell lines, it is shown that a number of antioxidants protect cells from A beta toxicity, suggesting that at least one pathway to A beta cytotoxicity results in free radical damage. A beta causes increased levels of H2O2 and lipid peroxides to accumulate in cells. The H2O2-degrading enzyme catalase protects cells from A beta toxicity. Clonal cell lines selected for their resistance to A beta toxicity also become resistant to the cytolytic action of H2O2. In addition, A beta induces the activity of NF-kappa B, a transcription factor thought to be regulated by oxidative stress. Finally, A beta-induced H2O2 production and A beta toxicity are blocked by reagents that inhibit flavin oxidases, suggesting that A beta activates a member of this class of enzymes. These results show that the cytotoxic action of A beta on neurons results from free radical damage to susceptible cells.			BEHL, C (corresponding author), SALK INST BIOL STUDIES, SAN DIEGO, CA 92186 USA.			Behl, Christian/0000-0001-8453-2378				ABE K, 1990, JPN J PHARMACOL, V53, P221, DOI 10.1254/jjp.53.221; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BAKALKIN GY, 1993, MOL BRAIN RES, V20, P137, DOI 10.1016/0169-328X(93)90119-A; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BEHL C, 1994, BRAIN RES, V645, P253, DOI 10.1016/0006-8993(94)91659-4; BRODIE AE, 1987, BIOCHEM BIOPH RES CO, V148, P120, DOI 10.1016/0006-291X(87)91084-9; BURDON RH, 1993, FREE RADICAL RES COM, V18, P369, DOI 10.3109/10715769309147503; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHOI DW, 1987, J NEUROSCI, V7, P369; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; CROSS AR, 1990, FREE RADICAL BIO MED, V8, P71, DOI 10.1016/0891-5849(90)90147-B; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; GLENNER GG, 1988, CELL, V52, P307, DOI 10.1016/S0092-8674(88)80021-7; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Halliwell B., 1989, FREE RADICAL BIO MED, V2nd; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HEDLEY D, 1992, CYTOMETRY, V13, P686, DOI 10.1002/cyto.990130704; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KESTON AS, 1965, ANAL BIOCHEM, V11, P1, DOI 10.1016/0003-2697(65)90034-5; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P7508, DOI 10.1073/pnas.90.16.7508; KIMURA H, 1992, J CELL BIOL, V116, P777, DOI 10.1083/jcb.116.3.777; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOJIMA S, 1993, FEBS LETT, V329, P125, DOI 10.1016/0014-5793(93)80207-B; LEES GJ, 1993, NEUROSCIENCE, V54, P287, DOI 10.1016/0306-4522(93)90254-D; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; OLANOW CW, 1992, ANN NEUROL, V32, pS2, DOI 10.1002/ana.410320703; ROBBERECHT W, 1994, J NEUROCHEM, V62, P384; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SANSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SCHUBERT D, 1993, BRAIN RES, V629, P275, DOI 10.1016/0006-8993(93)91331-L; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SCHUBERT D, 1992, P NATL ACAD SCI USA, V89, P8264, DOI 10.1073/pnas.89.17.8264; Schubert D., 1984, DEV BIOL CULTURED NE; SLATER TF, 1963, BIOCHIM BIOPHYS ACTA, V77, P383, DOI 10.1016/0006-3002(63)90513-4; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; VOGT M, 1963, P NATL ACAD SCI USA, V49, P171, DOI 10.1073/pnas.49.2.171; WOZNIAK A, 1989, IMMUNOLOGY, V68, P359; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	52	1953	2028	0	216	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					817	827		10.1016/0092-8674(94)90131-7	http://dx.doi.org/10.1016/0092-8674(94)90131-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004671				2022-12-24	WOS:A1994NT33100007
J	PTACEK, LJ; TAWIL, R; GRIGGS, RC; ENGEL, AG; LAYZER, RB; KWIECINSKI, H; MCMANIS, PG; SANTIAGO, L; MOORE, M; FOUAD, G; BRADLEY, P; LEPPERT, MF				PTACEK, LJ; TAWIL, R; GRIGGS, RC; ENGEL, AG; LAYZER, RB; KWIECINSKI, H; MCMANIS, PG; SANTIAGO, L; MOORE, M; FOUAD, G; BRADLEY, P; LEPPERT, MF			DIHYDROPYRIDINE RECEPTOR MUTATIONS CAUSE HYPOKALEMIC PERIODIC PARALYSIS	CELL			English	Article							CHANNEL ALPHA-SUBUNIT; SLOW CALCIUM CURRENT; SKELETAL-MUSCLE; SODIUM-CHANNEL; PARAMYOTONIA-CONGENITA; MUSCULAR DYSGENESIS; GENE; MICE; LINKAGE; DNA	Hypokalemic periodic paralysis (hypoKPP) is an autosomal dominant skeletal muscle disorder manifested by episodic weakness associated with low serum potassium. Genetic linkage analysis has localized the hypoKPP gene to chromosome 1q31-q32 near a dihydropyridine (DHP) receptor gene. This receptor functions as a voltage-gated calcium channel and is also critical for excitation-contraction coupling in a voltage-sensitive and calcium-independent manner. We have characterized patient-specific DHP receptor mutations in 11 probands of 33 independent hypoKPP kindreds that occur at one of two adjacent nucleotides within the same codon and predict substitution of a highly conserved arginine in the S4 segment of domain 4 with either histidine or glycine. In one kindred, the mutation arose de novo. Taken together, these data establish this DHP receptor as the hypoKPP gene. We are unaware of any other human diseases presently known to result from DHP receptor mutations.	UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132; UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84132; UNIV ROCHESTER,SCH MED,DEPT NEUROL,ROCHESTER,NY 14642; MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; MED ACAD WARSAW,DEPT NEUROL,PL-02097 WARSAW,POLAND	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University of Rochester; Mayo Clinic; University of California System; University of California San Francisco	PTACEK, LJ (corresponding author), UNIV UTAH,HLTH SCI CTR,DEPT NEUROL,SALT LAKE CITY,UT 84132, USA.			Griggs, Robert/0000-0001-7988-4854	NCRR NIH HHS [M01-RR00064] Funding Source: Medline; NHGRI NIH HHS [8 R01 HG00367] Funding Source: Medline; NICHD NIH HHS [1 K11 HD00940-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K11HD000940] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000367] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P455, DOI 10.1146/annurev.ne.11.030188.002323; BEAM KG, 1986, NATURE, V320, P168, DOI 10.1038/320168a0; CASLEY WL, 1992, GENOMICS, V14, P493, DOI 10.1016/S0888-7543(05)80249-6; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHAHINE M, 1994, NEURON, V12, P281, DOI 10.1016/0896-6273(94)90271-2; CHAUDHARI N, 1992, J BIOL CHEM, V267, P25636; CHEUNG JY, 1986, NEW ENGL J MED, V314, P1670; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EBERS GC, 1991, ANN NEUROL, V30, P810, DOI 10.1002/ana.410300610; ENGEL AG, 1970, MAYO CLIN PROC, V45, P774; FONTAINE B, 1990, SCIENCE, V250, P1000, DOI 10.1126/science.2173143; FONTAINE B, 1994, NAT GENET, V6, P267, DOI 10.1038/ng0394-267; Fontaine B, 1991, Neuromuscul Disord, V1, P235, DOI 10.1016/0960-8966(91)90095-A; GLUECKSOHNWAELS.S, 1963, SCIENCE, V142, P1269, DOI 10.1126/science.142.3597.1269; GOUW L, 1994, IN PRESS NEUROLOGY; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; GREGG RG, 1993, GENOMICS, V15, P107, DOI 10.1006/geno.1993.1017; GRIGGS RC, 1992, HOSP PRACT, V27, P123; HORNE WA, 1993, P NATL ACAD SCI USA, V90, P3787, DOI 10.1073/pnas.90.9.3787; KNUDSON CM, 1989, J BIOL CHEM, V264, P1345; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LEONARD JP, 1982, EXP NEUROL, V76, P121, DOI 10.1016/0014-4886(82)90106-6; LERCHE H, 1993, J PHYSIOL-LONDON, V470, P13, DOI 10.1113/jphysiol.1993.sp019843; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; MCLATCHEY AI, 1992, NAT GENET, V2, P148; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; POWELL JA, 1973, J CELL PHYSIOL, V82, P21, DOI 10.1002/jcp.1040820104; PTACEK LJ, 1993, ANN NEUROL, V33, P300, DOI 10.1002/ana.410330312; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1992, NEURON, V8, P891; PTACEK LJ, 1994, IN PRESS NEUROLOGY; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; RUDEL R, 1984, MUSCLE NERVE, V7, P110, DOI 10.1002/mus.880070205; RUDOLPH JA, 1992, NAT GENET, V2, P1144; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; WROGEMANN K, 1976, LANCET, V27, P672	38	334	352	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					863	868						6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004673				2022-12-24	WOS:A1994NT33100011
J	FERRANDON, D; ELPHICK, L; NUSSLEINVOLHARD, C; STJOHNSTON, D				FERRANDON, D; ELPHICK, L; NUSSLEINVOLHARD, C; STJOHNSTON, D			STAUFEN PROTEIN ASSOCIATES WITH THE 3'UTR OF BICOID MESSENGER-RNA TO FORM PARTICLES THAT MOVE IN A MICROTUBULE-DEPENDENT MANNER	CELL			English	Article							MESSENGER-RNA LOCALIZATION; EARLY DROSOPHILA EMBRYO; POLE CELL-FORMATION; POSTERIOR DETERMINANT; ANTERIOR LOCALIZATION; SECONDARY STRUCTURE; MOLECULAR ANALYSIS; MATERNAL GENE; PATTERN; OSKAR	Staufen protein is required in order to anchor bicoid (bcd) mRNA at the anterior pole of the Drosophila egg. Here we show that staufen protein colocalizes with bcd mRNA at the anterior, and that this localization depends upon Its association with the mRNA. Upon injection into the embryo, bcd transcripts specifically interact with staufen, and we have mapped the sequences required to three regions of the 3'UTR, each of which is predicted to form a long stem-loop. The resulting staufen-bcd 3'UTR complexes form particles that show a microtubule-dependent localization. Since staufen is also transported with oskar (osk) mRNA during oogenesis, staufen associates specifically with both osk and bcd mRNAs to mediate their localizations, but at two distinct stages of development.	WELLCOME CANC RES CAMPAIGN INST,CAMBRIDGE CB2 1QR,ENGLAND; DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND		FERRANDON, D (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,SPEMANNSTR 35-III,D-72076 TUBINGEN,GERMANY.		St Johnston, Daniel/C-9568-2009	FERRANDON, Dominique/0000-0001-7680-7773; St Johnston, Daniel/0000-0001-5582-3301	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; AKUSJARVI G, 1980, P NATL ACAD SCI-BIOL, V77, P2424, DOI 10.1073/pnas.77.5.2424; ALDEN CJ, 1979, J MOL BIOL, V132, P411, DOI 10.1016/0022-2836(79)90268-7; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; DEBRABANDER M, 1986, INT REV CYTOL, V101, P215; DRIEVER W, 1990, DEVELOPMENT, V109, P811; Driever Wolfgang, 1993, P301; EDGAR BA, 1987, GENE DEV, V1, P1226, DOI 10.1101/gad.1.10.1226; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; GANS M, 1975, GENETICS, V81, P683; GAVIS ER, 1992, CELL, V71, P310; GOTTLIEB E, 1992, P NATL ACAD SCI USA, V89, P7164, DOI 10.1073/pnas.89.15.7164; KARR TL, 1991, MECH DEVELOP, V34, P101, DOI 10.1016/0925-4773(91)90047-A; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; Kim-Ha Jeongsil, 1993, Development (Cambridge), V119, P169; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MACDONALD PM, 1993, DEVELOPMENT, V118, P1233; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; NEWMARK PA, 1994, DEVELOPMENT, V120, P1303; PEERY T, 1993, J VIROL, V67, P3534, DOI 10.1128/JVI.67.6.3534-3543.1993; SCHEJTER ED, 1993, ANNU REV CELL BIOL, V9, P67, DOI 10.1146/annurev.cellbio.9.1.67; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SEEGER MA, 1990, EMBO J, V9, P2977, DOI 10.1002/j.1460-2075.1990.tb07490.x; SINGER R H, 1992, Current Opinion in Cell Biology, V4, P15, DOI 10.1016/0955-0674(92)90053-F; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEPHENSON EC, 1987, DEV BIOL, V124, P1, DOI 10.1016/0012-1606(87)90453-2; STEPHENSON EC, 1988, GENE DEV, V2, P1655, DOI 10.1101/gad.2.12a.1655; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	49	350	358	0	15	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1221	1232		10.1016/0092-8674(94)90013-2	http://dx.doi.org/10.1016/0092-8674(94)90013-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001156				2022-12-24	WOS:A1994PZ86000013
J	WILKINSON, HA; FITZGERALD, K; GREENWALD, I				WILKINSON, HA; FITZGERALD, K; GREENWALD, I			RECIPROCAL CHANGES IN EXPRESSION OF THE RECEPTOR LIN-12 AND ITS LIGAND LAG-2 PRIOR TO COMMITMENT IN A C-ELEGANS CELL FATE DECISION	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA-NOTCH; GENE; HOMOLOG; SEQUENCES; AUTONOMY; ENCODES; MOTCH; SET	During development of the C. elegans hermaphrodite gonad, two cells interact with each other, so that one chooses to become the anchor cell (AC) and the other becomes a ventral uterine precursor cell (VU). This interaction is mediated by the receptor LIN-12 and its apparent ligand LAG-2. We show that initially lin-12 and lag-2 are expressed in both cells, but prior to commitment, the expression patterns change in a reciprocal manner, so that lin-12 expression becomes restricted to the presumptive VU and lag-2 expression becomes restricted to the presumptive AC. In addition, lin-12 activity promotes expression of lin-12 and represses expression of lag-2. Furthermore, we show that positive autoregulation of lin-12 transcription in the presumptive VU is mediated by a cis-acting 5' regulatory sequence and is necessary to specify the VU fate. Our results suggest that transcriptional control is a component of the feedback mechanism involved in specifying the AC and VU fates.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	WILKINSON, HA (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.				NIGMS NIH HHS [GM37602] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037602] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNER S, 1974, GENETICS, V77, P71; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DELAMO FF, 1992, DEVELOPMENT, V115, P737; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; EMMONS SW, 1979, P NATL ACAD SCI USA, V76, P1333, DOI 10.1073/pnas.76.3.1333; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FIRE A, 1993, GENET ANAL TECH APPL, V9, P151; FITZGERALD K, 1993, DEVELOPMENT, V119, P1019; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GREENWALD J, 1994, CURR OPIN GENET DEV, V4, P556; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HIRSH D, 1976, DEV BIOL, V49, P200, DOI 10.1016/0012-1606(76)90267-0; HODGKIN J, 1989, GENETICS, V123, P301; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KIMBLE J, 1979, DEV BIOL, V81, P208; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; REAUME AG, 1992, DEV BIOL, V154, P377, DOI 10.1016/0012-1606(92)90076-S; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SEYDOUX G, 1990, CELL, V61, P939, DOI 10.1016/0092-8674(90)90060-R; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SUNDARAM M, 1993, GENETICS, V135, P755; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; TAX FE, 1994, THESIS U WASHINGTON; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Wigglesworth VB, 1940, J EXP BIOL, V17, P180; WILKINSON HA, 1994, THESIS PRINCETON U P; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	44	212	216	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1187	1198		10.1016/0092-8674(94)90010-8	http://dx.doi.org/10.1016/0092-8674(94)90010-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001154				2022-12-24	WOS:A1994PZ86000010
J	CARPENTER, L; BARTLEY, M				CARPENTER, L; BARTLEY, M			FAT, FEMALE, AND POOR	LANCET			English	Editorial Material							ADULTHOOD; OBESITY		UNIV OXFORD NUFFIELD COLL,OXFORD,ENGLAND	University of Oxford	CARPENTER, L (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,OXFORD,ENGLAND.							Blaxter M., 1990, HLTH LIFESTYLES; BRADDON FFM, 1986, BMJ-BRIT MED J, V293, P299, DOI 10.1136/bmj.293.6542.299; Dex S., 1987, WOMENS OCCUPATIONAL; Erikson Robert, 1992, CONSTANT FLUX; GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406; JOSHI H, 1988, LONGITUDINAL DATA AN; LEON D, 1994, LANCET; POWER C, 1988, INT J OBESITY, V12, P445; SARGENT JD, 1994, ARCH PEDIAT ADOL MED, V148, P681, DOI 10.1001/archpedi.1994.02170070019003; SITTHIAMORN C, 1994, LANCET; STUNKARD AJ, 1993, NEW ENGL J MED, V329, P1036, DOI 10.1056/NEJM199309303291411; 1991, HLTH NATION	12	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1715	1716		10.1016/S0140-6736(94)92880-0	http://dx.doi.org/10.1016/S0140-6736(94)92880-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7996996				2022-12-24	WOS:A1994PY28100003
J	PETTIT, DL; PERLMAN, S; MALINOW, R				PETTIT, DL; PERLMAN, S; MALINOW, R			POTENTIATED TRANSMISSION AND PREVENTION OF FURTHER LTP BY INCREASED CAMKII ACTIVITY IN POSTSYNAPTIC HIPPOCAMPAL SLICE NEURONS	SCIENCE			English	Article							LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; DENSITY PROTEIN; FASCIA DENTATA; SYNAPTIC ENHANCEMENT; SYNTHETIC MACHINERY; NMDA RECEPTORS; CA1 NEURONS; CALMODULIN; ACTIVATION	Calcium-calmodulin-dependent protein kinase II (CaMKII) is a necessary component of the cellular machinery underlying learning and memory. Here, a constitutively active form of this enzyme, CaMKII(1-290), was introduced into neurons of hippocampal slices with a recombinant vaccinia virus to test the hypothesis that increased postsynaptic activity of this enzyme is sufficient to produce long-term synaptic potentiation (LTP), a prominent cellular model of learning and memory. Postsynaptic expression of CaMKII(1-290) increased CaMKII activity, enhanced synaptic transmission, and prevented more potentiation by an LTP-inducing protocol. These results, together with previous studies, suggest that postsynaptic CaMKII activity is necessary and sufficient to generate LTP.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; UNIV IOWA,NEUROSCI PROGRAM,DEPT PEDIAT,IOWA CITY,IA 52242; UNIV IOWA,NEUROSCI PROGRAM,DEPT MICROBIOL,IOWA CITY,IA 52242	Cold Spring Harbor Laboratory; University of Iowa; University of Iowa								AKERS RF, 1985, BRAIN RES, V334, P147, DOI 10.1016/0006-8993(85)90576-1; ALFORD S, 1993, J PHYSIOL-LONDON, V469, P693, DOI 10.1113/jphysiol.1993.sp019838; ASZTELY F, 1992, SYNAPSE, V11, P342, DOI 10.1002/syn.890110409; BAILINGER C, 1990, J CELL BIOL, V111, P1763; BLISS TVP, 1983, J PHYSIOL-LONDON, V334, P475, DOI 10.1113/jphysiol.1983.sp014507; CHARRIAUTMARLANGUE C, 1991, P NATL ACAD SCI USA, V88, P10232, DOI 10.1073/pnas.88.22.10232; COHEN ME, 1990, P NATL ACAD SCI USA, V87, P8990, DOI 10.1073/pnas.87.22.8990; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; Dingledine R., 1984, BRAIN SLICES; FUKANAGA K, 1993, J BIOL CHEM, V268, P7863; GOLDENRING JR, 1984, J NEUROCHEM, V42, P1077, DOI 10.1111/j.1471-4159.1984.tb12713.x; GUSTAFSSON B, 1988, NEUROSCI LETT, V85, P77, DOI 10.1016/0304-3940(88)90432-6; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MACKETT M, 1985, DNA CLONING PRACTICA; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALENKA RC, 1986, NATURE, V319, P774; MALENKA RC, 1986, NATURE, V321, P695; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1994, P NATL ACAD SCI USA, V91, P8170, DOI 10.1073/pnas.91.17.8170; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MCNAUGHTON BL, 1981, J NEUROPHYSIOL, V46, P952, DOI 10.1152/jn.1981.46.5.952; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MULLER D, 1988, P NATL ACAD SCI USA, V85, P6997, DOI 10.1073/pnas.85.18.6997; MULLER W, 1992, J NEUROPHYSIOL, V68, P2264, DOI 10.1152/jn.1992.68.6.2264; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PERKEL DJ, 1993, NEURON, V11, P817, DOI 10.1016/0896-6273(93)90111-4; PETTIT DL, 1983, COLD SPRING HARB SYM, V48, P745; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; REYMANN KG, 1986, BRAIN RES BULL, V17, P291, DOI 10.1016/0361-9230(86)90234-0; REYMANN KG, 1988, BRAIN RES, V440, P305, DOI 10.1016/0006-8993(88)91000-1; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STEWARD O, 1988, J NEUROSCI, V8, P176; STEWARD O, 1986, J NEUROSCI, V6, P3079; STEWARD O, 1991, J COMP NEUROL, V314, P545, DOI 10.1002/cne.903140311; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WEISSKOPF MG, 1993, NATURE, V362, P423, DOI 10.1038/362423a0; YAMAGATA Y, 1991, J BIOL CHEM, V266, P15391	53	257	259	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1881	1885		10.1126/science.7997883	http://dx.doi.org/10.1126/science.7997883			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997883				2022-12-24	WOS:A1994PX38300040
J	GRAHAM, A; FRANCISWEST, P; BRICKELL, P; LUMSDEN, A				GRAHAM, A; FRANCISWEST, P; BRICKELL, P; LUMSDEN, A			THE SIGNALING MOLECULE BMP4 MEDIATES APOPTOSIS IN THE RHOMBENCEPHALIC NEURAL CREST	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; VENTRALIZING FACTOR; HINDBRAIN; CELLS	THE pattern of skeletal structures and muscles in the branchial region of the head is profoundly influenced by the neural crest whose cells arise at discrete segmental levels of the chick hindbrain: specifically, rhombomeres (r)1 + 2, r4 and r6, whereas r3 and r5 are crest-depleted(2). We have demonstrated that an interaction between even-numbered rhombomeres and r3/r5 effects this depletion of neural crest, resulting in the sculpting of discrete migratory streams of neural crest(3). This mechanism acts through increased expression of msx2 and the induction of apoptosis in dorsal cells of r3 and r5 (ref. 3) (Fig. 1A). Here we demonstrate that the signalling molecule Bmp4 is expressed in r3 and r5 and is dependent on the neighbouring rhombomeres. Addition of recombinant BMP4 protein to explant cultures of r3 or r5, which produce neural crest when isolated from their neighbouring rhombomeres, upregulates msx2 and reinstates apoptosis in the neural crest population.	UCL, SCH MED, DEPT MOLEC PATHOL, MED MOLEC BIOL UNIT, LONDON W1P 6DB, ENGLAND	University of London; University College London; UCL Medical School	GRAHAM, A (corresponding author), UNITED MED & DENT SCH, GUYS HOSP, DIV ANAT & CELL BIOL, MRC, LONDON SE1 9RT, ENGLAND.		graham, anthony/B-1864-2008; Lumsden, Andrew/C-5146-2009	graham, anthony/0000-0003-2011-7188; 				ACHESON A, 1993, SOC NEUR ABSTR, V19; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; DALE L, 1992, DEVELOPMENT, V115, P573; DELANNET M, 1992, DEVELOPMENT, V116, P275; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GRAHAM A, 1993, DEVELOPMENT, V119, P233; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; JONES CM, 1992, DEVELOPMENT, V115, P639; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; VANIO S, 1993, CELL, V75, P45	12	441	448	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					684	686		10.1038/372684a0	http://dx.doi.org/10.1038/372684a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990961				2022-12-24	WOS:A1994PX30700088
J	FUJITA, A; OKA, C; ARIKAWA, Y; KATAGAI, T; TONOUCHI, A; KUHARA, S; MISUMI, Y				FUJITA, A; OKA, C; ARIKAWA, Y; KATAGAI, T; TONOUCHI, A; KUHARA, S; MISUMI, Y			A YEAST GENE NECESSARY FOR BUD-SITE SELECTION ENCODES A PROTEIN SIMILAR TO INSULIN-DEGRADING ENZYMES	NATURE			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; EXPRESSION; SEQUENCE; CLONING; DISRUPTION	CELLS Of the yeast Saccharomyces cerevisiae choose bud sites in a non-random spatial pattern that depends on mating type: axial for haploid cells and bipolar for ala diploid cells(1,2). We identified a mutant yeast, axl1, in which the budding pattern is altered from axial to bipolar. Expression of the AXL1 gene is repressed in a/alpha diploid cells. With the ectopic expression of AXL1, a/alpha cells exhibited an axial budding pattern, thus AXL1 is a key morphological determinant that distinguishes the budding pattern of haploid cells from that of ala diploid cells(2). AXL1 encodes a protein similar in sequence to the human and Drosophila insulin-degrading enzymes(3,4) and to the Escherichia coli ptr gene product(5). The axial budding pattern might result from degradation of a target protein by the putative Axl1 protease.	IND RES INST CHIBA PREFECTURE, WAKABA KU, CHIBA 264, JAPAN; NAGANO STATE LAB FOOD TECHNOL, NAGANO 380, JAPAN; KYUSHU UNIV, GRAD SCH GENET RESOURCES TECHNOL, HIGASHI KU, FUKUOKA 812, JAPAN; FUKUOKA UNIV, SCH MED, DEPT BIOCHEM, JONAN KU, FUKUOKA 81401, JAPAN	Kyushu University; Fukuoka University	FUJITA, A (corresponding author), AGCY IND SCI & TECHNOL, NATL INST BIOSCI & HUMAN TECHNOL, 1-1 HIGASHI, TSUKUBA, IBARAKI 305, JAPAN.							AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; BUTLER G, 1991, MOL CELL BIOL, V11, P476, DOI 10.1128/MCB.11.1.476; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHENG YSE, 1979, J BIOL CHEM, V254, P4698; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P7695, DOI 10.1093/nar/14.19.7695; FLESCHER EG, 1993, J CELL BIOL, V122, P373, DOI 10.1083/jcb.122.2.373; FUJITA A, 1990, GENE, V89, P93, DOI 10.1016/0378-1119(90)90210-I; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; KIRSCHNER RJ, 1983, J BIOL CHEM, V258, P967; KUO WL, 1990, MOL ENDOCRINOL, V4, P1580, DOI 10.1210/mend-4-10-1580; MILLER AM, 1985, NATURE, V314, P598, DOI 10.1038/314598a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RINE J, 1987, GENETICS, V116, P9; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; STILLMAN DJ, 1992, GENE DEV, V6, P93; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035	21	117	119	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 8	1994	372	6506					567	570		10.1038/372567a0	http://dx.doi.org/10.1038/372567a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990931				2022-12-24	WOS:A1994PW08200057
J	BRIDGES, AJ				BRIDGES, AJ			SILICONE IMPLANT CONTROVERSY CONTINUES	LANCET			English	Editorial Material							BREAST IMPLANTS; WOMEN				BRIDGES, AJ (corresponding author), UNIV WISCONSIN HOSP,MADISON,WI, USA.							ANGELL M, 1994, NEW ENGL J MED, V330, P1748, DOI 10.1056/NEJM199406163302409; BORENSTEIN D, 1993, ARTHRITIS RHEUM, V36, pS117; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; BRIDGES AJ, 1993, ARCH INTERN MED, V153, P2638, DOI 10.1001/archinte.153.23.2638; BRIDGES AJ, 1993, ARTHRITIS RHEUM, V36, pS191; BRIDGES AJ, IN PRESS J BIOMAT SC; CUELLAR ML, 1993, ARTHRITIS RHEUM, V36, pS219; DUGOWSON CE, 1992, ARTHRITIS RHEUM, V35, pS66; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; KOSSOVSKY N, 1993, J APPL BIOMATER, V4, P281, DOI 10.1002/jab.770040402; OJOAMAIZE EA, IN PRESS CLIN DIAG L; SOLOMON G, 1994, SEMIN ARTHRITIS RHEU, V24, P29, DOI 10.1016/0049-0172(94)90107-4; SPIERA H, 1993, J RHEUMATOL, V20, P958; TEUBER SS, 1993, J AUTOIMMUN, V6, P367, DOI 10.1006/jaut.1993.1031	14	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1451	1452		10.1016/S0140-6736(94)90284-4	http://dx.doi.org/10.1016/S0140-6736(94)90284-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968116				2022-12-24	WOS:A1994PT99500003
J	GOULDING, EH; TIBBS, GR; SIEGELBAUM, SA				GOULDING, EH; TIBBS, GR; SIEGELBAUM, SA			MOLECULAR MECHANISM OF CYCLIC-NUCLEOTIDE-GATED CHANNEL ACTIVATION	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; SUBUNIT STOICHIOMETRY; BINDING-SPECIFICITY; POTASSIUM CHANNELS; RECEPTOR CHIMERAS; INACTIVATION; MEMBRANE; DOMAIN; GMP	STUDIES on the activation of ligand- and voltage-gated ion channels have identified regions involved in both ligand binding(1) and voltage sensing(2), but relatively little is known about how such domains are coupled to channel opening. Here we investigate the structural basis for the activation of cyclic-nucleotide-gated channels, which are directly opened by cytoplasmic cyclic nucleotides(3,4) but are structurally homologous to voltage-gated channels(5-7). By constructing chimaeras between cyclic-nucleotide-gated channels cloned from bovine retinal photoreceptors(8) and catfish olfactory neurons(7), we identify two distinct domains that are important for ligand binding and channel gating. A putative alpha-helix in the carboxy-terminal binding domain determines the selectivity of the channel for activation by cGMP relative to cAMP. A domain in the amino-terminal region determines the ease with which channels open and thus influences agonist efficacy. We propose that channel opening is coupled to an allosteric conformational change in the binding site which enhances agonist binding. Thus, cyclic nucleotides activate the channel by binding tightly to the open state and stabilizing it.	COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT PHARMACOL,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	GOULDING, EH (corresponding author), COLUMBIA UNIV,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,DEPT PHYSIOL,722 W 168TH ST,NEW YORK,NY 10032, USA.							AVIS JM, 1993, BIOCHEMISTRY-US, V32, P5321, DOI 10.1021/bi00071a006; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; CASTILLO JD, 1957, P ROY SOC          B, V146, P369; CATTERALL WA, 1989, SCIENCE, V243, P236, DOI 10.1126/science.2536189; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; JACKSON MB, 1992, BIOPHYS J, V63, P1443, DOI 10.1016/S0006-3495(92)81706-X; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KRAMER RH, 1994, NEURON, V12, P655, DOI 10.1016/0896-6273(94)90220-8; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAKAMURA T, 1987, NATURE, V325, P342; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SHEN NV, 1993, NEURON, V11, P67; SKOOG DA, 1982, FUNDAMENTALS ANAL CH, P75; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	30	177	178	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					369	374		10.1038/372369a0	http://dx.doi.org/10.1038/372369a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969497				2022-12-24	WOS:A1994PU28700058
J	ZEIHER, AM; IHLING, C; PISTORIUS, K; SCHACHINGER, V; SCHAEFER, HE				ZEIHER, AM; IHLING, C; PISTORIUS, K; SCHACHINGER, V; SCHAEFER, HE			INCREASED TISSUE ENDOTHELIN IMMUNOREACTIVITY IN ATHEROSCLEROTIC LESIONS ASSOCIATED WITH ACUTE CORONARY SYNDROMES	LANCET			English	Note							ARTERY DISEASE; PATHOGENESIS; MECHANISMS; VASOSPASM	Acute coronary syndromes are accompanied by exaggerated vasoconstriction. Since thrombin induces production of the potent vasoconstrictor endothelin-1, we used immunohistochemistry on coronary atherosclerotic specimens from 30 consecutive patients. Endothelin-1-like immunoreactivity was present in 5 of 9 (55%) lesions from patients with stable angina, in 6 of 7 (86%) from crescendo angina, and in all 14 from angina at rest. Endothelin-1 immunoreactivity was most common in areas with a positive Prussian-blue reaction indicative of previous intraplaque haemorrhage. Tissue endothelin-1-like immunoreactivity might contribute to the exaggerated coronary vasoconstriction.	UNIV FREIBURG,DEPT PATHOL,D-79106 FREIBURG,GERMANY	University of Freiburg	ZEIHER, AM (corresponding author), UNIV FREIBURG,DEPT INTERNAL MED 3,DIV CARDIOL,D-79106 FREIBURG,GERMANY.							EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; HOLLANDER M, 1973, NONPARAMETRIC STATIS; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; WINKLES JA, 1993, BIOCHEM BIOPH RES CO, V191, P1081, DOI 10.1006/bbrc.1993.1327; YANG ZH, 1990, CIRCULATION, V82, P188, DOI 10.1161/01.CIR.82.1.188; YANIGASAWA M, 1988, NATURE, V332, P411; ZEIHER AM, 1991, CIRCULATION, V83, P1519, DOI 10.1161/01.CIR.83.5.1519; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391	11	90	93	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1405	1406		10.1016/S0140-6736(94)90571-1	http://dx.doi.org/10.1016/S0140-6736(94)90571-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968078				2022-12-24	WOS:A1994PR78600012
J	WOODARD, CT; BAEHRECKE, EH; THUMMEL, CS				WOODARD, CT; BAEHRECKE, EH; THUMMEL, CS			A MOLECULAR MECHANISM FOR THE STAGE SPECIFICITY OF THE DROSOPHILA PREPUPAL GENETIC RESPONSE TO ECDYSONE	CELL			English	Article							HORMONE-RECEPTOR SUPERFAMILY; POLYTENE CHROMOSOMES; INDUCIBLE GENE; PUPAL CUTICLE; EARLY PUFF; ECDYSTEROID TITERS; BINDING PROTEIN; IMAGINAL DISKS; FUSHI-TARAZU; ENCODES 2	Two successive pulses of ecdysone signal the ends of larval and prepupal development in Drosophila, inducing early and late puffs in the salivary gland polytene chromosomes. Early puff induction in prepupae is dependent on a preceding period of protein synthesis and low ecdysone concentration. We demonstrate here that the competence acquired during this interval can be provided by beta FTZ-F1, a nuclear hormone receptor superfamily member derived from the 75CD mid-prepupal puff. We show that beta FTZ-F1 represses its own transcription and is repressed by ecdysone, explaining its brief expression in mid-prepupae. We further show that ectopic beta FTZ-F1 expression leads to enhanced levels of ecdysone-induced BR-C, E74, and E75 early gene transcription and premature induction of the stage-specific 93F early puff and E93 transcription. These findings indicate that beta FTZ-F1 plays a central role in the prepupal genetic response to ecdysone and provide a molecular mechanism for stage-specific responses to steroid hormones.			WOODARD, CT (corresponding author), UNIV UTAH,ECCLES INST HUMAN GENET,HOWARD HUGHES MED INST,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.		Woodard, Craig/L-7293-2019					ANDRES AJ, 1994, METHOD CELL BIOL, V44, P565, DOI 10.1016/S0091-679X(08)60932-2; ANDRES AJ, 1993, DEV BIOL, V160, P388, DOI 10.1006/dbio.1993.1315; APPLE RT, 1991, DEV BIOL, V146, P569, DOI 10.1016/0012-1606(91)90257-4; ASHBURNER M, 1967, CHROMOSOMA, V21, P398, DOI 10.1007/BF00336950; ASHBURNER M, 1974, DEV BIOL, V39, P141, DOI 10.1016/S0012-1606(74)80016-3; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER HJ, 1959, CHROMOSOMA, V10, P654, DOI 10.1007/BF00396591; Bodenstein D, 1965, BIOL DROSOPHILA, P275; BOYD M, 1977, J INSECT PHYSIOL, V23, P517, DOI 10.1016/0022-1910(77)90263-3; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHAO AT, 1986, EMBO J, V5, P143, DOI 10.1002/j.1460-2075.1986.tb04188.x; CLEVER U, 1960, EXP CELL RES, V20, P623, DOI 10.1016/0014-4827(60)90141-5; CROWLEY TE, 1984, CELL, V39, P149, DOI 10.1016/0092-8674(84)90200-9; DIBELLO PR, 1991, GENETICS, V129, P385; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FECHTEL K, 1988, GENETICS, V120, P465; FECHTEL K, 1989, DEVELOPMENT, V106, P649; FRISTROM JW, 1982, DEV BIOL, V91, P337, DOI 10.1016/0012-1606(82)90040-9; FRISTROM JW, 1986, ARCH INSECT BIOCH S, V1, P119; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HANDLER AM, 1982, DEV BIOL, V93, P73, DOI 10.1016/0012-1606(82)90240-8; HUET F, 1993, DEVELOPMENT, V118, P613; KARIM FD, 1992, EMBO J, V11, P4083, DOI 10.1002/j.1460-2075.1992.tb05501.x; KARIM FD, 1991, GENE DEV, V5, P1067, DOI 10.1101/gad.5.6.1067; KARIM FD, 1993, DEVELOPMENT, V118, P977; KOELLE MR, 1992, THESIS STANFORD U ST; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LAVORGNA G, 1993, P NATL ACAD SCI USA, V90, P3004, DOI 10.1073/pnas.90.7.3004; MARONI G, 1983, DROS INFORM SERV, V59, P142; MARTIN P, 1978, GENETICS BIOL DROS A, V2, P219; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; RICHARDS G, 1981, BIOL REV, V56, P501, DOI 10.1111/j.1469-185X.1981.tb00358.x; RICHARDS G, 1976, DEV BIOL, V54, P264, DOI 10.1016/0012-1606(76)90304-3; RICHARDS G, 1981, MOL CELL ENDOCRINOL, V21, P181, DOI 10.1016/0303-7207(81)90013-7; RICHARDS G, 1976, DEV BIOL, V54, P256, DOI 10.1016/0012-1606(76)90303-1; Riddiford L., 1993, DEV DROSOPHILA MELAN, V2, P899; ROBB JA, 1969, J CELL BIOL, V41, P876, DOI 10.1083/jcb.41.3.876; Robertson CW, 1936, J MORPHOL, V59, P351, DOI 10.1002/jmor.1050590207; ROBERTSON HM, 1988, GENETICS, V118, P461; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1988, THESIS STANFORD U ST; SLITER TJ, 1992, GENETICS, V130, P555; STONE BL, 1993, CELL, V75, P307, DOI 10.1016/0092-8674(93)80072-M; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; Thummel CS, 1992, DROS INF SERV, V71, P150; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; UEDA H, 1990, GENE DEV, V4, P624, DOI 10.1101/gad.4.4.624; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0	50	178	186	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					607	615		10.1016/0092-8674(94)90546-0	http://dx.doi.org/10.1016/0092-8674(94)90546-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954827				2022-12-24	WOS:A1994PT48100008
J	NEHLS, M; PFEIFER, D; SCHORPP, M; HEDRICH, H; BOEHM, T				NEHLS, M; PFEIFER, D; SCHORPP, M; HEDRICH, H; BOEHM, T			NEW MEMBER OF THE WINGED-HELIX PROTEIN FAMILY DISRUPTED IN MOUSE AND RAT NUDE MUTATIONS	NATURE			English	Article							GENE FORK-HEAD; TRANSCRIPTION FACTORS; EMBRYO; THYMUS; DOMAIN; MICE	MUTATIONS at the nude locus of mice and rats disrupt normal hair growth and thymus development(1,2), causing nude mice and rats to be immune-deficient. The mouse nude locus has been localized on chromosome 11 (refs 3, 4) within a region of <1 megabase(5). Here we show that one of the genes from this critical region, designated whn, encodes a new member of the winged-helix domain family of transcription factors(6.7), and that it is disrupted on mouse au and rat rnuN alleles. Mutant transcripts do not encode the characteristic DNA-binding domain, strongly suggesting that the whn gene is the nude gene. Mutations in winged-helix domain genes cause homeotic transformations in Drosophila(8) and distort cell-fate decisions during vulval development in Caenorhabditis elegans(9). The whn gene is thus the first member of this class of genes to be implicated in a specific developmental defect in vertebrates.	HANNOVER MED SCH,ZENT TIERVERSUCHSANLAGE,D-30625 HANNOVER,GERMANY; UNIV FREIBURG,DEPT MED 1,MOLEC MED GRP,D-79106 FREIBURG,GERMANY	Hannover Medical School; University of Freiburg								BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CASH JM, 1993, MAMM GENOME, V4, P37, DOI 10.1007/BF00364661; CORDIER AC, 1980, AM J ANAT, V157, P227, DOI 10.1002/aja.1001570303; HEDRICH HJ, 1990, GENETIC MONITORING I; KOPFMAIER P, 1990, ACTA ANAT, V139, P178; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LI C, 1992, GENOMICS, V13, P658, DOI 10.1016/0888-7543(92)90138-I; LISITSYN AN, 1994, NAT GENET, V6, P57; Lyon M., 1989, GENETIC VARIANTS STR; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEHLS M, 1994, ONCOGENE, V9, P2169; NEHLS M, 1994, EUR J IMMUNOL, V24, P1721, DOI 10.1002/eji.1830240742; PALACIOS R, 1991, EUR J IMMUNOL, V21, P109, DOI 10.1002/eji.1830210117; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAHASHI Y, 1992, J EXP MED, V175, P873, DOI 10.1084/jem.175.3.873; VANVLIET E, 1985, EUR J IMMUNOL, V15, P675, DOI 10.1002/eji.1830150707; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5	21	537	547	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					103	107		10.1038/372103a0	http://dx.doi.org/10.1038/372103a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969402				2022-12-24	WOS:A1994PQ34800083
J	MIDDLETON, FA; STRICK, PL				MIDDLETON, FA; STRICK, PL			ANATOMICAL EVIDENCE FOR CEREBELLAR AND BASAL GANGLIA INVOLVEMENT IN HIGHER COGNITIVE FUNCTION	SCIENCE			English	Article							RHESUS-MONKEY; GLOBUS PALLIDUS; HORSERADISH-PEROXIDASE; FRONTAL-LOBE; PREFRONTAL CORTEX; MACACA-MULATTA; MOTOR CORTEX; PROJECTIONS; ORGANIZATION; CONNECTIONS	The possibility that neurons in the basal ganglia and cerebellum innervate areas of cerebral cortex that are involved in cognitive function has been a contriversial subject. Here, retrograde transneuronal transport of herpes simplex virus type 1 (HSV1) was used to identify subcortical neurons that project via the thalamus to area 46 of the primate prefrontal cortex. This cortical area is known to be involved in spatial working memory. Many neurons in restricted regions of the dentate nucleus of the cerebral and in the internal segment of the globus pallidus were labeled by transneuronal transport of visus from area 46. The location of these neurons was different from those labeled after HSV1 transport from motor areas of the cerebral cortex. These observations define an anatomical substrate for the involvement of basal ganglia and cerrebellar output in higher cognitive function.	VET ADM MED CTR, RES SERV, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT PHYSIOL, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, PROGRAM NEUROSCI, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT NEUROSURG, SYRACUSE, NY 13210 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center				Middleton, Frank/0000-0002-3107-7188	NINDS NIH HHS [NS24328] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024328] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKSHOOMOFF NA, 1992, BEHAV NEUROSCI, V106, P731, DOI 10.1037/0735-7044.106.5.731; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ANDERSON ME, 1985, J NEUROPHYSIOL, V54, P433, DOI 10.1152/jn.1985.54.2.433; BARBAS H, 1991, J COMP NEUROL, V313, P65, DOI 10.1002/cne.903130106; BARBAS H, 1989, J COMP NEUROL, V286, P353, DOI 10.1002/cne.902860306; BLOEDEL JR, 1993, TRENDS NEUROSCI, V16, P451, DOI 10.1016/0166-2236(93)90075-W; BRODAL P, 1979, NEUROSCIENCE, V4, P193, DOI 10.1016/0306-4522(79)90082-4; BUTTERS N, 1978, ARCH NEUROL-CHICAGO, V35, P585, DOI 10.1001/archneur.1978.00500330033006; CANAVAN AGM, 1994, BEHAV NEUROSCI, V108, P475, DOI 10.1037/0735-7044.108.3.475; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; DELONG MR, 1971, J NEUROPHYSIOL, V34, P414, DOI 10.1152/jn.1971.34.3.414; DEVITO JL, 1982, EXP BRAIN RES, V46, P107; EVARTS EV, 1969, ANNU REV PHYSIOL, V31, P451, DOI 10.1146/annurev.ph.31.030169.002315; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; Fuster J.M., 1985, CEREB CORTEX, V4, P151; Fuster J.M., 1989, PREFRONTAL CORTEX; GLICKSTEIN M, 1985, J COMP NEUROL, V235, P343, DOI 10.1002/cne.902350306; GLICKSTEIN M, 1993, TRENDS NEUROSCI, V16, P450, DOI 10.1016/0166-2236(93)90074-V; GOLDMAN PS, 1977, J COMP NEUROL, V171, P369, DOI 10.1002/cne.901710305; GOLDMANRAKIC PS, 1990, PROG BRAIN RES, V85, P325; GOLDMANRAKIC PS, 1985, J COMP NEUROL, V242, P535, DOI 10.1002/cne.902420406; GRAFMAN J, 1992, NEUROLOGY, V42, P1493, DOI 10.1212/WNL.42.8.1493; HOLSAPPLE JW, 1991, J NEUROSCI, V11, P2644; Hoover J. E., 1993, Society for Neuroscience Abstracts, V19, P1590; HOOVER JE, 1993, SCIENCE, V259, P819, DOI 10.1126/science.7679223; ITO M, 1993, TRENDS NEUROSCI, V16, P448, DOI 10.1016/0166-2236(93)90073-U; KEMP JM, 1971, PHILOS T R SOC B, V262, P441, DOI 10.1098/rstb.1971.0106; KIEVIT J, 1977, EXP BRAIN RES, V29, P299; Kievit J., 1972, CORTICOTHALAMIC PROJ, P91; KIM R, 1976, J COMP NEUROL, V169, P263, DOI 10.1002/cne.901690302; KIM SG, 1994, SCIENCE, V265, P949, DOI 10.1126/science.8052851; KUO JS, 1973, J COMP NEUROL, V151, P201, DOI 10.1002/cne.901510302; KUSAMA T, 1971, P JPN ACAD, V47, P505, DOI 10.2183/pjab1945.47.505; LEICHNETZ GR, 1984, J COMP NEUROL, V228, P388, DOI 10.1002/cne.902280307; LEINER HC, 1991, BEHAV BRAIN RES, V44, P113, DOI 10.1016/S0166-4328(05)80016-6; LEINER HC, 1993, TRENDS NEUROSCI, V16, P444, DOI 10.1016/0166-2236(93)90072-T; LYNCH JC, IN PRESS EXP BRAIN R; MINK JW, 1991, J NEUROPHYSIOL, V65, P273, DOI 10.1152/jn.1991.65.2.273; NAUTA WALLE J. H., 1966, BRAIN RES, V1, P3, DOI 10.1016/0006-8993(66)90103-X; olszewski j, 1952, THALAMUS MACACA MULA; ORIOLI PJ, 1989, J COMP NEUROL, V288, P612, DOI 10.1002/cne.902880408; PARENT A, 1982, BRAIN RES, V245, P201, DOI 10.1016/0006-8993(82)90802-2; PERCHERON G, 1977, J HIRNFORSCH, V18, P375; PETERSEN SE, 1993, ANNU REV NEUROSCI, V16, P509, DOI 10.1146/annurev.ne.16.030193.002453; SASAKI K, 1979, EXP BRAIN RES, V37, P193, DOI 10.1007/BF01474266; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; SELEMON LD, 1985, J NEUROSCI, V5, P776; SELEMON LD, 1988, J NEUROSCI, V8, P4049; STANTON GB, 1980, J COMP NEUROL, V190, P699, DOI 10.1002/cne.901900406; STRICK PL, 1993, INT CONGR SER, V1024, P171; STRICK PL, 1993, EXPT NEUROANATOMY PR, P81; STRUB RL, 1989, ARCH NEUROL-CHICAGO, V46, P1024, DOI 10.1001/archneur.1989.00520450096027; TAYLOR AE, 1986, BRAIN, V109, P845, DOI 10.1093/brain/109.5.845; VANKAN PLE, 1993, J NEUROPHYSIOL, V69, P57, DOI 10.1152/jn.1993.69.1.57; Walker AE, 1940, J COMP NEUROL, V73, P59, DOI 10.1002/cne.900730106; WETTS R, 1985, J NEUROPHYSIOL, V54, P231, DOI 10.1152/jn.1985.54.2.231; WIESENDANGER R, 1985, EXP BRAIN RES, V59, P105; YAMAMOTO T, 1992, BRAIN RES, V579, P315, DOI 10.1016/0006-8993(92)90067-J; YETERIAN EH, 1978, BRAIN RES, V139, P43, DOI 10.1016/0006-8993(78)90059-8; ZEMANICK MC, 1991, P NATL ACAD SCI USA, V88, P8048, DOI 10.1073/pnas.88.18.8048	60	944	966	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	1994	266	5184					458	461		10.1126/science.7939688	http://dx.doi.org/10.1126/science.7939688			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939688				2022-12-24	WOS:A1994PN27200041
J	VANLUENEN, HGAM; COLLOMS, SD; PLASTERK, RHA				VANLUENEN, HGAM; COLLOMS, SD; PLASTERK, RHA			THE MECHANISM OF TRANSPOSITION OF TC3 IN C-ELEGANS	CELL			English	Article							TRANSPOSABLE ELEMENT TC1; CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; INTEGRASE PROTEIN; FAMILY; EXCISION; INSERTION; GENE; DNA; SEQUENCES	The Tc3 transposon of C. elegans belongs to a family of inverted repeat DNA transposons, found in many different phyla. We studied the mechanism of Tc3 transposition by expression of Tc3 transposase from a heat-shock promoter in transgenic nematodes. Transposition is accompanied by the appearance of linear extrachromosomal Tc3 DNA. Analysis of the ends of this presumed transposition intermediate shows that the transposon is excised incompletely: the 5' ends of the transposon lack two nucleotides. The 3' ends coincide with the last nucleotide of the integrated element and carry 3' hydroxyls. The nucleotides that are not coexcised with the transposon remain at the donor site and result in a characteristic footprint. A model is derived for the mechanism of Tc3 jumping that probably applies to the entire family of Tc1/mariner transposable elements.			VANLUENEN, HGAM (corresponding author), NETHERLANDS CANC INST, DIV MOLEC BIOL, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS.			Colloms, Sean/0000-0003-2369-8168; van Luenen, Henri/0000-0002-5584-7968				ABAD P, 1991, J MOL EVOL, V33, P251, DOI 10.1007/BF02100676; ATKINSON PW, 1993, P NATL ACAD SCI USA, V90, P9693, DOI 10.1073/pnas.90.20.9693; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; BENJAMIN HW, 1992, P NATL ACAD SCI USA, V89, P4648, DOI 10.1073/pnas.89.10.4648; BREZINSKY L, 1990, NUCLEIC ACIDS RES, V18, P2053, DOI 10.1093/nar/18.8.2053; BRYAN G, 1990, GENETICS, V125, P103; CAIZZI R, 1993, GENETICS, V133, P335; CARR B, 1994, MOL CELL BIOL, V14, P3426, DOI 10.1128/MCB.14.5.3426; COLLINS J, 1989, GENETICS, V121, P47; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; DABOUSSI MJ, 1992, MOL GEN GENET, V232, P12, DOI 10.1007/BF00299131; DOAK TG, 1994, P NATL ACAD SCI USA, V91, P942, DOI 10.1073/pnas.91.3.942; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; EIDE D, 1988, MOL CELL BIOL, V8, P737, DOI 10.1128/MCB.8.2.737; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; FRANZ G, 1991, NUCLEIC ACIDS RES, V19, P6646, DOI 10.1093/nar/19.23.6646; GARCIAFERNANDEZ J, 1993, NATURE, V364, P109, DOI 10.1038/364109a0; HARRIS LJ, 1988, NUCLEIC ACIDS RES, V16, P5991, DOI 10.1093/nar/16.13.5991; HARRIS LJ, 1990, J MOL EVOL, V30, P359, DOI 10.1007/BF02101890; HEIERHORST J, 1992, P NATL ACAD SCI USA, V89, P6798, DOI 10.1073/pnas.89.15.6798; HEINKOFF S, 1992, NEW BIOL, V4, P382; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; KIFF JE, 1988, NATURE, V331, P631, DOI 10.1038/331631a0; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1992, J VIROL, V66, P7414, DOI 10.1128/JVI.66.12.7414-7419.1992; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MOORE SP, 1994, P NATL ACAD SCI USA, V91, P1843, DOI 10.1073/pnas.91.5.1843; OBROCHTA DA, 1991, MOL GEN GENET, V225, P387, DOI 10.1007/BF00261678; PLASTERK RHA, 1992, EMBO J, V11, P287, DOI 10.1002/j.1460-2075.1992.tb05051.x; PLASTERK RHA, 1991, EMBO J, V10, P1919, DOI 10.1002/j.1460-2075.1991.tb07718.x; RADICE AR, 1994, IN PRESS MOL GEN GEN; ROBERTSON HM, 1992, NUCLEIC ACIDS RES, V20, P6409, DOI 10.1093/nar/20.23.6409; ROSE AM, 1984, NATURE, V311, P485, DOI 10.1038/311485a0; RUAN KS, 1987, NUCLEIC ACIDS RES, V15, P6875, DOI 10.1093/nar/15.17.6875; RUAN KS, 1984, P NATL ACAD SCI-BIOL, V81, P4018, DOI 10.1073/pnas.81.13.4018; Sambrook J., 1989, MOL CLONING LAB MANU; SHIN CG, 1994, J VIROL, V68, P1633, DOI 10.1128/JVI.68.3.1633-1642.1994; SKALKA AM, 1993, GENE, V135, P175, DOI 10.1016/0378-1119(93)90063-9; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; SULSTON J, 1987, NEMATODE CAENORHABDI, P587; TAUSTA SL, 1989, CELL, V59, P1019, DOI 10.1016/0092-8674(89)90758-7; TENZEN T, 1990, J BACTERIOL, V172, P3830, DOI 10.1128/jb.172.7.3830-3836.1990; TUDOR M, 1992, MOL GEN GENET, V232, P126, DOI 10.1007/BF00299145; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANLUENEN HGAM, 1994, NUCLEIC ACIDS RES, V22, P262, DOI 10.1093/nar/22.3.262; VANLUENEN HGAM, 1993, EMBO J, V12, P2513, DOI 10.1002/j.1460-2075.1993.tb05906.x; VARMUS H, 1989, MOBILE DNA, P53; VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S; VOS JC, 1993, GENE DEV, V7, P1244, DOI 10.1101/gad.7.7a.1244; [No title captured]	58	164	169	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					293	301		10.1016/0092-8674(94)90198-8	http://dx.doi.org/10.1016/0092-8674(94)90198-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954797				2022-12-24	WOS:A1994PN63000013
J	SCHNEIDER, KR; SMITH, RL; OSHEA, EK				SCHNEIDER, KR; SMITH, RL; OSHEA, EK			PHOSPHATE-REGULATED INACTIVATION OF THE KINASE PHO80-PHO85 BY THE CDK INHIBITOR PHO81	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; SACCHAROMYCES-CEREVISIAE; G1 CYCLIN; GENE; PROTEIN; YEAST; SYSTEM; FAR1; IDENTIFICATION; COMPLEXES	A complex consisting of the cyclin-dependent kinase (CDK) PHO85 and the cyclin PHO80 phosphorylates and is thought to inactivate the transcription factor PHO4 when yeast cells are grown in medium containing high concentrations of phosphate. The CDK inhibitor PHO81 inhibits the kinase activity of the PHO80-PHO85 complex when Saccharomyces cerevisiae cells are grown in medium depleted of phosphate. A region of PHO81 with similarity to the mammalian CDK inhibitor p16(INK4) is sufficient for inhibition in vitro. These studies demonstrate that CDK inhibitors are used to regulate kinases involved in processes other than cell cycle control and suggest that the ankyrin repeat motif may be commonly used for interaction with cyclin-CDK complexes.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco				Schneider, Ken Robert/0000-0002-6638-6810				BAJWA W, 1984, NUCLEIC ACIDS RES, V12, P7721, DOI 10.1093/nar/12.20.7721; BOLLAG G, 1993, EMBO J, V12, P1923, DOI 10.1002/j.1460-2075.1993.tb05841.x; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CREASY CL, 1993, NUCLEIC ACIDS RES, V21, P1975, DOI 10.1093/nar/21.8.1975; GILLIQUET V, 1987, NUCLEIC ACIDS RES, V15, P5893, DOI 10.1093/nar/15.14.5893; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HARPER JW, 1993, CELL, V75, P805; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LEMIRE JM, 1985, MOL CELL BIOL, V5, P2131, DOI 10.1128/MCB.5.8.2131; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; OCONNELL KF, 1992, GENETICS, V132, P63; OGAWA N, 1993, MOL GEN GENET, V238, P444, DOI 10.1007/BF00292004; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHNEIDER K, UNPUB; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIKORSKI RS, 1989, GENETICS, V122, P19; Toh-e A, 1986, Yeast, V2, P129, DOI 10.1002/yea.320020209; TOHE A, 1988, MOL GEN GENET, V214, P162, DOI 10.1007/BF00340196; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; UEDA Y, 1975, J BACTERIOL, V122, P911, DOI 10.1128/JB.122.3.911-922.1975; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YOSHIDA K, 1989, MOL GEN GENET, V217, P40, DOI 10.1007/BF00330940	35	203	215	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	1994	266	5182					122	126		10.1126/science.7939631	http://dx.doi.org/10.1126/science.7939631			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939631				2022-12-24	WOS:A1994PK58200039
J	SAUNDERS, NJ				SAUNDERS, NJ			WHY MONITOR PEAK VANCOMYCIN CONCENTRATIONS	LANCET			English	Article							RENAL-FUNCTION; THERAPY	Peak and trough serum concentrations are routinely measured to monitor vancomycin therapy. Optimal therapy depends upon maintaining a concentration above that necessary for antibacterial activity and is therefore determined by the trough concentration. I determined the post dose increases in serum drug concentrations in routine clinical practice in adult patients without renal failure. Mean increases of 16.6 mg/L (SD 6.1) (peak samples collected 1 h post infusion) were measured from 165 paired samples. The results suggest that as long as trough concentrations do not exceed 15 mg/L, peak levels will not exceed normally accepted safe concentrations, and therefore do not need to be measured.			SAUNDERS, NJ (corresponding author), HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT INFECT DIS & BACTERIOL, DU CANE RD, LONDON W12 0NN, ENGLAND.		mouton, johan w/C-5915-2014; Saunders, Nigel J/W-6745-2019	mouton, johan w/0000-0001-6736-4149; Saunders, Nigel/0000-0002-0160-4573				ACKERMAN BH, 1992, ANTIMICROB AGENTS CH, V36, P1766, DOI 10.1128/AAC.36.8.1766; CANTU TG, 1994, CLIN INFECT DIS, V18, P533; EDWARDS DJ, 1987, CLIN PHARMACY, V6, P652; ENG RHK, 1989, CHEMOTHERAPY, V35, P320, DOI 10.1159/000238688; FARBER BF, 1983, ANTIMICROB AGENTS CH, V23, P138, DOI 10.1128/AAC.23.1.138; FREEMAN CD, 1993, ANN PHARMACOTHER, V27, P594; GERACI JE, 1956, P STAFF M MAYO CLIN, V31, P564; GERACI JE, 1958, P STAFF M MAYO CLIN, V33, P172; HOOK EW, 1978, AM J MED, V65, P411, DOI 10.1016/0002-9343(78)90766-0; KIRBY WMM, 1960, NEW ENGL J MED, V262, P49, DOI 10.1056/NEJM196001142620201; MOELLERING RC, 1994, CLIN INFECT DIS, V18, P544, DOI 10.1093/clinids/18.4.544; PEETERMANS WE, 1990, ANTIMICROB AGENTS CH, V34, P1869, DOI 10.1128/AAC.34.10.1869; RODVOLD KA, 1987, CLIN PHARMACY, V6, P655; SORRELL TC, 1982, ANN INTERN MED, V97, P344, DOI 10.7326/0003-4819-97-3-344; TRABER PG, 1981, ANN INTERN MED, V95, P458, DOI 10.7326/0003-4819-95-4-458; VACANI PF, 1993, J CLIN PATHOL, V46, P890, DOI 10.1136/jcp.46.10.890; WAISBREN BA, 1960, ARCH INTERN MED, V106, P179, DOI 10.1001/archinte.1960.03820020019005	17	70	74	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 24	1994	344	8939-4					1748	1750		10.1016/S0140-6736(94)92890-8	http://dx.doi.org/10.1016/S0140-6736(94)92890-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7997005				2022-12-24	WOS:A1994PY28100013
J	STAEHLINGHAMPTON, K; HOFFMANN, FM; BAYLIES, MK; RUSHTON, E; BATE, M				STAEHLINGHAMPTON, K; HOFFMANN, FM; BAYLIES, MK; RUSHTON, E; BATE, M			DPP INDUCES MESODERMAL GENE-EXPRESSION IN DROSOPHILA	NATURE			English	Article							DORSAL VENTRAL AXIS; GERM LAYERS; CELL FATES; ACTIVIN-A; BOX GENES; PATTERN; EMBRYO; INDUCTION; HOMOLOG; MORPHOGENESIS	INDUCTIVE interactions between germ layers are an essential feature of the development of many organisms. In several species these interactions are mediated by members of the transforming growth factor-beta (TGF beta) family(1,2). In amphibians, different concentrations of activin can induce different types of mesoderm in the animal cap assay(3-5). In Drosophila, a member of the TGF beta family, decapentaplegic (dpp)(6,7), acts as an inductive signal. Midway through embryogenesis, dpp is expressed in the visceral mesoderm, and enhances the expression of the homeotic gene labial in the underlying midgut endoderm(8,9). Earlier in development, however, dpp expression is limited to the dorsal ectoderm(10). At this stage in development, thickveins, a dpp receptor(11-13), is expressed in the mesoderm(12,13), and this suggests that ectodermal dpp might not only be required for development of dorsal ectoderm(14,15), but could also act inductively to mediate pattern formation in the underlying mesoderm. Here we show, by expressing dpp ectopically in the ectoderm and mesoderm and by examining dpp null mutant embryos, that dpp regulates expression of mesodermal genes.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	University of Cambridge	STAEHLINGHAMPTON, K (corresponding author), UNIV WISCONSIN,MCARDLE LAB CANC RES,1400 UNIV AVE,MADISON,WI 53706, USA.			Hoffmann, F. Michael/0000-0002-2770-9656	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BATE M, 1993, CR ACAD SCI III-VIE, V316, P1055; BEER J, 1987, ROUX ARCH DEV BIOL, V196, P222, DOI 10.1007/BF00376346; BODMER R, 1990, DEVELOPMENT, V110, P661; BODMER R, 1993, DEVELOPMENT, V118, P719; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CASTELLIGAIR J, 1994, DEVELOPMENT, V120, P1983; GOMEZ MR, 1993, EMBO J, V12, P1121; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; MICHELSON AM, 1994, DEVELOPMENT, V120, P755; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; RAY RP, 1991, DEVELOPMENT, V113, P35; Seidel F, 1940, NATURWISSENSCHAFTEN, V28, P433, DOI 10.1007/BF01557878; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; WHARTON KA, 1993, DEVELOPMENT, V117, P807	29	174	176	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					783	786						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997266				2022-12-24	WOS:A1994PY21200054
J	REDEKER, V; LEVILLIERS, N; SCHMITTER, JM; LECAER, JP; ROSSIER, J; ADOUTTE, A; BRE, MH				REDEKER, V; LEVILLIERS, N; SCHMITTER, JM; LECAER, JP; ROSSIER, J; ADOUTTE, A; BRE, MH			POLYGLYCYLATION OF TUBULIN - A POSTTRANSLATIONAL MODIFICATION IN AXONEMAL MICROTUBULES	SCIENCE			English	Article							ALPHA-TUBULIN; BETA-TUBULIN; TERMINAL DOMAIN; CELLS; PARAMECIUM; BRAIN; DETYROSINATION; NUCLEATION; SUBTILISIN; PROTEINS	A posttranslational modification was detected in the carboxyl-terminal region of axonemal tubulin from Paramecium. Tubulin carboxyl-terminal peptides were isolated and analyzed by Edman degradation sequencing, mass spectrometry, and amino acid analysis. All of the peptides, derived from both alpha and beta tubulin subunits, were modified by polyglycylation, containing up to 34 glycyl units covalently bound to the gamma carboxyl group of glutamyl residues. This modification, present in one of the most stable microtubular systems, may influence microtubule stability or axoneme function, or both.	INST ALFRED FESSARD,CNRS,UNITE PROPRE RECH 2212,F-91198 GIF SUR YVETTE,FRANCE; UNIV PARIS 11,BIOL CELLULAIRE LAB 4,CNRS,URA 1134,F-91405 ORSAY,FRANCE; ECOLE POLYTECH,BIOCHIM LAB,CNRS,URA 240,F-91128 PALAISEAU,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)			Redeker, Virginie/L-8929-2018	Redeker, Virginie/0000-0003-2694-8388				ADOUTTE A, 1991, BIOL CELL, V71, P227, DOI 10.1016/0248-4900(91)90069-Y; ADOUTTE A, 1980, J CELL BIOL, V84, P717, DOI 10.1083/jcb.84.3.717; ADOUTTE A, 1985, J MOL EVOL, V22, P220, DOI 10.1007/BF02099751; ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; BRE MH, 1987, J CELL BIOL, V105, P1283, DOI 10.1083/jcb.105.3.1283; BRE MH, 1994, CELL MOTIL CYTOSKEL, V27, P327; BULINSKI JC, 1988, J CELL BIOL, V106, P1213, DOI 10.1083/jcb.106.4.1213; CALLEN AM, IN PRESS BIOL CELL; CANAS B, 1993, ANAL BIOCHEM, V211, P179, DOI 10.1006/abio.1993.1253; Dentler W.L., 1990, P31; DUPUIS P, 1992, EMBO J, V11, P3713, DOI 10.1002/j.1460-2075.1992.tb05456.x; DUPUIS P, 1992, THESIS U PARIS 11; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; FACKENTHAL JD, 1993, DEV BIOL, V158, P213, DOI 10.1006/dbio.1993.1180; Fleury A., UNPUB; GEUENS G, 1989, J CELL BIOL, V108, P939, DOI 10.1083/jcb.108.3.939; GEUSS U, 1990, Journal of Protein Chemistry, V9, P299; GREER K, 1989, CELL MOVEMENT, V2, P47; HAGIWARA H, 1994, J BIOL CHEM, V269, P3581; Johnson Karl A., 1993, Trends in Cell Biology, V3, P156, DOI 10.1016/0962-8924(93)90136-O; KHAWAJA S, 1988, J CELL BIOL, V106, P2167; LEDIZET M, 1987, P NATL ACAD SCI USA, V84, P5720, DOI 10.1073/pnas.84.16.5720; LEVILLIERS N, UNPUB; MARY J, 1994, FEBS LETT, V353, P89, DOI 10.1016/0014-5793(94)01018-8; MATSUBARA H, 1970, METHOD ENZYMOL, V19, P642; MEJILLANO MR, 1991, J BIOL CHEM, V266, P657; MELKI R, 1991, BIOCHEMISTRY-US, V30, P11536, DOI 10.1021/bi00113a008; PATURLELAFANECHERE L, 1991, BIOCHEMISTRY-US, V30, P10523, DOI 10.1021/bi00107a022; PIPERNO G, 1977, P NATL ACAD SCI USA, V74, P1600, DOI 10.1073/pnas.74.4.1600; RAYBIN D, 1977, J CELL BIOL, V73, P492, DOI 10.1083/jcb.73.2.492; REDEKER V, 1991, J BIOL CHEM, V266, P23461; REDEKER V, 1992, FEBS LETT, V313, P185, DOI 10.1016/0014-5793(92)81441-N; RUDIGER M, 1993, EUR J BIOCHEM, V218, P107, DOI 10.1111/j.1432-1033.1993.tb18357.x; RUDIGER M, 1992, FEBS LETT, V308, P101, DOI 10.1016/0014-5793(92)81061-P; SACKETT DL, 1989, BIOCHEMISTRY-US, V28, P2662, DOI 10.1021/bi00432a045; SCHULZE E, 1987, J CELL BIOL, V105, P1020; SERRANO L, 1984, P NATL ACAD SCI-BIOL, V81, P5989, DOI 10.1073/pnas.81.19.5989; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; WEHLAND J, 1987, J CELL SCI, V88, P185	39	220	229	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1688	1691		10.1126/science.7992051	http://dx.doi.org/10.1126/science.7992051			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992051				2022-12-24	WOS:A1994PW30800035
J	BENEDETTI, J; COREY, L; ASHLEY, R				BENEDETTI, J; COREY, L; ASHLEY, R			RECURRENCE RATES IN GENITAL HERPES AFTER SYMPTOMATIC FIRST-EPISODE INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						CARDIAC PACING, ARTIFICIAL; PACEMAKER, ARTIFICIAL; SENSORS, ARTIFICIAL; HEART RATE; ARRHYTHMIA	SIMPLEX VIRUS-INFECTION; CANADIAN MULTICENTER TRIAL; ORAL ACYCLOVIR; DOUBLE-BLIND; INTRAVENOUS ACYCLOVIR; TYPE-2 INFECTION; TRANSMISSION; SUPPRESSION; ANTIBODIES; THERAPY	Objective: To evaluate the frequency of reactivation of genital herpes infection and to identify predictors for recurrence. Design: Prospective, observational cohort study. Setting: Research clinic. Patients: 457 consecutive patients who did not have acute-phase serum antibodies to herpes simplex virus type 2 (HSV-2) but who did have herpes simplex vines (HSV) isolated from genital lesions. Results: Eighty-nine percent of patients with HSV-2 had at least one recurrence during follow-up (median, 391 days); the median monthly recurrence rate was 0.34. Thirty-eight percent had at least 6 recurrences during the first year and 20% had more than 10 recurrences. The median monthly recurrence rate was 0.43 for men and 0.33 for women (difference, 0.10 [95% CI, 0.03 to 0.19]; P < 0.01). Twenty-six percent of women and 8% of men had no or 1 recurrence in year 1 of follow-up, whereas 14% of women and 26% of men had more than 10 recurrences. Patients who had severe primary HSV-2 infection (duration, greater than or equal to 35 days) had recurrences nearly twice as often (0.66 compared with 0.36 recurrences per month [95% CI, 0.18 to 0.57]) and had a shorter time to first recurrence when compared with those who had shorter first episodes. Conclusions: Almost all persons with initially symptomatic HSV-2 infection have symptomatic recurrences. More than 35% of such patients have frequent recurrences. Recurrence rates are especially high in persons with an extended first episode of infection, regardless of whether they receive antiviral chemotherapy with acyclovir. Men with genital HSV-2 infection have about 20% more recurrences than do women, a factor that may contribute to the higher rate of HSV-2 transmission from men to women than from women to men and to the continuing epidemic of genital herpes in the United States.	UNIV WASHINGTON, DIV VIROL, SEATTLE, WA 98144 USA	University of Washington; University of Washington Seattle			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NIAID NIH HHS [AI-30731, AI-30619] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030619, P01AI030731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY R, 1991, ANN INTERN MED, V115, P520, DOI 10.7326/0003-4819-115-7-520; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; ASHLEY RL, 1993, SEX TRANSM DIS, V20, P230, DOI 10.1097/00007435-199307000-00009; BERNSTEIN DI, 1984, AM J MED, V77, P1055, DOI 10.1016/0002-9343(84)90188-8; BOUCHER FD, 1990, PEDIATR INFECT DIS J, V9, P499, DOI 10.1097/00006454-199007000-00009; Breiman L, 1983, CLASSIFICATION REGRE; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; BRYSON YJ, 1983, NEW ENGL J MED, V308, P916, DOI 10.1056/NEJM198304213081602; BURKE RL, 1991, VIROLOGY, V181, P793; CHRISTENSON B, 1992, J INFECTION, V25, P147, DOI 10.1016/0163-4453(92)93943-K; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; COREY L, 1978, NEW ENGL J MED, V299, P986, DOI 10.1056/NEJM197811022991805; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1983, ANN INTERN MED, V98, P973, DOI 10.7326/0003-4819-98-6-973; COREY L, 1983, ANN INTERN MED, V98, P914, DOI 10.7326/0003-4819-98-6-914; COREY L, 1982, NEW ENGL J MED, V306, P1313, DOI 10.1056/NEJM198206033062201; COX DR, 1972, J R STAT SOC B, V34, P187; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; FRENKEL LM, 1993, ANN INTERN MED, V118, P414, DOI 10.7326/0003-4819-118-6-199303150-00003; JOHNSON R, 1993, US GENITAL HERPES TR; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LAFFERTY WE, 1984, ANTIMICROB AGENTS CH, V26, P887, DOI 10.1128/AAC.26.6.887; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; LEBLANC M, 1992, BIOMETRICS, V48, P411, DOI 10.2307/2532300; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1984, JAMA-J AM MED ASSOC, V252, P1147, DOI 10.1001/jama.252.9.1147; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MINDEL A, 1987, LANCET, V1, P1171; MINDEL A, 1982, LANCET, V1, P697; NAHMIAS AJ, 1990, SCAND J INFECT DIS, P19; NILSEN AE, 1982, LANCET, V2, P571; SACKS SL, 1991, J INFECT DIS, V164, P665, DOI 10.1093/infdis/164.4.665; SACKS SL, 1987, J INFECT DIS, V155, P178, DOI 10.1093/infdis/155.2.178; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401	35	305	312	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					847	854		10.7326/0003-4819-121-11-199412010-00004	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978697				2022-12-24	WOS:A1994PT62800004
J	LAZARO, C; RAVELLA, A; GAONA, A; VOLPINI, V; ESTIVILL, X				LAZARO, C; RAVELLA, A; GAONA, A; VOLPINI, V; ESTIVILL, X			NEUROFIBROMATOSIS TYPE-1 DUE TO GERM-LINE MOSAICISM IN A CLINICALLY NORMAL FATHER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VONRECKLINGHAUSEN NEUROFIBROMATOSIS; GONADAL MOSAICISM; MUTATION-RATE; NF1 GENE; DELETION; SEQUENCE; POLYMORPHISM; REPEAT; FAMILY; IV	Background. The mutation rate of the neurofibromatosis type 1 (NF1) gene is one of the highest in the human genome, with about 50 percent of cases being due to new mutations. We describe a family in which neurofibromatosis type 1 occurred in two siblings with clinically normal parents, and we demonstrate germ-line mosaicism in the father. Methods. We studied lymphocyte DNA from each member of the family and the father's spermatozoa for several polymorphic intragenic markers of the NF1 gene. Southern blots of DNA digested with several enzymes were hybridized with complementary DNA and individual NF1 exon probes to search for alterations in the gene. Results. The affected siblings, with a clinically severe form of neurofibromatosis type 1, showed no inheritance of paternal alleles for a marker in intron 38 of the NF1 gene, whereas they received alleles from both parents for other NF1 markers. Analysis with probes from this region of the NF1 gene showed a 12-kb deletion of the NF1 gene, involving exons 32 to 39, in the affected offspring. Ten percent of the father's spermatozoa carried the same NF1 deletion, but the abnormality was not detected in DNA from his lymphocytes. Conclusions. The presence of the NF1 mutation in 10 percent of the clinically normal father's spermatozoa supports the hypothesis that most germ-line mutations occur in precursors of gametes. In cases of spontaneous mutation, analyzing the specific NF1 mutation in the father's sperm might help in the detection of mosaicism and thus facilitate genetic counseling about further pregnancies.	LHOSP LLOBREGAT, HOSP DURAN & REYNALS, INST RECERCA ONCOL, DEPT MOLEC GENET, E-08907 BARCELONA, SPAIN; HOSP CREU ROJA DE BARCELONA, BARCELONA, SPAIN; HOSP CLIN BARCELONA, GENET SERV, E-08036 BARCELONA, SPAIN	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; University of Barcelona; Hospital Clinic de Barcelona			Estivill, Xavier/A-3125-2013; GARCIA, CONXI LAZARO/Q-2410-2016	Estivill, Xavier/0000-0002-0723-2256; GARCIA, CONXI LAZARO/0000-0002-7198-5906				ALLANSON JE, 1986, CLIN GENET, V29, P429; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BAKKER E, 1987, NATURE, V329, P554, DOI 10.1038/329554a0; BRADLEY TB, 1980, JOHNS HOPKINS MED J, V146, P236; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CAREY JC, 1986, ANN NY ACAD SCI, V486, P45, DOI 10.1111/j.1749-6632.1986.tb48061.x; CAWTHON, 1990, CELL, V62, P609; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; FRYNS JP, 1983, CLIN GENET, V24, P156; FUENTES JJ, 1993, INT J LEGAL MED, V105, P271, DOI 10.1007/BF01370384; GITSCHIER J, 1989, LANCET, V1, P273; HALL JG, 1988, AM J HUM GENET, V43, P355; HALL JG, 1987, AM J MED GENET, V28, P143, DOI 10.1002/ajmg.1320280121; HUSON SM, 1989, J MED GENET, V26, P704, DOI 10.1136/jmg.26.11.704; JADAYEL D, 1990, NATURE, V343, P558, DOI 10.1038/343558a0; LAZARO C, 1993, HUM GENET, V92, P429, DOI 10.1007/BF01247353; LAZARO C, 1993, HUM MOL GENET, V2, P725, DOI 10.1093/hmg/2.6.725; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; MADDALENA A, 1988, NEW ENGL J MED, V319, P999, DOI 10.1056/NEJM198810133191507; MILEWICZ DM, 1993, AM J HUM GENET, V53, P62; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MURRAY EW, 1992, AM J HUM GENET, V50, P199; RICCARDI VM, 1988, AM J HUM GENET, V42, P284; RICCARDI VM, 1986, NEUROIBROMATOSIS PHE; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SERGEYEV AS, 1975, HUMANGENETIK, V28, P129, DOI 10.1007/BF00735745; SOLERA J, 1992, AM J HUM GENET, V50, P434; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WALLACE MR, 1990, SCIENCE, V250, P1749; XU GF, 1991, NUCLEIC ACIDS RES, V19, P3764, DOI 10.1093/nar/19.13.3764; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	34	115	121	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1403	1407		10.1056/NEJM199411243312102	http://dx.doi.org/10.1056/NEJM199411243312102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7969279				2022-12-24	WOS:A1994PU53300002
J	MILLARD, PS; GENSHEIMER, KF; ADDISS, DG; SOSIN, DM; BECKETT, GA; HOUCKJANKOSKI, A; HUDSON, A				MILLARD, PS; GENSHEIMER, KF; ADDISS, DG; SOSIN, DM; BECKETT, GA; HOUCKJANKOSKI, A; HUDSON, A			AN OUTBREAK OF CRYPTOSPORIDIOSIS FROM FRESH-PRESSED APPLE CIDER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DAY-CARE-CENTER; TRANSMISSION; COMMUNITY; SYMPTOMS; GEORGIA; GIARDIA; DISEASE; OOCYSTS	Background.-Recent waterborne outbreaks have established Cryptosporidium as an emerging enteric pathogen, but foodborne transmission has rarely been reported. In October 1993, an outbreak of cryptosporidiosis occurred among students and staff attending a 1-day school agricultural fair in central Maine. Design.-Environmental/laboratory investigation and cohort study. Participants.-Attendees of the fair and their household members. Main Outcome Measures.-Clinical or laboratory-confirmed cryptosporidiosis. Clinical cryptosporidiosis was defined as 3 days of either diarrhea (three loose stools in a 24-hour period) or vomiting. Results.-Surveys were completed for 611 (81%) of the estimated 759 fair attendees. Among attendees who completed the survey, there were 160 (26%) primary cases. Cryptosporidium oocysts were detected in the stools of 50 (89%) of 56 primary and secondary case patients tested. The median incubation period was 6 days (range, 10 hours to 13 days); the median duration of illness was 6 days (range, 1 to 16 days). Eighty-four percent of primary case patients had diarrhea and 82% had vomiting. Persons drinking apple cider that was hand pressed in the afternoon were at increased risk for cryptosporidiosis (154 [54%] of 284 exposed vs six [2%] of 292 unexposed; relative risk, 26; 95% confidence interval, 12 to 59). Cryptosporidium oocysts were detected in the apple cider, on the cider press, and in the stool specimen of a calf on the farm that supplied the apples. The secondary household transmission rate was 15% (53/353). Conclusions.-This is the first large cryptosporidiosis outbreak in which foodborne transmission has been documented. It underscores the need for agricultural producers to take measures to avoid contamination of foodstuffs with infectious agents common to the farm environment.	MAINE BUR HLTH, DIV DIS CONTROL, AUGUSTA, ME 04333 USA; CTR DIS CONTROL & PREVENT, EPIDEMIOL PROGRAM OFF, DIV FIELD EPIDEMIOL, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, EPIDEMIOL PROGRAM OFF, EPIDEM INTELLIGENCE SERV, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV PARASIT DIS, ATLANTA, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA				Hudson, Arlene/0000-0003-3980-4383				ADDISS DG, 1991, PEDIATR INFECT DIS J, V10, P907, DOI 10.1097/00006454-199112000-00005; ALPERT G, 1986, PEDIATRICS, V77, P152; ANDERSON BC, 1985, AM J PUBLIC HEALTH, V75, P1433, DOI 10.2105/AJPH.75.12.1433; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; CAMPBELL I, 1982, VET REC, V111, P414, DOI 10.1136/vr.111.18.414; CASEMORE DP, 1990, EPIDEMIOL INFECT, V104, P1, DOI 10.1017/S0950268800054480; CASEMORE DP, 1990, LANCET, V336, P1427, DOI 10.1016/0140-6736(90)93115-6; CASEMORE DP, 1993, LANCET, V342, P312, DOI 10.1016/0140-6736(93)91863-H; COMBEE CL, 1986, PEDIATR INFECT DIS J, V5, P528, DOI 10.1097/00006454-198609000-00008; CURRENT WL, 1991, CLIN MICROBIOL REV, V4, P325, DOI 10.1128/CMR.4.3.325-358.1991; DANTONIO RG, 1985, ANN INTERN MED, V103, P886, DOI 10.7326/0003-4819-103-6-886; EGGER M, 1990, ARCH DIS CHILD, V65, P445, DOI 10.1136/adc.65.4.445; FREIDANK H, 1987, EUR J CLIN MICROBIOL, V6, P56, DOI 10.1007/BF02097194; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; JOKIPII L, 1986, NEW ENGL J MED, V315, P1643, DOI 10.1056/NEJM198612253152604; KOCH KL, 1985, ANN INTERN MED, V102, P593, DOI 10.7326/0003-4819-102-5-593; LELAND D, 1993, J AM WATER WORKS ASS, V85, P34; LENGERICH EJ, 1993, J INFECT DIS, V167, P1252, DOI 10.1093/infdis/167.5.1252; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MILLER RA, 1990, J INFECT DIS, V161, P312, DOI 10.1093/infdis/161.2.312; MIRON D, 1991, PEDIATR INFECT DIS J, V10, P438, DOI 10.1097/00006454-199106000-00004; NEWMAN RD, 1994, ANN INTERN MED, V120, P500, DOI 10.7326/0003-4819-120-6-199403150-00009; PALMER SR, 1990, BRIT MED J, V300, P774, DOI 10.1136/bmj.300.6727.774; Romanova T. V., 1992, Meditsinskaya Parazitologiya i Parazitarnye Bolezni, V0, P50; SHIELD J, 1990, J INFECTION, V21, P297, DOI 10.1016/0163-4453(90)94053-3; SMITH JL, 1993, J FOOD PROTECT, V56, P451, DOI 10.4315/0362-028X-56.5.451; STEHRGREEN JK, 1987, AM J TROP MED HYG, V36, P338, DOI 10.4269/ajtmh.1987.36.338; TANGERMANN RH, 1991, AM J EPIDEMIOL, V133, P471, DOI 10.1093/oxfordjournals.aje.a115914; UNGAR BLP, 1990, CRYPTOSPORIDIOSIS MA; 1975, MMWR-MORBID MORTAL W, V24, P87; 1993, MANUAL MASSACHUSETTS; 1992, EMERGING INFECTIONS; 1994, MMWR-MORBID MORTAL W, V42, P1; 1990, SAS RELEASE 6 03	35	224	240	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1592	1596		10.1001/jama.272.20.1592	http://dx.doi.org/10.1001/jama.272.20.1592			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR405	7966869				2022-12-24	WOS:A1994PR40500025
J	NIGHTINGALE, SL				NIGHTINGALE, SL			DEATHS ASSOCIATED WITH ALLERGENIC EXTRACTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1994, FDA MED B, P24	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1488	1488						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966836				2022-12-24	WOS:A1994PQ90000022
J	LLOYD, AM; SCHENA, M; WALBOT, V; DAVIS, RW				LLOYD, AM; SCHENA, M; WALBOT, V; DAVIS, RW			EPIDERMAL-CELL FATE DETERMINATION IN ARABIDOPSIS - PATTERNS DEFINED BY A STEROID-INDUCIBLE REGULATOR	SCIENCE			English	Article							MAMMALIAN GLUCOCORTICOID RECEPTOR; GENE; EXPRESSION; TRANSFORMATION; DROSOPHILA; SYSTEM; TRANSCRIPTION; SUPERFAMILY; HOMOLOGY; PROTEINS	The Arabidopsis mutant ttg lacks both trichomes (epidermal hairs) and anthocyanin pigments. Trichomes and anthocyanins are restored by the constitutive expression of the maize transcriptional regulator (R). The expression of an R-glucocorticoid receptor chimeric protein results in a steroid hormone-dependent, conditional allele of R that functions in whole Arabidopsis plants. The response of the chimeric protein to pulses of hormone was used to define the pattern ana timing of trichome formation on the developing leaf epidermis. Each adaxial epidermal leaf cell appears to have an equal probability of differentiating into a trichome; there is a temporal zone of decision for trichome cell fate that proceeds as a wave from the tip to the base of developing leaves.	STANFORD UNIV,DEPT SCI BIOL,STANFORD,CA 94305	Stanford University	LLOYD, AM (corresponding author), STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305, USA.			Walbot, Virginia/0000-0002-1596-7279	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32422] Funding Source: Medline; PHS HHS [R37-H600198] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; DRUMMHERREL H, 1981, PHOTOCHEM PHOTOBIOL, V33, P391, DOI 10.1111/j.1751-1097.1981.tb05435.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; GALWAY ME, IN PRESS DEV BIOL; GOFF SA, 1992, GENE DEV, V6, P864, DOI 10.1101/gad.6.5.864; HELD LI, 1991, BIOESSAYS, V13, P633, DOI 10.1002/bies.950131203; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; HULSKAMP M, 1994, CELL, V76, P555, DOI 10.1016/0092-8674(94)90118-X; Koornneef M., 1981, ARABID INF SERV, V18, P45; Koornneef M., 1990, ARABIDOPSIS INFO SER, V27, P1; KORN RW, 1981, DEV BIOL, V88, P115, DOI 10.1016/0012-1606(81)90223-2; LARKIN JC, 1993, PLANT CELL, V5, P1739, DOI 10.1105/tpc.5.12.1739; LLOYD AL, UNPUB; LLOYD AM, 1992, SCIENCE, V258, P1173; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; LUDWIG SR, 1990, SCIENCE, V247, P449, DOI 10.1126/science.247.4941.449; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; POWER RF, 1992, TRENDS PHARMACOL SCI, V13, P318, DOI 10.1016/0165-6147(92)90099-R; QUATTROCCHIO F, 1993, PLANT CELL, V5, P1497, DOI 10.1105/tpc.5.11.1497; ROTH BA, 1991, PLANT CELL, V3, P317, DOI 10.1105/tpc.3.3.317; SAMUELS HH, 1970, J MOL BIOL, V52, P57, DOI 10.1016/0022-2836(70)90177-4; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; SCHENA M, 1991, P NATL ACAD SCI USA, V88, P10421, DOI 10.1073/pnas.88.23.10421; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WILLIAMS MH, 1988, PROTOPLASMA, V147, P77, DOI 10.1007/BF01403879; YOSHINAGA SK, 1991, MOL ENDOCRINOL, V5, P844, DOI 10.1210/mend-5-6-844	33	203	215	2	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					436	439		10.1126/science.7939683	http://dx.doi.org/10.1126/science.7939683			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939683				2022-12-24	WOS:A1994PN27200035
J	REESE, JC; APONE, L; WALKER, SS; GRIFFIN, LA; GREEN, MR				REESE, JC; APONE, L; WALKER, SS; GRIFFIN, LA; GREEN, MR			YEAST TAF(II)S IN A MULTISUBUNIT COMPLEX REQUIRED FOR ACTIVATED TRANSCRIPTION	NATURE			English	Article							TATA-BINDING PROTEIN; POLYMERASE-II TRANSCRIPTION; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; DNA; SUBUNIT; INVITRO; GENE; TBP	IN higher eukaryotes the RNA polymerase II transcription factor TFIID is composed of a TATA-box-binding protein (TBP) and a set of tightly bound polypeptides, designated TBP-associated fao tors (TAF(II)s). One or more TAF(II)s are coactivators that are required for activated but not basal transcription(1-3). The eukaryotic transcription machinery is highly conserved and it is therefore puzzling that TAF(II)s have aot been identified in yeast. Here we use TBP as a protein-affinity ligand to isolate from yeast a multi-subunit complex that is required specifically for activated transcription by RNA polymerase II. Microsequence analysis and cloning of two subunits of this complex reveal that they are the homologues of known mammalian and Drosophila TAF(II)s. The genes encoding these two yeast TAF(II)s are essential, suggesting that activated transcription is required for viability of Saccharomyces cerevisiae.			REESE, JC (corresponding author), UNIV MASSACHUSETTS, MED CTR, HOWARD HUGHES MED INST, PROGRAM MOLEC MED, 373 PLANTAT ST, WORCESTER, MA 01605 USA.			reese, joseph/0000-0003-3578-4266				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; POON D, 1993, J BIOL CHEM, V268, P15325; PUGH BF, 1992, J BIOL CHEM, V267, P679; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	22	155	158	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	1994	371	6497					523	527		10.1038/371523a0	http://dx.doi.org/10.1038/371523a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935765				2022-12-24	WOS:A1994PK58900058
J	SAWADA, S; SCARBOROUGH, JD; KILLEEN, N; LITTMAN, DR				SAWADA, S; SCARBOROUGH, JD; KILLEEN, N; LITTMAN, DR			A LINEAGE-SPECIFIC TRANSCRIPTIONAL SILENCER REGULATES CD4 GENE-EXPRESSION DURING T-LYMPHOCYTE DEVELOPMENT	CELL			English	Article							CELL-SPECIFIC ENHANCER; TRANSGENIC MICE; EUKARYOTIC PROMOTERS; HOMEODOMAIN PROTEIN; NEGATIVE REGULATION; DROSOPHILA; REPRESSION; YEAST; ELEMENTS; IDENTIFICATION	During development of T lymphocytes, differential regulation of expression of the CD4 and CD8 glycoproteins is coupled to the choice of one of two pathways of differentiation. Thymocytes that express both of these coreceptors commit to either the helper lineage, shutting off CD8, or the cytotoxic lineage, shutting off CD4. We have used transgenic mice to identify an intronic regulatory region that controls CD4 gene expression during development. This region selectively extinguishes transgene expression in CD4(-)CD8(+), but not CD4(+)CD8(-) nor CD4(+)CD8(+) T cells. It also represses gene expression in CD4-CD8- immature thymocytes, indicating that the CD4 gene is derepressed during differentiation from the CD4(-)CD8(-) to the CD4(+)CD8(+) stage. The negative element(s) is both orientation and position independent and acts also on heterologous regulatory sequences. Its properties are functionally similar to those of silencers described in yeast and in Drosophila, suggesting that we have identified a developmentally regulated vertebrate transcriptional silencer.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	SAWADA, S (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA.							BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; Bienz Mariann, 1992, Current Opinion in Cell Biology, V4, P955, DOI 10.1016/0955-0674(92)90124-U; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BLUM MD, 1993, J EXP MED, V177, P1343, DOI 10.1084/jem.177.5.1343; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; FRELS W I, 1990, New Biologist, V2, P1024; GEORGOPOULOS K, 1988, EMBO J, V7, P2401, DOI 10.1002/j.1460-2075.1988.tb03085.x; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; HANNA Z, 1994, MOL CELL BIOL, V14, P1084, DOI 10.1128/MCB.14.2.1084; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HOGAN B, 1986, MANIPULATING MOUSE E, P153; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; ISHIDA I, 1990, P NATL ACAD SCI USA, V87, P3067, DOI 10.1073/pnas.87.8.3067; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KILLEEN N, 1993, PHILOS T ROY SOC B, V342, P25, DOI 10.1098/rstb.1993.0131; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LAUSTER R, 1993, EMBO J, V12, P4615, DOI 10.1002/j.1460-2075.1993.tb06150.x; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LOCKER J, 1993, GENE TRANSCRIPTION P, P321; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MULLER J, 1992, EMBO J, V11, P3653, DOI 10.1002/j.1460-2075.1992.tb05450.x; OHKUMA Y, 1990, CELL, V61, P475, DOI 10.1016/0092-8674(90)90529-N; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; RAICH N, 1992, BLOOD, V79, P861; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; SANDS JF, 1992, INT IMMUNOL, V4, P1183, DOI 10.1093/intimm/4.10.1183; SAWADA S, 1991, MOL CELL BIOL, V11, P5506, DOI 10.1128/MCB.11.11.5506; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SAYRE PH, 1987, P NATL ACAD SCI USA, V84, P2941, DOI 10.1073/pnas.84.9.2941; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X	54	360	368	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					917	929		10.1016/0092-8674(94)90140-6	http://dx.doi.org/10.1016/0092-8674(94)90140-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004678				2022-12-24	WOS:A1994NT33100016
J	PLATT, OS; BRAMBILLA, DJ; ROSSE, WF; MILNER, PF; CASTRO, O; STEINBERG, MH; KLUG, PP				PLATT, OS; BRAMBILLA, DJ; ROSSE, WF; MILNER, PF; CASTRO, O; STEINBERG, MH; KLUG, PP			MORTALITY IN SICKLE-CELL DISEASE - LIFE EXPECTANCY AND RISK-FACTORS FOR EARLY DEATH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-GLOBIN GENE; FAT-EMBOLISM; PAIN CRISIS; CHILDREN; THALASSEMIA; ANEMIA	Background. Information on life expectancy and risk factors for early death among patients with sickle cell disease (sickle cell anemia, sickle cell-hemoglobin C disease, and the sickle cell-P-thalassemias) is needed to counsel patients, target therapy, and design clinical trials. Methods. We followed 3764 patients who ranged from birth to 66 years of age at enrollment to determine the life expectancy and calculate the median age at death. In addition, we investigated the circumstances of death for all 209 adult patients who died during the study, and used proportional-hazards regression analysis to identify risk factors for early death among 964 adults with sickle cell anemia who were followed for at least two years. Results. Among children and adults with sickle cell anemia (homozygous for sickle hemoglobin), the median age at death was 42 years for males and 48 years for females. Among those with sickle cell-hemoglobin C disease, the median age at death was 60 years for males and 68 years for females. Among adults with sickle cell disease, 18 percent of the deaths occurred in patients with overt organ failure, predominantly renal. Thirty-three percent were clinically free of organ failure but died during an acute sickle crisis (78 percent had pain, the chest syndrome, or both; 22 percent had stroke). Modeling revealed that in patients with sickle cell anemia, the acute chest syndrome, renal failure, seizures, a base-line white-cell count above 15,000 cells per cubic millimeter, and a low level of fetal hemoglobin were associated with an increased risk of early death. Conclusions. Fifty percent of patients with sickle cell anemia survived beyond the fifth decade. A large proportion of those who died had no overt chronic organ failure but died during an acute episode of pain, chest syndrome, or stroke. Early mortality was highest among patients whose disease was symptomatic. A high level of fetal hemoglobin predicted improved survival and is probably a reliable childhood forecaster of adult life expectancy.	CHILDRENS HOSP,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; NEW ENGLAND RES INST,WATERTOWN,MA; DUKE UNIV,SCH MED,DEPT MED,DURHAM,NC 27706; MED COLL GEORGIA,DEPT MED,AUGUSTA,GA 30912; HOWARD UNIV,CTR SICKLE CELL DIS,DEPT MED,WASHINGTON,DC; DEPT VET AFFAIRS MED CTR,HEMATOL ONCOL SECT,JACKSON,MS; UNIV MISSISSIPPI,SCH MED,DEPT MED,JACKSON,MS; TEXAS TECH UNIV,HLTH SCI CTR,DIV HEMATOL,AMARILLO,TX	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; HealthCore, Inc; Duke University; University System of Georgia; Augusta University; Howard University; University of Mississippi; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo				Steinberg, Martin/0000-0001-8800-8020; Brambilla, Donald/0000-0002-7276-4689				CHARACHE S, 1967, ANN INTERN MED, V67, P1195, DOI 10.7326/0003-4819-67-6-1195; CNAAN A, 1989, STAT MED, V8, P1255, DOI 10.1002/sim.4780081009; COLE TB, 1986, AM J DIS CHILD, V140, P1255, DOI 10.1001/archpedi.1986.02140260057025; DACIE J, 1960, HAEMOLYTIC ANAEMIA 1; DELABRY LO, 1990, J CLIN EPIDEMIOL, V43, P153, DOI 10.1016/0895-4356(90)90178-R; Diggs LMAH., 1973, SICKLE CELL DIS DIAG; DIXON WJ, 1992, BMDP STATISTICAL SOF, V2; DOZY AM, 1979, NATURE, V280, P605, DOI 10.1038/280605a0; EMBURY SH, 1980, J CLIN INVEST, V66, P1319, DOI 10.1172/JCI109984; GASTON M, 1982, AM J PEDIAT HEMATOL, V4, P197; HAUPT HM, 1982, CHEST, V81, P332, DOI 10.1378/chest.81.3.332; HUTCHINSON RM, 1973, J CLIN PATHOL, V26, P620, DOI 10.1136/jcp.26.8.620; LEIKIN SL, 1989, PEDIATRICS, V84, P500; ODENHEIMER DJ, 1984, AM J MED GENET, V18, P461, DOI 10.1002/ajmg.1320180316; PARFREY NA, 1985, AM J CLIN PATHOL, V84, P209, DOI 10.1093/ajcp/84.2.209; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; POWARS D, 1990, SEMIN HEMATOL, V27, P360; SHAPIRO MP, 1984, ARCH INTERN MED, V144, P181, DOI 10.1001/archinte.144.1.181; STEINBERG MH, 1984, BLOOD, V63, P1353; THOMAS AN, 1982, BRIT MED J, V285, P633, DOI 10.1136/bmj.285.6342.633; 1988, DHHS PHS881101 PUBL	21	2191	2252	4	201	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	1994	330	23					1639	1644		10.1056/NEJM199406093302303	http://dx.doi.org/10.1056/NEJM199406093302303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP220	7993409				2022-12-24	WOS:A1994NP22000003
J	KIM, JS; URBAN, RG; STROMINGER, JL; WILEY, DC				KIM, JS; URBAN, RG; STROMINGER, JL; WILEY, DC			TOXIC SHOCK SYNDROME TOXIN-1 COMPLEXED WITH A CLASS-II MAJOR HISTOCOMPATIBILITY MOLECULE HLA-DR1	SCIENCE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-B; HIGH-AFFINITY BINDING; RECEPTOR BETA-CHAIN; HLA-DR; T-CELLS; MACROMOLECULAR CRYSTALLOGRAPHY; PROTEIN STRUCTURES; SUPERANTIGEN; ANTIGEN; IDENTIFICATION	The three-dimensional structure of a Staphylococcus aureus superantigen, toxic shock syndrome toxin-1 (TSST-1), complexed with a human class II major histocompatibility molecule (DR1), was determined by x-ray crystallography. The TSST-1 binding site on DR1 overlaps that of the superantigen S. aureus enterotoxin B (SEB), but the two binding modes differ. Whereas SEB binds primarily off one edge of the peptide binding site of DR1, TSST-1 extends over almost one-half of the binding site and contacts both the flanking alpha helices of the histocompatibility antigen and the bound peptide. This difference suggests that the T cell receptor (TCR) would bind to TSST-1:DR1 very differently than to DR1:peptide or SEB:DR1. It also suggests that TSST-1 binding may be dependent on the peptide, though less so than TCR binding, providing a possible explanation for the inability of TSST-1 to competitively block SEB binding to all DR1 molecules on cells (even though the binding sites of TSST-1 and SEB on DR1 overlap almost completely) and suggesting the possibility that T cell activation by superantigen could be directed by peptide antigen.	CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; CHILDRENS HOSP, MOLEC MED LAB, BOSTON, MA 02115 USA; HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University								ACHARYA KR, 1994, NATURE, V367, P94, DOI 10.1038/367094a0; BETHGE PH, 1984, J APPL CRYSTALLOGR, V17, P215, DOI 10.1107/S0021889884011365; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLANCO L, 1990, INFECT IMMUN, V58, P3020, DOI 10.1128/IAI.58.9.3020-3028.1990; BONVENTRE PF, 1993, INFECT IMMUN, V61, P793, DOI 10.1128/IAI.61.3.793-799.1993; BRAUNSTEIN NS, 1992, J EXP MED, V175, P1301, DOI 10.1084/jem.175.5.1301; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHINTAGUMPALA MM, 1991, J IMMUNOL, V147, P3876; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; EDWIN C, 1991, J INFECT DIS, V163, P524, DOI 10.1093/infdis/163.3.524; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; FLEISCHER B, 1991, EUR J IMMUNOL, V21, P1331, DOI 10.1002/eji.1830210537; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; GORGA JC, 1987, J BIOL CHEM, V262, P16087; HUDSON KR, COMMUNICATION; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KARP DR, 1990, NATURE, V346, P474, DOI 10.1038/346474a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MURRAY DL, 1993, 93RD GEN M AM SOC MI, V64; PANINABORDIGNON P, 1992, J EXP MED, V176, P1779, DOI 10.1084/jem.176.6.1779; PRASAD GS, 1993, BIOCHEMISTRY-US, V32, P13762, DOI 10.1021/bi00213a001; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1991, J EXP MED, V173, P1183, DOI 10.1084/jem.173.5.1183; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHOLL PR, 1989, J IMMUNOL, V143, P2583; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; SOOS JM, 1993, BIOCHEM BIOPH RES CO, V191, P1211, DOI 10.1006/bbrc.1993.1346; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; THIBODEAU J, 1994, SCIENCE, V266, P1874, DOI 10.1126/science.7997881; THIBODEAU J, 1994, J EXP MED, V179, P1029, DOI 10.1084/jem.179.3.1029; WANG BC, 1985, METHOD ENZYMOL, V115, P90	44	249	258	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 16	1994	266	5192					1870	1874		10.1126/science.7997880	http://dx.doi.org/10.1126/science.7997880			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997880				2022-12-24	WOS:A1994PX38300037
J	VARTIVARIAN, SE; PAPADAKIS, KA; PALACIOS, JA; MANNING, JT; ANAISSIE, EJ				VARTIVARIAN, SE; PAPADAKIS, KA; PALACIOS, JA; MANNING, JT; ANAISSIE, EJ			MUCOCUTANEOUS AND SOFT-TISSUE INFECTIONS CAUSED BY XANTHOMONAS-MALTOPHILIA - A NEW SPECTRUM	ANNALS OF INTERNAL MEDICINE			English	Article							GRAM-NEGATIVE BACILLI; PSEUDOMONAS-MALTOPHILIA	Objective: To describe the mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia in patients with cancer. Design: A retrospective 15-month clinical study. Setting: Academic, referral-based cancer center. Patients: Of 237 patients with X. maltophilia isolated from all sites during the 15-month study period, 114 patients were judged to have true X. maltophilia infections. Only patients with mucocutaneous and soft tissue infections were included in the study. Results: 17 (15%) of the 114 patients with X. maltophilia infection had mucocutaneous and soft tissue infections: Six patients had metastatic cellulitis, 5 had primary cellulitis usually associated with catheter use, and 6 had infected mucocutaneous ulcers. The metastatic cellulitis consisted of previously undescribed multiple, hard, tender nodules with surrounding and distant cellulitis (5 patients) or ecthyma gangrenosum (1 patient). Four of these patients died of the infection. Metastatic cellulitis and mucocutaneous infections occurred in hospitalized, neutropenic patients who received broad-spectrum antibiotics (beta-lactams, quinolones), often with in vitro activity against the infecting organisms. Response usually correlated with recovery from myelosuppression and administration of trimethoprim-sulfamethoxazole with or without ticarcillin-clavulanate. Catheter removal contributed to response in the treatment of primary cellulitis. Conclusions: Mucocutaneous and soft tissue infections caused by X. maltophilia are not uncommon, and X. maltophilia can cause metastatic nodular skin lesions that mimic disseminated fungal infections. It also causes serious morbidity and high mortality in patients with metastatic skin nodules and can cause superinfections in patients receiving broad-spectrum beta-lactam or quinolone antibiotics to which the organisms are susceptible when the infections develop. Catheter removal contributes to a favorable outcome in patients with catheter-associated cellulitis without bacteremia. Xanthomonas maltophilia infection should be added to the differential diagnosis of mucocutaneous or soft tissue infection in patients with cancer. Trimethoprim-sulfamethoxazole with or without ticarcillin-clavulanate is the current treatment of choice for culture-proven infections, but early empiric therapy may improve outcome.			VARTIVARIAN, SE (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, 1515 HOLCOMBE BLVD, BOX 47, HOUSTON, TX 77030 USA.							AGGER WA, 1986, REV INFECT DIS, V8, P927; BAGEL J, 1986, AM J MED, V80, P528, DOI 10.1016/0002-9343(86)90736-9; BALTIMORE RS, 1990, PEDIATR INFECT DIS J, V9, P143, DOI 10.1097/00006454-199002000-00017; BOTTONE EJ, 1986, J CLIN MICROBIOL, V24, P995, DOI 10.1128/JCM.24.6.995-997.1986; CALANDRA GB, 1992, CLIN INFECT DIS, V15, pS148, DOI 10.1093/clind/15.Supplement_1.S148; DYTE PH, 1977, MED J AUSTRALIA, V1, P444, DOI 10.5694/j.1326-5377.1977.tb130797.x; ELTING LS, 1990, MEDICINE, V69, P296, DOI 10.1097/00005792-199009000-00003; Fleming M G, 1987, Pediatr Dermatol, V4, P18, DOI 10.1111/j.1525-1470.1987.tb00746.x; GARDNER P, 1970, AM J MED, V48, P735, DOI 10.1016/S0002-9343(70)80009-2; GILARDI GL, 1972, ANN INTERN MED, V77, P211, DOI 10.7326/0003-4819-77-2-211; GILARDI GL, 1969, AM J CLIN PATHOL, V51, P58; HARLOWE HD, 1972, LARYNGOSCOPE, V82, P882, DOI 10.1288/00005537-197205000-00015; HOLMES B, 1979, J CLIN PATHOL, V32, P66, DOI 10.1136/jcp.32.1.66; Kealey G P, 1986, J Burn Care Rehabil, V7, P409, DOI 10.1097/00004630-198609000-00006; KERR KG, 1991, REV INFECT DIS, V13, P762; KHARDORI N, 1990, REV INFECT DIS, V12, P997; MARKLEY K, 1957, ANN SURG, V145, P175, DOI 10.1097/00000658-195702000-00005; MARSHALL WF, 1989, MAYO CLIN PROC, V64, P1097, DOI 10.1016/S0025-6196(12)64979-9; MORRISON AJ, 1986, J CLIN MICROBIOL, V24, P52, DOI 10.1128/JCM.24.1.52-55.1986; MUDER RR, 1987, ARCH INTERN MED, V147, P1672, DOI 10.1001/archinte.147.9.1672; NAGAI T, 1984, J CLIN MICROBIOL, V20, P1003, DOI 10.1128/JCM.20.5.1003-1005.1984; PEDERSEN MM, 1970, AM J CLIN PATHOL, V54, P178; PHAM BN, 1992, ARCH DERMATOL, V128, P702, DOI 10.1001/archderm.128.5.702b; PICOU KA, 1979, ARCH DERMATOL, V115, P459, DOI 10.1001/archderm.115.4.459; REED RK, 1976, J PEDIATR-US, V88, P977, DOI 10.1016/S0022-3476(76)81054-2; ROBERTS R, 1982, JAMA-J AM MED ASSOC, V248, P2156, DOI 10.1001/jama.248.17.2156; SANGEORZAN JA, 1990, ARCH DERMATOL, V126, P832, DOI 10.1001/archderm.126.6.832; SCHLOSSBERG D, 1980, ARCH DERMATOL, V116, P446, DOI 10.1001/archderm.116.4.446; SOUTHERN PM, 1974, TEX REP BIOL MED, V32, P880; VARTIVARIAN S, 1994, ANTIMICROB AGENTS CH, V38, P624, DOI 10.1128/AAC.38.3.624; WISHART MM, 1976, MED J AUSTRALIA, V2, P710, DOI 10.5694/j.1326-5377.1976.tb128238.x; ZURAVLEFF JJ, 1982, REV INFECT DIS, V4, P1236	32	83	87	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					969	973		10.7326/0003-4819-121-12-199412150-00011	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978724				2022-12-24	WOS:A1994PW08300011
J	LANDS, RH				LANDS, RH			CHOREA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1636	1636		10.1001/jama.272.21.1636	http://dx.doi.org/10.1001/jama.272.21.1636			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU759	7966874				2022-12-24	WOS:A1994PU75900001
J	LOPATIN, AN; MAKHINA, EN; NICHOLS, CG				LOPATIN, AN; MAKHINA, EN; NICHOLS, CG			POTASSIUM CHANNEL BLOCK BY CYTOPLASMIC POLYAMINES AS THE MECHANISM OF INTRINSIC RECTIFICATION	NATURE			English	Article							GUINEA-PIG HEART; INWARD RECTIFICATION; VENTRICULAR CELLS; MAGNESIUM BLOCK; EXPRESSION; MEMBRANE; MYOCYTES; CLONING; MG-2+	INWARDLY rectifying potassium channels conduct ions more readily in the inward than the outward direction, an essential property for normal electrical activity(1,2). Although voltage-dependent block by internal magnesium ions may underlie inward rectification in some channels(3-5), an intrinsic voltage-dependent closure of the channel plays a contributory, or even exclusive, role in others(4,6-9). Here me report that, rather than being intrinsic to the channel protein, so-called intrinsic rectification of strong inward rectifiers requires soluble factors that are not Mg2+ and can be released from Xenopus oocytes and other cells. Biochemical and biophysical characterization identifies these factors as polyamines (spermine, spermidine, putrescine and cadaverine). The results suggest that intrinsic rectification results from voltage-dependent block of the channel pore by polyamines, not from a voltage sensor intrinsic to the channel protein(10).	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Nichols, Colin/D-6336-2012					ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; Bachrach U., 1973, FUNCTION NATURALLY O; CALDARERA CM, 1974, J MOL CELL CARDIOL, V6, P95, DOI 10.1016/0022-2828(74)90013-3; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GERBAUT L, 1991, CLIN CHEM, V37, P2117; HATHAWAY GM, 1984, ARCH BIOCHEM BIOPHYS, V233, P133, DOI 10.1016/0003-9861(84)90609-X; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HORIE M, 1987, J PHYSIOL-LONDON, V387, P251, DOI 10.1113/jphysiol.1987.sp016572; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; LASCHET J, 1992, EPILEPSY RES, V12, P151, DOI 10.1016/0920-1211(92)90035-R; LEECH CA, 1981, J PHYSIOL-LONDON, V319, P295, DOI 10.1113/jphysiol.1981.sp013909; LOPATIN AN, 1994, J GEN PHYSIOL, V103, P203, DOI 10.1085/jgp.103.2.203; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MAKHIMA EN, J BIOL CHEM, V269, P20469; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; MIYAMOTO S, 1993, ARCH BIOCHEM BIOPHYS, V300, P63, DOI 10.1006/abbi.1993.1009; NICHOLS CG, 1994, J PHYSIOL-LONDON, V476, P399, DOI 10.1113/jphysiol.1994.sp020141; OLIVA C, 1990, J GEN PHYSIOL, V96, P299, DOI 10.1085/jgp.96.2.299; OSHOURNE HB, 1989, BIOCHEM BIOPH RES CO, V158, P520; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; SACAAN AI, 1990, MOL PHARMACOL, V38, P705; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; TANAKA Y, 1982, J BIOCHEM-TOKYO, V91, P2029, DOI 10.1093/oxfordjournals.jbchem.a133896; TRAUTWEIN W, 1958, PFLUG ARCH GES PHYS, V266, P324, DOI 10.1007/BF00416781; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0	30	719	731	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					366	369		10.1038/372366a0	http://dx.doi.org/10.1038/372366a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969496				2022-12-24	WOS:A1994PU28700057
J	PELTOLA, H; HEINONEN, OP; VALLE, M; PAUNIO, M; VIRTANEN, M; KARANKO, V; CANTELL, K				PELTOLA, H; HEINONEN, OP; VALLE, M; PAUNIO, M; VIRTANEN, M; KARANKO, V; CANTELL, K			THE ELIMINATION OF INDIGENOUS MEASLES, MUMPS, AND RUBELLA FROM FINLAND BY A 12-YEAR, 2-DOSE VACCINATION PROGRAM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; CHILDREN; VIRUS; IMMUNIZATION; ANTIBODY; VACCINES; PERSISTENCE; INCREASE; IMMUNITY; TRIAL	Background. In the 1970s measles, mumps, and rubella were rampant in Finland, and rates of immunization were inadequate. in 1982 a comprehensive national vaccination program began in which two doses of a combined live-virus vaccine were used. Methods. Public health nurses at 1036 child health centers administered the vaccine to children at 14 to 18 months of age and again at 6 years, and also to selected groups of older children and young adults. Vaccination was voluntary and free of charge. In follow-up studies, we focused on rates of vaccination, reasons for noncompliance, adverse reactions, immunogenicity, persistence of antibody, and incidence of the three diseases. Since 1987, paired serum samples have been collected from all patients with suspected cases of measles, mumps, or rubella. Results. Over a period of 12 years, 1.5 million of the 5 million people in Finland were vaccinated. Coverage now exceeds 95 percent. The vaccine was efficient and safe, even in those with a history of severe allergy. No deaths or persistent sequelae were attributable to vaccination. The most frequent complication requiring hospitalization was acute thrombocytopenic purpura, which occurred at a rate of 3.3 per 100,000 vaccinated persons. The 99 percent decrease in the incidence of the three diseases was accompanied by an increasing rate of false positive clinical diagnoses. In 655 vaccinated patients with clinically diagnosed disease, serologic studies confirmed the presence of measles in only 0.8 percent, mumps in 2.0 percent, and rubella in 1.2 percent. The few localized outbreaks were confined to patients in the partially vaccinated age groups. There are now fewer than 30 sporadic cases of each of the three diseases per year,and those are probably imported. Conclusions. Over a 12-year period, an immunization program using two doses of combined live-virus vaccine has eliminated indigenous measles, mumps, and rubella from Finland. Serologic studies show that most reported sporadic cases are now due to other causes, but a continued high rate of vaccination coverage is essential to prevent outbreaks resulting from exposure to imported disease.	UNIV HELSINKI,CHILDRENS HOSP,NATL PUBL HLTH INST,SF-00290 HELSINKI,FINLAND; UNIV HELSINKI,DEPT PUBL HLTH,HELSINKI,FINLAND	Finland National Institute for Health & Welfare; University of Helsinki; University of Helsinki	PELTOLA, H (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,DIV INFECT DIS,STENBACKINKATU 11,SF-00290 HELSINKI,FINLAND.							AABY P, 1986, J PEDIATR-US, V109, P40, DOI 10.1016/S0022-3476(86)80569-8; ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259, DOI 10.1017/S002217240002893X; BAYER WL, 1965, NEW ENGL J MED, V273, P1362, DOI 10.1056/NEJM196512162732504; BRUNELL PA, 1983, JAMA-J AM MED ASSOC, V250, P1409, DOI 10.1001/jama.250.11.1409; CARTER H, 1992, BRIT MED J, V304, P637, DOI 10.1136/bmj.304.6827.637; CHANTLER JK, 1985, NEW ENGL J MED, V313, P1117, DOI 10.1056/NEJM198510313131803; CHRISTENSON B, 1983, BRIT MED J, V287, P389, DOI 10.1136/bmj.287.6389.389; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; EDMONSON MB, 1990, JAMA-J AM MED ASSOC, V263, P2467, DOI 10.1001/jama.263.18.2467; FORREST JM, 1974, AUST NZ J MED, V4, P352, DOI 10.1111/j.1445-5994.1974.tb03203.x; GALLOWAY Y, 1991, COMMUN DIS NZ, V12, P107; GERSHON AA, 1979, DIAGNOSTIC PROCEDURE, P685; GRAHAM DY, 1974, JAMA-J AM MED ASSOC, V227, P1162, DOI 10.1001/jama.227.10.1162; HEINONEN OP, 1977, BIRTH DEFECTS DRUGS, P7; HETHCOTE HW, 1983, AM J EPIDEMIOL, V117, P2, DOI 10.1093/oxfordjournals.aje.a113511; HOWSON CP, 1992, PEDIATRICS, V89, P318; HUDSON JB, 1956, J PEDIATR-US, V48, P48, DOI 10.1016/S0022-3476(56)80116-9; HYOTY H, 1993, DIABETOLOGIA, V36, P1303, DOI 10.1007/BF00400810; JUNTUNENBACKMAN K, 1987, AM J DIS CHILD, V141, P1103, DOI 10.1001/archpedi.1987.04460100081032; KATZ SL, 1991, REP PEDIAT INFECT DI, V1, P1; KIEFABER RW, 1981, NEW ENGL J MED, V305, P225; KOSKINIEMI M, 1989, LANCET, V1, P31; LAU YL, 1992, J INFECT DIS, V165, P1111, DOI 10.1093/infdis/165.6.1111; LERMAN SJ, 1981, PEDIATRICS, V68, P18; LOKIETZ H, 1965, J LANCET, V85, P226; MARKOWITZ LE, 1992, J INFECT DIS, V166, P205, DOI 10.1093/infdis/166.1.205; NIEMINEN U, 1993, ACTA PAEDIATR, V82, P267, DOI 10.1111/j.1651-2227.1993.tb12657.x; Ohga Shouichi, 1992, Acta Paediatrica Japonica, V34, P447; PAUNIO M, 1991, AM J EPIDEMIOL, V133, P1152, DOI 10.1093/oxfordjournals.aje.a115827; PELTOLA H, 1993, LANCET, V341, P994, DOI 10.1016/0140-6736(93)91077-Y; PELTOLA H, 1986, LANCET, V1, P137; PELTOLA H, 1986, LANCET, V1, P939; PENTTINEN K, 1968, AM J EPIDEMIOL, V88, P234, DOI 10.1093/oxfordjournals.aje.a120882; UEDA K, 1986, AM J EPIDEMIOL, V124, P807, DOI 10.1093/oxfordjournals.aje.a114457; UKKONEN P, 1988, SCAND J INFECT DIS, V20, P255, DOI 10.3109/00365548809032448; VAANANEN P, 1979, J MED VIROL, V3, P245, DOI 10.1002/jmv.1890030402; VAHERI A, 1982, LANCET, V2, P685; VALMARI P, 1987, PEDIATR INFECT DIS J, V6, P59, DOI 10.1097/00006454-198701000-00015; VESIKARI T, 1984, AM J DIS CHILD, V138, P843, DOI 10.1001/archpedi.1984.02140470043013; VUORI M, 1962, Acta Otolaryngol, V55, P231, DOI 10.3109/00016486209127357; WEIBEL RE, 1980, P SOC EXP BIOL MED, V165, P260, DOI 10.3181/00379727-165-40967; WEIBEL RE, 1980, P SOC EXP BIOL MED, V165, P323, DOI 10.3181/00379727-165-40979; WILKINS J, 1979, J PEDIATR-US, V94, P865, DOI 10.1016/S0022-3476(79)80203-6; 1994, MMWR-MORBID MORTAL W, V43, P57; 1993, MMWR-MORBID MORTAL W, V42, P378	46	243	246	1	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1397	1402		10.1056/NEJM199411243312101	http://dx.doi.org/10.1056/NEJM199411243312101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7969278	Bronze			2022-12-24	WOS:A1994PU53300001
J	NIE, SM; CHIU, DT; ZARE, RN				NIE, SM; CHIU, DT; ZARE, RN			PROBING INDIVIDUAL MOLECULES WITH CONFOCAL FLUORESCENCE MICROSCOPY	SCIENCE			English	Article							SINGLE DNA-MOLECULES; CORRELATION SPECTROSCOPY; EXPERIMENTAL REALIZATION; GEL-ELECTROPHORESIS; OPTICAL MICROSCOPY; LIGHT-MICROSCOPY; PHYCOERYTHRIN; VISUALIZATION; MANIPULATION; DYES	Confocal fluorescence microscopy coupled with a diffraction-limited laser beam and a high-efficiency detection system has been used to study the diffusive movement and emission process of individual fluorescent molecules in the liquid phase at room temperature. The high detection sensitivity achieved at fast data acquisition speeds (greater than 1 kilohertz) allows real-time observation of single-molecule fluorescence without statistical analysis. The results show fluorescence-cycle saturation at the single-molecule level and multiple recrossings of a single molecule into and out of the probe volume as well as the triplet state.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	Stanford University			Zare, Richard N./A-8410-2009; Nie, Shuming/E-4843-2011	Zare, Richard/0000-0001-5266-4253				AMBROSE WP, 1994, SCIENCE, V265, P364, DOI 10.1126/science.265.5170.364; ASIMOV MM, 1990, J LUMIN, V46, P243, DOI 10.1016/0022-2313(90)90020-C; AUZANNEAU I, 1993, CR ACAD SCI III-VIE, V316, P459; BETZIG E, 1992, SCIENCE, V257, P189, DOI 10.1126/science.257.5067.189; BETZIG E, 1991, SCIENCE, V251, P1468, DOI 10.1126/science.251.5000.1468; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; BUSTAMANTE C, 1991, ANNU REV BIOPHYS BIO, V20, P415, DOI 10.1146/annurev.bb.20.060191.002215; Dempster D. N., 1974, Journal of Photochemistry, V2, P343, DOI 10.1016/0047-2670(73)80032-2; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; FELLER W, 1971, INTRO PROBABILITY TH, V1; GUTTLER F, 1994, CHEM PHYS LETT, V217, P393, DOI 10.1016/0009-2614(94)87003-9; ISHIKAWA M, 1994, JPN J APPL PHYS 1, V33, P1571, DOI 10.1143/JJAP.33.1571; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; KOPPEL DE, 1974, PHYS REV A, V10, P1938, DOI 10.1103/PhysRevA.10.1938; MAGDE D, 1974, BIOPOLYMERS, V13, P29, DOI 10.1002/bip.1974.360130103; MAGDE D, 1974, BIOPOLYMERS, V13, P1; MOERNER WE, 1994, SCIENCE, V265, P46, DOI 10.1126/science.265.5168.46; MORIKAWA K, 1981, J BIOCHEM-TOKYO, V89, P693, DOI 10.1093/oxfordjournals.jbchem.a133247; NG KC, 1992, ANAL CHEM, V69, P2914; NGUYEN DC, 1987, ANAL CHEM, V59, P2158, DOI 10.1021/ac00144a032; ORRIT M, 1993, J PHYS CHEM-US, V97, P10256, DOI 10.1021/j100142a003; PECK K, 1989, P NATL ACAD SCI USA, V86, P4087, DOI 10.1073/pnas.86.11.4087; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; QIAN H, 1991, APPL OPTICS, V30, P1185, DOI 10.1364/AO.30.001185; RAMPINO NJ, 1991, ANAL BIOCHEM, V194, P278, DOI 10.1016/0003-2697(91)90230-Q; RIGLER R, 1993, EUR BIOPHYS J BIOPHY, V22, P169, DOI 10.1007/BF00185777; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SCHNEIDER MB, 1981, APPL OPTICS, V20, P1382, DOI 10.1364/AO.20.001382; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; SOPER SA, 1993, PHOTOCHEM PHOTOBIOL, V57, P972, DOI 10.1111/j.1751-1097.1993.tb02957.x; TRAUTMAN JK, 1994, NATURE, V369, P40, DOI 10.1038/369040a0; WASHIZU M, 1990, IEEE T IND APPL, V26, P1165, DOI 10.1109/28.62403; WHITTEN WB, 1991, ANAL CHEM, V63, P1027, DOI 10.1021/ac00010a019; XIE XS, 1994, SCIENCE, V265, P361, DOI 10.1126/science.265.5170.361	36	518	584	3	194	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1018	1021		10.1126/science.7973650	http://dx.doi.org/10.1126/science.7973650			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973650				2022-12-24	WOS:A1994PQ92400036
J	CHONG, LD; TRAYNORKAPLAN, A; BOKOCH, GM; SCHWARTZ, MA				CHONG, LD; TRAYNORKAPLAN, A; BOKOCH, GM; SCHWARTZ, MA			THE SMALL GTP-BINDING PROTEIN-RHO REGULATES A PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE IN MAMMALIAN-CELLS	CELL			English	Article							NEUTROPHIL NADPH OXIDASE; ENDOTHELIAL-CELLS; GROWTH-FACTORS; ACTIVATION; CALCIUM; 4,5-BISPHOSPHATE; RAS; PURIFICATION; STIMULATION; REQUIREMENT	Integrin-mediated adhesion is known to stimulate production of phosphatidylinositol 4,5-bisphosphate (4,5-PIP2) and increase 4,5-PIP2 hydrolysis in response to platelet-derived growth factor (PDGF). We now show that treatment of cells with lovastatin, which inhibits modification of small GTP-binding proteins, reduced PIP2 levels and decreased calcium mobilization in response to PDGF and thrombin. In cell lysates, GTP gamma S stimulated PIP 5-kinase activity, and this effect was blocked by botulinum C3 exoenzyme, suggesting that Rho was responsible. GTP-bound recombinant Rho stimulated PIP B-kinase activity, whereas GDP-Rho was much less potent and GTP-bound Rac was ineffective. Microinjected botulinum C3 exoenzyme caused diminished calcium mobilization in response to PDGF or thrombin. Conversely, microinjection of activated Rho reversed the decrease in calcium mobilization normally seen in nonadherent cells. These data demonstrate that Rho regulates 4,5-PIP2 synthesis and, indirectly, 4,5-PIP2 hydrolysis. They also raise the possibility that PIP2 synthesis could mediate the effects of Rho on the actin cytoskeleton.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT MED, SAN DIEGO, CA 92103 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego				schwartz, martin/0000-0002-2071-1243	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL48728] Funding Source: Medline; NIGMS NIH HHS [R01 GM47214, R01 GM4428] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; AULLO P, 1993, EMBO J, V12, P921, DOI 10.1002/j.1460-2075.1993.tb05733.x; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BIFULCO M, 1993, J CELL PHYSIOL, V155, P340, DOI 10.1002/jcp.1041550215; BOKOCH GM, 1992, J CLIN INVEST, V89, P402, DOI 10.1172/JCI115599; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHILVERS ER, 1991, BIOCHEM J, V275, P373, DOI 10.1042/bj2750373; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; KACHINTORN U, 1993, AM J PHYSIOL, V264, pC671, DOI 10.1152/ajpcell.1993.264.3.C671; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LING LE, 1989, J BIOL CHEM, V264, P5080; MCNAMEE HM, 1992, J CELL BIOL, V121, P673; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SCHWARTZ MA, 1992, P NATL ACAD SCI USA, V89, P6138, DOI 10.1073/pnas.89.13.6138; SELF AJ, 1993, ONCOGENE, V8, P655; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; TUCKER RW, 1990, CELL CALCIUM, V11, P201, DOI 10.1016/0143-4160(90)90071-2; URUMOW T, 1986, FEBS LETT, V207, P253, DOI 10.1016/0014-5793(86)81499-5; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; ZHANG J, 1993, J BIOL CHEM, V268, P22251	36	603	611	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 4	1994	79	3					507	513		10.1016/0092-8674(94)90259-3	http://dx.doi.org/10.1016/0092-8674(94)90259-3			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954816				2022-12-24	WOS:A1994PQ48800013
J	LORI, F; MALYKH, A; CARA, A; SUN, D; WEINSTEIN, JN; LISZIEWICZ, J; GALLO, RC				LORI, F; MALYKH, A; CARA, A; SUN, D; WEINSTEIN, JN; LISZIEWICZ, J; GALLO, RC			HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE-1 REPLICATION	SCIENCE			English	Article							DRUG-COMBINATIONS; HTLV-III; INFECTION; PROTEASE; AIDS; ACTIVATION; MECHANISM; THERAPY; INVITRO; TISSUE	Hydroxyurea, a drug widely used in therapy of several human diseases, inhibits deoxynucleotide synthesis-and, consequently, DNA synthesis-by blocking the cellular enzyme ribonucleotide reductase. Hydroxyurea inhibits human immunodeficiency virus-type 1 (HIV-1) DNA synthesis in activated peripheral blood lymphocytes by decreasing the amount of intracellular deoxynucleotides, thus suggesting that this drug has an antiviral effect. Hydroxyurea has now been shown to block HIV-1 replication in acutely infected primary human lymphocytes (quiescent and activated) and macrophages, as well as in brood cells infected in vivo obtained from individuals with acquired immunodeficiency syndrome (AIDS). The antiviral effect was achieved at nontoxic doses of hydroxyurea, lower than those currently used in human therapy. Combination of hydroxyurea with the nucleoside analog didanosine (2',3'-dideoxyinosine, or ddl) generated a synergistic inhibitory effect without increasing toxicity. In some instances, inhibition of HIV-1 by hydroxyurea was irreversible, even several weeks after suspension of drug treatment. The indirect inhibition of HIV-1 by hydroxyurea is not expected to generate high rates of escape mutants. Hydroxyurea therefore appears to be a possible candidate for AIDS therapy.	NCI,MOLEC PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LORI, F (corresponding author), NCI,TUMOR CELL BIOL LAB,BLDG 37,BETHESDA,MD 20892, USA.		Cara, Andrea/AAA-4238-2021; Cara, Andrea/M-4865-2015	Cara, Andrea/0000-0003-4967-1895; Cara, Andrea/0000-0003-4967-1895; Lisziewicz, Julianna/0000-0002-3349-4495; Weinstein, John/0000-0001-9401-6908				ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; BELT RJ, 1980, CANCER, V46, P455, DOI 10.1002/1097-0142(19800801)46:3<455::AID-CNCR2820460306>3.0.CO;2-N; BIANCHI V, 1986, J BIOL CHEM, V261, P6037; BUNOW B, 1990, ANN NY ACAD SCI, V616, P490; CHARACHE S, 1991, HEMATOL ONCOL CLIN N, V5, P571, DOI 10.1016/S0889-8588(18)30432-5; DONEHOWER RC, 1992, SEMIN ONCOL, V19, P11; GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GOULAOUIC H, 1994, VIROLOGY, V200, P87, DOI 10.1006/viro.1994.1166; JACK JA, 1990, CELL, V61, P213; KAGEYAMA S, 1992, ANTIMICROB AGENTS CH, V36, P926, DOI 10.1128/AAC.36.5.926; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; LORI F, UNPUB; MALLEY SD, 1994, LANCET, V343, P1292, DOI 10.1016/S0140-6736(94)92182-2; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MEYERHANS A, 1994, J VIROL, V68, P535, DOI 10.1128/JVI.68.1.535-540.1994; MORGAN JS, 1986, BIOCHEM BIOPH RES CO, V134, P1254, DOI 10.1016/0006-291X(86)90385-2; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; OTTO MJ, 1993, P NATL ACAD SCI USA, V90, P7543, DOI 10.1073/pnas.90.16.7543; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; SELIGMANN M, 1994, LANCET, V343, P871; SLABAUGH MB, 1991, J VIROL, V65, P2290, DOI 10.1128/JVI.65.5.2290-2298.1991; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; WEINSTEIN JN, 1990, ANN NY ACAD SCI, V616, P367; YARBRO JW, 1992, SEMIN ONCOL, V19, P1; YARCHOAN R, 1993, TRENDS PHARMACOL SCI, V14, P196, DOI 10.1016/0165-6147(93)90208-2	29	319	340	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					801	805		10.1126/science.7973634	http://dx.doi.org/10.1126/science.7973634			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973634				2022-12-24	WOS:A1994PP75300039
J	PAPE, JW; VERDIER, RI; BONCY, M; BONCY, J; JOHNSON, WD				PAPE, JW; VERDIER, RI; BONCY, M; BONCY, J; JOHNSON, WD			CYCLOSPORA INFECTION IN ADULTS INFECTED WITH HIV - CLINICAL MANIFESTATIONS, TREATMENT, AND PROPHYLAXIS	ANNALS OF INTERNAL MEDICINE			English	Article						ACQUIRED IMMUNODEFICIENCY SYNDROME; DIARRHEA; CYCLOSPORA; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; HAITI	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; ISOSPORA-BELLI INFECTION; ORGANISM; DIARRHEA; TRAVELERS; NEPAL	Objective: To determine the prevalence and clinical manifestations of Cyclospora in Haitians infected with human immunodeficiency virus (HIV) who have diarrhea and to evaluate therapy and prophylaxis. Design: Cohort study. From 1990 to 1993, stool samples were collected from adults seropositive for HIV who had had diarrhea for at least 3 weeks. Setting: A clinic in Haiti. Interventions: Stool samples were examined for enteric protozoa after acid-fast staining. Patients with Cyclospora infection were treated with trimethoprim-sulfamethoxazole (160 mg and 800 mg, respectively) given orally four times a day for 10 days. After completion of therapy, patients were evaluated weekly and re-treated if clinical and parasitologic recurrences occurred, followed by trimethoprim-sulfamethoxazole prophylaxis three times a week. Results: 804 of 2400 patients (33%) seropositive for HIV had a history of chronic or intermittent diarrhea; 502 of these 804 patients (62%) currently had diarrhea, and 450 patients each provided two stool specimens for examination. Enteric protozoa identified included Cryptosporidium (30%), Isospora belli (12%), Cyclospora species (11%), Giardia lamblia (3%), and Entamoeba histolytica (1%). Forty-three patients with diarrhea and Cyclospora infection were studied; their symptoms were indistinguishable from those seen in patients with isosporiasis or cryptosporidiosis. In all patients, diarrhea ceased and results from stool examinations were negative within 2.5 days after beginning oral tri methoprim-sulfamethoxazole therapy. Recurrent symptomatic cyclosporiasis developed in 12 of 28 patients (43%) followed for 1 month or more, but it also responded promptly to trimethoprim-sulfamethoxazole therapy. These 12 patients received trimethoprim-sulfamethoxazole three times a week as secondary prophylaxis, with only a single recurrence after 7 months. Conclusion: Cyclospora infection is common in Haitian patients with HIV infection, responds to trimethoprim-sulfamethoxazole therapy, and has a high recurrence rate that can be largely prevented with long-term trimethoprim-sulfamethoxazole prophylaxis.	CORNELL UNIV, COLL MED, DIV INTERNAL MED, NEW YORK, NY 10021 USA; HAITIAN STUDY GRP KAPOSIS SARCOMA & OPPORTUNIST I, PORT AU PRINCE, HAITI	Cornell University					FOGARTY INTERNATIONAL CENTER [D43TW000018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033877, R37AI022624] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TW 00018] Funding Source: Medline; NIAID NIH HHS [R21 AI 33877, R37 AI 22624] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; DEHOVITZ JA, 1986, NEW ENGL J MED, V315, P87, DOI 10.1056/NEJM198607103150203; HART AS, 1990, LANCET, V335, P169, DOI 10.1016/0140-6736(90)90042-4; HOGE CW, 1993, LANCET, V341, P1175, DOI 10.1016/0140-6736(93)91002-4; Lennette E.H, 1985, MANUAL CLIN MICROBIO, V4th ed.; LEVINE ND, 1973, COCCIDIA, P1; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; PAPE JW, 1989, NEW ENGL J MED, V320, P1044, DOI 10.1056/NEJM198904203201604; PAPE JW, 1987, AM J TROP MED HYG, V36, P333, DOI 10.4269/ajtmh.1987.36.333; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; SOAVE R, 1986, CLIN RES, V34, pA533; SOAVE R, 1988, J INFECT DIS, V157, P225, DOI 10.1093/infdis/157.2.225; VERDIER RI, 1993, 8 INT C AIDS 3 STD W; WURTZ RM, 1993, CLIN INFECT DIS, V16, P136, DOI 10.1093/clinids/16.1.136; 1991, MMWR-MORBID MORTAL W, V40, P325	16	176	188	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					654	657		10.7326/0003-4819-121-9-199411010-00004	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944073				2022-12-24	WOS:A1994PN45000004
J	RODERICK, PJ; JONES, I; RALEIGH, VS; MCGEOWN, M; MALLICK, N				RODERICK, PJ; JONES, I; RALEIGH, VS; MCGEOWN, M; MALLICK, N			POPULATION NEED FOR RENAL REPLACEMENT THERAPY IN THAMES REGIONS - ETHNIC DIMENSION	BRITISH MEDICAL JOURNAL			English	Article							DISEASE; PREVALENCE; FAILURE; INSULIN; CENSUS; ASIANS	Objectives-To determine the use of renal replacement therapy by ethnic origin and to ascertain the variation in provision of such therapy and to relate this to the distribution of ethnic minority populations. Design-Analysis of retrospective and cross sectional data from 19 renal units. Setting-All four Thames regional health authorities. Subjects-Patients resident in the Thames regions who were accepted as new patients for renal replacement therapy during 1991 and 1992 and the patients who were already undergoing such treatment between December 1992 and April 1993. Main outcome measures-Rates of acceptance for and prevalence of renal replacement therapy among white, black, and Asian people. Results-The average annual acceptance rates per million in 1991-2 were 61 for white people, 175 for black people, and 178 for Asians, and the prevalences per million were 351, 918, and 957 respectively. The relative risks increased with age. A threefold increase in the acceptance rate occurred in people aged under 55 in both the black and Asian populations, suggesting that the higher rates are probably not due to factors related to access alone. Treatment rates varied considerably among districts, reflecting both the distribution of ethnic minority populations and access to services. Conclusion-Black and Asian people receive and have a greater need for renal replacement therapy, and the need will increase as these populations age. These findings have important implications for the provision of renal services in districts with a high proportion of ethnic minorities and for the management of diabetes mellitus and hypertension, two important causes of end stage renal failure in these populations.	NW THAMES REG HLTH AUTHOR,LONDON,ENGLAND; UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON,ENGLAND; UNIV SURREY,INST PUBL HLTH,GUILDFORD,SURREY,ENGLAND; QUEENS UNIV BELFAST,BELFAST,ANTRIM,NORTH IRELAND; MANCHESTER ROYAL INFIRM,MANCHESTER,LANCS,ENGLAND	University of London; Queen Mary University London; University of Surrey; Queens University Belfast; University of Manchester				Jones, Ian/0000-0002-1682-9134				BALARAJAN R, 1978, OPCS SERIES DS, V9, P103; BEECH R, 1994, HLTH CARE NEEDS ASSE; BURDEN AC, 1992, DIABETIC MED, V9, P641, DOI 10.1111/j.1464-5491.1992.tb01860.x; COWIE CC, 1990, DIABETES, V321, P1074; CRUICKSHANK JK, 1991, LANCET, V338, P842, DOI 10.1016/0140-6736(91)91501-K; Eggers P W, 1984, Health Care Financ Rev, V5, P69; FEEST TG, 1990, BRIT MED J, V301, P897, DOI 10.1136/bmj.301.6757.897; GARDNER MJ, 1989, STATISTICS CONFIDENC; GLOVER GR, 1993, BRIT MED J, V307, P506, DOI 10.1136/bmj.307.6902.506-a; HIATT RA, 1982, AM J PUBLIC HEALTH, V72, P829, DOI 10.2105/AJPH.72.8.829; HOPKINS A, 1993, ACCESSIBILITY HLTH C; MATHER HM, 1985, BRIT MED J, V291, P1081, DOI 10.1136/bmj.291.6502.1081; MCCLELLAN W, 1988, AM J KIDNEY DIS, V12, P285, DOI 10.1016/S0272-6386(88)80221-X; MCGEOWN MG, 1990, BRIT MED J, V301, P900, DOI 10.1136/bmj.301.6757.900; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; PAZIANAS M, 1991, NEPHROL DIAL TRANSPL, V6, P931, DOI 10.1093/ndt/6.12.931; ROSTAND SG, 1982, NEW ENGL J MED, V306, P1276, DOI 10.1056/NEJM198205273062106; SAMANTA A, 1986, BRIT MED J, V293, P366, DOI 10.1136/bmj.293.6543.366-a; SHULMAN NB, 1991, CIRCULATION, V83, P1477, DOI 10.1161/01.CIR.83.4.1477; THOMPSON EJ, 1993, BRIT MED J, V307, P803, DOI 10.1136/bmj.307.6907.803-b; 1991, PROVISION SERVICES A; [No title captured]; 1993, REPORT INDEPENDENT R; 1992, NEPHROL DIAL TRANSPL, V7, P10; 1994, 1991 CENSUS USER GUI	25	76	76	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1111	1114		10.1136/bmj.309.6962.1111	http://dx.doi.org/10.1136/bmj.309.6962.1111			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987102	Green Published			2022-12-24	WOS:A1994PP69100018
J	CULLY, DF; VASSILATIS, DK; LIU, KK; PARESS, PS; VANDERPLOEG, LHT; SCHAEFFER, JM; ARENA, JP				CULLY, DF; VASSILATIS, DK; LIU, KK; PARESS, PS; VANDERPLOEG, LHT; SCHAEFFER, JM; ARENA, JP			CLONING OF AN AVERMECTIN-SENSITIVE GLUTAMATE-GATED CHLORIDE CHANNEL FROM CAENORHABDITIS-ELEGANS	NATURE			English	Article							AMINO-ACID RECEPTORS; XENOPUS-OOCYTES; INSECT MUSCLE; BINDING-SITE; MEMBRANE; RNA; IVERMECTIN; MODULATION; EXPRESSION; FIBERS	THE avermectins are a family of macrocyclic lactones used in the control of nematode and arthropod parasites(1). Ivermectin (22,23-dihydroavermectin B-1a) is widely used as an anthelmintic in veterinary medicine and is used to treat onchocerciasis or river blindness in humans(1,2). Abamectin (avermectin B-1a) is a miticide and insecticide used in crop protection(1). Avermectins interact with vertebrate and invertebrate GABA receptors(3-7) and invertebrate glutamate-gated chloride channels(8-11). The soil nematode Caenorhabditis elegans has served as a useful model to study the mechanism of action of avermectins(11-15). A C. elegans messenger RNA expressed in Xenopus oocytes encodes an avermectin-sensitive glutamate-gated chloride channel(11,14). To elucidate the structure and properties of this channel, we used Xenopus oocytes for expression cloning of two functional complementary DNAs encoding an avermectin-sensitive glutamate-gated chloride channel. We find that the electrophysiological and structural properties of these proteins indicate that they are new members of the ligand-gated ion channel superfamily.	MERCK & CO INC, RES LABS, DEPT GENET & MOLEC BIOL, RAHWAY, NJ 07065 USA	Merck & Company	CULLY, DF (corresponding author), MERCK & CO INC, RES LABS, DEPT CELLULAR BIOCHEM & PHYSIOL, RAHWAY, NJ 07065 USA.							ARENA JP, 1992, MOL BRAIN RES, V15, P339, DOI 10.1016/0169-328X(92)90127-W; ARENA JP, 1991, MOL PHARMACOL, V40, P368; ARENA JP, IN PRESS J PARASITOL; AZIZ MA, 1982, LANCET, V2, P171; Campbell WW, 1989, IVERMECTIN ABAMECTIN; CULLCANDY SG, 1976, J PHYSIOL-LONDON, V255, P449, DOI 10.1113/jphysiol.1976.sp011289; CULLY DF, 1991, MOL PHARMACOL, V40, P326; DINGLEDINE R, 1990, FASEB J, V4, P2636, DOI 10.1096/fasebj.4.9.2161372; DUCE IR, 1985, BRIT J PHARMACOL, V85, P395, DOI 10.1111/j.1476-5381.1985.tb08874.x; FRASER SP, 1990, MOL BRAIN RES, V8, P331, DOI 10.1016/0169-328X(90)90047-H; FRITZ LC, 1979, P NATL ACAD SCI USA, V76, P2062, DOI 10.1073/pnas.76.4.2062; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KASS IS, 1980, P NATL ACAD SCI-BIOL, V77, P6211, DOI 10.1073/pnas.77.10.6211; LEA T J, 1973, Comparative and General Pharmacology, V4, P351, DOI 10.1016/0010-4035(73)90046-3; LEA T J, 1973, Comparative and General Pharmacology, V4, P333, DOI 10.1016/0010-4035(73)90045-1; LINGLE C, 1981, BRAIN RES, V212, P481, DOI 10.1016/0006-8993(81)90482-0; Maniatis T., 1982, MOL CLONING; MELLIN TN, 1983, NEUROPHARMACOLOGY, V22, P89, DOI 10.1016/0028-3908(83)90265-4; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PONG SS, 1982, J NEUROCHEM, V38, P375, DOI 10.1111/j.1471-4159.1982.tb08639.x; ROHERER SP, 1992, P NATL ACAD SCI USA, V89, P4168, DOI 10.1073/pnas.89.9.4168; SCHAEFFER JM, 1989, BIOCHEM PHARMACOL, V38, P2329, DOI 10.1016/0006-2952(89)90473-5; SCOTT RH, 1985, PESTIC SCI, V16, P599, DOI 10.1002/ps.2780160605; SIGEL E, 1987, MOL PHARMACOL, V32, P749; WAFFORD KA, 1989, J EXP BIOL, V144, P449; ZUFALL F, 1989, J EXP BIOL, V142, P191	28	560	590	8	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 20	1994	371	6499					707	711		10.1038/371707a0	http://dx.doi.org/10.1038/371707a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935817				2022-12-24	WOS:A1994PM77300058
J	SCHOENENBERGER, RA; HEIM, SM				SCHOENENBERGER, RA; HEIM, SM			INDICATION FOR COMPUTED-TOMOGRAPHY OF THE BRAIN IN PATIENTS WITH FIRST UNCOMPLICATED GENERALIZED SEIZURE	BRITISH MEDICAL JOURNAL			English	Article							1ST SEIZURE; EMERGENCY; EPILEPSY; ALCOHOL	Objectives-To assess the yield of emergency computed tomography of the brain in patients with a first generalised epileptic seizure and to evaluate a four item screening questionnaire on alcohol misuse (CAGE questionnaire) as a triage tool to avoid unnecessary scans in cases of seizures related to withdrawal from alcohol. Design-Prospective, observational. Setting-Medical casualty unit in a university hospital. Patients-119 adult patients presenting to casualty within one hour of a generalised seizure. Measurements-A clinical examination focusing on focal neurological symptoms, the CAGE questionnaire, and computed tomography of the brain with contrast enhancement. Results-Computed tomography showed a focal, structural lesion of the brain in 40 patients (34% (95% confidence interval 25% to 42%)). In 20 patients (17% (10% to 24%)) an important therapeutic intervention resulted. The presence of a focal neurological deficit had a sensitivity of 50% and a specificity of 89% in predicting focal lesions on computed tomography. Answering ''yes'' to fewer than two CAGE questions had a sensitivity of 90% and specificity of 44% in identifying patients with focal computed tomography lesions. Focal lesions were not detected on computed tomography in any of the 35 patients (0% (0% to 10%)) who showed no focal neurological symptoms and answered ''yes'' to two or more CAGE questions. Conclusions-The diagnostic yield of computed tomography of the brain in adults after a first generalised seizure is high. Combined with the clinical examination, the CAGE questionnaire can reliably identify patients with uncomplicated seizures related to withdrawal from alcohol, in whom computed tomography may not be absolutely necessary.	UNIV BASEL HOSP,DEPT MED,CH-4031 BASEL,SWITZERLAND; UNIV BASEL,DEPT NEUROL,BASEL,SWITZERLAND	University of Basel; University of Basel								BERESFORD TP, 1991, LANCET, V337, P1175; EARNEST M P, 1987, Neurology, V37, P142; EARNEST MP, 1976, EPILEPSIA, V17, P387, DOI 10.1111/j.1528-1157.1976.tb04450.x; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FEUSSNER JR, 1981, ANN INTERN MED, V94, P519, DOI 10.7326/0003-4819-94-4-519; GOODRIDGE DMG, 1983, BMJ-BRIT MED J, V287, P641, DOI 10.1136/bmj.287.6393.641; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HILLBOM ME, 1980, EPILEPSIA, V21, P459, DOI 10.1111/j.1528-1157.1980.tb04296.x; HOPKINS A, 1988, LANCET, V1, P721; MCKEE PJW, 1990, BRIT MED J, V300, P978, DOI 10.1136/bmj.300.6730.978; Morris J C, 1987, Emerg Med Clin North Am, V5, P827; RAMIREZLASSEPAS M, 1984, ANN NEUROL, V15, P536, DOI 10.1002/ana.410150605; ROSENTHAL RH, 1980, ANN EMERG MED, V9, P242, DOI 10.1016/S0196-0644(80)80379-9; RUSSO LS, 1983, ARCH NEUROL-CHICAGO, V40, P744, DOI 10.1001/archneur.1983.04050110062010; SAUNDERS S, 1975, EPILEPSIA, V16, P731; SCHEUER ML, 1990, NEW ENGL J MED, V323, P1468; SEMPERE AP, 1992, ACTA NEUROL SCAND, V86, P134, DOI 10.1111/j.1600-0404.1992.tb05054.x; TEASDALE G, 1974, LANCET, V2, P81; VANDONSELAAR CA, 1989, NEUROLOGY, V49, P267; YOUNG AC, 1982, LANCET, V2, P1446; 1990, SAS USERS GUIDE STAT; 1993, ANN EMERG MED, V22, P875	23	46	48	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					986	989		10.1136/bmj.309.6960.986	http://dx.doi.org/10.1136/bmj.309.6960.986			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950718	Green Published			2022-12-24	WOS:A1994PM41700020
J	DECETY, J; PERANI, D; JEANNEROD, M; BETTINARDI, V; TADARY, B; WOODS, R; MAZZIOTTA, JC; FAZIO, F				DECETY, J; PERANI, D; JEANNEROD, M; BETTINARDI, V; TADARY, B; WOODS, R; MAZZIOTTA, JC; FAZIO, F			MAPPING MOTOR REPRESENTATIONS WITH POSITRON EMISSION TOMOGRAPHY	NATURE			English	Article							ANTERIOR CINGULATE CORTEX; PET IMAGES; VOLUNTARY; MOVEMENTS	BRAIN activity was mapped in normal subjects during passive observation of the movements of an 'alien' hand and while imagining grasping objects with their own hand. None of the tasks required actual movement. Shifting from one mental task to the other greatly changed the pattern of brain activation. During observation of hand movements, activation was mainly found in visual cortical areas, but also in subcortical areas involved in motor behaviour, such as the basal ganglia and the cerebellum. During motor imagery, cortical and subcortical areas related to motor preparation and programming were strongly activated. These data support the notion that motor learning during observation of movements and mental practice involves rehearsal of neural pathways related to cognitive stages of motor control(1-3).	UNIV MILAN,SCI INST H SAN RAFFAELE,INB,CNR,I-20132 MILAN,ITALY; UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,DIV BRAIN MAPPING,LOS ANGELES,CA 90024	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	DECETY, J (corresponding author), INSERM,U94,16 AVE DOYEN LEPINE,F-69500 BRON,FRANCE.		Perani, Daniela/AAN-3221-2020					DECETY J, 1991, BEHAV BRAIN RES, V42, P1, DOI 10.1016/S0166-4328(05)80033-6; FOX PT, 1987, NEUR ABSTR, P1433; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; JEANNEROD M, 1994, BEHAV BRAIN SCI, V17, P187, DOI 10.1017/S0140525X00034026; MUSHIAKE H, 1991, J NEUROPHYSIOL, V66, P705, DOI 10.1152/jn.1991.66.3.705; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; PAUS T, 1993, J NEUROPHYSIOL, V70, P453, DOI 10.1152/jn.1993.70.2.453; PERRETT DI, 1989, J EXP BIOL, V146, P87; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P137, DOI 10.1152/jn.1980.43.1.137; SPINKS TJ, 1988, IEEE T NUCL SCI, V35, P721, DOI 10.1109/23.12819; Talairach J., 1988, COPLANAR STEREOTAXIC; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024; YUE G, 1992, J NEUROPHYSIOL, V67, P1114, DOI 10.1152/jn.1992.67.5.1114	17	766	772	2	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					600	602		10.1038/371600a0	http://dx.doi.org/10.1038/371600a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935791				2022-12-24	WOS:A1994PL55900050
J	NISWANDER, L; JEFFREY, S; MARTIN, GR; TICKLE, C				NISWANDER, L; JEFFREY, S; MARTIN, GR; TICKLE, C			A POSITIVE FEEDBACK LOOP COORDINATES GROWTH AND PATTERNING IN THE VERTEBRATE LIMB	NATURE			English	Article							APICAL ECTODERMAL RIDGE; CHICK WING DEVELOPMENT; SKELETAL-MUSCLE; RETINOIC ACID; HOX-4 GENES; FGF FAMILY; BUD CELLS; EXPRESSION; MOUSE; OUTGROWTH	LIMB development depends on signals from the apical ectodermal ridge and underlying mesenchyme(1,2). Fibroblast growth factor (FGF) can replace the ridge(3,4) and, because Fgf4 RNA is localized to the mouse posterior ridge(5), we proposed that FGF4 is the endogenous ridge signal(3). Ridge signals control limb outgrowth and maintain the zone of polarizing activity (ZPA) at the limb posterior margin(6), which is important in limb patterning: a ZPA graft to limb anterior mesenchyme causes cell respecification and mirror-image duplications(1,2). Sonic hedgehog (SHH7,8) has polarizing activity, and Shh RNA co-localizes with ZPA activity, suggesting SHH is the endogenous polarizing signal(7). We have investigated the molecular regulation of Fgf4 and Shh expression. We report here that Fgf4 expression in the ridge can be regulated by Shh-expressing cells. Moreover, Shh expression in mesenchyme can be activated by FGF4 in combination with retinoic acid. Once induced, Shh expression can be maintained by FGF4 alone, thus establishing a positive feedback loop between ZPA and ridge.	UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; UNIV COLL & MIDDLESEX SCH MED,DEPT ANAT & DEV BIOL,LONDON W1P 6DB,ENGLAND	University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center; University of London; University College London	NISWANDER, L (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.		Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594				ANDERSON R, 1993, DEVELOPMENT, V117, P1421; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; EICHELE G, 1985, J CELL BIOL, V101, P1913, DOI 10.1083/jcb.101.5.1913; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; HAN JK, 1993, DEV BIOL, V158, P549, DOI 10.1006/dbio.1993.1212; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; IZPISUABELMONTE JC, 1992, EMBO J, V11, P1451, DOI 10.1002/j.1460-2075.1992.tb05189.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KOYAMA E, 1993, DEV GROWTH DIFFER, V35, P189; LEE J, 1985, J EMBRYOL EXP MORPH, V90, P139; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; VOGEL A, 1993, DEVELOPMENT, V119, P199	23	612	631	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					609	612		10.1038/371609a0	http://dx.doi.org/10.1038/371609a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935794				2022-12-24	WOS:A1994PL55900053
J	KASS, EM; SZANIAWSKI, WK; LEVY, H; LEACH, J; SRINIVASAN, K; RIVES, C				KASS, EM; SZANIAWSKI, WK; LEVY, H; LEACH, J; SRINIVASAN, K; RIVES, C			RICKETTSIALPOX IN A NEW-YORK-CITY-HOSPITAL, 1980 TO 1989	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOUNTAIN SPOTTED-FEVER	Background. Rickettsialpox is caused by Rickettsia akari, which is transmitted from rodents to humans by bloodsucking mites. The initial skin lesion forms an eschar and is followed by the development of fever, malaise, myalgia, and 5 to 40 maculopapules and papulovesicles. The disease, which responds to tetracycline, can be mistaken for chickenpox. The diagnosis has been based on an increase in serum antibody titers against R. akari over a period of three to eight weeks. We discuss a more rapid technique that uses direct immunofluorescence to identify R. akari in paraffin-embedded tissue, and we describe the histopathological findings of lesional skin. Methods. We studied 13 patients (age, 11 months to 58 years) who were seen at Lincoln Hospital in New York City from 1980 to 1989 and were suspected of having rickettsialpox. In nine patients serum samples were obtained during the acute and convalescent phases of the illness for indirect fluorescent-antibody testing. Punch-biopsy specimens of skin lesions were examined by microscopy and by direct fluorescent-antibody testing with an anti-R. rickettsii globulin conjugated with fluorescein isothiocyanate. Results. The diagnosis was confirmed in all 13 patients by indirect or direct fluorescent-antibody techniques, Direct fluorescent-antibody testing of eschars from seven patients was positive in five patients, but negative in two patients who had serologically confirmed rickettsialpox. In contrast, direct fluorescent-antibody testing of papulovesicles from nine patients was positive in only one patient. Histopathological analysis of the eschars revealed extensive necrosis and inflammation. In biopsy specimens of papulovesicles, dermal edema, subepidermal vesicles, and vascular changes were present. Conclusions. The combination of direct fluorescent-antibody testing of an eschar from the presumed site of inoculation and histopathological examination of papulovesicles for distinctive features represents an improved method of diagnosing rickettsialpox.	DERMATOPATHOL ASSOCIATES NEW YORK,NEW ROCHELLE,NY 10805; NEW YORK MED COLL,DEPT DERMATOL,NEW YORK,NY; NEW YORK MED COLL,DEPT PATHOL,NEW YORK,NY; LINCOLN HOSP CTR,NEW YORK,NY; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341	New York Medical College; New York Medical College; Centers for Disease Control & Prevention - USA								BRETTMAN LR, 1981, MEDICINE, V60, P363, DOI 10.1097/00005792-198109000-00004; DOLGOPOL VB, 1948, AM J PATHOL, V24, P119; GREENBERG M, 1947, B NEW YORK ACAD MED, V23, P338; GREENBERG M, 1947, JAMA-J AM MED ASSOC, V133, P901, DOI 10.1001/jama.1947.02880130001001; HEBERT GA, 1980, J CLIN MICROBIOL, V11, P503; HUEBNER RJ, 1946, PUBLIC HEALTH REP, V61, P1605, DOI 10.2307/4585895; HUEBNER RJ, 1947, PUBLIC HEALTH REP, V62, P777, DOI 10.2307/4586142; HUEBNER RJ, 1946, PUBLIC HEALTH REP, V61, P1677, DOI 10.2307/4585913; JACKSON EB, 1957, AM J HYG, V66, P301, DOI 10.1093/oxfordjournals.aje.a119903; JACOBSON JM, 1989, INT J DERMATOL, V28, P271, DOI 10.1111/j.1365-4362.1989.tb04821.x; KRINSKY WL, 1983, REV INFECT DIS, V5, P1118; LACKMAN DB, 1963, CLIN PEDIATR, V2, P296, DOI 10.1177/000992286300200602; MCCALMONT C, 1989, DERMATOL CLIN, V7, P591, DOI 10.1016/S0733-8635(18)30588-6; NICHOLS E, 1953, ANN INTERN MED, V39, P92, DOI 10.7326/0003-4819-39-1-92; PATERSON PY, 1966, B NEW YORK ACAD MED, V42, P579; PHILIP RN, 1976, J CLIN MICROBIOL, V3, P51; ROSE HM, 1949, ANN INTERN MED, V31, P871, DOI 10.7326/0003-4819-31-5-871; SHANKMAN B, 1946, NEW YORK STATE J MED, V46, P2156; SUSSMAN L N, 1946, NY Med, V2, P27; WALKER DH, 1978, J INFECT DIS, V137, P206, DOI 10.1093/infdis/137.2.206; 1982, LANCET, V1, P148	21	56	56	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1612	1617		10.1056/NEJM199412153312403	http://dx.doi.org/10.1056/NEJM199412153312403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7969341	Bronze			2022-12-24	WOS:A1994PW44600003
J	HARRIES, AD; CULLINAN, T				HARRIES, AD; CULLINAN, T			HERBIS ET ORBIS - THE DANGERS OF TRADITIONAL EYE MEDICINES	LANCET			English	Editorial Material									COLL MED,DEPT COMMUNITY HLTH,BLANTYRE,MALAWI	University of Malawi	HARRIES, AD (corresponding author), COLL MED,DEPT MED,BLANTYRE,MALAWI.							CHIRAMBO MC, 1976, BRIT J OPHTHALMOL, V60, P665, DOI 10.1136/bjo.60.9.665; COURTRIGHT P, 1994, BRIT J OPHTHALMOL, V74, P810; MCMOLI TE, 1984, BRIT J OPHTHALMOL, V68, P401, DOI 10.1136/bjo.68.6.401; YORSTON D, 1994, J TROP MED HYG, V97, P211	4	7	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1588	1588		10.1016/S0140-6736(94)90403-0	http://dx.doi.org/10.1016/S0140-6736(94)90403-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983991				2022-12-24	WOS:A1994PW05100006
J	NAIMAN, JL				NAIMAN, JL			DIGITALIS PURPUREA (FOXGLOVE)	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											NAIMAN, JL (corresponding author), STANFORD UNIV,SCH MED,STANFORD,CA 94303, USA.								0	1	1	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1563	1563						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV292	7969327				2022-12-24	WOS:A1994PV29200006
J	AMARENCO, P; COHEN, A; TZOURIO, C; BERTRAND, B; HOMMEL, M; BESSON, G; CHAUVEL, C; TOUBOUL, PJ; BOUSSER, MG				AMARENCO, P; COHEN, A; TZOURIO, C; BERTRAND, B; HOMMEL, M; BESSON, G; CHAUVEL, C; TOUBOUL, PJ; BOUSSER, MG			ATHEROSCLEROTIC DISEASE OF THE AORTIC-ARCH AND THE RISK OF ISCHEMIC STROKE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CHOLESTEROL EMBOLIZATION; CARDIOPULMONARY BYPASS; SYSTEMIC EMBOLIZATION; CEREBRAL INFARCTION; EMBOLISM; PLAQUE; COMPLICATION; ATHEROMAS; THROMBUS	Background. Atherosclerotic disease of the aortic arch has been suspected to be a potential source of cerebral emboli. We conducted a study to quantify the risk of ischemic stroke associated with atherosclerotic disease of the aortic arch. Methods. Using transesophageal echocardiography, we performed a prospective case-control study of the frequency and thickness of atherosclerotic plaques in the ascending aorta and proximal arch in 250 consecutive patients admitted to the hospital with ischemic stroke and 250 consecutive controls, all over the age of 60 years. Results. Atherosclerotic plaques greater than or equal to 4 mm in thickness were found in 14.4 percent of the patients but in only 2 percent of the controls. After adjustment for atherosclerotic risk factors, the odds ratio for ischemic stroke among patients with such plaques was 9.1 (95 percent confidence interval, 3.3 to 25.2; P<0.001). Among the 78 patients who had brain infarcts with no obvious cause, 28.2 percent had plaques greater than or equal to 4 mm in thickness, as compared with 8.1 percent of the 172 patients who had infarcts whose possible or likely causes were known (odds ratio, 4.7; 95 percent confidence interval, 2.2 to 10.1; P<0.001). Plaques of greater than or equal to 4 mm in the aortic arch were not associated with the presence of atrial fibrillation or stenosis of the extracranial internal carotid artery. In contrast, plaques that were 1 to 3.9 mm thick were frequently associated with carotid stenosis of greater than or equal to 70 percent. Conclusions. These results indicate a strong, independent association between atherosclerotic disease of the aortic arch and the risk of ischemic stroke. The association was particularly strong with thick plaques. Atherosclerotic disease of the aortic arch should be regarded as a risk factor for ischemic stroke and as a possible source of cerebral emboli.	UNIV PARIS 06,HOP ST ANTOINE,SERV CARDIOL,PARIS,FRANCE; INSERM,U360,VILLEJUIF,FRANCE; CHU GRENOBLE,NEUROL CLIN,GRENOBLE,FRANCE; CHU GRENOBLE,CARDIOL CLIN,GRENOBLE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	AMARENCO, P (corresponding author), UNIV PARIS 06,HOP ST ANTOINE,SERV NEUROL,184 RUE FAUBOURG ST ANTOINE,F-75571 PARIS 12,FRANCE.		Tzourio, christophe/L-6344-2019; Tzourio, Christophe I/B-7459-2008; Tzourio, christophe/B-4015-2009	Tzourio, christophe/0000-0002-6517-2984; Tzourio, christophe/0000-0002-6517-2984; Touboul, Pierre-Jean/0000-0002-8872-9917				AMARENCO P, 1992, STROKE, V23, P1005, DOI 10.1161/01.STR.23.7.1005; AMARENCO P, 1992, NEW ENGL J MED, V326, P221, DOI 10.1056/NEJM199201233260402; BEAL MF, 1981, NEUROLOGY, V31, P860, DOI 10.1212/WNL.31.7.860; BRUNS FJ, 1978, AM J MED SCI, V275, P105, DOI 10.1097/00000441-197801000-00013; CAPLAN LR, 1993, NEUROLOGY, V43, P1281, DOI 10.1212/WNL.43.7.1281; CHESEBRO JH, 1990, NEW ENGL J MED, V323, P1556; COGAN DG, 1964, ARCH OPHTHALMOL-CHIC, V71, P308; Culliford Alfred T., 1993, Journal of the American College of Cardiology, V21, p342A; DAVID NJ, 1963, NEUROLOGY, V13, P708, DOI 10.1212/WNL.13.8.708; FAZIO GP, 1993, J AM COLL CARDIOL, V21, P144, DOI 10.1016/0735-1097(93)90729-K; FEDER W, 1961, ANN INTERN MED, V55, P911, DOI 10.7326/0003-4819-55-6-911; GARDNER TJ, 1985, ANN THORAC SURG, V40, P574, DOI 10.1016/S0003-4975(10)60352-9; GORE I, 1960, AM J CLIN PATHOL, V33, P416; HAUSMANN D, 1992, NEW ENGL J MED, V327, P500; HOLLENHORST RW, 1966, AM J OPHTHALMOL, V61, P1159, DOI 10.1016/0002-9394(66)90238-8; HOROWITZ DR, 1992, NEUROLOGY, V42, P1602, DOI 10.1212/WNL.42.8.1602; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; KATZ ES, 1992, J AM COLL CARDIOL, V20, P70, DOI 10.1016/0735-1097(92)90139-E; MCKIBBIN DW, 1976, J THORAC CARDIOV SUR, V71, P741; MOHR-KAHALY S, 1992, European Heart Journal, V13, P17; MOLDVEEN.M, 1967, CIRCULATION, V35, P946, DOI 10.1161/01.CIR.35.5.946; NIHOYANNOPOULOS P, 1993, AM J CARDIOL, V71, P1208, DOI 10.1016/0002-9149(93)90647-U; OSTER P, 1979, JAMA-J AM MED ASSOC, V242, P2070, DOI 10.1001/jama.242.19.2070; PFAFFENBACH DD, 1973, AM J OPHTHALMOL, V75, P66, DOI 10.1016/0002-9394(73)90653-3; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; PRICE DL, 1970, NEUROLOGY, V20, P1209, DOI 10.1212/WNL.20.12.1209; RAMIREZ G, 1978, ARCH INTERN MED, V138, P1430, DOI 10.1001/archinte.138.9.1430; RUSSELL RWR, 1983, VASCULAR DISEASE CTR, P394; SOLOWAY HB, 1964, ARCH NEUROL-CHICAGO, V11, P657, DOI 10.1001/archneur.1964.00460240089012; STURGILL BC, 1963, ARCH PATHOL, V76, P189; TOUBOUL PJ, 1992, J HYPERTENS, V10, pS37, DOI 10.1097/00004872-199207005-00006; TOYODA K, 1992, STROKE, V23, P1056, DOI 10.1161/01.STR.23.8.1056; TUNICK PA, 1990, AM HEART J, V120, P658, DOI 10.1016/0002-8703(90)90024-R; TUNICK PA, 1991, ANN INTERN MED, V115, P423, DOI 10.7326/0003-4819-115-6-423; TUNICK PA, 1992, AM HEART J, V124, P239; WINTER WJ, 1957, ARCH PATHOL, V64, P137; 1972, NEW ENGL J MED, V286, P1146; 1967, NEW ENGL J MED, V276, P1368; 1990, SAS USERS GUIDE, V1	39	722	742	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1474	1479		10.1056/NEJM199412013312202	http://dx.doi.org/10.1056/NEJM199412013312202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969297	Bronze			2022-12-24	WOS:A1994PU86600002
J	KINOSHITA, J; MERVIS, J				KINOSHITA, J; MERVIS, J			SEND IN THE CLONES	SCIENCE			English	Editorial Material																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1187	1187		10.1126/science.7973699	http://dx.doi.org/10.1126/science.7973699			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973699				2022-12-24	WOS:A1994PT13200038
J	ADLEMAN, LM				ADLEMAN, LM			MOLECULAR COMPUTATION OF SOLUTIONS TO COMBINATORIAL PROBLEMS	SCIENCE			English	Article								The tools of molecular biology were used to solve an instance of the directed Hamiltonian path problem. A small graph was encoded in molecules of DNA, and the ''operations'' of the computation were performed with standard protocols and enzymes. This experiment demonstrates the feasibility of carrying out computations at the molecular level.	UNIV SO CALIF,INST MOLEC & MED TECHNOL,LOS ANGELES,CA 90089	University of Southern California	ADLEMAN, LM (corresponding author), UNIV SO CALIF,DEPT COMP SCI,941 W 37TH PL,LOS ANGELES,CA 90089, USA.							BRADLEY D, 1993, SCIENCE, V259, P890, DOI 10.1126/science.259.5097.890; CRANDALL BC, 1992, NANOTECHNOLOGY; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; Feynman R. P., 1961, MINIATURIZATION, P282, DOI DOI 10.1201/9781315217178; Garey M.R., 1979, COMPUTERS INTRACTABI; Karp R. M., 1972, REDUCIBILITY COMBINA, P85; Merkle R. C., 1993, Nanotechnology, V4, P21, DOI 10.1088/0957-4484/4/1/002; Rogers Jr H., 1987, THEORY RECURSIVE FUN; Sambrook J., 1989, MOL CLONING; SCHNEIDER TD, 1991, J THEOR BIOL, V148, P125, DOI 10.1016/S0022-5193(05)80467-9; Watson J. D., 1987, MOL BIOL GENE	11	2662	2990	20	422	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1021	1024		10.1126/science.7973651	http://dx.doi.org/10.1126/science.7973651			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973651				2022-12-24	WOS:A1994PQ92400037
J	TUSCHL, T; GOHLKE, C; JOVIN, TM; WESTHOF, E; ECKSTEIN, F				TUSCHL, T; GOHLKE, C; JOVIN, TM; WESTHOF, E; ECKSTEIN, F			3-DIMENSIONAL MODEL FOR THE HAMMERHEAD RIBOZYME BASED ON FLUORESCENCE MEASUREMENTS	SCIENCE			English	Article							RESONANCE ENERGY-TRANSFER; 4-WAY DNA JUNCTION; RNA; CLEAVAGE; PREDICTIONS; PARAMETERS	For the understanding of the catalytic function of the RNA hammerhead ribozyme, a three-dimensional model is essential but neither a crystal nor a solution structure has been available. Fluorescence resonance energy transfer (FRET) was used to study the structure of the ribozyme in solution in order to establish the relative spatial orientation of the three constituent Watson-Crick base-paired helical segments. Synthetic constructs were labeled with the fluorescence donor (5-carboxyfluorescein) and acceptor (5-carboxytetramethylrhodamine) located at the ends of the strands constituting the ribozyme molecule. The acceptor helix in helix pairs I and III and in II and III was varied in length from 5 to 11 and 5 to 9 base pairs, respectively, and the FRET efficiencies were determined and correlated with a reference set of labeled RNA duplexes. The FRET efficiencies were predicted on the basis of vector algebra analysis, as a function of the relative helical orientations in the ribozyme constructs, and compared with experimental values. The data were consistent with a Y-shaped arrangement of the ribozyme with helices I and II in close proximity and helix III pointing away. These orientational constraints were used for molecular modeling of a three-dimensional structure of the complete ribozyme.	MAX PLANCK INST EXPTL MED, D-37075 GOTTINGEN, GERMANY; INST MOLEK BIOTECHNOL EV, MOLEK BIOL ABT, D-07745 JENA, GERMANY; MAX PLANCK INST BIOPHYS CHEM, D-37077 GOTTINGEN, GERMANY; CNRS, INST BIOL MOLEC & CELLULAIRE, F-67084 STRASBOURG, FRANCE	Max Planck Society; Max Planck Society; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ALTMAN S, 1993, P NATL ACAD SCI USA, V90, P10898, DOI 10.1073/pnas.90.23.10898; ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V48, P1392, DOI 10.1016/0006-291X(72)90867-4; AURUP H, 1994, NUCLEIC ACIDS RES, V22, P20, DOI 10.1093/nar/22.1.20; BRATTY J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P345, DOI 10.1016/0167-4781(93)90001-T; BRUENING G, 1989, METHOD ENZYMOL, V180, P546; CARDULLO RA, 1988, P NATL ACAD SCI USA, V85, P8790, DOI 10.1073/pnas.85.23.8790; CLEGG RM, 1993, P NATL ACAD SCI USA, V90, P2994, DOI 10.1073/pnas.90.7.2994; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; CLEGG RM, 1992, BIOCHEMISTRY-US, V31, P4846, DOI 10.1021/bi00135a016; Crooke S, 1993, ANTISENSE RES APPLIC, P83; DENMAN RB, 1993, BIOTECHNIQUES, V15, P1090; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; Forster, 1951, FLUORESZENZ ORGANISC; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FU DJ, 1993, BIOCHEMISTRY-US, V32, P10629, DOI 10.1021/bi00091a013; GAST FU, 1994, BIOCHEMISTRY-US, V33, P1788, DOI 10.1021/bi00173a023; GOHIKE C, IN PRESS P NATL ACAD; Goldstein H., 1980, CLASSICAL MECH, V2nd ed; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; HEUS HA, 1991, J MOL BIOL, V217, P113, DOI 10.1016/0022-2836(91)90615-D; HODGSON RAJ, 1994, NUCLEIC ACIDS RES, V22, P1620, DOI 10.1093/nar/22.9.1620; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JEFFRIES AC, 1989, NUCLEIC ACIDS RES, V17, P1371, DOI 10.1093/nar/17.4.1371; KEESE P, 1987, VIROIDS VIROID LIKE, P1; KIM R, 1994, ACTA CRYSTALLOGR D, V50, P290, DOI 10.1107/S0907444993013071; Lakowicz J.R., 2006, PRINCIPLES FLUORESCE, P1, DOI 10.1007/978-0-387-46312-4/COVER; LONG DM, 1993, FASEB J, V7, P25, DOI 10.1096/fasebj.7.1.8422971; MARSCHALL P, IN PRESS CELL MOL NE; MASSIRE C, 1994, J MOL GRAPHICS, V12, P201, DOI 10.1016/0263-7855(94)80088-X; MEI HY, 1989, P NATL ACAD SCI USA, V86, P9727, DOI 10.1073/pnas.86.24.9727; MERGNY JL, 1994, NUCLEIC ACIDS RES, V22, P920, DOI 10.1093/nar/22.6.920; MORRISON LE, 1993, BIOCHEMISTRY-US, V32, P3095, DOI 10.1021/bi00063a022; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; OZAKI H, 1992, NUCLEIC ACIDS RES, V20, P5205, DOI 10.1093/nar/20.19.5205; PLEY HW, 1993, J BIOL CHEM, V268, P19656; ROSSI JJ, 1992, AIDS RES HUM RETROV, V8, P183, DOI 10.1089/aid.1992.8.183; SIXOU S, IN PRESS DNA INTERAC; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; THEISEN P, 1992, TETRAHEDRON LETT, V33, P5033, DOI 10.1016/S0040-4039(00)61181-4; TUSCHL T, 1993, P NATL ACAD SCI USA, V90, P6991, DOI 10.1073/pnas.90.15.6991; TUSCHL T, 1993, BIOCHEMISTRY-US, V32, P11658, DOI 10.1021/bi00094a023; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8	43	212	218	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	1994	266	5186					785	789		10.1126/science.7973630	http://dx.doi.org/10.1126/science.7973630			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973630				2022-12-24	WOS:A1994PP75300034
J	OKANO, T; YOSHIZAWA, T; FUKADA, Y				OKANO, T; YOSHIZAWA, T; FUKADA, Y			PINOPSIN IS A CHICKEN PINEAL PHOTORECEPTIVE MOLECULE	NATURE			English	Article							N-ACETYLTRANSFERASE ACTIVITY; CONE VISUAL PIGMENTS; GLAND; RHODOPSIN; INVITRO; IDENTIFICATION; CULTURE; RETINA; CLOCK; LIGHT	IN avian pinealocytes, an environmental light signal resets the phase of the endogenous circadian pacemaker that controls the rhythmic production of melatonin(1-6). Investigation of the pineal phototransduction pathway should therefore reveal the molecular mechanism of the biological clock. The presence of rhodopsin-like photoreceptive pigment(4,5,7-9), transducin-like immunoreaction(10), and cyclic GMP-dependent cation-channel activity(11) in the avian pinealocytes suggests that there is a similarity between retinal rod cells and pinealocytes in the phototransduction pathway. We have now cloned chicken pineal cDNA encoding the photoreceptive molecule, which is 43-48% identical in amino-acid sequence to vertebrate retinal opsins. Pineal opsin, produced by transfection of complementary DNA into cultured cells, was reconstituted with 11-cis-retinal, resulting in formation of a blue-sensitive pigment (lambda(max) approximate to 470 nm). In the fight of this functional evidence and because the gene is specifically expressed only in the pineal gland, we conclude that it is a pineal photosensor and name it pinopsin.	OSAKA SANGYO UNIV, FAC ENGN, DEPT INFORMAT SYST ENGN, DAITO, OSAKA 574, JAPAN; UNIV TOKYO, COLL ARTS & SCI, DEPT PURE & APPL SCI, BUNKYO KU, TOKYO 153, JAPAN	University of Tokyo			吉孝, 深田/G-5090-2014	Okano, Toshiyuki/0000-0001-6740-6265				ARAKI M, 1992, DEV BRAIN RES, V65, P85, DOI 10.1016/0165-3806(92)90011-K; BINKLEY SA, 1978, SCIENCE, V202, P1198, DOI 10.1126/science.214852; DEGUCHI T, 1981, NATURE, V290, P706, DOI 10.1038/290706a0; DEGUCHI T, 1979, SCIENCE, V203, P1245, DOI 10.1126/science.424750; DRYER SE, 1991, NATURE, V353, P756, DOI 10.1038/353756a0; FOSTER RG, 1989, J COMP PHYSIOL A, V165, P553, DOI 10.1007/BF00611241; KASAL CA, 1979, SCIENCE, V203, P656, DOI 10.1126/science.569904; KOJIMA D, 1992, P NATL ACAD SCI USA, V89, P6841, DOI 10.1073/pnas.89.15.6841; KUWATA O, 1990, FEBS LETT, V272, P128, DOI 10.1016/0014-5793(90)80465-U; MASUDA H, 1994, TISSUE CELL, V26, P101, DOI 10.1016/0040-8166(94)90086-8; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; OKANO T, 1989, BIOCHEMISTRY-US, V28, P8848, DOI 10.1021/bi00448a025; OKANO T, 1992, P NATL ACAD SCI USA, V89, P5932, DOI 10.1073/pnas.89.13.5932; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU; SUN JH, 1991, NEUROSCI LETT, V133, P97, DOI 10.1016/0304-3940(91)90066-3; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAO M, 1988, VISION RES, V28, P471, DOI 10.1016/0042-6989(88)90169-1; VANVEEN T, 1986, P NATL ACAD SCI USA, V83, P912; WALLINGFORD JC, 1988, EXP EYE RES, V46, P909, DOI 10.1016/S0014-4835(88)80042-3; ZATZ M, 1988, BRAIN RES, V453, P63, DOI 10.1016/0006-8993(88)90143-6	21	268	275	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	1994	372	6501					94	97		10.1038/372094a0	http://dx.doi.org/10.1038/372094a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969427				2022-12-24	WOS:A1994PQ34800080
J	GRIGORIADIS, AE; WANG, ZQ; CECCHINI, MG; HOFSTETTER, W; FELIX, R; FLEISCH, HA; WAGNER, EF				GRIGORIADIS, AE; WANG, ZQ; CECCHINI, MG; HOFSTETTER, W; FELIX, R; FLEISCH, HA; WAGNER, EF			C-FOS - A KEY REGULATOR OF OSTEOCLAST-MACROPHAGE LINEAGE DETERMINATION AND BONE REMODELING	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; CELL-POPULATION; DIFFERENTIATION; EXPRESSION; RESORPTION; MARROW; MOUSE; PROLIFERATION	Mice lacking the proto-oncogene c-fos develop the bone disease osteopetrosis. Fos mutant mice were found to have a block in the differentiation of bone-resorbing osteoclasts that was intrinsic to hematopoietic cells. Bone marrow transplantation rescued the osteopetrosis, and ectopic c-fos expression overcame this differentiation block. The lack of Fos also caused a lineage shift between osteoclasts and macrophages that resulted in increased numbers of bone marrow macrophages. These results identify Fos as a key regulator of osteoclast-macrophage lineage determination in vivo and provide insights into the molecular mechanisms underlying metabolic bone diseases.	RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA; UNIV BERN, DEPT PATHOPHYSIOL, CH-3010 BERN, SWITZERLAND	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Bern				Hofstetter, Wilhelm/0000-0003-0126-8423; Wagner, Erwin F/0000-0001-7872-0196				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aubin Jane E., 1993, P1; CECCHINI MG, 1994, DEVELOPMENT, V120, P1357; CECCHINI MG, UNPUB; CHAMBERS TJ, 1989, BONE MINERAL RES, V6, P1; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; FELIX R, 1990, J BONE MINER RES, V5, P781; FELIX R, UNPUB; GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, UNPUB; Grigoriadis Agamemnon E., 1993, P497; HATTERSLEY G, 1991, BIOCHEM BIOPH RES CO, V177, P526, DOI 10.1016/0006-291X(91)92015-C; HO MK, 1982, J IMMUNOL, V128, P1221; HOFSTETTER W, 1992, P NATL ACAD SCI USA, V89, P9637, DOI 10.1073/pnas.89.20.9637; HOFSTETTER W, UNPUB; HOYLAND J, 1994, J BONE MINER RES, V9, P1191; HUME DA, 1984, J CELL SCI, V66, P189; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KERBY JA, 1992, J BONE MINER RES, V7, P353; KRATOCHWIL K, 1989, CELL, V57, P807, DOI 10.1016/0092-8674(89)90795-2; LEE MY, 1992, BLOOD, V80, P1710; LEENEN PJM, 1990, EUR J IMMUNOL, V20, P27, DOI 10.1002/eji.1830200105; LLIANG J, UNPUB; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; MARKS SC, 1989, AM J MED GENET, V34, P43, DOI 10.1002/ajmg.1320340110; MARKS SC, 1984, CLIN ORTHOP RELAT R, P239; MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; MULLER R, 1994, FOS JUN FAMILIES TRA, P189; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NIIDA S, 1994, J BONE MINER RES, V9, P873; OKADA S, 1994, MOL CELL BIOL, V14, P382, DOI 10.1128/MCB.14.1.382; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; RUTHER U, 1989, ONCOGENE, V4, P861; SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422; SANDBERG M, 1988, DEVELOPMENT, V102, P461; SANDBERG M, 1988, DEV BIOL, V130, P324, DOI 10.1016/0012-1606(88)90438-1; SCHEVEN BAA, 1986, ANAT RECORD, V214, P418, DOI 10.1002/ar.1092140413; SCHEVEN BAA, 1986, NATURE, V321, P79, DOI 10.1038/321079a0; SHERR CJ, 1990, BLOOD, V75, P1; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TAKAHASHI N, 1994, DEV BIOL, V163, P212, DOI 10.1006/dbio.1994.1137; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; WALKER DG, 1975, SCIENCE, V190, P784, DOI 10.1126/science.1105786; WANG ZQ, 1993, J BONE MINER RES, V8, P839; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WUCHERPFENNIG AL, 1994, J BONE MINER RES, V9, P549	56	1027	1057	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	1994	266	5184					443	448		10.1126/science.7939685	http://dx.doi.org/10.1126/science.7939685			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939685				2022-12-24	WOS:A1994PN27200037
J	GOURLAY, SG; FORBES, A; MARRINER, T; PETHICA, D; MCNEIL, JJ				GOURLAY, SG; FORBES, A; MARRINER, T; PETHICA, D; MCNEIL, JJ			PROSPECTIVE-STUDY OF FACTORS PREDICTING OUTCOME OF TRANSDERMAL NICOTINE TREATMENT IN SMOKING CESSATION	BRITISH MEDICAL JOURNAL			English	Article							QUITTING SMOKING; UNITED-STATES; CONTROLLED TRIAL; RELAPSE; HEAVINESS; CIGARETTE; REASONS; PATCHES; SMOKERS	Objective-To assess the factors associated with cessation of smoking with transdermal nicotine and brief behavioural counselling. Design-Interviews, treatment, and follow up for 26 weeks. Subjects-1481 subjects recruited by mass media publicity who smoked greater than or equal to 15 cigarettes a day and were motivated to stop smoking. Interventions-Twelve weeks' treatment with transdermal nicotine and brief behavioural counselling at monthly visits. Main outcome measure-Sustained smoking cessation for the 28 days before the visit at week 26 verified by expired carbon monoxide concentrations. The logistic regression analysis included all subjects. Results-Most subjects were dependent on nicotine, and the mean (SD) number of cigarettes smoked a day was 32 (12). Overall, 316/1481 subjects (21.3%) stopped smoking. Factors associated with stopping were being male (adjusted odds ratio 2.0; 95% confidence interval 1.5 to 2.7), age greater than or equal to 40 years (1.5; 1.1 to 2.0), living with a spouse or partner (1.5; 1.1 to 2.1), motivation (''want to quit'' 1.7; 1.2 to 2.3), and concern about weight gain (1.7; 1.3 to 2.2). Negative associations were smoking marijuana (0.4; 0.2 to 0.8) and the presence of other smokers in the household (0.8; 0.6 to 0.9). Almost all subjects who smoked three or more cigarettes in the first four weeks of treatment resumed smoking in the long term (525/547, 96%). Conclusions-Age, sex, marital status (living with a spouse or partner), motivation, concern about weight gain, recent marijuana smoking, and other smokers in the household were baseline factors associated with differences in outcome of smoking cessation attempts. Smoking three or more cigarettes in the first few weeks after stopping strongly predicted long term relapse.	CIBA GEIGY NEW ZEALAND,AUCKLAND,NEW ZEALAND		GOURLAY, SG (corresponding author), ALFRED HOSP,MONASH MED SCH,DEPT SOCIAL & PREVENT MED,PRAHRAN,VIC 3181,AUSTRALIA.		McNeil, John/L-6440-2019	McNeil, John/0000-0002-1049-5129; Forbes, Andrew/0000-0003-4269-914X				ABRAMS DB, 1992, PREV MED, V21, P679, DOI 10.1016/0091-7435(92)90075-S; Beck A. T., 1960, ARCH GEN PSYCHIAT, V4, P53, DOI DOI 10.1001/ARCHPSYC.1961.01710120031004; Beck AT., 1996, BECK DEPRESSION INVE; BLONDAL T, 1989, ARCH INTERN MED, V149, P1818, DOI 10.1001/archinte.149.8.1818; COAMBS RB, 1992, AM J EPIDEMIOL, V135, P240, DOI 10.1093/oxfordjournals.aje.a116277; Collins R L, 1990, J Subst Abuse, V2, P389; DUNCAN CL, 1992, J GEN INTERN MED, V7, P398, DOI 10.1007/BF02599155; FAGERSTROM KO, 1982, J BEHAV MED, V5, P343, DOI 10.1007/BF00846161; FIORE MC, 1990, JAMA-J AM MED ASSOC, V263, P2760, DOI 10.1001/jama.263.20.2760; FREUND KM, 1992, AM J EPIDEMIOL, V135, P957, DOI 10.1093/oxfordjournals.aje.a116407; GARVEY AJ, 1992, ADDICT BEHAV, V17, P367, DOI 10.1016/0306-4603(92)90042-T; GOURLAY S, 1994, MED J AUSTRALIA, V160, P152, DOI 10.5694/j.1326-5377.1994.tb126568.x; GOURLAY SG, 1990, MED J AUSTRALIA, V153, P699, DOI 10.5694/j.1326-5377.1990.tb126327.x; HATZIANDREU EJ, 1990, J NATL CANCER I, V82, P1402, DOI 10.1093/jnci/82.17.1402; HEATHERTON TF, 1989, BRIT J ADDICT, V84, P791; KABAT GC, 1987, AM J PUBLIC HEALTH, V77, P1301, DOI 10.2105/AJPH.77.10.1301; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; KILLEN JD, 1992, J CONSULT CLIN PSYCH, V60, P797, DOI 10.1037/0022-006X.60.5.797; NORREGAARD J, 1993, PREV MED, V22, P261, DOI 10.1006/pmed.1993.1021; OLSEN J, 1993, SCAND J SOC MED, V3, P197; ORLEANS CT, 1994, JAMA-J AM MED ASSOC, V271, P601, DOI 10.1001/jama.271.8.601; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P61, DOI 10.1001/jama.261.1.61; RUSSELL MAH, 1993, BRIT MED J, V306, P1308, DOI 10.1136/bmj.306.6888.1308; SACHS DPL, 1993, ARCH INTERN MED, V153, P1881, DOI 10.1001/archinte.153.16.1881; SALIVE ME, 1992, AM J PUBLIC HEALTH, V82, P1268, DOI 10.2105/AJPH.82.9.1268; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; VANREEK J, 1988, BRIT J ADDICT, V83, P588; 1993, BRIT MED J, V306, P1304; 1991, GOOD CLIN RES PRACTI; 1991, EGRET EPIDEMIOLOGICA; 1988, SAS USERS GUIDE STAT	32	155	155	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					842	846		10.1136/bmj.309.6958.842	http://dx.doi.org/10.1136/bmj.309.6958.842			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PK501	7950614	Green Published			2022-12-24	WOS:A1994PK50100021
J	HOWIE, JGR; HEANEY, DJ; MAXWELL, M				HOWIE, JGR; HEANEY, DJ; MAXWELL, M			EVALUATING CARE OF PATIENTS REPORTING PAIN IN FUNDHOLDING PRACTICES	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; NHS; PATTERNS; COSTS	Objective-To compare quality of care between 1990 and 1992 in patients with self diagnosed joint pain. Design-Questionnaire and record based study. Subjects-Patients identified at consecutive consultations during two weeks in 1990, 1991, and 1992. Setting-Six practice groups in pilot fundholding scheme in Scotland. Main outcome measures-length of consultation; numbers referred or investigated or prescribed drugs; responses to questions about enablement and satisfaction. Results-About 15% of patients consulted with joint pain each year. 25% (316) of them had social problems in 1990 and 37% (370) in 1992; about a fifth wanted to discuss their social problems. Social problems were associated with a raised general health questionnaire score. The mean length of consultation for patients with pain was 7.6 min in 1990 and 7.7 min in 1992. Patients wishing to discuss social problems received longer consultations (8.5 min 1990; 10.4 min 1992); but other patients with social problems received shorter consultations (7.4 min; 7.2 min). The level of prescribing was stable but the proportion of patients having investigations or attending hospital fell significantly from 1990 to 1992 (31% to 24%; 31% to 13% respectively). Fewer patients responded ''much better'' to six questions about enablement in 1992 than in 1990. Enablement was better after longer than shorter consultations for patients with social problems. Conclusions-Quality of care for patients with pain has been broadly maintained in terms of consultation times. The effects of lower rates of investigation and referral need to be investigated further.			HOWIE, JGR (corresponding author), UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH EH8 9DX,SCOTLAND.			Maxwell, Margaret/0000-0003-3318-9500				BAIN J, 1993, BRIT MED J, V306, P1185, DOI 10.1136/bmj.306.6886.1185; BAIN J, 1992, BRIT MED J, V304, P971, DOI 10.1136/bmj.304.6832.971; BAIN J, 1991, BRIT MED J, V302, P771, DOI 10.1136/bmj.302.6779.771; BAZANGER I, 1989, SOC SCI MED, V29, P425; BOWIE C, 1994, BRIT J GEN PRACT, V44, P38; CORNEY R, 1994, BRIT J GEN PRACT, V44, P34; COULTER A, 1993, BRIT MED J, V306, P433, DOI 10.1136/bmj.306.6875.433; COULTER A, 1992, BRIT MED J, V304, P397, DOI 10.1136/bmj.304.6824.397; COULTER A, 1993, BRIT MED J, V307, P1186; CROOK J, 1984, PAIN, V18, P299, DOI 10.1016/0304-3959(84)90824-8; CRUMP BJ, 1991, BRIT MED J, V302, P1582, DOI 10.1136/bmj.302.6792.1582; DAY P, 1991, BRIT MED J, V303, P168, DOI 10.1136/bmj.303.6795.168; GLENNERSTER H, 1992, FOOTHOLD FUNDHOLDING; HOPTON JL, 1991, FAM PRACT, V8, P253, DOI 10.1093/fampra/8.3.253; Howie J G, 1993, Health Bull (Edinb), V51, P94; Howie J G, 1992, Health Bull (Edinb), V50, P316; HOWIE JGR, 1991, BRIT J GEN PRACT, V41, P48; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; NEWTON J, 1993, BRIT MED J, V306, P375, DOI 10.1136/bmj.306.6874.375; PURVES IN, 1993, BRIT MED J, V306, P496, DOI 10.1136/bmj.306.6876.496; 1986, MORBIDITY STATISTICS	21	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					705	710		10.1136/bmj.309.6956.705	http://dx.doi.org/10.1136/bmj.309.6956.705			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7950524	Green Published			2022-12-24	WOS:A1994PH40700018
J	OWENS, DM; NELSON, DK; TALLEY, NJ				OWENS, DM; NELSON, DK; TALLEY, NJ			THE IRRITABLE-BOWEL-SYNDROME - LONG-TERM PROGNOSIS AND THE PHYSICIAN-PATIENT INTERACTION	ANNALS OF INTERNAL MEDICINE			English	Article						COLONIC DISEASES, FUNCTIONAL; PHYSICIAN-PATIENT RELATIONS; DIARRHEA; ABDOMINAL PAIN	ALTERNATIVE MEDICINE; EPIDEMIOLOGY; ENCOUNTERS; DISCOURSE; CRITIQUE	Objective: To evaluate the long-term course and prognosis associated with the irritable bowel syndrome (IBS) and to determine the influence of an effective physician-patient relationship on subsequent health care use. Design: Prospective review of medical records. Setting: Tertiary referral center. Patients: 112 consecutive Olmsted County, Minnesota, residents who were first diagnosed with IBS at the Mayo Clinic during the period 1961-1963. Results: The median follow-up was 29 years (range, 1 to 32 years) and patients made a median of 2 return visits for IBS-related symptoms (range, 0 to 12 visits). In addition to abdominal pain, diarrhea (reported by 50% of patients) was the predominant bowel symptom at diagnosis. Organic gastrointestinal disease occurred in 10 patients a median of 15 years after diagnosis of IBS. Survival in patients with IBS did not differ from expected survival (27 deaths; median survival > 30 years after initial diagnosis). A positive physician-patient interaction, defined a priori using objective criteria in the written record, was associated with fewer return visits for IBS. Of the eight variables examined, notations in the medical record about psychosocial history, precipitating factors, and discussion of diagnosis and treatment with patients were associated with fewer return visits for IBS-related symptoms. Conclusions: When diagnosed according to current criteria, IBS is associated with a good prognosis and the diagnosis is unlikely to be changed to that of an organic disease during follow-up. A positive physician-patient interaction may be related to reduced use of ambulatory health services by patients with IBS.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA	Mayo Clinic			Talley, Nicholas J/D-5399-2013	Talley, Nicholas J/0000-0003-2537-3092	NIA NIH HHS [R01 AG099440] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLPORT GW, 1942, B SOCIAL SCI RES COU, V49, pR12; BARFOOT M, 1990, PSYCHOL MED, V20, P263, DOI 10.1017/S0033291700017591; BERTAKIS KD, 1991, J FAM PRACTICE, V32, P175; CAMILLERI M, 1992, ANN INTERN MED, V116, P1001, DOI 10.7326/0003-4819-116-12-1001; CHAUDHARY NA, 1962, Q J MED, V31, P307; Drossman D., 1990, GASTR INT, V3, P159; DROSSMAN DA, 1992, ANN INTERN MED, V116, P1009, DOI 10.7326/0003-4819-116-12-1009; FREEMON B, 1971, PEDIATR RES, V5, P298; HALL JA, 1988, MED CARE, V26, P657, DOI 10.1097/00005650-198807000-00002; HARVEY RF, 1987, LANCET, V1, P963; HOLMES KM, 1982, BRIT MED J, V285, P1533, DOI 10.1136/bmj.285.6354.1533; Houston WR, 1938, ANN INTERN MED, V11, P1416, DOI 10.7326/0003-4819-11-8-1416; INUI TS, 1982, MED CARE, V20, P535, DOI 10.1097/00005650-198206000-00001; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; KLEIN KB, 1988, GASTROENTEROLOGY, V95, P232, DOI 10.1016/0016-5085(88)90319-8; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LUPTON D, 1992, AUST J PUBLIC HEALTH, V16, P145; PAGANO MP, 1992, COMMUNICATING EFFECT; PHILLIPS SF, 1992, MOTILITY DISORDERS G, P299; PUTNAM SM, 1985, MED CARE, V23, P74, DOI 10.1097/00005650-198501000-00008; Roter D.L., 1992, DOCTORS TALKING PATI; Ryle JA, 1928, LANCET, V2, P1115; SMART HL, 1986, GUT, V27, P826, DOI 10.1136/gut.27.7.826; SVENDSEN JH, 1985, SCAND J GASTROENTERO, V20, P415, DOI 10.3109/00365528509089673; TALLEY NJ, 1991, GASTROENTEROLOGY, V101, P927, DOI 10.1016/0016-5085(91)90717-Y; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; VERHOEF MJ, 1990, CAN MED ASSOC J, V142, P121; WAITZKIN H, 1990, MED CARE, V28, P473, DOI 10.1097/00005650-199006000-00001; WALLER SL, 1969, LANCET, V2, P753	29	248	252	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					107	+		10.7326/0003-4819-122-2-199501150-00005	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7992984				2022-12-24	WOS:A1995QC05900005
J	HIROSE, K; IINO, M				HIROSE, K; IINO, M			HETEROGENEITY OF CHANNEL DENSITY IN INOSITOL-1,4,5-SENSITIVE TRISPHOSPHATE-SENSITIVE CA2+ STORES	NATURE			English	Article							VASCULAR SMOOTH-MUSCLE; CALCIUM RELEASE; FLUORESCENT INDICATOR; INTRACELLULAR STORES; 1,4,5-TRISPHOSPHATE; CELLS; MECHANISM; MOBILIZATION; DEPENDENCE	INOSITOL-1,4,5-trisphosphate (InsP(3))-induced Ca2+ release is a key mechanism for intracellular Ca2+ mobilization(1). The rate of Ca2+ release declines progressively with time until a higher concentration of InsP(3) is added, which is referred to as the incremental detection mechanism(2). Two hypotheses have been postulated to explain these complex kinetics: (1) Ca2+ stores consist of multiple compartments (quanta) with different sensitivities to InsP(3) (refs 3-7), and (2) the rate of Ca2+ release is modulated by the Ca2+ concentration in the lumen of Ca2+ stores(8-12). We studied this phenomenon by real-time measurement of the luminal Ca2+ concentration of Ca2+ stores using a Ca2+-sensitive fluorescent dye, but our results were not explained by either of these hypotheses. Here we report that the complex kinetics of Ca2+ release results from the heterogeneous density of equally InsP(3)-sensitive channels on the Ca2+ stores. This heterogeneity creates Ca2+ stores with apparently different sensitivities to InsP(3), which may have different functions in Ca2+ mobilization.			HIROSE, K (corresponding author), UNIV TOKYO, FAC MED, DEPT PHARMACOL, BUNKYO KU, TOKYO 113, JAPAN.			Hirose, Kenzo/0000-0002-8944-6513				AHNERTHILGER G, 1988, TRENDS PHARMACOL SCI, V9, P195, DOI 10.1016/0165-6147(88)90081-8; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; HIROSE K, 1993, BIOCHEM BIOPH RES CO, V194, P726, DOI 10.1006/bbrc.1993.1882; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; INO M, 1989, J GEN PHYSIOL, V94, P363, DOI 10.1085/jgp.94.2.363; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KOBAYASHI S, 1988, BIOCHEM BIOPH RES CO, V153, P625, DOI 10.1016/S0006-291X(88)81141-0; LOOMISHUSSELBEE JW, 1993, BIOCHEM J, V289, P861, DOI 10.1042/bj2890861; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MUALLEM S, 1989, J BIOL CHEM, V264, P205; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARYS JB, 1993, J BIOL CHEM, V268, P25206; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; SHORT AD, 1993, J BIOL CHEM, V268, P25887; Somlyo AV, 1980, HDB PHYSL          2, P33; SWILLENS S, 1992, MOL PHARMACOL, V41, P110; UYAMA Y, 1992, BRIT J PHARMACOL, V106, P208, DOI 10.1111/j.1476-5381.1992.tb14316.x	29	114	116	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					791	794						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997268				2022-12-24	WOS:A1994PY21200056
J	NELSON, HD; NEVITT, MC; SCOTT, JC; STONE, KL; CUMMINGS, SR				NELSON, HD; NEVITT, MC; SCOTT, JC; STONE, KL; CUMMINGS, SR			SMOKING, ALCOHOL, AND NEUROMUSCULAR AND PHYSICAL FUNCTION OF OLDER WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; CIGARETTE-SMOKING; MAINTAINING MOBILITY; POSTMENOPAUSAL WOMEN; ARTERIAL-DISEASE; ALAMEDA COUNTY; HEART-DISEASE; BREAST-CANCER; LATE-LIFE; CONSUMPTION	Objective.-To determine the associations of current and lifetime smoking and alcohol use with physical function in an older population. Design.-Survey. Setting.-Four clinic centers in the United States. Participants.-A total of 9704 community-dwelling, ambulatory white women 65 years or older recruited from four areas of the United States. Main Outcome Measures.-Twelve performance tests of muscle strength, agility and coordination, gait and balance, and self-reported functional status. Results.-Compared with women who never smoked, current smokers had significantly poorer function on all of the performance measures except grip strength after adjusting for age, history of stroke, body mass index, clinic site, physical activity, and alcohol use (P<.05). This decrease in function was 50% to 100% as great as that associated with a 5-year increase in age, and most measures worsened with increasing numbers of pack-years. Compared with current moderate drinkers, nondrinkers had significantly poorer function on all of the performance measures except tandem walk (P<.05). Evaluation of a dose effect with alcohol was limited by the small number of heavy drinkers in the study. Conclusions.-In this population, women who currently smoke are weaker and have poorer balance and poorer performance on measures of integrated physical function than nonsmokers. Smoking is associated with a decline in physical function. Current moderate drinkers have better physical function compared with nondrinkers, but associations of function with heavy drinkers could not be assessed.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV MARYLAND,DEPT EPIDEMIOL & PREVENT MED,BALTIMORE,MD	University of California System; University of California San Francisco; University System of Maryland; University of Maryland Baltimore	NELSON, HD (corresponding author), OREGON HLTH SCI UNIV,DIV GEN INTERNAL MED,3181 SW SAM JACKSON PK RD,L475,PORTLAND,OR 97201, USA.			Ensrud, Kristine/0000-0002-9069-3036; Cauley, Jane A/0000-0003-0752-4408				ADAMS RD, 1977, PRINCIPLES NEUROLOGY, P812; ALANKO T, 1984, RES ADV ALCOHOL DRUG, V8, P209; ARMOR D, 1982, ENCY HDB ALCOHOLISM; BAER L, 1985, AM J MED, V78, P564, DOI 10.1016/0002-9343(85)90396-1; BALFOUR DJK, 1982, PHARMACOL THERAPEUT, V16, P269, DOI 10.1016/0163-7258(82)90058-4; BELCH JJF, 1984, THROMB HAEMOSTASIS, V51, P6; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; BOHANNON RW, 1986, PHYS THER, V66, P206, DOI 10.1093/ptj/66.2.206; BRANCH LG, 1982, AM J PUBLIC HEALTH, V72, P1373, DOI 10.2105/AJPH.72.12.1373; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; BUSBY WJ, 1988, J AM GERIATR SOC, V36, P301, DOI 10.1111/j.1532-5415.1988.tb02355.x; CASSIDENTI DL, 1990, AM J OBSTET GYNECOL, V163, P1953, DOI 10.1016/0002-9378(90)90780-B; CAULEY JA, 1987, J CHRON DIS, V40, P115, DOI 10.1016/0021-9681(87)90062-2; CERHAN JR, 1993, AM J EPIDEMIOL, V137, P870, DOI 10.1093/oxfordjournals.aje.a116748; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; CRIQUI MH, 1989, AM J EPIDEMIOL, V129, P1110, DOI 10.1093/oxfordjournals.aje.a115233; FITTI JE, 1987, VITAL HEALTH STAT, V21, P1; FORTMANN SP, 1986, AM J EPIDEMIOL, V124, P706, DOI 10.1093/oxfordjournals.aje.a114445; FOWKES FGR, 1989, BRIT MED J, V298, P405, DOI 10.1136/bmj.298.6671.405; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; GARG R, 1993, ARCH INTERN MED, V153, P1211, DOI 10.1001/archinte.153.10.1211; GAVALER JS, 1985, J STUD ALCOHOL, V46, P495, DOI 10.15288/jsa.1985.46.495; GURALNIK JM, 1989, AM J PUBLIC HEALTH, V79, P703, DOI 10.2105/AJPH.79.6.703; GURALNIK JM, 1993, AM J EPIDEMIOL, V137, P845, DOI 10.1093/oxfordjournals.aje.a116746; HARRIS T, 1989, AM J PUBLIC HEALTH, V79, P698, DOI 10.2105/AJPH.79.6.698; HATCHER EM, 1977, ALCOHOL CLIN EXP RES, V1, P371; HOFSTETTER A, 1986, NEW ENGL J MED, V314, P79, DOI 10.1056/NEJM198601093140204; KANNEL WB, 1985, J AM GERIATR SOC, V33, P13, DOI 10.1111/j.1532-5415.1985.tb02853.x; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KAWACHI I, 1993, JAMA-J AM MED ASSOC, V269, P232, DOI 10.1001/jama.269.2.232; KIRCH DG, 1988, CELL MOL NEUROBIOL, V8, P285, DOI 10.1007/BF00711170; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KRISKA AM, 1988, AM J EPIDEMIOL, V127, P1053, DOI 10.1093/oxfordjournals.aje.a114881; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747; LAPORTE RE, 1983, J GERONTOL, V38, P394, DOI 10.1093/geronj/38.4.394; Leveille S. G., 1992, J WOMENS HEALTH, V1, P53; Lohman TG, 1988, ANTHROPOMETRIC STAND, P177, DOI DOI 10.1002/AJHB.1310040323; MCBRIDE PE, 1992, MED CLIN N AM, V76, P333, DOI 10.1016/S0025-7125(16)30356-X; MOR V, 1989, J CLIN EPIDEMIOL, V42, P895, DOI 10.1016/0895-4356(89)90103-0; NEVITT JC, 1990, 2ND 50 YEARS PROMOTI, P263; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; NOWAK J, 1987, CIRCULATION, V76, P6, DOI 10.1161/01.CIR.76.1.6; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PINSKY JL, 1987, J CHRON DIS, V40, pS159, DOI 10.1016/S0021-9681(87)80045-0; SCHATZKIN A, 1987, NEW ENGL J MED, V316, P1169, DOI 10.1056/NEJM198705073161901; SCHERR PA, 1992, J AM GERIATR SOC, V40, P651, DOI 10.1111/j.1532-5415.1992.tb01954.x; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; TARTER RE, 1975, DIS NERV SYST, V36, P185; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701; VOGT MT, 1993, AM J EPIDEMIOL, V137, P559, DOI 10.1093/oxfordjournals.aje.a116709; WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; 1980, HLTH CONSEQUENCES SM	57	145	149	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1825	1831		10.1001/jama.272.23.1825	http://dx.doi.org/10.1001/jama.272.23.1825			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW980	7990216				2022-12-24	WOS:A1994PW98000030
J	DIAMOND, J				DIAMOND, J			HIV TESTING IN PRISON - WHATS THE CONTROVERSY	LANCET			English	Editorial Material							INMATES				DIAMOND, J (corresponding author), MERRITHEW MEM HOSP,MARTINEZ,CA 94553, USA.							ALBERT P, 1992, AIDS PRACTICE MANUAL, P14; ANDRUS JK, 1989, AM J PUBLIC HEALTH, V79, P840, DOI 10.2105/AJPH.79.7.840; BEHRENDT C, 1994, AM J EPIDEMIOL, V139, P918, DOI 10.1093/oxfordjournals.aje.a117098; CASTRO K, 1991, 7 INT C AIDS FLOR; GREENBERG R, 1994, 10 INT C AIDS YOK; HAMMETT T, 1994, 1992 UPDATE HIV AIDS; HARDING TW, 1992, WHO GLOBAL PROGRAMME, P15; HORSBURGH CR, 1990, AM J PUBLIC HEALTH, V80, P209, DOI 10.2105/AJPH.80.2.209; HOXIE NJ, 1990, AM J PUBLIC HEALTH, V80, P1129, DOI 10.2105/AJPH.80.9.1129; MAUER M, 1994, AM BARS INT USE INCA; 1994, MIDYEAR PRISONER STA; 1994, HIV AIDS SURVEILLANC, V6, P15; 1990, MMWR-MORBID MORTAL W, V39, P273; 1993, WHO GUIDELINES HIV I	14	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1650	1651		10.1016/S0140-6736(94)90451-0	http://dx.doi.org/10.1016/S0140-6736(94)90451-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PX302	7996954				2022-12-24	WOS:A1994PX30200002
J	LUNDBERG, JON; HELLSTROM, PM; LUNDBERG, JM; ALVING, K				LUNDBERG, JON; HELLSTROM, PM; LUNDBERG, JM; ALVING, K			GREATLY INCREASED LUMINAL NITRIC-OXIDE IN ULCERATIVE-COLITIS	LANCET			English	Note								A role for nitric oxide (NO) in ulcerative colitis has been suggested because mucosal NO synthase activity, measured by indirect assays, is increased in this disorder. We directly measured luminal NO in the colons of twelve controls and six patients with active ulcerative colitis. During colonoscopy, gas was aspirated from different parts of the colon and immediately analysed by a chemiluminescence technique. NO concentrations were more than 100 times higher in the patients than in the controls. Luminal NO is rapidly and easily measurable and may be used to monitor inflammatory bowel disease.	KAROLINSKA HOSP,DEPT MED,S-10401 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital	LUNDBERG, JON (corresponding author), KAROLINSKA INST,DEPT PHARMACOL,S-17177 STOCKHOLM,SWEDEN.		Alving, Kjell/M-4579-2014	Alving, Kjell/0000-0003-0784-0443; Hellstrom, Per/0000-0001-8428-0772; Lundberg, Jon/0000-0002-0174-5210				ALVING K, 1993, EUR RESPIR J, V6, P1368; BOUGHTONSMITH NK, 1993, LANCET, V342, P338, DOI 10.1016/0140-6736(93)91476-3; HARTLEY MG, 1992, J MED MICROBIOL, V36, P96, DOI 10.1099/00222615-36-2-96; JI XB, 1989, BIOCHEM ARCH, V5, P61; LUNDBERG JON, 1994, GUT, V35, P1543, DOI 10.1136/gut.35.11.1543; LUNDBERG JON, 1994, EUR RESPIR J, V7, P1501, DOI 10.1183/09031936.94.07081501; MIDDLETON SJ, 1993, LANCET, V341, P465, DOI 10.1016/0140-6736(93)90211-X; MONCADA S, 1991, PHARMACOL REV, V43, P109; TEPPERMAN BL, 1993, AM J PHYSIOL, V265, pG214, DOI 10.1152/ajpgi.1993.265.2.G214; WHITTLE BJR, 1994, NITRIC OXIDE GASTROI, P267	10	224	236	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1673	1674		10.1016/S0140-6736(94)90460-X	http://dx.doi.org/10.1016/S0140-6736(94)90460-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996962				2022-12-24	WOS:A1994PX30200011
J	BENEZRA, R				BENEZRA, R			AN INTERMOLECULAR DISULFIDE BOND STABILIZES E2A HOMODIMERS AND IS REQUIRED FOR DNA-BINDING AT PHYSIOLOGICAL TEMPERATURES	CELL			English	Article							LOOP-HELIX PROTEINS; NF-KAPPA-B; TRANSCRIPTIONAL-ACTIVATION; MYOD; INVIVO; GENE; DAUGHTERLESS; REGULATOR; MUTATIONS; SUBUNITS	It is demonstrated in this report that purified E2A helix-loop-helix (HLH) proteins spontaneously form homodimers that are linked by an intermolecular disulfide bond. These homodimers bind DNA at physiological temperatures but fail to associate with either Id or MyoD. When the disulfide bond is reduced by an activity present in muscle cell lysates or disrupted by site-directed mutagenesis, the monomeric form of the protein is strongly favored at 37 degrees C. These E2A monomers cannot bind DNA but heterodimerize efficiently with Id and MyoD. It is also shown that an intermolecular disulfide bond cross-links E2A homodimers in B cells but not in muscle cells in which only heterodimers have been detected. These results suggest a novel mechanism for regulating the dimerization status and DNA binding properties of E2A HLH transcription factors.			BENEZRA, R (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DAVIS RL, 1990, CELL, V60, P773; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GOLDENBERG DP, 1993, BIOCHEMISTRY-US, V32, P2835, DOI 10.1021/bi00062a015; HARA E, 1994, J BIOL CHEM, V269, P2139; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHIRAKATA M, 1993, GENE DEV, V7, P2456, DOI 10.1101/gad.7.12a.2456; SHUE GL, 1994, J BIOL CHEM, V269, P2707; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; TOLEDANO N, 1994, CELL, V78, P897; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; XANTHOUDAKIS S, 1992, EMBO J, V121, P3323	39	90	90	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1057	1067		10.1016/0092-8674(94)90036-1	http://dx.doi.org/10.1016/0092-8674(94)90036-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001133				2022-12-24	WOS:A1994PY08600015
J	XU, M; HU, XT; COOPER, DC; MORATALLA, R; GRAYBIEL, AM; WHITE, FJ; TONEGAWA, S				XU, M; HU, XT; COOPER, DC; MORATALLA, R; GRAYBIEL, AM; WHITE, FJ; TONEGAWA, S			ELIMINATION OF COCAINE-INDUCED HYPERACTIVITY AND DOPAMINE-MEDIATED NEUROPHYSIOLOGICAL EFFECTS IN DOPAMINE D1 RECEPTOR MUTANT MICE	CELL			English	Article							RAT NUCLEUS-ACCUMBENS; DISCRIMINATIVE STIMULUS PROPERTIES; LOCOMOTOR HYPERACTIVITY; STIMULATION ENABLES; ADENYLATE-CYCLASE; VENTRAL STRIATUM; XENOPUS OOCYTES; BASAL GANGLIA; D2 RECEPTORS; BRAIN	The brain mesoaccumbens dopamine system is intricately Involved in the psychomotor stimulant activities of cocaine. However, the extent to which different dopamine receptors mediate these effects has not yet been firmly established. The present study used dopamine D1 receptor mutant mice produced by gene targeting to investigate the role of this receptor in the effects induced by cocaine. In contrast with wild-type mice, which showed a dose-dependent increase in locomotion, D1 mutant mice exhibited a dose-dependent decrease. Electrophysiological studies of dopamine-sensitive nucleus accumbens neurons demonstrated a marked reduction in the inhibitory effects of cocaine on the generation of action potentials. In addition, the inhibitory effects of dopamine as well as D1 and D2 agonists were almost completely abolished, whereas those of serotonin were unaffected. DS-like dopamine receptor binding was also normal. These results demonstrate the essential role of the D1 receptor in the locomotor stimulant effects of cocaine and in dopamine-mediated neurophysiological effects within the nucleus accumbens.	MIT, CTR LEARNING & MEM, DEPT BIOL, CAMBRIDGE, MA 02139 USA; FINCH UNIV HLTH SCI, CHICAGO MED SCH, DEPT NEUROSCI, NEUROPSYCHOPHARMACOL LAB, N CHICAGO, IL 60064 USA; MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Chicago Medical School; Massachusetts Institute of Technology (MIT)	XU, M (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		Moratalla, Rosario V/H-9280-2015	Moratalla, Rosario V/0000-0002-7623-8010; Graybiel, Ann/0000-0002-4326-7720	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004093, R01DA008037, R37DA004093] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 08037, DA 00207, DA 04093] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ARNT J, 1987, EUR J PHARMACOL, V133, P137, DOI 10.1016/0014-2999(87)90144-0; ARNT J, 1992, EUR J PHARMACOL, V213, P259, DOI 10.1016/0014-2999(92)90690-6; BARRETT RL, 1989, PSYCHOPHARMACOLOGY, V99, P13, DOI 10.1007/BF00634445; Bergman J., 1990, Behav Pharmacol, V1, P355; BERTORELLO AM, 1990, NATURE, V347, P386, DOI 10.1038/347386a0; BHAT RV, 1993, J PHARMACOL EXP THER, V267, P496; BISCHOFF S, 1986, EUR J PHARMACOL, V129, P367, DOI 10.1016/0014-2999(86)90449-8; BRADBERRY CW, 1993, J NEUROCHEM, V60, P1429, DOI 10.1111/j.1471-4159.1993.tb03305.x; BRIGGS CA, 1991, BRIT J PHARMACOL, V104, P1038, DOI 10.1111/j.1476-5381.1991.tb12546.x; BRITTON DR, 1991, PHARMACOL BIOCHEM BE, V39, P911, DOI 10.1016/0091-3057(91)90052-4; CABIB S, 1991, PSYCHOPHARMACOLOGY, V105, P335, DOI 10.1007/BF02244427; CAINE SB, 1994, J PHARMACOL EXP THER, V270, P209; CALLAHAN PM, 1994, PSYCHOPHARMACOLOGY, V115, P110, DOI 10.1007/BF02244759; CALLAHAN PM, 1991, PSYCHOPHARMACOLOGY, V103, P50, DOI 10.1007/BF02244073; CAMPS M, 1989, NEUROSCIENCE, V28, P275, DOI 10.1016/0306-4522(89)90179-6; CHURCH WH, 1987, EUR J PHARMACOL, V139, P345, DOI 10.1016/0014-2999(87)90592-9; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; GALEY D, 1977, BRAIN RES, V124, P83, DOI 10.1016/0006-8993(77)90865-4; GERFEN CR, 1992, ANNU REV NEUROSCI, V15, P285, DOI 10.1146/annurev.ne.15.030192.001441; GEYER MA, 1976, BRAIN RES, V106, P257, DOI 10.1016/0006-8993(76)91024-6; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; GREEN AR, 1976, NATURE, V260, P487; HU XT, 1990, J NEUROSCI, V10, P2318; HU XT, 1994, SYNAPSE, V17, P43, DOI 10.1002/syn.890170106; HUBNER CB, 1991, PSYCHOPHARMACOLOGY, V105, P151, DOI 10.1007/BF02244301; JACOBS BL, 1976, LIFE SCI, V19, P777, DOI 10.1016/0024-3205(76)90303-9; JOHANSEN PA, 1991, J NEURAL TRANSM-GEN, V86, P97, DOI 10.1007/BF01250571; JOYCE EM, 1983, NEUROPHARMACOLOGY, V22, P1141, DOI 10.1016/0028-3908(83)90051-5; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; KOOB GF, 1987, NEUROSCI LETT, V79, P315, DOI 10.1016/0304-3940(87)90451-4; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; LINDVALL O, 1983, CHEM NEUROANATOMY, P229; LOH EA, 1990, PSYCHOPHARMACOLOGY, V101, P262, DOI 10.1007/BF02244137; MAHAN LC, 1990, P NATL ACAD SCI USA, V87, P2196, DOI 10.1073/pnas.87.6.2196; MALDONADO R, 1993, PHARMACOL BIOCHEM BE, V45, P239, DOI 10.1016/0091-3057(93)90112-7; Marsden C. D., 1992, SEMIN NEUROSCI, V4, P171; MCQUADE RD, 1988, LIFE SCI, V43, P1861, DOI 10.1016/S0024-3205(88)80003-1; MOGENSON GJ, 1980, PROG NEUROBIOL, V14, P69, DOI 10.1016/0301-0082(80)90018-0; MOGENSON GJ, 1987, PROG PSYCHOB PHYSIOL, V12, P117; MURRAY AM, 1989, EUR J PHARMACOL, V160, P377, DOI 10.1016/0014-2999(89)90093-9; PAUL ML, 1992, J NEUROSCI, V12, P3729, DOI 10.1523/jneurosci.12-10-03729.1992; PHILLIPS AG, 1983, PROG NEURO-PSYCHOPH, V7, P585, DOI 10.1016/0278-5846(83)90029-5; PRADHAN SN, 1978, COMMUN PSYCHOPHARMAC, V2, P481; PYCOCK CJ, 1980, NATURE, V286, P74, DOI 10.1038/286074a0; RAPPAPORT MS, 1993, BRAIN RES, V616, P242, DOI 10.1016/0006-8993(93)90215-9; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROBBINS TW, 1989, NEUROSCI BIOBEHAV R, V13, P155, DOI 10.1016/S0149-7634(89)80025-9; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SEGAL DS, 1987, PSYCHOPHARMACOL BULL, V23, P417; SIMON H, 1988, BRAIN RES, V447, P335, DOI 10.1016/0006-8993(88)91136-5; Spano P F, 1978, Adv Biochem Psychopharmacol, V19, P155; SPEALMAN RD, 1991, J PHARMACOL EXP THER, V258, P945; STOOF JC, 1984, LIFE SCI, V35, P2281, DOI 10.1016/0024-3205(84)90519-8; SURMEIER DJ, 1992, P NATL ACAD SCI USA, V89, P10178, DOI 10.1073/pnas.89.21.10178; SURMEIER DJ, 1993, TRENDS NEUROSCI, V16, P299, DOI 10.1016/0166-2236(93)90103-S; SVENSSON K, 1994, J NEURAL TRANSM-GEN, V95, P71, DOI 10.1007/BF01283032; TASSIN JP, 1978, BRAIN RES, V141, P267, DOI 10.1016/0006-8993(78)90197-X; TAYLOR D, 1979, RES COMMUN PSYCH PSY, V4, P447; TELLA SR, 1994, PHARMACOL BIOCHEM BE, V48, P151, DOI 10.1016/0091-3057(94)90511-8; UNDIE AS, 1990, J PHARMACOL EXP THER, V253, P987; VEZINA P, 1991, EUR J NEUROSCI, V3, P1001, DOI 10.1111/j.1460-9568.1991.tb00036.x; WACHTEL SR, 1992, PSYCHOPHARMACOLOGY, V109, P41, DOI 10.1007/BF02245478; WACHTEL SR, 1989, SYNAPSE, V4, P327, DOI 10.1002/syn.890040409; WADDINGTON JL, 1993, D1 D2 DOPAMINE RECEP, P51; WALAAS I, 1981, NEUROSCIENCE, V6, P399, DOI 10.1016/0306-4522(81)90132-9; WALTERS JR, 1987, SCIENCE, V236, P719; WATERS N, 1993, J NEURAL TRANSM-GEN, V94, P11, DOI 10.1007/BF01244979; White F.J., 1990, Behav Pharmacol, V1, P303; WHITE FJ, 1986, J NEUROSCI, V6, P274; WHITE FJ, 1988, PHARMACOL BIOCHEM BE, V30, P189, DOI 10.1016/0091-3057(88)90442-X; WHITE FJ, 1987, EUR J PHARMACOL, V135, P101, DOI 10.1016/0014-2999(87)90764-3; WHITE FJ, 1993, J PHARMACOL EXP THER, V266, P1075; WHITE FJ, 1994, IN PRESS NEUROBIOLOG; WHITE FJ, 1993, D1 D2 DOPAMINE RECEP, P79; WHITE FJ, 1992, COCAINE PHARM PHYSL, P261; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; WOOD DM, 1989, PHARMACOL BIOCHEM BE, V33, P453, DOI 10.1016/0091-3057(89)90529-7; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; ZAHM DS, 1992, NEUROSCIENCE, V50, P751, DOI 10.1016/0306-4522(92)90202-D	83	292	297	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 16	1994	79	6					945	955		10.1016/0092-8674(94)90026-4	http://dx.doi.org/10.1016/0092-8674(94)90026-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001143				2022-12-24	WOS:A1994PY08600005
J	LEVY, HL; WAISBREN, SE; LOBBREGT, D; ALLRED, E; SCHULER, A; TREFZ, FK; SCHWEITZER, SM; SARDHARWALLA, IB; WALTER, JH; BARWELL, BE; BERLIN, CM; LEVITON, A				LEVY, HL; WAISBREN, SE; LOBBREGT, D; ALLRED, E; SCHULER, A; TREFZ, FK; SCHWEITZER, SM; SARDHARWALLA, IB; WALTER, JH; BARWELL, BE; BERLIN, CM; LEVITON, A			MATERNAL MILD HYPERPHENYLALANINEMIA - AN INTERNATIONAL SURVEY OF OFFSPRING OUTCOME	LANCET			English	Article							HEAD CIRCUMFERENCE; PHENYLKETONURIA; INTELLIGENCE; PREGNANCIES; FETUS; BIRTH	Maternal phenylketonuria (PKU) has adverse effects on the offspring including microcephaly, mental retardation, congenital heart disease, and intrauterine growth retardation. Maternal non-PKU mild hyperphenyalaninaemia (MHP) is believed to be benign, but whether there may be long-term consequences to offspring is unclear. In an international survey we have obtained information about 86 MHP mothers with MHP (blood phenylalanine 167-715 mu mol/L), their 219 untreated pregnancies, and 173 offspring. Spontaneous fetal loss (13% of pregnancies), congenital heart disease (2.3% of offspring), and severe non-cardiac anomalies (2.9% of offspring) occurred at frequencies within expected limits for the general population. For weight and length at birth the median percentile was the 50th but that for birth head circumference was the 25th. Median z-scores for birth length and head circumference were significantly lower for offspring of mothers with phenylalanine concentrations above 400 mu mol/L than for those whose mothers had lower values (p=0.05 and p=0.005, respectively). The median intelligence quotient (IQ) of the offspring (3-27 years) was 100 for those whose mothers had higher phenylalanine concentrations and 108 for those of the lower phenylalaninaemia group. However, offspring IQ correlated slightly more closely with maternal IQ (r=0.53, p<0.01) than with maternal phenylalanine concentration (r=0.45, p=0.02). Maternal MHP does not seem to have serious consequences for the fetus. A maternal phenylalanine concentration of less than 400 mu mol/L does not warrant intervention. Nevertheless, maternal blood phenylalanine above this value is associated with slightly lower birth measurements and offspring IQ than lower maternal blood phenylalanine concentrations.	HARVARD UNIV,SCH MED,BOSTON,MA; PKU LAB,BUDAPEST,HUNGARY; UNIV HEIDELBERG,HEIDELBERG,GERMANY; CHILDRENS HOSP,HANNOVER,GERMANY; ROYAL MANCHESTER CHILDRENS HOSP,MANCHESTER,LANCS,ENGLAND; SHEFFIELD CHILDRENS HOSP,REG NEONATAL SCREENING LAB,SHEFFIELD,S YORKSHIRE,ENGLAND; PENN STATE UNIV,MILTON S HERSHEY MED CTR,HERSHEY,PA 17033	Harvard University; Harvard Medical School; Ruprecht Karls University Heidelberg; Royal Manchester Children's Hospital; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	LEVY, HL (corresponding author), CHILDRENS HOSP,IC SMITH ROOM 106,BOSTON,MA 02115, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD023149] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-2-3149] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CARTIER L, 1982, AM J PUBLIC HEALTH, V72, P1386, DOI 10.2105/AJPH.72.12.1386; COSTELLO PM, 1994, EUR J PEDIATR, V153, P260; DORMAN C, 1991, DEV MED CHILD NEUROL, V33, P267; DROGARI E, 1987, LANCET, V2, P927; GARDINER RM, 1990, J INHERIT METAB DIS, V13, P627, DOI 10.1007/BF01799517; GUTTLER F, 1980, ACTA PAEDIATR SC   S, V280, P7; HEINONEN OP, 1977, BIRTH DEFECTS DRUGS, P65; KOCH R, 1993, AM J DIS CHILD, V147, P1224, DOI 10.1001/archpedi.1993.02160350098015; LENKE RR, 1980, NEW ENGL J MED, V303, P1202, DOI 10.1056/NEJM198011203032104; LEVITON A, 1993, J CHILD NEUROL, V8, P64, DOI 10.1177/088307389300800109; LEVY HL, 1987, ENZYME, V38, P312, DOI 10.1159/000469221; LEVY HL, 1992, AM J MED GENET, V44, P439, DOI 10.1002/ajmg.1320440411; LEVY HL, 1983, NEW ENGL J MED, V309, P1269, DOI 10.1056/NEJM198311243092101; LEVY HL, 1984, J PEDIATR-US, V104, P245, DOI 10.1016/S0022-3476(84)81003-3; LYNN R, 1987, NATURE, V328, P797, DOI 10.1038/328797a0; Matarazzo J. D., 1972, WECHSLERS MEASUREMEN; MITCHELL SC, 1971, CIRCULATION, V43, P323, DOI 10.1161/01.CIR.43.3.323; NIKLASSON A, 1991, ACTA PAEDIATR SCAND, V80, P756, DOI 10.1111/j.1651-2227.1991.tb11945.x; NISWANDER KR, 1972, DHEW NIH73379 PUBL; PLATT LD, 1992, AM J OBSTET GYNECOL, V166, P1150, DOI 10.1016/S0002-9378(11)90601-2; ROCHE AF, 1987, PEDIATRICS, V79, P706; SCHOONHEYT WE, 1994, CLIN CHIM ACTA, V225, P165, DOI 10.1016/0009-8981(94)90044-2; SMITH I, 1990, ARCH DIS CHILD, V65, P472, DOI 10.1136/adc.65.5.472; VENTURA SJ, 1992, MONTHLY VITAL ST 6 S, V41; WAISBREN SE, 1990, J PEDIATR-US, V116, P926, DOI 10.1016/S0022-3476(05)80654-7; WAISBREN SE, 1988, AM J PUBLIC HEALTH, V78, P789, DOI 10.2105/AJPH.78.7.789; [No title captured]; 1994, J PEDIATR, V124, P383	28	35	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1589	1594		10.1016/S0140-6736(94)90404-9	http://dx.doi.org/10.1016/S0140-6736(94)90404-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983992				2022-12-24	WOS:A1994PW05100007
J	OBRIEN, E				OBRIEN, E			THE LAND MINE CRISIS - A GROWING EPIDEMIC OF MUTILATION	LANCET			English	Editorial Material											OBRIEN, E (corresponding author), ROYAL COLL SURGEONS IRELAND,SCH MED,DUBLIN,IRELAND.							Cahill K. M., 1995, CLEARING FIELDS SOLU; MCGRATH R, 1993, LANCET, V342, P628, DOI 10.1016/0140-6736(93)91751-7	2	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1522	1522		10.1016/S0140-6736(94)90345-X	http://dx.doi.org/10.1016/S0140-6736(94)90345-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983950				2022-12-24	WOS:A1994PV01700005
J	HAHNE, K; HAUCKE, V; RAMAGE, L; SCHATZ, G				HAHNE, K; HAUCKE, V; RAMAGE, L; SCHATZ, G			INCOMPLETE ARREST IN THE OUTER-MEMBRANE SORTS NADH-CYTOCHROME-B(5) REDUCTASE TO 2 DIFFERENT SUBMITOCHONDRIAL COMPARTMENTS	CELL			English	Article							MITOCHONDRIAL PROTEIN IMPORT; AMINO-TERMINAL REGION; RAT-LIVER MICROSOMES; YEAST MITOCHONDRIA; INTERMEMBRANE SPACE; SACCHAROMYCES-CEREVISIAE; INNER MEMBRANE; NADH-CYTOCHROME-B5 REDUCTASE; ENDOPLASMIC-RETICULUM; GEL-ELECTROPHORESIS	The S. cerevisiae gene MCR1 encodes two mitochondrial isoforms of NADH-cytochrome b(5) reductase. The primary translation product has an amino-terminal matrix-targeting signal, followed by a stretch of 21 uncharged amino acids. This precursor protein is inserted into the outer membrane, but only about one-third of the molecules become firmly anchored to the outer face of that membrane. The remaining molecules pass through the outer membrane into the inner membrane, are cleaved by inner membrane protease 1, and are released into the intermembrane space. Incomplete translocation arrest in the outer membrane is a novel mechanism by which the product of a single gene is sorted into different compartments of the same organelle.	UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND	University of Basel				Haucke, Volker/0000-0003-3119-6993	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037803] Funding Source: NIH RePORTER; NIGMS NIH HHS [2 RO1 GM37803] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BIBUS CR, 1988, J BIOL CHEM, V263, P13097; BOGUTA M, 1994, MOL CELL BIOL, V14, P2298, DOI 10.1128/MCB.14.4.2298; BORGESE N, 1990, BIOCHEM J, V266, P341, DOI 10.1042/bj2660341; BORGESE N, 1986, BIOCHEM J, V239, P393, DOI 10.1042/bj2390393; BRANDT A, 1991, METHOD CELL BIOL, V34, P369; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CHEVALLIER MR, 1980, GENE, V11, P11, DOI 10.1016/0378-1119(80)90082-7; CSUKAI M, 1994, EUR J BIOCHEM, V219, P441, DOI 10.1111/j.1432-1033.1994.tb19957.x; DAUM G, 1982, J BIOL CHEM, V257, P3028; DESANTIS A, 1984, ARCH BIOCHEM BIOPHYS, V232, P354; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GIETL C, 1992, BIOCHIM BIOPHYS ACTA, V1100, P217, DOI 10.1016/0167-4838(92)90476-T; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HASE T, 1986, FEBS LETT, V197, P199, DOI 10.1016/0014-5793(86)80326-X; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; HINES V, 1993, J BIOL CHEM, V268, P449; HORST M, 1993, EMBO J, V12, P3035, DOI 10.1002/j.1460-2075.1993.tb05972.x; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; JENSEN RE, 1992, MOL CELL BIOL, V12, P4677, DOI 10.1128/MCB.12.10.4677; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P187, DOI 10.1093/oxfordjournals.jbchem.a131434; Maniatis T., 1982, MOL CLONING; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NAKAI M, 1993, J BIOL CHEM, V268, P24262; NAKAI M, 1989, J BIOCHEM-TOKYO, V106, P181, DOI 10.1093/oxfordjournals.jbchem.a122811; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; NISHINO H, 1986, J BIOCHEM, V100, P1523, DOI 10.1093/oxfordjournals.jbchem.a121859; OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444; OZOLS J, 1985, J BIOL CHEM, V260, P1953; PASSON PG, 1972, BIOCHIM BIOPHYS ACTA, V275, P62, DOI 10.1016/0005-2728(72)90024-2; PERIMAN D, 1984, MOL CELL BIOL, V4, P1682; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PIETRINI G, 1992, J CELL BIOL, V117, P975, DOI 10.1083/jcb.117.5.975; PRATJE E, 1986, EMBO J, V5, P1313, DOI 10.1002/j.1460-2075.1986.tb04361.x; PROSSER IM, 1990, PLANT MOL BIOL, V15, P187, DOI 10.1007/BF00017743; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; REDDY VVR, 1977, J BIOL CHEM, V252, P2797; RIEZMAN H, 1983, EMBO J, V2, P1105, DOI 10.1002/j.1460-2075.1983.tb01553.x; ROISE D, 1988, J BIOL CHEM, V263, P4509; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ G, 1993, PROTEIN SCI, V2, P141; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SCOTT EM, 1959, BIOCHIM BIOPHYS ACTA, V34, P584, DOI 10.1016/0006-3002(59)90324-5; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPIESS M, 1989, J BIOL CHEM, V264, P19117; TOMATSU S, 1989, GENE, V80, P353; WESSELS HP, 1990, J CELL BIOL, V111, P2923, DOI 10.1083/jcb.111.6.2923; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YUBISUI T, 1987, P NATL ACAD SCI USA, V84, P3609, DOI 10.1073/pnas.84.11.3609; YUBISUI T, 1986, J BIOCH, V99, P401	70	106	107	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					829	839		10.1016/0092-8674(94)90072-8	http://dx.doi.org/10.1016/0092-8674(94)90072-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001120				2022-12-24	WOS:A1994PW05400010
J	SCHIESTL, RH; KHOGALI, F; CARLS, N				SCHIESTL, RH; KHOGALI, F; CARLS, N			REVERSION OF THE MOUSE PINK-EYED UNSTABLE MUTATION INDUCED BY LOW-DOSES OF X-RAYS	SCIENCE			English	Article							DOUBLE-STRAND BREAKS; INTRACHROMOSOMAL RECOMBINATION; IONIZING-RADIATION; CHROMOSOME-ABNORMALITIES; MOLECULAR-GENETICS; SPOT-TEST; CANCER; CELLS; CARCINOGENS; FREQUENCY	Deletions and other genome rearrangements can be caused by radiation and are associated with carcinogenesis and inheritable diseases. The pink-eyed unstable (p(un)) mutation in the mouse is caused by a gene duplication and reverts to wild type by deletion of one copy. Reversion events in the mouse embryo were detected as black spots on the fur of the animals or microscopically as partially black hair in a background of colorless hair. The frequency of partially black hair was increased by x-rays at very low doses. A linear dose-response relation was found between 1 and 100 centigray.			SCHIESTL, RH (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT MOLEC & CELLULAR TOXICOL, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006593] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06593] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLOCHER D, 1982, INT J RADIAT BIOL, V42, P317, DOI 10.1080/09553008214551231; BRENNAN RJ, 1994, MUTAT RES, V308, P159, DOI 10.1016/0027-5107(94)90151-1; BRILLIANT MH, 1991, SCIENCE, V252, P566, DOI 10.1126/science.1673574; CAIRNS J, 1981, NATURE, V289, P353, DOI 10.1038/289353a0; CARLS N, 1994, MUTAT RES, V320, P293, DOI 10.1016/0165-1218(94)90082-5; CHANG WP, 1991, INT J RADIAT BIOL, V60, P483, DOI 10.1080/09553009114552331; CHANG WSP, 1992, MUTAT RES, V270, P191, DOI 10.1016/0027-5107(92)90130-T; FAHRIG R, 1975, MOL GEN GENET, V138, P309, DOI 10.1007/BF00264800; GONDO Y, 1993, P NATL ACAD SCI USA, V90, P297, DOI 10.1073/pnas.90.1.297; GROSOVSKY AJ, 1985, P NATL ACAD SCI USA, V82, P2092, DOI 10.1073/pnas.82.7.2092; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.genet.21.1.321; HANSEN MF, 1988, CELL, V53, P172, DOI 10.1016/0092-8674(88)90376-5; HIROBE T, 1984, ANAT REC, V208, P589, DOI 10.1002/ar.1092080414; LITTLE JB, 1993, HEMATOL ONCOL CLIN N, V7, P337, DOI 10.1016/S0889-8588(18)30244-2; MAYER TC, 1973, DEV BIOL, V34, P39, DOI 10.1016/0012-1606(73)90337-0; MELVOLD RW, 1971, MUTAT RES, V12, P171, DOI 10.1016/0027-5107(71)90138-2; MITELMAN F, 1990, CANCER DETECT PREV, V14, P527; MODAN B, 1992, EUR J CANCER, V28A, P1010, DOI 10.1016/0959-8049(92)90442-5; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RUSSELL LB, 1981, MUTAT RES, V86, P355, DOI 10.1016/0165-1110(81)90011-7; RUSSELL LB, 1954, J CELL COMPAR PHYSL, V43, pA103, DOI 10.1002/jcp.1030430407; RUSSELL WL, 1962, P NATL ACAD SCI USA, V48, P1724, DOI 10.1073/pnas.48.10.1724; SANDBERG AA, 1991, MUTAT RES, V247, P231, DOI 10.1016/0027-5107(91)90019-K; SCHIESTL RH, 1988, GENETICS, V119, P237; SCHIESTL RH, 1989, NATURE, V337, P285, DOI 10.1038/337285a0; SCHIESTL RH, 1989, CARCINOGENESIS, V10, P1445, DOI 10.1093/carcin/10.8.1445; SCHLAGER G, 1967, GENETICS, V57, P319; SEARLE AG, 1982, MUTAT RES, V92, P205, DOI 10.1016/0027-5107(82)90224-X; STEPHENSON DA, 1988, MUTAT RES, V197, P101, DOI 10.1016/0027-5107(88)90145-5; STYLES JA, 1985, MUTAT RES, V154, P183, DOI 10.1016/0165-1110(85)90017-X; THACKER J, 1986, MUTAT RES, V160, P267, DOI 10.1016/0027-5107(86)90137-5; UPTON AC, 1992, ANNU REV PUBL HEALTH, V13, P127, DOI 10.1146/annurev.pu.13.050192.001015; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WARD JF, 1990, INT J RADIAT BIOL, V57, P1141, DOI 10.1080/09553009014551251; WARD JF, 1987, INT C ANTICARCINOGEN, P321; WINTERSBERGER U, 1982, NATURWISSENSCHAFTEN, V69, P107, DOI 10.1007/BF00376714; ZHANG LH, 1992, CARCINOGENESIS, V13, P609, DOI 10.1093/carcin/13.4.609	38	77	78	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 2	1994	266	5190					1573	1576		10.1126/science.7985029	http://dx.doi.org/10.1126/science.7985029			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985029				2022-12-24	WOS:A1994PV01500047
J	STEINER, NC; CLARKE, L				STEINER, NC; CLARKE, L			A NOVEL EPIGENETIC EFFECT CAN ALTER CENTROMERE FUNCTION IN FISSION YEAST	CELL			English	Article							POSITION-EFFECT VARIEGATION; SCHIZOSACCHAROMYCES-POMBE; TRANSCRIPTIONAL STATES; CHROMATIN STRUCTURE; CHROMOSOME; DNA; SEQUENCE; REGIONS; INHERITANCE; CEREVISIAE	A novel epigenetic mechanism that can affect minichromosome centromere function in vivo has been identified in S. pombe. This epigenetic system can result in the conversion of a nonfunctional centromere to a functional one without changes in the content, structural arrangement, or chemical modification state of the minichromosomal DNA. The conversion from a centromere-inactive to an active state, which is evident with minichromosomes carrying abbreviated centromeric DNA constructions, occurs with a relatively high frequency during mitotic cell divisions and readily provides an in vivo essay for proper centromere formation. The centromere-targeted epigenetic system supports a model for centromere function that involves specific de novo folding of centromeric components into a higher order chromatin structure.	UNIV CALIF SANTA BARBARA, DEPT BIOL SCI, SANTA BARBARA, CA 93106 USA	University of California System; University of California Santa Barbara					NIGMS NIH HHS [GM-33783] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033783] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; BAUM M, 1994, MOL BIOL CELL, V5, P747, DOI 10.1091/mbc.5.7.747; BLOOM K, 1993, CELL, V73, P621, DOI 10.1016/0092-8674(93)90242-I; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CLARKE L, 1986, P NATL ACAD SCI USA, V83, P8253, DOI 10.1073/pnas.83.21.8253; CLARKE L, 1985, ANNU REV GENET, V19, P29, DOI 10.1146/annurev.genet.19.1.29; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; CLARKE L, 1990, MOL CELL BIOL, V10, P1863, DOI 10.1128/MCB.10.5.1863; CLARKE L, 1993, COLD SPRING HARB SYM, V58, P687, DOI 10.1101/SQB.1993.058.01.076; EARNSHAW WC, 1985, CHROMOSOMA, V92, P290, DOI 10.1007/BF00329812; FISHEL B, 1988, MOL CELL BIOL, V8, P754, DOI 10.1128/MCB.8.2.754; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRIGLIATTI T, 1991, METHOD CELL BIOL, V35, P587; HAHNENBERGER KM, 1991, MOL CELL BIOL, V11, P2206, DOI 10.1128/MCB.11.4.2206; HAHNENBERGER KM, 1989, P NATL ACAD SCI USA, V86, P577, DOI 10.1073/pnas.86.2.577; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HSU TC, 1975, CYTOGENET CELL GENET, V15, P41, DOI 10.1159/000130497; KENDAL WS, 1988, CANCER RES, V48, P1060; Kohli J, 1989, MOL BIOL FISSION YEA, P75; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; Luria SE, 1943, GENETICS, V28, P491; LYON MF, 1992, ANNU REV GENET, V26, P17, DOI 10.1146/annurev.ge.26.120192.000313; Maniatis T., 1982, MOL CLONING; MANN C, 1983, P NATL ACAD SCI-BIOL, V80, P228, DOI 10.1073/pnas.80.1.228; MONK M, 1990, TRENDS GENET, V6, P110, DOI 10.1016/0168-9525(90)90124-O; MURAKAMI S, 1991, CHROMOSOMA, V101, P214, DOI 10.1007/BF00365153; NAKASEKO Y, 1986, EMBO J, V5, P1011, DOI 10.1002/j.1460-2075.1986.tb04316.x; NAKASEKO Y, 1987, NUCLEIC ACIDS RES, V15, P4705, DOI 10.1093/nar/15.12.4705; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; POLIZZI C, 1991, J CELL BIOL, V112, P191, DOI 10.1083/jcb.112.2.191; Sandell L L, 1992, Trends Cell Biol, V2, P10, DOI 10.1016/0962-8924(92)90138-D; SHAFFER CD, 1993, TRENDS GENET, V9, P35, DOI 10.1016/0168-9525(93)90171-D; SOLTER D, 1988, ANNU REV GENET, V22, P127; STEINER NC, 1993, MOL CELL BIOL, V13, P4578, DOI 10.1128/MCB.13.8.4578; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; WILLARD HF, 1990, TRENDS GENET, V6, P410, DOI 10.1016/0168-9525(90)90302-M	38	132	135	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					865	874		10.1016/0092-8674(94)90075-2	http://dx.doi.org/10.1016/0092-8674(94)90075-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001123				2022-12-24	WOS:A1994PW05400013
J	WALKER, S; HAYES, S; OHARE, P				WALKER, S; HAYES, S; OHARE, P			SITE-SPECIFIC CONFORMATIONAL ALTERATION OF THE OCT-1 POU DOMAIN-DNA COMPLEX AS THE BASIS FOR DIFFERENTIAL RECOGNITION BY VMW65 (VP16)	CELL			English	Article							IMMEDIATE-EARLY GENE; TYPE-1 TRANSACTIVATOR VMW65; OCTAMER-BINDING-PROTEIN; TRANSCRIPTION COMPLEX; REGULATORY PROTEIN; CELLULAR FACTOR; HOMEO DOMAIN; SEQUENCES; INTERACTS; SUBDOMAINS	We show that the presence of a regulatory cis-acting element that flanks the core octamer site and dictates selectivity in the response to Vmw65 (VP16), while dispensable for POU binding per se, induces a conformational alteration in the nature of the POU domain in the DNA complex. A single substitution in the flanking signal distorts the POU complex and without affecting overall POU binding prevents Vmw65 interaction. Alternatively, substitution of a residue in the homeodomain predicted to contact the GARAT region prevents its recognition even on a wild-type motif, causing a reversion to the DNA binding pattern seen on a cellular motif and at the same time inefficient recognition by Vmw65. The results indicate that Vmw65 recognizes a particular POU domain conformation induced by the presence of the flanking GARAT region.			WALKER, S (corresponding author), MARIE CURIE RES INST,CHART,OXTED RH8 OTL,SURREY,ENGLAND.							APRHYS CMJ, 1989, J VIROL, V63, P2798, DOI 10.1128/JVI.63.6.2798-2812.1989; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; HAYES S, 1993, J VIROL, V67, P852, DOI 10.1128/JVI.67.2.852-862.1993; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; KATAN M, 1990, NUCLEIC ACIDS RES, V18, P6871, DOI 10.1093/nar/18.23.6871; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KRISTIE TM, 1987, P NATL ACAD SCI USA, V84, P71, DOI 10.1073/pnas.84.1.71; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; MACKEM S, 1982, J VIROL, V44, P939, DOI 10.1128/JVI.44.3.939-949.1982; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OHARE P, 1993, ALPHA HERPESVIRUSES, P145; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; PRESTON CM, 1984, J VIROL, V50, P708, DOI 10.1128/JVI.50.3.708-716.1984; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; TULLIUS TD, 1989, ANNU REV BIOPHYS BIO, V18, P213, DOI 10.1146/annurev.bb.18.060189.001241; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974	33	76	77	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 2	1994	79	5					841	852		10.1016/0092-8674(94)90073-6	http://dx.doi.org/10.1016/0092-8674(94)90073-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001121				2022-12-24	WOS:A1994PW05400011
J	BURMEISTER, WP; HUBER, AH; BJORKMAN, PJ				BURMEISTER, WP; HUBER, AH; BJORKMAN, PJ			CRYSTAL-STRUCTURE OF THE COMPLEX OF RAT NEONATAL FC RECEPTOR WITH FC	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; IMMUNOGLOBULIN-G; NEWBORN RAT; INTESTINE; BINDING; CRYSTALLIZATION; EXPRESSION; REFINEMENT; TRANSPORT; FRAGMENT	THE neonatal Fc receptor (FcRn) transports maternal immunoglobulin G (IgG) to the bloodstream of the newborn. FcRn is structurally similar to class I major histocompatibility complex (MHC) molecules(1,2), despite differences in the ligands they bind (the Fc portion of IgG and antigenic peptides, respectively). A low-resolution crystal structure of the complex between FcRn and Fc localizes the binding site for Fc to the side of FcRn, distinct from the tops of the alpha 1 and alpha 2 domains which serve as the peptide and T-cell receptor binding sites in class I molecules. FcRn binds to Fc at the interface between the Fc C(H)2 and C(H)3 domains, which contains several histidine residues that could account for the sharply pH-dependent FcRn/IgG interaction(3). A dimer of FcRn heterodimers observed in the co-crystals and in the crystals of FcRn alone(2) could be involved in binding Fc, correlating with the 2:1 binding stoichiometry between FcRn and IgG (ref. 4) and suggesting an unusual orientation of FcRn on the membrane.	CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125; CALTECH,DIV BIOL 15629,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology				Burmeister, Wim/0000-0003-0876-6118				AHOUSE JJ, 1993, J IMMUNOL, V151, P6076; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; GUDDAT LW, 1993, P NATL ACAD SCI USA, V90, P4271, DOI 10.1073/pnas.90.9.4271; HARRIS LJ, 1992, NATURE, V360, P369, DOI 10.1038/360369a0; HOBBS SM, 1987, J BIOL CHEM, V262, P8041; HUBER AH, 1993, J MOL BIOL, V230, P1077, DOI 10.1006/jmbi.1993.1220; HUBER AH, 1994, THESIS CALTECH; JAKOI ER, 1985, J IMMUNOL, V135, P3360; JONES TA, 1993, CRYSTALLOGRAPHIC COM; Kabat EA, 1991, SEQUENCES PROTEINS I; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; RAGHAVAN M, 1994, IMMUNITY, V1, P303, DOI 10.1016/1074-7613(94)90082-5; RODEWALD R, 1976, J CELL BIOL, V71, P666, DOI 10.1083/jcb.71.2.666; RODEWALD R, 1973, J CELL BIOL, V58, P189, DOI 10.1083/jcb.58.1.189; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SIMISTER NE, 1989, COLD SPRING HARB SYM, V54, P571, DOI 10.1101/SQB.1989.054.01.068; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; WALLACE KH, 1980, BIOCHEM J, V188, P9, DOI 10.1042/bj1880009; ZHENG Y, 1991, BIOCHEMISTRY-US, V30, P9125, DOI 10.1021/bi00102a002; 1979, SERC UK COLLABORATIV	28	386	548	2	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					379	383		10.1038/372379a0	http://dx.doi.org/10.1038/372379a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969498				2022-12-24	WOS:A1994PU28700060
J	URSIN, G; PETERS, RK; HENDERSON, BE; DABLAING, G; MONROE, KR; PIKE, MC				URSIN, G; PETERS, RK; HENDERSON, BE; DABLAING, G; MONROE, KR; PIKE, MC			ORAL-CONTRACEPTIVE USE AND ADENOCARCINOMA OF CERVIX	LANCET			English	Article							UTERINE CERVIX; YOUNG-WOMEN; CANCER; RISK; ESTROGEN	The incidence of adenocarcinoma of the cervix in the USA more than doubled between the early 1970s and the mid 1980s among women under 35 years of age. It was suggested that this increase was due to the introduction of oral contraceptives in the early 1960s. Adenocarcinoma of the cervix diagnosed in women born after 1935 was identified between 1977 and 1991, from the Los Angeles County Cancer Surveillance Program, Data from personal interviews of 195 cases and 386 controls (matched on age, race, and neighbourhood) were analysed. Information on medical, sexual, contraceptive, reproductive history, previous cervical smears, sexually transmitted diseases was collected. Compared with never use, eve, use of oral contraceptives was associated with twice as great a risk of adenocarcinoma of the cervix (adjusted odds ratio 2.1, 95% CI 1.1-3.8). The highest risk was observed for oral contraceptive use for more than 12 years (4.4, 1.8-10.8). No additional increased risk was found for early age at start of oral contraceptive use, use before age 20 or before first pregnancy, time since first use, time since last use, or particular formulations, once total duration of use had been accounted for.	UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033; SALK INST BIOL STUDIES,LA JOLLA,CA 92037	University of Southern California; Salk Institute	URSIN, G (corresponding author), UNIV SO CALIF,SCH MED,DEPT PREVENT MED,1420 SAN PABLO ST,LOS ANGELES,CA 90033, USA.		Ursin, Giske/U-6637-2017	Ursin, Giske/0000-0002-0835-9507	NATIONAL CANCER INSTITUTE [R01CA044401] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44401-05, P01 CA1754] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1962, NOVAKS GYNECOLOGIC O; Breslow N, 1980, STATISTICAL METHODS, V32; BRINTON LA, 1986, INT J CANCER, V38, P339, DOI 10.1002/ijc.2910380307; BRINTON LA, 1990, INT J EPIDEMIOL, V19, P4, DOI 10.1093/ije/19.1.4; CANDY AA, 1968, JAMA-J AM MED ASSOC, V203, P85; CANO A, 1990, FERTIL STERIL, V54, P1058; CHILVERS C, 1987, BRIT MED J, V295, P1446, DOI 10.1136/bmj.295.6611.1446; DALLENBACHHELLWEG G, 1984, PATHOL RES PRACT, V179, P38, DOI 10.1016/S0344-0338(84)80059-X; EIDE TJ, 1987, J NATL CANCER I, V79, P199; FORD LC, 1983, GYNECOL ONCOL, V15, P27, DOI 10.1016/0090-8258(83)90113-0; GALL SA, 1969, J AMER MED ASSOC, V207, P2243, DOI 10.1001/jama.207.12.2243; GOLDACRE MJ, 1978, BRIT MED J, V1, P748, DOI 10.1136/bmj.1.6115.748; HARRISON HR, 1985, AM J OBSTET GYNECOL, V153, P244, DOI 10.1016/S0002-9378(85)80105-8; HENDERSON BE, 1982, CANCER RES, V42, P3232; HONORE LH, 1989, GYNECOL OBSTET INVES, V32, P98; HOROWITZ IR, 1988, GYNECOL ONCOL, V31, P25, DOI 10.1016/0090-8258(88)90265-X; JONES MW, 1989, OBSTET GYNECOL, V73, P984; KJAER SK, 1993, EPIDEMIOL REV, V15, P486, DOI 10.1093/oxfordjournals.epirev.a036131; KYRIAKOS M, 1968, CANCER, V22, P99, DOI 10.1002/1097-0142(196807)22:1<99::AID-CNCR2820220113>3.0.CO;2-4; LOUV WC, 1989, AM J OBSTET GYNECOL, V160, P396, DOI 10.1016/0002-9378(89)90456-0; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; PARAZZINI F, 1988, BRIT J CANCER, V57, P201, DOI 10.1038/bjc.1988.43; PERSSON E, 1987, EUR J OBSTET GYN R B, V26, P85, DOI 10.1016/0028-2243(87)90011-6; PETERS RK, 1986, JNCI-J NATL CANCER I, V76, P423; SCHWARTZ SM, 1986, AM J EPIDEMIOL, V124, P1045, DOI 10.1093/oxfordjournals.aje.a114474; SCOTT JR, 1990, DANFORTHS OBSTETRICS; SILCOCKS PBS, 1987, BRIT J CANCER, V55, P321, DOI 10.1038/bjc.1987.63; TAYLOR HB, 1967, J AMER MED ASSOC, V202, P637, DOI 10.1001/jama.202.7.637; URSIN G, 1994, ADV CONTRA DELI SYST, V10, P370	29	88	93	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1390	1394		10.1016/S0140-6736(94)90567-3	http://dx.doi.org/10.1016/S0140-6736(94)90567-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968074				2022-12-24	WOS:A1994PR78600008
J	MALINOW, R				MALINOW, R			LTP - DESPERATELY SEEKING RESOLUTION	SCIENCE			English	Editorial Material							LONG-TERM POTENTIATION; GLUTAMATE RELEASE; NMDA RECEPTORS; HIPPOCAMPUS; PROBABILITY; PLASTICITY; SYNAPSE				MALINOW, R (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.							BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLINE HT, 1991, TRENDS NEUROSCI, V14, P104, DOI 10.1016/0166-2236(91)90071-2; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1994, P NATL ACAD SCI USA, V91, P8170, DOI 10.1073/pnas.91.17.8170; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MORRIS RGM, 1990, PHILOS T ROY SOC B, V329, P187, DOI 10.1098/rstb.1990.0164; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; MURPHY TH, 1994, NATURE, V263, P529; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0	21	53	55	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1195	1196		10.1126/science.7973700	http://dx.doi.org/10.1126/science.7973700			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973700				2022-12-24	WOS:A1994PT13200041
J	MARCANTONIO, ER; JUAREZ, G; GOLDMAN, L; MANGIONE, CM; LUDWIG, LE; LIND, L; KATZ, N; COOK, EF; ORAV, EJ; LEE, TH				MARCANTONIO, ER; JUAREZ, G; GOLDMAN, L; MANGIONE, CM; LUDWIG, LE; LIND, L; KATZ, N; COOK, EF; ORAV, EJ; LEE, TH			THE RELATIONSHIP OF POSTOPERATIVE DELIRIUM WITH PSYCHOACTIVE MEDICATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURGICAL PATIENTS; ELDERLY PATIENT; ACTIVITY SCALE; RISK-FACTORS; ASSOCIATION; MEPERIDINE; PROGNOSIS; SURGERY	Objective.-To examine the role of medications with known psychoactive properties in the development of postoperative delirium. Design.-Nested case-control study within a prospective cohort study. Setting.-General surgery, orthopedic surgery, and gynecology services at Brigham and Women's Hospital, Boston, Mass. Patients.-Cases (n=91) were patients enrolled in a prospective cohort study who developed delirium during postoperative days 2 through 5. One or two controls (n=154) were matched to each case by the calculated preoperative risk for delirium using a predictive model developed and validated in the prospective cohort study. Main Outcome Measures.-Medication exposures were ascertained from the medical record by a reviewer blinded to the study hypothesis. Exposures to narcotics, benzodiazepines, and anticholinergics were recorded for the 24-hour period before delirium developed in the 91 cases and for the same 24-hour postoperative period for the 154 matched controls. Results.-Delirium was significantly associated with postoperative exposure to meperidine (odds ratio [OR], 2.7; 95% confidence interval [Cl], 1.3 to 5.5) and to benzodiazepines (OR, 3.0; 95% Cl, 1.3 to 6.8). Meperidine had similar associations with delirium whether administered via epidural or patient-controlled routes, although only the epidural route reached significance (OR, 2.4; 95% Cl, 1.3 to 4.4; OR, 2.1; 95% Cl, 0.4 to 10.7, respectively). For benzodiazepines, long-acting agents had a trend toward stronger association with delirium than did short-acting agents (OR, 5.4; 95% Cl, 1.0 to 29.2; vs 2.6; 1.1 to 6.5), and high-dose exposures had a trend toward slightly stronger association than low-dose exposures (OR, 3.3; 95% Cl, 1.0 to 11.0; vs 2.6; 0.8 to 9.1). Neither narcotics (OR, 1.4; 95% Cl, 0.5 to 4.3) nor anticholinergic drugs (OR, 1.5; 95% Cl, 0.6 to 3.4) were significantly associated with delirium as a class, although statistical power was limited because of the high use of narcotics and the low use of anticholinergics in the study population. Conclusions.-Clinicians caring for patients at risk for delirium should carefully evaluate the need for meperidine and benzodiazepines in the postoperative period and consider alternative therapies whenever possible.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CLIN EPIDEMIOL SECT,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GEN MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GERONTOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV CARDIOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT ANESTHESIA,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CLIN INITIAT DEV PROGRAM,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; CEDARS SINAI MED CTR,DEPT ANESTHESIA,LOS ANGELES,CA 90048	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Cedars Sinai Medical Center			Marcantonio, Edward R/U-3929-2017	Marcantonio, Edward R/0000-0002-2911-4250	AHRQ HHS [1RO1-HS06573] Funding Source: Medline; BHP HRSA HHS [5T32PE110011-04] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); BHP HRSA HHS		BRIZER DA, 1982, AM J PSYCHIAT, V139, P1343; EISENDRATH SJ, 1987, AM J PSYCHIAT, V144, P1062; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS J, 1992, J AM GERIATR SOC, V40, P829, DOI 10.1111/j.1532-5415.1992.tb01859.x; FRANCIS J, 1992, J AM GERIATR SOC, V40, P601, DOI 10.1111/j.1532-5415.1992.tb02111.x; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; FRANCIS J, 1990, J GEN INTERN MED, V5, P65, DOI 10.1007/BF02602312; FRANCIS J, 1992, J AM GERIATR SOC, V40, P848, DOI 10.1111/j.1532-5415.1992.tb01861.x; FRANCIS J, 1994, PRINCIPLES GERIATRIC; GILMAN AG, 1980, GOODMAN GILMANS PHAR; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GOLINGER RC, 1987, AM J PSYCHIAT, V144, P1218; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P325; Hegyvary ST, 1979, USERS MANUAL RUSH ME; HODSMAN NBA, 1987, ANAESTHESIA, V42, P1005, DOI 10.1111/j.1365-2044.1987.tb05377.x; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; LEE TH, 1988, AM HEART J, V115, P203, DOI 10.1016/0002-8703(88)90545-5; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; Lopez Oscar L, 2010, Neuroepidemiology, V34, P63, DOI 10.1159/000264678; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; MIETTINEN OS, 1976, AM J EPIDEMIOL, V104, P609, DOI 10.1093/oxfordjournals.aje.a112339; MILLAR HR, 1981, BRIT J PSYCHIAT, V138, P17, DOI 10.1192/bjp.138.1.17; MORSE RM, 1969, AM J PSYCHIAT, V126, P388, DOI 10.1176/ajp.126.3.388; MURRAY AM, 1993, J GERONTOL, V48, pM181, DOI 10.1093/geronj/48.5.M181; ROGERS MP, 1989, INT J PSYCHIAT MED, V19, P109; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; SEYMOUR DG, 1983, GERONTOLOGY, V29, P262, DOI 10.1159/000213125; STAMBAUGH JE, 1976, J CLIN PHARMACOL, V16, P245, DOI 10.1002/j.1552-4604.1976.tb02401.x; THOMAS RI, 1988, ARCH GEN PSYCHIAT, V45, P937; TUNE LE, 1981, LANCET, V2, P651; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x	33	361	375	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1518	1522		10.1001/jama.272.19.1518	http://dx.doi.org/10.1001/jama.272.19.1518			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PQ900	7966844				2022-12-24	WOS:A1994PQ90000031
J	NIGHTINGALE, SL				NIGHTINGALE, SL			LEFT-VENTRICULAR ASSIST DEVICE APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1488	1488						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966836				2022-12-24	WOS:A1994PQ90000023
J	BEHRINGER, RR; FINEGOLD, MJ; CATE, RL				BEHRINGER, RR; FINEGOLD, MJ; CATE, RL			MULLERIAN-INHIBITING SUBSTANCE FUNCTION DURING MAMMALIAN SEXUAL DEVELOPMENT	CELL			English	Article							DUCT SYNDROME; BIOLOGICAL-ACTIVITY; EXPRESSION CLONING; HORMONE GENE; RAT OVARY; MOUSE; MICE; RECEPTOR; FETAL; CELLS	To investigate the role of Mullerian-inhibiting substance (MIS) in mammalian sexual development, we generated MIS-deficient mice. Although MIS-deficient males had testes that were fully descended and produced functional sperm, they also developed female reproductive organs, which interfered with sperm transfer into females, rendering most of these males infertile. Their testes had Leydig cell hyperplasia and, in one instance, neoplasia. The actions of the two primary hormones of male sexual differentation were genetically eliminated using the testicular feminization (Tfm) mutation in combination with the MIS mutant allele. XY Tfm/MIS double mutants developed as females, with a uterus, coiled oviducts, and no male reproductive organs except undescended dysfunctional testes. These results suggest that eliminating the presumptive female reproductive tract in male fetuses facilitates fertility and that in testes MIS is a negative regulator of Leydig cell proliferation. Eliminating the presumptive male reproductive tract is necessary for proper oviductal morphogenesis during female mouse development.	BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; BIOGEN INC, CAMBRIDGE, MA 02142 USA	Baylor College of Medicine; Biogen	BEHRINGER, RR (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD030284] Funding Source: NIH RePORTER; NICHD NIH HHS [HD30284] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAARENDS WM, 1994, DEVELOPMENT, V120, P189; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BEZARD J, 1987, J REPROD FERTIL, V80, P509, DOI 10.1530/jrf.0.0800509; BISHOP CE, 1987, NUCLEIC ACIDS RES, V15, P2959, DOI 10.1093/nar/15.7.2959; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BUDZIK GP, 1985, DEV MECHANISMS NORMA, P207; CARREEUSEBE D, 1992, HUM GENET, V90, P389; Cate R. L., 1993, Genes in mammalian reproduction., P185; Cate R.L, 1990, PEPTIDE GROWTH FACTO, P179; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CATLIN EA, 1988, AM J OBSTET GYNECOL, V159, P1299, DOI 10.1016/0002-9378(88)90467-X; CHAREST NJ, 1991, MOL ENDOCRINOL, V5, P573, DOI 10.1210/mend-5-4-573; DICLEMENTE N, 1994, ENDOCRINE, V2, P553; DICLEMENTE N, 1992, DEVELOPMENT, V114, P721; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; DONAHOE PK, 1977, J PEDIATR SURG, V12, P323, DOI 10.1016/0022-3468(77)90008-2; GREEN MC, 1990, GENETIC VARIANTS STR; GUERRIER D, 1989, J CLIN ENDOCR METAB, V68, P46, DOI 10.1210/jcem-68-1-46; HAQQ C, 1992, GENOMICS, V12, P665, DOI 10.1016/0888-7543(92)90291-Y; HE WW, 1991, NUCLEIC ACIDS RES, V19, P2373, DOI 10.1093/nar/19.9.2373; HUTSON JM, 1986, ENDOCR REV, V7, P270, DOI 10.1210/edrv-7-3-270; IMBEAUD S, 1994, HUM MOL GENET, V3, P125, DOI 10.1093/hmg/3.1.125; JOSSO N, 1986, PHYSIOL REV, V66, P1038, DOI 10.1152/physrev.1986.66.4.1038; JOSSO N, 1993, RECENT PROG HORM RES, V48, P1; Jost, 1947, ARCH ANAT MICR MORPH, V36, P271; JOST A, 1972, J REPROD FERTIL, V29, P349, DOI 10.1530/jrf.0.0290349; JOST A, 1953, RECENT PROG HORM RES, V8, P379; KIM JH, 1992, J CLIN ENDOCR METAB, V75, P911, DOI 10.1210/jc.75.3.911; KNEBELMANN B, 1991, P NATL ACAD SCI USA, V88, P3767, DOI 10.1073/pnas.88.9.3767; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MEYERSWALLEN VN, 1989, BIOL REPROD, V41, P881, DOI 10.1095/biolreprod41.5.881; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PEPINSKY RB, 1988, J BIOL CHEM, V263, P18961; PICARD JY, 1984, MOL CELL ENDOCRINOL, V34, P23, DOI 10.1016/0303-7207(84)90155-2; PICARD JY, 1986, P NATL ACAD SCI USA, V83, P5464, DOI 10.1073/pnas.83.15.5464; PICON R, 1969, ARCH ANAT MICROSC MO, V58, P1; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKAHASHI M, 1986, BIOL REPROD, V35, P447, DOI 10.1095/biolreprod35.2.447; TRAN D, 1981, BIOL REPROD, V24, P923, DOI 10.1095/biolreprod24.4.923; UENO S, 1989, ENDOCRINOLOGY, V125, P1060, DOI 10.1210/endo-125-2-1060; UENO S, 1989, ENDOCRINOLOGY, V124, P1000, DOI 10.1210/endo-124-2-1000; VIGIER B, 1987, DEVELOPMENT, V100, P43; WILSON CA, 1993, MOL ENDOCRINOL, V7, P247, DOI 10.1210/me.7.2.247	51	512	532	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	1994	79	3					415	425		10.1016/0092-8674(94)90251-8	http://dx.doi.org/10.1016/0092-8674(94)90251-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954809				2022-12-24	WOS:A1994PQ48800005
J	FAN, C; MOEWS, PC; WALSH, CT; KNOX, JR				FAN, C; MOEWS, PC; WALSH, CT; KNOX, JR			VANCOMYCIN RESISTANCE - STRUCTURE OF D-ALANINE-D-ALANINE LIGASE AT 2.3-ANGSTROM RESOLUTION	SCIENCE			English	Article							ALANYL-D-ALANINE; GLYCOPEPTIDE RESISTANCE; GLUTATHIONE SYNTHETASE; ESCHERICHIA-COLI; ENZYMES; ATP; BIOSYNTHESIS; PROTEINS; GENE; VANA	The molecular structure of the D-alanine:D-alanine ligase of the ddlB gene of Escherichia coli, co-crystallized with an S,R-methylphosphinate and adenosine triphosphate, was determined by x-ray diffraction to a resolution of 2.3 angstroms. A catalytic mechanism for the ligation of two D-alanine substrates is proposed in which a helix dipole and a hydrogen-bonded triad of tyrosine, serine, and glutamic acid assist binding and deprotonation steps. From sequence comparison, it is proposed that a different triad exists in a recently discovered D-alanine:D-lactate ligase (VanA) present in vancomycin-resistant enterococci. A molecular mechanism for the altered specificity of VanA is suggested.	UNIV CONNECTICUT, DEPT MOLEC & CELL BIOL, STORRS, CT 06269 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	University of Connecticut; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034330] Funding Source: NIH RePORTER; NIAID NIH HHS [1RO1-AI-34330] Funding Source: Medline; NIGMS NIH HHS [GM-49338] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1992, CHEM B LACTAMS; ARTHUR M, 1993, ANTIMICROB AGENTS CH, V37, P1563, DOI 10.1128/AAC.37.8.1563; BRUNGER AT, 1990, X PLOR MANUAL VERSIO; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; DUTKAMALEN S, 1990, MOL GEN GENET, V224, P364, DOI 10.1007/BF00262430; DUTKAMALEN S, 1992, GENE, V112, P53, DOI 10.1016/0378-1119(92)90302-6; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HAMMES WP, 1981, PHARMACOL THERAPEUT, V14, P265; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JACK JS, 1988, J MOL GRAPHICS, V6, P224; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; MCDERMOTT AE, 1990, BIOCHEMISTRY-US, V29, P5767, DOI 10.1021/bi00476a018; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NEUHAUS FC, 1962, J BIOL CHEM, V237, P778; NEUHAUS FC, 1964, BIOCHEMISTRY-US, V3, P471, DOI 10.1021/bi00892a001; NEUHAUS FC, 1962, J BIOL CHEM, V237, P3128; PARSONS WH, 1988, J MED CHEM, V31, P1772, DOI 10.1021/jm00117a017; REYNOLDS PE, 1994, BIOCHEM J, V301, P5, DOI 10.1042/bj3010005; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SPRATT BG, 1994, SCIENCE, V264, P388, DOI 10.1126/science.8153626; STROMINGER JL, 1960, J AM CHEM SOC, V82, P998, DOI 10.1021/ja01489a058; TANAKA T, 1993, BIOCHEMISTRY-US, V32, P12398, DOI 10.1021/bi00097a018; TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615; Waley SG, 1992, CHEM BLACTAMS, P198; WALSH C, UNPUB; WALSH CT, 1989, J BIOL CHEM, V264, P2393; WALSH CT, 1993, SCIENCE, V261, P308, DOI 10.1126/science.8392747; WRIGHT GD, 1993, PROTEIN SCI, V2, P1765, DOI 10.1002/pro.5560021020; WRIGHT GD, 1992, ACCOUNTS CHEM RES, V25, P468, DOI 10.1021/ar00022a006; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106; ZAWADZKE LE, 1991, BIOCHEMISTRY-US, V30, P1673, DOI 10.1021/bi00220a033	34	245	249	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	1994	266	5184					439	443		10.1126/science.7939684	http://dx.doi.org/10.1126/science.7939684			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939684				2022-12-24	WOS:A1994PN27200036
J	HAY, RJ; CASTANON, RE; HERNANDEZ, HA; LOPEZ, GC; FUENTES, LFL; SOLIS, SP; ANDERSSON, N				HAY, RJ; CASTANON, RE; HERNANDEZ, HA; LOPEZ, GC; FUENTES, LFL; SOLIS, SP; ANDERSSON, N			WASTAGE OF FAMILY INCOME ON SKIN-DISEASE IN MEXICO	BRITISH MEDICAL JOURNAL			English	Article									UNIV AUTONOMA GUERRERO,CTR INVEST ENFERMEDADES TROP,ACAPULCO,GUERRERO,MEXICO		HAY, RJ (corresponding author), GUYS HOSP,ST JOHNS INST DERMATOL,LONDON SE1 9RT,ENGLAND.		Andersson, Neil/G-2248-2011					ANDERSSON N, 1992, HLTH POLICY PLANNING, V7, P1; BECHELLI LM, 1981, DERMATOLOGICA, V163, P78, DOI 10.1159/000250144; CASTELLS S, 1992, J INTELL DISABIL RES, V36, P29; Hay R, 1991, LANCET, V337, P906; TAPLIN D, 1991, LANCET, V337, P1016, DOI 10.1016/0140-6736(91)92669-S	5	57	58	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					848	848		10.1136/bmj.309.6958.848	http://dx.doi.org/10.1136/bmj.309.6958.848			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7950615	Green Published			2022-12-24	WOS:A1994PK50100024
J	MANFREDINI, R; GALLERANI, M; CARACCIOLO, S; TOMELLI, A; CALO, G; FERSINI, C				MANFREDINI, R; GALLERANI, M; CARACCIOLO, S; TOMELLI, A; CALO, G; FERSINI, C			CIRCADIAN VARIATION IN ATTEMPTED-SUICIDE BY DELIBERATE SELF-POISONING	BRITISH MEDICAL JOURNAL			English	Article									ST ANNA HOSP,DEPT ACCID & EMERGENCY,FERRARA,ITALY; UNIV FERRARA,SCH MED,DEPT PSYCHOL,I-44100 FERRARA,ITALY; UNIV FERRARA,INST PHARMACOL,I-44100 FERRARA,ITALY; WHO,PARASUICIDE MULTICTR STUDY,MENTAL HLTH SERV,FERRARA,ITALY	University of Ferrara; Arcispedale Sant'Anna; University of Ferrara; University of Ferrara; World Health Organization	MANFREDINI, R (corresponding author), UNIV FERRARA,SCH MED,INST INTERNAL MED,I-44100 FERRARA,ITALY.		Manfredini, Roberto/N-3859-2019; Manfredini, Roberto/AAJ-5442-2020; Manfredini, Roberto/A-3471-2008	Manfredini, Roberto/0000-0002-8364-2601; Manfredini, Roberto/0000-0002-8364-2601; Caracciolo, Stefano/0000-0002-3605-1905				MALDONADO G, 1991, SUICIDE LIFE-THREAT, V21, P174; MOTOHASHI Y, 1990, SUICIDE LIFE-THREAT, V20, P352; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; ROY A, 1988, ACTA PSYCHIAT SCAND, V78, P529, DOI 10.1111/j.1600-0447.1988.tb06380.x	5	22	23	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					774	775		10.1136/bmj.309.6957.774	http://dx.doi.org/10.1136/bmj.309.6957.774			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PJ282	7950563	Green Published			2022-12-24	WOS:A1994PJ28200020
J	VINCENT, JP; LAWRENCE, PA				VINCENT, JP; LAWRENCE, PA			DROSOPHILA WINGLESS SUSTAINS ENGRAILED EXPRESSION ONLY IN ADJOINING CELLS - EVIDENCE FROM MOSAIC EMBRYOS	CELL			English	Article							SEGMENT-POLARITY GENE; FUSHI-TARAZU; PROTEIN; PARASEGMENTS; EPIDERMIS; SECRETION; PATTERN; WNT-1	The wingless protein is secreted, but it is not known whether it acts only on cells near to its site of synthesis or whether it has a longer range. Here, we use mosaic Drosophila embryos to estimate the range of wingless as it acts to maintain expression of the engrailed gene. We find that expression of engrailed is often sustained in those wingless(-) cells that are located near a wildtype patch of tissue, but this is not invariably so. Also, the numbers of cells maintaining engrailed expression are small. From these findings, we argue that wing less-expressing cells sustain engrailed expression only in adjoining cells. The wingless gene is also needed for maintenance of its own expression; using mosaics, we find that the range of this action is short as well.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology				Lawrence, Peter/0000-0002-9554-8268				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; CRICK FHC, 1975, SCIENCE, V189, P340, DOI 10.1126/science.806966; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FOE VE, 1989, DEVELOPMENT, V107, P1; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; LAWRENCE PA, 1989, DEVELOPMENT, V107, P847; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1993, DEVELOPMENT, V119, P971; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; LI XL, 1993, EMBO J, V12, P4499, DOI 10.1002/j.1460-2075.1993.tb06139.x; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SAMPEDRO J, 1993, DEVELOPMENT, V117, P677; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; THURINGER F, 1993, P NATL ACAD SCI USA, V90, P3899, DOI 10.1073/pnas.90.9.3899; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; VINCENT JP, 1994, IN PRESS DEV BIOL; ZALOKAR M, 1971, P NATL ACAD SCI USA, V68, P1539, DOI 10.1073/pnas.68.7.1539	37	54	54	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					909	915		10.1016/0092-8674(94)90139-2	http://dx.doi.org/10.1016/0092-8674(94)90139-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004677				2022-12-24	WOS:A1994NT33100015
